Factors	NNS	O
predictive	VBP	O
of	IN	O
severe	JJ	O
hypoglycemia	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NNS	O
:	:	O
analysis	NN	O
from	IN	O
the	DT	O
Juvenile	NNP	O
Diabetes	NNP	O
Research	NNP	O
Foundation	NNP	O
continuous	JJ	O
glucose	JJ	O
monitoring	VBG	O
randomized	VBN	O
control	NN	O
trial	NN	O
dataset	NN	O
.	.	O

OBJECTIVE	NNP	O
Identify	NNP	O
factors	NNS	O
predictive	VBP	O
of	IN	O
severe	JJ	O
hypoglycemia	NN	O
(	(	O
SH	NNP	O
)	)	O
and	CC	O
assess	VB	O
the	DT	O
clinical	JJ	O
utility	NN	O
of	IN	O
continuous	JJ	Other
glucose	JJ	Other
monitoring	NN	Other
(	(	Other
CGM	NNP	Other
)	)	Other
to	TO	O
warn	VB	O
of	IN	O
impending	VBG	O
SH	NNP	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
a	DT	O
multicenter	NN	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
,	,	O
436	CD	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
treatment	NN	O
group	NN	O
that	WDT	O
used	VBD	O
CGM	NNP	Other
(	(	O
N	NNP	O
=	NNP	O
224	CD	O
)	)	O
,	,	O
or	CC	O
a	DT	O
control	NN	Control
group	NN	O
that	WDT	O
used	VBD	O
standard	JJ	Control
home	NN	Control
blood	NN	Control
glucose	JJ	Control
monitoring	NN	Control
(	(	O
N	NNP	O
=	NNP	O
212	CD	O
)	)	O
and	CC	O
completed	VBD	O
12	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
original	JJ	O
control	NN	O
group	NN	O
initiated	VBD	O
CGM	NNP	Other
while	IN	O
the	DT	O
treatment	NN	O
group	NN	O
continued	VBD	O
use	NN	O
of	IN	O
CGM	NNP	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Baseline	NNP	O
risk	NN	O
factors	NNS	O
for	IN	O
SH	NNP	O
were	VBD	O
evaluated	VBN	O
over	IN	O
12	CD	O
months	NNS	O
of	IN	O
follow-up	JJ	O
using	VBG	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
.	.	O

CGM-derived	JJ	O
indices	NNS	O
of	IN	O
hypoglycemia	NN	O
were	VBD	O
used	VBN	O
to	TO	O
predict	VB	O
episodes	NNS	O
of	IN	O
SH	NNP	O
over	IN	O
a	DT	O
24-h	JJ	O
time	NN	O
horizon	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
SH	NNP	O
rate	NN	O
was	VBD	O
17.9	CD	O
per	IN	O
100	CD	O
person-years	NNS	O
,	,	O
and	CC	O
a	DT	O
higher	JJR	O
rate	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
SH	NNP	O
in	IN	O
the	DT	O
prior	JJ	O
6	CD	O
months	NNS	O
and	CC	O
female	JJ	O
sex	NN	O
.	.	O

SH	NNP	O
frequency	NN	O
increased	VBD	O
eightfold	RB	O
when	WRB	O
30	CD	O
%	NN	O
of	IN	O
CGM	NNP	Other
values	NNS	O
were	VBD	O
?	.	O
70	CD	O
mg/dL	NN	O
on	IN	O
the	DT	O
prior	JJ	O
day	NN	O
(	(	O
4.5	CD	O
vs.	FW	O
0.5	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
the	DT	O
positive	JJ	O
predictive	JJ	O
value	NN	O
(	(	O
PPV	NNP	O
)	)	O
was	VBD	O
low	JJ	O
(	(	O
<	JJ	O
5	CD	O
%	NN	O
)	)	O
.	.	O

Results	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
hypoglycemic	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
and	CC	O
the	DT	O
low	JJ	O
blood	NN	O
glucose	NN	O
index	NN	O
calculated	VBN	O
by	IN	O
CGM	NNP	Other
.	.	O

CONCLUSIONS	NNP	O
SH	NNP	O
in	IN	O
the	DT	O
6	CD	O
months	NNS	O
prior	RB	O
to	TO	O
the	DT	O
study	NN	O
was	VBD	O
the	DT	O
strongest	JJS	O
predictor	NN	O
of	IN	O
SH	NNP	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

CGM-measured	JJ	O
hypoglycemia	NN	O
over	IN	O
a	DT	O
24-h	JJ	O
span	NN	O
is	VBZ	O
highly	RB	O
associated	VBN	O
with	IN	O
SH	NNP	O
the	DT	O
following	JJ	O
day	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
the	DT	O
PPV	NNP	O
is	VBZ	O
low	JJ	O
.	.	O

Anxiety	NN	O
sensitivity	NN	O
as	IN	O
an	DT	O
incremental	JJ	O
predictor	NN	O
of	IN	O
later	JJ	O
anxiety	NN	O
symptoms	NNS	O
and	CC	O
syndromes	NNS	O
.	.	O

Although	IN	O
anxiety	NN	O
sensitivity	NN	O
(	(	O
AS	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
predict	VB	O
anxiety	NN	O
symptoms	NNS	O
and	CC	O
panic	NN	O
,	,	O
this	DT	O
literature	NN	O
is	VBZ	O
limited	VBN	O
in	IN	O
regard	NN	O
to	TO	O
evaluating	VBG	O
AS	NNP	O
as	IN	O
an	DT	O
incremental	JJ	O
predictor	NN	O
of	IN	O
anxiety	NN	Psychological
psychopathology	NN	Psychological
relative	VBP	O
to	TO	O
other	JJ	O
established	VBN	O
risk	NN	O
factors	NNS	O
including	VBG	O
sex	NN	O
and	CC	O
negative	JJ	O
affect	NN	O
.	.	O

The	DT	O
present	JJ	O
report	NN	O
prospectively	RB	O
evaluated	VBD	O
whether	IN	O
AS	NNP	O
was	VBD	O
predictive	NN	O
of	IN	O
later	JJ	O
changes	NNS	O
in	IN	O
anxiety	NN	O
symptoms	NNS	O
after	IN	O
controlling	VBG	Other
for	IN	Other
potential	JJ	Other
confounding	NN	Other
factors	NNS	Other
.	.	Other

Consistent	JJ	O
with	IN	O
hypothesis	NN	O
,	,	O
AS	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
significant	JJ	O
,	,	O
incremental	JJ	O
predictor	NN	O
of	IN	O
anxiety	NN	O
symptoms	NNS	O
over	IN	O
time	NN	O
,	,	O
even	RB	O
after	IN	O
controlling	VBG	O
for	IN	O
sex	NN	O
and	CC	O
negative	JJ	O
affectivity	NN	O
.	.	O

These	DT	O
data	NNS	O
provide	VBP	O
novel	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
unique	JJ	O
association	NN	O
between	IN	O
AS	NNP	O
of	IN	O
the	DT	O
development	NN	O
of	IN	O
anxiety	NN	O
symptoms	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
three	CD	O
oral	JJ	O
analgesics	NNS	Pharmacological
on	IN	O
postoperative	JJ	O
pain	NN	O
following	VBG	O
root	JJ	O
canal	JJ	O
preparation	NN	O
:	:	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

AIM	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
three	CD	O
oral	JJ	O
medications	NNS	O
on	IN	O
postoperative	JJ	O
pain	NN	O
following	VBG	O
instrumentation	NN	O
of	IN	O
root	NN	O
canals	NNS	O
in	IN	O
teeth	NN	O
with	IN	O
irreversible	JJ	O
pulpitis	NN	O
.	.	O

METHODOLOGY	NNP	O
In	IN	O
this	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
100	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
anterior	CC	O
or	CC	O
premolar	JJ	O
teeth	NNS	O
with	IN	O
irreversible	JJ	O
pulpitis	NN	O
without	IN	O
any	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
acute	NN	O
or	CC	O
chronic	JJ	O
apical	JJ	O
periodontitis	NN	O
and	CC	O
moderate	VB	O
to	TO	O
severe	VB	O
pain	NN	O
were	VBD	O
divided	VBN	O
by	IN	O
balanced	JJ	O
block	NN	O
random	NN	O
allocation	NN	O
into	IN	O
four	CD	O
groups	NNS	O
of	IN	O
25	CD	O
each	DT	O
,	,	O
a	DT	O
control	NN	Control
group	NN	Control
receiving	VBG	O
a	DT	O
placebo	NN	Control
medication	NN	O
,	,	O
and	CC	O
three	CD	O
experimental	JJ	O
groups	NNS	O
receiving	VBG	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
either	DT	O
Tramadol	NNP	Pharmacological
(	(	O
100	CD	O
mg	NN	O
)	)	O
,	,	O
Novafen	NNP	Pharmacological
(	(	O
325	CD	O
mg	NN	O
of	IN	O
paracetamol	NN	Pharmacological
,	,	O
200	CD	O
mg	NN	O
ibuprofen	NN	Pharmacological
and	CC	O
40	CD	O
mg	NNS	O
caffeine	VBP	Pharmacological
anhydrous	JJ	Pharmacological
)	)	O
or	CC	O
Naproxen	NNP	Pharmacological
(	(	O
500	CD	O
mg	NN	O
)	)	O
immediately	RB	O
after	IN	O
the	DT	O
first	JJ	O
appointment	NN	O
where	WRB	O
the	DT	O
pulp	NN	O
was	VBD	O
removed	VBN	O
,	,	O
and	CC	O
the	DT	O
canals	NNS	O
were	VBD	O
fully	RB	O
prepared	VBN	O
.	.	O

The	DT	O
intensity	NN	O
of	IN	O
pain	NN	O
was	VBD	O
scored	VBN	O
based	VBN	O
on	IN	O
10-point	JJ	O
VAS	NNP	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
for	IN	O
up	IN	O
to	TO	O
24	CD	O
h	NN	O
postoperatively	RB	O
.	.	O

Data	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
repeated	VBN	O
analysis	NN	O
of	IN	O
variance	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
h	NNS	O
postoperative	JJ	O
intervals	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
the	DT	O
intensity	NN	O
of	IN	O
pain	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
experimental	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	Pharmacological
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Tramadol	NNP	Pharmacological
was	VBD	O
significantly	RB	O
less	RBR	O
effective	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
than	IN	O
Naproxen	NNP	Pharmacological
,	,	O
and	CC	O
Novafen	NNP	Pharmacological
that	WDT	O
were	VBD	O
similar	JJ	O
to	TO	O
each	DT	O
other	JJ	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
Naproxen	NNP	Pharmacological
,	,	O
Novafen	NNP	Pharmacological
and	CC	O
Tramadol	NNP	Pharmacological
taken	VBN	O
immediately	RB	O
after	IN	O
treatment	NN	O
reduced	VBD	O
postoperative	JJ	O
pain	NN	O
following	VBG	O
pulpectomy	NN	O
and	CC	O
root	JJ	O
canal	JJ	O
preparation	NN	O
of	IN	O
teeth	NNS	O
with	IN	O
irreversible	JJ	O
pulpitis	NN	O
.	.	O

Hydrogen	NNP	Pharmacological
peroxide	NN	Pharmacological
mouth	NN	Pharmacological
rinse	NN	Pharmacological
:	:	O
an	DT	O
analgesic	JJ	O
post-tonsillectomy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
hydrogen	NN	Pharmacological
peroxide	NN	Pharmacological
(	(	Pharmacological
H2O2	NNP	Pharmacological
)	)	Pharmacological
mouth	NN	Pharmacological
rinse	NN	Pharmacological
with	IN	O
control	NN	Control
for	IN	O
post-tonsillectomy	JJ	O
pain	NN	O
management	NN	O
.	.	O

DESIGN	NNP	O
Double-blinded	NNP	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Thirty-seven	JJ	O
patients	NNS	O
from	IN	O
5	CD	O
to	TO	O
14	CD	O
years	NNS	O
old	JJ	O
undergoing	JJ	O
electrocautery	NN	Surgical
tonsillectomy	NN	Surgical
were	VBD	O
randomized	VBN	O
to	TO	O
either	CC	O
the	DT	O
H2O2	NNP	Pharmacological
mouth	NN	Pharmacological
rinse	NN	Pharmacological
or	CC	O
the	DT	O
water	NN	Control
rinse	NN	Control
(	(	Control
control	NN	Control
)	)	Control
group	NN	Control
.	.	O

For	IN	O
14	CD	O
days	NNS	O
,	,	O
patients	NNS	O
recorded	VBD	O
pain	NN	O
levels	NNS	O
twice	RB	O
daily	RB	O
using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
.	.	O

Analgesic	JJ	O
uses	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
any	DT	O
complications	NNS	O
,	,	O
were	VBD	O
also	RB	O
noted	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
.	.	O

RESULTS	NNP	O
Thirty-seven	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
21	CD	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
and	CC	O
16	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Mean	NNP	O
postoperative	JJ	O
days	NNS	O
of	IN	O
pain	NN	O
were	VBD	O
10.3	CD	O
and	CC	O
8.3	CD	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
differed	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
.008	NNP	O
)	)	O
.	.	O

Mean	JJ	O
postoperative	JJ	O
days	NNS	O
of	IN	O
analgesic	JJ	O
use	NN	O
were	VBD	O
9.0	CD	O
and	CC	O
6.7	CD	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
differed	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
.005	NNP	O
)	)	O
.	.	O

Only	RB	O
one	CD	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
hemorrhage	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
study	NN	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
our	PRP$	O
study	NN	O
,	,	O
the	DT	O
H2O2	NNP	Pharmacological
mouth	NN	Pharmacological
rinse	NN	Pharmacological
does	VBZ	O
not	RB	O
provide	VB	O
a	DT	O
better	JJR	O
analgesic	JJ	O
effect	NN	O
than	IN	O
the	DT	O
water	NN	O
rinse	NN	O
for	IN	O
post-tonsillectomy	JJ	O
pain	NN	O
relief	NN	O
.	.	O

Learning	VBG	O
about	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
:	:	O
does	VBZ	O
comparing	VBG	O
with	IN	O
inequality	NN	O
symbols	NNS	O
help	VB	O
?	.	O
This	DT	O
study	NN	O
investigated	VBD	O
whether	IN	O
instruction	NN	Other
that	WDT	Other
involves	VBZ	Other
comparing	VBG	Other
the	DT	Other
equal	JJ	Psychological
sign	NN	Psychological
with	IN	Other
other	JJ	Other
relational	JJ	Other
symbols	NNS	Other
is	VBZ	O
more	RBR	O
effective	JJ	O
at	IN	O
imparting	VBG	O
a	DT	O
relational	JJ	O
interpretation	NN	O
of	IN	O
the	DT	O
equal	JJ	Psychological
sign	NN	Psychological
than	IN	O
instruction	NN	Other
about	IN	Other
the	DT	Other
equal	JJ	Psychological
sign	NN	Psychological
alone	RB	Other
.	.	O

Third-	JJ	O
and	CC	O
fourth-grade	JJ	O
students	NNS	O
in	IN	O
a	DT	O
comparing	NN	Educational
symbols	NNS	Educational
group	NN	Educational
learned	VBD	Educational
about	IN	Educational
the	DT	Educational
greater	JJR	Educational
than	IN	Educational
,	,	Educational
less	JJR	Educational
than	IN	Educational
,	,	Educational
and	CC	Educational
equal	JJ	Psychological
signs	NNS	Psychological
and	CC	Educational
had	VBD	Educational
the	DT	Educational
opportunity	NN	Educational
to	TO	Educational
compare	VB	Educational
the	DT	Educational
inequality	NN	Educational
symbols	VBZ	Educational
with	IN	Educational
the	DT	Educational
equal	JJ	Psychological
sign	NN	Psychological
.	.	O

Students	NNS	O
in	IN	O
an	DT	O
equal	JJ	Psychological
sign	NN	Psychological
group	NN	Educational
learned	VBD	Educational
about	IN	Educational
the	DT	Educational
equal	JJ	Psychological
sign	NN	Psychological
only	RB	Educational
.	.	Educational

A	NNP	O
third	JJ	O
group	NN	O
of	IN	O
students	NNS	O
served	VBD	O
as	IN	O
a	DT	O
control	NN	Control
group	NN	Control
.	.	O

Three	CD	O
aspects	NNS	O
of	IN	O
students	NNS	O
'	POS	O
knowledge	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
lesson	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
conceptual	JJ	O
understanding	NN	O
of	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
equation	NN	O
encoding	NN	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
problem	NN	O
solving	VBG	O
.	.	O

Students	NNS	O
in	IN	O
the	DT	O
comparing	NN	O
symbols	NNS	O
group	NN	O
showed	VBD	O
greater	JJR	O
gains	NNS	O
in	IN	O
conceptual	JJ	O
understanding	NN	O
from	IN	O
pretest	NN	O
to	TO	O
posttest	VB	O
than	IN	O
students	NNS	O
in	IN	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
,	,	O
and	CC	O
students	NNS	O
in	IN	O
the	DT	O
comparing	NN	O
symbols	NNS	O
group	NN	O
also	RB	O
scored	VBD	O
higher	JJR	O
on	IN	O
a	DT	O
posttest	NN	O
that	WDT	O
assessed	VBD	O
knowledge	NN	O
about	IN	O
inequality	NN	O
symbols	NNS	O
and	CC	O
inequality	NN	O
problem	NN	O
solving	VBG	O
.	.	O

Thus	RB	O
,	,	O
they	PRP	O
learned	VBD	O
about	IN	O
three	CD	O
symbols	NNS	O
in	IN	O
the	DT	O
same	JJ	O
amount	NN	O
of	IN	O
time	NN	O
as	IN	O
other	JJ	O
students	NNS	O
learned	VBD	O
about	IN	O
the	DT	O
equal	JJ	O
sign	NN	O
alone	RB	O
or	CC	O
not	RB	O
at	IN	O
all	DT	O
.	.	O

Therefore	NNP	O
,	,	O
an	DT	O
instructional	JJ	O
approach	NN	O
involving	VBG	O
comparison	NN	O
can	MD	O
be	VB	O
an	DT	O
effective	JJ	O
tool	NN	O
for	IN	O
learning	VBG	O
about	IN	O
concepts	NNS	O
in	IN	O
mathematics	NNS	O
.	.	O

Physostigmine	JJ	Pharmacological
reverses	VBZ	O
propofol-induced	JJ	O
unconsciousness	NN	O
and	CC	O
attenuation	NN	O
of	IN	O
the	DT	O
auditory	NN	O
steady	JJ	O
state	NN	O
response	NN	O
and	CC	O
bispectral	JJ	O
index	NN	O
in	IN	O
human	JJ	O
volunteers	NNS	O
.	.	O

BACKGROUND	IN	O
It	PRP	O
is	VBZ	O
postulated	VBN	O
that	IN	O
alteration	NN	O
of	IN	O
central	JJ	O
cholinergic	JJ	O
transmission	NN	O
plays	VBZ	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
the	DT	O
mechanism	NN	O
by	IN	O
which	WDT	O
anesthetics	NNS	O
produce	VBP	O
unconsciousness	JJ	O
.	.	O

The	DT	O
authors	NNS	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
altering	VBG	O
central	JJ	O
cholinergic	JJ	O
transmission	NN	O
,	,	O
by	IN	O
physostigmine	NN	Pharmacological
and	CC	O
scopolamine	NN	Pharmacological
,	,	O
on	IN	O
unconsciousness	NN	O
produced	VBN	O
by	IN	O
propofol	NN	O
.	.	O

METHODS	NNP	O
Propofol	NNP	Pharmacological
was	VBD	O
administered	VBN	O
to	TO	O
American	NNP	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
physical	JJ	O
status	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
volunteers	NNS	O
with	IN	O
use	NN	O
of	IN	O
a	DT	O
computer-controlled	JJ	O
infusion	NN	O
pump	NN	O
at	IN	O
increasing	VBG	O
concentrations	NNS	O
until	IN	O
unconsciousness	JJ	O
resulted	VBD	O
(	(	O
inability	NN	O
to	TO	O
respond	VB	O
to	TO	O
verbal	VB	O
commands	NNS	O
,	,	O
abolition	NN	O
of	IN	O
spontaneous	JJ	O
movement	NN	O
)	)	O
.	.	O

Central	NNP	O
nervous	JJ	O
system	NN	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
use	NN	O
of	IN	O
the	DT	O
Auditory	NNP	O
Steady	NNP	O
State	NNP	O
Response	NNP	O
(	(	O
ASSR	NNP	O
)	)	O
and	CC	O
Bispectral	NNP	O
Index	NNP	O
(	(	O
BIS	NNP	O
)	)	O
analysis	NN	O
of	IN	O
electrooculogram	NN	O
.	.	O

During	IN	O
continuous	JJ	O
administration	NN	O
of	IN	O
propofol	NN	O
,	,	O
reversal	NN	O
of	IN	O
unconsciousness	NN	O
produced	VBN	O
by	IN	O
physostigmine	NN	Pharmacological
(	(	O
28	CD	O
microgram/kg	NN	O
)	)	O
and	CC	O
block	NN	O
of	IN	O
this	DT	O
reversal	NN	O
by	IN	O
scopolamine	NN	Pharmacological
(	(	O
8.6	CD	O
microgram/kg	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Propofol	NNP	O
produced	VBD	O
unconsciousness	JJ	O
at	IN	O
a	DT	O
plasma	JJ	O
concentration	NN	O
of	IN	O
3.2	CD	O
+/-	JJ	O
0.8	CD	O
(	(	O
+/-	JJ	O
SD	NNP	O
)	)	O
microgram/ml	NN	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
.	.	O

Unconsciousness	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reductions	NNS	O
in	IN	O
ASSR	NNP	O
(	(	O
0.10	CD	O
+/-	JJ	O
0.08	CD	O
microV	NN	O
[	NNP	O
awake	VBP	O
baseline	JJ	O
0.32	CD	O
+/-	JJ	O
0.18	CD	O
microV	NN	O
]	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
BIS	NNP	O
(	(	O
55.7	CD	O
+/-	JJ	O
8.8	CD	O
[	JJ	O
awake	NN	O
baseline	NN	O
92.4	CD	O
+/-	JJ	O
3.9	CD	O
]	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Physostigmine	NNP	O
restored	VBD	O
consciousness	NN	O
in	IN	O
9	CD	O
of	IN	O
11	CD	O
subjects	NNS	O
,	,	O
with	IN	O
concomitant	JJ	O
increases	NNS	O
in	IN	O
ASSR	NNP	O
(	(	O
0.38	CD	O
+/-	JJ	O
0.17	CD	O
microV	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
BIS	NNP	O
(	(	O
75.3	CD	O
+/-	JJ	O
8.3	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
all	DT	O
subjects	NNS	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
scopolamine	NN	O
blocked	VBD	O
the	DT	O
physostigmine-induced	JJ	O
reversal	NN	O
of	IN	O
unconsciousness	NN	O
and	CC	O
the	DT	O
increase	NN	O
of	IN	O
the	DT	O
ASSR	NNP	O
and	CC	O
BIS	NNP	O
(	(	O
ASSR	NNP	O
and	CC	O
BIS	NNP	O
during	IN	O
propofol-induced	JJ	O
unconsciousness	NN	O
:	:	O
0.09	CD	O
+/-	JJ	O
0.09	CD	O
microV	NN	O
and	CC	O
58.2	CD	O
+/-	JJ	O
7.5	CD	O
,	,	O
respectively	RB	O
;	:	O
ASSR	NNP	O
and	CC	O
BIS	NNP	O
after	IN	O
physostigmine	JJ	O
administration	NN	O
:	:	O
0.08	CD	O
+/-	JJ	O
0.06	CD	O
microV	NN	O
and	CC	O
56.8	CD	O
+/-	JJ	O
6.7	CD	O
,	,	O
respectively	RB	O
,	,	O
NS	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
unconsciousness	NN	O
produced	VBN	O
by	IN	O
propofol	NN	O
is	VBZ	O
mediated	VBN	O
at	IN	O
least	JJS	O
in	IN	O
part	NN	O
via	IN	O
interruption	NN	O
of	IN	O
central	JJ	O
cholinergic	NN	O
muscarinic	JJ	O
transmission	NN	O
.	.	O

Effects	NNS	O
of	IN	O
tonabersat	NN	Pharmacological
on	IN	O
migraine	NN	O
with	IN	O
aura	NN	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Migraine	NNP	O
with	IN	O
aura	NN	O
is	VBZ	O
thought	VBN	O
likely	RB	O
to	TO	O
be	VB	O
caused	VBN	O
by	IN	O
cortical	JJ	O
spreading	VBG	O
depression	NN	O
(	(	O
CSD	NNP	O
)	)	O
.	.	O

Tonabersat	NNP	Pharmacological
inhibits	VBZ	O
CSD	NNP	O
,	,	O
and	CC	O
we	PRP	O
therefore	RB	O
investigated	VBD	O
whether	IN	O
tonabersat	NN	O
has	VBZ	O
a	DT	O
preventive	JJ	O
effect	NN	O
in	IN	O
migraine	NN	O
with	IN	O
aura	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
trial	NN	O
,	,	O
40	CD	O
mg	NN	O
tonabersat	NN	Pharmacological
once	IN	O
daily	JJ	O
was	VBD	O
compared	VBN	O
with	IN	O
matched	JJ	O
placebo	NN	Control
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
aura	NN	O
attack	NN	O
per	IN	O
month	NN	O
during	IN	O
the	DT	O
past	JJ	O
3	CD	O
months	NNS	O
.	.	O

Randomisation	NN	O
was	VBD	O
by	IN	O
computer-generated	JJ	O
list	NN	O
.	.	O

Patients	NNS	O
kept	VBD	O
a	DT	O
detailed	JJ	O
diary	NN	O
to	TO	O
enable	VB	O
objective	JJ	O
diagnosis	NN	O
of	IN	O
each	DT	O
attack	NN	O
as	IN	O
migraine	NN	O
with	IN	O
aura	NN	O
,	,	O
migraine	NN	O
without	IN	O
aura	NN	O
,	,	O
or	CC	O
other	JJ	O
type	NN	O
of	IN	O
headache	NN	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
were	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
aura	NN	O
attacks	NNS	O
with	IN	O
or	CC	O
without	IN	O
headache	NN	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
migraine	JJ	O
headache	NN	O
days	NNS	O
with	IN	O
or	CC	O
without	IN	O
an	DT	O
aura	NN	O
.	.	O

Analysis	NN	O
was	VBD	O
per	IN	O
protocol	NN	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
,	,	O
number	NN	O
NCT00332007	NNP	O
.	.	O

FINDINGS	NNP	O
39	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
of	IN	O
whom	WP	O
31	CD	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
statistical	JJ	O
analysis	NN	O
of	IN	O
efficacy	NN	O
.	.	O

Median	JJ	O
(	(	O
IQR	NNP	O
)	)	O
attacks	NNS	O
of	IN	O
aura	NN	O
were	VBD	O
reduced	VBN	O
from	IN	O
3.2	CD	O
(	(	O
1.0-5.0	JJ	O
)	)	O
per	IN	O
12	CD	O
weeks	NNS	O
on	IN	O
placebo	NN	Control
to	TO	O
1.0	CD	O
(	(	O
0-3.0	CD	O
)	)	O
on	IN	O
tonabersat	NN	O
(	(	O
p=0.01	NN	O
)	)	O
,	,	O
whereas	VBP	O
the	DT	O
other	JJ	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
,	,	O
median	JJ	O
migraine	NN	O
headache	NN	O
days	NNS	O
with	IN	O
or	CC	O
without	IN	O
aura	NN	O
,	,	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
placebo	NN	Control
and	CC	O
tonabersat	NN	Pharmacological
groups	NNS	O
(	(	O
3.0	CD	O
days	NNS	O
in	IN	O
each	DT	O
group	NN	O
;	:	O
p=0.09	NN	O
)	)	O
.	.	O

Tonabersat	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
but	CC	O
overall	JJ	O
had	VBD	O
more	RBR	O
side-effects	NNS	O
than	IN	O
placebo	NN	O
.	.	O

INTERPRETATION	NNP	O
Tonabersat	NNP	Pharmacological
showed	VBD	O
a	DT	O
preventive	JJ	O
effect	NN	O
on	IN	O
attacks	NNS	O
of	IN	O
migraine	NN	O
aura	NN	O
but	CC	O
no	DT	O
efficacy	NN	O
on	IN	O
non-aura	JJ	O
attacks	NNS	O
,	,	O
in	IN	O
keeping	VBG	O
with	IN	O
its	PRP$	O
known	JJ	O
inhibitory	JJ	O
effect	NN	O
on	IN	O
CSD	NNP	O
.	.	O

The	DT	O
results	NNS	O
support	VBD	O
the	DT	O
theory	NN	O
that	IN	O
auras	NNS	O
are	VBP	O
caused	VBN	O
by	IN	O
CSD	NNP	O
and	CC	O
that	IN	O
this	DT	O
phenomenon	NN	O
is	VBZ	O
not	RB	O
involved	VBN	O
in	IN	O
attacks	NNS	O
without	IN	O
aura	NN	O
.	.	O

FUNDING	NN	O
Minster	NNP	O
Pharmaceuticals	NNP	O
;	:	O
Lundbeck	NNP	O
Foundation	NNP	O
.	.	O

Dose	NNP	O
response	NN	O
effect	NN	O
of	IN	O
cyclical	JJ	Pharmacological
medroxyprogesterone	NN	Pharmacological
on	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

OBJECTIVE	VB	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
with	IN	O
placebo	PDT	Control
the	DT	O
dose-response	JJ	O
effect	NN	O
of	IN	O
cyclical	JJ	O
doses	NNS	O
of	IN	O
the	DT	O
C21	NNP	Pharmacological
progestogen	NN	Pharmacological
,	,	O
medroxyprogesterone	NN	Pharmacological
acetate	NN	Pharmacological
(	(	O
MPA	NNP	O
)	)	O
on	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
when	WRB	O
administered	VBN	O
to	TO	O
normotensive	JJ	O
postmenopausal	NN	O
women	NNS	O
receiving	VBG	O
a	DT	O
fixed	JJ	O
mid-range	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
conjugated	JJ	Pharmacological
equine	NN	Pharmacological
oestrogen	NN	Pharmacological
(	(	Pharmacological
CEE	NNP	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Twenty	NNP	O
normotensive	JJ	O
postmenopausal	NN	O
women	NNS	O
(	(	O
median	JJ	O
age	NN	O
53	CD	O
years	NNS	O
)	)	O
participated	VBD	O
in	IN	O
the	DT	O
study	NN	O
which	WDT	O
used	VBD	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
design	NN	O
.	.	O

There	EX	O
were	VBD	O
four	CD	O
randomised	VBN	O
treatment	NN	O
phases	NNS	O
,	,	O
each	DT	O
of	IN	O
4	CD	O
weeks	NNS	O
duration	NN	O
.	.	O

The	DT	O
four	CD	O
blinded	VBD	O
treatments	NNS	O
were	VBD	O
MPA	NNP	Pharmacological
2.5	CD	O
mg	NN	O
,	,	O
MPA	NNP	Pharmacological
5	CD	O
mg	NN	O
,	,	O
MPA	NNP	Pharmacological
10	CD	O
mg	NN	O
and	CC	O
matching	VBG	O
placebo	NN	Control
,	,	O
taken	VBN	O
for	IN	O
the	DT	O
last	JJ	O
14	CD	O
days	NNS	O
of	IN	O
each	DT	O
28	CD	O
day	NN	O
treatment	NN	O
cycle	NN	O
.	.	O

CEE	NNP	O
0.625	CD	O
mg	NN	O
was	VBD	O
also	RB	O
administered	VBN	O
once	RB	O
daily	JJ	O
as	IN	O
open	JJ	O
labelled	VBD	O
tablets	NNS	O
to	TO	O
all	DT	O
subjects	NNS	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Clinic	NNP	O
BP	NNP	O
was	VBD	O
measured	VBN	O
weekly	RB	O
with	IN	O
the	DT	O
mean	JJ	O
values	NNS	O
of	IN	O
weeks	NNS	O
3	CD	O
and	CC	O
4	CD	O
of	IN	O
each	DT	O
phase	NN	O
used	VBN	O
for	IN	O
analysis	NN	O
.	.	O

Ambulatory	NNP	O
BP	NNP	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
final	JJ	O
week	NN	O
of	IN	O
each	DT	O
phase	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
the	DT	O
placebo	NN	O
phase	NN	O
,	,	O
end	NN	O
of	IN	O
phase	NN	O
clinic	JJ	O
BP	NNP	O
was	VBD	O
unchanged	JJ	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
progestogen	NN	O
treatments	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose-dependent	JJ	O
decrease	NN	O
in	IN	O
ambulatory	JJ	O
daytime	JJ	O
diastolic	NN	O
and	CC	O
mean	JJ	O
arterial	JJ	O
BP	NNP	O
with	IN	O
the	DT	O
progestogen	NN	O
treatments	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
a	DT	O
regimen	NN	O
of	IN	O
postmenopausal	NN	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
with	IN	O
a	DT	O
fixed	JJ	O
mid-range	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
CEE	NNP	O
combined	VBD	O
with	IN	O
a	DT	O
cyclical	JJ	O
regimen	NN	O
of	IN	O
a	DT	O
C21	NNP	O
progestogen	NN	O
spanning	VBG	O
the	DT	O
current	JJ	O
clinical	JJ	O
dose	NN	O
range	NN	O
,	,	O
the	DT	O
progestogen	NN	Pharmacological
has	VBZ	O
either	CC	O
no	DT	O
effect	NN	O
or	CC	O
a	DT	O
small	JJ	O
dose-dependent	JJ	O
reduction	NN	O
in	IN	O
clinic	NN	O
and	CC	O
ambulatory	JJ	O
BPs	NNP	O
over	IN	O
one	CD	O
treatment	NN	O
cycle	NN	O
.	.	O

Effect	NN	O
of	IN	O
patient	NN	O
withdrawal	NN	O
on	IN	O
a	DT	O
study	NN	O
evaluating	VBG	O
pharmacist	JJ	Other
management	NN	Other
of	IN	Other
hypertension	NN	Other
.	.	O

STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
examine	VB	O
potential	JJ	O
threats	NNS	O
to	TO	O
internal	JJ	O
and	CC	O
external	JJ	O
study	NN	O
validity	NN	O
caused	VBN	O
by	IN	O
differential	JJ	O
patient	NN	O
withdrawal	NN	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
evaluating	VBG	O
pharmacist	JJ	O
management	NN	O
of	IN	O
hypertension	NN	O
,	,	O
to	TO	O
compare	VB	O
the	DT	O
characteristics	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
withdrew	VBP	O
with	IN	O
those	DT	O
of	IN	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
to	TO	O
identify	VB	O
characteristics	NNS	O
that	WDT	O
predispose	VBP	O
patients	NNS	O
to	TO	O
withdraw	VB	O
from	IN	O
hypertension	NN	O
management	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
comparative	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Network	NNP	O
of	IN	O
primary	JJ	O
care	NN	O
clinics	NNS	O
.	.	O

PATIENTS	VB	O
Four	CD	O
hundred	JJ	O
sixty-three	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
hypertension	NN	O
and	CC	O
a	DT	O
last	JJ	O
documented	JJ	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
of	IN	O
160	CD	O
mm	NNS	O
Hg	NNP	O
or	CC	O
greater	JJR	O
and/or	NNS	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
of	IN	O
100	CD	O
mm	NNS	O
Hg	NNP	O
or	CC	O
greater	JJR	O
.	.	O

INTERVENTION	NN	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
pharmacist	NN	Other
intervention	NN	Other
or	CC	O
usual-care	JJ	Control
(	(	Control
control	NN	Control
)	)	Control
group	NN	Other
.	.	O

Those	DT	O
in	IN	O
the	DT	O
pharmacist	NN	O
intervention	NN	O
group	NN	O
were	VBD	O
collaboratively	RB	O
managed	VBN	Other
by	IN	Other
a	DT	Other
primary	JJ	Other
care	NN	Other
clinical	JJ	Other
pharmacy	NN	Other
specialist	NN	Other
and	CC	Other
their	PRP$	Other
primary	JJ	Other
care	NN	Other
provider	NN	Other
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
usual	JJ	Control
care	NN	Control
from	IN	O
only	RB	O
their	PRP$	O
primary	JJ	Other
care	NN	Other
provider	NN	Other
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Of	IN	O
the	DT	O
463	CD	O
patients	NNS	O
,	,	O
191	CD	O
(	(	O
41	CD	O
%	NN	O
)	)	O
withdrew	NN	O
from	IN	O
the	DT	O
study	NN	O
after	IN	O
randomization	NN	O
and	CC	O
272	CD	O
(	(	O
59	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
who	WP	O
withdrew	VBP	O
from	IN	O
the	DT	O
pharmacist	NN	Other
intervention	NN	Other
group	NN	O
were	VBD	O
similar	JJ	O
to	TO	O
patients	NNS	O
who	WP	O
withdrew	VBP	O
from	IN	O
the	DT	O
usual-care	JJ	O
group	NN	O
with	IN	O
respect	NN	O
to	TO	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
insurance	NN	O
status	NN	O
,	,	O
and	CC	O
chronic	JJ	O
conditions	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
smoked	VBD	O
or	CC	O
had	VBD	O
commercial	JJ	O
insurance	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
withdraw	VB	O
from	IN	O
the	DT	O
study	NN	O
than	IN	O
the	DT	O
other	JJ	O
participants	NNS	O
.	.	O

However	RB	O
,	,	O
multivariate	JJ	O
analysis	NN	O
of	IN	O
all	DT	O
variables	NNS	O
,	,	O
when	WRB	O
adjusted	VBN	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
intervention	NN	O
,	,	O
revealed	VBD	O
that	IN	O
insurance	NN	O
status	NN	O
was	VBD	O
the	DT	O
only	JJ	O
variable	NN	O
associated	VBN	O
with	IN	O
a	DT	O
heightened	JJ	O
probability	NN	O
of	IN	O
withdrawal	NN	O
(	(	O
p=0.002	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
this	DT	O
study	NN	O
had	VBD	O
a	DT	O
high	JJ	O
withdrawal	NN	O
rate	NN	O
,	,	O
between-group	JJ	O
patient	NN	O
characteristics	NNS	O
remained	VBD	O
balanced	JJ	O
.	.	O

Therefore	RB	O
,	,	O
internal	JJ	O
validity	NN	O
was	VBD	O
preserved	VBN	O
,	,	O
and	CC	O
outcomes	RB	O
from	IN	O
the	DT	O
study	NN	O
groups	NNS	O
could	MD	O
be	VB	O
reliably	RB	O
compared	VBN	O
.	.	O

A	DT	O
lack	NN	O
of	IN	O
significant	JJ	O
differences	NNS	O
between	IN	O
patients	NNS	O
who	WP	O
withdrew	VBD	O
versus	FW	O
those	DT	O
who	WP	O
completed	VBD	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
insurance	NN	O
status	NN	O
,	,	O
suggests	VBZ	O
that	IN	O
external	JJ	O
validity	NN	O
was	VBD	O
not	RB	O
jeopardized	VBN	O
.	.	O

Dissociation	NN	O
between	IN	O
cortical	JJ	O
activation	NN	O
and	CC	O
cognitive	JJ	O
performance	NN	O
under	IN	O
pharmacological	JJ	O
blood	NN	O
pressure	NN	O
elevation	NN	O
in	IN	O
chronic	JJ	O
hypotension	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
explored	VBD	O
the	DT	O
impact	NN	O
of	IN	O
pharmacological	JJ	Pharmacological
blood	NN	Pharmacological
pressure	NN	Pharmacological
elevation	NN	Pharmacological
on	IN	O
cortical	JJ	O
activation	NN	O
and	CC	O
reaction	NN	O
time	NN	O
in	IN	O
chronic	JJ	O
hypotension	NN	O
.	.	O

Effects	NNS	O
of	IN	O
the	DT	O
sympathomimetic	JJ	O
etilefrine	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
50	CD	O
hypotensive	JJ	O
persons	NNS	O
based	VBN	O
on	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	Control
double	JJ	O
blind	NN	O
design	NN	O
.	.	O

As	IN	O
an	DT	O
indicator	NN	O
of	IN	O
cortical	JJ	O
excitability	NN	O
,	,	O
the	DT	O
contingent	NN	O
negative	JJ	O
variation	NN	O
(	(	O
CNV	NNP	O
)	)	O
,	,	O
induced	VBN	O
by	IN	O
a	DT	O
constant	JJ	O
foreperiod	NN	O
reaction	NN	O
time	NN	O
task	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
at	IN	O
frontal	JJ	O
(	(	O
F3	NNP	O
,	,	O
Fz	NNP	O
,	,	O
F4	NNP	O
)	)	O
and	CC	O
central	JJ	O
(	(	O
C3	NNP	O
,	,	O
Cz	NNP	O
,	,	O
C4	NNP	O
)	)	O
scalp	NN	O
sites	NNS	O
.	.	O

Etilefrine	NNP	Pharmacological
provoked	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
frontal	NN	O
and	CC	O
central	JJ	O
CNV	NNP	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
shorter	JJR	O
reaction	NN	O
times	NNS	O
were	VBD	O
observed	JJ	O
following	JJ	O
drug	NN	O
administration	NN	O
.	.	O

The	DT	O
degree	NN	O
of	IN	O
pharmacologically	RB	O
induced	VBN	O
blood	NN	O
pressure	NN	O
elevation	NN	O
was	VBD	O
correlated	VBN	O
to	TO	O
CNV	NNP	O
attrition	NN	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
performance	NN	O
enhancement	NN	O
.	.	O

Inhibitory	JJ	O
effects	NNS	O
of	IN	O
baroreceptor	NN	O
activation	NN	O
on	IN	O
cortical	JJ	O
excitability	NN	O
and	CC	O
enhanced	VBD	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
mediating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
blood	NN	O
pressure	NN	O
elevation	NN	O
on	IN	O
cerebral	JJ	O
functioning	NN	O
.	.	O

Implications	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
hypotension	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
thiopentone/guaifenesin	NN	Pharmacological
,	,	O
ketamine/guaifenesin	NN	Pharmacological
and	CC	O
ketamine/midazolam	NN	Pharmacological
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
horses	NNS	O
to	TO	O
be	VB	O
anaesthetised	VBN	O
with	IN	O
isoflurane	NN	O
.	.	O

Forty-eight	JJ	O
horses	NNS	O
subjected	VBN	O
to	TO	O
elective	VB	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
of	IN	O
16	CD	O
horses	NNS	O
.	.	O

After	IN	O
premedication	NN	O
with	IN	O
0.1	CD	O
mg/kg	NNS	O
acepromazine	VBP	Pharmacological
intramuscularly	RB	O
and	CC	O
0.6	CD	O
mg/kg	NNS	O
xylazine	JJ	Pharmacological
intravenously	RB	O
,	,	O
anaesthesia	NN	O
was	VBD	O
induced	VBN	O
either	RB	O
with	IN	O
2	CD	O
g	NNS	O
thiopentone	NN	Pharmacological
in	IN	O
500	CD	O
ml	NN	O
of	IN	O
a	DT	O
10	CD	O
per	IN	O
cent	NN	O
guaifenesin	NN	Pharmacological
solution	NN	O
,	,	O
given	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
ml/kg	NNS	O
(	(	O
group	NN	O
TG	NNP	O
)	)	O
,	,	O
or	CC	O
with	IN	O
100	CD	O
mg/kg	NNS	O
guaifenesin	NN	Pharmacological
and	CC	O
2.2	CD	O
mg/kg	NN	O
ketamine	NN	Pharmacological
given	VBN	O
intravenously	RB	O
(	(	O
group	NN	O
KG	NNP	O
)	)	O
,	,	O
or	CC	O
with	IN	O
0.06	CD	O
mg/kg	NNS	O
midazolam	NN	Pharmacological
,	,	O
and	CC	O
2.2	CD	O
mg/kg	NN	O
ketamine	NN	Pharmacological
given	VBN	O
intravenously	RB	O
(	(	O
group	NN	O
KM	NNP	O
)	)	O
.	.	O

Anaesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
isoflurane	NN	Pharmacological
.	.	Pharmacological

The	DT	O
mean	NN	O
(	(	O
sd	NN	O
)	)	O
end	NN	O
tidal	JJ	O
isoflurane	NN	Pharmacological
concentration	NN	O
(	(	O
per	IN	O
cent	NN	O
)	)	O
needed	VBD	O
to	TO	O
maintain	VB	O
a	DT	O
light	JJ	O
surgical	JJ	O
anaesthesia	NN	O
(	(	O
stage	NN	O
III	NNP	O
,	,	O
plane	NN	O
2	CD	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
KM	NNP	O
(	(	O
0.91	CD	O
[	RB	O
0.03	CD	O
]	NN	O
)	)	O
than	IN	O
in	IN	O
groups	NNS	O
TG	NNP	O
(	(	O
1.11	CD	O
[	RB	O
0.03	CD	O
]	NN	O
)	)	O
and	CC	O
KG	NNP	O
(	(	O
1.14	CD	O
[	RB	O
0.03	CD	O
]	NN	O
)	)	O
.	.	O

The	DT	O
mean	NN	O
(	(	O
sd	NN	O
)	)	O
arterial	JJ	O
pressure	NN	O
(	(	O
mmHg	NN	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
KG	NNP	O
(	(	O
67.4	CD	O
[	RB	O
2.07	CD	O
]	NN	O
)	)	O
than	IN	O
in	IN	O
groups	NNS	O
TC	NNP	O
(	(	O
75.6	CD	O
[	RB	O
2.23	CD	O
]	NN	O
)	)	O
and	CC	O
KM	NNP	O
(	(	O
81.0	CD	O
[	RB	O
2.16	CD	O
]	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
logarithm	NN	O
of	IN	O
the	DT	O
heart	NN	O
rate	NN	O
,	,	O
recovery	NN	O
time	NN	O
or	CC	O
quality	NN	O
of	IN	O
recovery	NN	O
between	IN	O
the	DT	O
three	CD	O
induction	NN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
pronounced	VBD	O
ataxia	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
horses	NNS	O
of	IN	O
group	NN	O
KM	NNP	O
,	,	O
especially	RB	O
after	IN	O
periods	NNS	O
of	IN	O
anaesthesia	NN	O
lasting	VBG	O
less	JJR	O
than	IN	O
75	CD	O
minutes	NNS	O
.	.	O

Transcutaneous	JJ	Physical
electrical	JJ	Physical
nerve	NN	Physical
stimulation	NN	Physical
following	VBG	O
appendicectomy	NN	O
:	:	O
the	DT	O
placebo	NN	O
effect	NN	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
transcutaneous	JJ	Physical
electrical	JJ	Physical
nerve	NN	Physical
stimulation	NN	Physical
(	(	Physical
TENS	NNP	Physical
)	)	Physical
with	IN	O
standard	JJ	O
intramuscular	JJ	O
opiate	NN	Pharmacological
analgesia	NN	Pharmacological
in	IN	O
the	DT	O
management	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
following	VBG	O
appendicectomy	NN	O
.	.	O

Consecutive	JJ	O
patients	NNS	O
undergoing	VBG	O
emergency	NN	Surgical
appendicectomy	NN	Surgical
were	VBD	O
randomised	VBN	O
into	IN	O
control	NN	O
,	,	O
sham	NN	Physical
TENS	NNP	Physical
and	CC	O
active	JJ	Physical
TENS	NNP	Physical
groups	NNS	Physical
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
pain	NN	O
severity	NN	O
and	CC	O
analgesic	JJ	O
intake	NN	O
in	IN	O
both	DT	O
active	JJ	Physical
and	CC	Physical
sham	JJ	Physical
TENS	NNP	Physical
groups	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	Control
group	NN	Control
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
pain	NN	O
severity	NN	O
between	IN	O
active	JJ	Physical
and	CC	Physical
sham	JJ	Physical
TENS	NNP	Physical
groups	NNS	O
but	CC	O
the	DT	O
active	JJ	Physical
TENS	NNP	Physical
group	NN	O
required	VBD	O
slightly	RB	O
less	JJR	O
analgesia	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
major	JJ	O
benefit	NN	O
of	IN	O
TENS	NNP	Physical
in	IN	O
the	DT	O
postappendicectomy	NN	O
patient	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
its	PRP$	O
'placebo	JJ	O
effect	NN	O
'	POS	O
and	CC	O
its	PRP$	O
use	NN	O
in	IN	O
this	DT	O
situation	NN	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
.	.	O

The	DT	O
dipeptidyl	JJ	Pharmacological
peptidase-4	JJ	Pharmacological
inhibitor	NN	Pharmacological
PHX1149	NNP	Pharmacological
improves	VBZ	O
blood	NN	O
glucose	NN	O
control	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
mellitus	RB	O
.	.	O

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
PHX1149	NNP	Pharmacological
,	,	O
a	DT	O
novel	JJ	O
dipeptidyl	NN	O
peptidase-4	NN	O
(	(	O
DPP4	NNP	O
)	)	O
inhibitor	NN	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
is	VBZ	O
a	DT	O
multicentre	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
4-week	JJ	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
with	IN	O
suboptimal	JJ	O
metabolic	JJ	O
control	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
baseline	NN	O
haemoglobin	NN	O
A	NNP	O
(	(	O
1c	CD	O
)	)	O
(	(	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
)	)	O
of	IN	O
7.3	CD	O
to	TO	O
11.0	CD	O
%	NN	O
were	VBD	O
randomized	VBN	O
1	CD	O
:	:	O
1	CD	O
:	:	O
1	CD	O
:	:	O
1	CD	O
to	TO	O
receive	VB	O
once-daily	JJ	O
oral	JJ	O
therapy	NN	O
with	IN	O
either	DT	O
PHX1149	NNP	Pharmacological
(	(	O
100	CD	O
,	,	O
200	CD	O
or	CC	O
400	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	Control
;	:	O
patients	NNS	O
were	VBD	O
on	IN	O
a	DT	O
constant	JJ	O
background	NN	O
therapy	NN	O
of	IN	O
either	DT	O
metformin	NN	O
alone	RB	O
or	CC	O
metformin	JJ	O
plus	CC	O
a	DT	O
glitazone	NN	O
.	.	O

RESULTS	NNP	O
Treatment	NNP	O
with	IN	O
100	CD	O
,	,	O
200	CD	O
or	CC	O
400	CD	O
mg	NN	O
of	IN	O
PHX1149	NNP	O
significantly	RB	O
decreased	VBD	O
postprandial	JJ	O
glucose	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
AUC	NNP	O
(	(	O
0-2	JJ	O
h	NN	O
)	)	O
by	IN	O
approximately	RB	O
20	CD	O
%	NN	O
(	(	O
+0.11	JJ	O
+/-	JJ	O
0.50	CD	O
,	,	O
-2.08	VBD	O
+/-	JJ	O
0.51	CD	O
,	,	O
-1.73	VBD	O
+/-	JJ	O
0.49	CD	O
and	CC	O
-1.88	VB	O
+/-	JJ	O
0.48	CD	O
mmol/l	NN	O
x	NN	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
placebo	NN	O
and	CC	O
100	CD	O
,	,	O
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
(	(	O
p	JJ	O
=	NN	O
0.002	CD	O
,	,	O
0.008	CD	O
and	CC	O
0.004	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Postprandial	JJ	O
AUC	NNP	O
(	(	O
0-2	JJ	O
h	NN	O
)	)	O
of	IN	O
intact	JJ	O
glucagon-like	JJ	O
peptide-1	NN	O
,	,	O
the	DT	O
principal	JJ	O
mediator	NN	O
of	IN	O
the	DT	O
biological	JJ	O
effects	NNS	O
of	IN	O
DPP4	NNP	O
inhibitors	NNS	O
,	,	O
was	VBD	O
increased	VBN	O
by	IN	O
3.90	CD	O
+/-	JJ	O
2.83	CD	O
,	,	O
11.63	CD	O
+/-	JJ	O
2.86	CD	O
,	,	O
16.42	CD	O
+/-	JJ	O
2.72	CD	O
and	CC	O
15.75	CD	O
+/-	JJ	O
2.71	CD	O
pmol/l	NN	O
x	NN	O
h	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
placebo	NN	O
and	CC	O
100	CD	O
,	,	O
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
(	(	O
p	JJ	O
=	NN	O
0.053	CD	O
,	,	O
0.001	CD	O
and	CC	O
0.002	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

Mean	JJ	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
was	VBD	O
lower	JJR	O
in	IN	O
all	DT	O
dose	JJ	O
groups	NNS	O
;	:	O
the	DT	O
placebo-corrected	JJ	O
change	NN	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
400	CD	O
mg	JJ	O
PHX1149	NNP	O
was	VBD	O
-0.28	VBN	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

DPP4	NNP	O
inhibition	NN	O
on	IN	O
day	NN	O
28	CD	O
was	VBD	O
53	CD	O
,	,	O
73	CD	O
and	CC	O
78	CD	O
%	NN	O
at	IN	O
24	CD	O
h	NN	O
postdose	NN	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
100	CD	O
,	,	O
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
PHX1149	NNP	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
adverse	JJ	O
events	NNS	O
between	IN	O
PHX1149-treated	NNP	O
and	CC	O
placebo	JJ	O
subjects	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Addition	NNP	O
of	IN	O
the	DT	O
DPP4	NNP	O
inhibitor	NN	O
PHX1149	NNP	O
to	TO	O
a	DT	O
stable	JJ	O
regimen	NN	O
of	IN	O
metformin	NN	O
or	CC	O
metformin	NN	O
plus	CC	O
a	DT	O
glitazone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
improved	VBN	O
blood	NN	O
glucose	NN	O
control	NN	O
.	.	O

Long	RB	Surgical
pediatric	JJ	Surgical
colonoscope	NN	Surgical
versus	NN	O
intermediate	JJ	Surgical
length	NN	Surgical
adult	NN	Surgical
colonoscope	NN	Surgical
for	IN	O
colonoscopy	NN	O
.	.	O

BACKGROUND	NNP	O
Controversy	NNP	O
exists	VBZ	O
on	IN	O
how	WRB	O
the	DT	O
length	NN	O
and	CC	O
diameter	NN	O
of	IN	O
colonoscopes	NNS	O
affect	VBP	O
the	DT	O
quality	NN	O
of	IN	O
colonoscopy	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
long	JJ	Surgical
pediatric	JJ	Surgical
colonoscope	NN	Surgical
with	IN	O
an	DT	O
intermediate	JJ	Surgical
length	NN	Surgical
adult	NN	Surgical
colonoscope	NN	Surgical
with	IN	O
regards	NNS	O
to	TO	O
completion	NN	O
rate	NN	O
and	CC	O
cecal	JJ	O
intubation	NN	O
time	NN	O
.	.	O

Whether	CC	O
either	DT	O
scope	NN	O
may	MD	O
be	VB	O
more	RBR	O
efficient	JJ	O
in	IN	O
any	DT	O
subgroups	NN	O
was	VBD	O
also	RB	O
investigated	VBN	O
.	.	O

METHODS	NNP	O
Asymptomatic	JJ	O
patients	NNS	O
admitted	VBN	O
to	TO	O
the	DT	O
physical	JJ	O
check-up	JJ	O
department	NN	O
of	IN	O
Buddhist	NNP	O
Dalin	NNP	O
Tzu	NNP	O
Chi	NNP	O
General	NNP	O
Hospital	NNP	O
were	VBD	O
included	VBN	O
.	.	O

A	DT	O
single	JJ	O
endoscopist	NN	O
performed	VBD	O
all	DT	O
of	IN	O
the	DT	O
colonoscopic	NN	Physical
examinations	NNS	Physical
under	IN	O
sedation	NN	O
.	.	O

Consecutive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
undergo	VB	O
colonoscopy	NN	Surgical
with	IN	Surgical
either	DT	Surgical
intermediate	JJ	Surgical
length	NN	Surgical
adult	NN	Surgical
colonoscope	NN	Surgical
(	(	Surgical
CF-240I	NNP	Surgical
)	)	Surgical
or	CC	O
long	JJ	Surgical
pediatric	JJ	Surgical
colonoscope	NN	Surgical
(	(	Surgical
PCF-240L	NNP	Surgical
)	)	Surgical
.	.	O

The	DT	O
success	NN	O
rate	NN	O
and	CC	O
time	NN	O
required	VBN	O
to	TO	O
reach	VB	O
cecum	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
April	NNP	O
2005	CD	O
and	CC	O
February	NNP	O
2006	CD	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
918	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Incomplete	NNP	O
colonoscopy	NN	O
occurred	VBD	O
in	IN	O
21	CD	O
(	(	O
2.3	CD	O
%	NN	O
)	)	O
cases	NNS	O
(	(	O
14	CD	O
in	IN	O
the	DT	O
CF-240I	NNP	O
group	NN	O
and	CC	O
seven	CD	O
in	IN	O
the	DT	O
PCF-240L	NNP	O
group	NN	O
,	,	O
P	NNP	O
>	NNP	O
0.1	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
cecal	JJ	O
mean	NN	O
insertion	NN	O
time	NN	O
was	VBD	O
6.00	CD	O
+/-	JJ	O
3.66	CD	O
min	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
CF-240I	NNP	Surgical
and	CC	O
PCF	NNP	Surgical
240L	CD	Surgical
groups	NNS	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
cecal	JJ	O
intubation	NN	O
rate	NN	O
(	(	O
96.9	CD	O
%	NN	O
vs	JJ	O
98.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.18	CD	O
)	)	O
,	,	O
the	DT	O
need	NN	O
for	IN	O
abdominal	JJ	O
pressure	NN	O
(	(	O
71.7	CD	O
%	NN	O
vs	JJ	O
73.4	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.55	CD	O
)	)	O
and	CC	O
change	NN	O
of	IN	O
position	NN	O
(	(	O
13.5	CD	O
%	NN	O
vs	JJ	O
11.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.37	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
cecal	JJ	O
intubation	NN	O
time	NN	O
was	VBD	O
shorter	RBR	O
in	IN	O
the	DT	O
CF-240I	NNP	O
group	NN	O
(	(	O
5.75	CD	O
+/-	JJ	O
3.18	CD	O
vs	JJ	O
6.26	CD	O
+/-	JJ	O
3.30	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Subgroup	NNP	O
analysis	NN	O
by	IN	O
sex	NN	O
,	,	O
age	NN	O
,	,	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
showed	VBD	O
comparable	JJ	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
except	IN	O
that	IN	O
the	DT	O
cecal	JJ	O
intubation	NN	O
times	NNS	O
were	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
CF-240I	NNP	O
group	NN	O
when	WRB	O
only	RB	O
men	NNS	O
(	(	O
4.78	CD	O
+/-	JJ	O
2.57	CD	O
vs	JJ	O
5.50	CD	O
+/-	JJ	O
2.93	CD	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
or	CC	O
those	DT	O
younger	JJR	O
than	IN	O
50	CD	O
years	NNS	O
(	(	O
5.50	CD	O
+/-	JJ	O
2.90	CD	O
vs	JJ	O
6.25	CD	O
+/-	JJ	O
3.68	CD	O
min	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
were	VBD	O
considered	VBN	O
.	.	O

CONCLUSION	NNP	O
Cecal	NNP	O
intubation	NN	O
time	NN	O
is	VBZ	O
shorter	RBR	O
in	IN	O
patients	NNS	O
examined	VBN	O
with	IN	O
an	DT	O
intermediate	JJ	Surgical
length	NN	Surgical
adult	NN	Surgical
colonoscope	NN	Surgical
,	,	O
mainly	RB	O
in	IN	O
the	DT	O
subgroups	NNS	O
of	IN	O
men	NNS	O
and	CC	O
those	DT	O
younger	JJR	O
than	IN	O
50	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Effects	NNS	O
of	IN	O
bifidobacterium	NN	Pharmacological
breve	VBP	Pharmacological
supplementation	NN	O
on	IN	O
intestinal	JJ	O
flora	NNS	O
of	IN	O
low	JJ	O
birth	NN	O
weight	NN	O
infants	NNS	O
.	.	O

BACKGROUND	IN	O
It	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
the	DT	O
bifidobacteria	NN	O
flora	VBP	O
play	NN	O
important	JJ	O
roles	NNS	O
in	IN	O
mucosal	NN	O
host	NN	O
defense	NN	O
and	CC	O
can	MD	O
prevent	VB	O
infectious	JJ	O
diseases	NNS	O
.	.	O

Because	IN	O
bacterial	JJ	O
populations	NNS	O
develop	VBP	O
during	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
life	NN	O
,	,	O
the	DT	O
authors	NNS	O
examined	VBD	O
whether	IN	O
the	DT	O
early	JJ	O
administration	NN	O
of	IN	O
bifidobacteria	NN	O
has	VBZ	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
the	DT	O
health	NN	O
of	IN	O
low	JJ	O
birth	NN	O
weight	NN	O
infants	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
effects	NNS	O
of	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
Bifidobacterium	NNP	Pharmacological
breve	NN	Pharmacological
(	(	Pharmacological
B.	NNP	Pharmacological
breve	VBP	Pharmacological
)	)	Pharmacological
supplements	NNS	Pharmacological
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
controlled	JJ	O
trial	NN	O
with	IN	O
low	JJ	O
birth	NN	O
weight	NN	O
infants	NNS	O
(	(	O
average	JJ	O
birth	NN	O
weight	NN	O
1489	CD	O
g	NN	O
)	)	O
.	.	O

The	DT	O
infants	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
Group	NNP	O
A	NNP	O
and	CC	O
B	NNP	O
received	VBD	O
a	DT	O
dose	NN	O
of	IN	O
1.6	CD	O
x	NNS	O
10	CD	O
(	(	O
8	CD	O
)	)	O
cells	NNS	O
of	IN	O
B.	NNP	O
breve	VBP	O
supplement	NN	O
twice	RB	O
a	DT	O
day	NN	O
,	,	O
commencing	VBG	O
either	CC	O
from	IN	O
several	JJ	O
hours	NNS	O
after	IN	O
birth	NN	O
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
24	CD	O
h	NN	O
after	IN	O
birth	NN	O
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Group	NNP	O
C	NNP	O
,	,	O
the	DT	O
control	NN	Control
group	NN	Control
,	,	O
received	VBD	O
no	DT	O
supplement	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
birth	NN	O
weight	NN	O
,	,	O
treatment	NN	O
with	IN	O
antibiotics	NNS	O
,	,	O
and	CC	O
the	DT	O
starting	JJ	O
time	NN	O
of	IN	O
breast-feeding	NN	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

A	DT	O
Bifidobacterium-predominant	JJ	O
flora	NN	O
was	VBD	O
formed	VBN	O
at	IN	O
an	DT	O
average	NN	O
of	IN	O
2	CD	O
weeks	NNS	O
after	IN	O
birth	NN	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
at	IN	O
an	DT	O
average	NN	O
of	IN	O
4	CD	O
weeks	NNS	O
after	IN	O
birth	NN	O
in	IN	O
group	NN	O
B	NNP	O
,	,	O
while	IN	O
no	DT	O
Bifidobacterium	NNP	O
was	VBD	O
isolated	VBN	O
in	IN	O
eight	CD	O
out	IN	O
of	IN	O
10	CD	O
infants	NNS	O
in	IN	O
group	NN	O
C	NNP	O
during	IN	O
the	DT	O
observation	NN	O
period	NN	O
of	IN	O
7	CD	O
weeks	NNS	O
.	.	O

In	IN	O
comparison	NN	O
between	IN	O
group	NN	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
Bifidobacterium	NNP	O
was	VBD	O
detected	VBN	O
significantly	RB	O
earlier	RBR	O
in	IN	O
group	NN	O
A	NNP	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
Enterobacteriaceae	NNP	O
present	NN	O
in	IN	O
the	DT	O
infants	NNS	O
at	IN	O
2	CD	O
weeks	NNS	O
after	IN	O
birth	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
suggest	VBP	O
that	IN	O
very	RB	O
early	JJ	O
administration	NN	O
of	IN	O
B.	NNP	O
breve	VBP	O
to	TO	O
low	JJ	O
birth	NN	O
weight	NN	O
infants	NNS	O
is	VBZ	O
useful	JJ	O
in	IN	O
promoting	VBG	O
the	DT	O
colonization	NN	O
of	IN	O
the	DT	O
Bifidobacterium	NNP	O
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
a	DT	O
normal	JJ	O
intestinal	JJ	O
flora	NN	O
.	.	O

Echocardiographic	JJ	O
evaluation	NN	O
of	IN	O
children	NNS	O
with	IN	O
systemic	JJ	O
ventricular	JJ	O
dysfunction	NN	O
treated	VBN	O
with	IN	O
carvedilol	NN	Pharmacological
.	.	Pharmacological

Echocardiography	NN	Physical
is	VBZ	O
used	VBN	O
to	TO	O
measure	VB	O
the	DT	O
therapeutic	JJ	O
effectiveness	NN	O
of	IN	O
heart	NN	O
failure	NN	O
therapy	NN	O
in	IN	O
adults	NNS	O
and	CC	O
children	NNS	O
.	.	O

The	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
(	(	O
1	CD	O
)	)	O
to	TO	O
assess	VB	O
baseline	JJ	O
echocardiographic	JJ	O
predictors	NNS	O
of	IN	O
clinical	JJ	O
outcome	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
to	TO	O
investigate	VB	O
changes	NNS	O
in	IN	O
echocardiographic	JJ	O
parameters	NNS	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
to	TO	O
compare	VB	O
these	DT	O
echocardiographic	JJ	O
changes	NNS	O
with	IN	O
changes	NNS	O
in	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
b-type	JJ	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
BNP	NNP	O
)	)	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
children	NNS	O
with	IN	O
systemic	JJ	O
ventricular	JJ	O
dysfunction	NN	O
and	CC	O
symptomatic	JJ	O
heart	NN	O
failure	NN	O
treated	VBN	O
with	IN	O
carvedilol	NN	Pharmacological
or	CC	O
placebo	NN	Control
.	.	O

All	DT	O
available	JJ	O
baseline	NN	O
and	CC	O
6-month	JJ	O
echocardiograms	NNS	O
from	IN	O
Pediatric	NNP	O
Carvedilol	NNP	O
Trial	NNP	O
(	(	O
PCT	NNP	O
)	)	O
participants	NNS	O
(	(	O
carvedilol	JJ	Pharmacological
n	RB	O
=	JJ	O
161	CD	O
;	:	O
placebo	NN	Control
n	IN	O
=	$	O
55	CD	O
)	)	O
were	VBD	O
reviewed	VBN	O
.	.	O

Systolic	NNP	O
and	CC	O
diastolic	JJ	O
sphericity	NN	O
index	NN	O
(	(	O
SI	NNP	O
;	:	O
n	CC	O
=	VB	O
110	CD	O
)	)	O
,	,	O
TEI	NNP	O
index	NN	O
(	(	O
n	JJ	O
=	NNP	O
145	CD	O
)	)	O
,	,	O
and	CC	O
systemic	JJ	O
ventricular	NN	O
dP/dt	NN	O
(	(	O
n	JJ	O
=	NNP	O
70	CD	O
)	)	O
were	VBD	O
measured	VBN	O
.	.	O

The	DT	O
PCT	NNP	O
composite	JJ	O
definition	NN	O
of	IN	O
clinical	JJ	O
outcome	NN	O
(	(	O
i.e.	FW	O
,	,	O
worsened	VBD	O
,	,	O
improved	VBN	O
,	,	O
or	CC	O
unchanged	JJ	O
)	)	O
was	VBD	O
used	VBN	O
.	.	O

For	IN	O
all	DT	O
patients	NNS	O
,	,	O
baseline	VBP	O
TEI	NNP	O
index	NN	O
was	VBD	O
a	DT	O
predictor	NN	O
of	IN	O
worsened	JJ	O
outcome	NN	O
.	.	O

Only	RB	O
children	NNS	O
treated	VBD	O
with	IN	O
carvedilol	NN	Pharmacological
showed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
systolic	JJ	O
SI	NNP	O
(	(	O
P	NNP	O
B	NNP	O
0.0001	CD	O
)	)	O
,	,	O
diastolic	JJ	O
SI	NNP	O
(	(	O
P	NNP	O
B	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
TEI	NNP	O
index	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

An	DT	O
inverse	JJ	O
correlation	NN	O
between	IN	O
changes	NNS	O
in	IN	O
BNP	NNP	O
and	CC	O
changes	NNS	O
in	IN	O
dP/dt	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.45	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
was	VBD	O
found	VBN	O
only	RB	O
in	IN	O
the	DT	O
carvedilol	NN	Pharmacological
group	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
TEI	NNP	O
index	NN	O
predicted	VBD	O
outcome	NN	O
in	IN	O
children	NNS	O
with	IN	O
systemic	JJ	O
ventricular	JJ	O
dysfunction	NN	O
and	CC	O
heart	NN	O
failure	NN	O
.	.	O

Carvedilol	NN	Pharmacological
may	MD	O
have	VB	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
reversal	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
remodeling	NN	O
and	CC	O
global	JJ	O
ventricular	NN	O
function	NN	O
in	IN	O
pediatric	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Computer-navigated	JJ	Surgical
versus	NN	O
conventional	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	IN	Surgical
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
literature	NN	O
lacks	VBZ	O
studies	NNS	O
that	IN	O
confirm	VBP	O
whether	IN	O
the	DT	O
improved	JJ	O
radiographic	JJ	O
alignment	NN	O
that	WDT	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
computer-navigated	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
improves	VBZ	O
patients?	JJ	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
or	CC	O
the	DT	O
durability	NN	O
of	IN	O
total	JJ	O
knee	NN	O
prostheses	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
computer-navigated	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
improves	VBZ	O
the	DT	O
clinical	JJ	O
function	NN	O
,	,	O
alignment	NN	O
,	,	O
and	CC	O
survivorship	NN	O
of	IN	O
the	DT	O
components	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
compared	VBN	O
the	DT	O
results	NNS	O
of	IN	O
520	CD	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	O
who	WP	O
underwent	VBD	O
computer-navigated	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
for	IN	O
one	CD	O
knee	NN	O
and	CC	O
conventional	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
for	IN	O
the	DT	O
other	JJ	O
.	.	O

The	DT	O
assignment	NN	O
of	IN	O
the	DT	O
knee	NN	O
to	TO	O
navigation	NN	O
or	CC	O
not	RB	O
was	VBD	O
done	VBN	O
randomly	RB	O
.	.	O

There	EX	O
were	VBD	O
452	CD	O
women	NNS	O
(	(	O
904	CD	O
knees	NNS	O
)	)	O
and	CC	O
sixty-eight	JJ	O
men	NNS	O
(	(	O
136	CD	O
knees	NNS	O
)	)	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
sixty-eight	JJ	O
years	NNS	O
(	(	O
range	NN	O
,	,	O
forty-nine	JJ	O
to	TO	O
eighty-eight	JJ	O
years	NNS	O
)	)	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
index	NN	O
arthroplasty	NN	O
.	.	O

The	DT	O
mean	JJ	O
follow-up	JJ	O
period	NN	O
was	VBD	O
10.8	CD	O
years	NNS	O
(	(	O
range	NN	O
,	,	O
ten	VB	O
to	TO	O
twelve	VB	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
clinically	RB	O
and	CC	O
radiographically	RB	O
with	IN	O
the	DT	O
rating	NN	O
system	NN	O
of	IN	O
the	DT	O
Knee	NNP	O
Society	NNP	O
and	CC	O
with	IN	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
score	NN	O
at	IN	O
three	CD	O
months	NNS	O
,	,	O
one	CD	O
year	NN	O
,	,	O
and	CC	O
annually	RB	O
thereafter	RB	O
.	.	O

RESULTS	NNP	O
Total	JJ	O
knee	NN	O
scores	NNS	O
,	,	O
knee	NN	O
function	NN	O
scores	NNS	O
,	,	O
pain	NN	O
scores	NNS	O
,	,	O
WOMAC	NNP	O
scores	VBZ	O
,	,	O
knee	VB	O
motion	NN	O
,	,	O
and	CC	O
activity	NN	O
scores	NNS	O
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
preoperatively	RB	O
or	CC	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
final	JJ	O
follow-up	NN	O
.	.	O

Alignment	NNP	O
and	CC	O
the	DT	O
survivorship	NN	O
of	IN	O
the	DT	O
components	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
Kaplan-Meier	NNP	O
survivorship	NN	O
with	IN	O
revision	NN	O
as	IN	O
the	DT	O
end	NN	O
point	NN	O
at	IN	O
10.8	CD	O
years	NNS	O
was	VBD	O
98.8	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.96	CD	O
to	TO	O
1.00	CD	O
)	)	O
in	IN	O
the	DT	O
computernavigated	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
group	NN	O
and	CC	O
99.2	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.96	CD	O
to	TO	O
1.00	CD	O
)	)	O
in	IN	O
the	DT	O
conventional	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
data	NNS	O
demonstrated	VBD	O
no	DT	O
difference	NN	O
in	IN	O
clinical	JJ	O
function	NN	O
or	CC	O
alignment	NN	O
and	CC	O
survivorship	NN	O
of	IN	O
the	DT	O
components	NNS	O
between	IN	O
the	DT	O
knees	NNS	O
that	WDT	O
underwent	VBD	O
computer-navigated	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
and	CC	O
those	DT	O
that	WDT	O
underwent	JJ	O
conventional	JJ	Surgical
total	JJ	Surgical
knee	NN	Surgical
arthroplasty	NN	Surgical
.	.	O

Observer	NNP	O
variation	NN	O
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
outcome	NN	O
in	IN	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
:	:	O
experience	NN	O
from	IN	O
a	DT	O
multicenter	NN	O
,	,	O
international	JJ	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
Accurate	NNP	O
and	CC	O
consistent	JJ	O
outcome	NN	O
assessment	NN	O
is	VBZ	O
essential	JJ	O
to	TO	O
randomized	VB	O
clinical	JJ	O
trials	NNS	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
explore	VB	O
observer	JJ	O
variation	NN	O
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
outcome	NN	O
in	IN	O
a	DT	O
recently	RB	O
completed	VBN	O
trial	NN	O
of	IN	O
dexanabinol	NN	Pharmacological
in	IN	O
head	JJ	O
injury	NN	O
and	CC	O
to	TO	O
consider	VB	O
steps	NNS	O
to	TO	O
reduce	VB	O
such	JJ	O
variation	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	O
hundred	VBD	O
sixty-one	JJ	O
patients	NNS	O
with	IN	O
severe	JJ	O
traumatic	JJ	O
brain	NN	O
injury	NN	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
86	CD	O
centers	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
multicenter	NN	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
Phase	NNP	O
III	NNP	O
trial	NN	O
.	.	O

Outcome	NNP	O
was	VBD	O
assessed	VBN	O
at	IN	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
postinjury	NN	O
using	VBG	O
the	DT	O
extended	JJ	O
Glasgow	NNP	O
Outcome	NNP	O
Scale	NNP	O
;	:	O
standardized	VBD	O
assessment	NN	O
was	VBD	O
facilitated	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
structured	JJ	O
interview	NN	O
.	.	O

Before	IN	O
initiation	NN	O
of	IN	O
trial	NN	O
centers	NNS	O
,	,	O
outcome	JJ	O
ratings	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
sample	JJ	O
cases	NNS	O
to	TO	O
establish	VB	O
initial	JJ	O
levels	NNS	O
of	IN	O
agreement	NN	O
.	.	O

Training	NN	O
sessions	NNS	O
in	IN	O
outcome	JJ	O
assessment	NN	O
were	VBD	O
held	VBN	O
,	,	O
and	CC	O
problems	NNS	O
in	IN	O
assigning	VBG	O
outcome	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

During	IN	O
the	DT	O
trial	NN	O
,	,	O
a	DT	O
process	NN	O
of	IN	O
central	JJ	O
review	NN	O
was	VBD	O
established	VBN	O
to	TO	O
monitor	VB	O
performance	NN	O
.	.	O

Interobserver	NNP	O
variation	NN	O
was	VBD	O
analyzed	VBN	O
using	VBG	O
the	DT	O
kappa	NN	O
statistic	JJ	O
.	.	O

RESULTS	NNP	O
Substantial	NNP	O
observer	JJ	O
variation	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
rating	NN	O
of	IN	O
sample	JJ	O
cases	NNS	O
(	(	O
weighted	JJ	O
kappa	NN	O
,	,	O
0.72	CD	O
;	:	O
confidence	NN	O
interval	NN	O
,	,	O
0.68-0.75	JJ	O
)	)	O
and	CC	O
in	IN	O
assigning	VBG	O
outcome	NN	O
based	VBN	O
on	IN	O
completed	VBN	O
structured	JJ	O
interviews	NNS	O
(	(	O
weighted	JJ	O
kappa	NN	O
,	,	O
0.61	CD	O
;	:	O
confidence	NN	O
interval	NN	O
,	,	O
0.57-0.64	JJ	O
)	)	O
.	.	O

In	IN	O
the	DT	O
early	JJ	O
stages	NNS	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
a	DT	O
relatively	RB	O
large	JJ	O
number	NN	O
of	IN	O
discrepancies	NNS	O
(	(	O
29-37	CD	O
%	NN	O
)	)	O
were	VBD	O
identified	VBN	O
on	IN	O
central	JJ	O
review	NN	O
.	.	O

This	DT	O
number	NN	O
declined	VBD	O
as	IN	O
the	DT	O
trial	NN	O
progressed	VBD	O
and	CC	O
coincided	VBD	O
with	IN	O
investigator	NN	O
training	NN	O
and	CC	O
feedback	NN	O
from	IN	O
central	JJ	O
review	NN	O
.	.	O

Centers	NNS	O
with	IN	O
higher	JJR	O
enrollment	NN	O
rates	NNS	O
showed	VBD	O
better	JJR	O
performance	NN	O
.	.	O

CONCLUSION	NNP	O
Observer	NNP	O
variation	NN	O
in	IN	O
outcome	JJ	O
assessment	NN	O
is	VBZ	O
a	DT	O
significant	JJ	O
problem	NN	O
for	IN	O
head	NN	O
injury	NN	O
trials	NNS	O
.	.	O

Consistency	NN	O
can	MD	O
be	VB	O
improved	VBN	O
by	IN	O
standardizing	VBG	O
procedures	NNS	O
,	,	O
training	VBG	O
assessors	NNS	O
,	,	O
and	CC	O
monitoring	VBG	O
the	DT	O
quality	NN	O
of	IN	O
assessments	NNS	O
and	CC	O
providing	VBG	O
feedback	NN	O
to	TO	O
interviewers	NNS	O
.	.	O

Whole-body	JJ	Other
CT	NNP	Other
screening	NN	Other
:	:	O
scan	JJ	O
delay	NN	O
and	CC	O
contrast	NN	Pharmacological
injection	NN	Pharmacological
duration	NN	O
for	IN	O
optimal	JJ	O
enhancement	NN	O
of	IN	O
abdominal	JJ	O
organs	NNS	O
and	CC	O
deep	JJ	O
vessels	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
optimal	JJ	O
scan	JJ	O
delays	NNS	O
and	CC	O
contrast	NN	O
injection	NN	O
durations	NNS	O
for	IN	O
contrast-enhanced	JJ	Other
whole-body	NN	Other
computed	VBN	Other
tomography	NN	Other
(	(	Other
CT	NNP	Other
)	)	Other
.	.	Other

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
One	CD	O
hundred	VBD	O
forty-two	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
:	:	O
protocol	NN	O
A-scan	JJ	O
delay	NN	O
of	IN	O
65	CD	O
s	NNS	O
after	IN	O
starting	VBG	O
contrast	NN	Pharmacological
injection	NN	Pharmacological
over	IN	O
30	CD	O
s	NNS	O
;	:	O
protocol	CC	O
B-105	NNP	O
and	CC	O
70	CD	O
s	NN	O
;	:	O
and	CC	O
protocol	VB	O
C-145	NNP	O
and	CC	O
110	CD	O
s	NN	O
,	,	O
respectively	RB	O
.	.	O

Contrast	NNP	O
enhancement	NN	O
and	CC	O
diagnostic	JJ	O
acceptability	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Qualitative	JJ	O
assessment	NN	O
was	VBD	O
subtle	JJ	O
among	IN	O
the	DT	O
three	CD	O
protocols	NNS	O
.	.	O

Homogenous	JJ	O
enhancement	NN	O
of	IN	O
deep	JJ	O
veins	NNS	O
was	VBD	O
more	RBR	O
assuredly	RB	O
achieved	VBN	O
with	IN	O
protocol	NN	O
C.	NNP	O
CONCLUSION	NNP	O
With	IN	O
protocol	NN	O
C	NNP	O
,	,	O
qualitatively	RB	O
acceptable	JJ	O
enhancement	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
in	IN	O
whole-body	JJ	Other
CT	NNP	Other
.	.	Other

Oral	NNP	O
health	NN	O
impacts	NNS	O
on	IN	O
daily	JJ	O
living	NN	O
related	VBN	O
to	TO	O
four	CD	O
different	JJ	O
treatment	NN	O
protocols	NNS	O
for	IN	O
chronic	JJ	O
periodontitis	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
oral	JJ	O
health	NN	O
impacts	NNS	O
perceived	VBN	O
by	IN	O
patients	NNS	O
submitted	VBN	O
to	TO	O
different	JJ	O
treatments	NNS	O
of	IN	O
chronic	JJ	O
periodontitis	NN	O
and	CC	O
their	PRP$	O
association	NN	O
with	IN	O
clinical	JJ	O
parameters	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
therapeutic	JJ	O
groups	NNS	O
:	:	O
control	NN	O
,	,	O
treated	VBN	O
with	IN	O
full-mouth	JJ	Physical
scaling	NN	Physical
and	CC	O
root	NN	Physical
planing	NN	Physical
(	(	Physical
SRP	NNP	Physical
)	)	Physical
;	:	O
test	$	O
1	CD	O
,	,	O
treated	VBN	O
with	IN	O
SRP	NNP	Surgical
and	CC	O
400	CD	O
mg	NNS	O
systemically	RB	O
administered	VBN	O
metronidazole	NN	Pharmacological
(	(	O
MET	NNP	O
)	)	O
three	CD	O
times	NNS	O
per	IN	O
day	NN	O
for	IN	O
10	CD	O
days	NNS	O
;	:	O
test	JJS	O
2	CD	O
,	,	O
treated	VBN	O
with	IN	O
SRP	NNP	Physical
and	CC	O
professional	JJ	Physical
supragingival	NN	Physical
plaque	NN	Physical
removal	NN	Physical
(	(	Physical
PP	NNP	Physical
)	)	Physical
every	DT	O
week	NN	O
for	IN	O
3	CD	O
months	NNS	O
;	:	O
and	CC	O
test	VB	O
3	CD	O
,	,	O
treated	VBN	O
with	IN	O
SRP	NNP	Surgical
and	CC	O
MET	NNP	Pharmacological
plus	CC	O
PP	NNP	O
.	.	O

Clinical	NNP	O
periodontal	JJ	O
measurements	NNS	O
and	CC	O
data	NNS	O
regarding	VBG	O
patients	NNS	O
'	POS	O
oral	JJ	O
health	NN	O
impacts	NNS	O
(	(	O
perceived	VBN	O
impacts	NNS	O
on	IN	O
bleeding	VBG	O
gums	NNS	O
,	,	O
gingival	JJ	O
recession	NN	O
,	,	O
sensitivity	NN	O
to	TO	O
cold	VB	O
,	,	O
packing	VBG	O
foods	NNS	O
,	,	O
aesthetics	NNS	O
,	,	O
bad	JJ	O
breath	NN	O
,	,	O
and	CC	O
tooth	DT	O
mobility	NN	O
)	)	O
were	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
groups	NNS	O
presented	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
oral	JJ	O
health	NN	O
perceived	VBD	O
impacts	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
improvement	NN	O
of	IN	O
oral	JJ	O
health	NN	O
impacts	NNS	O
among	IN	O
groups	NNS	O
subjected	VBN	O
to	TO	O
different	JJ	O
treatments	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
data	NNS	O
of	IN	O
percentage	NN	O
of	IN	O
deep	JJ	O
probing	VBG	O
depth	NN	O
,	,	O
deep	JJ	O
clinical	JJ	O
attachment	NN	O
level	NN	O
,	,	O
and	CC	O
bleeding	VBG	O
on	IN	O
probing	VBG	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
correlated	VBN	O
significantly	RB	O
with	IN	O
oral	JJ	O
health	NN	O
impacts	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Periodontal	NNP	Physical
treatment	NN	Physical
leads	VBZ	O
to	TO	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
self-perceived	JJ	O
impacts	NNS	O
regardless	RB	O
of	IN	O
the	DT	O
non-surgical	JJ	O
treatment	NN	O
protocol	NN	O
employed	VBN	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
clinical	JJ	O
data	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
oral	JJ	O
health	NN	O
impacts	NNS	O
.	.	O

Intravenous	JJ	Pharmacological
or	CC	Pharmacological
intramuscular	JJ	Pharmacological
teicoplanin	NN	Pharmacological
once	RB	O
daily	JJ	O
for	IN	O
skin	NN	O
and	CC	O
soft-tissue	JJ	O
infections	NNS	O
.	.	O

Teicoplanin	NNP	Pharmacological
is	VBZ	O
a	DT	O
new	JJ	O
glycopeptide	NN	O
antibiotic	JJ	O
with	IN	O
potent	JJ	O
activity	NN	O
against	IN	O
gram-positive	JJ	O
bacteria	NNS	O
and	CC	O
pharmacokinetics	NNS	O
that	WDT	O
allow	VBP	O
once	RB	O
daily	JJ	O
administration	NN	O
.	.	O

To	TO	O
study	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
teicoplanin	NN	Pharmacological
for	IN	O
skin	NN	O
and	CC	O
soft-tissue	NN	O
infections	NNS	O
,	,	O
75	CD	O
patients	NNS	O
received	VBD	O
teicoplanin	JJ	Pharmacological
intravenously	RB	Pharmacological
(	(	Pharmacological
38	CD	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
intramuscularly	RB	Pharmacological
(	(	O
37	CD	O
,	,	O
of	IN	O
which	WDT	O
16	CD	O
were	VBD	O
outpatients	NNS	O
)	)	O
.	.	O

Of	IN	O
62	CD	O
clinically	RB	O
evaluable	JJ	O
patients	NNS	O
,	,	O
97	CD	O
percent	NN	O
of	IN	O
teicoplanin	NN	Pharmacological
iv	NN	O
and	CC	O
93	CD	O
percent	NN	O
of	IN	O
teicoplanin	NN	Pharmacological
im	NN	O
patients	NNS	O
were	VBD	O
cured	VBN	O
or	CC	O
improved	VBN	O
.	.	O

All	DT	O
teicoplanin	JJ	Pharmacological
iv	NN	O
patients	NNS	O
and	CC	O
64	CD	O
percent	NN	O
of	IN	O
teicoplanin	NN	Pharmacological
im	NN	O
patients	NNS	O
were	VBD	O
cured	VBN	O
microbiologically	RB	O
at	IN	O
24-48	JJ	O
hours	NNS	O
posttherapy	NN	O
.	.	O

Persistence	NN	O
of	IN	O
organisms	NNS	O
frequently	RB	O
was	VBD	O
associated	VBN	O
with	IN	O
skin	JJ	O
ulcers	NNS	O
or	CC	O
abscess	JJ	O
cavities	NNS	O
and	CC	O
usually	RB	O
had	VBD	O
no	DT	O
bearing	NN	O
on	IN	O
clinical	JJ	O
outcome	NN	O
.	.	O

Possible	JJ	O
adverse	JJ	O
clinical	JJ	O
and	CC	O
laboratory	JJ	O
reactions	NNS	O
caused	VBN	O
by	IN	O
teicoplanin	NN	Pharmacological
occurred	VBD	O
in	IN	O
4	CD	O
of	IN	O
38	CD	O
teicoplanin	JJ	O
iv	NN	O
patients	NNS	O
(	(	O
11	CD	O
percent	NN	O
)	)	O
and	CC	O
in	IN	O
8	CD	O
of	IN	O
37	CD	O
teicoplanin	JJ	Pharmacological
im	NN	O
patients	NNS	O
(	(	O
22	CD	O
percent	NN	O
)	)	O
.	.	O

Reactions	NNPS	O
were	VBD	O
mild	JJ	O
and	CC	O
resolved	VBN	O
with	IN	O
discontinuation	NN	O
of	IN	O
teicoplanin	NN	Pharmacological
in	IN	O
most	JJS	O
cases	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
teicoplanin	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	O
,	,	O
efficacious	JJ	O
,	,	O
and	CC	O
convenient	NN	O
for	IN	O
both	DT	O
hospital	JJ	O
staff	NN	O
and	CC	O
patients	NNS	O
,	,	O
and	CC	O
potentially	RB	O
cost-effective	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
skin	NN	O
and	CC	O
soft-tissue	JJ	O
infections	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
teicoplanin	JJ	Pharmacological
appears	VBZ	O
to	TO	O
be	VB	O
appropriate	JJ	O
for	IN	O
outpatient	JJ	O
parenteral	JJ	O
therapy	NN	O
.	.	O

[	JJ	O
Clinical	NNP	O
observation	NN	O
on	IN	O
different	JJ	O
acupuncture	NN	Physical
and	CC	O
moxibustion	NN	Pharmacological
therapies	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
postsurgical	JJ	O
gastroparesis	NN	O
syndrome	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
optimize	VB	O
therapy	NN	O
of	IN	O
acupuncture	NN	Physical
and	CC	O
moxibustion	NN	Pharmacological
for	IN	O
postsurgical	JJ	O
gastroparesis	NN	O
syndrome	NN	O
(	(	O
PGS	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Forty-one	JJ	O
cases	NNS	O
of	IN	O
PGS	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
in	IN	O
order	NN	O
of	IN	O
visiting	VBG	O
.	.	O

Group	NNP	O
A	NNP	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
were	VBD	O
treated	VBN	O
by	IN	O
warming	VBG	O
needle	JJ	O
moxibustion	NN	Pharmacological
,	,	O
group	NN	O
B	NNP	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
by	IN	O
acupuncture	NN	Physical
plus	CC	O
auricular	JJ	Physical
point	NN	Physical
sticking	NN	Physical
,	,	O
and	CC	O
group	NN	O
C	NNP	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
by	IN	O
routine	JJ	Physical
acupuncture	NN	Physical
.	.	Physical

Changes	NNS	O
of	IN	O
gastric	JJ	O
drainage	NN	O
volume	NN	O
,	,	O
therapeutic	JJ	O
times	NNS	O
and	CC	O
cured	JJ	O
rate	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
the	DT	O
3	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
All	PDT	O
the	DT	O
3	CD	O
therapeutic	JJ	O
methods	NNS	O
could	MD	O
significantly	RB	O
decrease	VB	O
gastric	JJ	O
drainage	NN	O
volume	NN	O
.	.	O

The	DT	O
cured	JJ	O
rate	NN	O
was	VBD	O
100.0	CD	O
%	NN	O
and	CC	O
the	DT	O
therapeutic	JJ	O
times	NNS	O
was	VBD	O
(	(	O
7.24	CD	O
+/-	JJ	O
3.87	CD	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
A	NNP	O
,	,	O
66.7	CD	O
%	NN	O
,	,	O
(	(	O
9.83	CD	O
+/-	JJ	O
4.60	CD	O
)	)	O
times	NNS	O
in	IN	O
the	DT	O
group	NN	O
B	NNP	O
and	CC	O
75.0	CD	O
%	NN	O
,	,	O
(	(	O
15.25	CD	O
+/-	JJ	O
3.81	CD	O
)	)	O
times	NNS	O
in	IN	O
the	DT	O
group	NN	O
C	NNP	O
,	,	O
with	IN	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
cured	JJ	O
rate	NN	O
and	CC	O
the	DT	O
therapeutic	JJ	O
times	NNS	O
among	IN	O
the	DT	O
3	CD	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
warming	VBG	O
needle	JJ	O
moxibustion	NN	Pharmacological
is	VBZ	O
the	DT	O
best	JJS	O
method	NN	O
for	IN	O
PGS	NNP	O
,	,	O
with	IN	O
less	RBR	O
therapeutic	JJ	O
times	NNS	O
,	,	O
high	JJ	O
cured	VBN	O
rate	NN	O
and	CC	O
rapid	JJ	O
effect	NN	O
.	.	O

The	DT	O
additional	JJ	O
value	NN	O
of	IN	O
a	DT	O
night	NN	Physical
splint	NN	Physical
to	TO	O
eccentric	VB	Physical
exercises	NNS	Physical
in	IN	O
chronic	JJ	O
midportion	NN	O
Achilles	NNP	O
tendinopathy	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

AIM	NNP	O
To	TO	O
assess	VB	O
whether	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
night	NN	Physical
splint	NN	Physical
is	VBZ	O
of	IN	O
added	JJ	O
benefit	NN	O
on	IN	O
functional	JJ	O
outcome	NN	O
in	IN	O
treating	VBG	O
chronic	JJ	O
midportion	NN	O
Achilles	NNP	O
tendinopathy	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
single-blind	JJ	O
,	,	O
prospective	JJ	O
,	,	O
single	JJ	O
centre	NN	O
,	,	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
set	NN	O
in	IN	O
the	DT	O
Sports	NNP	O
Medical	NNP	O
Department	NNP	O
,	,	O
The	DT	O
Hague	NNP	O
Medical	NNP	O
Centre	NNP	O
,	,	O
The	DT	O
Netherlands	NNP	O
.	.	O

Inclusion	NNP	O
criteria	NNS	O
were	VBD	O
:	:	O
age	NN	O
18-70	CD	O
years	NNS	O
,	,	O
active	JJ	O
participation	NN	O
in	IN	O
sports	NNS	O
,	,	O
and	CC	O
tendon	VB	O
pain	NN	O
localised	VBN	O
at	IN	O
2-7	JJ	O
cm	NN	O
from	IN	O
distal	JJ	O
insertion	NN	O
.	.	O

Exclusion	NN	O
criteria	NNS	O
were	VBD	O
:	:	O
insertional	JJ	O
disorders	NNS	O
,	,	O
partial	JJ	O
or	CC	O
complete	JJ	O
ruptures	NNS	O
,	,	O
or	CC	O
systemic	JJ	O
illness	NN	O
.	.	O

70	CD	O
tendons	NNS	O
were	VBD	O
included	VBN	O
and	CC	O
randomised	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
eccentric	JJ	Physical
exercises	NNS	Physical
with	IN	Physical
a	DT	Physical
night	NN	Physical
splint	NN	Physical
(	(	O
night	NN	O
splint	NN	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
36	CD	O
)	)	O
or	CC	O
eccentric	JJ	Physical
exercises	NNS	Physical
only	RB	Physical
(	(	O
eccentric	JJ	O
group	NN	O
,	,	O
n	RB	O
=	VBZ	O
34	CD	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
Both	DT	O
groups	NNS	O
completed	VBD	O
a	DT	O
12-week	JJ	O
heavy-load	NN	Physical
eccentric	JJ	Physical
training	NN	Physical
programme	NN	Physical
.	.	Physical

One	CD	O
group	NN	O
received	VBD	O
a	DT	O
night	NN	Physical
splint	NN	Physical
in	IN	O
addition	NN	O
to	TO	O
eccentric	JJ	Physical
exercises	NNS	Physical
.	.	O

At	IN	O
baseline	NN	O
and	CC	O
follow-up	NN	O
at	IN	O
12	CD	O
weeks	NNS	O
,	,	O
patient	JJ	O
satisfaction	NN	O
,	,	O
Victorian	NNP	O
Institute	NNP	O
of	IN	O
Sport	NNP	O
Assessment-Achilles	NNP	O
questionnaire	NN	O
(	(	O
VISA-A	NNP	O
)	)	O
score	NN	O
and	CC	O
reported	VBD	O
compliance	NN	O
were	VBD	O
recorded	VBN	O
by	IN	O
a	DT	O
single-blind	NN	O
trained	JJ	O
researcher	NN	O
who	WP	O
was	VBD	O
blinded	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
12	CD	O
weeks	NNS	O
,	,	O
patient	JJ	O
satisfaction	NN	O
in	IN	O
the	DT	O
eccentric	JJ	O
group	NN	O
was	VBD	O
63	CD	O
%	NN	O
compared	VBN	O
with	IN	O
48	CD	O
%	NN	O
in	IN	O
the	DT	O
night	NN	Physical
splint	NN	Physical
group	NN	O
.	.	O

The	DT	O
VISA-A	NNP	O
score	NN	O
significantly	RB	O
improved	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
;	:	O
in	IN	O
the	DT	O
eccentric	JJ	O
group	NN	O
from	IN	O
50.1	CD	O
to	TO	O
68.8	CD	O
(	(	O
p	NN	O
=	RB	O
0.001	CD	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
night	NN	O
splint	NN	O
group	NN	O
from	IN	O
49.4	CD	O
to	TO	O
67.0	CD	O
(	(	O
p	NN	O
<	RB	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
VISA-A	NNP	O
score	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.815	CD	O
)	)	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.261	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
night	NN	Physical
splint	NN	Physical
is	VBZ	O
not	RB	O
beneficial	JJ	O
in	IN	O
addition	NN	O
to	TO	O
eccentric	VB	O
exercises	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
midportion	NN	O
Achilles	NNP	O
tendinopathy	NN	O
.	.	O

Morphological	JJ	O
onset	NN	O
and	CC	O
early	JJ	O
diagnosis	NN	O
in	IN	O
apical	JJ	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
:	:	O
a	DT	O
long	JJ	O
term	NN	O
analysis	NN	O
with	IN	O
nuclear	JJ	Other
magnetic	JJ	Other
resonance	NN	Other
imaging	NN	Other
.	.	Other

OBJECTIVES	VB	O
A	DT	O
long-term	JJ	O
follow-up	NN	O
study	NN	O
with	IN	O
nuclear	JJ	Other
magnetic	JJ	Other
resonance	NN	Other
(	(	Other
NMR	NNP	Other
)	)	Other
imaging	NN	Other
was	VBD	O
undertaken	VBN	O
to	TO	O
detect	VB	O
the	DT	O
morphological	JJ	O
onset	NN	O
and	CC	O
to	TO	O
establish	VB	O
the	DT	O
early	JJ	O
diagnosis	NN	O
in	IN	O
apical	JJ	O
hypertrophic	JJ	O
cardiomyopathy	NN	O
(	(	O
HCM	NNP	O
)	)	O
.	.	O

BACKGROUND	VB	O
A	DT	O
spadelike	JJ	O
configuration	NN	O
on	IN	O
left	JJ	O
ventriculogram	NN	O
(	(	O
LVG	NNP	O
)	)	O
is	VBZ	O
regarded	VBN	O
as	IN	O
a	DT	O
diagnostic	JJ	O
criterion	NN	O
for	IN	O
the	DT	O
classical	JJ	O
apical	JJ	O
HCM	NNP	O
.	.	O

There	EX	O
also	RB	O
exists	VBZ	O
a	DT	O
segmented	JJ	O
hypertrophy	NN	O
at	IN	O
the	DT	O
apical	JJ	O
level	NN	O
without	IN	O
indicating	VBG	O
the	DT	O
spadelike	NN	O
features	NNS	O
(	(	O
a	DT	O
nonspade	NN	O
configuration	NN	O
)	)	O
.	.	O

To	TO	O
detect	VB	O
the	DT	O
hypertrophied	JJ	O
myocardium	NN	O
of	IN	O
the	DT	O
nonspade	JJ	O
configuration	NN	O
,	,	O
circumferential	JJ	O
scrutiny	NN	O
of	IN	O
the	DT	O
apex	NN	O
is	VBZ	O
required	VBN	O
.	.	O

Although	IN	O
both	DT	O
configurations	NNS	O
can	MD	O
be	VB	O
underlying	JJ	O
causes	NNS	O
of	IN	O
giant	JJ	O
negative	JJ	O
T	NNP	O
waves	NNS	O
,	,	O
etiological	JJ	O
relationship	NN	O
between	IN	O
the	DT	O
two	CD	O
is	VBZ	O
not	RB	O
clarified	VBN	O
.	.	O

METHODS	NNP	O
The	DT	O
criteria	NN	O
for	IN	O
the	DT	O
spadelike	NN	O
configuration	NN	O
defined	VBN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
short-axis	JJ	O
NMR	NNP	Other
images	NNS	Other
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
(	(	O
apical	JJ	O
maximal	NN	O
thickness	NN	O
>	NN	O
or	CC	O
=	$	O
15	CD	O
mm	NN	O
)	)	O
,	,	O
(	(	O
apical	JJ	O
anterior	NN	O
thickness	NN	O
over	IN	O
basal	JJ	O
anterior	JJ	O
thickness	NN	O
>	NN	O
or	CC	O
=	VB	O
1.3	CD	O
)	)	O
and	CC	O
(	(	O
apical	JJ	O
posterior	NN	O
thickness	NN	O
over	IN	O
basal	JJ	O
posterior	JJ	O
thickness	NN	O
>	NN	O
or	CC	O
=1.3	NN	O
)	)	O
.	.	O

Thirteen	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
predominant	JJ	O
hypertrophy	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
15	CD	O
mm	NN	O
)	)	O
at	IN	O
the	DT	O
apical	JJ	O
level	NN	O
without	IN	O
the	DT	O
spadelike	NN	O
configuration	NN	O
underwent	JJ	O
NMR	NNP	Other
imaging	VBG	Other
twice	RB	O
before	RB	O
and	CC	O
after	IN	O
54+/-10	JJ	O
months	NNS	O
'	POS	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Apical	NNP	O
hypertrophy	NN	O
that	WDT	O
had	VBD	O
been	VBN	O
confined	VBN	O
to	TO	O
the	DT	O
lateral	JJ	O
wall	NN	O
in	IN	O
four	CD	O
,	,	O
the	DT	O
anterior-lateral	JJ	O
wall	NN	O
in	IN	O
two	CD	O
,	,	O
and	CC	O
the	DT	O
septal-anterior	JJ	O
wall	NN	O
in	IN	O
one	CD	O
developed	NN	O
to	TO	O
become	VB	O
circumferential	JJ	O
hypertrophy	NN	O
that	WDT	O
fulfilled	VBD	O
the	DT	O
criteria	NNS	O
for	IN	O
the	DT	O
spadelike	NN	O
configuration	NN	O
after	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
spadelike	NN	O
configuration	NN	O
can	MD	O
begin	VB	O
with	IN	O
the	DT	O
nonspade	JJ	O
configuration	NN	O
and	CC	O
therefore	NN	O
,	,	O
both	DT	O
can	MD	O
constitute	VB	O
a	DT	O
single	JJ	O
disease	NN	O
entity	NN	O
of	IN	O
apical	JJ	O
HCM	NNP	O
.	.	O

The	DT	O
early	JJ	O
diagnosis	NN	O
of	IN	O
apical	JJ	O
HCM	NNP	O
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
identifying	VBG	O
the	DT	O
hypertrophy	NN	O
frequently	RB	O
confined	VBN	O
to	TO	O
the	DT	O
lateral	JJ	O
wall	NN	O
at	IN	O
the	DT	O
apical	JJ	O
level	NN	O
.	.	O

Autism-Spectrum	JJ	Other
Quotient-Japanese	JJ	Other
version	NN	O
and	CC	O
its	PRP$	O
short	JJ	O
forms	NNS	O
for	IN	O
screening	VBG	O
normally	RB	O
intelligent	JJ	O
persons	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

A	DT	O
Japanese	JJ	Other
version	NN	Other
of	IN	Other
the	DT	Other
Autism	NNP	Other
Spectrum	NNP	Other
Quotient	NNP	Other
(	(	Other
AQ	NNP	Other
)	)	Other
,	,	Other
AQ-J	NNP	Other
was	VBD	O
administered	VBN	O
to	TO	O
25	CD	O
normally	RB	O
intelligent	JJ	O
high-functioning	JJ	O
pervasive	JJ	O
developmental	NN	O
disorder	NN	O
(	(	O
HPDD	NNP	O
)	)	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
24.2	CD	O
years	NNS	O
;	:	O
24	CD	O
male	NN	O
,	,	O
one	CD	O
female	NN	O
)	)	O
and	CC	O
215	CD	O
controls	NNS	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
30.4	CD	O
years	NNS	O
;	:	O
86	CD	O
male	NN	O
,	,	O
129	CD	O
female	NN	O
)	)	O
randomly	RB	O
selected	VBN	O
from	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

The	DT	O
AQ-J	NNP	Other
had	VBD	O
satisfactory	JJ	O
internal	JJ	O
consistency	NN	O
reliability	NN	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
>	VBD	O
0.70	CD	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
)	)	O
,	,	O
test-retest	JJ	O
reliability	NN	O
,	,	O
and	CC	O
discriminant	JJ	O
validity	NN	O
[	NNP	O
i.e	NN	O
.	.	O

the	DT	O
AQ-J	NNP	O
score	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
HPDD	NNP	O
(	(	O
mean	NN	O
,	,	O
29.6	CD	O
)	)	O
than	IN	O
controls	NNS	O
(	(	O
mean	VB	O
,	,	O
22.2	CD	O
)	)	O
]	NN	O
.	.	O

At	IN	O
a	DT	O
cut-off	NN	O
of	IN	O
26	CD	O
,	,	O
the	DT	O
AQ-J	NNP	Other
had	VBD	O
satisfactory	JJ	O
sensitivity	NN	O
,	,	O
specificity	NN	O
,	,	O
and	CC	O
negative	JJ	O
predictive	JJ	O
value	NN	O
,	,	O
but	CC	O
it	PRP	O
had	VBD	O
low	JJ	O
positive	JJ	O
predictive	NN	O
value	NN	O
(	(	O
0.24	CD	O
)	)	O
possibly	RB	O
due	JJ	O
to	TO	O
the	DT	O
facts	NNS	O
that	IN	O
the	DT	O
25	CD	O
mild	JJ	O
HPDD	NNP	O
patients	NNS	O
scored	VBD	O
lower	JJR	O
and	CC	O
the	DT	O
controls	NNS	O
scored	VBD	O
higher	JJR	O
on	IN	O
the	DT	O
AQ-J	NNP	Other
than	IN	O
British	NNP	O
counterparts	NNS	O
on	IN	O
the	DT	O
AQ	NNP	O
.	.	O

The	DT	O
AQ-J-21	NNP	Other
(	(	O
consisting	VBG	O
of	IN	O
21	CD	O
items	NNS	O
significantly	RB	O
associated	VBN	O
with	IN	O
HPDD	NNP	O
diagnosis	NN	O
)	)	O
and	CC	O
the	DT	O
AQ-J-10	NNP	Other
(	(	O
consisting	VBG	O
of	IN	O
10	CD	O
of	IN	O
the	DT	O
21	CD	O
items	NNS	O
with	IN	O
an	DT	O
effect	NN	O
size	NN	O
>	NNP	O
0.17	CD	O
)	)	O
had	VBD	O
higher	JJR	O
,	,	O
although	IN	O
not	RB	O
satisfactory	JJ	O
,	,	O
positive	JJ	O
predictive	JJ	O
values	NNS	O
of	IN	O
0.35	CD	O
and	CC	O
0.46	CD	O
at	IN	O
cut-offs	NNS	O
of	IN	O
12	CD	O
and	CC	O
7	CD	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
the	DT	O
AQ-J	NNP	Other
.	.	Other

The	DT	O
AQ-J	JJ	Other
and	CC	O
two	CD	O
short	JJ	O
forms	NNS	O
are	VBP	O
useful	JJ	O
not	RB	O
to	TO	O
predict	VB	O
but	CC	O
to	TO	O
rule	VB	O
out	RP	O
mild	NN	O
HPDD	NNP	O
,	,	O
the	DT	O
most	RBS	O
difficult	JJ	O
part	NN	O
of	IN	O
HPDD	NNP	O
to	TO	O
be	VB	O
distinguished	VBN	O
from	IN	O
non-PDD	JJ	O
conditions	NNS	O
,	,	O
in	IN	O
persons	NNS	O
scoring	VBG	O
under	IN	O
the	DT	O
cut-offs	NNS	O
and	CC	O
to	TO	O
consider	VB	O
professionals	NNS	O
'	POS	O
examination	NN	O
of	IN	O
HPDD	NNP	O
in	IN	O
persons	NNS	O
scoring	VBG	O
over	IN	O
them	PRP	O
,	,	O
because	IN	O
their	PRP$	O
negative	JJ	O
predictive	JJ	O
values	NNS	O
were	VBD	O
satisfactory	JJ	O
.	.	O

Is	VBZ	O
a	DT	O
calculated	JJ	O
total	JJ	O
hip	NN	O
BMD	NNP	O
of	IN	O
clinical	JJ	O
use	NN	O
?	.	O
The	DT	O
diagnosis	NN	O
of	IN	O
osteoporosis	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
bone	NN	O
mass	NN	O
measurement	NN	O
.	.	O

To	TO	O
avoid	VB	O
the	DT	O
errors	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
measurement	NN	O
of	IN	O
spinal	JJ	O
bone	NN	O
density	NN	O
the	DT	O
total	JJ	O
hip	NN	O
has	VBZ	O
been	VBN	O
accepted	VBN	O
as	IN	O
the	DT	O
standard	JJ	O
measurement	NN	O
site	NN	O
.	.	O

This	DT	O
information	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
for	IN	O
many	JJ	O
early	JJ	O
measurements	NNS	O
.	.	O

We	PRP	O
have	VBP	O
assessed	VBN	O
whether	IN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
derive	VB	O
clinically	RB	O
useful	JJ	O
information	NN	O
about	IN	O
total	JJ	Other
hip	NN	Other
bone	NN	Other
mineral	JJ	Other
density	NN	Other
(	(	O
BMD	NNP	O
)	)	O
from	IN	O
measurements	NNS	O
at	IN	O
other	JJ	O
hip	NN	O
sites	NNS	O
.	.	O

The	DT	O
bone	NN	O
mass	NN	O
measurements	NNS	O
of	IN	O
46	CD	O
patients	NNS	O
participating	VBG	O
in	IN	O
a	DT	O
current	JJ	O
trial	NN	O
of	IN	O
therapy	NN	O
for	IN	O
osteoporosis	NN	O
were	VBD	O
reviewed	VBN	O
.	.	O

The	DT	O
total	JJ	O
hip	NN	O
BMD	NNP	O
as	IN	O
directly	RB	O
measured	VBN	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
obtained	VBN	O
from	IN	O
the	DT	O
formula	NN	O
:	:	O
Total	JJ	O
hip	NN	O
BMD	NNP	O
=	VBZ	O
0.48	CD	O
x	NN	O
Neck	NNP	O
BMD	NNP	O
+	VBD	O
0.62	CD	O
x	NNP	O
Trochanteric	NNP	O
BMD	NNP	O
+	VBD	O
0.03	CD	O
.	.	O

In	IN	O
30	CD	O
patients	NNS	O
with	IN	O
follow-up	JJ	O
data	NNS	O
the	DT	O
rate	NN	O
of	IN	O
change	NN	O
in	IN	O
hip	NN	O
BMD	NNP	O
over	IN	O
a	DT	O
year	NN	O
was	VBD	O
also	RB	O
determined	VBN	O
by	IN	O
both	DT	O
methods	NNS	O
.	.	O

In	IN	O
the	DT	O
pretreatment	NN	O
state	NN	O
there	EX	O
was	VBD	O
good	JJ	O
agreement	NN	O
between	IN	O
the	DT	O
two	CD	O
measures	NNS	O
(	(	O
r2	VB	O
=	RB	O
0.96	CD	O
,	,	O
SEE	NNP	O
0.012	CD	O
g/cm2	NN	O
)	)	O
.	.	O

If	IN	O
the	DT	O
formula	NN	O
was	VBD	O
used	VBN	O
to	TO	O
compute	VB	O
a	DT	O
change	NN	O
in	IN	O
total	JJ	O
hip	NN	O
BMD	NNP	O
,	,	O
the	DT	O
agreement	NN	O
between	IN	O
both	DT	O
methods	NNS	O
remained	VBD	O
good	JJ	O
.	.	O

However	RB	O
,	,	O
the	DT	O
standard	JJ	O
error	NN	O
of	IN	O
the	DT	O
estimate	NN	O
of	IN	O
the	DT	O
change	NN	O
represented	VBD	O
59	CD	O
%	NN	O
of	IN	O
the	DT	O
observed	JJ	O
change	NN	O
.	.	O

This	DT	O
indicates	VBZ	O
that	IN	O
the	DT	O
error	NN	O
associated	VBN	O
with	IN	O
this	DT	O
estimate	NN	O
is	VBZ	O
too	RB	O
great	JJ	O
to	TO	O
allow	VB	O
clinically	RB	O
meaningful	JJ	O
conclusions	NNS	O
to	TO	O
be	VB	O
drawn	VBN	O
from	IN	O
calculated	VBN	O
total	JJ	O
hip	NN	O
BMD	NNP	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
whilst	VB	O
it	PRP	O
may	MD	O
be	VB	O
possible	JJ	O
to	TO	O
obtain	VB	O
reasonable	JJ	O
point	NN	O
estimates	NNS	O
of	IN	O
total	JJ	O
hip	NN	O
BMD	NNP	O
from	IN	O
other	JJ	O
measures	NNS	O
in	IN	O
the	DT	O
hip	NN	O
,	,	O
these	DT	O
estimates	NNS	O
are	VBP	O
too	RB	O
imprecise	JJ	O
to	TO	O
allow	VB	O
conclusions	NNS	O
about	IN	O
change	NN	O
in	IN	O
BMD	NNP	O
to	TO	O
be	VB	O
made	VBN	O
.	.	O

0.1	CD	O
%	NN	O
bupivacaine	NN	Pharmacological
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
requirement	NN	O
for	IN	O
epidural	JJ	O
fentanyl	NN	O
infusion	NN	O
after	IN	O
major	JJ	O
abdominal	JJ	O
surgery	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Although	IN	O
local	JJ	O
anesthesia	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
to	TO	O
potentiate	VB	O
spinal	JJ	O
morphine	NN	O
analgesia	NN	O
in	IN	O
animal	JJ	O
studies	NNS	O
,	,	O
results	NNS	O
comparing	VBG	O
epidural	JJ	O
local	JJ	O
anesthesia/opioid	NN	O
mixtures	NNS	O
with	IN	O
opioid	JJ	O
alone	NN	O
are	VBP	O
contradictory	JJ	O
in	IN	O
clinical	JJ	O
studies	NNS	O
.	.	O

The	DT	O
hypothesis	NN	O
was	VBD	O
that	IN	O
,	,	O
although	IN	O
the	DT	O
concentration	NN	O
of	IN	O
bupivacaine	NN	Pharmacological
(	(	O
0.1	CD	O
%	NN	O
)	)	O
was	VBD	O
low	JJ	O
to	TO	O
minimize	VB	O
its	PRP$	O
adverse	JJ	O
effects	NNS	O
,	,	O
if	IN	O
the	DT	O
infusion	NN	O
rate	NN	O
of	IN	O
a	DT	O
fentanyl/bupivacaine	JJ	Pharmacological
solution	NN	O
was	VBD	O
closely	RB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
need	NN	O
,	,	O
the	DT	O
presence	NN	O
bupivacaine	NN	O
would	MD	O
reduce	VB	O
the	DT	O
requirement	NN	O
for	IN	O
epidural	JJ	O
fentanyl	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
fentanyl	NN	Pharmacological
(	(	O
10	CD	O
micrograms/mL	NN	O
)	)	O
or	CC	O
a	DT	O
fentanyl/bupivacaine	NN	Pharmacological
(	(	O
0.1	CD	O
%	NN	O
)	)	O
mixture	NN	O
epidurally	RB	O
corresponding	VBG	O
to	TO	O
the	DT	O
dermatome	NN	O
of	IN	O
the	DT	O
surgical	JJ	O
incision	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
for	IN	O
the	DT	O
first	JJ	O
18	CD	O
hours	NNS	O
after	IN	O
major	JJ	O
abdominal	JJ	O
surgery	NN	O
.	.	O

The	DT	O
infusion	NN	O
was	VBD	O
titrated	VBN	O
for	IN	O
each	DT	O
patient	NN	O
to	TO	O
the	DT	O
rate	NN	O
required	VBN	O
for	IN	O
pain	NN	O
relief	NN	O
during	IN	O
forced	VBN	O
inspiration	NN	O
(	(	O
pain	NN	O
score	NN	O
<	NN	O
or	CC	O
=	$	O
2	CD	O
,	,	O
maximum	JJ	O
10	CD	O
)	)	O
.	.	O

Pain	NN	O
scores	NNS	O
,	,	O
the	DT	O
fentanyl	JJ	O
doses	NNS	O
required	VBN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
fentanyl	NN	O
at	IN	O
18	CD	O
hours	NNS	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
reported	VBD	O
similar	JJ	O
median	JJ	O
pain	NN	O
scores	NNS	O
and	CC	O
were	VBD	O
equally	RB	O
satisfied	VBN	O
with	IN	O
pain	NN	O
relief	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
mean	NN	O
required	VBN	O
post-operative	JJ	O
fentanyl	JJ	O
infusion	NN	O
rate	NN	O
(	(	O
57.7	CD	O
+/-	JJ	O
19.5	CD	O
micrograms/h	NN	O
)	)	O
and	CC	O
the	DT	O
plasma	NN	O
concentrations	NNS	O
(	(	O
0.84	CD	O
+/-	JJ	O
0.36	CD	O
ng/mL	NN	O
)	)	O
in	IN	O
the	DT	O
fentanyl	NN	O
group	NN	O
were	VBD	O
comparable	JJ	O
to	TO	O
the	DT	O
infusion	NN	O
rate	NN	O
(	(	O
54.4	CD	O
+/-	JJ	O
19.2	CD	O
micrograms/h	NN	O
)	)	O
and	CC	O
the	DT	O
plasma	NN	O
concentrations	NNS	O
(	(	O
0.86	CD	O
+/-	JJ	O
0.36	CD	O
ng/mL	NN	O
)	)	O
in	IN	O
the	DT	O
fentanyl/bupivacaine	NN	O
group	NN	O
.	.	O

Respiratory	NNP	O
and	CC	O
cardiovascular	JJ	O
functions	NNS	O
were	VBD	O
preserved	VBN	O
,	,	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
,	,	O
pruritus	NN	O
,	,	O
and	CC	O
periods	NNS	O
of	IN	O
drowsiness	NN	O
or	CC	O
sleep	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
low	JJ	O
concentrations	NNS	O
(	(	O
0.1	CD	O
%	NN	O
)	)	O
,	,	O
bupivacaine	NN	Pharmacological
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
titrated	JJ	O
dose	NN	O
of	IN	O
epidural	JJ	O
fentanyl	NN	O
required	VBN	O
for	IN	O
adequate	JJ	O
pain	NN	O
relief	NN	O
during	IN	O
forced	VBN	O
inspiration	NN	O
after	IN	O
major	JJ	O
abdominal	JJ	O
surgery	NN	O
.	.	O

The	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
also	RB	O
comparable	JJ	O
whether	IN	O
or	CC	O
not	RB	O
low-dose	JJ	O
bupivacaine	NN	Pharmacological
infusion	NN	O
was	VBD	O
used	VBN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
evaluator-blind	JJ	O
,	,	O
multicenter	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
Perlane	NNP	Pharmacological
versus	NN	O
Zyplast	NNP	Pharmacological
in	IN	O
the	DT	O
correction	NN	O
of	IN	O
nasolabial	JJ	O
folds	NNS	O
.	.	O

Bovine	NNP	Pharmacological
collagen	NN	Pharmacological
is	VBZ	O
widely	RB	O
used	VBN	O
as	IN	O
a	DT	O
dermal	JJ	O
filler	NN	O
for	IN	O
facial	JJ	O
soft-tissue	JJ	O
augmentation	NN	O
,	,	O
but	CC	O
it	PRP	O
provides	VBZ	O
only	RB	O
temporary	JJ	O
cosmetic	JJ	O
improvement	NN	O
.	.	O

Nonanimal	NNP	Pharmacological
stabilized	VBD	Pharmacological
hyaluronic	JJ	Pharmacological
acid	NN	Pharmacological
has	VBZ	O
reduced	VBN	O
potential	JJ	O
for	IN	O
immunogenicity	NN	O
and	CC	O
hypersensitivity	NN	O
and	CC	O
may	MD	O
provide	VB	O
a	DT	O
more	RBR	O
durable	JJ	O
aesthetic	JJ	O
result	NN	O
.	.	O

Sixty-eight	JJ	O
patients	NNS	O
with	IN	O
prominent	JJ	O
nasolabial	JJ	O
folds	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
intradermal	VB	O
treatment	NN	O
with	IN	O
nonanimal	JJ	Pharmacological
stabilized	VBN	Pharmacological
hyaluronic	JJ	Pharmacological
acid	NN	Pharmacological
gel	NN	Pharmacological
(	(	Pharmacological
Perlane	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
bovine	JJ	Pharmacological
collagen	NN	Pharmacological
(	(	Pharmacological
Zyplast	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
contralateral	JJ	O
sides	NNS	O
of	IN	O
the	DT	O
face	NN	O
.	.	O

On	IN	O
achievement	NN	O
of	IN	O
optimal	JJ	O
cosmetic	JJ	O
result	NN	O
(	(	O
baseline	NN	O
)	)	O
,	,	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
6	CD	O
months	NNS	O
;	:	O
bilateral	JJ	O
retreatment	NN	O
with	IN	O
Perlane	NNP	Pharmacological
was	VBD	O
offered	VBN	O
at	IN	O
6	CD	O
or	CC	O
9	CD	O
months	NNS	O
after	IN	O
baseline	NN	O
.	.	O

Responses	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
baseline	NN	O
.	.	O

Investigator-based	JJ	O
and	CC	O
patient-based	JJ	O
ratings	NNS	O
indicated	VBD	O
that	IN	O
Perlane	NNP	Pharmacological
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
Zyplast	NNP	Pharmacological
in	IN	O
maintaining	VBG	O
cosmetic	JJ	O
correction	NN	O
.	.	O

According	VBG	O
to	TO	O
investigator-based	JJ	O
Wrinkle	NNP	O
Severity	NNP	O
Rating	NNP	O
Scale	NNP	O
assessments	NNS	O
at	IN	O
6	CD	O
and	CC	O
9	CD	O
months	NNS	O
after	IN	O
baseline	NN	O
,	,	O
Perlane	NNP	Pharmacological
was	VBD	O
superior	JJ	O
in	IN	O
50.0	CD	O
percent	NN	O
and	CC	O
48.8	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
,	,	O
respectively	RB	O
,	,	O
whereas	IN	O
Zyplast	NNP	Pharmacological
was	VBD	O
superior	JJ	O
in	IN	O
10.3	CD	O
percent	NN	O
and	CC	O
14.0	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.0004	CD	O
)	)	O
.	.	O

Investigator-based	JJ	O
Global	NNP	O
Aesthetic	NNP	O
Improvement	NNP	O
Scale	NNP	O
assessment	NN	O
at	IN	O
9	CD	O
months	NNS	O
after	IN	O
baseline	NN	O
indicated	VBD	O
that	IN	O
Perlane	NNP	Pharmacological
was	VBD	O
superior	JJ	O
in	IN	O
48.8	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
,	,	O
whereas	IN	O
Zyplast	NNP	Pharmacological
was	VBD	O
superior	JJ	O
in	IN	O
14.0	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.0025	CD	O
)	)	O
.	.	O

Optimal	NNP	O
cosmetic	JJ	O
result	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
a	DT	O
smaller	JJR	O
volume	NN	O
of	IN	O
Perlane	NNP	Pharmacological
than	IN	O
Zyplast	NNP	Pharmacological
(	(	O
mean	NN	O
,	,	O
1.2	CD	O
ml	NN	O
versus	NN	O
2.1	CD	O
ml	NN	O
)	)	O
.	.	O

Local	JJ	O
injection-site	JJ	O
reactions	NNS	O
(	(	O
redness	NN	O
,	,	O
swelling	VBG	O
,	,	O
pruritus	NN	O
,	,	O
and	CC	O
induration	NN	O
)	)	O
were	VBD	O
less	RBR	O
frequent	JJ	O
with	IN	O
Perlane	NNP	Pharmacological
than	IN	O
with	IN	O
Zyplast	NNP	Pharmacological
.	.	Pharmacological

Delayed-onset	JJ	O
reactions	NNS	O
were	VBD	O
rare	JJ	O
and	CC	O
did	VBD	O
not	RB	O
reoccur	VB	O
after	IN	O
Perlane	NNP	Pharmacological
retreatment	NN	O
.	.	O

Perlane	NNP	Pharmacological
has	VBZ	O
acceptable	JJ	O
long-term	JJ	O
safety	NN	O
and	CC	O
offers	VBZ	O
a	DT	O
longer-lasting	JJ	O
aesthetic	JJ	O
improvement	NN	O
than	IN	O
Zyplast	NNP	Pharmacological
.	.	Pharmacological

Creon	NNP	Pharmacological
10,000	CD	Pharmacological
Minimicrospheres	NNP	Pharmacological
vs.	FW	O
Creon	NNP	Pharmacological
8,000	CD	Pharmacological
microspheres	NNS	Pharmacological
--	:	O
an	DT	O
open	JJ	O
randomised	VBN	O
crossover	NN	O
preference	NN	O
study	NN	O
.	.	O

Creon	NNP	Pharmacological
10,000	CD	Pharmacological
Minimicrospherestrade	NNP	Pharmacological
mark	NN	Pharmacological
(	(	Pharmacological
Creon	NNP	Pharmacological
)	)	Pharmacological
10,000	CD	Pharmacological
MMS	NNP	Pharmacological
)	)	Pharmacological
is	VBZ	O
a	DT	O
pancreatic	JJ	O
enzyme	NN	O
formulation	NN	O
that	IN	O
contains	VBZ	O
smaller	JJR	O
spheres	NNS	O
of	IN	O
pancreatin	NN	O
in	IN	O
a	DT	O
50	CD	O
%	NN	O
smaller	JJR	O
capsule	NN	O
than	IN	O
conventional	JJ	O
microspheres	NNS	Pharmacological
(	(	Pharmacological
Creon	NNP	Pharmacological
)	)	Pharmacological
8,000	CD	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

This	DT	O
three-centre	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
preference	NN	O
of	IN	O
cystic	JJ	O
fibrosis	NN	O
(	(	O
CF	NNP	O
)	)	O
patients	NNS	O
for	IN	O
these	DT	O
products	NNS	O
.	.	O

In	IN	O
one	CD	O
centre	NN	O
,	,	O
72	CD	O
h	NN	O
stool	NN	O
fat	JJ	O
excretion	NN	O
and	CC	O
coefficient	NN	O
of	IN	O
fat	JJ	O
absorption	NN	O
(	(	O
CFA	NNP	O
)	)	O
were	VBD	O
also	RB	O
compared	VBN	O
.	.	O

Fifty-nine	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
10	CD	O
years	NNS	O
(	(	O
range	VB	O
3-17	NNP	O
)	)	O
took	VBD	O
Creon	NNP	O
8,000	CD	O
ms	NN	O
for	IN	O
14	CD	O
days	NNS	O
and	CC	O
were	VBD	O
then	RB	O
randomised	VBN	O
to	TO	O
28	CD	O
days	NNS	O
of	IN	O
Creon	NNP	Pharmacological
8,000	CD	Pharmacological
ms	NN	Pharmacological
followed	VBN	O
by	IN	O
28	CD	O
days	NNS	O
of	IN	O
Creon	NNP	Pharmacological
10,000	CD	Pharmacological
MMS	NNP	Pharmacological
,	,	O
or	CC	O
vice	NN	O
versa	NN	O
.	.	O

Dosing	NNP	O
was	VBD	O
lipase	NN	O
for	IN	O
lipase	NN	O
according	VBG	O
to	TO	O
the	DT	O
labelled	VBN	O
declaration	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
second	JJ	O
treatment	NN	O
period	NN	O
,	,	O
51	CD	O
of	IN	O
54	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
expressed	VBD	O
a	DT	O
preference	NN	O
,	,	O
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
preference	NN	O
in	IN	O
favour	NN	O
of	IN	O
Creon	NNP	O
10,000	CD	O
MMS	NNP	O
(	(	O
47/51	CD	O
;	:	O
87	CD	O
%	NN	O
)	)	O
vs.	FW	O
Creon	NNP	O
8,000	CD	O
ms	NN	O
(	(	O
4/51	CD	O
;	:	O
7.4	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Stool	NNP	O
fat	NN	O
(	(	O
g/day	NN	O
)	)	O
and	CC	O
CFA	NNP	O
(	(	O
%	NN	O
)	)	O
were	VBD	O
measured	VBN	O
in	IN	O
24	CD	O
patients	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
treatment	NN	O
period	NN	O
:	:	O
the	DT	O
products	NNS	O
were	VBD	O
therapeutically	RB	O
equivalent	JJ	O
(	(	O
Creon	JJ	Pharmacological
10,000	CD	O
:	:	O
8.4	CD	O
g/day	NN	O
,	,	O
91.3	CD	O
%	NN	O
CFA	NNP	O
;	:	O
Creon	NNP	O
8,000	CD	O
:	:	O
6.7	CD	O
g/day	NN	O
,	,	O
93.5	CD	O
%	NN	O
CFA	NNP	O
)	)	O
.	.	O

Both	DT	O
products	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
in	IN	O
CF	NNP	O
children	NNS	O
we	PRP	O
found	VBD	O
a	DT	O
clear	JJ	O
preference	NN	O
for	IN	O
Creon	NNP	O
10,000	CD	O
MMS	NNP	O
compared	VBN	O
with	IN	O
Creon	NNP	O
8,000	CD	O
ms	NN	O
with	IN	O
no	DT	O
difference	NN	O
in	IN	O
fat	JJ	O
absorption	NN	O
between	IN	O
the	DT	O
two	CD	O
products	NNS	O
.	.	O

Creon	NNP	Pharmacological
10,000s	CD	O
smaller	JJR	O
capsules	NNS	O
are	VBP	O
easier	JJR	O
to	TO	O
take	VB	O
and	CC	O
should	MD	O
aid	VB	O
patient	NN	O
compliance	NN	O
.	.	O

Effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
Levitan	NNP	Physical
FPS	NNP	Physical
Scope?	NNP	Physical
for	IN	O
tracheal	JJ	O
intubation	NN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
with	IN	O
a	DT	O
simulated	JJ	O
difficult	JJ	O
airway	NN	O
.	.	O

PURPOSE	NNP	O
Studies	NNP	O
show	VBP	O
that	IN	O
the	DT	O
Levitan	NNP	Physical
FPS	NNP	Physical
(	(	Physical
first	JJ	Physical
pass	NN	Physical
success	NN	Physical
)	)	Physical
Scope?	NNP	Physical
(	(	Physical
LFS	NNP	Physical
)	)	Physical
is	VBZ	O
analogous	JJ	O
to	TO	O
a	DT	O
bougie	NN	O
in	IN	O
simulated	JJ	O
difficult	JJ	O
airways	NNS	O
with	IN	O
comparable	JJ	O
tracheal	JJ	O
intubation	NN	O
success	NN	O
rates	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
tracheal	JJ	O
intubation	NN	O
with	IN	O
the	DT	O
LFS	NNP	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
Macintosh	NNP	O
laryngoscope	NN	O
utilizing	VBG	O
manual	JJ	O
in-line	JJ	O
stabilization	NN	O
(	(	O
MILS	NNP	O
)	)	O
to	TO	O
simulate	VB	O
difficult	JJ	O
airways	NNS	O
.	.	O

METHODS	NNP	O
Ninety-four	JJ	O
subjects	NNS	O
successfully	RB	O
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

Manual	JJ	O
in-line	JJ	O
stabilization	NN	O
of	IN	O
the	DT	O
cervical	JJ	O
spine	NN	O
was	VBD	O
applied	VBN	O
and	CC	O
the	DT	O
initial	JJ	O
laryngoscopy	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
either	CC	O
the	DT	O
Macintosh	NNP	Physical
or	CC	O
the	DT	O
LFS	NNP	Physical
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
Macintosh	NNP	O
.	.	O

Following	VBG	O
the	DT	O
initial	JJ	O
grading	NN	O
,	,	O
a	DT	O
second	JJ	O
laryngoscopy	NN	O
was	VBD	O
repeated	VBN	O
using	VBG	O
the	DT	O
second	JJ	O
randomized	JJ	O
technique	NN	O
.	.	O

Cormack-Lehane	NNP	O
grades	NNS	O
,	,	O
percentage	NN	O
of	IN	O
glottic	JJ	O
opening	NN	O
(	(	O
POGO	NNP	O
)	)	O
scores	VBZ	O
,	,	O
time	NN	O
to	TO	O
intubate	VB	O
,	,	O
number	NN	O
of	IN	O
intubation	NN	O
attempts	NNS	O
,	,	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
alternate	NN	O
techniques	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
anesthesiologist	NN	O
rated	VBD	O
the	DT	O
subjective	JJ	O
difficulty	NN	O
in	IN	O
using	VBG	O
each	DT	O
technique	NN	O
with	IN	O
a	DT	O
numeric	JJ	O
rating	NN	O
scale	NN	O
and	CC	O
a	DT	O
visual	JJ	O
rating	NN	O
scale	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
good	JJ	O
laryngoscopic	NN	O
views	NNS	O
(	(	O
Cormack-Lehane	NNP	O
grade	VBD	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
compared	VBN	O
with	IN	O
poor	JJ	O
laryngoscopic	JJ	O
views	NNS	O
(	(	O
Cormack-Lehane	NNP	O
grade	VBD	O
3	CD	O
and	CC	O
4	CD	O
)	)	O
between	IN	O
the	DT	O
LFS	NNP	O
and	CC	O
the	DT	O
Macintosh	NNP	O
.	.	O

There	EX	O
were	VBD	O
higher	JJR	O
POGO	NNP	O
scores	NNS	O
with	IN	O
the	DT	O
LFS	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
Macintosh	NNP	O
(	(	O
80	CD	O
%	NN	O
vs	JJ	O
20	CD	O
%	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
translate	VB	O
to	TO	O
easier	JJR	O
intubations	NNS	O
,	,	O
as	IN	O
documented	VBN	O
by	IN	O
the	DT	O
need	NN	O
for	IN	O
an	DT	O
alternate	JJ	O
intubation	NN	O
technique	NN	O
or	CC	O
time	NN	O
to	TO	O
intubate	VB	O
(	(	O
<	JJ	O
30	CD	O
and	CC	O
<	$	O
60	CD	O
sec	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
mucosal	NN	O
trauma	NN	O
,	,	O
sore	RB	O
throat	NN	O
,	,	O
and	CC	O
hemodynamic	JJ	O
responses	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
techniques	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
LFS	NNP	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
Macintosh	NNP	Physical
laryngoscope	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
the	DT	O
efficacy	NN	O
or	CC	O
safety	NN	O
of	IN	O
tracheal	JJ	O
intubation	NN	O
in	IN	O
a	DT	O
simulated	JJ	O
difficult	JJ	O
airway	NN	O
.	.	O

The	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
fluid	JJ	O
intake	NN	O
on	IN	O
urine	JJ	O
specific	JJ	O
gravity	NN	O
and	CC	O
fluid	JJ	O
retention	NN	O
in	IN	O
a	DT	O
mildly	RB	O
dehydrated	JJ	O
state	NN	O
.	.	O

Many	JJ	O
athletes	NNS	O
arrive	VBP	O
at	IN	O
training	NN	O
sessions	NNS	O
and	CC	O
competitions	NNS	O
in	IN	O
a	DT	O
mildly	RB	O
hypohydrated	VBN	O
(	(	O
HYPO	NNP	O
)	)	O
state	NN	O
and	CC	O
are	VBP	O
instructed	VBN	O
to	TO	O
drink	VB	O
fluids	NNS	O
before	IN	O
exercise	NN	O
to	TO	O
reach	VB	O
a	DT	O
euhydrated	JJ	O
(	(	O
HYD	NNP	O
)	)	O
state	NN	O
.	.	O

Ten	CD	O
recreational	JJ	O
athletes	NNS	O
(	(	O
6	CD	O
women	NNS	O
,	,	O
4	CD	O
men	NNS	O
;	:	O
71.9	CD	O
?	.	O
4.6	CD	O
kg	NN	O
,	,	O
25.2	CD	O
?	.	O
0.9	CD	O
years	NNS	O
)	)	O
participated	VBD	O
in	IN	O
the	DT	O
studies	NNS	O
to	TO	O
examine	VB	O
(	(	O
a	DT	O
)	)	O
the	DT	O
day-to-day	JJ	O
variability	NN	O
of	IN	O
morning	NN	O
urine	NN	O
specific	JJ	O
gravity	NN	O
(	(	O
USG	NNP	O
)	)	O
,	,	O
(	(	O
b	NN	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
consuming	VBG	O
600	CD	Educational
ml	NN	Educational
of	IN	Educational
water	NN	Educational
on	IN	O
the	DT	O
hydration	NN	O
status	NN	O
of	IN	O
HYD	NNP	O
and	CC	O
HYPO	NNP	O
(	(	O
USG	NNP	O
>	NNP	O
1.020	CD	O
)	)	O
subjects	NNS	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
consuming	VBG	O
water	NN	Educational
(	(	Educational
W	NNP	Educational
)	)	Educational
,	,	O
salt-water	JJ	Educational
(	(	Educational
SW	NNP	O
,	,	O
40	CD	O
mM	NN	O
Na	NNP	O
)	)	O
,	,	O
a	DT	O
carbohydrate-electrolyte	JJ	Educational
solution	NN	Educational
with	IN	Educational
3	CD	Educational
%	NN	Educational
or	CC	Educational
light	JJ	Educational
carbohydrate	NN	Educational
(	(	Educational
CES-L	NNP	O
,	,	O
20	CD	O
mM	NN	O
Na	NNP	O
)	)	O
or	CC	O
a	DT	O
CES	NN	Educational
with	IN	Educational
6	CD	Educational
%	NN	Educational
carbohydrate	NN	Educational
(	(	Educational
CES	NNP	O
,	,	O
20	CD	O
mM	NN	O
Na	NNP	O
)	)	O
on	IN	O
the	DT	O
hydration	NN	O
status	NN	O
of	IN	O
HYPO	NNP	O
subjects	NNS	O
.	.	O

The	DT	O
hydration	NN	O
status	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
USG	NNP	O
and	CC	O
body	NN	O
mass	NN	O
measures	NNS	O
and	CC	O
urine	JJ	O
volume	NN	O
collections	NNS	O
.	.	O

The	DT	O
day-to-day	JJ	O
variability	NN	O
in	IN	O
morning	NN	O
USG	NNP	O
(	(	O
coefficient	NN	O
of	IN	O
variation	NN	O
=	FW	O
0.2	CD	O
?	.	O
0.1	CD	O
%	NN	O
)	)	O
was	VBD	O
low	JJ	O
and	CC	O
the	DT	O
responses	NNS	O
to	TO	O
600	CD	O
ml	NN	O
of	IN	O
W	NNP	O
ingestion	NN	O
were	VBD	O
repeatable	JJ	O
.	.	O

Pretrial	JJ	O
USG	NNP	O
was	VBD	O
1.022	CD	O
?	.	O
0.001	CD	O
in	IN	O
the	DT	O
HYPO	NNP	O
trial	NN	O
and	CC	O
decreased	VBD	O
<	NNS	O
1.020	CD	O
by	IN	O
45	CD	O
minutes	NNS	O
(	(	O
1.013	CD	O
?	.	O
0.003	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
CES	NNP	O
study	NN	O
,	,	O
HYPO	NNP	O
subjects	VBZ	O
reached	VBN	O
HYD	NNP	O
status	NN	O
at	IN	O
45	CD	O
minutes	NNS	O
in	IN	O
all	DT	O
conditions	NNS	O
(	(	O
W	NNP	O
1.013	CD	O
?	.	O
0.003	CD	O
,	,	O
SW	NNP	O
1.013	CD	O
?	.	O
0.003	CD	O
,	,	O
CES-L	NNP	O
1.011	CD	O
?	.	O
0.003	CD	O
,	,	O
CES	NNP	O
1.017	CD	O
?	.	O
0.004	CD	O
)	)	O
because	IN	O
salt	NN	O
or	CC	O
CES	NNP	O
ingestion	NN	O
did	VBD	O
not	RB	O
affect	VB	O
fluid	NN	O
retention	NN	O
(	(	O
W	NNP	O
68	CD	O
%	NN	O
,	,	O
SW	NNP	O
72	CD	O
%	NN	O
,	,	O
CES-L	JJ	O
68	CD	O
%	NN	O
,	,	O
CES	NNP	O
76	CD	O
%	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
mildly	RB	O
HYPO	NNP	O
subjects	NNS	O
could	MD	O
reach	VB	O
euhydration	NN	O
within	IN	O
45	CD	O
minutes	NNS	O
of	IN	O
the	DT	O
ingestion	NN	O
of	IN	O
600	CD	O
ml	NN	O
of	IN	O
W	NNP	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
salt	NN	O
and	CC	O
CES	NNP	O
solutions	NNS	O
.	.	O

Following	VBG	O
this	DT	O
practice	NN	O
will	MD	O
minimize	VB	O
the	DT	O
incidence	NN	O
of	IN	O
starting	VBG	O
a	DT	O
practice	NN	O
or	CC	O
competition	NN	O
hypohydrated	VBN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
breast	NN	O
size	NN	O
on	IN	O
late	JJ	O
radiation	NN	O
effects	NNS	O
and	CC	O
association	NN	O
with	IN	O
radiotherapy	NN	O
dose	JJ	O
inhomogeneity	NN	O
.	.	O

A	DT	O
prospective	JJ	O
assessment	NN	O
of	IN	O
late	JJ	O
changes	NNS	O
in	IN	O
breast	NN	O
appearance	NN	O
in	IN	O
559	CD	O
patients	NNS	O
after	IN	O
tumour	JJ	Surgical
excision	NN	Surgical
and	CC	O
radiotherapy	NN	Physical
for	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
noted	VBD	O
a	DT	O
strong	JJ	O
association	NN	O
with	IN	O
breast	NN	O
size	NN	O
.	.	O

Only	RB	O
3/48	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
patients	NNS	O
with	IN	O
small	JJ	O
breasts	NNS	O
developed	VBD	O
moderate	JJ	O
or	CC	O
severe	JJ	O
late	JJ	O
changes	NNS	O
compared	VBN	O
with	IN	O
94/423	CD	O
(	(	O
22	CD	O
%	NN	O
)	)	O
with	IN	O
medium	NN	O
sized	VBN	O
breasts	NNS	O
and	CC	O
34/88	CD	O
(	(	O
39	CD	O
%	NN	O
)	)	O
patients	NNS	O
with	IN	O
large	JJ	O
breasts	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

One	CD	O
possibility	NN	O
is	VBZ	O
that	IN	O
greater	JJR	O
radiation	NN	O
changes	NNS	O
are	VBP	O
related	VBN	O
to	TO	O
greater	JJR	O
dose	JJ	O
inhomogeneity	NN	O
in	IN	O
women	NNS	O
with	IN	O
large	JJ	O
breasts	NNS	O
.	.	O

To	TO	O
explore	VB	O
this	DT	O
hypothesis	NN	O
,	,	O
radiation	NN	O
dose	JJ	O
distributions	NNS	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
separate	JJ	O
group	NN	O
of	IN	O
37	CD	O
women	NNS	O
in	IN	O
whom	WP	O
three-level	JJ	O
transverse	NN	O
computer	NN	O
tomographic	JJ	O
images	NNS	O
of	IN	O
the	DT	O
breast	NN	O
in	IN	O
the	DT	O
treatment	NN	O
position	NN	O
were	VBD	O
available	JJ	O
.	.	O

A	DT	O
significant	JJ	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
breast	NN	O
size	NN	O
and	CC	O
dose	NN	O
inhomogeneity	NN	O
which	WDT	O
may	MD	O
account	VB	O
for	IN	O
the	DT	O
marked	JJ	O
changes	NNS	O
in	IN	O
breast	NN	O
appearance	NN	O
reported	VBD	O
in	IN	O
women	NNS	O
with	IN	O
large	JJ	O
breasts	NNS	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
vitamin/mineral	JJ	Pharmacological
supplement	NN	Pharmacological
on	IN	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
autism	NN	O
.	.	O

BACKGROUND	NNP	O
Vitamin/mineral	NNP	Pharmacological
supplements	NNS	Pharmacological
are	VBP	O
among	IN	O
the	DT	O
most	RBS	O
commonly	RB	O
used	JJ	O
treatments	NNS	O
for	IN	O
autism	NN	O
,	,	O
but	CC	O
the	DT	O
research	NN	O
on	IN	O
their	PRP$	O
use	NN	O
for	IN	O
treating	VBG	O
autism	NN	O
has	VBZ	O
been	VBN	O
limited	VBN	O
.	.	O

METHOD	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
three	CD	O
month	NN	O
vitamin/mineral	JJ	Pharmacological
treatment	NN	Pharmacological
study	NN	Pharmacological
.	.	Pharmacological

The	DT	O
study	NN	O
involved	VBD	O
141	CD	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
autism	NN	O
,	,	O
and	CC	O
pre	NN	O
and	CC	O
post	NN	O
symptoms	NNS	O
of	IN	O
autism	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
participants	NNS	O
had	VBD	O
taken	VBN	O
a	DT	O
vitamin/mineral	JJ	Pharmacological
supplement	NN	Pharmacological
in	IN	O
the	DT	O
two	CD	O
months	NNS	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

For	IN	O
a	DT	O
subset	NN	O
of	IN	O
the	DT	O
participants	NNS	O
(	(	O
53	CD	O
children	NNS	O
ages	VBZ	O
5-16	JJ	O
)	)	O
pre	NN	O
and	CC	O
post	NN	O
measurements	NNS	O
of	IN	O
nutritional	JJ	O
and	CC	O
metabolic	JJ	O
status	NN	O
were	VBD	O
also	RB	O
conducted	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
vitamin/mineral	JJ	Pharmacological
supplement	NN	Pharmacological
was	VBD	O
generally	RB	O
well-tolerated	JJ	O
,	,	O
and	CC	O
individually	RB	O
titrated	VBN	O
to	TO	O
optimum	JJ	O
benefit	NN	O
.	.	O

Levels	NNP	O
of	IN	O
many	JJ	O
vitamins	NNS	O
,	,	O
minerals	NNS	O
,	,	O
and	CC	O
biomarkers	NNS	O
improved/increased	VBD	O
showing	VBG	O
good	JJ	O
compliance	NN	O
and	CC	O
absorption	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
improvements	NNS	O
in	IN	O
metabolic	JJ	O
status	NN	O
were	VBD	O
many	JJ	O
including	VBG	O
:	:	O
total	JJ	O
sulfate	NN	O
(	(	O
+17	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
S-adenosylmethionine	NNP	O
(	(	O
SAM	NNP	O
;	:	O
+6	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.003	CD	O
)	)	O
,	,	O
reduced	VBD	O
glutathione	NN	O
(	(	O
+17	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.0008	CD	O
)	)	O
,	,	O
ratio	NN	O
of	IN	O
oxidized	JJ	O
glutathione	NN	O
to	TO	O
reduced	VB	O
glutathione	NN	O
(	(	O
GSSG	NNP	O
:	:	O
GSH	NNP	O
;	:	O
-27	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.002	CD	O
)	)	O
,	,	O
nitrotyrosine	JJ	O
(	(	O
-29	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
ATP	NNP	O
(	(	O
+25	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.000001	CD	O
)	)	O
,	,	O
NADH	NNP	O
(	(	O
+28	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.0002	CD	O
)	)	O
,	,	O
and	CC	O
NADPH	NNP	O
(	(	O
+30	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

Most	JJS	O
of	IN	O
these	DT	O
metabolic	JJ	O
biomarkers	NNS	O
improved	VBN	O
to	TO	O
normal	JJ	O
or	CC	O
near-normal	JJ	O
levels.The	JJ	O
supplement	NN	Pharmacological
group	NN	O
had	VBD	O
significantly	RB	O
greater	JJR	O
improvements	NNS	O
than	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
on	IN	O
the	DT	O
Parental	NNP	O
Global	NNP	O
Impressions-Revised	JJ	O
(	(	O
PGI-R	NNP	O
,	,	O
Average	NNP	O
Change	NNP	O
,	,	O
p	NN	O
=	NNP	O
0.008	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
subscores	NNS	O
for	IN	O
Hyperactivity	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
,	,	O
Tantrumming	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.009	CD	O
)	)	O
,	,	O
Overall	NNP	O
(	(	O
p	NN	O
=	RB	O
0.02	CD	O
)	)	O
,	,	O
and	CC	O
Receptive	JJ	O
Language	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

For	IN	O
the	DT	O
other	JJ	O
three	CD	O
assessment	NN	O
tools	VBZ	O
the	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
group	NN	O
and	CC	O
placebo	NN	O
group	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant.Regression	JJ	O
analysis	NN	O
revealed	VBD	O
that	IN	O
the	DT	O
degree	NN	O
of	IN	O
improvement	NN	O
on	IN	O
the	DT	O
Average	JJ	O
Change	NN	O
of	IN	O
the	DT	O
PGI-R	NNP	O
was	VBD	O
strongly	RB	O
associated	VBN	O
with	IN	O
several	JJ	O
biomarkers	NNS	O
(	(	O
adj	NN	O
.	.	O

R2	NNP	O
=	VBD	O
0.61	CD	O
,	,	O
p	NN	O
<	NNP	O
0.0005	CD	O
)	)	O
with	IN	O
the	DT	O
initial	JJ	O
levels	NNS	O
of	IN	O
biotin	NN	O
and	CC	O
vitamin	NN	O
K	NNP	O
being	VBG	O
the	DT	O
most	RBS	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
both	DT	O
biotin	NN	O
and	CC	O
vitamin	NN	O
K	NNP	O
are	VBP	O
made	VBN	O
by	IN	O
beneficial	JJ	O
intestinal	JJ	O
flora	NN	O
.	.	O

CONCLUSIONS	NNP	O
Oral	NNP	O
vitamin/mineral	JJ	Pharmacological
supplementation	NN	Pharmacological
is	VBZ	O
beneficial	JJ	O
in	IN	O
improving	VBG	O
the	DT	O
nutritional	JJ	O
and	CC	O
metabolic	JJ	O
status	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
including	VBG	O
improvements	NNS	O
in	IN	O
methylation	NN	O
,	,	O
glutathione	NN	O
,	,	O
oxidative	JJ	O
stress	NN	O
,	,	O
sulfation	NN	O
,	,	O
ATP	NNP	O
,	,	O
NADH	NNP	O
,	,	O
and	CC	O
NADPH	NNP	O
.	.	O

The	DT	O
supplement	NN	Pharmacological
group	NN	O
had	VBD	O
significantly	RB	O
greater	JJR	O
improvements	NNS	O
than	IN	O
did	VBD	O
the	DT	O
placebo	NN	Control
group	NN	O
on	IN	O
the	DT	O
PGI-R	JJ	O
Average	JJ	O
Change	NN	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
a	DT	O
vitamin/mineral	JJ	Pharmacological
supplement	NN	Pharmacological
is	VBZ	O
a	DT	O
reasonable	JJ	O
adjunct	JJ	O
therapy	NN	O
to	TO	O
consider	VB	O
for	IN	O
most	JJS	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
autism	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
NUMBER	NNP	O
NCT01225198	NNP	O
.	.	O

Tetracaine	NNP	Pharmacological
(	(	Pharmacological
ametop	NN	Pharmacological
)	)	Pharmacological
compared	VBN	O
to	TO	O
placebo	VB	O
for	IN	O
reducing	VBG	O
pain	NN	O
associated	VBN	O
with	IN	O
intramuscular	JJ	O
injection	NN	O
of	IN	O
palivizumab	NN	O
(	(	O
synagis	NN	O
)	)	O
.	.	O

Infants	NNS	O
receive	VBP	O
many	JJ	O
painful	JJ	O
immunizations	NNS	O
before	IN	O
they	PRP	O
are	VBP	O
2	CD	O
years	NNS	O
old	JJ	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
if	IN	O
topical	JJ	Pharmacological
tetracaine	NN	Pharmacological
reduces	VBZ	O
the	DT	O
pain	NN	O
of	IN	O
intramuscular	JJ	O
palivizumab	NNS	Pharmacological
compared	VBN	O
to	TO	O
placebo	VB	Control
.	.	Control

There	EX	O
were	VBD	O
two	CD	O
study	NN	O
injections	NNS	O
,	,	O
one	CD	O
with	IN	O
tetracaine	NN	Pharmacological
and	CC	O
one	CD	O
with	IN	O
placebo	NN	Control
.	.	Control

Pain	NN	O
was	VBD	O
scored	VBN	O
by	IN	O
their	PRP$	O
parents	NNS	O
and	CC	O
a	DT	O
pediatric	JJ	O
nurse	NN	O
.	.	O

Topical	JJ	O
tetracaine	NN	Pharmacological
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
pain	NN	O
score	NN	O
,	,	O
although	IN	O
it	PRP	O
did	VBD	O
lead	VB	O
to	TO	O
faster	VB	O
recovery	NN	O
times	NNS	O
.	.	O

Additional	JJ	O
pain-reduction	NN	O
strategies	NNS	O
are	VBP	O
required	VBN	O
.	.	O

Effect	NN	O
of	IN	O
upper	JJ	O
arm	NN	O
brachial	NN	O
basilic	NN	O
and	CC	O
prosthetic	JJ	O
forearm	NN	O
arteriovenous	JJ	O
fistula	NN	O
on	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
.	.	O

BACKGROUND	NNP	O
Creation	NNP	O
of	IN	O
an	DT	O
arteriovenous	JJ	O
fistula	NN	O
(	(	O
AVF	NNP	O
)	)	O
may	MD	O
increase	VB	O
left	VBD	O
ventricular	JJ	O
hypertrophy	NN	O
in	IN	O
the	DT	O
hemodialysis	NN	O
population	NN	O
.	.	O

Aim	NNP	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
brachial-basilic	JJ	Physical
(	(	Physical
BB	NNP	Physical
)	)	Physical
AVF	NNP	Physical
and	CC	O
the	DT	O
prosthetic	JJ	Physical
brachial-antecubital	JJ	Physical
forearm	NN	Physical
loop	NN	Physical
access	NN	Physical
(	(	O
PTFE	NNP	O
)	)	O
on	IN	O
cardiac	JJ	O
performance	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
BB-AVF	NNP	Physical
or	CC	Physical
prosthetic	JJ	Physical
brachial-antecubital	JJ	Physical
forearm	NN	Physical
loop	NN	Physical
access	NN	Physical
.	.	Physical

Before	IN	O
and	CC	O
three	CD	O
months	NNS	O
after	IN	O
AVF	NNP	O
creation	NN	O
patients	NNS	O
underwent	VBD	O
an	DT	O
echocardiographic	JJ	O
examination	NN	O
.	.	O

Mann-Whitney	JJ	O
U-test	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
relative	JJ	O
increase	NN	O
between	IN	O
the	DT	O
measured	JJ	O
cardiac	JJ	O
parameters	NNS	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Twenty-seven	JJ	O
patients	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
relative	JJ	O
increase	NN	O
in	IN	O
left	JJ	O
ventricular	JJ	O
parameters	NNS	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Only	RB	O
left	VBD	O
ventricular	JJ	O
end-diastolic	JJ	O
diameter	NN	O
tended	VBD	O
to	TO	O
be	VB	O
of	IN	O
significance	NN	O
.	.	O

Mean	NNP	O
blood	NN	O
flow	NN	O
through	IN	O
the	DT	O
brachial	JJ	O
artery	NN	O
was	VBD	O
1680+/-156	JJ	O
and	CC	O
1450+/-221	JJ	O
mL/min	NNS	O
three	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
for	IN	O
the	DT	O
PTFE	NNP	O
and	CC	O
the	DT	O
BB-AVF	NNP	O
group	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	NN	O
After	IN	O
three	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
changes	NNS	O
in	IN	O
cardiac	JJ	O
structure	NN	O
were	VBD	O
comparable	JJ	O
between	IN	O
patients	NNS	O
with	IN	O
BB	NNP	O
and	CC	O
PTFE	NNP	O
AVFs	NNP	O
.	.	O

Also	RB	O
access	NN	O
flow	NN	O
was	VBD	O
comparable	JJ	O
at	IN	O
this	DT	O
time	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
creation	NN	O
of	IN	O
a	DT	O
fistula	NN	O
on	IN	O
LV	NNP	O
structure	NN	O
were	VBD	O
limited	VBN	O
.	.	O

Longer	RBR	O
follow	VB	O
up	RP	O
time	NN	O
may	MD	O
be	VB	O
needed	VBN	O
to	TO	O
explore	VB	O
the	DT	O
long	JJ	O
term	NN	O
effects	NNS	O
of	IN	O
different	JJ	O
vascular	JJ	O
accesses	NNS	O
on	IN	O
cardiac	JJ	O
function	NN	O
.	.	O

Monitoring	VBG	O
tumour	NN	O
cells	NNS	O
in	IN	O
the	DT	O
peripheral	JJ	O
blood	NN	O
of	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Flow	NNP	Other
cytometry	NN	Other
was	VBD	O
used	VBN	O
to	TO	O
enumerate	VB	O
tumour	JJ	O
cells	NNS	O
in	IN	O
longitudinal	JJ	O
studies	NNS	O
of	IN	O
peripheral	JJ	O
blood	NN	O
from	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
SCLC	NNP	O
)	)	O
patients	NNS	O
,	,	O
together	RB	O
with	IN	O
magnetic	JJ	O
bead	NN	O
selection	NN	O
to	TO	O
isolate	VB	O
and	CC	O
identify	VB	O
these	DT	O
cells	NNS	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
a	DT	O
trial	NN	O
,	,	O
11	CD	O
patients	NNS	O
received	VBD	O
either	RB	O
standard	JJ	O
(	(	O
four	CD	O
weekly	RB	O
)	)	O
chemotherapy	NN	Pharmacological
with	IN	O
ifosfamide	NN	Pharmacological
,	,	O
carboplatin	NN	Pharmacological
,	,	O
and	CC	O
etoposide	RB	Pharmacological
(	(	Pharmacological
ICE	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
accelerated	VBN	O
(	(	O
two	CD	O
weekly	RB	O
)	)	O
ICE	NNP	Pharmacological
with	IN	Pharmacological
filgrastim	NN	Pharmacological
(	(	Pharmacological
granulocyte	JJ	Pharmacological
colony-stimulating	NN	Pharmacological
factor	NN	Pharmacological
[	IN	Pharmacological
G-CSF	NNP	Pharmacological
]	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
autologous	JJ	Pharmacological
stem	NN	Pharmacological
cell	NN	Pharmacological
support	NN	Pharmacological
.	.	O

METHODS	NNP	O
Fresh	NNP	O
venous	JJ	O
blood	NN	O
was	VBD	O
taken	VBN	O
throughout	IN	O
treatment	NN	O
and	CC	O
follow-up	NN	O
.	.	O

Aliquots	NNS	O
were	VBD	O
stained	VBN	O
with	IN	O
a	DT	O
tumour-specific	JJ	O
antibody	NN	O
against	IN	O
epithelial	JJ	O
tissue	NN	O
(	(	O
Ber	NNP	O
EP4	NNP	O
)	)	O
,	,	O
verified	VBD	O
as	IN	O
a	DT	O
good	JJ	O
marker	NN	O
of	IN	O
SCLC	NNP	O
cells	NNS	O
by	IN	O
immunohistochemistry	NN	O
.	.	O

Matched	NNP	O
samples	NNS	O
labelled	VBD	O
with	IN	O
Ber	NNP	O
EP4	NNP	O
were	VBD	O
separated	VBN	O
magnetically	RB	O
by	IN	O
adding	VBG	O
a	DT	O
secondary	JJ	O
bead-antibody	NN	O
conjugate	NN	O
for	IN	O
confirmation	NN	O
of	IN	O
tumour	NN	O
cell	NN	O
identity	NN	O
.	.	O

RESULTS	NNP	O
Circulating	NNP	O
tumour	JJ	O
cells	NNS	O
were	VBD	O
detected	VBN	O
and	CC	O
monitored	VBN	O
throughout	IN	O
treatment	NN	O
periods	NNS	O
.	.	O

An	DT	O
initial	JJ	O
rise	NN	O
in	IN	O
circulating	VBG	O
cells	NNS	O
after	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
fall	NN	O
in	IN	O
both	DT	O
treatment	NN	O
arms	NNS	O
to	TO	O
baseline	NN	O
levels	NNS	O
set	VBN	O
by	IN	O
normal	JJ	O
controls	NNS	O
.	.	O

This	DT	O
was	VBD	O
achieved	VBN	O
by	IN	O
week	NN	O
12	CD	O
in	IN	O
the	DT	O
accelerated	JJ	O
treatment	NN	O
arm	NN	O
and	CC	O
by	IN	O
week	NN	O
24	CD	O
in	IN	O
the	DT	O
standard	JJ	O
arm	NN	O
.	.	O

CONCLUSIONS	NNP	O
Flow	NNP	O
cytometry	NN	O
and	CC	O
magnetic	JJ	O
bead	NN	O
isolation	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
identify	VB	O
changes	NNS	O
in	IN	O
numbers	NNS	O
of	IN	O
circulating	VBG	O
tumour	JJ	O
cells	NNS	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
chemotherapy	NN	Pharmacological
for	IN	O
SCLC	NNP	O
and	CC	O
thereafter	RB	O
during	IN	O
follow-up	JJ	O
periods	NNS	O
.	.	O

Absence	NN	O
of	IN	O
tumour	JJ	O
cells	NNS	O
may	MD	O
indicate	VB	O
a	DT	O
more	RBR	O
favourable	JJ	O
patient	NN	O
group	NN	O
who	WP	O
would	MD	O
benefit	VB	O
from	IN	O
a	DT	O
more	RBR	O
intense	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
.	.	O

Effects	NNS	O
of	IN	O
sibutramine	NN	Pharmacological
on	IN	O
thermogenesis	NN	O
in	IN	O
obese	JJ	O
patients	NNS	O
assessed	VBD	O
via	IN	O
immersion	NN	O
calorimetry	NN	O
.	.	O

Glucose	NNP	O
utilization	JJ	O
studies	NNS	O
show	VBP	O
that	IN	O
sibutramine-induced	JJ	Pharmacological
thermogenesis	NN	O
is	VBZ	O
mediated	VBN	O
via	IN	O
selective	JJ	O
sympathetic	JJ	O
activation	NN	O
of	IN	O
brown	JJ	O
adipose	JJ	O
tissue	NN	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
use	VB	O
a	DT	O
new	JJ	O
calorimetry	NN	O
method	NN	O
in	IN	O
which	WDT	O
resting	VBG	O
metabolic	JJ	O
rate	NN	O
is	VBZ	O
enhanced	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
sibutramine	JJ	Pharmacological
treatment	NN	O
on	IN	O
thermogenesis	NN	O
.	.	O

Sixty	NNP	O
obese	JJ	O
women	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
2	CD	O
equal	JJ	O
groups-the	JJ	O
placebo	NN	Control
and	CC	O
sibutramine	JJ	Pharmacological
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
sibutramine	NN	Pharmacological
group	NN	O
was	VBD	O
given	VBN	O
sibutramine	JJ	Pharmacological
10	CD	O
mg	JJ	O
daily	RB	O
for	IN	O
12	CD	O
wk	NN	O
.	.	O

At	IN	O
baseline	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
12-wk	JJ	O
treatment	NN	O
period	NN	O
,	,	O
thermogenic	JJ	O
measurements	NNS	O
were	VBD	O
taken	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
water	NN	O
immersion	NN	O
calorimetry	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
examined	VBN	O
at	IN	O
weeks	NNS	O
4	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
12	CD	O
of	IN	O
treatment	NN	O
to	TO	O
identify	VB	O
adverse	JJ	O
effects	NNS	O
.	.	O

Body	NNP	O
mass	NN	O
index	NN	O
,	,	O
measured	VBN	O
at	IN	O
31.5+/-2.05	JJ	O
kg/m2	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
decreased	VBN	O
to	TO	O
30.4+/-2.94	JJ	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
after	IN	O
12	CD	O
wk	NN	O
(	(	O
P=.07	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
sibutramine	NN	Pharmacological
group	NN	O
,	,	O
it	PRP	O
decreased	VBD	O
from	IN	O
33.5+/-4.1	JJ	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
to	TO	O
30.9+/-4.8	JJ	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
sibutramine	NN	Pharmacological
group	NN	O
,	,	O
mean	VBP	O
thermogenic	JJ	O
response	NN	O
changed	VBD	O
from	IN	O
a	DT	O
baseline	NN	O
value	NN	O
of	IN	O
1.27+/-0.29	JJ	O
kcal/kg/h	NN	O
to	TO	O
1.44+/-0.13	JJ	O
kcal/kg/h	NN	O
after	IN	O
12	CD	O
wk	NN	O
of	IN	O
treatment	NN	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
the	DT	O
baseline	NN	O
value	NN	O
was	VBD	O
1.56+/-0.27	JJ	O
kcal/kg/h	NN	O
;	:	O
it	PRP	O
changed	VBD	O
to	TO	O
1.33+/-0.36	JJ	O
kcal/kg/h	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
12	CD	O
wk	NN	O
.	.	O

The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
sibutramine	NN	O
treatment	NN	O
promotes	VBZ	O
thermogenesis	NN	O
,	,	O
thus	RB	O
facilitating	VBG	O
weight	JJ	O
loss	NN	O
.	.	O

Calorimetry	NNP	O
enhances	VBZ	O
resting	VBG	O
metabolism	NN	O
through	IN	O
more	RBR	O
efficient	JJ	O
heat	NN	O
transfer	NN	O
from	IN	O
the	DT	O
body	NN	O
.	.	O

[	JJ	O
Methodologic	NNP	O
comparison	NN	O
of	IN	O
the	DT	O
polyfrequency	NN	Physical
oscillation	NN	Physical
method	NN	Physical
,	,	O
transcutaneous	JJ	O
oxygen	NN	O
pressure	NN	O
measurement	NN	O
and	CC	O
body	NN	O
plethysmography	NN	O
in	IN	O
bronchial	JJ	O
provocation	NN	O
with	IN	O
methacholine	JJ	Pharmacological
]	NN	O
.	.	O

A	DT	O
bronchial	JJ	O
provocation	NN	O
challenge	NN	O
test	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
30	CD	O
subjects	NNS	O
using	VBG	O
metacholin	NN	Pharmacological
.	.	Pharmacological

In	IN	O
randomised	JJ	O
sequence	NN	O
lung	NN	O
function	NN	O
analysis	NN	O
tests	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
with	IN	O
the	DT	O
bodyplethysmograph	NN	Physical
(	(	O
Raw	NNP	O
,	,	O
FEV1	NNP	O
)	)	O
and	CC	O
the	DT	O
polyfrequent	JJ	O
oscillation	NN	O
method	NN	O
(	(	O
resistance	NN	O
,	,	O
reactance	NN	O
between	IN	O
2	CD	O
and	CC	O
52	CD	O
Hz	NNP	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
transcutaneous	JJ	Pharmacological
oxygen	NN	Pharmacological
pressure	NN	Pharmacological
(	(	O
tc-PO2	JJ	O
)	)	O
was	VBD	O
measured	VBN	O
continuously	RB	O
.	.	O

Correlations	NNS	O
between	IN	O
the	DT	O
various	JJ	O
parameters	NNS	O
,	,	O
the	DT	O
change	NN	O
of	IN	O
the	DT	O
values	NNS	O
at	IN	O
PD60	NNP	O
sGaw	NN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
initial	JJ	O
values	NNS	O
,	,	O
the	DT	O
interindividual	JJ	O
variability	NN	O
and	CC	O
the	DT	O
reactivity	NN	O
were	VBD	O
determined	VBN	O
.	.	O

Medium	JJ	O
correlations	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
oscillatory	NN	O
parameters	NNS	O
and	CC	O
Raw	NNP	O
,	,	O
whereas	IN	O
for	IN	O
tc-PO2	NN	O
and	CC	O
Raw	NNP	O
the	DT	O
correlation	NN	O
was	VBD	O
markedly	RB	O
lower	JJR	O
.	.	O

In	IN	O
terms	NNS	O
of	IN	O
percentage	NN	O
the	DT	O
greatest	JJS	O
change	NN	O
was	VBD	O
found	VBN	O
in	IN	O
reactance	NN	O
,	,	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
initial	JJ	O
value	NN	O
,	,	O
followed	VBN	O
by	IN	O
Raw	NNP	O
and	CC	O
FEV1	NNP	O
.	.	O

The	DT	O
interindividual	JJ	O
variability	NN	O
resulted	VBD	O
in	IN	O
the	DT	O
highest	JJS	O
values	NNS	O
for	IN	O
the	DT	O
reactance	NN	O
,	,	O
followed	VBN	O
by	IN	O
Raw	NNP	O
and	CC	O
FEV1	NNP	O
.	.	O

Interindividual	NNP	O
variability	NN	O
showed	VBD	O
the	DT	O
highest	JJS	O
values	NNS	O
for	IN	O
the	DT	O
reactance	NN	O
before	IN	O
oscillatory	JJ	O
resistance	NN	O
and	CC	O
Raw	NNP	O
.	.	O

In	IN	O
respect	NN	O
of	IN	O
reactivity	NN	O
,	,	O
reactance	NN	O
also	RB	O
had	VBD	O
the	DT	O
highest	JJS	O
values	NNS	O
.	.	O

Overall	JJ	O
evaluation	NN	O
showed	VBD	O
that	IN	O
bodyplethysmography	NN	Physical
and	CC	O
the	DT	O
polyfrequent	JJ	Physical
oscillation	NN	Physical
method	NN	Physical
(	(	O
reactance	NN	O
or	CC	O
resonance	NN	O
frequency	NN	O
)	)	O
are	VBP	O
comparably	RB	O
sensitive	JJ	O
.	.	O

[	RB	O
Long	NNP	O
term	NN	O
observation	NN	O
in	IN	O
effects	NNS	O
of	IN	O
potassium	NN	Pharmacological
and	CC	O
calcium	NN	Pharmacological
supplementation	NN	Pharmacological
on	IN	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
sodium	NN	O
metabolism	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
higher	JJR	O
blood	NN	O
pressure	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
potassium	NN	Pharmacological
and	CC	O
calcium	NN	Pharmacological
supplementation	NN	Pharmacological
in	IN	O
table	JJ	O
salt	NN	O
on	IN	O
reduction	NN	O
of	IN	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
sodium	NN	O
metabolism	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
higher	JJR	O
blood	NN	O
pressure	NN	O
.	.	O

METHODS	CC	O
A	DT	O
single	JJ	O
blind	NN	O
placebo-controlled	JJ	Control
trial	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
for	IN	O
two	CD	O
years	NNS	O
in	IN	O
220	CD	O
adolescents	NNS	O
with	IN	O
higher	JJR	O
blood	NN	O
pressure	NN	O
,	,	O
aged	VBD	O
18	CD	O
-	:	O
22	CD	O
years	NNS	O
,	,	O
who	WP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
supplementary	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	O
)	)	O
and	CC	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	O
)	)	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
subjects	NNS	O
in	IN	O
the	DT	O
supplementary	JJ	O
group	NN	O
and	CC	O
their	PRP$	O
family	NN	O
members	NNS	O
was	VBD	O
given	VBN	O
10	CD	O
mmol	NN	O
of	IN	O
potassium	NN	Pharmacological
and	CC	O
10	CD	O
mmol	NN	O
of	IN	O
calcium	NN	Pharmacological
mixed	VBN	O
in	IN	O
their	PRP$	O
table	JJ	O
salt	JJ	O
daily	RB	O
for	IN	O
24	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Night	NNP	O
urinary	JJ	O
sodium	NN	O
and	CC	O
potassium	JJ	O
excretion	NN	O
increased	VBD	O
(	(	O
urinary	JJ	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
;	:	O
urinary	JJ	O
K	NNP	O
(	(	O
+	NNP	O
)	)	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
blood	NN	O
pressure	NN	O
lowered	VBN	O
by	IN	O
5.3	CD	O
mm	NNS	O
Hg/1.8	NNP	O
mm	NN	O
Hg	NNP	O
in	IN	O
average	NN	O
from	IN	O
the	DT	O
baseline	NN	O
in	IN	O
the	DT	O
supplementary	JJ	O
group	NN	O
two	CD	O
years	NNS	O
after	IN	O
potassium	NN	Pharmacological
and	CC	O
calcium	NN	Pharmacological
supplementation	NN	Pharmacological
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
increased	VBN	O
by	IN	O
(	(	O
1.3/1.7	CD	O
)	)	O
mm	NN	O
Hg	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Adequate	NNP	O
supplement	NN	Pharmacological
of	IN	Pharmacological
potassium	NN	Pharmacological
and	CC	O
calcium	NN	Pharmacological
in	IN	O
daily	JJ	O
table	JJ	O
salt	NN	O
intake	NN	O
was	VBD	O
an	DT	O
effective	JJ	O
way	NN	O
to	TO	O
prevent	VB	O
form	NN	O
hypertension	NN	O
and	CC	O
could	MD	O
promote	VB	O
their	PRP$	O
urinary	JJ	O
sodium	NN	O
excretion	NN	O
and	CC	O
reduction	NN	O
of	IN	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
higher	JJR	O
blood	NN	O
pressure	NN	O
.	.	O

Long-term	JJ	O
exposure	NN	O
to	TO	O
belatacept	VB	O
in	IN	O
recipients	NNS	O
of	IN	O
extended	JJ	O
criteria	NNS	O
donor	JJ	O
kidneys	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
BENEFIT-EXT	NNP	O
study	NN	O
received	VBD	O
extended	JJ	O
criteria	NNS	O
donor	JJ	O
kidneys	NNS	O
and	CC	O
a	DT	O
more	RBR	O
intensive	JJ	Pharmacological
(	(	Pharmacological
MI	NNP	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
less	RBR	Pharmacological
intensive	JJ	Pharmacological
(	(	Pharmacological
LI	NNP	Pharmacological
)	)	Pharmacological
belatacept	IN	Pharmacological
immunosuppression	NN	Pharmacological
regimen	NNS	Pharmacological
,	,	O
or	CC	O
cyclosporine	VB	Pharmacological
A	NNP	Pharmacological
(	(	Pharmacological
CsA	NNP	Pharmacological
)	)	Pharmacological
.	.	O

Patients	NNS	O
who	WP	O
remained	VBD	O
on	IN	O
assigned	JJ	O
therapy	NN	O
through	IN	O
year	NN	O
3	CD	O
were	VBD	O
eligible	JJ	O
to	TO	O
enter	VB	O
a	DT	O
long-term	JJ	O
extension	NN	O
(	(	O
LTE	NNP	O
)	)	O
study	NN	O
.	.	O

Three	CD	O
hundred	VBD	O
four	CD	O
patients	NNS	O
entered	VBD	O
the	DT	O
LTE	NNP	O
(	(	O
n	JJ	O
=	$	O
104	CD	O
MI	NNP	O
;	:	O
n	CC	O
=	$	O
113	CD	O
LI	NNP	O
;	:	O
n	CC	O
=	$	O
87	CD	O
CsA	NNP	O
)	)	O
,	,	O
and	CC	O
260	CD	O
continued	VBD	O
treatment	NN	O
through	IN	O
year	NN	O
5	CD	O
(	(	O
n	JJ	O
=	$	O
91	CD	O
MI	NNP	O
;	:	O
n	CC	O
=	$	O
100	CD	O
LI	NNP	O
;	:	O
n	CC	O
=	$	O
69	CD	O
CsA	NNP	O
)	)	O
.	.	O

Twenty	CD	O
patients	NNS	O
died	VBD	O
during	IN	O
the	DT	O
LTE	NNP	O
(	(	O
n	JJ	O
=	$	O
5	CD	O
MI	NNP	O
;	:	O
n	CC	O
=	$	O
9	CD	O
LI	NNP	O
;	:	O
n	CC	O
=	$	O
6	CD	O
CsA	NNP	O
)	)	O
,	,	O
and	CC	O
eight	CD	O
experienced	VBD	O
graft	NN	O
loss	NN	O
(	(	O
n	JJ	O
=	$	O
2	CD	O
MI	NNP	O
;	:	O
n	CC	O
=	$	O
1	CD	O
LI	NNP	O
;	:	O
n	CC	O
=	$	O
5	CD	O
CsA	NNP	O
)	)	O
.	.	O

Three	CD	O
patients	NNS	O
experienced	VBD	O
an	DT	O
acute	JJ	O
rejection	NN	O
episode	NN	O
(	(	O
n	JJ	O
=	$	O
2	CD	O
MI	NNP	O
;	:	O
n	CC	O
=	$	O
1	CD	O
LI	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
rate	NN	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
,	,	O
viral	JJ	O
infections	NNS	O
and	CC	O
fungal	JJ	O
infections	NNS	O
was	VBD	O
similar	JJ	O
across	IN	O
groups	NNS	O
during	IN	O
the	DT	O
LTE	NNP	O
.	.	O

There	EX	O
were	VBD	O
four	CD	O
cases	NNS	O
of	IN	O
posttransplant	JJ	O
lymphoproliferative	JJ	O
disorder	NN	O
(	(	O
PTLD	NNP	O
)	)	O
from	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
LTE	NNP	O
to	TO	O
year	NN	O
5	CD	O
(	(	O
n	JJ	O
=	$	O
3	CD	O
LI	NNP	O
;	:	O
n	CC	O
=	$	O
1	CD	O
CsA	NNP	O
)	)	O
;	:	O
two	CD	O
of	IN	O
three	CD	O
PTLD	NNP	O
cases	NNS	O
in	IN	O
the	DT	O
LI	NNP	O
group	NN	O
were	VBD	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
seronegative	JJ	O
for	IN	O
Epstein-Barr	NNP	O
virus	NN	O
(	(	O
EBV	NNP	O
(	(	O
-	:	O
)	)	O
)	)	O
at	IN	O
transplantation	NN	O
.	.	O

Mean	NNP	O
?	.	O
SD	NNP	O
calculated	VBD	O
GFR	NNP	O
at	IN	O
year	NN	O
5	CD	O
was	VBD	O
55.9	CD	O
?	.	O
17.5	CD	O
(	(	O
MI	NNP	O
)	)	O
,	,	O
59.0	CD	O
?	.	O
29.1	CD	O
(	(	O
LI	NNP	O
)	)	O
and	CC	O
44.6	CD	O
?	.	O
16.4	CD	O
(	(	O
CsA	NNP	O
)	)	O
mL/min/1.73	NN	O
m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Continued	VBN	O
treatment	NN	O
with	IN	O
belatacept	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
consistent	JJ	O
safety	NN	O
profile	NN	O
and	CC	O
sustained	VBD	O
improvement	NN	O
in	IN	O
renal	JJ	O
function	NN	O
versus	NN	O
CsA	NNP	O
over	IN	O
time	NN	O
.	.	O

Secretin	NNP	Pharmacological
and	CC	O
sleep	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
pilot	NN	O
study	NN	O
were	VBD	O
1	CD	O
)	)	O
to	TO	O
examine	VB	O
possible	JJ	O
effects	NNS	O
of	IN	O
secretin	JJ	Pharmacological
infusions	NNS	O
on	IN	O
sleep-wake	JJ	O
state	NN	O
organization	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
and	CC	O
2	CD	O
)	)	O
to	TO	O
assess	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
home	NN	O
recordings	NNS	O
using	VBG	O
time-lapse	JJ	O
videosomnography	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
a	DT	O
subset	NN	O
of	IN	O
subjects	NNS	O
from	IN	O
two	CD	O
double	JJ	O
blind	NN	O
,	,	O
placebo-control	NN	O
,	,	O
multi-center	JJ	O
clinical	JJ	O
trials	NNS	O
.	.	O

One	CD	O
trial	NN	O
,	,	O
the	DT	O
UC	NNP	O
Irvine	NNP	O
study	NN	O
,	,	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
porcine	NN	Pharmacological
secretin	NN	Pharmacological
vs.	FW	Pharmacological
saline	NN	Control
infusions	NNS	Control
on	IN	O
children	NNS	O
's	POS	O
behavior	NN	O
,	,	O
language	NN	O
and	CC	O
IQ	NNP	O
.	.	O

The	DT	O
UC	NNP	O
Davis	NNP	O
trial	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
synthetic	JJ	Pharmacological
human	JJ	Pharmacological
secretin	NN	Pharmacological
vs.	FW	O
saline	NN	Control
infusions	NNS	Control
on	IN	O
behavior	NN	O
,	,	O
language	NN	O
and	CC	O
gastrointestinal	JJ	O
function	NN	O
.	.	O

The	DT	O
sleep	NN	O
study	NN	O
enrolled	VBD	O
some	DT	O
of	IN	O
the	DT	O
children	NNS	O
from	IN	O
each	DT	O
of	IN	O
the	DT	O
two	CD	O
trials	NNS	O
to	TO	O
observe	VB	O
possible	JJ	O
secretin	JJ	O
effects	NNS	O
on	IN	O
sleep	NN	O
.	.	O

To	TO	O
examine	VB	O
sleep	NN	O
,	,	O
the	DT	O
UC	NNP	O
Irvine	NNP	O
trial	NN	O
used	VBD	O
the	DT	O
Children	NNP	O
's	POS	O
Sleep	NNP	O
Habits	NNP	O
Questionnaire	NNP	O
and	CC	O
daily	JJ	O
sleep	NN	O
diaries	NNS	O
,	,	O
whereas	IN	O
the	DT	O
UC	NNP	O
Davis	NNP	O
study	NN	O
used	VBD	O
home-recorded	JJ	O
time-lapse	JJ	O
videosomnography	NN	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
,	,	O
the	DT	O
results	NNS	O
from	IN	O
both	DT	O
trials	NNS	O
are	VBP	O
preliminary	JJ	O
.	.	O

They	PRP	O
suggest	VBP	O
that	IN	O
secretin	NN	Pharmacological
,	,	Pharmacological
porcine	NN	Pharmacological
or	CC	Pharmacological
synthetic	JJ	Pharmacological
,	,	O
does	VBZ	O
not	RB	O
improve	VB	O
sleep-wake	NN	O
state	NN	O
organization	NN	O
dramatically	RB	O
.	.	O

Migration	NN	O
of	IN	O
the	DT	O
acetabular	JJ	O
component	NN	O
:	:	O
effect	NN	O
of	IN	O
cement	NN	Physical
pressurization	NN	Physical
and	CC	O
significance	NN	O
of	IN	O
early	JJ	O
radiolucency	NN	O
:	:	O
a	DT	O
randomized	JJ	O
5-year	JJ	O
study	NN	O
using	VBG	O
radiostereometry	NN	Other
.	.	Other

BACKGROUND	NNP	O
Cementing	NNP	O
technique	NN	O
is	VBZ	O
a	DT	O
crucial	JJ	O
factor	NN	O
in	IN	O
prosthesis	NN	O
fixation	NN	O
.	.	O

No	DT	O
randomized	JJ	O
studies	NNS	O
have	VBP	O
been	VBN	O
published	VBN	O
,	,	O
however	RB	O
,	,	O
comparing	VBG	O
the	DT	O
outcome	NN	O
of	IN	O
conventional	JJ	O
fingerpacking	NN	O
with	IN	O
the	DT	O
outcome	NN	O
of	IN	O
pressurization	NN	O
of	IN	O
the	DT	O
cement	NN	O
prior	RB	O
to	TO	O
cup	VB	O
insertion	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
We	PRP	O
randomized	VBD	O
50	CD	O
THAs	NNP	O
to	TO	O
either	VB	O
fingerpacking	NN	Other
or	CC	O
sequential	JJ	Physical
pressurization	NN	Physical
(	(	Other
including	VBG	Other
individual	JJ	Other
pressurization	NN	Other
of	IN	Other
each	DT	Other
anchorage	NN	Other
hole	NN	Other
)	)	Other
and	CC	O
followed	VBD	O
the	DT	O
patients	NNS	O
with	IN	O
RSA	NNP	Other
for	IN	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
penetration	NN	O
of	IN	O
cement	NN	O
into	IN	O
the	DT	O
anchorage	NN	O
holes	NNS	O
was	VBD	O
measured	VBN	O
on	IN	O
digital	JJ	O
radiographs	NN	O
.	.	O

Postoperative	JJ	O
radiolucent	NN	O
lines	NNS	O
around	IN	O
the	DT	O
cup	NN	O
were	VBD	O
correlated	VBN	O
to	TO	O
later	RBR	O
RSA	NNP	O
results	NNS	O
.	.	O

For	IN	O
clinical	JJ	O
evaluation	NN	O
,	,	O
we	PRP	O
used	VBD	O
SF-36	NNP	O
and	CC	O
HHS	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
pressurized	JJ	O
group	NN	O
of	IN	O
THAs	NNP	O
was	VBD	O
more	RBR	O
stable	JJ	O
regarding	VBG	O
changes	NNS	O
in	IN	O
inclination	NN	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
other	JJ	O
difference	NN	O
in	IN	O
the	DT	O
migratory	NN	O
behavior	NN	O
.	.	O

The	DT	O
cement	NN	O
penetration	NN	O
into	IN	O
the	DT	O
anchorage	NN	O
holes	NNS	O
was	VBD	O
deeper	RBR	O
with	IN	O
the	DT	O
pressurization	NN	O
technique	NN	O
than	IN	O
with	IN	O
fingerpacking	NN	O
.	.	O

For	IN	O
the	DT	O
whole	JJ	O
group	NN	O
taken	VBN	O
together	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
relation	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
radiolucent	NN	O
lines	NNS	O
as	IN	O
measured	VBN	O
on	IN	O
the	DT	O
postoperative	JJ	O
radiograph	NN	O
and	CC	O
later	JJ	O
migration	NN	O
observed	VBN	O
by	IN	O
RSA	NNP	O
at	IN	O
2	CD	O
and	CC	O
5	CD	O
years	NNS	O
.	.	O

INTERPRETATION	NNP	O
Pressurization	NNP	O
of	IN	O
the	DT	O
cement	NN	O
produced	VBD	O
better	JJR	O
cement	NN	O
penetration	NN	O
and	CC	O
increased	VBD	O
the	DT	O
cup	NN	O
stability	NN	O
in	IN	O
terms	NNS	O
of	IN	O
changes	NNS	O
in	IN	O
inclination	NN	O
.	.	O

Early	JJ	O
findings	NNS	O
of	IN	O
radiolucent	NN	O
lines	NNS	O
can	MD	O
predict	VB	O
later	RB	O
unfavorable	JJ	O
cup	NN	O
migration	NN	O
.	.	O

Acute	JJ	O
exposure	NN	O
to	TO	O
acid	VB	O
fog	NN	O
:	:	O
influence	NN	O
of	IN	O
breathing	VBG	O
pattern	NN	O
on	IN	O
effective	JJ	O
dose	NN	O
.	.	O

Concern	JJ	O
about	IN	O
the	DT	O
possible	JJ	O
adverse	JJ	O
health	NN	O
effects	NNS	O
of	IN	O
acid	NN	O
fog	NN	O
has	VBZ	O
been	VBN	O
fed	VBN	O
by	IN	O
two	CD	O
observations	NNS	O
:	:	O
air	NN	O
pollution	NN	O
disasters	NNS	O
earlier	RBR	O
in	IN	O
this	DT	O
century	NN	O
were	VBD	O
typically	RB	O
associated	VBN	O
with	IN	O
fog	NN	O
,	,	O
and	CC	O
current	JJ	O
samples	NNS	O
of	IN	O
fog	JJ	O
water	NN	O
can	MD	O
be	VB	O
strongly	RB	O
acid	JJ	O
.	.	O

To	TO	O
study	VB	O
the	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
acid	JJ	O
fog	NN	O
on	IN	O
the	DT	O
lung	NN	O
,	,	O
the	DT	O
authors	NNS	O
generated	VBD	O
a	DT	O
monodisperse	JJ	Pharmacological
10	CD	Pharmacological
microM	NN	Pharmacological
MMAD	NNP	Pharmacological
aerosol	NN	Pharmacological
of	IN	Pharmacological
H2SO4	NNP	Pharmacological
with	IN	O
a	DT	O
pH	NN	O
of	IN	O
2.0	CD	O
and	CC	O
a	DT	O
nominal	JJ	O
concentration	NN	O
of	IN	O
500	CD	O
micrograms/m3	NNS	O
.	.	O

They	PRP	O
exposed	VBD	O
seven	CD	O
healthy	JJ	O
young	JJ	O
men	NNS	O
on	IN	O
alternate	NN	O
days	NNS	O
to	TO	O
acid	VB	Control
or	CC	Control
control	VB	Control
equiosmolar	JJ	Control
NaCl	NNP	Control
aerosol	NN	Control
during	IN	O
40	CD	O
min	NNS	O
of	IN	O
resting	VBG	O
ventilation	NN	O
and	CC	O
20	CD	O
min	NN	O
of	IN	O
exercise	NN	O
;	:	O
the	DT	O
latter	NN	O
was	VBD	O
sufficiently	RB	O
intense	JJ	O
to	TO	O
induce	VB	O
oronasal	RP	O
breathing	VBG	O
.	.	O

Exposure	NN	O
was	VBD	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
head	NN	O
dome	NN	O
,	,	O
a	DT	O
head-only	JJ	O
exposure	NN	O
device	NN	O
that	WDT	O
permitted	VBD	O
continuous	JJ	O
measurement	NN	O
(	(	O
unfettered	JJ	O
breathing	NN	O
)	)	O
of	IN	O
Vr	NNP	O
,	,	O
f	NN	O
,	,	O
VE	NNP	O
,	,	O
and	CC	O
the	DT	O
onset	NN	O
and	CC	O
persistence	NN	O
of	IN	O
oronasal	NN	O
breathing	NN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
the	DT	O
authors	NNS	O
compare	VBP	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
parameters	NNS	O
contributing	VBG	O
to	TO	O
the	DT	O
between-subject	JJ	O
variability	NN	O
in	IN	O
estimated	VBN	O
hydrogen	NN	O
ion	NN	O
dose	NN	O
to	TO	O
the	DT	O
lower	JJR	O
airways	NNS	O
(	(	O
H+LAW	NNP	O
)	)	O
,	,	O
based	VBN	O
on	IN	O
analysis	NN	O
of	IN	O
variance	NN	O
.	.	O

Physiologic	NNP	O
parameters	NNS	O
accounted	VBD	O
for	IN	O
70	CD	O
%	NN	O
of	IN	O
the	DT	O
variability	NN	O
,	,	O
of	IN	O
which	WDT	O
34	CD	O
%	NN	O
was	VBD	O
due	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
duration	NN	O
of	IN	O
oronasal	NN	O
breathing	NN	O
(	(	O
tON	NN	O
)	)	O
and	CC	O
36	CD	O
%	NN	O
to	TO	O
differences	NNS	O
in	IN	O
ventilation	NN	O
rate	NN	O
during	IN	O
oronasal	NN	O
breathing	NN	O
(	(	O
VE	NNP	O
(	(	O
ON	NNP	O
)	)	O
)	)	O
;	:	O
inhaled	VBN	O
hydrogen	NN	O
ion	NN	O
concentration	NN	O
[	NNP	O
H+	NNP	O
]	NNP	O
,	,	O
the	DT	O
environmental	JJ	O
parameter	NN	O
,	,	O
contributed	VBD	O
only	RB	O
30	CD	O
%	NN	O
.	.	O

Minute	JJ	O
ventilation	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
transition	NN	O
from	IN	O
nasal	NN	O
to	TO	O
oronasal	VB	O
breathing	VBG	O
varied	JJ	O
significantly	RB	O
among	IN	O
subjects	NNS	O
even	RB	O
if	IN	O
normalized	VBN	O
to	TO	O
FVC	NNP	O
,	,	O
an	DT	O
index	NN	O
of	IN	O
lung	NN	O
size	NN	O
.	.	O

Double-blind	NNP	O
comparison	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
trandolapril	JJ	Pharmacological
2	CD	O
mg	NN	O
and	CC	O
hydrochlorothiazide	VB	Pharmacological
25	CD	O
mg	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
mild-to-moderate	JJ	O
essential	JJ	O
hypertension	NN	O
.	.	O

Investigator	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

This	DT	O
multicenter	NN	O
international	JJ	O
trial	NN	O
recruited	VBD	O
205	CD	O
patients	NNS	O
from	IN	O
16	CD	O
investigators	NNS	O
.	.	O

After	IN	O
a	DT	O
4-week	JJ	O
,	,	O
single-blind	JJ	O
placebo	NN	Control
run-in	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
16	CD	O
weeks	NNS	O
of	IN	O
trandolapril	JJ	Pharmacological
2	CD	O
mg/day	NN	O
(	(	O
68	CD	O
patients	NNS	O
)	)	O
,	,	O
hydrochlorothiazide	RB	Pharmacological
(	(	Pharmacological
HCTZ	NNP	Pharmacological
)	)	Pharmacological
25	CD	O
mg/day	NN	O
(	(	O
68	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
the	DT	O
combination	NN	O
(	(	O
69	CD	O
patients	NNS	O
)	)	O
.	.	O

Morning	VBG	O
predosing	VBG	O
supine	NN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
DBP	NNP	O
)	)	O
was	VBD	O
the	DT	O
primary	JJ	O
efficacy	NN	O
measurement	NN	O
.	.	O

Intention-to-treat	JJ	O
analysis	NN	O
showed	VBD	O
significant	JJ	O
decreases	NNS	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
in	IN	O
mean	JJ	O
(	(	O
+/-	JJ	O
SEM	NNP	O
)	)	O
supine	NN	O
DBP	NNP	O
throughout	IN	O
the	DT	O
study	NN	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
differences	NNS	O
at	IN	O
week	NN	O
16	CD	O
between	IN	O
trandolapril	NN	O
(	(	O
-10.6	JJ	O
+/-	JJ	O
1.3	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
and	CC	O
HCTZ	NNP	O
(	(	O
-10.9	JJ	O
+/-	JJ	O
1.3	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
.	.	O

The	DT	O
combination	NN	O
gave	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
than	IN	O
either	DT	O
drug	NN	O
alone	RB	O
(	(	O
-15.1	JJ	O
+/-	JJ	O
1.13	CD	O
mm	NN	O
Hg	NNP	O
)	)	O
.	.	O

Blood	NNP	O
pressure	NN	O
was	VBD	O
normalized	VBN	O
in	IN	O
the	DT	O
combination	NN	O
group	NN	O
in	IN	O
67	CD	O
%	NN	O
of	IN	O
patients	NNS	O
,	,	O
a	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
than	IN	O
either	DT	O
trandolapril	NN	O
(	(	O
63	CD	O
%	NN	O
)	)	O
or	CC	O
HCTZ	NNP	O
(	(	O
60	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.04	CD	O
)	)	O
.	.	O

Each	DT	O
treatment	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
.	.	O

Trandolapril	NNP	O
2	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
is	VBZ	O
an	DT	O
effective	JJ	O
antihypertensive	JJ	O
agent	NN	O
,	,	O
comparable	JJ	O
to	TO	O
HCTZ	NNP	O
.	.	O

Furthermore	NNP	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
was	VBD	O
shown	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
the	DT	O
two	CD	O
compounds	NNS	O
alone	RB	O
.	.	O

Moderate	NNP	Pharmacological
sodium	NN	Pharmacological
restriction	NN	Pharmacological
,	,	O
angiotensin	NN	Pharmacological
converting	VBG	Pharmacological
enzyme	JJ	Pharmacological
inhibition	NN	Pharmacological
,	,	O
and	CC	O
thiazide	RB	Pharmacological
diuretic	JJ	Pharmacological
in	IN	O
the	DT	O
management	NN	O
of	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Dietary	NNP	Physical
sodium	JJ	Physical
restriction	NN	Physical
alone	RB	O
is	VBZ	O
effective	JJ	O
in	IN	O
lowering	VBG	O
blood	NN	O
pressure	NN	O
in	IN	O
some	DT	O
,	,	O
but	CC	O
not	RB	O
all	DT	O
,	,	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Homeostatic	JJ	O
mechanisms	NNS	O
,	,	O
including	VBG	O
activation	NN	O
of	IN	O
the	DT	O
renin-aldosterone	NN	O
system	NN	O
,	,	O
may	MD	O
counteract	VB	O
the	DT	O
effects	NNS	O
of	IN	O
sodium	JJ	Physical
restriction	NN	O
.	.	O

Angiotensin	NNP	Pharmacological
converting	VBG	Pharmacological
enzyme	NN	Pharmacological
(	(	Pharmacological
ACE	NNP	Pharmacological
)	)	Pharmacological
inhibitors	NNS	Pharmacological
are	VBP	O
also	RB	O
effective	JJ	O
as	IN	O
sole	JJ	O
therapy	NN	O
in	IN	O
many	JJ	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
,	,	O
but	CC	O
may	MD	O
be	VB	O
less	RBR	O
effective	JJ	O
in	IN	O
those	DT	O
with	IN	O
low-renin	JJ	O
hypertension	NN	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
dietary	JJ	Pharmacological
sodium	NN	Pharmacological
restriction	NN	Pharmacological
with	IN	O
blockade	NN	O
of	IN	O
the	DT	O
renin	NN	O
system	NN	O
by	IN	O
an	DT	O
ACE	NNP	Pharmacological
inhibitor	NN	Pharmacological
is	VBZ	O
a	DT	O
particularly	RB	O
effective	JJ	O
way	NN	O
to	TO	O
improve	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
.	.	O

Addition	NNP	O
of	IN	O
a	DT	O
thiazide	JJ	Pharmacological
diuretic	NN	Pharmacological
will	MD	O
reduce	VB	O
pressure	NN	O
further	RBR	O
.	.	O

Comparison	NNP	O
of	IN	O
neodymium-doped	JJ	Surgical
yttrium	NN	Surgical
aluminum	NN	Surgical
garnet	NN	Surgical
laser	NN	Surgical
treatment	NN	Surgical
with	IN	O
cold	JJ	Surgical
knife	NN	Surgical
endoscopic	NN	Surgical
incision	NN	Surgical
of	IN	O
urethral	JJ	O
strictures	NNS	O
in	IN	O
male	JJ	O
patients	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
visual	JJ	Surgical
laser	NN	Surgical
ablation	NN	Surgical
treatment	NN	Surgical
with	IN	Surgical
neodymium-doped	JJ	Surgical
yttrium	NN	Surgical
aluminum	NN	Surgical
garnet	NN	Surgical
(	(	Surgical
Nd	NNP	Surgical
:	:	Surgical
YAG	NN	Surgical
)	)	Surgical
laser	NN	O
in	IN	O
male	JJ	O
patients	NNS	O
with	IN	O
urethral	JJ	O
strictures	NNS	O
and	CC	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
with	IN	O
those	DT	O
obtained	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
Sachse	NNP	O
's	POS	O
optical	JJ	O
urethrotomy	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Fifty	NNP	O
patients	NNS	O
aged	VBD	O
22	CD	O
to	TO	O
83	CD	O
(	(	O
mean	JJ	O
age	NN	O
61.8	CD	O
)	)	O
with	IN	O
primary	JJ	O
(	(	O
n	JJ	O
=	NN	O
26	CD	O
,	,	O
52	CD	O
%	NN	O
)	)	O
and	CC	O
recurrent	NN	O
(	(	O
n	JJ	O
=	NN	O
24	CD	O
,	,	O
48	CD	O
%	NN	O
)	)	O
urethral	JJ	O
strictures	VBZ	O
0.3	CD	O
to	TO	O
2.4	CD	O
cm	NNS	O
long	RB	O
qualified	VBD	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
30	CD	O
men	NNS	O
treated	VBD	O
using	VBG	O
visual	JJ	Surgical
laser	NN	Surgical
ablation	NN	Surgical
of	IN	Surgical
urethral	JJ	Surgical
strictures	NNS	Surgical
(	(	Surgical
VLASU	NNP	Surgical
)	)	Surgical
with	IN	Surgical
Nd	NNP	Surgical
:	:	Surgical
YAGlaser	NN	Surgical
and	CC	O
20	CD	O
men	NNS	O
treated	VBN	O
by	IN	O
correction	NN	O
of	IN	O
urethral	JJ	O
strictures	NNS	O
using	VBG	O
Sachse	NNP	Surgical
's	POS	Surgical
optical	JJ	Surgical
urethrotomy	NN	Surgical
.	.	O

RESULTS	VB	O
At	IN	O
12-month	JJ	O
follow-up	NN	O
,	,	O
seven	CD	O
(	(	O
35	CD	O
%	NN	O
)	)	O
patients	NNS	O
who	WP	O
underwent	JJ	O
optical	JJ	Surgical
urethrotomy	NN	Surgical
and	CC	O
21	CD	O
(	(	O
70	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
VLASU	NNP	Surgical
group	NN	O
did	VBD	O
not	RB	O
require	VB	O
repetition	NN	O
of	IN	O
the	DT	O
procedure	NN	O
.	.	O

The	DT	O
choice	NN	O
of	IN	O
VLASU	NNP	Surgical
as	IN	O
a	DT	O
method	NN	O
of	IN	O
treatment	NN	O
significantly	RB	O
decreased	VBD	O
the	DT	O
probability	NN	O
of	IN	O
therapeutic	JJ	O
failure	NN	O
and	CC	O
recurrence	NN	O
of	IN	O
urethral	JJ	O
strictures	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
VLASU	NNP	Surgical
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
method	NN	O
of	IN	O
treatment	NN	O
of	IN	O
this	DT	O
disorder	NN	O
.	.	O

It	PRP	O
is	VBZ	O
an	DT	O
effective	JJ	O
,	,	O
modern	JJ	O
,	,	O
low-invasive	JJ	O
,	,	O
and	CC	O
repeatable	JJ	O
technique	NN	O
and	CC	O
is	VBZ	O
technically	RB	O
simple	JJ	O
and	CC	O
easy	JJ	O
to	TO	O
master	NN	O
.	.	O

It	PRP	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
cases	NNS	O
in	IN	O
which	WDT	O
introduction	NN	O
of	IN	O
a	DT	O
22	CD	O
Char	NNP	O
optical	JJ	O
urethrotome	NN	O
into	IN	O
the	DT	O
stricture	NN	O
site	NN	O
is	VBZ	O
impossible	JJ	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
for	IN	O
treatment	NN	O
of	IN	O
multiple	JJ	O
strictures	NNS	O
during	IN	O
one	CD	O
procedure	NN	O
.	.	O

Gastric	JJ	O
ulcer	NN	O
treatment	NN	O
with	IN	O
intravenous	JJ	O
human	JJ	Pharmacological
epidermal	JJ	Pharmacological
growth	NN	Pharmacological
factor	NN	Pharmacological
:	:	Pharmacological
a	DT	O
double-blind	NN	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
.	.	O

We	PRP	O
introduced	VBD	O
a	DT	O
double-blind	NN	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
to	TO	O
compare	VB	O
intravenous	JJ	Pharmacological
human	JJ	Pharmacological
epidermal	JJ	Pharmacological
growth	NN	Pharmacological
factor	NN	Pharmacological
(	(	Pharmacological
hEGF	NN	Pharmacological
)	)	Pharmacological
to	TO	O
cetraxate	VB	Pharmacological
hydrochloride	NN	Pharmacological
(	(	Pharmacological
CH	NNP	Pharmacological
)	)	Pharmacological
,	,	O
an	DT	O
antiulcer	JJ	O
drug	NN	O
,	,	O
for	IN	O
their	PRP$	O
healing	NN	O
effect	NN	O
on	IN	O
gastric	JJ	O
ulcers	NNS	O
.	.	O

We	PRP	O
also	RB	O
prospected	VBD	O
an	DT	O
oral	JJ	O
use	NN	O
of	IN	O
EGF	NNP	Pharmacological
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
our	PRP$	O
experimental	JJ	O
evidence	NN	O
.	.	O

In	IN	O
the	DT	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
ulcer	NN	O
healing	VBG	O
within	IN	O
8	CD	O
weeks	NNS	O
was	VBD	O
77.9	CD	O
%	NN	O
(	(	O
67/86	CD	O
)	)	O
in	IN	O
patients	NNS	O
receiving	VBG	O
6	CD	O
micrograms	NNS	O
EGF	NNP	Pharmacological
intravenously	RB	O
twice	RB	O
a	DT	O
week	NN	O
,	,	O
being	VBG	O
significantly	RB	O
greater	JJR	O
than	IN	O
51.7	CD	O
%	NN	O
(	(	O
45/87	CD	O
)	)	O
in	IN	O
those	DT	O
given	VBN	O
CH	NNP	Pharmacological
.	.	Pharmacological

Taking	VBG	O
together	RB	O
all	DT	O
aspects	NNS	O
assessed	VBD	O
including	VBG	O
the	DT	O
healing	NN	O
rate	NN	O
,	,	O
pain	NN	O
relief	NN	O
,	,	O
blood	NN	O
examination	NN	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
,	,	O
we	PRP	O
judged	VBD	O
the	DT	O
hEGF	NN	Pharmacological
to	TO	O
be	VB	O
a	DT	O
useful	JJ	O
and	CC	O
safe	JJ	O
anticuler	NN	O
drug	NN	O
.	.	O

In	IN	O
rats	NNS	O
,	,	O
50	CD	O
micrograms/kg	NN	O
mouse	NN	O
EGF	NNP	O
(	(	O
mEGF	NN	O
)	)	O
and	CC	O
2	CD	O
%	NN	O
hydroxypropyl	NN	Pharmacological
cellulose	NN	Pharmacological
(	(	O
HPC	NNP	O
)	)	O
or	CC	O
1.0	CD	O
g/kg	JJ	O
sucralfate	NN	O
given	VBN	O
by	IN	O
gastric	JJ	O
intubation	NN	O
significantly	RB	O
raised	VBD	O
the	DT	O
residual	JJ	O
mEGF	NN	O
levels	NNS	O
in	IN	O
both	DT	O
gastric	JJ	O
luminal	JJ	O
content	NN	O
(	(	O
HPC	NNP	O
:	:	O
x	JJ	O
30	CD	O
;	:	O
sucralfate	NN	O
:	:	O
x	RB	O
300	CD	O
as	RB	O
high	JJ	O
as	IN	O
those	DT	O
in	IN	O
EGF	NNP	O
alone	RB	O
)	)	O
and	CC	O
tissue	NN	O
(	(	O
HPC	NNP	O
:	:	O
x	JJ	O
60	CD	O
;	:	O
sucralfate	NN	O
:	:	O
x	JJ	O
100	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
combined	JJ	O
treatments	NNS	O
significantly	RB	O
promoted	VBD	O
healing	NN	O
of	IN	O
rat	NN	O
gastric	JJ	O
ulcers	NNS	O
whereas	VBP	O
each	DT	O
agent	NN	O
alone	RB	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
as	IN	O
compared	VBN	O
with	IN	O
control	NN	O
(	(	O
saline	NN	O
)	)	O
.	.	O

This	DT	O
indicated	VBD	O
the	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
ulcers	NNS	O
of	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
EGF	NNP	Pharmacological
with	IN	O
agents	NNS	O
allowing	VBG	O
it	PRP	O
to	TO	O
remain	VB	O
at	IN	O
high	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
stomach	NN	O
,	,	O
whereas	IN	O
most	JJS	O
reports	NNS	O
suggested	VBD	O
less	RBR	O
effect	NN	O
of	IN	O
oral	JJ	O
EGF	NNP	O
on	IN	O
healing	NN	O
of	IN	O
gastroduodenal	JJ	O
ulcers	NNS	O
.	.	O

Subsequent	JJ	O
to	TO	O
the	DT	O
clinical	JJ	O
study	NN	O
,	,	O
evaluation	NN	O
of	IN	O
oral	JJ	O
use	NN	O
of	IN	O
EGF	NNP	Pharmacological
may	MD	O
be	VB	O
expected	VBN	O
as	IN	O
the	DT	O
next	JJ	O
step	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ulcers	NNS	O
.	.	O

The	DT	O
experimental	JJ	O
evidence	NN	O
above	IN	O
would	MD	O
possibly	RB	O
be	VB	O
a	DT	O
guide	NN	O
for	IN	O
such	JJ	O
trial	NN	O
.	.	O

Optimization	NN	O
of	IN	O
acid	JJ	O
suppression	NN	O
for	IN	O
patients	NNS	O
with	IN	O
peptic	JJ	O
ulcer	NN	O
bleeding	NN	O
:	:	O
an	DT	O
intragastric	JJ	O
pH-metry	NN	O
study	NN	O
with	IN	O
omeprazole	NN	Pharmacological
.	.	Pharmacological

OBJECTIVE	UH	O
To	TO	O
study	VB	O
whether	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
dose	NN	O
of	IN	O
omeprazole	NN	Pharmacological
(	(	O
80	CD	O
mg	NN	O
+	VBD	O
8	CD	O
mg/h	NN	O
)	)	O
during	IN	O
24	CD	O
h	NNS	O
can	MD	O
be	VB	O
subsequently	RB	O
reduced	VBN	O
with	IN	O
maintained	JJ	O
effect	NN	O
.	.	O

Second	NNP	O
,	,	O
to	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
oral	JJ	O
omeprazole	JJ	Pharmacological
20	CD	O
mg	NN	O
given	VBN	O
once	RB	O
or	CC	O
twice	RB	O
daily	RB	O
up	IN	O
to	TO	O
day	NN	O
10	CD	O
,	,	O
after	IN	O
cessation	NN	O
of	IN	O
a	DT	O
3-day	JJ	O
intravenous	JJ	O
infusion	NN	O
(	(	O
80	CD	O
mg	NN	O
+	VBD	O
8	CD	O
mg/h	NN	O
)	)	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
partly	RB	O
blinded	VBD	O
study	NN	O
.	.	O

METHODS	NNP	O
Twelve	NNP	O
Helicobacter	NNP	O
pylori	NN	O
(	(	O
+	NNP	O
)	)	O
patients	NNS	O
and	CC	O
12	CD	O
H.	NNP	O
pylori	NN	O
(	(	O
-	:	O
)	)	O
subjects	NNS	O
were	VBD	O
included	VBN	O
.	.	O

In	IN	O
part	NN	O
I	PRP	O
the	DT	O
patients	NNS	O
received	VBD	O
omeprazole	JJ	Pharmacological
,	,	O
80	CD	O
mg	NN	O
+	VBD	O
8	CD	O
mg/h	NN	O
,	,	O
during	IN	O
24	CD	O
h	NN	O
followed	VBN	O
by	IN	O
8	CD	O
,	,	O
4	CD	O
or	CC	O
2	CD	O
mg/h	NN	O
.	.	O

In	IN	O
part	NN	O
II	NNP	O
the	DT	O
subjects	NNS	O
received	VBD	O
80	CD	O
mg	NNS	O
+	VBD	O
8	CD	O
mg/h	NN	O
during	IN	O
3	CD	O
days	NNS	O
followed	VBN	O
by	IN	O
20	CD	O
mg	NNS	O
omeprazole	JJ	Pharmacological
orally	RB	O
,	,	O
once	RB	O
or	CC	O
twice	JJ	O
daily	JJ	O
until	IN	O
day	NN	O
10	CD	O
.	.	O

Intragastric	NNP	O
pH	NN	O
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
H.	NNP	O
pylori	FW	O
(	(	O
+	NN	O
)	)	O
patients	NNS	O
showed	VBD	O
a	DT	O
rapid	JJ	O
increase	NN	O
of	IN	O
intragastric	JJ	O
pH	NN	O
with	IN	O
a	DT	O
mean	JJ	O
intragastric	JJ	O
pH	NN	O
of	IN	O
6.7	CD	O
during	IN	O
the	DT	O
second	JJ	O
half	NN	O
of	IN	O
the	DT	O
first	JJ	O
day	NN	O
.	.	O

After	IN	O
the	DT	O
subsequent	JJ	O
dose	NN	O
reduction	NN	O
,	,	O
the	DT	O
mean	JJ	O
pH	NN	O
decreased	VBD	O
to	TO	O
6.1-6.2	JJ	O
.	.	O

Patients	NNPS	O
continuing	VBG	O
on	IN	O
8	CD	O
mg/h	NN	O
showed	VBD	O
the	DT	O
best	JJS	O
results	NNS	O
.	.	O

Likewise	NNP	O
,	,	O
all	DT	O
H.	NNP	O
pylori	NN	O
(	(	O
-	:	O
)	)	O
subjects	VBZ	O
showed	VBD	O
a	DT	O
rapid	JJ	O
and	CC	O
sustained	JJ	O
reduction	NN	O
of	IN	O
intragastric	JJ	O
acidity	NN	O
during	IN	O
the	DT	O
infusion	NN	O
.	.	O

Subsequent	NNP	O
dose	JJ	O
reduction	NN	O
to	TO	O
20	CD	O
mg	NNS	O
once	RB	O
daily	RB	O
led	VBN	O
to	TO	O
a	DT	O
stable	JJ	O
fraction	NN	O
of	IN	O
time	NN	O
with	IN	O
pH	JJ	O
>	JJ	O
3	CD	O
of	IN	O
72	CD	O
%	NN	O
.	.	O

CONCLUSIONS	NNP	O
Omeprazole	NNP	Pharmacological
given	VBN	O
as	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
80	CD	O
mg	NNS	O
+	VBD	O
8	CD	O
mg/h	NN	O
for	IN	O
72	CD	O
h	NN	O
followed	VBN	O
by	IN	O
omeprazole	JJ	Pharmacological
20	CD	O
mg	NN	O
once	RB	O
daily	RB	O
raised	VBD	O
the	DT	O
intragastric	JJ	O
pH	NN	O
to	TO	O
and	CC	O
above	JJ	O
levels	NNS	O
alleged	VBN	O
to	TO	O
allow	VB	O
haemostasis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
peptic	JJ	O
ulcer	NN	O
bleeding	NN	O
and	CC	O
subsequent	JJ	O
healing	NN	O
of	IN	O
the	DT	O
ulcer	NN	O
.	.	O

Lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
food	NN	Physical
on	IN	O
the	DT	O
steady	JJ	O
state	NN	O
pharmacokinetics	NNS	O
of	IN	O
BMS-181101	NNP	O
,	,	O
an	DT	O
antidepressant	NN	O
,	,	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
food	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
BMS-181101	NNP	Pharmacological
,	,	O
a	DT	O
new	JJ	O
anti-depressant	JJ	O
under	IN	O
development	NN	O
,	,	O
was	VBD	O
investigated	VBN	O
in	IN	O
12	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
at	IN	O
steady	JJ	O
state	NN	O
.	.	O

Each	DT	O
subject	NN	O
received	VBD	O
a	DT	O
15	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
BMS-181101	NNP	Pharmacological
twice	NN	O
a	DT	O
day	NN	O
(	(	O
q	JJ	O
12	CD	O
h	NN	O
)	)	O
for	IN	O
11	CD	O
days	NNS	O
and	CC	O
a	DT	O
morning	NN	O
dose	NN	O
of	IN	O
BMS-181101	NNP	Pharmacological
on	IN	O
day	NN	O
12	CD	O
.	.	O

Six	CD	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
BMS-181101	NNP	Pharmacological
under	IN	O
fasted	VBN	O
conditions	NNS	O
from	IN	O
days	NNS	O
1	CD	O
to	TO	O
6	CD	O
and	CC	O
then	RB	O
crossed	VBD	O
over	IN	O
to	TO	O
fed	VB	O
conditions	NNS	O
from	IN	O
days	NNS	O
7	CD	O
to	TO	O
12	CD	O
.	.	O

The	DT	O
other	JJ	O
six	CD	O
subjects	NNS	O
received	VBD	O
the	DT	O
reverse	NN	O
conditions	NNS	O
,	,	O
fed	VBN	O
for	IN	O
days	NNS	O
1-6	CD	O
and	CC	O
fasted	VBN	O
for	IN	O
days	NNS	O
7-12	CD	O
.	.	O

Serial	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
up	RB	O
to	TO	O
12	CD	O
h	NNS	O
on	IN	O
days	NNS	O
6	CD	O
and	CC	O
12	CD	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
morning	NN	O
dose	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
trough	IN	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
on	IN	O
days	NNS	O
4	CD	O
,	,	O
5	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
11	CD	O
prior	RB	O
to	TO	O
the	DT	O
morning	NN	O
dose	NN	O
.	.	O

Plasma	NNP	O
samples	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
intact	JJ	O
BMS-181101	NNP	Pharmacological
using	VBG	O
a	DT	O
validated	JJ	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
method	NN	O
with	IN	O
an	DT	O
electrochemical	JJ	O
detector	NN	O
.	.	O

BMS-181101	NNP	O
was	VBD	O
well	RB	O
tolerated	VBN	O
both	DT	O
with	IN	O
and	CC	O
without	IN	O
ingestion	NN	O
of	IN	O
food	NN	O
.	.	O

The	DT	O
statistical	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
Cmin	NNP	O
values	NNS	O
indicated	VBD	O
that	IN	O
steady	JJ	O
state	NN	O
of	IN	O
BMS-181101	NNP	Pharmacological
was	VBD	O
achieved	VBN	O
by	IN	O
the	DT	O
fourth	JJ	O
day	NN	O
of	IN	O
dosing	VBG	O
regardless	NN	O
of	IN	O
whether	IN	O
the	DT	O
subject	NN	O
was	VBD	O
fasted	VBN	O
or	CC	O
fed	VBN	O
.	.	O

When	WRB	O
BMS-181101	NNP	O
was	VBD	O
administered	VBN	O
with	IN	O
food	NN	O
,	,	O
Cmax	NNP	O
was	VBD	O
reduced	VBN	O
by	IN	O
about	IN	O
25	CD	O
%	NN	O
and	CC	O
tmax	NN	O
was	VBD	O
prolonged	VBN	O
by	IN	O
1	CD	O
h.	NN	O
However	RB	O
,	,	O
AUCtau	NNP	O
,	,	O
t1/2	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
attain	VB	O
steady	JJ	O
state	NN	O
of	IN	O
BMS-181101	NNP	O
were	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
ingestion	NN	O
of	IN	O
food	NN	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
BMS-181101	NNP	Pharmacological
can	MD	O
be	VB	O
given	VBN	O
with	IN	O
food	NN	O
without	IN	O
adversely	RB	O
impacting	VBG	O
the	DT	O
safety	NN	O
or	CC	O
pharmacokinetic	JJ	O
profiles	NNS	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

Sex	NN	O
risk	NN	O
behavior	NN	O
among	IN	O
adolescent	JJ	O
and	CC	O
young	JJ	O
adult	NN	O
children	NNS	O
of	IN	O
opiate	JJ	O
addicts	NNS	O
:	:	O
outcomes	NNS	O
from	IN	O
the	DT	O
focus	NN	O
on	IN	O
families	NNS	O
prevention	VBP	O
trial	NN	O
and	CC	O
an	DT	O
examination	NN	O
of	IN	O
childhood	NN	O
and	CC	O
concurrent	JJ	O
predictors	NNS	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
.	.	O

This	DT	O
study	NN	O
reports	VBZ	O
on	IN	O
rates	NNS	O
and	CC	O
predictors	NNS	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
among	IN	O
a	DT	O
sample	NN	O
of	IN	O
adolescent	NN	O
and	CC	O
young	JJ	O
adult	NN	O
children	NNS	O
of	IN	O
parents	NNS	O
enrolled	VBN	O
in	IN	O
methadone	NN	Pharmacological
treatment	NN	O
for	IN	O
opiate	JJ	O
addiction	NN	O
.	.	O

Data	NNS	O
are	VBP	O
from	IN	O
151	CD	O
participants	NNS	O
(	(	O
80	CD	O
males	NNS	O
,	,	O
71	CD	O
females	NNS	O
)	)	O
in	IN	O
the	DT	O
Focus	NNP	O
on	IN	O
Families	NNP	O
(	(	O
FOF	NNP	O
)	)	O
project	NN	O
,	,	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
family	NN	Educational
intervention	NN	Educational
and	CC	O
a	DT	O
study	NN	O
of	IN	O
the	DT	O
development	NN	O
of	IN	O
at-risk	JJ	O
children	NNS	O
.	.	O

The	DT	O
study	NN	O
participants	NNS	O
are	VBP	O
children	NNS	O
of	IN	O
parents	NNS	O
enrolled	VBN	O
in	IN	O
methadone	NN	Pharmacological
treatment	NN	O
between	IN	O
1990	CD	O
and	CC	O
1993	CD	O
.	.	O

Participants	NNS	O
were	VBD	O
interviewed	VBN	O
in	IN	O
2005	CD	O
when	WRB	O
they	PRP	O
ranged	VBD	O
in	IN	O
age	NN	O
from	IN	O
15	CD	O
to	TO	O
29	CD	O
years	NNS	O
.	.	O

In	IN	O
the	DT	O
year	NN	O
prior	RB	O
to	TO	O
the	DT	O
follow-up	NN	O
,	,	O
79	CD	O
%	NN	O
of	IN	O
the	DT	O
males	NNS	O
and	CC	O
83	CD	O
%	NN	O
of	IN	O
females	NNS	O
were	VBD	O
sexually	RB	O
active	JJ	O
,	,	O
26	CD	O
%	NN	O
of	IN	O
males	NNS	O
and	CC	O
10	CD	O
%	NN	O
of	IN	O
females	NNS	O
had	VBD	O
more	JJR	O
than	IN	O
one	CD	O
partner	NN	O
in	IN	O
the	DT	O
prior	JJ	O
year	NN	O
,	,	O
and	CC	O
34	CD	O
%	NN	O
of	IN	O
males	NNS	O
and	CC	O
24	CD	O
%	NN	O
of	IN	O
females	NNS	O
reported	VBN	O
having	VBG	O
sex	NN	O
outside	IN	O
of	IN	O
a	DT	O
committed	JJ	O
relationship	NN	O
.	.	O

Twenty-four	CD	O
percent	NN	O
of	IN	O
males	NNS	O
and	CC	O
17	CD	O
%	NN	O
of	IN	O
females	NNS	O
met	VBD	O
criteria	NNS	O
for	IN	O
high-risk	JJ	O
sexual	JJ	O
behavior	NN	O
,	,	O
reporting	VBG	O
casual	JJ	O
or	CC	O
multiple	JJ	O
partners	NNS	O
in	IN	O
the	DT	O
prior	JJ	O
year	NN	O
and	CC	O
inconsistent	NN	O
condom	NN	O
use	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	Other
and	CC	O
control	NN	Control
conditions	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
terms	NNS	O
of	IN	O
any	DT	O
measure	NN	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
examined	VBN	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
measures	NNS	O
of	IN	O
parent	NN	O
behavior	NN	O
and	CC	O
family	NN	O
processes	NNS	O
derived	VBN	O
from	IN	O
data	NNS	O
at	IN	O
baseline	NN	O
of	IN	O
the	DT	O
FOF	NNP	O
study	NN	O
predicted	VBD	O
whether	IN	O
participants	NNS	O
engaged	VBN	O
in	IN	O
high-risk	JJ	O
sex	NN	O
.	.	O

Among	IN	O
measures	NNS	O
derived	VBN	O
from	IN	O
data	NNS	O
collected	VBN	O
at	IN	O
long-term	JJ	O
follow-up	NN	O
,	,	O
however	RB	O
,	,	O
having	VBG	O
ever	RB	O
met	VBN	O
criteria	NNS	O
for	IN	O
substance	NN	O
abuse	NN	O
or	CC	O
dependence	NN	O
predicted	VBN	O
greater	JJR	O
likelihood	NN	O
of	IN	O
high-risk	JJ	O
sexual	JJ	O
behavior	NN	O
,	,	O
and	CC	O
being	VBG	O
married	VBD	O
or	CC	O
being	VBG	O
in	IN	O
a	DT	O
romantic	JJ	O
relationship	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
likelihood	NN	O
of	IN	O
high-risk	JJ	O
sexual	JJ	O
behavior	NN	O
.	.	O

The	DT	O
findings	NNS	O
point	NN	O
to	TO	O
the	DT	O
important	JJ	O
role	NN	O
of	IN	O
committed	JJ	O
relationships	NNS	O
in	IN	O
regulating	VBG	O
sex	NN	O
risk	NN	O
behavior	NN	O
among	IN	O
this	DT	O
population	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
heightened	VBN	O
levels	NNS	O
of	IN	O
sex	NN	O
risk	NN	O
behavior	NN	O
associated	VBN	O
with	IN	O
substance	NN	O
abuse	NN	O
or	CC	O
dependence	NN	O
.	.	O

Short-	JJ	O
and	CC	O
long-term	JJ	O
effects	NNS	O
of	IN	O
tactile	JJ	Physical
massage	NN	Physical
on	IN	O
salivary	JJ	O
cortisol	NN	O
concentrations	NNS	O
in	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
is	VBZ	O
a	DT	O
chronic	JJ	O
neurodegenerative	JJ	O
disorder	NN	O
with	IN	O
limited	JJ	O
knowledge	NN	O
about	IN	O
the	DT	O
normal	JJ	O
function	NN	O
and	CC	O
effects	NNS	O
of	IN	O
non-pharmacological	JJ	Other
therapies	NNS	Other
on	IN	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
(	(	O
HPA	NNP	O
)	)	O
axis	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
analyse	VB	O
the	DT	O
basal	NN	O
diurnal	JJ	O
and	CC	O
total	JJ	O
secretion	NN	O
of	IN	O
salivary	JJ	O
cortisol	NN	O
in	IN	O
short-	JJ	O
and	CC	O
long-term	JJ	O
aspects	NNS	O
of	IN	O
tactile	JJ	Physical
massage	NN	Physical
(	(	Physical
TM	NNP	Physical
)	)	Physical
.	.	Other

METHODS	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
,	,	O
Controlled	NNP	O
and	CC	O
Randomised	VBD	O
Multicentre	NNP	O
Trial	NNP	O
.	.	O

SETTING	NN	O
AND	JJ	O
INTERVENTIONS	NNP	O
Forty-five	NNP	O
women	NNS	O
and	CC	O
men	NNS	O
,	,	O
aged	VBN	O
50-79	CD	O
years	NNS	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

Twenty-nine	NN	O
of	IN	O
them	PRP	O
were	VBD	O
blindly	RB	O
randomised	VBN	O
to	TO	O
tactile	VB	Other
massage	NN	Other
(	(	Other
TM	NNP	Other
)	)	Other
and	CC	O
16	CD	O
of	IN	O
them	PRP	O
to	TO	O
the	DT	O
control	NN	Control
group	NN	O
,	,	O
rest	NN	Control
to	TO	Control
music	NN	Control
(	(	Control
RTM	NNP	Control
)	)	Control
.	.	Control

Ten	CD	O
interventions	NNS	O
were	VBD	O
given	VBN	O
during	IN	O
8	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
26	CD	O
weeks	NNS	O
of	IN	O
follow	JJ	O
up	RB	O
.	.	O

Salivary	JJ	O
cortisol	NN	O
was	VBD	O
collected	VBN	O
at	IN	O
8	CD	O
am	VBP	O
,	,	O
1	CD	O
pm	NN	O
,	,	O
8	CD	O
pm	NN	O
,	,	O
and	CC	O
8	CD	O
am	VBP	O
the	DT	O
next	JJ	O
day	NN	O
,	,	O
on	IN	O
five	CD	O
occasions	NNS	O
.	.	O

With	IN	O
the	DT	O
first	JJ	O
and	CC	O
eighth	JJ	O
interventions	NNS	O
,	,	O
it	PRP	O
was	VBD	O
collected	VBN	O
immediately	RB	O
before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
aim	NN	O
was	VBD	O
to	TO	O
assess	VB	O
and	CC	O
compare	VB	O
cortisol	JJ	O
concentrations	NNS	O
before	IN	O
and	CC	O
immediately	RB	O
after	IN	O
intervention	NN	O
and	CC	O
also	RB	O
during	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
secondary	JJ	O
aim	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
,	,	O
duration	NN	O
and	CC	O
severity	NN	O
of	IN	O
PD	NNP	O
,	,	O
effects	NNS	O
of	IN	O
interventional	JJ	O
time-point	NN	O
of	IN	O
the	DT	O
day	NN	O
,	,	O
and	CC	O
levodopa	JJ	O
doses	NNS	O
on	IN	O
cortisol	JJ	O
concentration	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
cortisol	NN	O
concentrations	NNS	O
for	IN	O
all	DT	O
participants	NNS	O
were	VBD	O
16.0	CD	O
,	,	O
5.8	CD	O
,	,	O
2.8	CD	O
,	,	O
and	CC	O
14.0	CD	O
nmol/L	NN	O
at	IN	O
baseline	NN	O
,	,	O
later	RB	O
reproduced	VBD	O
four	CD	O
times	NNS	O
without	IN	O
significant	JJ	O
differences	NNS	O
.	.	O

Cortisol	NNP	O
concentrations	NNS	O
decreased	VBD	O
significantly	RB	O
after	IN	O
TM	NNP	Physical
intervention	NN	O
but	CC	O
no	DT	O
change	NN	O
in	IN	O
diurnal	JJ	O
salivary	JJ	O
cortisol	NN	O
pattern	NN	O
was	VBD	O
found	VBN	O
.	.	O

The	DT	O
findings	NNS	O
of	IN	O
reduced	JJ	O
salivary	JJ	O
cortisol	NN	O
concentrations	NNS	O
immediately	RB	O
after	IN	O
the	DT	O
interventions	NNS	O
are	VBP	O
in	IN	O
agreement	NN	O
with	IN	O
previous	JJ	O
studies	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
TM	NNP	Physical
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
correlations	NNS	O
between	IN	O
cortisol	JJ	O
concentrations	NNS	O
and	CC	O
age	NN	O
,	,	O
gender	NN	O
,	,	O
BMI	NNP	O
,	,	O
time-point	NN	O
for	IN	O
intervention	NN	O
,	,	O
time	NN	O
interval	NN	O
between	IN	O
anti-parkinson	JJ	O
pharmacy	NN	O
intake	NN	O
and	CC	O
sampling	NN	O
,	,	O
levodopa	NN	O
doses	NNS	O
,	,	O
duration	NN	O
,	,	O
or	CC	O
severity	NN	O
of	IN	O
PD	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Diurnal	NNP	O
salivary	JJ	O
cortisol	NN	O
rhythm	NN	O
was	VBD	O
normal	JJ	O
.	.	O

Salivary	JJ	O
cortisol	NN	O
concentrations	NNS	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
the	DT	O
TM	NNP	Physical
intervention	NN	O
and	CC	O
after	IN	O
RTM	NNP	Control
,	,	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
and	CC	O
no	DT	O
sustained	JJ	O
long-term	JJ	O
effect	NN	O
.	.	O

No	CC	O
associations	NNS	O
were	VBD	O
seen	VBN	O
between	IN	O
salivary	JJ	O
cortisol	NN	O
concentration	NN	O
and	CC	O
clinical	JJ	O
and/or	NN	O
pharmacological	JJ	O
characteristics	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrial.gov	NNP	O
,	,	O
NCT01734876	NNP	O
and	CC	O
FoU	NNP	O
Sweden	NNP	O
108881	CD	O
.	.	O

Efficacy	NN	O
of	IN	O
a	DT	O
family	NN	Educational
practice-based	JJ	Educational
lifestyle	JJ	Educational
intervention	NN	Educational
program	NN	Educational
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
reduce	VB	O
clinical	JJ	O
and	CC	O
physiological	JJ	O
markers	NNS	O
of	IN	O
vascular	JJ	O
health	NN	O
in	IN	O
patients	NNS	O
with	IN	O
high	JJ	O
normal	JJ	O
blood	NN	O
pressure	NN	O
and/or	RB	O
high	JJ	O
normal	JJ	O
blood	NN	O
glucose	NN	O
(	(	O
SNAC	NNP	O
)	)	O
:	:	O
study	NN	O
protocol	NN	O
for	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	JJ	O
interventions	NNS	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
reduce	VB	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
have	VBP	O
been	VBN	O
targeted	VBN	O
at	IN	O
individuals	NNS	O
with	IN	O
established	VBN	O
disease	NN	O
;	:	O
less	CC	O
attention	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
to	TO	O
intervention	VB	O
among	IN	O
individuals	NNS	O
with	IN	O
high	JJ	O
risk	NN	O
for	IN	O
disease	NN	O
nor	CC	O
has	VBZ	O
there	RB	O
been	VBN	O
determination	NN	O
of	IN	O
the	DT	O
influence	NN	O
of	IN	O
setting	VBG	O
in	IN	O
which	WDT	O
the	DT	O
intervention	NN	O
is	VBZ	O
provided	VBN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
family	NN	O
practice	NN	O
represents	VBZ	O
an	DT	O
ideal	JJ	O
setting	NN	O
for	IN	O
the	DT	O
provision	NN	O
and	CC	O
long-term	JJ	O
maintenance	NN	O
of	IN	O
lifestyle	JJ	O
interventions	NNS	O
for	IN	O
patients	NNS	O
at	IN	O
risk	NN	O
(	(	O
ie	JJ	O
high-normal	JJ	O
blood	NN	O
pressure	NN	O
or	CC	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
)	)	O
.	.	O

METHODS/DESIGN	PDT	O
The	DT	O
Staged	NNP	O
Nutrition	NNP	O
and	CC	O
Activity	NNP	O
Counseling	NNP	O
(	(	O
SNAC	NNP	O
)	)	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
clustered	JJ	O
design	NN	O
clinical	JJ	O
trial	NN	O
that	WDT	O
will	MD	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
a	DT	O
multi-component	JJ	Educational
lifestyle	JJ	Educational
intervention	NN	Educational
on	IN	O
cardiovascular	JJ	O
disease	NN	O
risk	NN	O
factors	NNS	O
and	CC	O
vascular	JJ	O
function	NN	O
in	IN	O
patients	NNS	O
at	IN	O
risk	NN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

Patients	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
by	IN	O
practice	NN	O
to	TO	O
either	VB	O
a	DT	O
standard	NN	Educational
of	IN	Educational
care	NN	Educational
lifestyle	JJ	Educational
intervention	NN	Educational
or	CC	O
a	DT	O
behaviourally-based	JJ	Educational
,	,	Educational
matched	VBD	Educational
prescriptive	JJ	Educational
physical	JJ	Educational
activity	NN	Educational
and	CC	Educational
diet	JJ	Educational
change	NN	Educational
program	NN	Educational
.	.	O

The	DT	O
primary	JJ	O
goal	NN	O
is	VBZ	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
improve	VB	O
dietary	JJ	O
intake	NN	O
according	VBG	O
to	TO	O
Canada	NNP	O
's	POS	O
Guides	NNP	O
to	TO	O
Physical	NNP	O
Activity	NNP	O
Healthy	NNP	O
Eating	NNP	O
over	IN	O
24	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
intention	NN	O
to	TO	O
treat	VB	O
analysis	NN	O
will	MD	O
compare	VB	O
behavioral	JJ	O
,	,	O
physiological	JJ	O
and	CC	O
metabolic	JJ	O
outcomes	NNS	O
at	IN	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
post-randomization	JJ	O
including	VBG	O
estimation	NN	O
of	IN	O
incident	JJ	O
hypertension	NN	O
and/or	NN	O
diabetes	VBZ	O
.	.	O

DISCUSSION	VB	O
The	DT	O
design	NN	O
features	NNS	O
of	IN	O
our	PRP$	O
trial	NN	O
,	,	O
and	CC	O
the	DT	O
practical	JJ	O
problems	NNS	O
(	(	O
and	CC	O
solutions	NNS	O
)	)	O
associated	VBN	O
with	IN	O
implementing	VBG	O
these	DT	O
design	NN	O
features	NNS	O
,	,	O
particularly	RB	O
those	DT	O
that	IN	O
result	NN	O
in	IN	O
potential	JJ	O
delay	NN	O
between	IN	O
recruitment	NN	O
,	,	O
baseline	NN	O
data	NNS	O
collection	NN	O
,	,	O
randomization	NN	O
,	,	O
intervention	NN	O
,	,	O
and	CC	O
assessment	NN	O
will	MD	O
be	VB	O
discussed	VBN	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
SNAC	NNP	O
trial	NN	O
will	MD	O
provide	VB	O
scientific	JJ	O
rationale	NN	O
for	IN	O
the	DT	O
implementation	NN	O
of	IN	O
this	DT	O
lifestyle	JJ	O
intervention	NN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ISRCTN	NNP	O
:	:	O
ISRCTN:42921300	NNP	O
.	.	O

Niacin	NNP	Pharmacological
revisited	VBD	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
of	IN	O
wax-matrix	JJ	O
sustained-release	JJ	O
niacin	NN	Pharmacological
in	IN	O
hypercholesterolemia	NN	O
.	.	O

Two	CD	O
hundred	VBD	O
one	CD	O
male	NN	O
and	CC	O
female	JJ	O
subjects	NNS	O
,	,	O
aged	VBD	O
20	CD	O
to	TO	O
70	CD	O
years	NNS	O
,	,	O
with	IN	O
elevated	VBN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
values	NNS	O
(	(	O
in	IN	O
the	DT	O
75th	CD	O
to	TO	O
95th	CD	O
percentiles	NNS	O
)	)	O
,	,	O
participated	VBN	O
in	IN	O
a	DT	O
randomized	NN	O
,	,	O
controlled	VBN	O
,	,	O
double-blind	NN	O
study	NN	O
using	VBG	O
a	DT	O
new	JJ	O
form	NN	O
of	IN	O
niacin	NN	Pharmacological
(	(	Pharmacological
Enduracin	NNP	Pharmacological
)	)	Pharmacological
,	,	O
which	WDT	O
employs	VBZ	O
a	DT	O
wax-matrix	JJ	O
vehicle	NN	O
for	IN	O
sustained	JJ	O
release	NN	O
.	.	O

Four	CD	O
niacin	JJ	Pharmacological
treatment	NN	O
groups	NNS	O
(	(	O
daily	JJ	O
doses	NNS	O
of	IN	O
2000	CD	O
,	,	O
1500	CD	O
,	,	O
1250	CD	O
,	,	O
and	CC	O
1000	CD	O
mg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
placebo-	JJ	Control
and	CC	O
diet-treated	JJ	Control
controls	NNS	Control
to	TO	O
determine	VB	O
side-effect	JJ	O
profile	NN	O
and	CC	O
optimal	JJ	O
range	NN	O
of	IN	O
efficacy	NN	O
.	.	O

The	DT	O
groups	NNS	O
given	VBN	O
2000	CD	O
and	CC	O
1500	CD	O
mg	NN	O
demonstrated	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
values	NNS	O
of	IN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
-26	CD	O
%	NN	O
and	CC	O
-19.3	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
-18.4	CD	O
%	NN	O
and	CC	O
-13.3	NNP	O
%	NN	O
)	)	O
,	,	O
and	CC	O
total	JJ	O
cholesterol-high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
ratio	NN	O
(	(	O
-20.4	CD	O
%	NN	O
and	CC	O
-19.4	CD	O
%	NN	O
)	)	O
when	WRB	O
compared	VBN	O
with	IN	O
diet-	JJ	O
and	CC	O
placebo-treated	JJ	O
controls	NNS	O
.	.	O

Smaller	NN	O
improvements	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
high-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
and	CC	O
triglyceride	NN	O
levels	NNS	O
.	.	O

Blood	NNP	O
chemistry	NN	O
monitoring	NN	O
indicated	VBD	O
that	DT	O
reduction	NN	O
in	IN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
level	NN	O
strongly	RB	O
correlated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
baseline	JJ	O
levels	NNS	O
of	IN	O
some	DT	O
enzymes	NNS	O
for	IN	O
niacin-treated	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
improved	JJ	O
side-effect	JJ	O
profile	NN	O
of	IN	O
the	DT	O
wax-matrix	JJ	O
form	NN	O
of	IN	O
niacin	NN	Pharmacological
was	VBD	O
particularly	RB	O
notable	JJ	O
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
was	VBD	O
only	RB	O
3.4	CD	O
%	NN	O
and	CC	O
was	VBD	O
coupled	VBN	O
with	IN	O
good	JJ	O
medication	NN	O
compliance	NN	O
.	.	O

A	DT	O
prospective	JJ	O
randomised	JJ	O
comparison	NN	O
of	IN	O
sublingual	JJ	Pharmacological
and	CC	Pharmacological
vaginal	JJ	Pharmacological
misoprostol	NN	Pharmacological
in	IN	O
second	JJ	O
trimester	NN	O
termination	NN	O
of	IN	O
pregnancy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
,	,	O
side	NN	O
effects	NNS	O
and	CC	O
acceptability	NN	O
of	IN	O
sublingual	JJ	Pharmacological
and	CC	Pharmacological
vaginal	JJ	Pharmacological
misoprostol	NN	Pharmacological
for	IN	O
second	JJ	O
trimester	NN	O
medical	JJ	O
abortion	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
randomised	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
Tertiary	JJ	O
referral	JJ	O
unit	NN	O
and	CC	O
a	DT	O
teaching	JJ	O
hospital	NN	O
.	.	O

POPULATION	NNP	O
Two	CD	O
hundred	VBD	O
and	CC	O
twenty-four	JJ	O
women	NNS	O
at	IN	O
12	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
of	IN	O
gestation	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
women	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
sublingual	JJ	Pharmacological
or	CC	Pharmacological
vaginal	JJ	Pharmacological
misoprostol	NN	Pharmacological
400	CD	Pharmacological
microg	NN	Pharmacological
every	DT	O
3	CD	O
hours	NNS	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
five	CD	O
doses	NNS	O
.	.	O

The	DT	O
course	NN	O
of	IN	O
misoprostol	NN	Pharmacological
was	VBD	O
repeated	VBN	O
if	IN	O
the	DT	O
woman	NN	O
did	VBD	O
not	RB	O
abort	VB	O
within	IN	O
24	CD	O
hours	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
success	NN	O
rate	NN	O
at	IN	O
48	CD	O
hours	NNS	O
,	,	O
induction-to-abortion	NN	O
interval	NN	O
and	CC	O
the	DT	O
side	NN	O
effects	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
success	NN	O
rate	NN	O
at	IN	O
48	CD	O
hours	NNS	O
(	(	O
sublingual	JJ	O
:	:	O
91	CD	O
%	NN	O
;	:	O
vaginal	JJ	O
:	:	O
95	CD	O
%	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
success	NN	O
rate	NN	O
at	IN	O
24	CD	O
hours	NNS	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
vaginal	JJ	O
group	NN	O
(	(	O
85	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
sublingual	JJ	O
group	NN	O
(	(	O
64	CD	O
%	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
median	JJ	O
induction-to-abortion	NN	O
interval	NN	O
(	(	O
sublingual	JJ	O
:	:	O
13.8	CD	O
hours	NNS	O
;	:	O
vaginal	JJ	O
:	:	O
12.0	CD	O
hours	NNS	O
)	)	O
.	.	O

Significantly	RB	O
more	JJR	O
women	NNS	O
in	IN	O
the	DT	O
sublingual	JJ	O
group	NN	O
preferred	VBD	O
the	DT	O
route	NN	O
to	TO	O
which	WDT	O
they	PRP	O
were	VBD	O
assigned	VBN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
vaginal	JJ	O
group	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
fever	NN	O
was	VBD	O
also	RB	O
less	RBR	O
in	IN	O
the	DT	O
sublingual	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
use	NN	O
of	IN	O
vaginal	JJ	Pharmacological
misoprostol	NN	Pharmacological
for	IN	O
second	JJ	O
trimester	NN	O
medical	JJ	O
abortion	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
higher	JJR	O
success	NN	O
rate	NN	O
than	IN	O
sublingual	JJ	O
misoprostol	NN	Pharmacological
at	IN	O
24	CD	O
hours	NNS	O
but	CC	O
the	DT	O
abortion	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
at	IN	O
48	CD	O
hours	NNS	O
.	.	O

Vaginal	NNP	Pharmacological
misoprostol	NN	Pharmacological
should	MD	O
be	VB	O
the	DT	O
regimen	NNS	O
of	IN	O
choice	NN	O
but	CC	O
sublingual	JJ	Pharmacological
misoprostol	NN	Pharmacological
is	VBZ	O
also	RB	O
an	DT	O
effective	JJ	O
alternative	NN	O
.	.	O

Effects	NNS	O
of	IN	O
20	CD	O
mg	NNS	O
rosuvastatin	NN	Pharmacological
on	IN	O
VLDL1-	NNP	O
,	,	O
VLDL2-	NNP	O
,	,	O
IDL-	NNP	O
and	CC	O
LDL-ApoB	NNP	O
kinetics	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

AIMS/HYPOTHESIS	NNP	O
In	IN	O
addition	NN	O
to	TO	O
its	PRP$	O
efficacy	NN	O
in	IN	O
reducing	VBG	O
LDL-cholesterol	NNP	O
,	,	O
rosuvastatin	NN	Pharmacological
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
significantly	RB	O
decrease	VB	O
plasma	NN	O
triacylglycerol	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
rosuvastatin	NN	Pharmacological
may	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
,	,	O
who	WP	O
usually	RB	O
have	VBP	O
increased	VBN	O
triacylglycerol	NN	O
levels	NNS	O
.	.	O

However	RB	O
,	,	O
its	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
triacylglycerol-rich	JJ	O
lipoproteins	NNS	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
remains	VBZ	O
unknown	JJ	O
.	.	O

METHODS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
randomised	JJ	O
double-blind	NN	O
crossover	NN	O
trial	NN	O
of	IN	O
6-week	JJ	O
treatment	NN	O
with	IN	O
placebo	NN	Control
or	CC	O
rosuvastatin	VB	Pharmacological
20	CD	O
mg	NN	O
in	IN	O
eight	CD	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
who	WP	O
were	VBD	O
being	VBG	O
treated	VBN	O
with	IN	O
oral	JJ	O
glucose-lowering	JJ	O
agents	NNS	O
.	.	O

In	IN	O
each	DT	O
patient	NN	O
,	,	O
an	DT	O
in	IN	O
vivo	NN	O
kinetic	JJ	O
study	NN	O
of	IN	O
apolipoprotein	NN	O
B	NNP	O
(	(	O
ApoB	NNP	O
)	)	O
-containing	VBG	O
lipoproteins	NNS	O
with	IN	O
[	JJ	O
13C	CD	O
]	JJ	O
leucine	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
treatment	NN	O
period	NN	O
.	.	O

A	DT	O
central	JJ	O
randomisation	NN	O
centre	NN	O
used	VBN	O
computer-generated	JJ	O
tables	NNS	O
to	TO	O
allocate	VB	O
treatments	NNS	O
.	.	O

Participants	NNS	O
,	,	O
caregivers	NNS	O
and	CC	O
those	DT	O
assessing	VBG	O
the	DT	O
outcomes	NNS	O
were	VBD	O
blinded	VBN	O
to	TO	O
group	NN	O
assignment	NN	O
.	.	O

RESULTS	NNP	O
Rosuvastatin	NNP	Pharmacological
20	CD	O
mg	NN	O
significantly	RB	O
reduced	VBN	O
plasma	JJ	O
LDL-cholesterol	NNP	O
,	,	O
triacylglycerol	NN	O
and	CC	O
total	JJ	O
ApoB	NNP	O
.	.	O

It	PRP	O
also	RB	O
significantly	RB	O
reduced	VBN	O
ApoB	NNP	O
pool	NN	O
sizes	NNS	O
of	IN	O
larger	JJR	O
triacylglycerol-rich	JJ	O
VLDL	NNP	O
particles	NNS	O
(	(	O
VLDL1	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.011	CD	O
)	)	O
,	,	O
smaller	JJR	O
VLDL	NNP	O
particles	NNS	O
(	(	O
VLDL2	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.011	CD	O
)	)	O
,	,	O
intermediate	JJ	O
density	NN	O
lipoprotein	NN	O
(	(	O
IDL	NNP	O
;	:	O
p	VBZ	O
=	$	O
0.011	CD	O
)	)	O
and	CC	O
LDL	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

This	DT	O
reduction	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
total	JJ	O
fractional	JJ	O
catabolic	NN	O
rate	NN	O
of	IN	O
VLDL1-ApoB	NNP	O
(	(	O
6.70	CD	O
+/-	JJ	O
3.24	CD	O
vs	JJ	O
4.52	CD	O
+/-	JJ	O
2.34	CD	O
pool/day	NN	O
,	,	O
p	NN	O
=	NNP	O
0.049	CD	O
)	)	O
,	,	O
VLDL2-ApoB	NNP	O
(	(	O
8.72	CD	O
+/-	JJ	O
3.37	CD	O
vs	JJ	O
5.36	CD	O
+/-	JJ	O
2.64	CD	O
,	,	O
p	NN	O
=	NNP	O
0.011	CD	O
)	)	O
,	,	O
IDL-ApoB	NNP	O
(	(	O
7.06	CD	O
+/-	JJ	O
1.68	CD	O
vs	JJ	O
4.21	CD	O
+/-	JJ	O
1.51	CD	O
,	,	O
p	NN	O
=	NNP	O
0.011	CD	O
)	)	O
and	CC	O
LDL-ApoB	NNP	O
(	(	O
1.02	CD	O
+/-	JJ	O
0.27	CD	O
vs	JJ	O
0.59	CD	O
+/-	JJ	O
0.13	CD	O
,	,	O
p	NN	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

Rosuvastatin	NNPS	Pharmacological
did	VBD	O
not	RB	O
change	VB	O
the	DT	O
production	NN	O
rates	NNS	O
of	IN	O
VLDL2-	NNP	O
,	,	O
IDL-	NNP	O
or	CC	O
LDL-	NNP	O
,	,	O
but	CC	O
did	VBD	O
reduce	VB	O
VLDL1-ApoB	NNP	O
production	NN	O
rate	NN	O
(	(	O
12.4	CD	O
+/-	JJ	O
4.5	CD	O
vs	JJ	O
19.5	CD	O
+/-	JJ	O
8.4	CD	O
mg	NN	O
kg	NN	O
(	(	O
-1	JJ	O
)	)	O
day	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
p	JJ	O
=	NNP	O
0.035	CD	O
)	)	O
.	.	O

No	DT	O
side	NN	O
effects	NNS	O
of	IN	O
rosuvastatin	NN	O
were	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS/INTERPRETATION	NNP	O
In	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
rosuvastatin	VBP	Pharmacological
20	CD	O
mg	NN	O
not	RB	O
only	RB	O
induces	VBZ	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
LDL-ApoB	JJ	O
catabolism	NN	O
(	(	O
73	CD	O
%	NN	O
)	)	O
,	,	O
but	CC	O
also	RB	O
has	VBZ	O
favourable	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
catabolism	NN	O
of	IN	O
triacylglycerol-rich	JJ	O
lipoproteins	NNS	O
,	,	O
e.g	NN	O
.	.	O

a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
catabolism	NN	O
of	IN	O
VLDL1-ApoB	NNP	O
(	(	O
48	CD	O
%	NN	O
)	)	O
,	,	O
VLDL2-ApoB	NNP	O
(	(	O
63	CD	O
%	NN	O
)	)	O
and	CC	O
IDL-ApoB	NNP	O
(	(	O
68	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
production	NN	O
rate	NN	O
of	IN	O
VLDL1-ApoB	NNP	O
(	(	O
-36	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
rosuvastatin	NN	Pharmacological
on	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
triacylglycerol-rich	JJ	O
lipoproteins	NNS	O
may	MD	O
be	VB	O
beneficial	JJ	O
for	IN	O
prevention	NN	O
of	IN	O
atherosclerosis	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
.	.	O

Shorter	NNP	O
treatment	NN	O
for	IN	O
vaginal	JJ	O
candidosis	NN	O
:	:	O
comparison	NN	O
between	IN	O
single-dose	JJ	O
oral	JJ	O
fluconazole	NN	Pharmacological
and	CC	O
three-day	JJ	O
treatment	NN	O
with	IN	O
local	JJ	O
miconazole	NN	Pharmacological
.	.	Pharmacological

Fluconazole	NNP	Pharmacological
is	VBZ	O
an	DT	O
effective	JJ	O
,	,	O
simple	JJ	O
and	CC	O
safe	JJ	O
,	,	O
although	IN	O
slightly	RB	O
expensive	JJ	O
,	,	O
agent	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
vaginal	JJ	O
candidosis	NN	O
.	.	O

Single-dose	JJ	O
fluconazole	NN	Pharmacological
(	(	O
150	CD	O
mg	NN	O
)	)	O
administered	VBD	O
orally	RB	O
in	IN	O
capsule	NN	O
form	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
three-day	JJ	O
local	JJ	O
treatment	NN	O
with	IN	O
miconazole	JJ	Pharmacological
pessaries	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
vaginal	JJ	O
candidosis	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
in	IN	O
Finland	NNP	O
.	.	O

Cure	NN	O
rates	NNS	O
were	VBD	O
good	JJ	O
(	(	O
>	JJ	O
80	CD	O
%	NN	O
)	)	O
in	IN	O
randomized	VBN	O
patient	NN	O
groups	NNS	O
assessed	VBD	O
both	DT	O
clinically	RB	O
and	CC	O
by	IN	O
the	DT	O
results	NNS	O
of	IN	O
yeast	JJ	O
cultures	NNS	O
.	.	O

Oral	JJ	O
administration	NN	O
was	VBD	O
preferred	VBN	O
to	TO	O
local	JJ	O
therapy	NN	O
by	IN	O
patients	NNS	O
in	IN	O
both	DT	O
the	DT	O
miconazole	NN	Pharmacological
and	CC	O
fluconazole	JJ	Pharmacological
groups	NNS	O
.	.	O

For	IN	O
the	DT	O
time	NN	O
being	VBG	O
,	,	O
fluconazole	NN	Pharmacological
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
during	IN	O
pregnancy	NN	O
or	CC	O
lactation	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
effect	NN	O
of	IN	O
valproate	NN	Pharmacological
on	IN	O
glyceryltrinitrate	NN	O
induced	VBN	O
migraine	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
the	DT	O
human	JJ	O
glyceryltrinitrate	NN	O
(	(	O
GTN	NNP	O
)	)	O
model	NN	O
of	IN	O
migraine	NN	O
was	VBD	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
used	VBN	O
to	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
prophylactic	JJ	O
drug	NN	O
.	.	O

We	PRP	O
chose	VBD	O
to	TO	O
test	VB	O
valproate	NN	Pharmacological
due	JJ	O
to	TO	O
its	PRP$	O
well	RB	O
documented	JJ	O
effect	NN	O
as	IN	O
a	DT	O
migraine	JJ	Pharmacological
prophylactic	JJ	Pharmacological
drug	NN	Pharmacological
.	.	Pharmacological

Efficacy	NN	O
of	IN	O
this	DT	O
compound	NN	O
would	MD	O
support	VB	O
the	DT	O
usefulness	NN	O
of	IN	O
the	DT	O
model	NN	O
in	IN	O
prophylactic	JJ	O
antimigraine	JJ	O
drug	NN	O
development	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
with	IN	O
migraine	NN	O
without	IN	O
aura	NN	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	NN	O
crossover	NN	O
study	NN	O
.	.	O

Valproate	VB	Pharmacological
1000	CD	O
mg	NN	O
or	CC	O
placebo	NN	Control
was	VBD	O
given	VBN	O
daily	RB	O
,	,	O
each	DT	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
13	CD	O
days	NNS	O
.	.	O

On	IN	O
the	DT	O
last	JJ	O
treatment	NN	O
day	NN	O
of	IN	O
each	DT	O
arm	NN	O
a	DT	O
20	CD	O
min	NN	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
GTN	NNP	Pharmacological
(	(	O
0.25	CD	O
microg/kg/min	NN	O
)	)	O
was	VBD	O
given	VBN	O
.	.	O

Headache	NNP	O
was	VBD	O
registered	VBN	O
for	IN	O
12	CD	O
h	NN	O
after	IN	O
the	DT	O
infusion	NN	O
and	CC	O
headache	NN	O
intensity	NN	O
was	VBD	O
scored	VBN	O
on	IN	O
a	DT	O
scale	NN	O
from	IN	O
0	CD	O
to	TO	O
10	CD	O
.	.	O

Fulfillment	NN	O
of	IN	O
IHS	NNP	O
criteria	NNS	O
was	VBD	O
recorded	VBN	O
for	IN	O
24	CD	O
h.	PDT	O
The	DT	O
middle	JJ	O
cerebral	JJ	O
arteries	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
transcranial	JJ	O
Doppler	NNP	O
and	CC	O
the	DT	O
diameter	NN	O
of	IN	O
the	DT	O
superficial	JJ	O
temporal	JJ	O
and	CC	O
radial	JJ	O
arteries	NNS	O
were	VBD	O
measured	VBN	O
with	IN	O
high	JJ	O
frequency	NN	O
ultrasound	NN	O
.	.	O

GTN	NNP	Pharmacological
evoked	VBD	O
migraine	JJ	O
fulfilling	NN	O
IHS	NNP	O
criteria	NNS	O
1.1	CD	O
in	IN	O
6	CD	O
patients	NNS	O
after	IN	O
placebo	NN	Control
and	CC	O
in	IN	O
2	CD	O
patients	NNS	O
after	IN	O
valproate	NN	Pharmacological
(	(	O
P	NNP	O
=	NNP	O
0.125	CD	O
)	)	O
.	.	O

Including	VBG	O
additionally	RB	O
3	CD	O
patients	NNS	O
on	IN	O
placebo	NN	Control
and	CC	O
1	CD	O
patient	NN	O
on	IN	O
valproate	NN	Pharmacological
who	WP	O
felt	VBD	O
they	PRP	O
had	VBD	O
suffered	VBN	O
a	DT	O
migraine	JJ	O
attack	NN	O
,	,	O
but	CC	O
who	WP	O
had	VBD	O
as	IN	O
associated	VBN	O
symptoms	NNS	O
only	RB	O
photophobia	VBP	O
or	CC	O
phonophobia	VBP	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
induced	JJ	O
migraine	NN	O
after	IN	O
valproate	NN	Pharmacological
was	VBD	O
seen	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
.	.	O

Median	JJ	O
peak	NN	O
headache	NN	O
intensity	NN	O
was	VBD	O
1	CD	O
(	(	O
range	VB	O
0-9	NN	O
)	)	O
after	IN	O
valproate	NN	Pharmacological
compared	VBN	O
to	TO	O
4.5	CD	O
(	(	O
range	VB	O
0-8	NN	O
)	)	O
after	IN	O
placebo	NN	Control
(	(	O
P	NNP	O
=	NNP	O
0.120	CD	O
)	)	O
.	.	O

Pretreatment	NN	O
with	IN	O
valproate	NN	Pharmacological
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	Control
reduced	VBN	O
the	DT	O
velocity	NN	O
in	IN	O
both	DT	O
middle	JJ	O
cerebral	NN	O
arteries	NNS	O
after	IN	O
GTN	NNP	O
(	(	O
left	VBN	O
P	NNP	O
=	NNP	O
0.021	CD	O
,	,	O
right	JJ	O
P	NNP	O
=	NNP	O
0.031	CD	O
)	)	O
.	.	O

No	DT	O
effect	NN	O
of	IN	O
valproate	NN	Pharmacological
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
diameter	NN	O
of	IN	O
the	DT	O
superficial	JJ	O
temporal	JJ	O
artery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.781	CD	O
)	)	O
or	CC	O
the	DT	O
radial	JJ	O
artery	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.367	CD	O
)	)	O
before	IN	O
or	CC	O
after	IN	O
GTN	NNP	O
.	.	O

The	DT	O
study	NN	O
indicates	VBZ	O
that	IN	O
a	DT	O
prophylactic	JJ	O
effect	NN	O
of	IN	O
valproate	NN	Pharmacological
may	MD	O
be	VB	O
demonstrated	VBN	O
using	VBG	O
the	DT	O
GTN	NNP	Pharmacological
human	JJ	Pharmacological
migraine	NN	Pharmacological
model	NN	Pharmacological
.	.	Pharmacological

Although	IN	O
,	,	O
all	DT	O
headache	NN	O
parameters	NNS	O
were	VBD	O
reduced	VBN	O
after	IN	O
valproate	NN	Pharmacological
compared	VBN	O
to	TO	O
placebo	VB	Control
,	,	O
only	RB	O
one	CD	O
parameter	NN	O
was	VBD	O
statistically	RB	O
significantly	RB	O
reduced	VBN	O
probably	RB	O
because	IN	O
of	IN	O
the	DT	O
small	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
size	NN	O
of	IN	O
the	DT	O
effect	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
valproate	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

The	DT	O
GTN	NNP	Pharmacological
model	NN	Pharmacological
may	MD	O
therefore	RB	O
be	VB	O
a	DT	O
valid	JJ	O
tool	NN	O
for	IN	O
testing	VBG	O
new	JJ	O
prophylactic	JJ	O
antimigraine	NN	O
drugs	NNS	O
.	.	O

In-hospital	JJ	O
costs	NNS	O
of	IN	O
self-expanding	JJ	Surgical
nitinol	JJ	Surgical
stent	NN	Surgical
implantation	NN	Surgical
versus	NN	O
balloon	NN	Surgical
angioplasty	NN	Surgical
in	IN	O
the	DT	O
femoropopliteal	JJ	O
artery	NN	O
(	(	O
the	DT	O
VascuCoil	NNP	O
Trial	NNP	O
)	)	O
.	.	O

PURPOSE	NNP	O
Although	IN	O
several	JJ	O
prospective	JJ	O
studies	NNS	O
have	VBP	O
examined	VBN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
stent	JJ	Surgical
placement	NN	Surgical
for	IN	O
femoropopliteal	JJ	O
arterial	JJ	O
disease	NN	O
,	,	O
the	DT	O
current	JJ	O
cost	NN	O
of	IN	O
these	DT	O
procedures	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	O

To	TO	O
estimate	VB	O
and	CC	O
compare	VB	O
hospital	NN	O
costs	NNS	O
associated	VBN	O
with	IN	O
conventional	JJ	Surgical
balloon	NN	Surgical
angioplasty	NN	Surgical
(	(	Surgical
percutaneous	JJ	Surgical
transluminal	NN	Surgical
angioplasty	NN	Surgical
[	NNP	Surgical
PTA	NNP	Surgical
]	NNP	Surgical
)	)	Surgical
and	CC	O
stent	JJ	Surgical
placement	NN	Surgical
for	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
,	,	O
the	DT	O
authors	NNS	O
performed	VBD	O
a	DT	O
prospective	JJ	O
economic	JJ	O
evaluation	NN	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
Intracoil	NNP	O
Femoropopliteal	NNP	O
Stent	NNP	O
Trial	NNP	O
(	(	O
VascuCoil	NNP	O
)	)	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
May	NNP	O
1997	CD	O
and	CC	O
December	NNP	O
1999	CD	O
,	,	O
266	CD	O
patients	NNS	O
with	IN	O
stenotic	JJ	O
or	CC	O
occluded	VBN	O
superficial	JJ	O
femoral	JJ	O
or	CC	O
popliteal	JJ	O
arteries	NNS	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
the	DT	O
IntraCoil	NNP	Surgical
stent	NN	Surgical
or	CC	O
PTA	NNP	Surgical
.	.	Surgical

Detailed	NNP	O
resource	NN	O
use	NN	O
and	CC	O
cost	NN	O
data	NNS	O
for	IN	O
each	DT	O
patient	NN	O
's	POS	O
initial	JJ	O
revascularization	NN	O
procedure	NN	O
and	CC	O
ensuing	VBG	O
hospitalization	NN	O
were	VBD	O
collected	VBN	O
and	CC	O
analyzed	VBN	O
on	IN	O
an	DT	O
intention-to-treat	JJ	O
basis	NN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
conventional	JJ	Surgical
balloon	NN	Surgical
angioplasty	NN	Surgical
,	,	O
stent	JJ	Surgical
placement	NN	Surgical
did	VBD	O
not	RB	O
improve	VB	O
clinical	JJ	O
outcomes	NNS	O
but	CC	O
increased	JJ	O
procedure	NN	O
duration	NN	O
,	,	O
equipment	NN	O
costs	NNS	O
,	,	O
and	CC	O
physician	JJ	O
services	NNS	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
,	,	O
initial	JJ	O
hospital	NN	O
costs	NNS	O
were	VBD	O
approximately	RB	O
3,500	CD	O
dollars	NNS	O
higher	JJR	O
for	IN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
IntraCoil	NNP	Surgical
stent	NN	Surgical
,	,	O
compared	VBN	O
with	IN	O
PTA	NNP	Surgical
(	(	O
8,435	CD	O
dollars	NNS	O
vs	RB	O
4,980	CD	O
dollars	NNS	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
As	IN	O
performed	VBN	O
in	IN	O
the	DT	O
VascuCoil	NNP	O
trial	NN	O
,	,	O
primary	JJ	O
stent	NN	O
placement	NN	O
for	IN	O
femoropopliteal	JJ	O
disease	NN	O
did	VBD	O
not	RB	O
improve	VB	O
clinical	JJ	O
outcomes	NNS	O
but	CC	O
increased	VBD	O
initial	JJ	O
treatment	NN	O
costs	NNS	O
by	IN	O
more	JJR	O
than	IN	O
3,000	CD	O
dollars	NNS	O
.	.	O

Because	IN	O
there	EX	O
were	VBD	O
no	DT	O
substantial	JJ	O
differences	NNS	O
in	IN	O
subsequent	JJ	O
clinical	JJ	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
that	IN	O
these	DT	O
increased	VBN	O
initial	JJ	O
costs	NNS	O
would	MD	O
be	VB	O
offset	VBN	O
by	IN	O
savings	NNS	O
in	IN	O
follow-up	JJ	O
costs	NNS	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
strategy	NN	O
of	IN	O
routine	JJ	O
stent	NN	Physical
implantation	NN	O
for	IN	O
patients	NNS	O
undergoing	VBG	O
femoropopliteal	JJ	O
PTA	NNP	Physical
is	VBZ	O
not	RB	O
optimal	JJ	O
on	IN	O
economic	JJ	O
grounds	NNS	O
and	CC	O
that	DT	O
PTA	NNP	Physical
with	IN	O
provisional	JJ	Physical
stent	JJ	Physical
implantation	NN	Physical
is	VBZ	O
preferred	VBN	O
.	.	O

Junctional	NNP	O
ectopic	NN	O
tachycardia	NN	O
after	IN	O
congenital	JJ	O
heart	NN	O
surgery	NN	O
in	IN	O
the	DT	O
current	JJ	O
surgical	JJ	O
era	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
junctional	JJ	O
ectopic	NN	O
tachycardia	NN	O
(	(	O
JET	NNP	O
)	)	O
in	IN	O
a	DT	O
modern	JJ	O
cohort	NN	O
of	IN	O
pediatric	JJ	O
patients	NNS	O
,	,	O
evaluate	VBP	O
possible	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
JET	NNP	O
,	,	O
and	CC	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
JET	NNP	O
on	IN	O
postoperative	JJ	O
morbidity	NN	O
and	CC	O
mortality	NN	O
.	.	O

JET	NN	O
is	VBZ	O
common	JJ	O
after	IN	O
congenital	JJ	O
heart	NN	O
surgery	NN	O
.	.	O

JET-related	JJ	O
mortality	NN	O
has	VBZ	O
been	VBN	O
a	DT	O
rare	JJ	O
event	NN	O
at	IN	O
our	PRP$	O
center	NN	O
,	,	O
which	WDT	O
is	VBZ	O
different	JJ	O
from	IN	O
previous	JJ	O
reports	NNS	O
.	.	O

We	PRP	O
reviewed	VBD	O
records	NNS	O
for	IN	O
pediatric	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
postoperative	JJ	O
arrhythmias	NN	O
between	IN	O
January	NNP	O
2006	CD	O
and	CC	O
June	NNP	O
2010	CD	O
at	IN	O
a	DT	O
large	JJ	O
tertiary-care	JJ	O
children	NNS	O
's	POS	O
hospital	NN	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
matched	VBN	O
case-control	NN	O
study	NN	O
to	TO	O
identify	VB	O
risk	NN	O
factors	NNS	O
for	IN	O
JET	NNP	O
and	CC	O
a	DT	O
matched-cohort	NN	O
study	NN	O
to	TO	O
compare	VB	O
outcomes	NNS	O
between	IN	O
patients	NNS	O
and	CC	O
controls	NNS	O
.	.	O

Whenever	NNP	O
possible	JJ	O
,	,	O
each	DT	O
JET	NNP	O
case	NN	O
was	VBD	O
randomly	RB	O
matched	VBN	O
to	TO	O
two	CD	O
controls	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
lesion	NN	O
,	,	O
repair	NN	O
,	,	O
and	CC	O
surgical	JJ	O
period	NN	O
.	.	O

We	PRP	O
identified	VBD	O
54	CD	O
patients	NNS	O
with	IN	O
JET	NNP	O
(	(	O
incidence	NN	O
=	RB	O
1.4	CD	O
%	NN	O
)	)	O
.	.	O

After	IN	O
multivariate	JJ	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
,	,	O
low	JJ	O
operative	JJ	O
weight	NN	O
,	,	O
cardiopulmonary	JJ	O
bypass	NN	O
(	(	O
CPB	NNP	O
)	)	O
duration	NN	O
>	$	O
100	CD	O
min	NN	O
,	,	O
and	CC	O
immediate	JJ	O
postoperative	JJ	O
serum	NN	O
lactic	JJ	O
acid	NN	O
level	NN	O
>	VBD	O
20	CD	O
mg/dl	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
increased	JJ	O
odds	NNS	O
of	IN	O
developing	VBG	O
JET	NNP	O
.	.	O

Patients	NNS	O
with	IN	O
JET	NNP	O
had	VBD	O
longer	RBR	O
mechanical	JJ	O
ventilation	NN	O
time	NN	O
,	,	O
cardiac	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
CICU	NNP	O
)	)	O
stay	NN	O
,	,	O
and	CC	O
hospital	NN	O
stay	NN	O
.	.	O

There	EX	O
was	VBD	O
only	RB	O
one	CD	O
death	NN	O
in	IN	O
JET	NNP	O
group	NN	O
(	(	O
1.8	CD	O
%	NN	O
)	)	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

JET	NNP	O
remains	VBZ	O
a	DT	O
relatively	RB	O
common	JJ	O
postoperative	JJ	O
arrhythmia	NN	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
less	RBR	O
frequent	JJ	O
than	IN	O
previously	RB	O
reported	VBN	O
.	.	O

JET	NNP	O
occurs	VBZ	O
more	JJR	O
commonly	RB	O
in	IN	O
smaller	JJR	O
patients	NNS	O
with	IN	O
longer	JJR	O
CPB	NNP	O
runs	NNS	O
and	CC	O
significant	JJ	O
postoperative	JJ	O
lactic	JJ	O
acidosis	NN	O
levels	NNS	O
.	.	O

Mortality	NNP	O
associated	VBD	O
with	IN	O
JET	NNP	O
is	VBZ	O
lower	JJR	O
than	IN	O
historically	RB	O
reported	VBN	O
,	,	O
but	CC	O
morbidity	NN	O
remains	VBZ	O
high	JJ	O
.	.	O

A	DT	O
double-blind	JJ	O
randomized	JJ	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
enamel	JJ	Pharmacological
matrix	NNS	Pharmacological
derivative	JJ	Pharmacological
proteins	NNS	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
proximal	JJ	O
class-II	JJ	O
furcation	NN	O
involvements	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
clinical	JJ	O
response	NN	O
of	IN	O
proximal	JJ	O
furcations	NNS	O
treated	VBN	O
with	IN	O
enamel	JJ	Pharmacological
matrix	NNS	Pharmacological
derivative	JJ	Pharmacological
proteins	NNS	Pharmacological
(	(	Pharmacological
EMD	NNP	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Fifteen	NNP	O
patients	NNS	O
,	,	O
each	DT	O
with	IN	O
a	DT	O
pair	NN	O
of	IN	O
contralateral	JJ	O
class-II	JJ	O
proximal	JJ	O
furcation	NN	O
involvements	NNS	O
,	,	O
presenting	VBG	O
probing	VBG	O
depths	NNS	O
(	(	O
PDs	NNP	O
)	)	O
>	VBP	O
/=5	JJ	O
mm	NN	O
and	CC	O
bleeding	NN	O
on	IN	O
probing	VBG	O
(	(	O
BOP	NNP	O
)	)	O
were	VBD	O
selected	VBN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
:	:	O
control	NN	Control
group	NN	Control
(	(	O
n=15	NN	O
)	)	O
-	:	O
open	JJ	Control
flap	NN	Control
debridement	NN	Control
(	(	Control
OFD	NNP	Control
)	)	Control
+24	CD	Control
%	NN	Control
ethylenediaminetetraacetic	JJ	Control
acid	NN	Control
(	(	Control
EDTA	NNP	Control
)	)	Control
conditioning	NN	Control
;	:	Pharmacological
test	CC	O
group	NN	O
(	(	O
n=15	NN	O
)	)	O
-	:	O
OFD+24	CD	Pharmacological
%	NN	Pharmacological
EDTA	NNP	Pharmacological
conditioning+EMD	NN	Pharmacological
application	NN	Pharmacological
.	.	Pharmacological

Plaque	NNP	O
index	NN	O
(	(	O
PI	NNP	O
)	)	O
,	,	O
BOP	NNP	O
,	,	O
PD	NNP	O
,	,	O
gingival	NN	O
margin	NN	O
position	NN	O
(	(	O
GMP	NNP	O
)	)	O
,	,	O
relative	JJ	O
vertical	NN	O
and	CC	O
horizontal	JJ	O
clinical	JJ	O
attachment	NN	O
level	NN	O
(	(	O
RVCAL	NNP	O
and	CC	O
RHCAL	NNP	O
)	)	O
,	,	O
vertical	JJ	O
and	CC	O
horizontal	JJ	O
bone	NN	O
level	NN	O
(	(	O
VBL	NNP	O
and	CC	O
HBL	NNP	O
)	)	O
and	CC	O
furcation	JJ	O
closure	NN	O
were	VBD	O
evaluated	VBN	O
immediately	RB	O
before	IN	O
and	CC	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
the	DT	O
surgeries	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
RVCAL	NNP	O
gains	NNS	O
of	IN	O
the	DT	O
control	NN	O
and	CC	O
test	NN	O
group	NN	O
were	VBD	O
0.39	CD	O
+/-	JJ	O
1.00	CD	O
and	CC	O
0.54	CD	O
+/-	JJ	O
0.95	CD	O
mm	NN	O
,	,	O
while	IN	O
the	DT	O
RHCAL	NNP	O
gains	NNS	O
were	VBD	O
1.21	CD	O
+/-	JJ	O
2.28	CD	O
and	CC	O
1.36	CD	O
+/-	JJ	O
1.26	CD	O
mm	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
VBL	NNP	O
and	CC	O
HBL	NNP	O
gains	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
1.04	CD	O
+/-	JJ	O
1.12	CD	O
and	CC	O
1.00	CD	O
+/-	JJ	O
1.79	CD	O
mm	NN	O
,	,	O
and	CC	O
0.82	CD	O
+/-	JJ	O
1.82	CD	O
and	CC	O
1.17	CD	O
+/-	JJ	O
1.38	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
statistical	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
the	DT	O
remaining	VBG	O
class-II	JJ	O
furcations	NNS	O
between	IN	O
the	DT	O
test	NN	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
this	DT	O
period	NN	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
may	MD	O
be	VB	O
concluded	VBN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
EMD	NNP	Pharmacological
in	IN	O
proximal	JJ	O
furcations	NNS	O
did	VBD	O
not	RB	O
promote	VB	O
a	DT	O
superior	JJ	O
reduction	NN	O
in	IN	O
PD	NNP	O
or	CC	O
a	DT	O
gain	NN	O
in	IN	O
clinical	JJ	O
and	CC	O
osseous	JJ	O
attachment	NN	O
levels	NNS	O
,	,	O
but	CC	O
resulted	VBD	O
in	IN	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
class-II	NN	O
to	TO	O
class-I	JJ	O
furcation	NN	O
conversion	NN	O
.	.	O

Effects	NNS	O
of	IN	O
long-term	JJ	Pharmacological
vitamin	NN	Pharmacological
E	NNP	Pharmacological
supplementation	NN	Pharmacological
on	IN	O
cardiovascular	JJ	O
events	NNS	O
and	CC	O
cancer	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

CONTEXT	NNP	O
Experimental	NNP	O
and	CC	O
epidemiological	JJ	O
data	NNS	O
suggest	VBP	O
that	IN	O
vitamin	NN	Pharmacological
E	NNP	Pharmacological
supplementation	NN	Pharmacological
may	MD	O
prevent	VB	O
cancer	NN	O
and	CC	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

Clinical	JJ	O
trials	NNS	O
have	VBP	O
generally	RB	O
failed	VBN	O
to	TO	O
confirm	VB	O
benefits	NNS	O
,	,	O
possibly	RB	O
due	JJ	O
to	TO	O
their	PRP$	O
relatively	RB	O
short	JJ	O
duration	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
whether	IN	O
long-term	JJ	Pharmacological
supplementation	NN	Pharmacological
with	IN	Pharmacological
vitamin	JJ	Pharmacological
E	NN	Pharmacological
decreases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
cancer	NN	O
,	,	O
cancer	NN	O
death	NN	O
,	,	O
and	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PATIENTS	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
international	JJ	O
trial	NN	O
(	(	O
the	DT	O
initial	JJ	O
Heart	NNP	O
Outcomes	NNP	O
Prevention	NNP	O
Evaluation	NNP	O
[	NNP	O
HOPE	NNP	O
]	NNP	O
trial	NN	O
conducted	VBD	O
between	IN	O
December	NNP	O
21	CD	O
,	,	O
1993	CD	O
,	,	O
and	CC	O
April	NNP	O
15	CD	O
,	,	O
1999	CD	O
)	)	O
of	IN	O
patients	NNS	O
at	IN	O
least	JJS	O
55	CD	O
years	NNS	O
old	JJ	O
with	IN	O
vascular	JJ	O
disease	NN	O
or	CC	O
diabetes	VBZ	O
mellitus	NN	O
was	VBD	O
extended	VBN	O
(	(	O
HOPE-The	NNP	O
Ongoing	NNP	O
Outcomes	NNP	O
[	NNP	O
HOPE-TOO	NNP	O
]	NNP	O
)	)	O
between	IN	O
April	NNP	O
16	CD	O
,	,	O
1999	CD	O
,	,	O
and	CC	O
May	NNP	O
26	CD	O
,	,	O
2003	CD	O
.	.	O

Of	IN	O
the	DT	O
initial	JJ	O
267	CD	O
HOPE	NNP	O
centers	NNS	O
that	WDT	O
had	VBD	O
enrolled	VBN	O
9541	CD	O
patients	NNS	O
,	,	O
174	CD	O
centers	NNS	O
participated	VBN	O
in	IN	O
the	DT	O
HOPE-TOO	NNP	O
trial	NN	O
.	.	O

Of	IN	O
7030	CD	O
patients	NNS	O
enrolled	VBN	O
at	IN	O
these	DT	O
centers	NNS	O
,	,	O
916	CD	O
were	VBD	O
deceased	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
extension	NN	O
,	,	O
1382	CD	O
refused	VBD	O
participation	NN	O
,	,	O
3994	CD	O
continued	VBD	O
to	TO	O
take	VB	O
the	DT	O
study	NN	O
intervention	NN	O
,	,	O
and	CC	O
738	CD	O
agreed	VBD	O
to	TO	O
passive	VB	O
follow-up	NN	O
.	.	O

Median	JJ	O
duration	NN	O
of	IN	O
follow-up	NN	O
was	VBD	O
7.0	CD	O
years	NNS	O
.	.	O

INTERVENTION	NNP	O
Daily	NNP	O
dose	NN	O
of	IN	O
natural	JJ	Pharmacological
source	NN	Pharmacological
vitamin	NN	Pharmacological
E	NNP	Pharmacological
(	(	O
400	CD	O
IU	NNP	O
)	)	O
or	CC	O
matching	VBG	O
placebo	NN	Control
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Primary	NNP	O
outcomes	NNS	O
included	VBD	O
cancer	NN	O
incidence	NN	O
,	,	O
cancer	NN	O
deaths	NNS	O
,	,	O
and	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
(	(	O
myocardial	JJ	O
infarction	NN	O
,	,	O
stroke	NN	O
,	,	O
and	CC	O
cardiovascular	JJ	O
death	NN	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
heart	NN	O
failure	NN	O
,	,	O
unstable	JJ	O
angina	NN	O
,	,	O
and	CC	O
revascularizations	NNS	O
.	.	O

RESULTS	NNP	O
Among	IN	O
all	DT	O
HOPE	NNP	O
patients	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
analysis	NN	O
:	:	O
for	IN	O
cancer	NN	O
incidence	NN	O
,	,	O
there	EX	O
were	VBD	O
552	CD	O
patients	NNS	O
(	(	O
11.6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
vitamin	NN	Pharmacological
E	NNP	Pharmacological
group	NN	O
vs	VBD	O
586	CD	O
(	(	O
12.3	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
,	,	O
0.94	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.84-1.06	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.30	NNP	O
)	)	O
;	:	O
for	IN	O
cancer	NN	O
deaths	NNS	O
,	,	O
156	CD	O
(	(	O
3.3	CD	O
%	NN	O
)	)	O
vs	NN	O
178	CD	O
(	(	O
3.7	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
RR	NNP	O
,	,	O
0.88	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.71-1.09	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.24	NNP	O
)	)	O
;	:	O
and	CC	O
for	IN	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
,	,	O
1022	CD	O
(	(	O
21.5	CD	O
%	NN	O
)	)	O
vs	NN	O
985	CD	O
(	(	O
20.6	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
RR	NNP	O
,	,	O
1.04	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.96-1.14	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.34	NNP	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
vitamin	NN	Pharmacological
E	NNP	Pharmacological
group	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
heart	NN	O
failure	NN	O
(	(	O
RR	NNP	O
,	,	O
1.13	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01-1.26	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
and	CC	O
hospitalization	NN	O
for	IN	O
heart	NN	O
failure	NN	O
(	(	O
RR	NNP	O
,	,	O
1.21	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.00-1.47	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.045	NNP	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
among	IN	O
patients	NNS	O
enrolled	VBN	O
at	IN	O
the	DT	O
centers	NNS	O
participating	VBG	O
in	IN	O
the	DT	O
HOPE-TOO	NNP	O
trial	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
cancer	NN	O
incidence	NN	O
,	,	O
cancer	NN	O
deaths	NNS	O
,	,	O
and	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
,	,	O
but	CC	O
higher	JJR	O
rates	NNS	O
of	IN	O
heart	NN	O
failure	NN	O
and	CC	O
hospitalizations	NNS	O
for	IN	O
heart	NN	O
failure	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
vascular	JJ	O
disease	NN	O
or	CC	O
diabetes	VBZ	O
mellitus	NNS	O
,	,	O
long-term	JJ	Pharmacological
vitamin	NN	Pharmacological
E	NNP	Pharmacological
supplementation	NN	Pharmacological
does	VBZ	O
not	RB	O
prevent	VB	O
cancer	NN	O
or	CC	O
major	JJ	O
cardiovascular	JJ	O
events	NNS	O
and	CC	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
for	IN	O
heart	NN	O
failure	NN	O
.	.	O

Clofarabine	NNP	Pharmacological
?	.	Pharmacological
fludarabine	NN	Pharmacological
with	IN	O
once	RB	O
daily	JJ	O
i.v	NN	O
.	.	O

busulfan	NN	O
as	IN	O
pretransplant	JJ	O
conditioning	NN	O
therapy	NN	O
for	IN	O
advanced	JJ	O
myeloid	NN	O
leukemia	NN	O
and	CC	O
MDS	NNP	O
.	.	O

Although	IN	O
a	DT	O
combination	NN	O
of	IN	O
i.v	NN	O
.	.	O

busulfan	NN	O
(	(	O
Bu	NNP	O
)	)	O
and	CC	O
fludarabine	NN	Pharmacological
(	(	O
Flu	NNP	O
)	)	O
is	VBZ	O
a	DT	O
safe	JJ	O
,	,	O
reduced-toxicity	JJ	O
conditioning	NN	O
program	NN	O
for	IN	O
acute	JJ	O
myelogenous	JJ	O
leukemia/myelodysplastic	JJ	O
syndromes	NNS	O
(	(	O
AML/MDS	NNP	O
)	)	O
,	,	O
recurrent	JJ	O
leukemia	NN	O
posttransplantation	NN	O
remains	VBZ	O
a	DT	O
problem	NN	O
.	.	O

To	TO	O
enhance	VB	O
the	DT	O
conditioning	NN	O
regimen	NN	O
's	POS	O
antileukemic	JJ	O
effect	NN	O
,	,	O
we	PRP	O
decided	VBD	O
to	TO	O
supplant	VB	O
Flu	NNP	O
with	IN	O
clofarabine	NN	Pharmacological
(	(	O
Clo	NNP	O
)	)	O
,	,	O
and	CC	O
assayed	VBD	O
the	DT	O
interactions	NNS	O
of	IN	O
these	DT	O
nucleoside	JJ	O
analogs	NNS	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
Bu	NNP	O
in	IN	O
Bu-resistant	NNP	O
human	NN	O
cell	NN	O
lines	NNS	O
in	IN	O
vitro	NN	O
.	.	O

We	PRP	O
found	VBD	O
pronounced	VBD	O
synergy	NN	O
between	IN	O
each	DT	O
nucleoside	NN	O
and	CC	O
the	DT	O
alkylator	NN	O
but	CC	O
even	RB	O
more	RBR	O
enhanced	JJ	O
cytotoxic	NN	O
synergy	NN	O
when	WRB	O
the	DT	O
nucleoside	JJ	O
analogs	NNS	O
were	VBD	O
combined	VBN	O
prior	RB	O
to	TO	O
exposing	VBG	O
the	DT	O
cells	NNS	O
to	TO	O
Bu	NNP	O
.	.	O

We	PRP	O
then	RB	O
designed	VBD	O
a	DT	O
4-arm	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
myeloid	JJ	O
leukemia	NN	O
undergoing	VBG	O
allogeneic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
allo-SCT	JJ	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
adaptively	RB	O
randomized	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
Arm	JJ	O
I-Clo	NN	O
:	:	O
Flu	CD	O
10:30	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
Arm	NNP	O
II-20:20	NNP	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
Arm	NNP	O
III-30:10	NNP	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
,	,	O
and	CC	O
Arm	NNP	O
IV-single-agent	NNP	O
Clo	NNP	O
at	IN	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

The	DT	O
nucleoside	JJ	O
analog	NN	O
(	(	O
s	PRP	O
)	)	O
were/was	NN	O
infused	VBN	O
over	IN	O
1	CD	O
hour	NN	O
once	RB	O
daily	JJ	O
for	IN	O
4	CD	O
days	NNS	O
,	,	O
followed	VBD	O
on	IN	O
each	DT	O
day	NN	O
by	IN	O
Bu	NNP	O
,	,	O
infused	VBD	O
over	IN	O
3	CD	O
hours	NNS	O
to	TO	O
a	DT	O
pharmacokinetically	RB	O
targeted	VBN	O
daily	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
of	IN	O
6000	CD	O
?Mol-min	NN	O
?	.	O
10	CD	O
%	NN	O
.	.	O

Fifty-one	CD	O
patients	NNS	O
have	VBP	O
been	VBN	O
enrolled	VBN	O
with	IN	O
a	DT	O
minimum	JJ	O
follow-up	JJ	O
exceeding	VBG	O
100	CD	O
days	NNS	O
.	.	O

There	EX	O
were	VBD	O
32	CD	O
males	NNS	O
and	CC	O
19	CD	O
females	NNS	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
age	NN	O
of	IN	O
45	CD	O
years	NNS	O
(	(	O
range	NN	O
:	:	O
6-59	JJ	O
)	)	O
.	.	O

Nine	JJ	O
patients	NNS	O
had	VBD	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
(	(	O
CML	NNP	O
)	)	O
(	(	O
BC	NNP	O
:	:	O
2	CD	O
,	,	O
second	JJ	O
AP	NNP	O
:	:	O
3	CD	O
,	,	O
and	CC	O
tyrosine-kinase	JJ	O
inhibitor	NN	O
refractory	NN	O
first	RB	O
chronic	JJ	O
phase	NN	O
[	NNP	O
CP	NNP	O
]	NN	O
:	:	O
4	CD	O
)	)	O
.	.	O

Forty-two	JJ	O
patients	NNS	O
had	VBD	O
AML	NNP	O
:	:	O
14	CD	O
were	VBD	O
induction	NN	O
failures	NNS	O
,	,	O
8	CD	O
in	IN	O
first	JJ	O
chemotherapy-refractory	JJ	O
relapse	NN	O
,	,	O
7	CD	O
in	IN	O
untreated	JJ	O
relapse	NN	O
,	,	O
3	CD	O
in	IN	O
second	JJ	O
or	CC	O
subsequent	JJ	O
relapse	NN	O
,	,	O
4	CD	O
were	VBD	O
in	IN	O
second	JJ	O
complete	JJ	O
remission	NN	O
(	(	O
CR	NNP	O
)	)	O
,	,	O
and	CC	O
3	CD	O
in	IN	O
second	JJ	O
CR	NNP	O
without	IN	O
platelet	NN	O
recovery	NN	O
(	(	O
CRp	NNP	O
)	)	O
,	,	O
2	CD	O
were	VBD	O
in	IN	O
high-risk	JJ	O
CR1	NNP	O
.	.	O

Finally	NNP	O
,	,	O
1	CD	O
patient	NN	O
was	VBD	O
in	IN	O
first	JJ	O
CRp	NNP	O
.	.	O

Graft-versus-host	NNP	O
disease	NN	O
(	(	O
GVHD	NNP	O
)	)	O
prophylaxis	NN	O
was	VBD	O
tacrolimus	JJ	O
and	CC	O
mini-methorexate	JJ	O
(	(	O
MTX	NNP	O
)	)	O
,	,	O
and	CC	O
those	DT	O
who	WP	O
had	VBD	O
an	DT	O
unrelated	JJ	O
or	CC	O
1	CD	O
antigen-mismatched	JJ	O
donor	NN	O
received	VBD	O
low-dose	JJ	O
rabbit-ATG	NN	O
(	(	O
Thymoglobulin?	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
engrafted	VBN	O
.	.	O

Forty-one	CD	O
patients	NNS	O
had	VBD	O
active	JJ	O
leukemia	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
transplant	NN	O
,	,	O
and	CC	O
35	CD	O
achieved	VBN	O
CR	NNP	O
(	(	O
85	CD	O
%	NN	O
)	)	O
.	.	O

Twenty	CD	O
of	IN	O
the	DT	O
42	CD	O
AML	NNP	O
patients	NNS	O
and	CC	O
5	CD	O
of	IN	O
9	CD	O
CML	NNP	O
patients	NNS	O
are	VBP	O
alive	JJ	O
with	IN	O
a	DT	O
projected	JJ	O
median	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
of	IN	O
23	CD	O
months	NNS	O
.	.	O

Marrow	NNP	O
and	CC	O
blood	NN	O
(	(	O
T	NNP	O
cell	NN	O
)	)	O
chimerism	NN	O
studies	NNS	O
at	IN	O
day	NN	O
+100	NNP	O
revealed	VBD	O
that	IN	O
both	DT	O
in	IN	O
the	DT	O
lower-dose	JJ	O
Clo	NNP	O
groups	NNS	O
(	(	O
groups	NNS	O
1+2	CD	O
)	)	O
and	CC	O
the	DT	O
higher-dose	JJ	O
Clo	NNP	O
groups	NNS	O
(	(	O
groups	NNS	O
3+4	CD	O
)	)	O
,	,	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
median	NN	O
of	IN	O
100	CD	O
%	NN	O
donor	NN	O
(	(	O
T	NNP	O
cell	NN	O
)	)	O
-derived	VBD	O
DNA	NNP	O
.	.	O

There	EX	O
has	VBZ	O
been	VBN	O
no	DT	O
secondary	JJ	O
graft	NN	O
failure	NN	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
100	CD	O
days	NNS	O
,	,	O
1	CD	O
patient	NN	O
died	VBD	O
of	IN	O
pneumonia	NN	O
,	,	O
and	CC	O
1	CD	O
of	IN	O
liver	NN	O
GVHD	NNP	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
(	(	O
1	CD	O
)	)	O
Clo	NNP	O
?	.	O
Flu	NNP	O
with	IN	O
i.v	NN	O
.	.	O

Bu	NNP	O
as	IN	O
pretransplant	JJ	O
conditioning	NN	O
is	VBZ	O
safe	JJ	O
in	IN	O
high-risk	JJ	O
myeloid	JJ	O
leukemia	NN	O
patients	NNS	O
;	:	O
(	(	O
2	CD	O
)	)	O
clofarabine	NN	O
is	VBZ	O
sufficiently	RB	O
immunosuppressive	JJ	O
to	TO	O
support	VB	O
allo-SCT	NN	O
in	IN	O
myeloid	JJ	O
leukemia	NN	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
median	JJ	O
OS	NNP	O
of	IN	O
23	CD	O
months	NNS	O
in	IN	O
this	DT	O
high-risk	JJ	O
patient	NN	O
population	NN	O
is	VBZ	O
encouraging	VBG	O
.	.	O

Additional	JJ	O
studies	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
antileukemic	JJ	O
efficacy	NN	O
of	IN	O
Clo	NNP	O
?	.	O
Flu	NNP	O
with	IN	O
i.v	NN	O
.	.	O

Bu	NNP	O
as	IN	O
pretransplant	JJ	O
conditioning	NN	O
therapy	NN	O
are	VBP	O
warranted	VBN	O
.	.	O

Pegfilgrastim	NN	Pharmacological
for	IN	O
peripheral	JJ	O
CD34+	NNP	O
mobilization	NN	O
in	IN	O
patients	NNS	O
with	IN	O
solid	JJ	O
tumours	NNS	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
pegfilgrastim+/-chemotherapy	NN	Pharmacological
for	IN	O
mobilizing	VBG	O
stem	NN	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
solid	JJ	O
tumours	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

In	IN	O
cycle	NN	O
0	CD	O
,	,	O
a	DT	O
14-day	JJ	O
prechemotherapy	NN	O
cycle	NN	O
,	,	O
patients	NNS	O
(	(	O
N=61	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
open-label	NN	O
to	TO	O
single	JJ	O
doses	NNS	O
of	IN	O
pegfilgrastim	NN	Pharmacological
(	(	O
6	CD	O
,	,	O
12	CD	O
or	CC	O
18	CD	O
mg	NN	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
,	,	O
or	CC	O
daily	RB	O
filgrastim	NNS	Pharmacological
(	(	O
10	CD	O
microg/kg	NN	O
)	)	O
for	IN	O
<	NN	O
or	CC	O
=7	JJ	O
days	NNS	O
.	.	O

Mean	JJ	O
peak	JJ	O
peripheral	JJ	O
CD34+	NNP	O
cell	NN	O
counts	NNS	O
increased	VBD	O
with	IN	O
pegfilgrastim	NN	Pharmacological
dose	NN	O
,	,	O
but	CC	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
filgrastim	JJR	Pharmacological
only	RB	O
at	IN	O
the	DT	O
18	CD	O
mg	NN	O
dose	NN	O
(	(	O
10.17	CD	O
vs	RB	O
4.96	CD	O
x	JJ	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/ml	NN	O
;	:	O
P=0.014	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
clinically	NN	O
relevant	JJ	O
period	NN	O
of	IN	O
days	NNS	O
3-7	CD	O
,	,	O
both	DT	O
12	CD	O
and	CC	O
18	CD	O
mg	NN	O
pegfilgrastim	NN	Pharmacological
doses	NNS	O
produced	VBD	O
significantly	RB	O
higher	JJR	O
peak	NN	O
CD34+	NNP	O
counts	VBZ	O
(	(	O
8.18	CD	O
and	CC	O
9.96	CD	O
vs	NN	O
4.51	CD	O
x	NN	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/ml	NN	O
for	IN	O
filgrastim	NN	Pharmacological
;	:	Pharmacological
P=0.034	NNP	O
and	CC	O
0.006	CD	O
)	)	O
.	.	O

In	IN	O
cycle	NN	O
1	CD	O
,	,	O
patients	NNS	O
received	VBD	O
carboplatin/paclitaxel	NNS	Pharmacological
on	IN	O
day	NN	O
1	CD	O
,	,	O
followed	VBD	O
from	IN	O
day	NN	O
2	CD	O
by	IN	O
pegfilgrastim	JJ	Pharmacological
6-18	JJ	O
mg	NN	O
or	CC	O
daily	JJ	O
filgrastim	NN	Pharmacological
(	(	O
5	CD	O
microg/kg/day	NN	O
for	IN	O
<	NN	O
or	CC	O
=14	NNP	O
days	NNS	O
)	)	O
as	IN	O
per	IN	O
randomization	NN	O
in	IN	O
cycle	NN	O
0	CD	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
mean	JJ	O
peak	NN	O
CD34+	NNP	O
count	NN	O
between	IN	O
pegfilgrastim	NN	Pharmacological
and	CC	O
filgrastim	NN	Pharmacological
,	,	O
but	CC	O
there	EX	O
was	VBD	O
an	DT	O
advantage	NN	O
for	IN	O
pegfilgrastim	NN	Pharmacological
18	CD	O
mg	NN	O
in	IN	O
the	DT	O
relevant	JJ	O
period	NN	O
of	IN	O
days	NNS	O
7-12	NNP	O
(	(	O
3.14	CD	O
vs	RB	O
1.19	CD	O
x	JJ	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/ml	NN	O
;	:	O
P=0.043	NNP	O
)	)	O
.	.	O

A	DT	O
single	JJ	O
pegfilgrastim	NN	Pharmacological
dose	NN	O
(	(	O
>	CD	O
or	CC	O
=6	VB	O
mg	NN	O
)	)	O
could	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
daily	JJ	O
filgrastim	NN	Pharmacological
in	IN	O
cytokine-only	JJ	O
peripheral	JJ	O
CD34+	NNP	O
cell	NN	O
mobilization	NN	O
.	.	O

PROCLAIM	NN	O
:	:	O
pilot	NN	O
study	NN	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
clopidogrel	NN	Pharmacological
on	IN	O
inflammatory	JJ	O
markers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	JJ	O
receiving	VBG	O
low-dose	JJ	O
aspirin	NN	Pharmacological
.	.	Pharmacological

Metabolic	NNP	O
syndrome	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
intravascular	JJ	O
inflammation	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
inflammatory	NN	O
biomarkers	NNS	O
and	CC	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
ischemic	JJ	O
atherothrombotic	JJ	O
events	NNS	O
.	.	O

Evidence	NN	O
suggests	VBZ	O
that	IN	O
atherothrombosis	NN	O
and	CC	O
intravascular	JJ	O
inflammation	NN	O
share	NN	O
predictive	JJ	O
biomarkers	NNS	O
,	,	O
including	VBG	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
,	,	O
CD40	NNP	O
ligand	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
.	.	O

Patients	NNS	O
who	WP	O
had	VBD	O
metabolic	JJ	O
syndrome	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
clopidogrel	NN	Pharmacological
75	CD	O
mg/day	JJ	O
plus	CC	O
aspirin	JJ	Pharmacological
81	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
89	CD	O
)	)	O
or	CC	O
placebo	JJ	Control
plus	CC	O
aspirin	JJ	Pharmacological
81	CD	O
mg/day	NN	O
(	(	O
n	JJ	O
=	NNP	O
92	CD	O
)	)	O
for	IN	O
9	CD	O
weeks	NNS	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
each	DT	O
treatment	NN	O
in	IN	O
suppression	NN	O
of	IN	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

Change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
levels	NNS	O
of	IN	O
high-sensitivity	NN	O
C-reactive	JJ	O
protein	NN	O
,	,	O
CD40	NNP	O
ligand	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
at	IN	O
6	CD	O
weeks	NNS	O
was	VBD	O
assessed	VBN	O
to	TO	O
evaluate	VB	O
each	DT	O
treatment	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
at	IN	O
Week	JJ	O
6	CD	O
in	IN	O
model-adjusted	JJ	O
CD40-ligand	NNP	O
levels	NNS	O
in	IN	O
favor	NN	O
of	IN	O
clopidogrel	NN	Pharmacological
plus	CC	O
aspirin	JJ	Pharmacological
compared	VBN	O
with	IN	O
placebo	NN	Control
plus	CC	O
aspirin	NN	Pharmacological
in	IN	O
both	DT	O
the	DT	O
intent-to-treat	JJ	O
population	NN	O
(	(	O
difference	NN	O
between	IN	O
least-squares	NNS	O
means	NNS	O
=	VBP	O
-186.5	NNP	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-342.3	NN	O
to	TO	O
-30.8	VB	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
the	DT	O
per-protocol	JJ	O
population	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
treatment	NN	O
arms	NNS	O
for	IN	O
high-sensitivity	JJ	O
C-reactive	JJ	O
protein	NN	O
,	,	O
P-selectin	NNP	O
,	,	O
and	CC	O
N-terminal	JJ	O
pro-brain	JJ	O
natriuretic	JJ	O
peptide	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
deaths	NNS	O
or	CC	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
either	DT	O
treatment	NN	O
arm	NN	O
.	.	O

Data	NNS	O
from	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
clopidogrel	NN	Pharmacological
can	MD	O
decrease	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
CD40-ligand	NNP	O
biomarker	NN	O
.	.	O

Small	NN	O
but	CC	O
important	JJ	O
errors	NNS	O
in	IN	O
cardiovascular	JJ	O
risk	NN	O
calculation	NN	O
by	IN	O
practice	NN	O
nurses	NNS	O
:	:	O
a	DT	O
cross-sectional	JJ	O
study	NN	O
in	IN	O
randomised	JJ	O
trial	NN	O
setting	NN	O
.	.	O

BACKGROUND	NNP	O
Practice	NNP	O
nurses	NNS	O
play	VBP	O
an	DT	O
increasingly	RB	O
important	JJ	O
role	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cardiovascular	JJ	O
diseases	NNS	O
but	CC	O
we	PRP	O
do	VBP	O
not	RB	O
have	VB	O
evidence	NN	O
about	IN	O
the	DT	O
accuracy	NN	O
of	IN	O
their	PRP$	O
cardiovascular	JJ	O
risk	NN	O
assessments	NNS	O
during	IN	O
real	JJ	O
practice	NN	O
consultations	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
examine	VB	O
how	WRB	O
nurses	NNS	O
perform	VBP	O
with	IN	O
regard	NN	O
to	TO	O
absolute	VB	O
10-year	JJ	O
cardiovascular	JJ	O
risk	NN	O
assessment	NN	O
in	IN	O
actual	JJ	O
practice	NN	O
.	.	O

DESIGN	NNP	O
Cross-sectional	JJ	O
study	NN	O
.	.	O

SETTING	NN	O
This	DT	O
study	NN	O
was	VBD	O
nested	VBN	O
in	IN	O
the	DT	O
IMPALA	NNP	O
study	NN	O
,	,	O
a	DT	O
clustered	VBN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
involving	VBG	O
24	CD	O
general	JJ	O
practices	NNS	O
in	IN	O
The	DT	O
Netherlands	NNP	O
.	.	O

PARTICIPANTS	VB	O
24	CD	O
practice	NN	O
nurses	NNS	O
,	,	O
trained	VBN	O
in	IN	O
10-year	JJ	O
cardiovascular	JJ	O
risk	NN	O
assessment	NN	O
,	,	O
calculated	VBD	O
the	DT	O
risk	NN	O
of	IN	O
a	DT	O
total	NN	O
of	IN	O
421	CD	O
patients	NNS	O
without	IN	O
established	VBN	O
cardiovascular	JJ	O
diseases	NNS	O
but	CC	O
eligible	JJ	O
for	IN	O
cardiovascular	JJ	O
risk	NN	O
assessment	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
accuracy	NN	Other
of	IN	Other
risk	NN	Other
assessments	NNS	Other
,	,	O
defined	VBN	O
as	IN	O
(	(	O
1	CD	O
)	)	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
10-year	JJ	O
cardiovascular	JJ	O
risk	NN	O
percentage	NN	O
calculated	VBN	O
by	IN	O
nurses	NNS	Other
and	CC	O
an	DT	O
independent	JJ	O
assessor	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
the	DT	O
agreement	NN	O
between	IN	O
the	DT	O
treatment	NN	O
categories	NNS	O
assigned	VBN	O
by	IN	O
the	DT	O
nurses	NNS	Other
(	(	O
low	JJ	O
,	,	O
moderate	JJ	O
or	CC	O
high	JJ	O
risk	NN	O
)	)	O
and	CC	O
those	DT	O
assigned	VBN	O
by	IN	O
the	DT	O
independent	JJ	O
assessor	NN	O
.	.	O

RESULTS	VB	O
Thirty-one	NNP	O
(	(	O
7.4	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
calculated	JJ	O
risk	NN	O
percentages	NNS	O
differed	VBN	O
by	IN	O
more	JJR	O
than	IN	O
our	PRP$	O
preset	NN	O
limits	NNS	O
,	,	O
25	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
being	VBG	O
underestimations	NNS	O
.	.	O

Elderly	JJ	O
patients	NNS	O
(	(	O
OR	NNP	O
1.1	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.0-1.1	CD	O
)	)	O
,	,	O
male	JJ	O
patients	NNS	O
(	(	O
vs.	FW	O
female	NN	O
OR	NNP	O
3.1	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.2-7.3	CD	O
)	)	O
,	,	O
and	CC	O
smoking	NN	O
patients	NNS	O
(	(	O
vs.	IN	O
non-smoking	NN	O
OR	NNP	O
3.8	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.7-8.9	CD	O
)	)	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
their	PRP$	O
cardiovascular	JJ	O
risk	NN	O
miscalculated	VBD	O
.	.	O

Ten	NNP	O
(	(	O
28	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
36	CD	O
patients	NNS	O
who	WP	O
should	MD	O
be	VB	O
assigned	VBN	O
to	TO	O
the	DT	O
high-risk	JJ	O
treatment	NN	O
category	NN	O
according	VBG	O
to	TO	O
the	DT	O
independent	JJ	O
calculation	NN	O
,	,	O
were	VBD	O
missed	VBN	O
as	IN	O
high-risk	JJ	O
patients	NNS	O
by	IN	O
the	DT	O
practice	NN	O
nurses	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
overall	JJ	O
standard	NN	O
of	IN	O
accuracy	NN	O
of	IN	O
cardiovascular	JJ	Other
risk	NN	Other
assessment	NN	Other
by	IN	O
trained	JJ	O
practice	NN	O
nurses	NNS	O
in	IN	O
actual	JJ	O
practice	NN	O
is	VBZ	O
high	JJ	O
.	.	O

However	RB	O
,	,	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
high-risk	JJ	O
patients	NNS	O
were	VBD	O
misclassified	VBN	O
,	,	O
with	IN	O
the	DT	O
probability	NN	O
that	IN	O
it	PRP	O
led	VBD	O
to	TO	O
missed	VBN	O
opportunities	NNS	O
for	IN	O
risk-reducing	JJ	O
interventions	NNS	O
.	.	O

As	IN	O
cardiovascular	JJ	O
risk	NN	O
assessments	NNS	O
are	VBP	O
frequently	RB	O
done	VBN	O
by	IN	O
nurses	NNS	O
in	IN	O
general	JJ	O
practice	NN	O
,	,	O
further	JJ	O
specific	JJ	O
training	NN	O
should	MD	O
be	VB	O
considered	VBN	O
to	TO	O
prevent	VB	O
undertreatment	NN	O
.	.	O

Perioperative	JJ	O
myocardial	JJ	O
infarctions	NNS	O
are	VBP	O
common	JJ	O
and	CC	O
often	RB	O
unrecognized	JJ	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
hip	JJ	O
fracture	NN	O
surgery	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
cohort	NN	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
incidence	NN	O
and	CC	O
characteristics	NNS	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
surgery	NN	O
for	IN	O
acute	JJ	O
hip	NN	O
fracture	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
consecutive	JJ	O
cohort	NN	O
of	IN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NN	O
200	CD	O
,	,	O
68	CD	O
men	NNS	O
)	)	O
referred	VBD	O
to	TO	O
acute	VB	Surgical
surgical	JJ	Surgical
correction	NN	Surgical
of	IN	Surgical
hip	NN	Surgical
fracture	NN	Surgical
was	VBD	O
studied	VBN	O
.	.	O

Troponin	NNP	Other
T	NNP	Other
(	(	Other
TnT	NNP	Other
)	)	Other
measurements	NNS	Other
and	CC	O
electrocardiographic	JJ	Other
(	(	Other
ECG	NNP	Other
)	)	Other
recordings	NNS	Other
were	VBD	O
performed	VBN	O
at	IN	O
admission	NN	O
,	,	O
before	IN	O
operation	NN	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
first	JJ	O
and	CC	O
2nd	CD	O
postoperative	JJ	O
days	NNS	O
,	,	O
which	WDT	O
were	VBD	O
used	VBN	O
for	IN	O
diagnosis	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
ranged	VBD	O
from	IN	O
32	CD	O
to	TO	O
98	CD	O
years	NNS	O
(	(	O
mean	NN	O
,	,	O
80.8	CD	O
years	NNS	O
)	)	O
,	,	O
and	CC	O
65	CD	O
patients	NNS	O
had	VBD	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

A	DT	O
significant	JJ	O
rise	NN	O
in	IN	O
TnT	NNP	O
as	IN	O
a	DT	O
sign	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
71	CD	O
patients	NNS	O
(	(	O
35.5	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
25	CD	O
of	IN	O
them	PRP	O
had	VBD	O
a	DT	O
TnT	NNP	O
elevation	NN	O
exceeding	VBG	O
five	CD	O
times	NNS	O
the	DT	O
upper	JJ	O
normal	JJ	O
limit	NN	O
.	.	O

TnT	NNP	O
elevation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
36	CD	O
patients	NNS	O
(	(	O
51	CD	O
%	NN	O
)	)	O
already	RB	O
before	RB	O
surgery	NN	O
.	.	O

Seven	CD	O
patients	NNS	O
(	(	O
10	CD	O
%	NN	O
)	)	O
had	VBD	O
ST	NNP	O
elevation	NN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
23	CD	O
patients	NNS	O
(	(	O
32	CD	O
%	NN	O
)	)	O
had	VBD	O
new	JJ	O
ST	NNP	O
depressions	NNS	O
,	,	O
and	CC	O
21	CD	O
patients	NNS	O
(	(	O
30	CD	O
%	NN	O
)	)	O
had	VBD	O
no	DT	O
new	JJ	O
ST	NNP	O
segment	NN	O
changes	NNS	O
in	IN	O
the	DT	O
serial	JJ	O
electrocardiographic	JJ	O
recordings	NNS	O
.	.	O

In	IN	O
40	CD	O
patients	NNS	O
(	(	O
56	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
perioperative	JJ	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
the	DT	O
first	JJ	O
manifestation	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Multivariate	NNP	O
logistic	JJ	O
regression	NN	O
revealed	VBD	O
that	IN	O
old	JJ	O
age	NN	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	NNP	O
,	,	O
1.06	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.02-1.10	JJ	O
;	:	O
p	VB	O
=	$	O
0.002	CD	O
)	)	O
,	,	O
earlier	JJR	O
revascularization	NN	O
(	(	O
OR	NNP	O
,	,	O
3.29	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.12-9.73	CD	O
;	:	O
p	CC	O
=	VB	O
0.03	CD	O
)	)	O
,	,	O
and	CC	O
heart	NN	O
failure	NN	O
(	(	O
OR	NNP	O
,	,	O
2.42	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.04-5.61	CD	O
;	:	O
p	CC	O
=	VB	O
0.04	CD	O
)	)	O
were	VBD	O
independent	JJ	O
predictors	NNS	O
of	IN	O
TnT	NNP	O
elevation	NN	O
.	.	O

Majority	NNP	O
of	IN	O
myocardial	JJ	O
infarctions	NNS	O
were	VBD	O
asymptomatic	JJ	O
or	CC	O
unrecognized	JJ	O
.	.	O

Evidence-based	JJ	O
medications	NNS	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
seldom	RB	O
started	VBN	O
and	CC	O
cardiologist	NN	O
was	VBD	O
consulted	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
(	(	O
16.9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	JJ	O
Patients	NNS	O
with	IN	O
hip	JJ	O
fracture	NN	O
often	RB	O
develop	VBZ	O
asymptomatic	JJ	O
and	CC	O
clinically	RB	O
unrecognized	JJ	O
perioperative	JJ	O
myocardial	JJ	O
infarctions	NNS	O
.	.	O

Earlier	JJR	O
diagnosis	NN	O
and	CC	O
appropriate	JJ	O
treatment	NN	O
of	IN	O
cardiac	JJ	O
infarction	NN	O
may	MD	O
improve	VB	O
survival	NN	O
of	IN	O
hip	NN	O
fracture	NN	O
patients	NNS	O
.	.	O

LEVEL	NNP	O
OF	IN	O
EVIDENCE	NNP	O
Epidemiologic	NNP	O
study	NN	O
,	,	O
level	NN	O
III	NNP	O
.	.	O

Treatment	NN	O
with	IN	O
metformin	NN	Pharmacological
of	IN	O
non-diabetic	JJ	O
men	NNS	O
with	IN	O
hypertension	NN	O
,	,	O
hypertriglyceridaemia	NN	O
and	CC	O
central	JJ	O
fat	JJ	O
distribution	NN	O
:	:	O
the	DT	O
BIGPRO	NNP	O
1.2	CD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
the	DT	O
BIGPRO	NNP	O
1	CD	O
trial	NN	O
,	,	O
one	CD	O
year	NN	O
of	IN	O
treatment	NN	O
with	IN	O
metformin	NN	Pharmacological
in	IN	O
non-diabetic	JJ	O
obese	JJ	O
subjects	NNS	O
with	IN	O
a	DT	O
central	JJ	O
fat	JJ	O
distribution	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
fasting	VBG	O
plasma	JJ	O
triglyceride	JJ	O
concentration	NN	O
or	CC	O
on	IN	O
blood	NN	O
pressure	NN	O
despite	IN	O
a	DT	O
decrease	NN	O
in	IN	O
weight	NN	O
,	,	O
fasting	VBG	O
plasma	JJ	O
insulin	NN	O
and	CC	O
glucose	JJ	O
concentrations	NNS	O
.	.	O

To	TO	O
re-evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
metformin	NN	Pharmacological
on	IN	O
fasting	VBG	O
triglyceride	JJ	O
concentration	NN	O
and	CC	O
on	IN	O
blood	NN	O
pressure	NN	O
,	,	O
the	DT	O
BIGPRO	NNP	O
1.2	CD	O
trial	NN	O
included	VBD	O
non-diabetic	JJ	O
men	NNS	O
(	(	O
n=168	NN	O
)	)	O
with	IN	O
a	DT	O
fasting	VBG	O
plasma	NN	O
triglyceride	JJ	O
concentration	NN	O
>	NN	O
or	CC	O
=1.7	NN	O
and	CC	O
<	NN	O
or	CC	O
=6.5	NN	O
mmol/l	NN	O
,	,	O
high	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
systolic	JJ	O
>	NN	O
or	CC	O
=140	NN	O
and	CC	O
<	NN	O
or	CC	O
=180	VB	O
and/or	JJ	O
diastolic	JJ	O
>	NN	O
or	CC	O
=90	NN	O
and	CC	O
<	NN	O
or	CC	O
=105	NN	O
mmHg	NN	O
,	,	O
or	CC	O
treatment	NN	O
for	IN	O
hypertension	NN	O
)	)	O
and	CC	O
a	DT	O
waist-to-hip	JJ	O
ratio	NN	O
>	NN	O
or	CC	O
=0.95	NN	O
.	.	O

METHODS	NNP	O
A	DT	O
randomised	JJ	O
double-blind	JJ	O
trial	NN	O
comparing	VBG	O
metformin	NN	Pharmacological
treatment	NN	O
(	(	O
850	CD	O
mg	RB	O
bid	NN	O
)	)	O
with	IN	O
placebo	NN	Control
.	.	O

RESULTS	NNP	O
Metformin	NNP	Pharmacological
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
either	DT	O
on	IN	O
blood	NN	O
pressure	NN	O
or	CC	O
plasma	NN	O
triglyceride	JJ	O
concentration	NN	O
.	.	O

In	IN	O
comparison	NN	O
with	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
,	,	O
fasting	VBG	O
plasma	JJ	O
insulin	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.04	CD	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
Apo	NNP	O
B	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.008	CD	O
)	)	O
concentrations	NNS	O
decreased	VBD	O
more	RBR	O
in	IN	O
the	DT	O
metformin	NN	O
group	NN	O
in	IN	O
the	DT	O
BIGPRO	NNP	O
1	CD	O
.	.	O

2	CD	O
trial	NN	O
,	,	O
confirming	VBG	O
most	JJS	O
of	IN	O
the	DT	O
previous	JJ	O
results	NNS	O
of	IN	O
the	DT	O
BIGPRO	NNP	O
1	CD	O
trial	NN	O
.	.	O

Tissue	NNP	O
plasminogen	NN	O
activator	NN	O
antigen	NN	O
concentration	NN	O
decreased	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
only	RB	O
in	IN	O
the	DT	O
metformin	NN	Pharmacological
group	NN	O
,	,	O
but	CC	O
this	DT	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.12	CD	O
)	)	O
;	:	O
further	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
plasminogen	NN	O
activator	NN	O
inhibitor	NN	O
1	CD	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
consistency	NN	O
of	IN	O
the	DT	O
two	CD	O
BIGPRO	NNP	O
trials	NNS	O
supports	VBZ	O
the	DT	O
conclusion	NN	O
that	IN	O
metformin	VBZ	Pharmacological
affects	NNS	O
several	JJ	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
favourably	RB	O
in	IN	O
non-diabetic	JJ	O
subjects	NNS	O
with	IN	O
a	DT	O
central	JJ	O
fat	JJ	O
distribution	NN	O
.	.	O

A	DT	O
description	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
characteristics	NNS	O
at	IN	O
baseline	NN	O
of	IN	O
patients	NNS	O
recruited	VBN	O
into	IN	O
the	DT	O
Carvedilol	NNP	Pharmacological
or	CC	O
Metoprolol	NNP	Pharmacological
European	JJ	O
Trial	NNP	O
(	(	O
COMET	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
&	CC	O
AIMS	NNP	O
The	DT	O
COMET	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomised	JJ	O
trial	NN	O
comparing	VBG	O
carvedilol	NN	Pharmacological
,	,	O
a	DT	O
comprehensive	JJ	O
adrenergic	NN	O
receptor	NN	O
antagonist	NN	Pharmacological
,	,	O
with	IN	O
metoprolol	NN	Pharmacological
,	,	O
a	DT	O
beta-1-selective	JJ	Pharmacological
agent	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
and	CC	O
left	VBD	O
ventricular	JJ	O
systolic	JJ	O
dysfunction	NN	O
.	.	O

The	DT	O
trial	NN	O
showed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
mortality	NN	O
with	IN	O
carvedilol	NN	Pharmacological
that	WDT	O
was	VBD	O
consistent	JJ	O
across	IN	O
subgroups	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
report	NN	O
is	VBZ	O
to	TO	O
describe	VB	O
in	IN	O
greater	JJR	O
detail	NN	O
the	DT	O
heterogeneity	NN	O
of	IN	O
this	DT	O
population	NN	O
at	IN	O
baseline	NN	O
with	IN	O
particular	JJ	O
reference	NN	O
to	TO	O
the	DT	O
impact	NN	O
of	IN	O
symptomatic	JJ	O
severity	NN	O
,	,	O
age	NN	O
and	CC	O
gender	NN	O
on	IN	O
patient	JJ	O
characteristics	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
descriptive	JJ	O
report	NN	O
using	VBG	O
data	NNS	O
entered	VBN	O
in	IN	O
the	DT	O
COMET	NNP	O
study	NN	O
data-base	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
population	NN	O
studied	VBN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
in	IN	O
previous	JJ	O
trials	NNS	O
of	IN	O
beta-blockers	NNS	O
.	.	O

Almost	NNP	O
all	DT	O
patients	NNS	O
were	VBD	O
receiving	VBG	O
diuretics	NNS	Pharmacological
and	CC	O
ACE	NNP	Pharmacological
inhibitors	NNS	Pharmacological
with	IN	O
few	JJ	O
patients	NNS	O
taking	VBG	O
angiotensin	JJ	Pharmacological
receptor	NN	Pharmacological
blockers	NNS	Pharmacological
.	.	Pharmacological

As	IN	O
expected	VBN	O
,	,	O
older	JJR	O
patients	NNS	O
had	VBD	O
more	RBR	O
co-morbidity	JJ	O
.	.	O

Older	JJR	O
patients	NNS	O
and	CC	O
women	NNS	O
reported	VBD	O
worse	JJR	O
symptoms	NNS	O
and	CC	O
poorer	JJR	O
well-being	JJ	O
despite	IN	O
similar	JJ	O
ventricular	JJ	O
dimensions	NNS	O
and	CC	O
systolic	JJ	O
dysfunction	NN	O
.	.	O

NT-proBNP	NNP	O
was	VBD	O
higher	RBR	O
in	IN	O
patients	NNS	O
with	IN	O
more	RBR	O
severe	JJ	O
symptoms	NNS	O
and	CC	O
older	JJR	O
patients	NNS	O
but	CC	O
not	RB	O
in	IN	O
women	NNS	O
,	,	O
although	IN	O
differences	NNS	O
in	IN	O
NT-proBNP	NNP	O
may	MD	O
have	VB	O
been	VBN	O
confounded	VBN	O
by	IN	O
differences	NNS	O
in	IN	O
renal	JJ	O
function	NN	O
.	.	O

CONCLUSION	NNP	O
Age	NNP	O
and	CC	O
gender	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
severity	NN	O
of	IN	O
cardiac	JJ	O
dysfunction	NN	O
,	,	O
appear	VBP	O
to	TO	O
have	VB	O
an	DT	O
important	JJ	O
effect	NN	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
heart	NN	O
failure	NN	O
symptoms	NNS	O
and	CC	O
patient	JJ	O
'well-being	NN	O
'	POS	O
.	.	O

This	DT	O
could	MD	O
have	VB	O
important	JJ	O
implications	NNS	O
for	IN	O
the	DT	O
relationship	NN	O
between	IN	O
symptoms	NNS	O
and	CC	O
prognosis	NN	O
and	CC	O
therefore	RB	O
the	DT	O
way	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
are	VBP	O
selected	VBN	O
for	IN	O
clinical	JJ	O
trials	NNS	O
and	CC	O
the	DT	O
goals	NNS	O
of	IN	O
treatment	NN	O
.	.	O

This	DT	O
will	MD	O
be	VB	O
the	DT	O
subject	NN	O
of	IN	O
further	JJ	O
analyses	NNS	O
.	.	O

An	DT	O
open	JJ	O
and	CC	O
randomized	JJ	O
study	NN	O
comparing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
standard	JJ	Pharmacological
danazol	NN	Pharmacological
and	CC	O
modified	VBD	Pharmacological
triptorelin	NN	Pharmacological
regimens	NNS	Pharmacological
for	IN	O
postoperative	JJ	O
disease	NN	O
management	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	JJ	O
endometriosis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
danazol	NN	Pharmacological
and	CC	O
triptorelin	NN	Pharmacological
(	(	O
Decapeptyl	NNP	O
CR	NNP	O
,	,	O
Ferring	NNP	O
,	,	O
Kiel	NNP	O
,	,	O
Germany	NNP	O
)	)	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
moderate	JJ	O
and	CC	O
severe	JJ	O
endometriosis	NN	O
in	IN	O
terms	NNS	O
of	IN	O
symptom	NN	O
control	NN	O
and	CC	O
revised	VBN	O
American	JJ	O
Fertility	NNP	O
Society	NNP	O
(	(	O
AFS	NNP	O
)	)	O
score	NN	O
reduction	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
hormonal	JJ	O
profile	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
triptorelin	NN	Pharmacological
every	DT	O
6	CD	O
weeks	NNS	O
.	.	O

DESIGN	NNP	O
Open	NNP	O
and	CC	O
randomized	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
Kwong	NNP	O
Wah	NNP	O
Hospital	NNP	O
,	,	O
a	DT	O
large	JJ	O
public	JJ	O
hospital	NN	O
in	IN	O
an	DT	O
urban	JJ	O
location	NN	O
(	(	O
Hong	NNP	O
Kong	NNP	O
)	)	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Forty	NNP	O
patients	NNS	O
after	IN	O
their	PRP$	O
first	JJ	O
conservative	JJ	O
operation	NN	O
for	IN	O
endometriosis	NN	O
,	,	O
with	IN	O
surgical	JJ	O
confirmation	NN	O
of	IN	O
revised	VBN	O
AFS	NNP	O
stage	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
endometriosis	NN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
Postoperative	VBP	O
6	CD	O
months	NNS	O
'	POS	O
therapy	NN	O
of	IN	O
danazol	NN	Pharmacological
or	CC	O
triptorelin	NN	Pharmacological
every	DT	O
6	CD	O
weeks	NNS	O
,	,	O
postmedical	JJ	O
therapy	NN	O
second-look	NN	O
laparoscopy	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Symptom	NNP	O
control	NN	O
and	CC	O
patients	NNS	O
'	POS	O
tolerance	NN	O
during	IN	O
medical	JJ	O
therapy	NN	O
,	,	O
posttherapy	NN	O
revised	VBD	O
AFS	NNP	O
score	NN	O
,	,	O
hormonal	JJ	O
profile	NN	O
during	IN	O
triptorelin	JJ	O
therapy	NN	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Pain	NNP	O
control	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
danazol	NN	Pharmacological
and	CC	O
triptorelin	NN	Pharmacological
therapy	NN	O
.	.	O

There	EX	O
was	VBD	O
less	JJR	O
breakthrough	IN	O
bleeding	NN	O
with	IN	O
triptorelin	NN	Pharmacological
.	.	Pharmacological

More	JJR	O
patients	NNS	O
failed	VBD	O
to	TO	O
complete	VB	O
the	DT	O
whole	JJ	O
course	NN	O
of	IN	O
danazol	NN	Pharmacological
because	IN	O
of	IN	O
its	PRP$	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
revised	JJ	O
AFS	NNP	O
score	NN	O
at	IN	O
second-look	JJ	O
laparoscopy	NN	O
did	VBD	O
not	RB	O
show	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
medications	NNS	O
.	.	O

Adequate	NNP	O
pituitary	JJ	O
suppression	NN	O
was	VBD	O
observed	VBN	O
with	IN	O
injection	NN	O
of	IN	O
triptorelin	NN	Pharmacological
every	DT	O
6	CD	O
weeks	NNS	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
Lengthening	NNP	O
of	IN	O
triptorelin	JJ	Pharmacological
administration	NN	O
intervals	NNS	O
from	IN	O
4	CD	O
weeks	NNS	O
to	TO	O
6	CD	O
weeks	NNS	O
is	VBZ	O
effective	JJ	O
in	IN	O
maintaining	VBG	O
a	DT	O
hypoestrogenic	JJ	O
state	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
more	RBR	O
compliant	JJ	O
with	IN	O
triptorelin	NN	Pharmacological
than	IN	O
danazol	NN	Pharmacological
.	.	Pharmacological

Thus	RB	O
,	,	O
triptorelin	JJ	Pharmacological
injection	NN	O
every	DT	O
6	CD	O
weeks	NNS	O
is	VBZ	O
more	JJR	O
cost-effective	JJ	O
than	IN	O
conventional	JJ	O
regimens	NNS	O
.	.	O

Prophylactic	JJ	Pharmacological
vs	NN	Pharmacological
therapeutic	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
for	IN	O
obstetric	JJ	O
patients	NNS	O
with	IN	O
accidental	JJ	O
dural	JJ	O
puncture	NN	O
--	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

Epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
is	VBZ	O
a	DT	O
standard	JJ	O
treatment	NN	O
for	IN	O
obstetric	JJ	O
patients	NNS	O
experiencing	VBG	O
a	DT	O
severe	JJ	O
post-dural	JJ	O
puncture	NN	O
headache	NN	O
.	.	O

Patients	NNS	O
who	WP	O
sustained	VBD	O
an	DT	O
accidental	JJ	O
dural	JJ	O
puncture	NN	O
during	IN	O
establishment	NN	O
of	IN	O
epidural	JJ	O
analgesia	NN	O
during	IN	O
labour	NN	O
or	CC	O
at	IN	O
caesarean	JJ	O
delivery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
a	DT	O
prophylactic	JJ	Pharmacological
epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
or	CC	O
conservative	JJ	Pharmacological
treatment	NN	Pharmacological
with	IN	Pharmacological
a	DT	Pharmacological
therapeutic	JJ	Pharmacological
epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
if	IN	O
required	VBN	O
.	.	O

Eleven	NNP	O
of	IN	O
60	CD	O
(	(	O
18.3	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
prophylactic	JJ	Pharmacological
epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
group	NN	O
developed	VBD	O
a	DT	O
post-dural	JJ	O
puncture	NN	O
headache	NN	O
compared	VBN	O
with	IN	O
39	CD	O
of	IN	O
49	CD	O
(	(	O
79.6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
therapeutic	JJ	Pharmacological
epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

A	DT	O
blood	NN	O
patch	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
36	CD	O
(	(	O
73.4	CD	O
%	NN	O
)	)	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
therapeutic	JJ	O
group	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
needed	VBD	O
a	DT	O
second	JJ	O
blood	NN	O
patch	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
:	:	O
6	CD	O
(	(	O
10.0	CD	O
%	NN	O
)	)	O
for	IN	O
prophylactic	JJ	Pharmacological
epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
and	CC	O
4	CD	O
(	(	O
11.1	CD	O
%	NN	O
)	)	O
for	IN	O
therapeutic	JJ	Pharmacological
epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	Pharmacological
.	.	Pharmacological

We	PRP	O
conclude	VBP	O
that	IN	O
prophylactic	JJ	Pharmacological
epidural	JJ	Pharmacological
blood	NN	Pharmacological
patch	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
method	NN	O
to	TO	O
reduce	VB	O
the	DT	O
development	NN	O
of	IN	O
post-dural	JJ	O
puncture	NN	O
headache	NN	O
in	IN	O
obstetric	JJ	O
patients	NNS	O
.	.	O

Effect	NN	O
of	IN	O
cigarette	NN	O
smoking	NN	O
on	IN	O
gastric	JJ	O
emptying	NN	O
of	IN	O
solids	NNS	O
in	IN	O
Japanese	JJ	O
smokers	NNS	O
:	:	O
a	DT	O
crossover	NN	O
study	NN	O
using	VBG	O
the	DT	O
13C-octanoic	JJ	O
acid	NN	O
breath	NN	O
test	NN	O
.	.	O

BACKGROUND	NNP	O
Cigarette	NNP	O
smoking	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
peptic	JJ	O
ulcer	NN	O
and	CC	O
gastroesophageal	NN	O
reflux	NN	O
disease	NN	O
.	.	O

Gastric	NNP	O
emptying	VBG	O
disorders	NNS	O
may	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
these	DT	O
upper	JJ	O
gastrointestinal	NN	O
diseases	NNS	O
.	.	O

Thus	RB	O
,	,	O
studies	NNS	O
examining	VBG	O
a	DT	O
link	NN	O
between	IN	O
smoking	VBG	O
and	CC	O
gastric	JJ	O
emptying	VBG	O
disorders	NNS	O
have	VBP	O
clinical	JJ	O
relevance	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
smoking	VBG	O
on	IN	O
gastric	JJ	O
emptying	NN	O
of	IN	O
solids	NNS	O
in	IN	O
Japanese	JJ	O
smokers	NNS	O
.	.	O

METHODS	PDT	O
The	DT	O
(	(	Other
13	CD	Other
)	)	Other
C-octanoic	NNP	Other
acid	JJ	Other
breath	NN	Other
test	NN	Other
was	VBD	O
performed	VBN	O
in	IN	O
eight	CD	O
male	JJ	O
habitual	JJ	O
smokers	NNS	O
on	IN	O
two	CD	O
randomized	JJ	O
occasions	NNS	O
(	(	O
either	DT	O
sham	NN	O
smoking	NN	O
or	CC	O
actively	RB	O
smoking	VBG	O
)	)	O
.	.	O

The	DT	O
time	NN	O
vs	NN	O
(	(	O
13	CD	O
)	)	O
CO	NNP	O
(	(	O
2	CD	O
)	)	O
excretion	NN	O
rate	NN	O
curve	NN	O
was	VBD	O
mathematically	RB	O
fitted	VBN	O
to	TO	O
a	DT	O
conventional	JJ	O
formula	NN	O
of	IN	O
y	NN	O
(	(	O
t	NN	O
)	)	O
=	NN	O
m*k*beta*e	NN	O
(	(	O
-k*t	NNP	O
)	)	O
*	NNP	O
(	(	O
1	CD	O
-	:	O
e	NN	O
(	(	O
-k*t	NNP	O
)	)	O
)	)	O
(	(	O
beta-1	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
parameters	NNS	O
of	IN	O
k	NN	O
and	CC	O
beta	NN	O
were	VBD	O
determined	VBN	O
:	:	O
under	IN	O
the	DT	O
crossover	NN	O
protocol	NN	O
,	,	O
a	DT	O
larger	JJR	O
(	(	O
smaller	JJR	O
)	)	O
beta	NN	O
indicates	VBZ	O
slower	JJR	O
(	(	O
faster	RBR	O
)	)	O
emptying	VBG	O
in	IN	O
the	DT	O
early	JJ	O
phase	NN	O
,	,	O
and	CC	O
a	DT	O
larger	JJR	O
(	(	O
smaller	JJR	O
)	)	O
k	NN	O
indicates	VBZ	O
faster	RBR	O
(	(	O
slower	JJR	O
)	)	O
emptying	VBG	O
in	IN	O
the	DT	O
later	JJ	O
phase	NN	O
.	.	O

The	DT	O
half	NN	O
(	(	O
13	CD	O
)	)	O
CO	NNP	O
(	(	O
2	CD	O
)	)	O
excretion	NN	O
time	NN	O
(	(	O
t	NN	O
(	(	O
1/2b	CD	O
)	)	O
=	SYM	O
-	:	O
[	NN	O
ln	NN	O
(	(	O
1	CD	O
-	:	O
2	CD	O
(	(	O
-1/beta	NNP	O
)	)	O
)	)	O
]	FW	O
/k	NN	O
)	)	O
and	CC	O
the	DT	O
time	NN	O
of	IN	O
maximal	NN	O
(	(	O
13	CD	O
)	)	O
CO	NNP	O
(	(	O
2	CD	O
)	)	O
excretion	NN	O
rate	NN	O
(	(	O
t	NN	O
(	(	O
max	NN	O
)	)	O
=	VBZ	O
[	JJ	O
lnbeta	NN	O
]	NNP	O
/k	NNP	O
)	)	O
were	VBD	O
also	RB	O
calculated	VBN	O
.	.	O

Between	IN	O
the	DT	O
two	CD	O
occasions	NNS	O
,	,	O
k	NN	O
,	,	O
beta	NN	O
,	,	O
t	NN	O
(	(	O
1/2b	CD	O
)	)	O
,	,	O
and	CC	O
t	NN	O
(	(	O
max	NN	O
)	)	O
were	VBD	O
compared	VBN	O
by	IN	O
the	DT	O
Wilcoxon	NNP	O
signed-rank	JJ	O
test	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
smoking	VBG	O
,	,	O
k	NN	O
was	VBD	O
significantly	RB	O
increased	VBN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
beta	NN	O
,	,	O
t	NN	O
(	(	O
1/2	CD	O
)	)	O
,	,	O
and	CC	O
t	NN	O
(	(	O
max	NN	O
)	)	O
between	IN	O
the	DT	O
two	CD	O
occasions	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
increase	NN	O
in	IN	O
k	JJ	O
suggests	VBZ	O
the	DT	O
acceleration	NN	O
of	IN	O
gastric	JJ	O
emptying	VBG	O
in	IN	O
the	DT	O
later	JJ	O
phase	NN	O
.	.	O

For	IN	O
the	DT	O
first	JJ	O
time	NN	O
,	,	O
this	DT	O
study	NN	O
has	VBZ	O
revealed	VBN	O
that	IN	O
acute	JJ	O
smoking	NN	O
speeds	VBZ	O
the	DT	O
gastric	JJ	O
emptying	NN	O
of	IN	O
solids	NNS	O
in	IN	O
Japanese	JJ	O
habitual	JJ	O
smokers	NNS	O
.	.	O

Step-down	JJ	O
approach	NN	O
using	VBG	O
either	CC	O
cyclosporin	VB	Pharmacological
A	DT	Pharmacological
or	CC	O
methotrexate	NN	Pharmacological
as	IN	O
maintenance	NN	O
therapy	NN	O
in	IN	O
early	JJ	O
rheumatoid	NN	O
arthritis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
feasibility	NN	O
and	CC	O
outcome	NN	O
of	IN	O
the	DT	O
step-down	JJ	O
approach	NN	O
using	VBG	O
either	CC	O
cyclosporin	VB	Pharmacological
A	NNP	Pharmacological
(	(	Pharmacological
CSA	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
methotrexate	NN	Pharmacological
(	(	Pharmacological
MTX	NNP	Pharmacological
)	)	Pharmacological
as	IN	O
maintenance	NN	O
therapy	NN	O
following	VBG	O
6	CD	O
months	NNS	O
treatment	NN	O
with	IN	O
these	DT	O
2	CD	O
agents	NNS	O
in	IN	O
combination	NN	O
in	IN	O
early	JJ	O
,	,	O
nonerosive	JJ	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fifty-seven	JJ	O
patients	NNS	O
younger	JJR	O
than	IN	O
65	CD	O
years	NNS	O
with	IN	O
early	JJ	O
,	,	O
nonerosive	JJ	O
RA	NNP	O
were	VBD	O
first	RB	O
treated	VBN	O
with	IN	O
CSA	NNP	Pharmacological
and	CC	O
MTX	NNP	Pharmacological
in	IN	O
combination	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

They	PRP	O
were	VBD	O
then	RB	O
randomly	RB	O
stepped	VBD	O
down	RB	O
to	TO	O
single-agent	JJ	O
maintenance	NN	O
treatment	NN	O
for	IN	O
another	DT	O
18	CD	O
months	NNS	O
.	.	O

Safety	NNP	O
,	,	O
clinical	JJ	O
efficacy	NN	O
,	,	O
survival	NN	O
on	IN	O
treatment	NN	O
,	,	O
and	CC	O
radiographic	JJ	O
progression	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
When	WRB	O
being	VBG	O
treated	VBN	O
with	IN	O
combination	NN	O
therapy	NN	O
,	,	O
7	CD	O
of	IN	O
the	DT	O
57	CD	O
patients	NNS	O
(	(	O
12.3	CD	O
%	NN	O
)	)	O
withdrew	NN	O
because	IN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

Of	IN	O
the	DT	O
remaining	VBG	O
50	CD	O
patients	NNS	O
,	,	O
42	CD	O
(	(	O
84.0	CD	O
%	NN	O
)	)	O
were	VBD	O
American	JJ	O
College	NNP	O
of	IN	O
Rheumatology	NNP	O
(	(	O
ACR	NNP	O
)	)	O
20	CD	O
%	NN	O
responders	NNS	O
,	,	O
30	CD	O
(	(	O
60.0	CD	O
%	NN	O
)	)	O
were	VBD	O
ACR	NNP	O
50	CD	O
%	NN	O
responders	NNS	O
,	,	O
and	CC	O
23	CD	O
(	(	O
46.0	CD	O
%	NN	O
)	)	O
were	VBD	O
ACR	NNP	O
70	CD	O
%	NN	O
responders	NNS	O
.	.	O

At	IN	O
month	NN	O
6	CD	O
,	,	O
22	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
CSA	NNP	Pharmacological
and	CC	O
27	CD	O
to	TO	O
MTX	NNP	Pharmacological
.	.	Pharmacological

During	IN	O
this	DT	O
trial	NN	O
period	NN	O
,	,	O
the	DT	O
treatment	NN	O
was	VBD	O
discontinued	VBN	O
by	IN	O
16	CD	O
patients	NNS	O
taking	VBG	O
CSA	NNP	Pharmacological
(	(	O
mainly	RB	O
because	IN	O
of	IN	O
loss	NN	O
of	IN	O
efficacy	NN	O
)	)	O
and	CC	O
by	IN	O
4	CD	O
taking	VBG	O
MTX	NNP	Pharmacological
.	.	Pharmacological

At	IN	O
month	NN	O
24	CD	O
,	,	O
the	DT	O
probability	NN	O
(	(	O
+/-	JJ	O
SEM	NNP	O
)	)	O
of	IN	O
survival	NN	O
on	IN	O
treatment	NN	O
was	VBD	O
0.273	CD	O
+/-	JJ	O
0.09	CD	O
for	IN	O
CSA	NNP	Pharmacological
and	CC	O
0.852	CD	O
+/-	JJ	O
0.07	CD	O
for	IN	O
MTX	NNP	Pharmacological
.	.	Pharmacological

Of	IN	O
the	DT	O
6	CD	O
CSA	NNP	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
trial	NN	O
,	,	O
4	CD	O
(	(	O
66.7	CD	O
%	NN	O
)	)	O
were	VBD	O
ACR	NNP	O
20	CD	O
%	NN	O
responders	NNS	O
,	,	O
and	CC	O
3	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
were	VBD	O
both	DT	O
ACR	NNP	O
50	CD	O
%	NN	O
and	CC	O
ACR	NNP	O
70	CD	O
%	NN	O
responders	NNS	O
.	.	O

Of	IN	O
the	DT	O
23	CD	O
completers	NNS	O
in	IN	O
the	DT	O
MTX	NNP	Pharmacological
arm	NN	O
,	,	O
21	CD	O
(	(	O
91.3	CD	O
%	NN	O
)	)	O
were	VBD	O
ACR	NNP	O
20	CD	O
%	NN	O
responders	NNS	O
,	,	O
18	CD	O
(	(	O
78.3	CD	O
%	NN	O
)	)	O
were	VBD	O
ACR	NNP	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
10	CD	O
(	(	O
43.5	CD	O
%	NN	O
)	)	O
were	VBD	O
ACR	NNP	O
70	CD	O
%	NN	O
responders	NNS	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
not	RB	O
responsible	JJ	O
for	IN	O
severe	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

Radiography	NNP	O
showed	VBD	O
a	DT	O
slow	JJ	O
progression	NN	O
in	IN	O
the	DT	O
damage	NN	O
score	NN	O
and	CC	O
number	NN	O
of	IN	O
eroded	JJ	O
joints	NNS	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Stepping	VBG	O
down	RP	O
to	TO	O
single	JJ	O
agent	JJ	O
maintenance	NN	O
therapy	NN	O
following	VBG	O
6	CD	O
months	NNS	O
of	IN	O
combination	NN	O
treatment	NN	O
with	IN	O
CSA	NNP	Pharmacological
and	CC	O
MTX	NNP	Pharmacological
in	IN	O
early	JJ	O
RA	NNP	O
was	VBD	O
only	RB	O
successful	JJ	O
with	IN	O
MTX	NNP	Pharmacological
.	.	Pharmacological

Because	IN	O
this	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
prevent	VB	O
some	DT	O
radiographic	JJ	O
progression	NN	O
,	,	O
other	JJ	O
approaches	NNS	O
(	(	O
e.g.	NN	O
,	,	O
step-up	JJ	O
approach	NN	O
)	)	O
may	MD	O
be	VB	O
more	JJR	O
appropriate	JJ	O
in	IN	O
early	JJ	O
RA	NNP	O
.	.	O

Relation	NN	O
of	IN	O
total	JJ	O
homocysteine	NN	O
and	CC	O
lipid	JJ	O
levels	NNS	O
in	IN	O
children	NNS	O
to	TO	O
premature	VB	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
male	JJ	O
relatives	NNS	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
lipid	JJ	O
,	,	O
apo	JJ	O
B	NNP	O
,	,	O
lipoprotein	NN	O
(	(	O
a	DT	O
)	)	O
[	NN	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
]	NN	O
,	,	O
and	CC	O
total	JJ	O
homocysteine	NN	O
(	(	O
tHcy	NN	O
)	)	O
levels	NNS	O
in	IN	O
children	NNS	O
in	IN	O
relation	NN	O
to	TO	O
premature	VB	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
family	NN	O
members	NNS	O
.	.	O

Parents	NNS	O
of	IN	O
381	CD	O
girls	NNS	O
and	CC	O
375	CD	O
boys	NNS	O
age	NN	O
8-12	JJ	O
y	NN	O
completed	VBN	O
family	NN	Other
history	NN	Other
questionnaires	NNS	Other
.	.	Other

Nonfasting	VBG	O
serum	JJ	O
lipid	JJ	O
and	CC	O
lipoproteins	NNS	O
and	CC	O
plasma	NN	O
tHcy	NN	O
and	CC	O
cysteine	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
the	DT	O
children	NNS	O
.	.	O

Serum	NNP	O
folate	NN	O
and	CC	O
vitamin	NN	O
B12	NNP	O
levels	NNS	O
were	VBD	O
determined	VBN	O
in	IN	O
a	DT	O
random	JJ	O
subsample	NN	O
of	IN	O
23	CD	O
%	NN	O
of	IN	O
the	DT	O
children	NNS	O
,	,	O
who	WP	O
participated	VBD	O
in	IN	O
a	DT	O
food	NN	O
frequency	NN	O
interview	NN	O
.	.	O

Children	NNP	O
whose	WP$	O
parents	NNS	O
reported	VBD	O
hypercholesterolemia	NN	O
had	VBD	O
higher	JJR	O
total	JJ	O
and	CC	O
non-HDL	JJ	O
cholesterol	NN	O
and	CC	O
apo	NN	O
B	NNP	O
levels	NNS	O
than	IN	O
the	DT	O
rest	NN	O
,	,	O
but	CC	O
these	DT	O
levels	NNS	O
were	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

tHcy	NN	O
levels	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
girls	NNS	O
and	CC	O
boys	NNS	O
.	.	O

tHcy	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
children	NNS	O
whose	WP$	O
father	NN	O
,	,	O
grandfather	NN	O
,	,	O
or	CC	O
uncle	NN	O
died	VBN	O
at	IN	O
age	NN	O
<	NN	O
or	CC	O
=	$	O
55	CD	O
y	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
sudden	JJ	O
cardiac	JJ	O
arrest	NN	O
(	(	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
than	IN	O
in	IN	O
control	NN	O
children	NNS	O
[	VBP	O
5.92	CD	O
mumol/L	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
of	IN	O
5.47-6.36	NNP	O
)	)	O
versus	NN	O
5.25	CD	O
mumol/L	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
5.16-5.34	JJ	O
)	)	O
]	NN	O
,	,	O
also	RB	O
after	IN	O
adjustment	NN	O
for	IN	O
socioeconomic	JJ	O
group	NN	O
.	.	O

Intake	NNP	O
and	CC	O
serum	NN	O
levels	NNS	O
of	IN	O
vitamin	NN	O
B12	NNP	O
and	CC	O
folate	NN	O
were	VBD	O
within	IN	O
recommended	VBN	O
or	CC	O
reference	NN	O
ranges	NNS	O
.	.	O

In	IN	O
a	DT	O
stepwise	NN	O
multiple	JJ	O
regression	NN	O
analysis	NN	O
,	,	O
serum	NN	O
folate	NN	O
(	(	O
negative	JJ	O
correlation	NN	O
)	)	O
,	,	O
plasma	JJ	O
creatinine	NN	O
,	,	O
and	CC	O
sugar	RB	O
intake	VB	O
as	IN	O
percent	NN	O
of	IN	O
dietary	JJ	O
energy	NN	O
(	(	O
positive	JJ	O
correlations	NNS	O
)	)	O
were	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
tHcy	NN	O
(	(	O
multiple	JJ	O
r	NN	O
=	NN	O
0.44	CD	O
,	,	O
adjusted	VBN	O
r2	NN	O
=	VBZ	O
18	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
5-30	JJ	O
%	NN	O
)	)	O
.	.	O

Our	PRP$	O
data	NNS	O
show	VBP	O
that	IN	O
a	DT	O
modest	JJ	O
elevation	NN	O
in	IN	O
tHcy	NN	O
in	IN	O
children	NNS	O
was	VBD	O
related	VBN	O
to	TO	O
premature	VB	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
their	PRP$	O
male	NN	O
relatives	NNS	O
and	CC	O
may	MD	O
partly	RB	O
account	VB	O
for	IN	O
the	DT	O
contribution	NN	O
of	IN	O
family	NN	O
history	NN	O
to	TO	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

tHcy	NN	O
may	MD	O
be	VB	O
modifiable	JJ	O
through	IN	O
the	DT	O
diet	NN	O
,	,	O
even	RB	O
in	IN	O
children	NNS	O
with	IN	O
apparently	RB	O
adequate	JJ	O
vitamin	JJ	O
nutriture	NN	O
.	.	O

Information	NNP	Educational
source	NN	Educational
affects	VBZ	O
peers	NNS	O
'	POS	O
initial	JJ	O
attitudes	NNS	O
toward	IN	O
autism	NN	O
.	.	O

Authors	NNS	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
information	NN	O
source	NN	O
on	IN	O
peers	NNS	O
'	POS	O
cognitive	NN	O
and	CC	O
behavioral	JJ	O
attitudes	NNS	O
toward	IN	O
an	DT	O
unfamiliar	JJ	O
child	NN	O
with	IN	O
autism	NN	O
.	.	O

Children	NNP	O
(	(	O
N=296	NNP	O
;	:	O
M	NNP	O
age=10.21	IN	O
years	NNS	O
)	)	O
received	VBD	O
information	NN	O
about	IN	O
an	DT	O
unfamiliar	JJ	O
child	NN	O
with	IN	O
autism	NN	O
from	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
sources	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
videotape	NN	Educational
,	,	O
(	(	O
b	NN	O
)	)	O
teacher	NN	Educational
,	,	O
(	(	O
c	NN	O
)	)	O
hypothetical	JJ	Educational
mother	NN	Educational
,	,	O
(	(	O
d	NN	O
)	)	O
hypothetical	JJ	Educational
father	NN	Educational
,	,	O
or	CC	O
(	(	O
e	NN	O
)	)	O
hypothetical	JJ	Educational
doctor	NN	Educational
.	.	Educational

Interactive	JJ	O
effects	NNS	O
between	IN	O
source	NN	O
,	,	O
and	CC	O
sex	NN	O
and	CC	O
grade	NN	O
were	VBD	O
found	VBN	O
for	IN	O
cognitive	JJ	O
and	CC	O
behavioral	JJ	O
attitudes	NNS	O
.	.	O

Fifth-graders	NNS	O
reported	VBD	O
more	RBR	O
favorable	JJ	O
cognitive	JJ	O
and	CC	O
behavioral	JJ	O
attitudes	NNS	O
when	WRB	O
information	NN	O
was	VBD	O
provided	VBN	O
by	IN	O
extra-familial	JJ	O
sources	NNS	O
(	(	O
i.e.	NN	O
,	,	O
doctor	NN	O
)	)	O
versus	NN	O
parent	NN	O
sources	NNS	O
.	.	O

Mother	NNP	O
yielded	VBD	O
more	RBR	O
persuasive	JJ	O
effects	NNS	O
on	IN	O
behavioral	JJ	O
attitudes	NNS	O
for	IN	O
third-graders	NNS	O
versus	JJ	O
fifth-graders	NNS	O
.	.	O

Attitudes	NNS	O
toward	IN	O
autism	NN	O
differ	VBP	O
depending	VBG	O
on	IN	O
who	WP	O
provides	VBZ	O
information	NN	O
about	IN	O
the	DT	O
disability	NN	O
.	.	O

Persuasion	NNP	O
theory	NN	O
appears	VBZ	O
useful	JJ	O
to	TO	O
guide	VB	O
evaluation	NN	O
of	IN	O
educational	JJ	O
interventions	NNS	O
to	TO	O
improve	VB	O
attitudes	NNS	O
towards	IN	O
autism	NN	O
.	.	O

Implications	NNS	O
of	IN	O
the	DT	O
findings	NNS	O
,	,	O
study	NN	O
limitations	NNS	O
,	,	O
and	CC	O
recommendations	NNS	O
for	IN	O
future	JJ	O
research	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Treatment	NN	O
of	IN	O
stable	JJ	O
angina	NN	O
of	IN	O
effort	NN	O
with	IN	O
verapamil	NN	Pharmacological
:	:	Pharmacological
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
randomized	VBN	O
crossover	NN	O
study	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
verapamil	NN	Pharmacological
were	VBD	O
assessed	VBN	O
in	IN	O
26	CD	O
patients	NNS	O
with	IN	O
stable	JJ	O
exertional	JJ	O
angina	NN	O
pectoris	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
randomized	VBN	O
crossover	NN	O
protocol	NN	O
using	VBG	O
serial	JJ	O
treadmill	NN	O
tests	NNS	O
.	.	O

Verapamil	NNP	Pharmacological
,	,	O
480	CD	O
mg/day	NN	O
,	,	O
reduced	VBD	O
anginal	JJ	O
frequency	NN	O
from	IN	O
5.6	CD	O
+/-	JJ	O
7.3	CD	O
to	TO	O
2.2	CD	O
+/-	JJ	O
3.9	CD	O
attacks	NNS	O
per	IN	O
week	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
nitroglycerin	JJ	Pharmacological
consumption	NN	O
from	IN	O
3.4	CD	O
+/-	JJ	O
4.9	CD	O
to	TO	O
1.2	CD	O
+/-	JJ	O
2.5	CD	O
tablets	NNS	O
per	IN	O
week	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	Control
.	.	Control

Treadmill	NNP	O
time	NN	O
increased	VBD	O
from	IN	O
6.4	CD	O
+/-	JJ	O
2.1	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
placebo	NN	Control
phase	NN	O
to	TO	O
7.5	CD	O
+/-	JJ	O
1.8	CD	O
minutes	NNS	O
during	IN	O
the	DT	O
verapamil	JJ	Pharmacological
phase	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Verapamil	NNP	Pharmacological
's	POS	Pharmacological
beneficial	JJ	O
effect	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
related	VBN	O
,	,	O
in	IN	O
part	NN	O
,	,	O
to	TO	O
a	DT	O
10	CD	O
%	NN	O
reduction	NN	O
of	IN	O
the	DT	O
rate-pressure	JJ	O
product	NN	O
at	IN	O
rest	NN	O
(	(	O
p	IN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
and	CC	O
a	DT	O
12	CD	O
%	NN	O
reduction	NN	O
during	IN	O
submaximal	JJ	O
exercise	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Verapamil	NNP	Pharmacological
also	RB	O
caused	VBD	O
less	JJR	O
marked	JJ	O
ST-segment	JJ	O
depressions	NNS	O
at	IN	O
peak	NN	O
exercise	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
at	IN	O
a	DT	O
similar	JJ	O
rate-pressure	NN	O
product	NN	O
,	,	O
suggesting	VBG	O
a	DT	O
favorable	JJ	O
redistribution	NN	O
of	IN	O
coronary	JJ	O
blood	NN	O
flow	NN	O
to	TO	O
the	DT	O
ischemic	JJ	O
zone	NN	O
.	.	O

Side	JJ	O
effects	NNS	O
from	IN	O
verapamil	NN	Pharmacological
were	VBD	O
minimal	JJ	O
,	,	O
consisting	VBG	O
mainly	RB	O
of	IN	O
constipation	NN	O
(	(	O
six	CD	O
patients	NNS	O
)	)	O
.	.	O

Verapamil	NNP	Pharmacological
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
drug	NN	O
for	IN	O
treating	VBG	O
angina	NN	O
of	IN	O
effort	NN	O
.	.	O

Immunogenicity	NN	O
and	CC	O
safety	NN	O
of	IN	O
a	DT	O
plasma-derived	JJ	Pharmacological
heat-inactivated	JJ	Pharmacological
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
(	(	Pharmacological
CLB	NNP	Pharmacological
)	)	Pharmacological
.	.	O

Studies	NNPS	O
in	IN	O
volunteers	NNS	O
at	IN	O
a	DT	O
low	JJ	O
risk	NN	O
of	IN	O
infection	NN	O
with	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
a	DT	O
plasma-derived	JJ	Pharmacological
heat-inactivated	JJ	Pharmacological
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
(	(	Pharmacological
CLB	NNP	Pharmacological
)	)	Pharmacological
were	VBD	O
evaluated	VBN	O
in	IN	O
471	CD	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
,	,	O
who	WP	O
,	,	O
both	DT	O
in	IN	O
their	PRP$	O
occupations	NNS	O
and	CC	O
in	IN	O
their	PRP$	O
private	JJ	O
lives	NNS	O
,	,	O
had	VBD	O
been	VBN	O
at	IN	O
minimal	JJ	O
risk	NN	O
of	IN	O
being	VBG	O
infected	VBN	O
with	IN	O
hepatitis	NN	O
B	NNP	O
virus	NN	O
.	.	O

The	DT	O
first	JJ	O
202	JJ	O
individuals	NNS	O
received	VBD	O
three	CD	O
3-micrograms	JJ	O
doses	NNS	O
of	IN	O
heat-inactivated	JJ	Pharmacological
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
surface	NN	Pharmacological
antigen	NN	Pharmacological
(	(	Pharmacological
HBsAg	NNP	Pharmacological
)	)	Pharmacological
at	IN	O
one-month	JJ	O
intervals	NNS	O
(	(	O
trial	NN	O
A	DT	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
42	CD	O
%	NN	O
one	CD	O
month	NN	O
after	IN	O
the	DT	O
first	JJ	O
injection	NN	O
,	,	O
84	CD	O
%	NN	O
after	IN	O
two	CD	O
months	NNS	O
,	,	O
and	CC	O
93	CD	O
%	NN	O
after	IN	O
five	CD	O
months	NNS	O
had	VBD	O
become	VBN	O
anti-HBs	JJ	O
(	(	O
antibody	NN	O
to	TO	O
hepatitis	VB	O
B	NNP	O
surface	NN	O
antigen	NN	O
)	)	O
positive	JJ	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
randomized	VBN	O
study	NN	O
(	(	O
trial	NN	O
B	NNP	O
)	)	O
,	,	O
the	DT	O
immunogenicity	NN	O
of	IN	O
five	CD	O
different	JJ	O
dosages	NNS	O
of	IN	O
the	DT	O
vaccine	NN	O
was	VBD	O
compared	VBN	O
in	IN	O
269	CD	O
volunteers	NNS	O
.	.	O

When	WRB	O
the	DT	O
dose	NN	O
of	IN	O
HBsAg	NNP	O
was	VBD	O
diminished	VBN	O
from	IN	O
3	CD	O
micrograms	NNS	O
to	TO	O
1.5	CD	O
,	,	O
0.6	CD	O
,	,	O
and	CC	O
0.25	CD	O
microgram	NN	O
,	,	O
no	DT	O
decrease	NN	O
of	IN	O
the	DT	O
anti-HBs	JJ	O
response	NN	O
was	VBD	O
observed	VBN	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
the	DT	O
dose	NN	O
was	VBD	O
diminished	VBN	O
to	TO	O
0.1	CD	O
microgram	NN	O
of	IN	O
HBsAg	NNP	O
,	,	O
the	DT	O
anti-HBs	JJ	O
response	NN	O
dropped	VBD	O
significantly	RB	O
to	TO	O
63	CD	O
%	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
recipients	NNS	O
of	IN	O
all	DT	O
five	CD	O
vaccine	NN	O
dosages	NNS	O
,	,	O
no	DT	O
influence	NN	O
of	IN	O
sex	NN	O
and	CC	O
age	NN	O
was	VBD	O
found	VBN	O
on	IN	O
the	DT	O
anti-HBs	JJ	O
conversion	NN	O
rates	NNS	O
.	.	O

During	IN	O
the	DT	O
eight-month	JJ	O
observation	NN	O
period	NN	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
vaccinees	NNS	O
became	VBD	O
HBsAg	NNP	O
and/or	IN	O
anti-HBc	JJ	O
(	(	O
antibody	NN	O
to	TO	O
hepatitis	VB	O
B	NNP	O
core	NN	O
antigen	NN	O
)	)	O
positive	JJ	O
,	,	O
and	CC	O
none	NN	O
developed	VBD	O
antibodies	NNS	O
associated	VBN	O
with	IN	O
autoimmune	JJ	O
liver	NN	O
disease	NN	O
.	.	O

No	DT	O
serious	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Timing	VBG	O
for	IN	O
delivering	VBG	O
individualized	JJ	Educational
patient	JJ	Educational
education	NN	Educational
intervention	NN	Educational
to	TO	O
Coronary	NNP	O
Artery	NNP	O
Bypass	NNP	O
Graft	NNP	O
patients	NNS	O
:	:	O
An	DT	O
RCT	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
primary	JJ	O
focus	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
on	IN	O
the	DT	O
timing	NN	O
of	IN	O
the	DT	O
delivery	NN	O
of	IN	O
education	NN	O
to	TO	O
patients	NNS	O
who	WP	O
had	VBD	O
CABG	NNP	Surgical
surgery	NN	Surgical
.	.	Surgical

AIM	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
individualized	JJ	Educational
telephone	NN	Educational
patient	JJ	Educational
education	NN	Educational
intervention	NN	Educational
,	,	O
delivered	VBN	O
at	IN	O
two	CD	O
different	JJ	O
points	NNS	O
in	IN	O
time	NN	O
(	(	O
1-2	JJ	O
days	NNS	O
pre-discharge	JJ	O
versus	JJ	O
1-2	JJ	O
days	NNS	O
post-discharge	NN	O
)	)	O
in	IN	O
enhancing	VBG	O
the	DT	O
CABG	NNP	O
patient	NN	O
's	POS	O
knowledge	NN	O
of	IN	O
self-care	JJ	O
behaviours	NNS	O
,	,	O
performance	NN	O
of	IN	O
self-care	JJ	O
behaviours	NNS	O
,	,	O
and	CC	O
symptom	JJ	O
frequency	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
that	WDT	O
included	VBD	O
a	DT	O
convenience	NN	O
sample	NN	O
of	IN	O
first	JJ	O
time	NN	O
CABG	NNP	O
patients	NNS	O
.	.	O

Individuals	NNS	O
who	WP	O
received	VBD	O
education	NN	Educational
pre-discharge	NN	Educational
were	VBD	O
compared	VBN	O
to	TO	O
individuals	NNS	O
who	WP	O
received	VBD	O
education	NN	O
post-discharge	NN	O
on	IN	O
the	DT	O
outcomes	NNS	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
indicated	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

As	NNP	O
well	RB	O
,	,	O
anxiety	NN	O
levels	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
pre-discharge	NN	O
group	NN	O
than	IN	O
the	DT	O
post-discharge	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
individualized	JJ	O
nature	NN	O
of	IN	O
the	DT	O
educational	JJ	Educational
intervention	NN	Educational
may	MD	O
have	VB	O
accounted	VBN	O
for	IN	O
non-significant	JJ	O
findings	NNS	O
reported	VBN	O
in	IN	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
time	NN	O
points	NNS	O
.	.	O

PRACTICE	NNP	O
IMPLICATIONS	NNP	O
Nurses	NNP	O
may	MD	O
consider	VB	O
assessing	VBG	O
anxiety	NN	O
levels	NNS	O
prior	RB	O
to	TO	O
delivery	NN	O
of	IN	O
educational	JJ	O
interventions	NNS	O
,	,	O
implement	JJ	O
interventions	NNS	O
aimed	VBN	O
at	IN	O
reducing	VBG	O
anxiety	NN	O
levels	NNS	O
,	,	O
and	CC	O
provide	VB	O
individualized	JJ	O
teaching	NN	O
.	.	O

Sodium	NN	Pharmacological
bicarbonate	NN	Pharmacological
,	,	O
N-acetylcysteine	NNP	Pharmacological
,	,	O
and	CC	O
saline	NN	Control
for	IN	O
prevention	NN	O
of	IN	O
radiocontrast-induced	JJ	O
nephropathy	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
3	CD	O
regimens	NNS	O
for	IN	O
protecting	VBG	O
contrast-induced	JJ	O
nephropathy	JJ	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	Surgical
procedures	NNS	Surgical
.	.	Surgical

A	DT	O
single-center	JJ	O
prospective	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Several	NNP	O
protective	JJ	O
therapies	NNS	O
have	VBP	O
been	VBN	O
developed	VBN	O
to	TO	O
prevent	VB	O
contrast-induced	JJ	O
nephropathy	JJ	O
(	(	O
CIN	NNP	O
)	)	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
sodium	NN	Pharmacological
bicarbonate	NN	Pharmacological
by	IN	O
comparing	VBG	O
2	CD	O
other	JJ	O
regimens	NNS	O
,	,	O
including	VBG	O
combination	NN	O
of	IN	O
N-acetylcysteine	NNP	Surgical
(	(	Surgical
NAC	NNP	Surgical
)	)	Surgical
plus	CC	O
sodium	JJ	Pharmacological
chloride	NN	Pharmacological
and	CC	O
sodium	NN	Pharmacological
chloride	NN	Pharmacological
alone	RB	O
,	,	O
to	TO	O
prevent	VB	O
CIN	NNP	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
cardiovascular	JJ	O
procedures	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
enrolled	VBD	O
264	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
cardiovascular	JJ	O
procedures	NNS	O
and	CC	O
had	VBD	O
a	DT	O
baseline	JJ	O
creatinine	NN	O
level	NN	O
>	VBD	O
1.2	CD	O
mg/dL	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
1	CD	O
of	IN	O
3	CD	O
prophylactic	JJ	O
regimens	NNS	O
:	:	O
infusion	NN	O
of	IN	O
sodium	NN	Pharmacological
bicarbonate	NN	Pharmacological
,	,	O
sodium	NN	Pharmacological
chloride	NN	Pharmacological
,	,	O
sodium	NN	Pharmacological
chloride	NN	Pharmacological
plus	CC	O
oral	JJ	O
NAC	NNP	Pharmacological
(	(	O
600	CD	O
mg	RB	O
bid	NN	O
)	)	O
.	.	O

Contrast-induced	JJ	O
nephropathy	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
creatinine	NN	O
level	NN	O
>	VBD	O
25	CD	O
%	NN	O
or	CC	O
0.5	CD	O
mg/dL	NNS	O
after	IN	O
48	CD	O
hours	NNS	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
among	IN	O
groups	NNS	O
regarding	VBG	O
baseline	NN	O
demographic	JJ	O
properties	NNS	O
and	CC	O
nephropathy	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

The	DT	O
change	NN	O
in	IN	O
creatinine	JJ	O
clearance	NN	O
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
sodium	NN	Pharmacological
bicarbonate	NN	Pharmacological
group	NN	O
than	IN	O
other	JJ	O
2	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.007	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
CIN	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
sodium	NN	Pharmacological
bicarbonate	NN	Pharmacological
group	NN	O
(	(	O
4.5	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
sodium	JJ	Pharmacological
chloride	NN	Pharmacological
alone	RB	O
(	(	O
13.6	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.036	NNP	O
)	)	O
and	CC	O
tended	VBD	O
to	TO	O
be	VB	O
lower	JJR	O
than	IN	O
in	IN	O
the	DT	O
combination	NN	O
group	NN	O
(	(	O
12.5	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
.059	NNP	O
)	)	O
.	.	O

After	IN	O
adjusting	VBG	O
the	DT	O
Mehran	NNP	O
nephropathy	NN	O
risk	NN	O
score	NN	O
,	,	O
the	DT	O
risk	NN	O
of	IN	O
CIN	NNP	O
significantly	RB	O
reduced	VBD	O
with	IN	O
sodium	NN	Pharmacological
bicarbonate	NN	Pharmacological
compared	VBN	O
with	IN	O
sodium	JJ	Pharmacological
chloride	NN	Pharmacological
alone	RB	O
(	(	O
adjusted	VBN	O
risk	NN	O
ratio	NN	O
0.29	CD	O
,	,	O
P	NNP	O
=	NNP	O
.043	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Hydration	NNP	O
with	IN	O
sodium	JJ	Pharmacological
bicarbonate	NN	Pharmacological
provides	VBZ	O
better	JJR	O
protection	NN	O
against	IN	O
CIN	NNP	O
than	IN	O
the	DT	O
sodium	NN	Pharmacological
chloride	JJ	Pharmacological
infusion	NN	Pharmacological
does	VBZ	O
alone	RB	O
.	.	O

Combination	NNP	O
therapy	NN	O
of	IN	O
NAC	NNP	Pharmacological
plus	CC	Pharmacological
sodium	JJ	Pharmacological
chloride	NN	Pharmacological
did	VBD	O
not	RB	O
offer	VB	O
additional	JJ	O
benefit	NN	O
over	IN	O
hydration	NN	O
with	IN	O
sodium	JJ	Pharmacological
chloride	NN	Pharmacological
alone	RB	O
.	.	O

Genotyping	VBG	Other
of	IN	Other
CYP21	NNP	Other
,	,	O
linked	VBD	O
chromosome	NN	O
6p	CD	O
markers	NNS	O
,	,	O
and	CC	O
a	DT	O
sex-specific	JJ	O
gene	NN	O
in	IN	O
neonatal	JJ	O
screening	NN	O
for	IN	O
congenital	JJ	O
adrenal	JJ	O
hyperplasia	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
feasibility	NN	O
and	CC	O
diagnostic	JJ	O
utility	NN	O
of	IN	O
genotyping	VBG	Other
9	CD	Other
CYP21	NNP	Other
mutations	NNS	O
,	,	O
linked	VBD	O
chromosome	NN	O
6p	CD	O
markers	NNS	O
,	,	O
and	CC	O
a	DT	O
dimorphic	JJ	O
X-Y	JJ	O
marker	NN	O
from	IN	O
neonatal	JJ	O
screening	NN	O
samples	NNS	O
.	.	O

Blood-impregnated	JJ	Other
filter	NN	Other
papers	NNS	Other
(	(	O
Guthrie	NNP	O
cards	NNS	O
)	)	O
from	IN	O
603	CD	O
randomly	RB	O
chosen	VBN	O
New	NNP	O
Zealand	NNP	O
neonates	NNS	O
were	VBD	O
genotyped	VBN	O
blind	IN	O
to	TO	O
17-hydroxyprogesterone	CD	Other
(	(	O
17-OHP	CD	O
)	)	O
levels	NNS	O
.	.	O

Another	DT	O
50	CD	O
samples	NNS	O
from	IN	O
Swiss	NNP	O
and	CC	O
North	NNP	O
American	JJ	O
infants	NNS	O
with	IN	O
correlative	JJ	O
hormonal	JJ	O
data	NNS	O
were	VBD	O
also	RB	O
genotyped	VBN	O
.	.	O

DNA	NN	O
was	VBD	O
extracted	VBN	O
,	,	O
and	CC	O
gene-specific	JJ	O
PCR	NNP	O
was	VBD	O
performed	VBN	O
.	.	O

CYP21	NNP	Other
PCR	NNP	Other
products	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
ligase	VB	O
detection	NN	O
reaction	NN	O
,	,	O
simultaneously	RB	O
analyzing	VBG	O
9	CD	O
CYP21	NNP	O
mutations	NNS	O
;	:	O
PCR	NNP	O
products	NNS	O
of	IN	O
other	JJ	O
genes	NNS	O
were	VBD	O
subjected	VBN	O
to	TO	O
direct	VB	O
gel	JJ	O
analysis	NN	O
.	.	O

CYP21	NNP	Other
genotyping	VBG	O
indicated	VBD	O
a	DT	O
heterozygote	NN	O
rate	NN	O
of	IN	O
2.8	CD	O
%	NN	O
for	IN	O
classic	JJ	O
mutations	NNS	O
(	(	O
excluding	VBG	O
CYP21	NNP	O
deletions	NNS	O
)	)	O
,	,	O
and	CC	O
2.0	CD	O
%	NN	O
for	IN	O
nonclassic	JJ	O
mutations	NNS	O
in	IN	O
New	NNP	O
Zealanders	NNP	O
.	.	O

Ten	CD	O
full-term	JJ	O
affected	JJ	O
neonates	NNS	O
showed	VBD	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
17-OHP	JJ	O
levels	NNS	O
(	(	O
15-1400	JJ	O
nmol/L	NN	O
)	)	O
.	.	O

Sick	NNP	O
or	CC	O
preterm	JJ	O
infants	NNS	O
or	CC	O
infants	NNS	O
screened	VBN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
life	NN	O
with	IN	O
high	JJ	O
17-OHP	JJ	O
proved	VBN	O
genetically	RB	O
unaffected	JJ	O
.	.	O

Genetic	JJ	O
linkage	NN	O
disequilibrium	NN	O
was	VBD	O
found	VBN	O
between	IN	O
two	CD	O
CYP21	NNP	O
mutations	NNS	O
and	CC	O
chromosome	NN	O
6p	CD	O
markers	NNS	O
.	.	O

Guthrie	NNP	O
cards	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
accurately	RB	O
genotype	VB	O
CYP21	NNP	O
and	CC	O
other	JJ	O
relevant	JJ	O
markers	NNS	O
,	,	O
potentially	RB	O
enhancing	VBG	O
the	DT	O
specificity	NN	O
and	CC	O
sensitivity	NN	O
of	IN	O
congenital	JJ	O
adrenal	JJ	O
hyperplasia	NN	O
screening	NN	O
.	.	O

CYP21	NNP	Other
heterozygote	JJ	O
frequency	NN	O
for	IN	O
classic	JJ	O
mutations	NNS	O
is	VBZ	O
higher	JJR	O
than	IN	O
expected	VBN	O
based	VBN	O
on	IN	O
genotype	NN	O
compared	VBN	O
with	IN	O
that	DT	O
predicted	VBN	O
by	IN	O
hormonal	JJ	O
newborn	JJ	O
screening	NN	O
.	.	O

No	DT	O
effect	NN	O
of	IN	O
acetylsalicylic	JJ	Pharmacological
acid	NN	Pharmacological
on	IN	O
B-thromboglobulin	NNP	O
and	CC	O
platelet	VB	O
factor	NN	O
4	CD	O
plasma	NN	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
transient	JJ	O
ischaemic	JJ	O
attacks	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acetylsalicylic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
ASA	NNP	Pharmacological
)	)	Pharmacological
versus	NN	O
placebo	NN	Control
on	IN	O
B-thromboglobulin	NNP	O
(	(	O
B-TG	NNP	O
)	)	O
and	CC	O
platelet	JJ	O
factor	NN	O
4	CD	O
(	(	O
PF4	NNP	O
)	)	O
plasma	NN	O
levels	NNS	O
and	CC	O
ADP-induced	NNP	O
platelet	NN	O
aggregation	NN	O
in	IN	O
25	CD	O
male	JJ	O
patients	NNS	O
with	IN	O
transient	JJ	O
ischaemic	JJ	O
attacks	NNS	O
(	(	O
TIA	NNP	O
)	)	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
to	TO	O
two	CD	O
groups	NNS	O
:	:	O
14	CD	O
patients	NNS	O
received	JJ	O
oral	JJ	O
treatment	NN	O
with	IN	O
ASA	NNP	Pharmacological
500	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

for	IN	O
14	CD	O
days	NNS	O
,	,	O
11	CD	O
patients	NNS	O
placebo	JJ	Control
b.i.d	NN	O
.	.	O

for	IN	O
the	DT	O
same	JJ	O
period	NN	O
.	.	O

B-TG	NNP	O
and	CC	O
PF4	NNP	O
plasma	NN	O
levels	NNS	O
and	CC	O
ADP-induced	NNP	O
platelet	NN	O
aggregation	NN	O
were	VBD	O
determined	VBN	O
in	IN	O
basal	NN	O
conditions	NNS	O
,	,	O
and	CC	O
two	CD	O
hours	NNS	O
,	,	O
and	CC	O
seven	CD	O
and	CC	O
fourteen	JJ	O
days	NNS	O
after	IN	O
starting	VBG	O
with	IN	O
ASA	NNP	O
or	CC	O
placebo	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
same	JJ	O
parameters	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
20	CD	O
healthy	JJ	O
males	NNS	O
of	IN	O
matched	JJ	O
age	NN	O
.	.	O

Basal	NNP	O
levels	NNS	O
of	IN	O
plasma	JJ	O
B-TG	NNP	O
and	CC	O
PF4	NNP	O
and	CC	O
the	DT	O
maximal	JJ	O
amplitude	NN	O
of	IN	O
ADP-induced	NNP	O
platelet	NN	O
aggregation	NN	O
were	VBD	O
abnormally	RB	O
high	JJ	O
in	IN	O
TIA	NNP	O
patients	NNS	O
.	.	O

ASA	NNP	O
caused	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
B-TG	NNP	O
plasma	NN	O
levels	NNS	O
in	IN	O
TIA	NNP	O
patients	NNS	O
2	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
administration	NN	O
,	,	O
but	CC	O
no	DT	O
effect	NN	O
was	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
7th	CD	O
and	CC	O
14th	CD	O
day	NN	O
of	IN	O
treatment	NN	O
.	.	O

PF4	NNP	O
plasma	NN	O
levels	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
ASA	NNP	O
treatment	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
ASA	NNP	O
,	,	O
at	IN	O
the	DT	O
dose	NN	O
conventionally	RB	O
used	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
release	NN	O
of	IN	O
two	CD	O
alpha-granule	JJ	O
proteins	NNS	O
.	.	O

Maternal	JJ	O
breast-milk	NN	O
and	CC	O
intestinal	JJ	O
bifidobacteria	NNS	O
guide	VBP	O
the	DT	O
compositional	JJ	O
development	NN	O
of	IN	O
the	DT	O
Bifidobacterium	NNP	O
microbiota	NN	O
in	IN	O
infants	NNS	O
at	IN	O
risk	NN	O
of	IN	O
allergic	JJ	O
disease	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
sources	NNS	O
and	CC	O
the	DT	O
impact	NN	O
of	IN	O
maternal	JJ	O
bacteria	NNS	O
on	IN	O
the	DT	O
initial	JJ	O
inoculum	NN	O
of	IN	O
the	DT	O
intestinal	JJ	O
microflora	NN	O
of	IN	O
newborn	JJ	O
infants	NNS	O
remain	VBP	O
elusive	JJ	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
assess	VB	O
the	DT	O
association	NN	O
between	IN	O
maternal	JJ	O
breast-milk	NN	O
and	CC	O
fecal	JJ	O
bifidobacteria	NN	O
and	CC	O
infants	NNS	O
'	POS	O
fecal	JJ	O
bifidobacteria	NN	O
.	.	O

METHODS	NNP	O
Sixty-one	JJ	O
mother-infant	JJ	O
pairs	NNS	O
were	VBD	O
included	VBN	O
,	,	O
special	JJ	O
emphasis	NN	O
being	VBG	O
placed	VBN	O
on	IN	O
the	DT	O
maternal	JJ	O
allergic	NN	O
status	NN	O
.	.	O

Bifidobacteria	NNP	O
were	VBD	O
analysed	VBN	O
by	IN	O
a	DT	O
direct	JJ	O
PCR	NNP	O
method	NN	O
in	IN	O
fecal	JJ	O
samples	NNS	O
from	IN	O
mothers	NNS	O
at	IN	O
30-35	JJ	O
weeks	NNS	O
of	IN	O
gestation	NN	O
and	CC	O
from	IN	O
infants	NNS	O
at	IN	O
1	CD	O
month	NN	O
of	IN	O
age	NN	O
and	CC	O
from	IN	O
breast-milk	JJ	Physical
samples	NNS	Physical
1	CD	O
month	NN	O
post-partum	NN	O
.	.	O

RESULTS	NNP	O
Fecal	NNP	O
Bifidobacterium	NNP	O
adolescentis	NN	O
and	CC	O
Bifidobacterium	NNP	O
bifidum	NN	O
colonization	NN	O
frequencies	NNS	O
and	CC	O
counts	NNS	O
among	IN	O
mother-infant	JJ	O
pairs	NNS	O
correlated	VBN	O
significantly	RB	O
(	(	O
P=0.005	NNP	O
and	CC	O
0.02	CD	O
for	IN	O
frequencies	NNS	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
P=0.002	NNP	O
and	CC	O
0.01	CD	O
for	IN	O
counts	NNS	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Only	JJ	O
infants	NNS	O
of	IN	O
allergic	NN	O
,	,	O
atopic	NN	O
mothers	NNS	O
were	VBD	O
colonized	VBN	O
with	IN	O
B.	NNP	O
adolescentis	NN	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
breast-milk	NN	O
samples	NNS	O
contained	VBN	O
bifidobacteria	NNS	O
[	NNP	O
median	JJ	O
1.4	CD	O
x	JJ	O
10	CD	O
(	(	O
3	CD	O
)	)	O
bacterial	JJ	O
cells/mL	NN	O
;	:	O
interquartile	JJ	O
range	NN	O
(	(	O
IQR	NNP	O
)	)	O
48.7-3.8	CD	O
x	$	O
10	CD	O
(	(	O
3	CD	O
)	)	O
]	NN	O
.	.	O

Bifidobacterium	NNP	O
longum	NN	O
was	VBD	O
the	DT	O
most	RBS	O
frequently	RB	O
detected	VBN	O
species	NNS	O
in	IN	O
breast-milk	NN	O
.	.	O

Allergic	NNP	O
mothers	NNS	O
had	VBD	O
significantly	RB	O
lower	JJR	O
amounts	NNS	O
of	IN	O
bifidobacteria	NN	O
in	IN	O
breast-milk	NN	O
compared	VBN	O
with	IN	O
non-allergic	JJ	O
mothers	NNS	O
[	VBP	O
median	JJ	O
1.3	CD	O
x	JJ	O
10	CD	O
(	(	O
3	CD	O
)	)	O
bacterial	NN	O
cells/mL	NN	O
(	(	O
IQR	NNP	O
22.4-3.0	CD	O
x	NNP	O
10	CD	O
(	(	O
3	CD	O
)	)	O
)	)	O
vs.	FW	O
5.6	CD	O
x	$	O
10	CD	O
(	(	O
3	CD	O
)	)	O
bacterial	NN	O
cells/mL	NN	O
(	(	O
1.8	CD	O
x	RB	O
10	CD	O
(	(	O
3	CD	O
)	)	O
-1.8	NN	O
x	$	O
10	CD	O
(	(	O
4	CD	O
)	)	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
(	(	O
P=0.004	NNP	O
)	)	O
]	NN	O
,	,	O
and	CC	O
their	PRP$	O
infants	NNS	O
had	VBD	O
concurrently	RB	O
lower	JJR	O
counts	NNS	O
of	IN	O
bifidobacteria	NN	O
in	IN	O
feces	NNS	O
[	VBP	O
3.9	CD	O
x	JJ	O
10	CD	O
(	(	O
8	CD	O
)	)	O
bacterial	NN	O
cells/g	NN	O
(	(	O
IQR	NNP	O
6.5	CD	O
x	NN	O
10	CD	O
(	(	O
6	CD	O
)	)	O
-1.5	NN	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
)	)	O
in	IN	O
infants	NNS	O
of	IN	O
allergic	JJ	O
mothers	NNS	O
,	,	O
vs.	FW	O
2.5	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
bacterial	NN	O
cells/g	NN	O
(	(	O
6.5	CD	O
x	RB	O
10	CD	O
(	(	O
8	CD	O
)	)	O
-3.2	NN	O
x	$	O
10	CD	O
(	(	O
10	CD	O
)	)	O
)	)	O
in	IN	O
infants	NNS	O
of	IN	O
non-allergic	JJ	O
mothers	NNS	O
,	,	O
P=0.013	NNP	O
]	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Breast-milk	NNP	O
contains	VBZ	O
significant	JJ	O
numbers	NNS	O
of	IN	O
bifidobacteria	NN	O
and	CC	O
the	DT	O
maternal	JJ	O
allergic	NN	O
status	NN	O
further	RBR	O
deranges	VBZ	O
the	DT	O
counts	NNS	O
of	IN	O
bifidobacteria	NN	O
in	IN	O
breast-milk	NN	O
.	.	O

Maternal	NNP	O
fecal	JJ	O
and	CC	O
breast-milk	JJ	O
bifidobacterial	JJ	O
counts	NNS	O
impacted	VBN	O
on	IN	O
the	DT	O
infants	NNS	O
'	POS	O
fecal	JJ	O
Bifidobacterium	NN	O
levels	NNS	O
.	.	O

Breast-milk	NNP	O
bacteria	NN	O
should	MD	O
thus	RB	O
be	VB	O
considered	VBN	O
an	DT	O
important	JJ	O
source	NN	O
of	IN	O
bacteria	NNS	O
in	IN	O
the	DT	O
establishment	NN	O
of	IN	O
infantile	JJ	O
intestinal	JJ	O
microbiota	NN	O
.	.	O

Aminocaproic	NNP	Pharmacological
acid	VBZ	Pharmacological
versus	FW	O
prednisone	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
traumatic	JJ	O
hyphema	NN	O
.	.	O

A	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

One	CD	O
hundred	VBD	O
twelve	NN	O
patients	NNS	O
who	WP	O
sustained	VBD	O
hyphema	NN	O
after	IN	O
blunt	NN	O
trauma	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
determine	VB	O
the	DT	O
relative	JJ	O
efficacies	NNS	O
of	IN	O
aminocaproic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
Amicar	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
systemic	JJ	Pharmacological
prednisone	NN	Pharmacological
for	IN	O
reducing	VBG	O
the	DT	O
rate	NN	O
of	IN	O
secondary	JJ	O
hemorrhage	NN	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
received	VBD	O
an	DT	O
oral	JJ	O
dosage	NN	O
of	IN	O
50	CD	O
mg/kg	NN	O
of	IN	O
aminocaproic	JJ	Pharmacological
acid	NN	Pharmacological
every	DT	O
4	CD	O
hours	NNS	O
for	IN	O
5	CD	O
days	NNS	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
30	CD	O
g	JJ	O
daily	JJ	O
,	,	O
and	CC	O
56	CD	O
patients	NNS	O
received	VBD	O
an	DT	O
oral	JJ	O
dosage	NN	O
of	IN	O
40	CD	O
mg	NN	O
of	IN	O
prednisone	JJ	Pharmacological
daily	JJ	O
(	(	O
adjusted	VBN	O
for	IN	O
weight	NN	O
)	)	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
.	.	O

Placebo	NNP	Control
pills	NNS	O
and	CC	O
liquids	NNS	O
were	VBD	O
given	VBN	O
to	TO	O
each	DT	O
patient	NN	O
to	TO	O
mask	VB	O
the	DT	O
treatment	NN	O
schedules	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
patient	NN	O
populations	NNS	O
for	IN	O
any	DT	O
demographic	JJ	O
or	CC	O
clinical	JJ	O
characteristic	NN	O
(	(	O
e.g.	JJ	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
intraocular	JJ	O
pressure	NN	O
[	NNP	O
IOP	NNP	O
]	NNP	O
,	,	O
initial	JJ	O
hyphema	NN	O
size	NN	O
)	)	O
measured	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Blacks	NNS	O
comprised	VBD	O
53	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
population	NN	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
was	VBD	O
23.5	CD	O
years	NNS	O
.	.	O

Four	CD	O
patients	NNS	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
experienced	VBD	O
a	DT	O
secondary	JJ	O
hemorrhage	NN	O
;	:	O
the	DT	O
rebleed	NN	O
rate	NN	O
was	VBD	O
7.1	CD	O
%	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Hyperbaric	NNP	Pharmacological
oxygen	NN	Pharmacological
attenuation	NN	O
of	IN	O
lipopolysaccharide-induced	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
involves	VBZ	O
heme	JJ	O
oxygenase-1	NN	O
.	.	O

BACKGROUND	NNP	O
Hyperbaric	NNP	Pharmacological
oxygen	NN	Pharmacological
(	(	Pharmacological
HBO	NNP	Pharmacological
)	)	Pharmacological
attenuates	VBZ	O
lipopolysaccharide	JJ	O
(	(	O
LPS	NNP	O
)	)	O
-induced	VBD	O
acute	JJ	O
lung	NN	O
injury	NN	O
.	.	O

This	DT	O
beneficial	JJ	O
effect	NN	O
of	IN	O
HBO	NNP	O
involves	VBZ	O
inhibition	NN	O
of	IN	O
inducible	JJ	O
nitric	JJ	O
oxide	NN	O
synthase	NN	O
(	(	O
iNOS	NN	O
)	)	O
expression	NN	O
and	CC	O
subsequent	JJ	O
nitric	JJ	O
oxide	NN	O
(	(	O
NO	NNP	O
)	)	O
biosynthesis	NN	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
heme	JJ	O
oxygenase-1	JJ	O
(	(	O
HO-1	NNP	O
)	)	O
on	IN	O
this	DT	O
HBO	NNP	O
inhibition	NN	O
of	IN	O
iNOS	JJ	O
induction	NN	O
and	CC	O
acute	NN	O
lung	NN	O
injury	NN	O
in	IN	O
septic	JJ	O
rat	NN	O
lungs	NNS	O
.	.	O

METHODS	NNP	O
Before	IN	O
the	DT	O
experiment	NN	O
,	,	O
72	CD	O
rats	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
HBO	NNP	Pharmacological
or	CC	O
air	NN	Pharmacological
treatment	NN	Pharmacological
.	.	O

With	IN	O
or	CC	O
without	IN	O
HBO	NNP	Pharmacological
pre-treatment	NN	O
,	,	O
the	DT	O
rats	NNS	O
were	VBD	O
further	RB	O
divided	VBN	O
into	IN	O
the	DT	O
following	JJ	O
subgroups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
:	:	O
(	(	O
i	NN	O
)	)	O
LPS	NNP	Pharmacological
injection	NN	Pharmacological
,	,	O
(	(	O
ii	NN	O
)	)	O
normal	JJ	Control
saline	NN	Control
(	(	Control
N/S	NNP	Control
)	)	Control
injection	NN	Control
,	,	O
(	(	O
iii	NN	O
)	)	O
hemin	NN	Pharmacological
(	(	Pharmacological
a	DT	Pharmacological
HO-1	NNP	Pharmacological
inducer	NN	Pharmacological
)	)	Pharmacological
plus	CC	Pharmacological
LPS	NNP	Pharmacological
,	,	O
(	(	O
iv	NN	O
)	)	O
hemin	NN	Pharmacological
alone	RB	O
,	,	O
(	(	O
v	NN	O
)	)	O
tin	NN	Pharmacological
protoporphyrin	NN	Pharmacological
(	(	Pharmacological
SnPP	NNP	Pharmacological
;	:	Pharmacological
a	DT	Pharmacological
HO-1	NNP	Pharmacological
inhibitor	NN	Pharmacological
)	)	Pharmacological
plus	CC	Pharmacological
LPS	NNP	Pharmacological
,	,	O
and	CC	O
(	(	O
vi	NN	O
)	)	O
SnPP	NNP	Pharmacological
alone	RB	O
.	.	O

All	DT	O
rats	NNS	O
were	VBD	O
maintained	VBN	O
for	IN	O
6	CD	O
h	NN	O
and	CC	O
then	RB	O
sacrificed	VBD	O
with	IN	O
a	DT	O
high-dose	JJ	Pharmacological
pentobarbital	JJ	Pharmacological
injection	NN	Pharmacological
.	.	Pharmacological

Lung	NNP	O
injuries	NNS	O
and	CC	O
relevant	JJ	O
enzymes	NNS	O
expression	NN	O
were	VBD	O
thus	RB	O
assayed	VBN	O
.	.	O

RESULTS	NNP	O
Histological	NNP	O
analysis	NN	O
,	,	O
PMNs/alveoli	NNP	O
ratio	NN	O
,	,	O
and	CC	O
wet/dry	JJ	O
weight	NN	O
ratio	NN	O
measurements	NNS	O
demonstrated	VBD	O
that	IN	O
LPS	NNP	O
caused	VBD	O
significant	JJ	O
lung	JJ	O
injury	NN	O
and	CC	O
HBO	NNP	O
and/or	VBP	O
hemin	NN	O
significantly	RB	O
attenuated	VBD	O
this	DT	O
LPS-induced	JJ	O
lung	NN	O
injury	NN	O
.	.	O

Increased	VBD	O
pulmonary	JJ	O
iNOS	NN	O
expression	NN	O
and	CC	O
NO	DT	O
production	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
lung	JJ	O
injury	NN	O
.	.	O

Induction	NN	O
of	IN	O
HO-1	NNP	O
,	,	O
by	IN	O
HBO	NNP	O
and/or	NN	O
hemin	NN	O
,	,	O
significantly	RB	O
attenuated	VBD	O
this	DT	O
LPS-induced	JJ	O
iNOS	NN	O
expression	NN	O
and	CC	O
acute	NN	O
lung	NN	O
injury	NN	O
.	.	O

SnPP	NNP	O
,	,	O
on	IN	O
the	DT	O
contrary	JJ	O
,	,	O
offset	VB	O
the	DT	O
effects	NNS	O
of	IN	O
HBO	NNP	Pharmacological
and	CC	O
worsened	VBD	O
the	DT	O
LPS-induced	NNP	O
lung	NN	O
injury	NN	O
.	.	O

CONCLUSIONS	NNP	O
HBO	NNP	Pharmacological
may	MD	O
act	VB	O
through	IN	O
inhibiting	VBG	O
pulmonary	JJ	O
iNOS	NN	O
expression	NN	O
to	TO	O
attenuate	VB	O
LPS-induced	NNP	O
acute	NN	O
lung	NN	O
injury	NN	O
in	IN	O
septic	JJ	O
rats	NNS	O
.	.	O

Furthermore	RB	O
,	,	O
this	DT	O
HBO	NNP	Pharmacological
attenuation	NN	O
of	IN	O
iNOS	JJ	O
expression	NN	O
involves	VBZ	O
HO-1	NNP	O
induction	NN	O
.	.	O

Immunological	JJ	O
changes	NNS	O
after	IN	O
minimally	RB	Surgical
invasive	JJ	Surgical
or	CC	O
conventional	JJ	Surgical
esophageal	JJ	Surgical
resection	NN	Surgical
for	IN	O
cancer	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
This	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
a	DT	O
substudy	NN	O
analysis	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
conventional	JJ	Surgical
open	JJ	Surgical
esophagectomy	NN	Surgical
[	NNP	O
open	JJ	O
surgical	JJ	O
technique	NN	O
(	(	O
OE	NNP	O
)	)	O
]	NN	O
by	IN	O
thoracotomy	NN	Surgical
and	CC	O
laparotomy	NN	Surgical
with	IN	O
minimally	RB	Surgical
invasive	JJ	Surgical
esophagectomy	NN	Surgical
[	NNP	O
minimally	RB	O
invasive	JJ	O
procedure	NN	O
(	(	O
MIE	NNP	O
)	)	O
]	NN	O
by	IN	O
thoracoscopy	NN	Surgical
and	CC	O
laparoscopy	NN	Surgical
.	.	O

This	DT	O
additional	JJ	O
analysis	NN	O
focuses	VBZ	O
on	IN	O
the	DT	O
immunological	JJ	O
changes	NNS	O
and	CC	O
surgical	JJ	O
stress	NN	O
response	NN	O
in	IN	O
these	DT	O
two	CD	O
randomized	VBD	O
groups	NNS	O
of	IN	O
a	DT	O
single	JJ	O
center	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
a	DT	O
resectable	JJ	O
esophageal	NN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
OE	NNP	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
or	CC	O
MIE	NNP	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
neoadjuvant	JJ	Pharmacological
chemoradiotherapy	NN	Pharmacological
.	.	Pharmacological

The	DT	O
immunological	JJ	O
response	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
means	NNS	O
of	IN	O
leukocyte	NN	O
counts	NNS	O
,	,	O
HLA-DR	NNP	O
expression	NN	O
on	IN	O
monocytes	NNS	O
,	,	O
the	DT	O
acute-phase	JJ	O
response	NN	O
by	IN	O
means	NNS	O
of	IN	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
interleukin-6	JJ	O
(	(	O
IL-6	NNP	O
)	)	O
,	,	O
and	CC	O
interleukin-8	JJ	O
(	(	O
IL-8	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
stress	NN	O
response	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
cortisol	NN	O
,	,	O
growth	NN	O
hormone	NN	O
,	,	O
and	CC	O
prolactin	NN	O
.	.	O

All	DT	O
parameters	NNS	O
were	VBD	O
determined	VBN	O
at	IN	O
baseline	NN	O
(	(	O
preoperatively	RB	O
)	)	O
and	CC	O
24	CD	O
,	,	O
72	CD	O
,	,	O
96	CD	O
,	,	O
and	CC	O
168	CD	O
h	NN	O
postoperatively	RB	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
MIE	NNP	O
group	NN	O
with	IN	O
regard	NN	O
to	TO	O
leukocyte	VB	O
counts	NNS	O
,	,	O
IL-8	NNP	O
,	,	O
and	CC	O
prolactin	NN	O
at	IN	O
168	CD	O
h	NN	O
(	(	O
1	CD	O
week	NN	O
)	)	O
postoperatively	RB	O
.	.	O

For	IN	O
HLA-DR	NNP	O
expression	NN	O
,	,	O
IL-6	NNP	O
,	,	O
and	CC	O
CRP	NNP	O
levels	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
clear	JJ	O
rise	NN	O
in	IN	O
levels	NNS	O
upon	IN	O
operation	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
this	DT	O
substudy	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
minimally	RB	O
invasive	JJ	O
and	CC	O
conventional	JJ	O
open	JJ	O
esophagectomies	NNS	O
for	IN	O
cancer	NN	O
,	,	O
significantly	RB	O
better	RBR	O
preserved	VBN	O
leukocyte	JJ	O
counts	NNS	O
and	CC	O
IL-8	JJ	O
levels	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
MIE	NNP	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
open	JJ	O
group	NN	O
.	.	O

Both	DT	O
findings	NNS	O
can	MD	O
be	VB	O
related	VBN	O
to	TO	O
fewer	JJR	O
respiratory	NN	O
infections	NNS	O
found	VBD	O
postoperatively	RB	O
in	IN	O
the	DT	O
MIE	NNP	O
group	NN	O
.	.	O

Moreover	RB	O
,	,	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
prolactin	NN	O
levels	NNS	O
at	IN	O
168	CD	O
h	NN	O
after	IN	O
surgery	NN	O
imply	NN	O
that	IN	O
the	DT	O
stress	NN	O
response	NN	O
is	VBZ	O
better	RBR	O
preserved	VBN	O
in	IN	O
the	DT	O
MIE	NNP	Surgical
group	NN	O
.	.	O

These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
less	JJR	O
surgical	JJ	O
trauma	NN	O
could	MD	O
lead	VB	O
to	TO	O
better	JJR	O
preserved	VBN	O
acute-phase	NN	O
and	CC	O
stress	NN	O
responses	NNS	O
and	CC	O
fewer	JJR	O
clinical	JJ	O
manifestations	NNS	O
of	IN	O
respiratory	JJ	O
infections	NNS	O
.	.	O

Sunbathing	VBG	O
and	CC	O
sunbed	VBN	O
use	NN	O
related	VBN	O
to	TO	O
self-image	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
sample	NN	O
of	IN	O
Swedish	JJ	O
adolescents	NNS	O
.	.	O

In	IN	O
1996	CD	O
a	DT	O
randomized	JJ	O
sample	NN	O
of	IN	O
4,020	CD	O
Swedish	JJ	O
adolescents	NNS	O
from	IN	O
three	CD	O
birth	NN	O
cohorts	NNS	O
were	VBD	O
sent	VBN	O
a	DT	O
questionnaire	NN	O
consisting	NN	O
of	IN	O
50	CD	O
items	NNS	O
concerning	VBG	O
habitual	JJ	O
sun-related	JJ	O
behaviours	NNS	O
and	CC	O
attitudes	NNS	O
,	,	O
knowledge	NN	O
about	IN	O
melanoma	NN	O
,	,	O
risk	NN	O
perception	NN	O
and	CC	O
self-image	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
2,615	CD	O
questionnaires	NNS	O
were	VBD	O
returned	VBN	O
.	.	O

Girls	NNP	O
sunbathed	VBD	O
and	CC	O
used	VBD	O
sunbeds	NNS	O
more	RBR	O
than	IN	O
boys	NNS	O
at	IN	O
all	DT	O
ages	NNS	O
.	.	O

Sunbathing	VBG	O
and	CC	O
sunbed	VBN	O
use	NN	O
increased	VBN	O
with	IN	O
age	NN	O
.	.	O

Boys	NNS	O
who	WP	O
were	VBD	O
most	RBS	O
satisfied	JJ	O
and	CC	O
girls	NNS	O
least	JJS	O
satisfied	JJ	O
with	IN	O
themselves	PRP	O
sunbathed	VBD	O
most	JJS	O
.	.	O

Those	DT	O
who	WP	O
were	VBD	O
least	JJS	O
satisfied	JJ	O
with	IN	O
themselves	PRP	O
used	VBD	O
sunbeds	NNS	O
most	RBS	O
frequently	RB	O
.	.	O

Girls	NNP	O
reported	VBD	O
a	DT	O
higher	JJR	O
perceived	JJ	O
susceptibility	NN	O
to	TO	O
melanoma	VB	O
than	IN	O
did	VBD	O
boys	VB	O
.	.	O

The	DT	O
perception	NN	O
of	IN	O
susceptibility	NN	O
increased	VBN	O
with	IN	O
age	NN	O
.	.	O

Those	DT	O
who	WP	O
were	VBD	O
least	JJS	O
satisfied	JJ	O
with	IN	O
themselves	PRP	O
reported	VBD	O
feeling	VBG	O
most	RBS	O
susceptible	JJ	O
.	.	O

The	DT	O
overall	JJ	O
main	JJ	O
reason	NN	O
for	IN	O
sunbathing	NN	O
was	VBD	O
appearance	NN	O
,	,	O
both	DT	O
for	IN	O
own	JJ	O
sunbathing	NN	O
,	,	O
and	CC	O
to	TO	O
an	DT	O
even	RB	O
higher	JJR	O
degree	NN	O
,	,	O
as	IN	O
a	DT	O
supposed	JJ	O
reason	NN	O
for	IN	O
other	JJ	O
adolescents	NNS	O
'	POS	O
behaviour	NN	O
,	,	O
and	CC	O
was	VBD	O
reported	VBN	O
most	JJS	O
frequently	RB	O
by	IN	O
girls	NNS	O
and	CC	O
the	DT	O
older	JJR	O
age	NN	O
groups	NNS	O
.	.	O

The	DT	O
second	JJ	O
most	RBS	O
'important	JJ	O
'	POS	O
reason	NN	O
for	IN	O
sunbathing	NN	O
was	VBD	O
'feeling	VBG	O
warm	JJ	O
and	CC	O
comfortable	JJ	O
'	''	O
.	.	O

Preventive	JJ	O
programmes	NNS	O
aimed	VBN	O
at	IN	O
a	DT	O
change	NN	O
of	IN	O
sun	NN	O
related	VBN	O
behaviours	NNS	O
among	IN	O
Swedish	JJ	O
adolescents	NNS	O
have	VBP	O
to	TO	O
be	VB	O
tailored	VBN	O
to	TO	O
the	DT	O
climate	NN	O
and	CC	O
cultural	JJ	O
conditions	NNS	O
and	CC	O
must	MD	O
take	VB	O
into	IN	O
account	NN	O
that	IN	O
having	VBG	O
a	DT	O
tan	NN	O
,	,	O
and	CC	O
the	DT	O
warmth	NN	O
of	IN	O
the	DT	O
sun	NN	O
,	,	O
are	VBP	O
highly	RB	O
valued	VBN	O
by	IN	O
most	JJS	O
adolescents	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
Endeavor	NNP	Physical
zotarolimus-eluting	JJ	Physical
stent	NN	Physical
versus	IN	O
the	DT	O
TAXUS	NNP	Physical
paclitaxel-eluting	JJ	Physical
stent	NN	Physical
in	IN	O
de	FW	O
novo	FW	O
native	JJ	O
coronary	JJ	O
lesions	NNS	O
12-month	JJ	O
outcomes	NNS	O
from	IN	O
the	DT	O
ENDEAVOR	NNP	O
IV	NNP	O
trial	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
ENDEAVOR	NNP	O
IV	NNP	O
(	(	O
Randomized	NNP	O
Comparison	NNP	O
of	IN	O
Zotarolimus-Eluting	NNP	Physical
and	CC	O
Paclitaxel-Eluting	NNP	Physical
Stents	NNP	Physical
in	IN	O
Patients	NNP	O
with	IN	O
Coronary	NNP	O
Artery	NNP	O
Disease	NNP	O
)	)	O
trial	NN	O
evaluated	VBD	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
the	DT	O
zotarolimus-eluting	JJ	Physical
stent	NN	Physical
(	(	Physical
ZES	NNP	Physical
)	)	Physical
compared	VBN	O
with	IN	O
the	DT	O
paclitaxel-eluting	JJ	Physical
stent	NN	Physical
(	(	Physical
PES	NNP	Physical
)	)	Physical
.	.	O

BACKGROUND	NNP	O
First-generation	NNP	O
drug-eluting	NN	O
stents	NNS	O
have	VBP	O
reduced	VBN	O
angiographic	JJ	O
and	CC	O
clinical	JJ	O
restenosis	NN	O
,	,	O
but	CC	O
long-term	JJ	O
safety	NN	O
remains	VBZ	O
controversial	JJ	O
.	.	O

A	DT	O
second-generation	JJ	O
drug-eluting	JJ	O
stent	NN	O
,	,	O
which	WDT	O
delivers	VBZ	O
zotarolimus	NN	Pharmacological
,	,	O
a	DT	O
potent	JJ	O
antiproliferative	JJ	O
agent	NN	O
,	,	O
via	IN	O
a	DT	O
biocompatible	JJ	O
phosphorylcholine	NN	O
polymer	NN	O
on	IN	O
a	DT	O
cobalt	JJ	O
alloy	NN	O
thin-strut	JJ	O
stent	NN	O
has	VBZ	O
shown	VBN	O
promising	JJ	O
experimental	JJ	O
and	CC	O
early	JJ	O
clinical	JJ	O
results	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
is	VBZ	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
(	(	O
1:1	CD	O
)	)	O
,	,	O
single-blind	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
comparing	VBG	O
outcomes	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
single	JJ	O
de	FW	O
novo	FW	O
coronary	JJ	O
lesions	NNS	O
treated	VBN	O
with	IN	O
ZES	NNP	O
or	CC	O
PES	NNP	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
noninferiority	NN	O
of	IN	O
9-month	JJ	O
target	NN	O
vessel	JJ	O
failure	NN	O
defined	VBD	O
as	IN	O
cardiac	JJ	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
or	CC	O
target	VB	O
vessel	JJ	O
revascularization	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
a	DT	O
total	NN	O
of	IN	O
1,548	CD	O
patients	NNS	O
assigned	VBN	O
to	TO	O
ZES	NNP	Physical
(	(	O
n	JJ	O
=	NNP	O
773	CD	O
)	)	O
or	CC	O
PES	NNP	O
(	(	O
n	JJ	O
=	NNP	O
775	CD	O
)	)	O
,	,	O
at	IN	O
9	CD	O
months	NNS	O
,	,	O
ZES	NNP	O
was	VBD	O
noninferior	JJ	O
to	TO	O
PES	VB	O
with	IN	O
rates	NNS	O
of	IN	O
target	NN	O
vessel	JJ	O
failure	NN	O
6.6	CD	O
%	NN	O
versus	IN	O
7.1	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
p	NN	O
(	(	O
noninferiority	NN	O
)	)	O
<	NN	O
or	CC	O
=	VB	O
0.001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
fewer	JJR	O
periprocedural	JJ	O
myocardial	JJ	O
infarctions	NNS	O
with	IN	O
ZES	NNP	Physical
(	(	O
0.5	CD	O
%	NN	O
vs.	FW	O
2.2	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.007	CD	O
)	)	O
,	,	O
whereas	VBP	O
at	IN	O
12	CD	O
months	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
in	IN	O
rates	NNS	O
of	IN	O
cardiac	JJ	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
target	NN	O
vessel	NN	O
revascularization	NN	O
,	,	O
or	CC	O
stent	JJ	O
thrombosis	NN	O
.	.	O

Although	IN	O
incidence	NN	O
of	IN	O
8-month	JJ	O
binary	JJ	O
angiographic	JJ	O
in-segment	JJ	O
restenosis	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
ZES	NNP	Physical
versus	NN	O
PES	NNP	O
(	(	O
15.3	CD	O
%	NN	O
vs.	FW	O
10.4	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.284	CD	O
)	)	O
,	,	O
rates	NNS	O
of	IN	O
12-month	JJ	O
target	NN	O
lesion	NN	O
revascularization	NN	O
were	VBD	O
similar	JJ	O
(	(	O
4.5	CD	O
%	NN	O
vs.	FW	O
3.2	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.228	CD	O
)	)	O
,	,	O
especially	RB	O
in	IN	O
patients	NNS	O
without	IN	O
planned	JJ	O
angiographic	JJ	O
follow-up	NN	O
(	(	O
3.6	CD	O
%	NN	O
vs.	FW	O
3.2	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.756	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
demonstrate	VBP	O
that	IN	O
ZES	NNP	Physical
has	VBZ	O
similar	JJ	O
clinical	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
compared	VBN	O
with	IN	O
PES	NNP	Physical
in	IN	O
simple	JJ	O
and	CC	O
medium	JJ	O
complexity	NN	O
single	JJ	O
de	FW	O
novo	FW	O
coronary	JJ	O
lesions	NNS	O
.	.	O

(	(	O
ENDEAVOR	NNP	O
IV	NNP	O
Clinical	NNP	O
Trial	NNP	O
;	:	O
NCT00217269	NNP	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
H	NNP	O
reflex	NN	O
and	CC	O
V	NNP	O
wave	VBP	O
following	VBG	O
short-term	JJ	Physical
endurance	NN	Physical
and	CC	O
strength	NN	Physical
training	NN	Physical
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
3	CD	O
wk	NN	O
of	IN	O
either	DT	O
endurance	NN	Physical
or	CC	O
strength	NN	Physical
training	NN	Physical
on	IN	O
plasticity	NN	O
of	IN	O
the	DT	O
neural	JJ	O
mechanisms	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
soleus	NN	O
H	NNP	O
reflex	NN	O
and	CC	O
V	NNP	O
wave	VBP	O
.	.	O

Twenty-five	JJ	O
sedentary	JJ	O
healthy	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
an	DT	O
endurance	NN	Physical
group	NN	Physical
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
or	CC	O
strength	NN	Physical
group	NN	Physical
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
.	.	O

Evoked	VBN	O
V-wave	JJ	O
,	,	O
H-reflex	NNP	O
,	,	O
and	CC	O
M-wave	NNP	O
recruitment	NN	O
curves	NNS	O
,	,	O
maximal	JJ	O
voluntary	JJ	O
contraction	NN	O
(	(	O
MVC	NNP	O
)	)	O
,	,	O
and	CC	O
time-to-task-failure	NN	O
(	(	O
isometric	JJ	O
contraction	NN	O
at	IN	O
40	CD	O
%	NN	O
MVC	NNP	O
)	)	O
of	IN	O
the	DT	O
plantar	NN	O
flexors	NNS	O
were	VBD	O
recorded	VBN	O
before	IN	O
and	CC	O
after	IN	O
training	VBG	O
.	.	O

Following	VBG	O
strength	NN	Physical
training	NN	Physical
,	,	O
MVC	NNP	O
of	IN	O
the	DT	O
plantar	NN	O
flexors	NNS	O
increased	VBN	O
by	IN	O
14.4	CD	O
?	.	O
5.2	CD	O
%	NN	O
in	IN	O
the	DT	O
strength	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
whereas	JJ	O
time-to-task-failure	NN	O
was	VBD	O
prolonged	VBN	O
in	IN	O
the	DT	O
endurance	NN	O
group	NN	O
(	(	O
22.7	CD	O
?	.	O
17.1	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
V	NNP	O
wave-to-maximal	JJ	O
M	NNP	O
wave	NN	O
(	(	O
V/M	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
ratio	NN	O
increased	VBN	O
significantly	RB	O
(	(	O
55.1	CD	O
?	.	O
28.3	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
following	VBG	O
strength	NN	O
training	NN	O
,	,	O
but	CC	O
the	DT	O
maximal	JJ	O
H	NNP	O
wave-to-maximal	JJ	O
M	NNP	O
wave	NN	O
(	(	O
H	NNP	O
(	(	O
max	NN	O
)	)	O
/M	NN	O
(	(	O
max	NN	O
)	)	O
)	)	O
ratio	NN	O
remained	VBD	O
unchanged	JJ	O
.	.	O

Conversely	RB	O
,	,	O
in	IN	O
the	DT	O
endurance	NN	O
group	NN	O
the	DT	O
V/M	NNP	O
(	(	O
max	NN	O
)	)	O
ratio	NN	O
was	VBD	O
not	RB	O
altered	VBN	O
,	,	O
whereas	IN	O
the	DT	O
H	NNP	O
(	(	O
max	NN	O
)	)	O
/M	NN	O
(	(	O
max	NN	O
)	)	O
ratio	NN	O
increased	VBN	O
by	IN	O
30.8	CD	O
?	.	O
21.7	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
endurance	NN	Physical
training	NN	Physical
group	NN	O
also	RB	O
displayed	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
H-reflex	NNP	O
excitability	NN	O
threshold	NN	O
while	IN	O
the	DT	O
H-reflex	NNP	O
amplitude	NN	O
on	IN	O
the	DT	O
ascending	VBG	O
limb	NN	O
of	IN	O
the	DT	O
recruitment	NN	O
curve	NN	O
increased	VBD	O
.	.	O

Strength	NNP	O
training	VBG	O
only	RB	O
elicited	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
H-reflex	NNP	O
excitability	NN	O
threshold	NN	O
,	,	O
while	IN	O
H-reflex	NNP	O
amplitudes	NNS	O
over	IN	O
the	DT	O
ascending	VBG	O
limb	NN	O
remained	VBD	O
unchanged	JJ	O
.	.	O

These	DT	O
observations	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
H-reflex	NNP	O
pathway	NN	O
is	VBZ	O
strongly	RB	O
involved	VBN	O
in	IN	O
the	DT	O
enhanced	JJ	O
endurance	NN	O
resistance	NN	O
that	WDT	O
occurs	VBZ	O
following	VBG	O
endurance	NN	Physical
training	NN	Physical
.	.	O

On	IN	O
the	DT	O
contrary	JJ	O
,	,	O
the	DT	O
improvements	NNS	O
in	IN	O
MVC	NNP	O
following	VBG	O
strength	NN	O
training	NN	O
are	VBP	O
likely	JJ	O
attributed	VBN	O
to	TO	O
increased	VBN	O
descending	VBG	O
drive	NN	O
and/or	NN	O
modulation	NN	O
in	IN	O
afferents	NNS	O
other	JJ	O
than	IN	O
Ia	JJ	O
afferents	NNS	O
.	.	O

The	DT	O
aging	VBG	O
motor	NN	O
system	NN	O
as	IN	O
a	DT	O
model	NN	O
for	IN	O
plastic	JJ	O
changes	NNS	O
of	IN	O
GABA-mediated	NNP	O
intracortical	JJ	O
inhibition	NN	O
and	CC	O
their	PRP$	O
behavioral	JJ	O
relevance	NN	O
.	.	O

Since	IN	O
GABAA-mediated	JJ	O
intracortical	JJ	O
inhibition	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
underlie	VB	O
plastic	NN	O
changes	NNS	O
throughout	IN	O
the	DT	O
lifespan	NN	O
from	IN	O
development	NN	O
to	TO	O
aging	VBG	O
,	,	O
here	RB	O
,	,	O
the	DT	O
aging	VBG	O
motor	NN	O
system	NN	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
model	NN	O
to	TO	O
analyze	VB	O
the	DT	O
interdependence	NN	O
of	IN	O
plastic	JJ	O
alterations	NNS	O
within	IN	O
the	DT	O
inhibitory	JJ	O
motorcortical	JJ	O
network	NN	O
and	CC	O
level	NN	O
of	IN	O
behavioral	JJ	O
performance	NN	O
.	.	O

Double-pulse	JJ	Physical
transcranial	JJ	Physical
magnetic	JJ	Physical
stimulation	NN	Physical
(	(	Physical
dpTMS	NN	Physical
)	)	Physical
was	VBD	Physical
used	VBN	Physical
to	TO	Physical
examine	VB	Physical
inhibition	NN	Physical
by	IN	Physical
means	NNS	Physical
of	IN	Physical
short-interval	JJ	Physical
intracortical	JJ	Physical
inhibition	NN	Physical
(	(	Physical
SICI	NNP	Physical
)	)	Physical
of	IN	Physical
the	DT	Physical
contralateral	JJ	Physical
primary	JJ	Physical
motor	NN	Physical
cortex	NN	Physical
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
64	CD	O
healthy	JJ	O
right-handed	JJ	O
human	JJ	O
subjects	NNS	O
covering	VBG	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
the	DT	O
adult	NN	O
lifespan	NN	O
(	(	O
age	NN	O
range	NN	O
20-88	CD	O
years	NNS	O
,	,	O
mean	VB	O
47.6	CD	O
?	.	O
20.7	CD	O
,	,	O
34	CD	O
female	NN	O
)	)	O
.	.	O

SICI	NNP	O
was	VBD	O
evaluated	VBN	O
during	IN	O
resting	VBG	O
state	NN	O
and	CC	O
in	IN	O
an	DT	O
event-related	JJ	O
condition	NN	O
during	IN	O
movement	NN	O
preparation	NN	O
in	IN	O
a	DT	O
visually	RB	O
triggered	VBN	O
simple	JJ	O
reaction	NN	O
time	NN	O
task	NN	O
.	.	O

In	IN	O
a	DT	O
subgroup	NN	O
(	(	O
N	NNP	O
=	NNP	O
23	CD	O
)	)	O
,	,	O
manual	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
tested	VBN	O
with	IN	O
tasks	NNS	O
of	IN	O
graded	VBN	O
dexterous	JJ	O
demand	NN	O
.	.	O

Weak	JJ	O
resting-state	JJ	O
inhibition	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
overall	JJ	O
lower	JJR	O
manual	JJ	O
motor	NN	O
performance	NN	O
.	.	O

Better	RBR	O
event-related	JJ	O
modulation	NN	O
of	IN	O
inhibition	NN	O
correlated	VBN	O
with	IN	O
better	JJR	O
performance	NN	O
in	IN	O
more	RBR	O
demanding	JJ	O
tasks	NNS	O
,	,	O
in	IN	O
which	WDT	O
fast	RB	O
alternating	VBG	O
activation	NN	O
of	IN	O
cortical	JJ	O
representations	NNS	O
are	VBP	O
necessary	JJ	O
.	.	O

Declining	VBG	O
resting-state	JJ	O
inhibition	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
weakened	JJ	O
event-related	JJ	O
modulation	NN	O
of	IN	O
inhibition	NN	O
.	.	O

Therefore	NN	O
,	,	O
reduced	VBD	O
resting-state	JJ	O
inhibition	NN	O
might	MD	O
lead	VB	O
to	TO	O
a	DT	O
subsequent	JJ	O
loss	NN	O
of	IN	O
modulatory	JJ	O
capacity	NN	O
,	,	O
possibly	RB	O
reflecting	VBG	O
malfunctioning	VBG	O
precision	NN	O
in	IN	O
GABAAergic	NNP	O
neurotransmission	NN	O
;	:	O
the	DT	O
consequence	NN	O
is	VBZ	O
an	DT	O
inevitable	JJ	O
decline	NN	O
in	IN	O
motor	NN	O
function	NN	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
liu	NN	Pharmacological
wei	NN	Pharmacological
di	NN	Pharmacological
huang	NN	Pharmacological
or	CC	O
jin	NN	Pharmacological
gui	NN	Pharmacological
shen	NN	Pharmacological
qi	JJ	Pharmacological
decoction	NN	Pharmacological
as	IN	O
on	IN	O
adjuvant	JJ	O
treatment	NN	O
in	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
]	NNP	O
.	.	O

Eighty-three	JJ	O
patients	NNS	O
with	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
with	IN	O
or	CC	O
without	IN	O
using	VBG	O
a	DT	O
traditional	JJ	Pharmacological
Chinese	JJ	Pharmacological
Kidney-tonifying	NNP	Pharmacological
decoction	NN	Pharmacological
(	(	O
Liu	NNP	Pharmacological
Wei	NNP	Pharmacological
Di	NNP	Pharmacological
Huang	NNP	Pharmacological
or	CC	O
Jin	NNP	Pharmacological
Gui	NNP	Pharmacological
Shen	NNP	Pharmacological
Qi	NNP	Pharmacological
medicinal	JJ	Pharmacological
decoction	NN	Pharmacological
)	)	O
in	IN	O
chemotherapy	NN	O
or	CC	O
radiotherapy	NN	O
courses	NNS	O
.	.	O

74	CD	O
patients	NNS	O
were	VBD	O
availble	JJ	O
to	TO	O
be	VB	O
analysis	NN	O
.	.	O

The	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
well-matched	JJ	O
in	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
stage	NN	O
and	CC	O
performance	NN	O
status	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	O
rate	NN	O
and	CC	O
the	DT	O
median	JJ	O
survival	NN	O
between	IN	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
(	(	O
CR+PR	NNP	O
)	)	O
was	VBD	O
91.5	CD	O
%	NN	O
for	IN	O
Chinese	JJ	Pharmacological
herb	NN	Pharmacological
group	NN	O
and	CC	O
46.9	CD	O
%	NN	O
for	IN	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
16	CD	O
months	NNS	O
for	IN	O
the	DT	O
traditional	JJ	O
Chinese	JJ	Pharmacological
Kidney-tonifying	NNP	Pharmacological
decoction	NN	Pharmacological
group	NN	O
,	,	O
and	CC	O
10	CD	O
months	NNS	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Survival	JJ	O
curve	NN	O
(	(	O
Kaplan-meire	NNP	O
's	POS	O
)	)	O
of	IN	O
the	DT	O
Chinese	NNP	O
herb	NN	O
group	NN	O
was	VBD	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

10	CD	O
patients	NNS	O
of	IN	O
Chinese	JJ	Pharmacological
herb	NN	Pharmacological
group	NN	O
was	VBD	O
alive	JJ	O
beyond	IN	O
more	JJR	O
than	IN	O
2	CD	O
years	NNS	O
.	.	O

Until	IN	O
now	RB	O
,	,	O
4	CD	O
patients	NNS	O
in	IN	O
the	DT	O
Chinese	JJ	Pharmacological
herb	NN	Pharmacological
group	NN	O
,	,	O
one	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
are	VBP	O
still	RB	O
enjoying	VBG	O
their	PRP$	O
disease-free	JJ	O
life	NN	O
for	IN	O
more	JJR	O
than	IN	O
7	CD	O
years	NNS	O
.	.	O

Hematologic	NNP	O
toxicities	NNS	O
were	VBD	O
observed	VBN	O
much	RB	O
frequently	RB	O
in	IN	O
the	DT	O
patients	NNS	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.005	CD	O
and	CC	O
0.01/WBC	CD	O
and	CC	O
BPC	NNP	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
animal	JJ	O
experiments	NNS	O
with	IN	O
the	DT	O
same	JJ	O
traditional	JJ	O
medicinal	JJ	O
decoctions	NNS	O
as	IN	O
used	VBN	O
in	IN	O
clinic	NN	O
have	VBP	O
showed	VBN	O
immuno-enhancement	JJ	O
activities	NNS	O
.	.	O

These	DT	O
results	NNS	O
have	VBP	O
showed	VBN	O
that	IN	O
the	DT	O
traditional	JJ	Pharmacological
Chinese	JJ	Pharmacological
Kidney-tonifying	NNP	Pharmacological
decoction	NN	Pharmacological
may	MD	O
enhance	VB	O
non-specific	JJ	O
immunology	NN	O
activities	NNS	O
and	CC	O
may	MD	O
be	VB	O
much	JJ	O
useful	JJ	O
for	IN	O
solid	JJ	O
cancer	NN	O
patients	NNS	O
as	IN	O
an	DT	O
adjuvant	JJ	O
treatment	NN	O
.	.	O

[	JJ	O
Radiotherapy	NNP	Surgical
of	IN	O
malignant	JJ	O
brain	NN	O
gliomas	NN	O
using	VBG	O
teniposide	JJ	Pharmacological
]	NNP	O
.	.	O

Efficacy	NN	O
of	IN	O
radiochemotherapy	NN	Pharmacological
of	IN	O
malignantly-converted	JJ	O
brain	NN	O
gliomas	NN	O
using	VBG	O
teniposide	NN	Pharmacological
was	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

Combined	VBN	O
use	NN	O
of	IN	O
cytostatics	NNS	Pharmacological
and	CC	O
irradiation	NN	Surgical
appeared	VBD	O
safe	JJ	O
,	,	O
tolerable	JJ	O
and	CC	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
radiotherapy	RB	Surgical
alone	RB	O
as	IN	O
assessed	VBN	O
by	IN	O
local	JJ	O
control	NN	O
of	IN	O
tumor	NN	O
and	CC	O
survival	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
dietary	JJ	Pharmacological
fibre	NN	Pharmacological
source	NN	Pharmacological
and	CC	O
gender	NN	O
on	IN	O
the	DT	O
postprandial	JJ	O
glucose	NN	O
and	CC	O
lipid	JJ	O
response	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

BACKGROUND	NNP	O
Consumption	NNP	O
of	IN	O
soluble	JJ	Pharmacological
dietary	JJ	Pharmacological
fibre	NN	Pharmacological
is	VBZ	O
correlated	VBN	O
with	IN	O
decreased	JJ	O
postprandial	JJ	O
glucose	NN	O
and	CC	O
insulin	NN	O
responses	NNS	O
and	CC	O
hence	NN	O
has	VBZ	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

AIM	NNP	O
OF	IN	O
THE	NNP	O
STUDY	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
on	IN	O
postprandial	JJ	O
glucose	NN	O
,	,	O
insulin	NN	O
and	CC	O
triglyceride	JJ	O
concentrations	NNS	O
of	IN	O
meals	NNS	O
enriched	VBN	O
with	IN	O
soluble	JJ	O
dietary	JJ	O
fibres	NNS	O
from	IN	O
oats	NNS	O
,	,	O
rye	NN	O
bran	NN	O
,	,	O
sugar	JJ	O
beet	NN	O
fibre	NN	O
or	CC	O
a	DT	O
mixture	NN	O
of	IN	O
these	DT	O
three	CD	O
fibres	NNS	O
.	.	O

METHODS	NNP	O
Thirteen	NNP	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
(	(	O
6	CD	O
men	NNS	O
and	CC	O
7	CD	O
women	NNS	O
,	,	O
aged	VBN	O
20-28	CD	O
years	NNS	O
)	)	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
subjects	NNS	O
came	VBD	O
to	TO	O
the	DT	O
study	NN	O
centre	NN	O
once	RB	O
a	DT	O
week	NN	O
after	IN	O
an	DT	O
overnight	JJ	O
fast	NN	O
to	TO	O
ingest	VB	O
test	NN	O
meals	NNS	Pharmacological
and	CC	O
a	DT	O
control	NN	O
meal	NN	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

The	DT	O
meals	NNS	O
contained	VBD	O
either	CC	O
oat	JJ	Pharmacological
powder	NN	Pharmacological
(	(	O
62	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
2.7	CD	O
soluble	JJ	O
fibre	NN	O
)	)	O
,	,	O
rye	NN	Pharmacological
bran	NN	Pharmacological
(	(	O
31	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
1.7	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
)	)	O
,	,	O
sugar	JJ	Pharmacological
beet	NN	Pharmacological
fibre	NN	Pharmacological
(	(	O
19	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
5	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
)	)	O
,	,	O
a	DT	O
mixture	NN	Other
of	IN	O
these	DT	O
three	CD	O
fibres	NNS	O
(	(	O
74	CD	O
g	NN	O
,	,	O
of	IN	O
which	WDT	O
1.7	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
from	IN	O
each	DT	O
source	NN	O
,	,	O
giving	VBG	O
5	CD	O
g	NN	O
soluble	JJ	O
fibre	NN	O
)	)	O
or	CC	O
no	DT	O
added	JJ	Control
fibre	NN	Control
(	(	Control
control	NN	Control
)	)	Control
and	CC	O
were	VBD	O
all	DT	O
adjusted	VBN	O
to	TO	O
contain	VB	O
the	DT	O
same	JJ	O
total	JJ	O
amount	NN	O
of	IN	O
available	JJ	O
carbohydrates	NNS	Other
.	.	Other

Blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
before	RB	O
and	CC	O
every	DT	O
30	CD	O
min	NN	O
up	RB	O
to	TO	O
180	CD	O
min	NN	O
after	IN	O
the	DT	O
meals	NNS	O
.	.	O

RESULTS	NNP	O
Meals	NNP	Pharmacological
with	IN	Pharmacological
rye	NN	Pharmacological
bran	NN	Pharmacological
gave	VBD	O
a	DT	O
lower	JJR	O
postprandial	JJ	O
glucose	NN	O
peak	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
meal	NN	O
,	,	O
and	CC	O
this	DT	O
effect	NN	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
women	NNS	O
compared	VBN	O
to	TO	O
men	NNS	O
.	.	O

Oat	NNP	Pharmacological
powder	NN	Pharmacological
,	,	O
containing	VBG	O
a	DT	O
low	JJ	O
amount	NN	O
of	IN	O
total	JJ	O
fibre	NN	O
and	CC	O
a	DT	O
high	JJ	O
amount	NN	O
of	IN	O
carbohydrates	NNS	O
in	IN	O
liquid	NN	O
matrix	NN	O
,	,	O
gave	VBD	O
a	DT	O
higher	JJR	O
incremental	JJ	O
glucose	JJ	O
peak	NN	O
concentration	NN	O
compared	VBN	O
to	TO	O
rye	VB	O
bran	NN	O
and	CC	O
sugar	NN	O
beet	NN	O
fibre	NN	O
and	CC	O
higher	JJR	O
insulin	NN	O
incremental	JJ	O
area	NN	O
under	IN	O
curve	NN	O
compared	VBN	O
to	TO	O
control	VB	O
.	.	O

The	DT	O
oat	NN	Pharmacological
powder	NN	Pharmacological
also	RB	O
influenced	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
mixed	JJ	O
meal	NN	O
,	,	O
diminishing	VBG	O
the	DT	O
glucose-lowering	JJ	O
effects	NNS	O
.	.	O

Postprandial	NNP	O
triglyceride	NN	O
levels	NNS	O
tended	VBD	O
to	TO	O
be	VB	O
higher	JJR	O
after	IN	O
all	DT	O
fibre-rich	JJ	O
meals	NNS	O
,	,	O
but	CC	O
only	RB	O
significant	JJ	O
for	IN	O
oat	NN	O
powder	NN	O
and	CC	O
the	DT	O
mixed	JJ	O
meal	NN	Pharmacological
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
meal	NN	Control
.	.	Pharmacological

CONCLUSIONS	NNP	O
Postprandial	NNP	O
glucose	NN	O
,	,	O
insulin	NN	O
and	CC	O
triglyceride	JJ	O
concentrations	NNS	O
are	VBP	O
influenced	VBN	O
by	IN	O
dietary	JJ	Pharmacological
fibre-rich	JJ	Pharmacological
meals	NNS	Pharmacological
,	,	O
depending	VBG	O
on	IN	O
fibre	NN	O
source	NN	O
,	,	O
dose	NN	O
of	IN	O
soluble	JJ	O
and	CC	O
total	JJ	O
fibre	NN	O
and	CC	O
possibly	RB	O
gender	NN	O
.	.	O

Mechanisms	NNP	O
underlying	VBG	O
the	DT	O
lack	NN	O
of	IN	O
effect	NN	O
of	IN	O
implantable	JJ	Surgical
cardioverter-defibrillator	JJ	Surgical
therapy	NN	Surgical
on	IN	O
mortality	NN	O
in	IN	O
high-risk	JJ	O
patients	NNS	O
with	IN	O
recent	JJ	O
myocardial	JJ	O
infarction	NN	O
:	:	O
insights	NNS	O
from	IN	O
the	DT	O
Defibrillation	NNP	O
in	IN	O
Acute	NNP	O
Myocardial	NNP	O
Infarction	NNP	O
Trial	NNP	O
(	(	O
DINAMIT	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
although	IN	O
implantable	JJ	Surgical
cardioverter-defibrillators	NNS	Surgical
(	(	O
ICDs	NNP	O
)	)	O
lower	JJR	O
mortality	NN	O
in	IN	O
stable	JJ	O
patients	NNS	O
with	IN	O
low	JJ	O
ejection	NN	O
fraction	NN	O
late	RB	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
randomized	VBN	O
trials	NNS	O
of	IN	O
ICD	NNP	Surgical
versus	FW	O
control	NN	O
subjects	NNS	O
implanted	VBD	O
early	RB	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
do	VBP	O
not	RB	O
show	VB	O
mortality	NN	O
benefit	NN	O
.	.	O

Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
possible	JJ	O
mechanisms	NNS	O
underlying	VBG	O
the	DT	O
lack	NN	O
of	IN	O
mortality	NN	O
benefit	NN	O
in	IN	O
the	DT	O
Defibrillation	NNP	O
in	IN	O
Acute	NNP	O
Myocardial	NNP	O
Infarction	NNP	O
Trial	NNP	O
(	(	O
DINAMIT	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
this	DT	O
is	VBZ	O
a	DT	O
secondary	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
prospective	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Outpatients	NNS	O
with	IN	O
recent	JJ	O
(	(	O
6	CD	O
to	TO	O
40	CD	O
days	NNS	O
)	)	O
acute	VBP	O
myocardial	JJ	O
infarction	NN	O
,	,	O
left	VBD	O
ventricular	JJ	O
dysfunction	NN	O
(	(	O
ejection	JJ	O
fraction	NN	O
<	VBD	O
35	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
low	JJ	O
heart	NN	O
rate	NN	O
variability	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
ICD	NNP	Surgical
(	(	O
n=311	NN	O
)	)	O
or	CC	O
to	TO	O
standard	VB	Control
medical	JJ	Control
therapy	NN	Control
(	(	O
n=342	JJ	O
)	)	O
.	.	O

In	IN	O
a	DT	O
competing-risks	JJ	O
analysis	NN	O
,	,	O
those	DT	O
factors	NNS	O
that	WDT	O
increased	VBD	O
the	DT	O
risk	NN	O
of	IN	O
arrhythmic	JJ	O
death	NN	O
also	RB	O
increased	VBD	O
the	DT	O
risk	NN	O
of	IN	O
nonarrhythmic	JJ	O
deaths	NNS	O
.	.	O

After	IN	O
adjustment	NN	O
for	IN	O
these	DT	O
factors	NNS	O
,	,	O
receiving	VBG	O
an	DT	O
ICD	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decreased	JJ	O
risk	NN	O
of	IN	O
arrhythmic	JJ	O
death	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.15	CD	O
to	TO	O
0.71	CD	O
)	)	O
but	CC	O
an	DT	O
increase	NN	O
in	IN	O
nonarrhythmic	JJ	O
death	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
1.70	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.00	CD	O
to	TO	O
2.80	CD	O
)	)	O
.	.	O

In	IN	O
an	DT	O
adjusted	JJ	O
time-dependent	JJ	O
analysis	NN	O
,	,	O
patients	NNS	O
receiving	VBG	O
an	DT	O
ICD	NNP	O
and	CC	O
having	VBG	O
appropriate	JJ	O
ICD	NNP	O
therapy	NN	O
had	VBD	O
a	DT	O
15.1	CD	O
%	NN	O
yearly	RB	O
hazard	NN	O
of	IN	O
mortality	NN	O
compared	VBN	O
with	IN	O
5.2	CD	O
%	NN	O
in	IN	O
ICD	NNP	O
patients	NNS	O
with	IN	O
no	DT	O
appropriate	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
reduction	NN	O
in	IN	O
sudden	JJ	O
death	NN	O
in	IN	O
ICD	NNP	O
patients	NNS	O
was	VBD	O
completely	RB	O
offset	VBN	O
by	IN	O
increased	JJ	O
nonarrhythmic	JJ	O
deaths	NNS	O
,	,	O
which	WDT	O
were	VBD	O
greatest	JJS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
ICD	NNP	O
shock	NN	O
therapy	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
6.0	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
2.8	CD	O
to	TO	O
12.7	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
in	IN	O
patients	NNS	O
receiving	VBG	O
ICDs	NNP	O
early	RB	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
those	DT	O
factors	NNS	O
that	WDT	O
are	VBP	O
associated	VBN	O
with	IN	O
arrhythmia	NN	O
requiring	VBG	O
ICD	NNP	O
therapy	NN	O
are	VBP	O
also	RB	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
risk	NN	O
of	IN	O
nonsudden	JJ	O
death	NN	O
,	,	O
negating	VBG	O
the	DT	O
benefit	NN	O
of	IN	O
ICDs	NNP	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
gonadotropin-releasing	NN	Pharmacological
hormone	NN	Pharmacological
analog	NN	Pharmacological
(	(	Pharmacological
Diphereline	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
Cabergoline	NNP	Pharmacological
(	(	Pharmacological
Dostinex	NNP	Pharmacological
)	)	Pharmacological
treatment	NN	O
on	IN	O
uterine	JJ	O
myoma	NN	O
regression	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
cabergoline	NN	Pharmacological
(	(	Pharmacological
Dostinex	NNP	Pharmacological
,	,	Pharmacological
a	DT	Pharmacological
dopamine	JJ	Pharmacological
agonist	NN	Pharmacological
)	)	Pharmacological
on	IN	O
the	DT	O
myoma	NN	O
growth	NN	O
compared	VBN	O
to	TO	O
Diphereline	NNP	Pharmacological
(	(	Pharmacological
a	DT	Pharmacological
gonadotropin-releasing	NN	Pharmacological
hormone	NN	Pharmacological
agonist	NN	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

METHODS	NNP	O
This	DT	O
study	NN	O
took	VBD	O
place	NN	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Obstetrics	NNP	O
and	CC	O
Gynecology	NNP	O
of	IN	O
Tabriz	NNP	O
University	NNP	O
of	IN	O
Medical	NNP	O
Sciences	NNPS	O
,	,	O
Tabriz	NNP	O
,	,	O
Iran	NNP	O
from	IN	O
July	NNP	O
2004	CD	O
to	TO	O
December	NNP	O
2005	CD	O
.	.	O

Fifty	NNP	O
women	NNS	O
with	IN	O
uterine	JJ	O
myoma	NN	O
,	,	O
who	WP	O
met	VBD	O
the	DT	O
criteria	NNS	O
of	IN	O
the	DT	O
study	NN	O
thoroughly	RB	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
into	IN	O
2	CD	O
equal	JJ	O
groups	NNS	O
to	TO	O
take	VB	O
either	DT	O
Diphereline	NNP	Pharmacological
or	CC	O
Cabergoline	NNP	Pharmacological
.	.	Pharmacological

The	DT	O
first	JJ	O
Group	NNP	O
took	VBD	O
3.75	CD	O
mg	NN	O
of	IN	O
Diphereline	NNP	Pharmacological
4	CD	O
times	NNS	O
every	DT	O
28	CD	O
days	NNS	O
and	CC	O
the	DT	O
second	JJ	O
group	NN	O
took	VBD	O
0.5	CD	O
mg	NN	O
of	IN	O
Cabergoline	NNP	Pharmacological
once	RB	O
a	DT	O
week	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
Cabergoline	NNP	Pharmacological
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
fewer	JJR	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
noted	VBN	O
.	.	O

The	DT	O
tumor	NN	O
regressed	VBD	O
significantly	RB	O
and	CC	O
volume	NN	O
reduction	NN	O
rate	NN	O
of	IN	O
individual	JJ	O
tumor	NN	O
nodule	NN	O
varied	VBD	O
from	IN	O
46-53	CD	O
%	NN	O
.	.	O

The	DT	O
gonadotropin	NN	Pharmacological
releasing	VBG	Pharmacological
hormone	JJ	Pharmacological
agonist	NN	Pharmacological
group	NN	O
all	DT	O
responded	VBD	O
to	TO	O
the	DT	O
treatment	NN	O
,	,	O
and	CC	O
volume	NN	O
reduction	NN	O
rate	NN	O
of	IN	O
the	DT	O
individual	JJ	O
tumor	NN	O
nodule	NN	O
varied	VBD	O
from	IN	O
21-97	CD	O
%	NN	O
.	.	O

The	DT	O
extent	NN	O
of	IN	O
tumor	NN	O
shrinkage	NN	O
was	VBD	O
positively	RB	O
correlated	VBN	O
to	TO	O
the	DT	O
number	NN	O
of	IN	O
nodules	NNS	O
(	(	O
p=0.881	NN	O
,	,	O
p	NN	O
<	VBD	O
0.005	CD	O
and	CC	O
0.701	CD	O
,	,	O
p	NN	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
light	NN	O
of	IN	O
therapeutic	JJ	O
efficacy	NN	O
and	CC	O
few	JJ	O
adverse	JJ	O
effects	NNS	O
,	,	O
the	DT	O
dopamine	NN	Pharmacological
agonists	NNS	Pharmacological
may	MD	O
hold	VB	O
promise	NN	O
as	IN	O
novel	JJ	O
treatment	NN	O
modalities	NNS	O
for	IN	O
leiomyoma	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
strategy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
leiomyoma	NN	O
through	IN	O
these	DT	O
agents	NNS	O
.	.	O

Motion	NNP	Physical
style	NN	Physical
acupuncture	NN	Physical
treatment	NN	Physical
(	(	Physical
MSAT	NNP	Physical
)	)	Physical
for	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
with	IN	O
severe	JJ	O
disability	NN	O
:	:	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
protocol	NN	O
.	.	O

BACKGROUND	NNP	O
Acupuncture	NNP	O
is	VBZ	O
widely-used	JJ	O
to	TO	O
treat	VB	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
,	,	O
despite	IN	O
insufficient	JJ	O
evidence	NN	O
of	IN	O
the	DT	O
technique	NN	O
's	POS	O
efficacy	NN	O
for	IN	O
acute	NN	O
back	RB	O
pain	NN	O
.	.	O

Motion	NNP	Physical
style	NN	Physical
acupuncture	NN	Physical
treatment	NN	Physical
(	(	Physical
MSAT	NNP	Physical
)	)	Physical
is	VBZ	O
a	DT	O
non-traditional	JJ	O
acupuncture	NN	O
treatment	NN	O
requiring	VBG	O
a	DT	O
patient	NN	O
to	TO	O
exercise	VB	O
while	IN	O
receiving	VBG	O
acupuncture	NN	O
.	.	O

In	IN	O
Korea	NNP	O
,	,	O
MSAT	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
reduce	VB	O
musculoskeletal	JJ	O
pain	NN	O
and	CC	O
improve	VB	O
functional	JJ	O
status	NN	O
.	.	O

The	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
MSAT	NNP	O
on	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
with	IN	O
severe	JJ	O
disability	NN	O
.	.	O

METHODS/DESIGN	NNP	O
This	DT	O
study	NN	O
is	VBZ	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
active-controlled	JJ	O
trial	NN	O
with	IN	O
two	CD	O
parallel	JJ	O
arms	NNS	O
.	.	O

Participants	NNS	O
with	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
and	CC	O
severe	JJ	O
functional	JJ	O
disability	NN	O
,	,	O
defined	VBD	O
as	IN	O
an	DT	O
Oswestry	NNP	O
Disability	NNP	O
Index	NNP	O
(	(	O
ODI	NNP	O
)	)	O
value	NN	O
>	$	O
60	CD	O
%	NN	O
,	,	O
will	MD	O
be	VB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
acupuncture	NN	Physical
group	NN	O
and	CC	O
the	DT	O
nonsteroidal	JJ	Pharmacological
anti-inflammatory	JJ	Pharmacological
drug	NN	Pharmacological
(	(	Pharmacological
NSAID	NNP	Pharmacological
)	)	Pharmacological
injection	NN	Pharmacological
group	NN	Pharmacological
.	.	O

The	DT	O
acupuncture	NN	O
group	NN	O
will	MD	O
receive	VB	O
MSAT	NNP	Physical
and	CC	O
the	DT	O
NSAID	NNP	Pharmacological
injection	NN	Pharmacological
group	NN	Pharmacological
will	MD	O
receive	VB	O
an	DT	O
intramuscular	JJ	O
injection	NN	O
of	IN	O
diclofenac	NN	Pharmacological
.	.	Pharmacological

All	DT	O
procedures	NNS	O
will	MD	O
be	VB	O
limited	VBN	O
to	TO	O
one	CD	O
session	NN	O
and	CC	O
the	DT	O
symptoms	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
will	MD	O
be	VB	O
measured	VBN	O
by	IN	O
assessors	NNS	O
blinded	VBD	O
to	TO	O
treatment	NN	O
allocation	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
will	MD	O
be	VB	O
measured	VBN	O
at	IN	O
30	CD	O
minutes	NNS	O
after	IN	O
treatment	NN	O
using	VBG	O
the	DT	O
numerical	JJ	O
rating	NN	O
scale	NN	O
(	(	O
NRS	NNP	O
)	)	O
of	IN	O
low	JJ	O
back	RB	O
pain	NN	O
while	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
moving	VBG	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
will	MD	O
be	VB	O
measured	VBN	O
at	IN	O
30	CD	O
minutes	NNS	O
after	IN	O
treatment	NN	O
using	VBG	O
the	DT	O
NRS	NNP	O
of	IN	O
leg	NN	O
pain	NN	O
,	,	O
ODI	NNP	O
,	,	O
patient	NN	O
global	JJ	O
impression	NN	O
of	IN	O
change	NN	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
of	IN	O
the	DT	O
lumbar	NN	O
spine	NN	O
,	,	O
and	CC	O
degrees	NNS	O
of	IN	O
straight	JJ	O
leg	NN	O
raising	VBG	O
(	(	O
SLR	NNP	O
)	)	O
.	.	O

Post-treatment	JJ	O
follow-up	NN	O
will	MD	O
be	VB	O
performed	VBN	O
to	TO	O
measure	VB	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
ROM	NNP	O
and	CC	O
SLR	NNP	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
24	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
.	.	O

DISCUSSION	NNP	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
trial	NN	O
will	MD	O
be	VB	O
discussed	VBN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrial.gov	NNP	O
NCT01315561	NNP	O
.	.	O

Epirubicin	NNP	Pharmacological
and	CC	O
cyclophosphamide	VB	Pharmacological
versus	NN	O
epirubicin	NN	Pharmacological
and	CC	O
docetaxel	NN	Pharmacological
as	IN	O
first-line	JJ	O
therapy	NN	O
for	IN	O
women	NNS	O
with	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomised	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
This	DT	O
randomised	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
epirubicin	NN	Pharmacological
and	CC	O
cyclophosphamide	NN	Pharmacological
(	(	Pharmacological
EC	NNP	Pharmacological
)	)	Pharmacological
with	IN	O
epirubicin	NN	Pharmacological
and	CC	O
docetaxel	NN	Pharmacological
(	(	Pharmacological
Taxotere	NNP	Pharmacological
)	)	Pharmacological
(	(	Pharmacological
ED	NNP	Pharmacological
)	)	Pharmacological
as	IN	O
first-line	JJ	O
chemotherapy	NN	O
for	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNP	O
(	(	O
n	JJ	O
=	NNP	O
240	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
ED	NNP	Pharmacological
(	(	Pharmacological
epirubicin	JJ	Pharmacological
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
and	CC	O
docetaxel	$	Pharmacological
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
or	CC	O
EC	NNP	Pharmacological
(	(	Pharmacological
epirubicin	VBP	Pharmacological
90	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
and	CC	O
cyclophosphamide	$	Pharmacological
600	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
objective	JJ	O
response	NN	O
rate	NN	O
(	(	O
ORR	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
,	,	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
,	,	O
and	CC	O
safety	NN	O
.	.	O

RESULTS	NNP	O
ORR	NNP	O
for	IN	O
patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
EC	NNP	Pharmacological
and	CC	O
ED	NNP	Pharmacological
were	VBD	O
42	CD	O
%	NN	O
and	CC	O
47	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.63	CD	O
)	)	O
.	.	O

Median	JJ	O
PFS	NNP	O
[	NNP	O
10.1	CD	O
versus	NN	O
10.3	CD	O
months	NNS	O
;	:	O
hazard	VBN	O
ratio	NN	O
(	(	O
HR	NNP	O
)	)	O
0.98	CD	O
;	:	O
log-rank	JJ	O
P	NNP	O
=	NNP	O
0.38	CD	O
]	NN	O
and	CC	O
OS	NNP	O
(	(	O
19.9	CD	O
versus	NN	O
30.0	CD	O
months	NNS	O
;	:	O
HR	NNP	O
0.663	CD	O
;	:	O
log-rank	JJ	O
P	NNP	O
=	NNP	O
0.21	CD	O
)	)	O
were	VBD	O
comparable	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

Although	IN	O
grade	JJ	O
3/4	CD	O
leucopenia	NN	O
occurred	VBD	O
more	RBR	O
frequently	RB	O
with	IN	O
ED	NNP	Pharmacological
(	(	O
81	CD	O
%	NN	O
versus	IN	O
73	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
febrile	JJ	O
neutropenia	NN	O
and	CC	O
grade	VBD	O
3/4	CD	O
infections	NNS	O
.	.	O

Grade	VB	O
3/4	CD	O
non-haematologic	JJ	O
toxicity	NN	O
was	VBD	O
infrequent	JJ	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

Congestive	JJ	O
heart	NN	O
failure	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
one	CD	O
patient	NN	O
in	IN	O
each	DT	O
arm	NN	O
.	.	O

CONCLUSION	NN	O
In	IN	O
this	DT	O
randomised	JJ	O
trial	NN	O
,	,	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
efficacy	NN	O
study	VBD	O
end	JJ	O
points	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
arms	NNS	O
.	.	O

Comparative	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
twice	JJ	O
daily	JJ	O
fluticasone	NN	Pharmacological
propionate	NN	Pharmacological
powder	NN	Pharmacological
versus	NN	O
placebo	NN	Control
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
asthma	NN	O
.	.	O

BACKGROUND	NNP	O
Fluticasone	NNP	Pharmacological
propionate	NN	Pharmacological
,	,	O
an	DT	O
inhaled	JJ	O
corticosteroid	NN	O
with	IN	O
negligible	JJ	O
systemic	JJ	O
bioavailability	NN	O
via	IN	O
the	DT	O
oral	JJ	O
route	NN	O
,	,	O
is	VBZ	O
efficacious	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
asthma	NN	O
when	WRB	O
administered	VBN	O
via	IN	O
metered-dose	JJ	O
inhaler	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
inhaled	JJ	Pharmacological
fluticasone	NN	Pharmacological
propionate	NN	Pharmacological
powder	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
asthma	NNS	O
previously	RB	O
treated	VBN	O
with	IN	O
an	DT	O
inhaled	JJ	O
corticosteroid	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel-group	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
of	IN	O
342	CD	O
adolescent	NN	O
and	CC	O
adult	NN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
asthma	NNS	O
[	RB	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
second	JJ	O
(	(	O
FEV1	NNP	O
)	)	O
between	IN	O
50	CD	O
%	NN	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
predicted	JJ	O
]	NNP	O
treated	VBD	O
previously	RB	O
by	IN	O
beclomethasone	NN	Pharmacological
dipropionate	NN	Pharmacological
or	CC	O
triamcinolone	NN	Pharmacological
acetonide	RB	Pharmacological
.	.	Pharmacological

Patients	NNS	O
received	VBD	O
fluticasone	JJ	Pharmacological
propionate	NN	Pharmacological
powder	NN	Pharmacological
50	CD	O
micrograms	NNS	O
,	,	O
100	CD	O
micrograms	NNS	O
,	,	O
250	CD	O
micrograms	NNS	O
,	,	O
or	CC	O
placebo	NN	Control
via	IN	O
a	DT	O
breath-actuated	JJ	O
inhalation	NN	O
device	NN	O
,	,	O
the	DT	O
Diskhaler	NNP	O
,	,	O
twice	RB	O
daily	RB	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
in	IN	O
the	DT	O
fluticasone	NN	O
propionate	NN	O
groups	NNS	O
experienced	VBD	O
a	DT	O
mean	JJ	O
increase	NN	O
from	IN	O
baseline	NN	O
to	TO	O
endpoint	VB	O
in	IN	O
FEV1	NNP	O
ranging	VBG	O
from	IN	O
0.43	CD	O
L	NNP	O
to	TO	O
0.47	CD	O
L.	NNP	O
Patients	NNPS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
experienced	VBD	O
a	DT	O
mean	JJ	O
decrease	NN	O
from	IN	O
baseline	NN	O
of	IN	O
0.22	CD	O
L	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
probability	NN	O
of	IN	O
patients	NNS	O
remaining	VBG	O
in	IN	O
the	DT	O
study	NN	O
over	IN	O
time	NN	O
without	IN	O
developing	VBG	O
signs	NNS	O
of	IN	O
exacerbating	VBG	O
asthma	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
fluticasone	NN	O
propionate	NN	O
groups	NNS	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Asthma	NNP	O
symptom	NN	O
scores	NNS	O
,	,	O
supplemental	JJ	O
rescue	NN	O
albuterol	NN	O
use	NN	O
,	,	O
and	CC	O
number	NN	O
of	IN	O
nighttime	JJ	O
awakenings	NNS	O
due	JJ	O
to	TO	O
asthma	VB	O
requiring	VBG	O
treatment	NN	O
also	RB	O
improved	VBN	O
significantly	RB	O
with	IN	O
all	DT	O
fluticasone	NN	O
propionate	NN	O
treatment	NN	O
regimens	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
at	IN	O
endpoint	NN	O
among	IN	O
the	DT	O
three	CD	O
fluticasone	NN	O
propionate	NN	O
groups	NNS	O
.	.	O

No	DT	O
serious	JJ	O
drug-related	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
.	.	O

CONCLUSIONS	NNP	O
Fluticasone	NNP	O
propionate	NN	O
powder	NN	O
(	(	O
50	CD	O
,	,	O
100	CD	O
,	,	O
and	CC	O
250	CD	O
micrograms	NNS	O
)	)	O
was	VBD	O
well-tolerated	JJ	O
and	CC	O
significantly	RB	O
improved	VBN	O
lung	NN	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
asthma	NNS	O
.	.	O

Long-term	JJ	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
study	NN	O
using	VBG	O
repetitive	JJ	O
education	NN	O
at	IN	O
six-month	JJ	O
intervals	NNS	O
and	CC	O
monitoring	NN	O
for	IN	O
adherence	NN	O
in	IN	O
heart	NN	O
failure	NN	O
outpatients	NNS	O
:	:	O
the	DT	O
REMADHE	NNP	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
effectiveness	NN	O
of	IN	O
heart	NN	O
failure	NN	O
disease	NN	O
management	NN	O
programs	NNS	O
in	IN	O
patients	NNS	O
under	IN	O
cardiologists	NNS	O
'	POS	O
care	NN	O
over	IN	O
long-term	JJ	O
follow-up	NN	O
is	VBZ	O
not	RB	O
established	VBN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
disease	JJ	Other
management	NN	Other
program	NN	Other
with	IN	Other
repetitive	JJ	Other
education	NN	Other
and	CC	O
telephone	NN	Other
monitoring	NN	Other
on	IN	O
primary	JJ	O
(	(	O
combined	VBN	O
death	NN	O
or	CC	O
unplanned	JJ	O
first	JJ	O
hospitalization	NN	O
and	CC	O
quality-of-life	JJ	O
changes	NNS	O
)	)	O
and	CC	O
secondary	JJ	O
end	NN	O
points	NNS	O
(	(	O
hospitalization	NN	O
,	,	O
death	NN	O
,	,	O
and	CC	O
adherence	NN	O
)	)	O
.	.	O

The	DT	O
REMADHE	NNP	O
[	NNP	O
Repetitive	NNP	O
Education	NNP	Other
and	CC	Other
Monitoring	NNP	Other
for	IN	O
ADherence	NNP	O
for	IN	O
Heart	NNP	O
Failure	NNP	O
]	NNP	O
trial	NN	O
is	VBZ	O
a	DT	O
long-term	JJ	O
randomized	NN	O
,	,	O
prospective	JJ	O
,	,	O
parallel	JJ	O
trial	NN	O
designed	VBN	O
to	TO	O
compare	VB	O
intervention	NN	O
with	IN	O
control	NN	Control
.	.	Control

One	CD	O
hundred	VBD	O
seventeen	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
usual	JJ	O
care	NN	O
,	,	O
and	CC	O
233	CD	O
to	TO	O
additional	JJ	O
intervention	NN	O
.	.	O

The	DT	O
mean	JJ	O
follow-up	NN	O
was	VBD	O
2.47+/-1.75	CD	O
years	NNS	O
,	,	O
with	IN	O
54	CD	O
%	NN	O
adherence	NN	O
to	TO	O
the	DT	O
program	NN	O
.	.	O

In	IN	O
the	DT	O
intervention	NN	O
group	NN	O
,	,	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
composite	NN	O
of	IN	O
death	NN	O
or	CC	O
unplanned	JJ	O
hospitalization	NN	O
was	VBD	O
reduced	VBN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.64	CD	O
;	:	O
confidence	NN	O
interval	NN	O
,	,	O
0.43	CD	O
to	TO	O
0.88	CD	O
;	:	O
P=0.008	NNP	O
)	)	O
,	,	O
driven	VBN	O
by	IN	O
reduction	NN	O
in	IN	O
hospitalization	NN	O
.	.	O

The	DT	O
quality-of-life	JJ	O
questionnaire	NN	O
score	NN	O
improved	VBD	O
only	RB	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.003	CD	O
)	)	O
.	.	O

Mortality	NNP	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Number	NNP	O
of	IN	O
hospitalizations	NNS	O
(	(	O
1.3+/-1.7	JJ	O
versus	NN	O
0.8+/-1.3	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
total	JJ	O
hospital	NN	O
days	NNS	O
during	IN	O
the	DT	O
follow-up	JJ	O
(	(	O
19.9+/-51	JJ	O
versus	NN	O
11.1+/-24	JJ	O
days	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
emergency	NN	O
visits	NNS	O
(	(	O
4.5+/-10.6	JJ	O
versus	NN	O
1.6+/-2.4	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

Beneficial	JJ	O
effects	NNS	O
were	VBD	O
homogeneous	JJ	O
for	IN	O
sex	NN	O
,	,	O
race	NN	O
,	,	O
diabetes	NNS	O
and	CC	O
no	DT	O
diabetes	NN	O
,	,	O
age	NN	O
,	,	O
functional	JJ	O
class	NN	O
,	,	O
and	CC	O
etiology	NN	O
.	.	O

CONCLUSIONS	NNP	O
For	IN	O
a	DT	O
longer	RBR	O
follow-up	JJ	O
period	NN	O
than	IN	O
in	IN	O
previous	JJ	O
studies	NNS	O
,	,	O
this	DT	O
heart	NN	O
failure	NN	O
disease	JJ	O
management	NN	O
program	NN	O
model	NN	O
of	IN	O
patients	NNS	O
under	IN	O
the	DT	O
supervision	NN	O
of	IN	O
a	DT	O
cardiologist	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
unplanned	JJ	O
hospitalization	NN	O
,	,	O
a	DT	O
reduction	NN	O
of	IN	O
total	JJ	O
hospital	NN	O
days	NNS	O
,	,	O
and	CC	O
a	DT	O
reduced	JJ	O
need	NN	O
for	IN	O
emergency	NN	O
care	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
improved	VBN	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
despite	IN	O
modest	JJ	O
program	NN	O
adherence	NN	O
over	IN	O
time	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
body	NN	O
positioning	VBG	O
upon	IN	O
maximal	JJ	Pharmacological
oxygenation	NN	Pharmacological
of	IN	O
patients	NNS	O
with	IN	O
unilateral	JJ	O
lung	NN	O
pathology	NN	O
.	.	O

A	DT	O
quasi-experimental	JJ	O
,	,	O
repeated-measures	JJ	O
cross-over	NN	O
design	NN	O
study	NN	O
on	IN	O
the	DT	O
effect	NN	O
of	IN	O
body	NN	O
position	NN	O
on	IN	O
oxygenation	NN	Pharmacological
(	(	Pharmacological
SaO2	NNP	Pharmacological
)	)	Pharmacological
blood	NN	O
pressure	NN	O
,	,	O
respiration	NN	O
and	CC	O
pulse	NN	O
in	IN	O
patients	NNS	O
with	IN	O
unilateral	JJ	O
lung	NN	O
pathology	NN	O
was	VBD	O
conducted	VBN	O
.	.	O

Previous	JJ	O
research	NN	O
strongly	RB	O
suggests	VBZ	O
that	IN	O
positioning	VBG	O
with	IN	O
the	DT	O
healthy	JJ	O
(	(	O
unaffected	JJ	O
)	)	O
lung	NN	O
in	IN	O
the	DT	O
dependent	JJ	O
lateral	NN	O
(	(	O
down	RP	O
)	)	O
position	NN	O
is	VBZ	O
related	VBN	O
to	TO	O
improved	VBN	O
oxygenation	NN	O
,	,	O
but	CC	O
knowledge	VBP	O
about	IN	O
whether	IN	O
this	DT	O
effect	NN	O
is	VBZ	O
maintained	VBN	O
over	IN	O
time	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
was	VBD	O
to	TO	O
determine	VB	O
:	:	O
(	(	O
1	CD	O
)	)	O
Is	VBZ	O
positioning	VBG	O
with	IN	O
the	DT	O
unaffected	JJ	O
lung	NN	O
in	IN	O
the	DT	O
dependent	JJ	O
lateral	JJ	O
position	NN	O
related	VBN	O
to	TO	O
increased	VBN	O
arterial	JJ	O
blood	NN	O
saturation	NN	O
levels	NNS	O
and	CC	O
decreased	VBD	O
blood	NN	O
pressure	NN	O
,	,	O
pulse	NN	O
and	CC	O
respiration	NN	O
?	.	O
(	(	O
2	CD	O
)	)	O
What	WP	O
is	VBZ	O
the	DT	O
relationship	NN	O
between	IN	O
the	DT	O
dependent	JJ	O
variables	NNS	O
--	:	O
oxygenation	NN	O
saturation	NN	O
levels	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
pulse	NN	O
and	CC	O
respiration	NN	O
--	:	O
and	CC	O
the	DT	O
independent	JJ	O
variables	NNS	O
--	:	O
body	NN	O
position	NN	O
and	CC	O
time	NN	O
in	IN	O
the	DT	O
position	NN	O
?	.	O
Thirty-nine	JJ	O
patients	NNS	O
with	IN	O
unilateral	JJ	O
lung	NN	O
pathology	NN	O
were	VBD	O
positioned	VBN	O
on	IN	O
their	PRP$	O
sides	NNS	O
with	IN	O
the	DT	O
unaffected	JJ	O
lung	NN	O
down	RP	O
,	,	O
on	IN	O
their	PRP$	O
sides	NNS	O
with	IN	O
the	DT	O
affected	JJ	O
lung	NN	O
down	RB	O
,	,	O
and	CC	O
also	RB	O
in	IN	O
semi-Fowler	NN	O
's	POS	O
position	NN	O
.	.	O

Arterial	NNP	Physical
(	(	Physical
SaO2	NNP	Physical
)	)	Physical
blood	NN	Physical
saturation	NN	Physical
and	CC	O
vital	JJ	Physical
signs	NNS	Physical
were	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
0	CD	O
,	,	O
15	CD	O
and	CC	O
30	CD	O
minutes	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
relationship	NN	O
between	IN	O
oxygenation	NN	O
level	NN	O
or	CC	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Diastolic	NNP	O
blood	NN	O
pressure	NN	O
,	,	O
respiration	NN	O
and	CC	O
pulse	NN	O
did	VBD	O
vary	JJ	O
significantly	RB	O
with	IN	O
position	NN	O
.	.	O

Pilot	NNP	O
comparison	NN	O
between	IN	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	NN	Surgical
laser	NN	Surgical
and	CC	O
bipolar	JJ	Surgical
radiofrequency	NN	Surgical
in	IN	O
paediatric	JJ	O
tonsillectomy	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
advantages	NNS	O
and	CC	O
disadvantages	NNS	O
of	IN	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	NN	Surgical
laser	NN	Surgical
with	IN	O
those	DT	O
of	IN	O
bipolar	JJ	Surgical
radiofrequency	NN	Surgical
techniques	NNS	Surgical
,	,	O
in	IN	O
paediatric	JJ	O
tonsillectomy	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomised	VBD	O
,	,	O
clinical	JJ	O
study	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
From	NNP	O
July	NNP	O
2004	CD	O
to	TO	O
April	NNP	O
2006	CD	O
,	,	O
80	CD	O
patients	NNS	O
aged	VBN	O
between	IN	O
10	CD	O
and	CC	O
15	CD	O
years	NNS	O
,	,	O
with	IN	O
tonsillectomy	NN	Surgical
planned	VBN	O
for	IN	O
chronic	JJ	O
tonsillitis	NN	O
,	,	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Children	NNP	O
were	VBD	O
prospectively	RB	O
randomised	VBN	O
into	IN	O
two	CD	O
equal	JJ	O
groups	NNS	O
:	:	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	NN	Surgical
laser	NN	Surgical
tonsillectomy	NN	Surgical
and	CC	O
bipolar	JJ	Surgical
radiofrequency	NN	Surgical
tonsillectomy	NN	Surgical
.	.	O

Operative	JJ	O
time	NN	O
and	CC	O
intra-operative	JJ	O
blood	NN	O
loss	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
scheduled	VBN	O
for	IN	O
follow	VB	O
up	RP	O
during	IN	O
the	DT	O
first	JJ	O
,	,	O
second	JJ	O
and	CC	O
fourth	JJ	O
post-operative	JJ	O
weeks	NNS	O
.	.	O

They	PRP	O
were	VBD	O
asked	VBN	O
to	TO	O
record	VB	O
their	PRP$	O
pain	NN	O
and	CC	O
discomfort	NN	O
on	IN	O
a	DT	O
standardised	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
,	,	O
from	IN	O
zero	CD	O
(	(	O
no	DT	O
pain	NN	O
)	)	O
to	TO	O
10	CD	O
(	(	O
severe	JJ	O
pain	NN	O
)	)	O
.	.	O

Post-operative	JJ	O
complications	NNS	O
were	VBD	O
also	RB	O
recorded	VBN	O
and	CC	O
managed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	VBP	Surgical
laser	NN	Surgical
group	NN	Surgical
showed	VBD	O
a	DT	O
slightly	RB	O
longer	RBR	O
operative	JJ	O
time	NN	O
(	(	O
mean	JJ	O
12	CD	O
minutes	NNS	O
)	)	O
than	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
group	NN	O
(	(	O
mean	JJ	O
10	CD	O
minutes	NNS	O
)	)	O
.	.	O

Intra-operative	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	VBP	Surgical
laser	NN	Surgical
group	NN	O
(	(	O
mean	JJ	O
21	CD	O
cm3	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
bipolar	JJ	Surgical
radiofrequency	NN	Surgical
group	NN	Surgical
(	(	O
mean	JJ	O
30	CD	O
cm3	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
week	NN	O
,	,	O
post-operative	JJ	O
pain	NN	O
scores	NNS	O
were	VBD	O
less	RBR	O
in	IN	O
the	DT	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	VBP	Surgical
laser	NN	Surgical
group	NN	O
than	IN	O
in	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
group	NN	O
(	(	O
means	VBZ	O
7.5	CD	O
and	CC	O
8.5	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
second	JJ	O
week	NN	O
pain	NN	O
scores	NNS	O
increased	VBD	O
more	RBR	O
in	IN	O
the	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
group	NN	O
(	(	O
means	VBZ	O
8.5	CD	O
and	CC	O
6	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

In	IN	O
the	DT	O
fourth	JJ	O
week	NN	O
,	,	O
both	DT	O
groups	NNS	O
showed	VBD	O
equal	JJ	O
and	CC	O
nearly	RB	O
normal	JJ	O
pain	NN	O
scores	NNS	O
.	.	O

No	DT	O
case	NN	O
of	IN	O
reactionary	JJ	O
post-tonsillectomy	JJ	O
haemorrhage	NN	O
was	VBD	O
recorded	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

Only	RB	O
one	CD	O
case	NN	O
of	IN	O
secondary	JJ	O
post-tonsillectomy	JJ	O
haemorrhage	NN	O
was	VBD	O
recorded	VBN	O
,	,	O
in	IN	O
the	DT	O
potassium	NN	O
titanyl	NN	O
phosphate	VBP	O
laser	NN	O
group	NN	O
(	(	O
2.5	CD	O
per	IN	O
cent	NN	O
)	)	O
,	,	O
managed	VBD	O
conservatively	RB	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
the	DT	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	NN	Surgical
and	CC	O
the	DT	O
bipolar	JJ	Surgical
radiofrequency	NN	Surgical
techniques	NNS	Surgical
were	VBD	O
safe	JJ	O
and	CC	O
easy	JJ	O
to	TO	O
use	VB	O
for	IN	O
tonsillectomy	NN	O
,	,	O
with	IN	O
reduced	VBN	O
operative	JJ	O
time	NN	O
,	,	O
blood	NN	O
loss	NN	O
and	CC	O
complication	NN	O
rates	NNS	O
and	CC	O
better	JJR	O
post-operative	JJ	O
general	JJ	O
patient	NN	O
condition	NN	O
.	.	O

Potassium	NNP	Surgical
titanyl	JJ	Surgical
phosphate	NN	Surgical
laser	NN	Surgical
resulted	VBD	O
in	IN	O
reduced	JJ	O
operative	JJ	O
bleeding	NN	O
and	CC	O
immediate	JJ	O
post-operative	JJ	O
pain	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
technique	NN	O
.	.	O

However	RB	O
,	,	O
potassium	NN	Surgical
titanyl	NN	Surgical
phosphate	VBP	Surgical
laser	NN	Surgical
required	VBN	O
slightly	RB	O
more	RBR	O
operative	JJ	O
time	NN	O
and	CC	O
caused	VBD	O
more	JJR	O
late	JJ	O
post-operative	JJ	O
pain	NN	O
than	IN	O
the	DT	O
bipolar	JJ	O
radiofrequency	NN	O
technique	NN	O
.	.	O

The	DT	O
low	JJ	O
rate	NN	O
of	IN	O
recorded	VBN	O
complications	NNS	O
showed	VBD	O
that	IN	O
both	DT	O
techniques	NNS	O
cause	VBP	O
little	JJ	O
damage	NN	O
to	TO	O
the	DT	O
tonsillar	JJ	O
bed	NN	O
during	IN	O
dissection	NN	O
,	,	O
thus	RB	O
minimising	VBG	O
complications	NNS	O
.	.	O

Coagulation	NNP	Pharmacological
factor	NN	Pharmacological
concentrate	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
haemorrhagic	JJ	O
diathesis	NN	O
of	IN	O
fulminant	JJ	O
hepatic	JJ	O
failure	NN	O
.	.	O

To	TO	O
assess	VB	O
the	DT	O
value	NN	O
of	IN	O
clotting	VBG	Pharmacological
factor	NN	Pharmacological
concentrate	NN	Pharmacological
infusions	NNS	Pharmacological
in	IN	O
fulminant	JJ	O
hepatic	JJ	O
failure	NN	O
,	,	O
a	DT	O
controlled	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
which	WDT	O
nine	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
concentrate	NN	Pharmacological
alone	RB	Pharmacological
or	CC	Pharmacological
concentrate	VB	Pharmacological
plus	CC	Pharmacological
heparin	VB	Pharmacological
.	.	Pharmacological

The	DT	O
five	CD	O
patients	NNS	O
receiving	VBG	O
concentrate	VB	Pharmacological
alone	RB	O
all	DT	O
died	VBD	O
,	,	O
with	IN	O
major	JJ	O
bleeding	VBG	O
as	IN	O
the	DT	O
direct	JJ	O
cause	NN	O
of	IN	O
death	NN	O
in	IN	O
three	CD	O
,	,	O
whereas	NNS	O
in	IN	O
the	DT	O
four	CD	O
receiving	VBG	O
heparin	NN	Pharmacological
as	RB	O
well	RB	O
there	EX	O
was	VBD	O
only	RB	O
one	CD	O
instance	NN	O
of	IN	O
bleeding	NN	O
and	CC	O
one	CD	O
patient	NN	O
survived	VBD	O
.	.	O

Clinical	JJ	O
evidence	NN	O
of	IN	O
intravascular	JJ	O
coagulation	NN	O
appeared	VBD	O
in	IN	O
two	CD	O
patients	NNS	O
treated	VBD	O
with	IN	O
concentrate	NN	Pharmacological
alone	RB	O
and	CC	O
the	DT	O
laboratory	JJ	O
evidence	NN	O
of	IN	O
this	DT	O
progressed	VBN	O
during	IN	O
the	DT	O
period	NN	O
of	IN	O
infusions	NNS	O
in	IN	O
all	DT	O
patients	NNS	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
although	IN	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
in	IN	O
those	DT	O
receiving	VBG	O
heparin	NN	Pharmacological
.	.	Pharmacological

Additional	JJ	O
evidence	NN	O
for	IN	O
intravascular	JJ	O
coagulation	NN	O
came	VBD	O
from	IN	O
the	DT	O
changes	NNS	O
observed	VBN	O
in	IN	O
factor	NN	O
VIII	NNP	O
levels	NNS	O
which	WDT	O
,	,	O
although	IN	O
initially	RB	O
high	JJ	O
in	IN	O
all	DT	O
patients	NNS	O
,	,	O
fell	VBD	O
subsequently	RB	O
,	,	O
particularly	RB	O
in	IN	O
those	DT	O
given	VBN	O
concentrate	VBP	Pharmacological
alone	RB	O
.	.	O

There	EX	O
was	VBD	O
some	DT	O
improvement	NN	O
in	IN	O
the	DT	O
prothrombin	NN	O
ratio	NN	O
in	IN	O
both	DT	O
groups	NNS	O
of	IN	O
patients	NNS	O
but	CC	O
not	RB	O
complete	JJ	O
correction	NN	O
,	,	O
and	CC	O
serial	JJ	O
assays	NNS	O
of	IN	O
clotting	VBG	O
factors	NNS	O
showed	VBD	O
that	IN	O
although	IN	O
factor	NN	O
II	NNP	O
rose	VBD	O
to	TO	O
high	JJ	O
levels	NNS	O
during	IN	O
treatment	NN	O
,	,	O
factors	NNS	O
IX	NNP	O
and	CC	O
X	NNP	O
showed	VBD	O
little	JJ	O
response	NN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
concentrate	NN	O
of	IN	O
factor	NN	O
IX	NNP	O
in	IN	O
this	DT	O
trial	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
potentiating	VBG	O
intravascular	JJ	O
coagulation	NN	O
,	,	O
was	VBD	O
inadequate	JJ	O
as	IN	O
replacement	NN	O
for	IN	O
the	DT	O
clotting	NN	O
factor	NN	O
deficiencies	NNS	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
multi-faceted	JJ	Physical
intervention	NN	Physical
on	IN	O
gingival	JJ	O
health	NN	O
among	IN	O
adults	NNS	O
with	IN	O
systemic	JJ	O
sclerosis	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
adaptive	JJ	Surgical
oral	JJ	Surgical
hygiene	NN	Surgical
devices	NNS	Surgical
and	CC	O
orofacial	JJ	Physical
exercise	NN	Physical
to	TO	O
improve	VB	O
gingival	JJ	O
health	NN	O
among	IN	O
adults	NNS	O
with	IN	O
systemic	JJ	O
sclerosis	NN	O
(	(	O
SSc	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Forty-eight	JJ	O
patients	NNS	O
with	IN	O
SSc	NNP	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
the	DT	O
multifaceted	VBN	Physical
oral	JJ	Physical
health	NN	Physical
intervention	NN	Physical
or	CC	O
usual	JJ	Control
dental	JJ	Control
care	NN	Control
control	NN	O
group	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
a	DT	O
rechargeable	JJ	O
,	,	O
powered	JJ	O
Oral-B?	NNP	Physical
oscillating-rotating-pulsating	NN	Physical
toothbrush	NN	Physical
and	CC	O
a	DT	O
Reach?	NNP	Physical
Access?	NNP	Physical
Flosser	NNP	Physical
that	WDT	O
has	VBZ	O
a	DT	O
toothbrush-like	JJ	O
handle	NN	O
.	.	O

For	IN	O
those	DT	O
with	IN	O
an	DT	O
oral	JJ	O
aperture	NN	O
of	IN	O
less	JJR	O
than	IN	O
40	CD	O
mm	NN	O
,	,	O
orofacial	JJ	O
exercises	NNS	O
were	VBD	O
taught	VBN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
each	DT	O
given	VBN	O
a	DT	O
manual	JJ	O
toothbrush	NN	O
and	CC	O
dental	JJ	O
floss	NN	O
.	.	O

Participants	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
received	VBD	O
instructions	NNS	O
and	CC	O
demonstration	NN	O
on	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
devices	NNS	O
,	,	O
and	CC	O
were	VBD	O
requested	VBN	O
to	TO	O
perform	VB	O
the	DT	O
respective	JJ	O
intervention	NN	O
twice	RB	O
a	DT	O
day	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Evaluations	NNS	O
were	VBD	O
at	IN	O
baseline	NN	O
,	,	O
3-	JJ	O
,	,	O
and	CC	O
6-months	NNS	O
.	.	O

The	DT	O
main	JJ	O
outcome	NN	O
was	VBD	O
gingival	JJ	O
index	NN	O
(	(	O
GI	NNP	O
)	)	O
,	,	O
an	DT	O
indicator	NN	O
of	IN	O
gingival	JJ	O
inflammation	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
reduction	NN	O
in	IN	O
GI	NNP	O
scores	NNS	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
ps	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

Reduction	NN	O
in	IN	O
GI	NNP	O
scores	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
group	NN	O
at	IN	O
6	CD	O
months	NNS	O
was	VBD	O
20.8	CD	O
%	NN	O
which	WDT	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
clinically	RB	O
significant	JJ	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
and	CC	O
larger	JJR	O
reduction	NN	O
in	IN	O
GI	NNP	O
score	NN	O
by	IN	O
8	CD	O
%	NN	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
p=0.0007	NN	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Results	NNP	O
support	NN	O
the	DT	O
use	NN	O
of	IN	O
adaptive	JJ	Surgical
devices	NNS	Surgical
and	CC	O
orofacial	JJ	Physical
exercise	NN	Physical
to	TO	O
improve	VB	O
gingival	NN	O
health	NN	O
in	IN	O
adults	NNS	O
with	IN	O
SSc	NNP	O
when	WRB	O
compared	VBN	O
to	TO	O
use	VB	O
of	IN	O
manual	JJ	Control
toothbrushing	NN	Control
and	CC	O
finger-held	JJ	Control
flossing	NN	Control
.	.	O

Recommending	VBG	O
and	CC	O
educating	VBG	O
patients	NNS	O
with	IN	O
SSc	NNP	O
to	TO	O
use	VB	O
adaptive	JJ	O
devices	NNS	O
to	TO	O
clean	VB	O
the	DT	O
tooth	NN	O
surfaces	NNS	O
looks	VBZ	O
promising	VBG	O
for	IN	O
long-term	JJ	O
oral	JJ	O
health	NN	O
improvement	NN	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	VBN	O
study	NN	O
of	IN	O
parent-assisted	JJ	Educational
Children	NNP	Educational
's	POS	Educational
Friendship	NNP	Educational
Training	NNP	Educational
with	IN	O
children	NNS	O
having	VBG	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
Children	NNP	Educational
's	POS	Educational
Friendship	NNP	Educational
Training	NNP	Educational
(	(	Educational
CFT	NNP	Educational
)	)	Educational
,	,	Educational
a	DT	Educational
manualized	JJ	Educational
parent-assisted	JJ	Educational
intervention	NN	Educational
to	TO	O
improve	VB	O
social	JJ	O
skills	NNS	O
among	IN	O
second	JJ	O
to	TO	O
fifth	VB	O
grade	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Comparison	NNP	O
was	VBD	O
made	VBN	O
with	IN	O
a	DT	O
delayed	JJ	Educational
treatment	NN	Educational
control	NN	Educational
group	NN	Educational
(	(	Educational
DTC	NNP	Educational
)	)	Educational
.	.	O

Targeted	VBN	O
skills	NNS	O
included	VBD	O
conversational	JJ	O
skills	NNS	O
,	,	O
peer	VBP	O
entry	NN	O
skills	NNS	O
,	,	O
developing	VBG	O
friendship	JJ	O
networks	NNS	O
,	,	O
good	JJ	O
sportsmanship	NN	O
,	,	O
good	JJ	O
host	NN	O
behavior	NN	O
during	IN	O
play	NN	O
dates	NNS	O
,	,	O
and	CC	O
handling	VBG	O
teasing	NN	O
.	.	O

At	IN	O
post-testing	NN	O
,	,	O
the	DT	O
CFT	NNP	O
group	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
DTC	NNP	O
group	NN	O
on	IN	O
parent	NN	O
measures	NNS	O
of	IN	O
social	JJ	O
skill	NN	O
and	CC	O
play	NN	O
date	NN	O
behavior	NN	O
,	,	O
and	CC	O
child	JJ	O
measures	NNS	O
of	IN	O
popularity	NN	O
and	CC	O
loneliness	NN	O
,	,	O
At	IN	O
3-month	JJ	O
follow-up	NN	O
,	,	O
parent	NN	O
measures	NNS	O
showed	VBD	O
significant	JJ	O
improvement	NN	O
from	IN	O
baseline	NN	O
.	.	O

Post-hoc	JJ	O
analysis	NN	O
indicated	VBD	O
more	JJR	O
than	IN	O
87	CD	O
%	NN	O
of	IN	O
children	NNS	O
receiving	VBG	O
CFT	NNP	Educational
showed	VBD	O
reliable	JJ	O
change	NN	O
on	IN	O
at	IN	O
least	JJS	O
one	CD	O
measure	NN	O
at	IN	O
post-test	NN	O
and	CC	O
66.7	CD	O
%	NN	O
after	IN	O
3	CD	O
months	NNS	O
follow-up	RB	O
.	.	O

Study	NN	O
of	IN	O
the	DT	O
vaginal	JJ	O
tolerance	NN	O
to	TO	O
Acidform	NNP	Pharmacological
,	,	Pharmacological
an	DT	Pharmacological
acid-buffering	JJ	Pharmacological
,	,	Pharmacological
bioadhesive	JJ	Pharmacological
gel	NN	Pharmacological
.	.	Pharmacological

Vaginal	JJ	O
tolerance	NN	O
tests	NNS	O
were	VBD	O
performed	VBN	O
with	IN	O
a	DT	O
new	JJ	O
potential	JJ	O
microbicidal	NN	O
and	CC	O
spermicidal	JJ	O
product	NN	O
,	,	O
an	DT	O
acid-buffering	JJ	Pharmacological
vaginal	JJ	Pharmacological
gel	NN	Pharmacological
(	(	Pharmacological
Acidform	NNP	Pharmacological
)	)	Pharmacological
without	IN	Pharmacological
or	CC	Pharmacological
with	IN	Pharmacological
nonoxynol-9	JJ	Pharmacological
(	(	Pharmacological
N-9	NNP	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

The	DT	O
potential	JJ	O
advantages	NNS	O
over	IN	O
other	JJ	O
vaginal	JJ	O
products	NNS	O
include	VBP	O
keeping	VBG	O
a	DT	O
low	JJ	O
pH	NN	O
,	,	O
decrease	NN	O
of	IN	O
the	DT	O
irritating	VBG	O
effect	NN	O
of	IN	O
N-9	NNP	Pharmacological
on	IN	O
the	DT	O
cervix	NN	O
or	CC	O
vaginal	JJ	O
mucosa	NN	O
associated	VBN	O
with	IN	O
greater	JJR	O
retention	NN	O
of	IN	O
the	DT	O
product	NN	O
after	IN	O
application	NN	O
,	,	O
and	CC	O
decreasing	VBG	O
messiness	NN	O
as	IN	O
compared	VBN	O
to	TO	O
other	JJ	O
vaginal	JJ	O
products	NNS	O
.	.	O

Three	CD	O
groups	NNS	O
of	IN	O
six	CD	O
women	NNS	O
were	VBD	O
admitted	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
use	VB	O
Acidform	NNP	Pharmacological
with	IN	O
0	CD	O
%	NN	O
,	,	O
2.5	CD	O
%	NN	O
,	,	O
and	CC	O
5	CD	O
%	NN	O
N-9	NNP	Pharmacological
.	.	Pharmacological

Colposcopic	NNP	O
evaluation	NN	O
for	IN	O
vulvar	NN	O
,	,	O
vaginal	JJ	O
,	,	O
and	CC	O
cervical	JJ	O
signs	NNS	O
of	IN	O
irritation	NN	O
was	VBD	O
performed	VBN	O
and	CC	O
photographs	NNS	O
were	VBD	O
taken	VBN	O
,	,	O
following	VBG	O
a	DT	O
specific	JJ	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
protocol	NN	O
,	,	O
at	IN	O
time	NN	O
0	CD	O
,	,	O
and	CC	O
after	IN	O
24	CD	O
h	NN	O
and	CC	O
6	CD	O
days	NNS	O
of	IN	O
application	NN	O
of	IN	O
the	DT	O
gel	NN	O
.	.	O

No	DT	O
irritation	NN	O
or	CC	O
symptom	NN	O
was	VBD	O
reported	VBN	O
by	IN	O
users	NNS	O
of	IN	O
Acidform	NNP	Pharmacological
without	IN	Pharmacological
N-9	NNP	Pharmacological
.	.	Pharmacological

A	NNP	O
generalized	JJ	O
and	CC	O
intense	JJ	O
erythema	NN	O
in	IN	O
cervix	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
10	CD	O
of	IN	O
12	CD	O
Acidform/N-9	JJ	Pharmacological
users	NNS	O
and	CC	O
abrasion	NN	O
occurred	VBD	O
in	IN	O
nine	CD	O
of	IN	O
them	PRP	O
.	.	O

Vulvar	NNP	O
irritation	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
seven	CD	O
of	IN	O
these	DT	O
10	CD	O
volunteers	NNS	O
.	.	O

N-9	JJ	O
concentration	NN	O
in	IN	O
the	DT	O
gel	NN	O
(	(	O
2.5	CD	O
%	NN	O
or	CC	O
5.0	CD	O
%	NN	O
)	)	O
was	VBD	O
not	RB	O
related	VBN	O
to	TO	O
the	DT	O
findings	NNS	O
.	.	O

No	DT	O
ulcer	NN	O
,	,	O
exulceration	NN	O
,	,	O
or	CC	O
de-epithelialization	NN	O
was	VBD	O
observed	VBN	O
.	.	O

Acidform	VB	Pharmacological
without	IN	Pharmacological
N-9	NNP	Pharmacological
was	VBD	O
well	RB	O
tolerated	VBN	O
by	IN	O
volunteers	NNS	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
unable	JJ	O
to	TO	O
protect	VB	O
the	DT	O
cervix	NN	O
,	,	O
vagina	NN	O
,	,	O
and	CC	O
vulva	NN	O
from	IN	O
the	DT	O
N-9	JJ	O
effects	NNS	O
.	.	O

Comparative	JJ	O
drug	NN	O
effects	NNS	O
and	CC	O
abuse	NN	O
liability	NN	O
of	IN	O
lorazepam	NN	Pharmacological
,	,	O
buspirone	NN	Pharmacological
,	,	O
and	CC	O
secobarbital	NN	Pharmacological
in	IN	O
nondependent	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
pharmacologic	JJ	O
effects	NNS	O
of	IN	O
lorazepam	NN	Pharmacological
(	(	O
2	CD	O
mg	NN	O
)	)	O
,	,	O
buspirone	NN	Pharmacological
(	(	O
20	CD	O
mg	NN	O
,	,	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
secobarbital	JJ	Pharmacological
(	(	O
100	CD	O
mg	NN	O
)	)	O
,	,	O
and	CC	O
placebo	NN	Control
were	VBD	O
compared	VBN	O
in	IN	O
15	CD	O
male	NN	O
,	,	O
experienced	VBD	O
,	,	O
intermittent	JJ	O
nontherapeutic	JJ	O
drug	NN	O
users	NNS	O
.	.	O

All	DT	O
drugs	NNS	O
produced	VBD	O
a	DT	O
drug	NN	O
effect	NN	O
,	,	O
however	RB	O
,	,	O
buspirone	RB	Pharmacological
20	CD	O
mg	NN	O
was	VBD	O
significantly	RB	O
less	JJR	O
liked	JJ	O
than	IN	O
were	VBD	O
lorazepam	JJ	Pharmacological
,	,	O
secobarbital	JJ	Pharmacological
,	,	O
or	CC	O
buspirone	RB	Pharmacological
10	CD	O
mg	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
.05	NN	O
)	)	O
but	CC	O
not	RB	O
placebo	VB	Control
.	.	Control

Lorazepam	NNP	Pharmacological
was	VBD	O
liked	VBN	O
better	RBR	O
than	IN	O
were	VBD	O
other	JJ	O
drugs	NNS	O
only	RB	O
at	IN	O
1	CD	O
hour	NN	O
and	CC	O
only	RB	O
compared	VBN	O
with	IN	O
buspirone	NN	Pharmacological
20	CD	O
and	CC	O
placebo	NN	Control
.	.	Control

Compared	VBN	O
with	IN	O
other	JJ	O
drugs	NNS	O
,	,	O
lorazepam	JJ	Pharmacological
drug	NN	O
effects	NNS	O
were	VBD	O
greater	JJR	O
and	CC	O
resulted	VBD	O
in	IN	O
more	RBR	O
prolonged	JJ	O
impairment	NN	O
of	IN	O
a	DT	O
motor	NN	O
tracking	VBG	O
task	NN	O
,	,	O
standing	VBG	O
steadiness	NN	O
,	,	O
and	CC	O
memory	NN	O
.	.	O

Buspirone	CD	Pharmacological
20	CD	O
mg	NNS	O
significantly	RB	O
impaired	JJ	O
memory	NN	O
at	IN	O
1	CD	O
hour	NN	O
compared	VBN	O
with	IN	O
placebo	NN	Pharmacological
.	.	Pharmacological

Subjects	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
identify	VB	O
buspirone	NN	Pharmacological
as	IN	O
unfamiliar	JJ	O
.	.	O

Because	IN	O
buspirone	NN	Pharmacological
20	CD	O
mg	NN	O
was	VBD	O
less	JJR	O
liked	JJ	O
than	IN	O
were	VBD	O
other	JJ	O
drugs	NNS	O
,	,	O
dose	JJ	O
escalation	NN	O
as	IN	O
part	NN	O
of	IN	O
drug	NN	O
abuse	NN	O
is	VBZ	O
not	RB	O
likely	JJ	O
to	TO	O
occur	VB	O
.	.	O

Lorazepam	NNP	Pharmacological
also	RB	O
was	VBD	O
not	RB	O
particularly	RB	O
liked	VBN	O
and	CC	O
was	VBD	O
not	RB	O
different	JJ	O
from	IN	O
placebo	NN	Control
on	IN	O
most	JJS	O
subjective	JJ	O
abuse-relevant	JJ	O
measures	NNS	O
.	.	O

Use	NNP	O
and	CC	O
limitations	NNS	O
of	IN	O
Holter	NNP	Physical
electrocardiography	NN	Physical
in	IN	O
assessing	VBG	O
drug	NN	O
therapy	NN	O
of	IN	O
myocardial	JJ	O
ischemia	NN	O
during	IN	O
the	DT	O
peri-PTCA	JJ	O
period	NN	O
.	.	O

Incidence	NN	O
and	CC	O
pattern	NN	O
of	IN	O
myocardial	JJ	O
ischemia	NN	O
during	IN	O
the	DT	O
peri-PTCA	JJ	O
(	(	O
percutaneous	JJ	O
transluminal	JJ	O
coronary	JJ	O
angioplasty	NN	O
)	)	O
period	NN	O
and	CC	O
the	DT	O
possible	JJ	O
role	NN	O
of	IN	O
continuous	JJ	Pharmacological
intravenous	JJ	Pharmacological
isosorbide	NN	Pharmacological
dinitrate	NN	Pharmacological
in	IN	O
its	PRP$	O
prevention	NN	O
were	VBD	O
examined	VBN	O
prospectively	RB	O
in	IN	O
30	CD	O
patients	NNS	O
.	.	O

Holter	NNP	Physical
electrocardiographic	JJ	Physical
monitoring	NN	Physical
was	VBD	O
performed	VBN	O
for	IN	O
21	CD	O
+/-	JJ	O
3	CD	O
h	NN	O
before	IN	O
PTCA	NNP	O
and	CC	O
continued	VBN	O
during	IN	O
and	CC	O
for	IN	O
41	CD	O
+/-	JJ	O
8	CD	O
h	NN	O
after	IN	O
the	DT	O
procedure	NN	O
.	.	O

Before	IN	O
PTCA	NNP	O
,	,	O
19	CD	O
ischemic	JJ	O
episodes	NNS	O
were	VBD	O
present	JJ	O
in	IN	O
10	CD	O
(	(	O
33	CD	O
%	NN	O
)	)	O
of	IN	O
30	CD	O
patients	NNS	O
.	.	O

PTCA	NNP	O
produced	VBD	O
an	DT	O
abrupt	JJ	O
decrease	NN	O
in	IN	O
number	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.015	CD	O
)	)	O
and	CC	O
duration	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
of	IN	O
spontaneous	JJ	O
ischemic	JJ	O
episodes	NNS	O
.	.	O

The	DT	O
rarity	NN	O
of	IN	O
recurrent	JJ	O
myocardial	JJ	O
ischemic	JJ	O
events	NNS	O
by	IN	O
Holter	NNP	Physical
monitoring	NN	Physical
after	IN	O
PTCA	NNP	O
negated	VBD	O
any	DT	O
attempt	NN	O
at	IN	O
assessing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
intravenous	JJ	O
isosorbide	JJ	Pharmacological
dinitrate	NN	Pharmacological
in	IN	O
their	PRP$	O
prevention	NN	O
.	.	O

Holter	NNP	Physical
monitoring	NN	Physical
could	MD	O
not	RB	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
early	JJ	O
predictor	NN	O
of	IN	O
late	JJ	O
coronary	JJ	O
restenosis	NN	O
.	.	O

Differential	JJ	O
effects	NNS	O
of	IN	O
amino	NN	O
acid	NN	O
and	CC	O
ketoacid	VB	O
on	IN	O
protein	NN	O
metabolism	NN	O
in	IN	O
humans	NNS	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
insulin	NN	O
,	,	O
amino	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
,	,	O
and	CC	O
branched-chain	JJ	O
ketoacid	NN	O
(	(	O
KA	NNP	O
)	)	O
availability	NN	O
on	IN	O
leucine	JJ	O
kinetics	NNS	O
in	IN	O
eight	CD	O
healthy	JJ	O
volunteers	NNS	O
(	(	O
age	NN	O
=	VBZ	O
22	CD	O
+/-	JJ	O
2	CD	O
y	NN	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
=	VBD	O
24	CD	O
+/-	JJ	O
1	CD	O
kg	NN	O
)	)	O
by	IN	O
using	VBG	O
the	DT	O
euglycemic	JJ	Surgical
insulin	NN	Surgical
clamp	NN	Surgical
and	CC	Surgical
[	JJ	Surgical
1-14C	JJ	Surgical
]	NNP	Surgical
leucine	NN	Surgical
turnover	NN	Surgical
techniques	NNS	Surgical
.	.	Surgical

Four	CD	O
experimental	JJ	O
conditions	NNS	O
were	VBD	O
studied	VBN	O
:	:	O
study	NN	O
I	PRP	O
,	,	O
hyperinsulinemia	NN	O
;	:	O
study	NN	O
II	NNP	O
,	,	O
hyperinsulinemia	NN	O
with	IN	O
maintenance	NN	O
of	IN	O
basal	NN	O
plasma	NN	O
AA	NNP	O
and	CC	O
branched-chain	JJ	O
KA	NNP	O
concentrations	NNS	O
;	:	O
study	NN	O
III	NNP	O
,	,	O
hyperinsulinemia	NN	O
with	IN	O
hyperaminoacidemia	NN	O
and	CC	O
basal	NN	O
plasma	VBP	O
branched-chain	NN	O
KA	NNP	O
concentrations	NNS	O
;	:	O
and	CC	O
study	VB	O
IV	NNP	O
,	,	O
hyperinsulinemia	NN	O
plus	CC	O
basal	NN	O
plasma	VBP	O
AA	NNP	O
concentrations	NNS	O
and	CC	O
elevated	VBD	O
branched-chain	NN	O
KA	NNP	O
levels	NNS	O
.	.	O

Basal	NNP	O
endogenous	JJ	O
leucine	NN	O
flux	NN	O
(	(	O
ELF	NNP	O
)	)	O
averaged	VBD	O
1.20	CD	O
+/-	JJ	O
0.05	CD	O
(	(	O
mumol.kg-1.min-1	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
SE	NNP	O
)	)	O
;	:	O
basal	CC	O
leucine	JJ	O
oxidation	NN	O
(	(	O
LOX	NNP	O
)	)	O
was	VBD	O
0.25	CD	O
+/-	JJ	O
0.01	CD	O
;	:	O
and	CC	O
basal	VB	O
non-oxidative	JJ	O
leucine	NN	O
disposal	NN	O
(	(	O
NOLD	NNP	O
)	)	O
was	VBD	O
0.95	CD	O
+/-	JJ	O
0.04	CD	O
.	.	O

ELF	NNP	O
significantly	RB	O
decreased	VBD	O
in	IN	O
study	NN	O
I	PRP	O
(	(	O
0.77	CD	O
+/-	JJ	O
0.06	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
.	.	O

When	WRB	O
plasma	NN	O
AA	NNP	O
and	CC	O
branched-chain	JJ	O
KA	NNP	O
were	VBD	O
either	RB	O
maintained	VBN	O
at	IN	O
their	PRP$	O
basal	NN	O
levels	NNS	O
(	(	O
study	VB	O
II	NNP	O
)	)	O
or	CC	O
increased	VBN	O
above	IN	O
baseline	NN	O
values	NNS	O
(	(	O
studies	NNS	O
III	NNP	O
and	CC	O
IV	NNP	O
)	)	O
,	,	O
ELF	NNP	O
declined	VBD	O
further	RBR	O
(	(	O
0.64	CD	O
+/-	JJ	O
0.05	CD	O
,	,	O
0.66	CD	O
+/-	JJ	O
0.02	CD	O
,	,	O
and	CC	O
0.66	CD	O
+/-	JJ	O
0.03	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
respectively	RB	O
;	:	O
all	DT	O
Ps	NNP	O
<	NNP	O
0.01	CD	O
versus	NN	O
basal	NN	O
and	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
versus	NN	O
study	NN	O
I	PRP	O
)	)	O
.	.	O

LOX	NNP	O
declined	VBD	O
in	IN	O
study	NN	O
I	PRP	O
(	(	O
0.12	CD	O
+/-	JJ	O
0.02	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
but	CC	O
increased	VBD	O
significantly	RB	O
in	IN	O
studies	NNS	O
II	NNP	O
,	,	O
III	NNP	O
,	,	O
and	CC	O
IV	NNP	O
(	(	O
0.31	CD	O
+/-	JJ	O
0.04	CD	O
,	,	O
0.37	CD	O
+/-	JJ	O
0.03	CD	O
,	,	O
and	CC	O
0.40	CD	O
+/-	JJ	O
0.03	CD	O
mumol.kg-1.min-1	NN	O
,	,	O
respectively	RB	O
,	,	O
all	DT	O
Ps	NNP	O
<	NNP	O
0.01	CD	O
versus	NN	O
basal	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
study	NN	O
IV	NNP	O
versus	NN	O
study	NN	O
II	NNP	O
,	,	O
and	CC	O
P	NNP	O
<	NNP	O
0.05	CD	O
study	NN	O
III	NNP	O
versus	NN	O
study	NN	O
II	NNP	O
)	)	O
.	.	O

NOLD	NNP	O
declined	VBD	O
in	IN	O
study	NN	O
I	PRP	O
(	(	O
0.65	CD	O
+/-	JJ	O
0.05	CD	O
mumol/kg.min	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
,	,	O
whereas	IN	O
neither	CC	O
the	DT	O
maintenance	NN	O
of	IN	O
basal	NN	O
plasma	IN	O
AA/branched-chain	NNP	O
KA	NNP	O
levels	NNS	O
(	(	O
study	NN	O
II	NNP	O
;	:	O
0.89	CD	O
+/-	JJ	O
0.2	CD	O
mumol.kg-1.min-1	NN	O
)	)	O
nor	CC	O
the	DT	O
elevation	NN	O
of	IN	O
plasma	JJ	O
branched-chain	JJ	O
KA	NNP	O
concentration	NN	O
(	(	O
study	JJ	O
IV	NNP	O
;	:	O
0.96	CD	O
+/-	JJ	O
0.1	CD	O
mumol.kg-1.min-1	NN	O
)	)	O
increased	VBD	O
NOLD	NNP	O
above	IN	O
baseline	NN	O
level	NN	O
.	.	O

A	DT	O
stimulation	NN	O
of	IN	O
NOLD	NNP	O
was	VBD	O
observed	VBN	O
only	RB	O
when	WRB	O
plasma	JJ	O
AA	NNP	O
levels	NNS	O
were	VBD	O
increased	VBN	O
(	(	O
study	NN	O
III	NNP	O
;	:	O
1.23	CD	O
+/-	JJ	O
0.03	CD	O
mumol/kg.min	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.01	CD	O
versus	NN	O
basal	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
present	JJ	O
data	NNS	O
do	VBP	O
not	RB	O
support	VB	O
the	DT	O
concept	NN	O
of	IN	O
a	DT	O
direct	JJ	O
anabolic	JJ	O
action	NN	O
of	IN	O
ketoanalogs	NNS	O
but	CC	O
do	VBP	O
provide	VB	O
additional	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
pivotal	JJ	O
role	NN	O
of	IN	O
AA	NNP	O
availability	NN	O
in	IN	O
the	DT	O
stimulation	NN	O
of	IN	O
whole-body	NN	O
protein	NN	O
synthesis	NN	O
.	.	O

Does	NNP	O
temporary	JJ	Surgical
clamping	NN	Surgical
of	IN	Surgical
drains	NNS	Surgical
following	VBG	O
knee	NN	O
arthroplasty	JJ	O
reduce	VB	O
blood	NN	O
loss	NN	O
?	.	O
A	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
randomised	JJ	O
,	,	O
blinded	VBD	O
study	NN	O
76	CD	O
patients	NNS	O
undergoing	JJ	O
primary	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
either	DT	O
immediate	JJ	Surgical
drain	NN	Surgical
opening	NN	Surgical
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
or	CC	O
drains	NNS	Surgical
opened	VBN	Surgical
at	IN	Surgical
2	CD	Surgical
h	NN	Surgical
(	(	O
n	JJ	O
=	NNP	O
31	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
for	IN	O
the	DT	O
volume	NN	O
of	IN	O
drained	JJ	O
blood	NN	O
,	,	O
transfusion	NN	O
requirements	NNS	O
,	,	O
knee	JJ	O
motion	NN	O
or	CC	O
wound	NN	O
status	NN	O
.	.	O

The	DT	O
authors	NNS	O
conclude	VBP	O
that	IN	O
the	DT	O
practice	NN	O
of	IN	O
clamping	VBG	Surgical
drains	NNS	Surgical
has	VBZ	O
no	DT	O
benefit	NN	O
in	IN	O
routine	JJ	O
knee	NN	O
arthroplasty	NN	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
faced	VBN	O
with	IN	O
immediate	JJ	O
brisk	JJ	O
blood	NN	O
loss	NN	O
,	,	O
the	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
drains	NNS	Surgical
can	MD	O
be	VB	O
clamped	VBN	O
without	IN	O
any	DT	O
excess	JJ	O
morbidity	NN	O
.	.	O

Effects	NNS	O
of	IN	O
interaction	NN	O
of	IN	O
RRR-alpha-tocopheryl	NNP	Pharmacological
acetate	NN	Pharmacological
and	CC	O
fish	JJ	Pharmacological
oil	NN	Pharmacological
on	IN	O
low-density-lipoprotein	JJ	O
oxidation	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
and	CC	O
without	IN	O
hormone-replacement	JJ	Pharmacological
therapy	NN	Pharmacological
.	.	Pharmacological

We	PRP	O
evaluated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
RRR-alpha-tocpheryl	NNP	Pharmacological
acetate	NN	Pharmacological
(	(	Pharmacological
alpha-tocopheryl	JJ	Pharmacological
acetate	NN	Pharmacological
)	)	Pharmacological
and	CC	O
hormone-replacement	JJ	Pharmacological
therapy	NN	Pharmacological
(	(	Pharmacological
HRT	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
the	DT	O
oxidative	JJ	O
susceptibility	NN	O
of	IN	O
low-density	NN	O
lipoprotein	NN	O
(	(	O
LDL	NNP	O
)	)	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
consuming	VBG	O
a	DT	O
fish	JJ	Pharmacological
oil	NN	Pharmacological
supplement	NN	Pharmacological
.	.	Pharmacological

The	DT	O
independent	JJ	O
effect	NN	O
of	IN	O
fish	JJ	O
oil	NN	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

Forty-eight	JJ	O
women	NNS	O
,	,	O
equally	RB	O
divided	VBD	O
between	IN	O
women	NNS	O
using	VBG	O
and	CC	O
not	RB	O
using	VBG	O
HRT	NNP	Pharmacological
,	,	O
participated	VBD	O
in	IN	O
a	DT	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
four	CD	O
periods	NNS	O
lasted	VBD	O
5	CD	O
wk	NN	O
and	CC	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
4-wk	JJ	O
washout	NN	O
interval	NN	O
.	.	O

During	IN	O
each	DT	O
period	NN	O
all	DT	O
subjects	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
15-g	JJ	O
supplement	NN	O
of	IN	O
fish	JJ	O
oil	NN	O
and	CC	O
either	RB	O
0	CD	O
(	(	O
placebo	NN	Control
)	)	O
,	,	O
100	CD	O
,	,	O
200	CD	O
,	,	O
or	CC	O
400	CD	O
mg	JJ	O
alpha-tocopheryl	JJ	Pharmacological
acetate	JJ	Pharmacological
daily	JJ	O
.	.	O

LDL	NNP	O
resistance	NN	O
to	TO	O
oxidative	VB	O
modification	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
calculating	VBG	O
lag	NN	O
time	NN	O
,	,	O
propagation	NN	O
rate	NN	O
,	,	O
and	CC	O
maximum	JJ	O
production	NN	O
of	IN	O
conjugated	JJ	O
dienes	NNS	O
.	.	O

Supplementation	NN	O
with	IN	O
fish	JJ	O
oil	NN	O
and	CC	O
placebo	NN	Control
shortened	VBN	O
lag	JJ	O
time	NN	O
and	CC	O
slowed	VBN	O
propagation	NN	O
rate	NN	O
in	IN	O
women	NNS	O
both	DT	O
using	VBG	O
and	CC	O
not	RB	O
using	VBG	O
HRT	NNP	O
.	.	O

After	IN	O
subjects	NNS	O
consumed	VBD	O
fish	JJ	O
oil	NN	O
,	,	O
supplementation	NN	O
with	IN	O
alpha-tocopheryl	JJ	O
acetate	NN	O
increased	VBD	O
plasma	NN	O
and	CC	O
LDL	NNP	O
alpha-tocopherol	NN	O
contents	NNS	O
significantly	RB	O
and	CC	O
lengthened	VBD	O
lag	NN	O
time	NN	O
(	(	O
at	IN	O
even	RB	O
the	DT	O
lowest	JJS	O
concentration	NN	O
)	)	O
but	CC	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
propagation	NN	O
rate	NN	O
or	CC	O
maximum	JJ	O
production	NN	O
compared	VBN	O
with	IN	O
values	NNS	O
measured	VBN	O
after	IN	O
consumption	NN	O
of	IN	O
fish	JJ	O
oil	NN	O
alone	RB	O
.	.	O

Women	NNP	O
not	RB	O
using	VBG	O
HRT	NNP	O
had	VBD	O
faster	JJR	O
propagation	NN	O
rates	NNS	O
and	CC	O
higher	JJR	O
maximum	NN	O
production	NN	O
than	IN	O
women	NNS	O
using	VBG	O
HRT	NNP	O
;	:	O
after	IN	O
supplementation	NN	O
with	IN	O
fish	JJ	O
oil	NN	O
and	CC	O
alpha-tocopheryl	JJ	Pharmacological
acetate	NN	O
these	DT	O
differences	NNS	O
prevailed	VBD	O
.	.	O

Supplements	NNS	O
as	RB	O
low	JJ	O
as	IN	O
100	CD	O
mg	JJ	O
alpha-tocopheryl	JJ	O
acetate/d	NN	O
increase	VB	O
the	DT	O
resistance	NN	O
of	IN	O
LDL	NNP	O
to	TO	O
oxidation	VB	O
when	WRB	O
fish	JJ	O
oil	NN	O
supplements	NNS	O
are	VBP	O
used	VBN	O
.	.	O

HRT	NNP	O
and	CC	O
fish	JJ	O
oil	NN	O
supplements	NNS	O
may	MD	O
independently	RB	O
affect	VB	O
LDL	NNP	O
oxidative	JJ	O
susceptibility	NN	O
.	.	O

Mechanical	JJ	O
efficiency	NN	O
and	CC	O
propulsion	NN	O
technique	NN	O
after	IN	O
7	CD	O
weeks	NNS	O
of	IN	O
low-intensity	JJ	O
wheelchair	NN	O
training	NN	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
7-week	JJ	O
low-intensity	NN	O
hand	NN	O
rim	VBZ	O
wheelchair	JJ	O
training	VBG	O
on	IN	O
the	DT	O
submaximal	JJ	O
metabolic	NN	O
cost	NN	O
,	,	O
mechanical	JJ	O
efficiency	NN	O
and	CC	O
propulsion	NN	O
technique	NN	O
in	IN	O
able-bodied	JJ	O
participants	NNS	O
.	.	O

METHODS	JJ	O
Participants	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
over	RP	O
an	DT	O
experimental	JJ	O
group	NN	O
(	(	O
n=14	CC	O
)	)	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
n=7	RB	O
)	)	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
received	VBD	O
7	CD	O
weeks	NNS	O
wheelchair	JJ	Physical
training	NN	Physical
(	(	O
3	CD	O
week	NN	O
(	(	O
-1	NN	O
)	)	O
,	,	O
70	CD	O
min	NN	O
)	)	O
at	IN	O
a	DT	O
low	JJ	O
intensity	NN	O
(	(	O
30	CD	O
%	NN	O
of	IN	O
the	DT	O
heart	NN	O
rate	NN	O
reserve	NN	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
control	NN	Educational
group	NN	O
did	VBD	Educational
not	RB	Educational
receive	VB	Educational
training	NN	Educational
.	.	O

During	IN	O
pre-	JJ	O
and	CC	O
post-tests	NNS	O
,	,	O
submaximal	JJ	O
exercise	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
stationary	JJ	O
wheelchair	NN	Physical
ergometer	NN	O
at	IN	O
fixed	JJ	O
levels	NNS	O
of	IN	O
power	NN	O
output	NN	O
.	.	O

Mechanical	JJ	O
efficiency	NN	O
,	,	O
oxygen	NN	O
uptake	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
timing	VBG	O
parameters	NNS	O
and	CC	O
stroke	NN	O
angles	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Video	NNP	O
recordings	NNS	O
were	VBD	O
made	VBN	O
to	TO	O
determine	VB	O
the	DT	O
stroke	NN	O
pattern	NN	O
.	.	O

FINDINGS	NNP	O
Mechanical	NNP	O
efficiency	NN	O
increased	VBD	O
and	CC	O
metabolic	JJ	O
cost	NN	O
decreased	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Push	NNP	O
time	NN	O
increased	VBD	O
and	CC	O
cycle	NN	O
frequency	NN	O
decreased	VBD	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
training	NN	O
.	.	O

The	DT	O
stroke	NN	O
angle	NN	O
increased	VBD	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
during	IN	O
the	DT	O
training	NN	O
period	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
preferred	VBD	O
double-looping	NN	O
over	IN	O
propulsion	NN	O
,	,	O
while	IN	O
the	DT	O
control	NN	O
group	NN	O
mainly	RB	O
used	VBD	O
single-looping	NN	O
over	IN	O
propulsion	NN	O
patterns	NNS	O
during	IN	O
the	DT	O
post-test	JJ	O
.	.	O

INTERPRETATION	VB	O
A	DT	O
low-intensity	NN	O
,	,	O
7-week	JJ	O
training	NN	O
protocol	NN	O
has	VBZ	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
mechanical	JJ	O
efficiency	NN	O
and	CC	O
metabolic	JJ	O
cost	NN	O
of	IN	O
wheelchair	NN	O
propulsion	NN	O
in	IN	O
able-bodied	JJ	O
participants	NNS	O
.	.	O

The	DT	O
improved	JJ	O
mechanical	JJ	O
efficiency	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
result	NN	O
of	IN	O
changes	NNS	O
in	IN	O
propulsion	NN	O
technique	NN	O
that	WDT	O
were	VBD	O
found	VBN	O
.	.	O

Effect	NN	O
of	IN	O
testosterone	NN	Pharmacological
and	CC	O
a	DT	O
nutritional	JJ	Pharmacological
supplement	NN	Pharmacological
,	,	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
,	,	O
on	IN	O
hospital	JJ	O
admissions	NNS	O
in	IN	O
undernourished	JJ	O
older	JJR	O
men	NNS	O
and	CC	O
women	NNS	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
older	JJR	O
people	NNS	O
,	,	O
undernutrition	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
hospitalization	NN	O
rates	NNS	O
and	CC	O
mortality	NN	O
.	.	O

Because	IN	O
weight	JJ	O
loss	NN	O
in	IN	O
older	JJR	O
people	NNS	O
often	RB	O
reflects	VBZ	O
a	DT	O
disproportionate	JJ	O
reduction	NN	O
of	IN	O
skeletal	JJ	O
muscle	NN	O
,	,	O
anabolic	JJ	O
treatments	NNS	O
may	MD	O
be	VB	O
beneficial	JJ	O
.	.	O

OBJECTIVE	NNP	O
Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
hypothesis	NN	O
that	WDT	O
testosterone	NN	Pharmacological
treatment	NN	O
and	CC	O
a	DT	O
nutritional	JJ	Pharmacological
supplement	NN	Pharmacological
have	VBP	O
additive	JJ	O
benefits	NNS	O
.	.	O

DESIGN	NNP	O
Oral	NNP	O
testosterone	NN	Pharmacological
undecanoate	NN	Pharmacological
(	(	O
40	CD	O
mg	NNS	O
daily	RB	O
for	IN	O
women	NNS	O
,	,	O
80	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
men	NNS	O
)	)	O
and	CC	O
an	DT	O
oral	JJ	O
nutritional	JJ	Pharmacological
supplement	NN	Pharmacological
(	(	O
475	CD	O
kcal/d	NN	O
)	)	O
were	VBD	O
administered	VBN	O
,	,	O
alone	RB	O
or	CC	O
combined	VBN	O
,	,	O
for	IN	O
1	CD	O
y	NNS	O
to	TO	O
49	CD	O
community-dwelling	NN	O
,	,	O
undernourished	JJ	O
people	NNS	O
[	VBP	O
Mini	NNP	O
Nutritional	NNP	O
Assessment	NNP	O
score	VBD	O
<	JJ	O
24	CD	O
and	CC	O
low	JJ	O
body	NN	O
weight	NN	O
(	(	O
body	JJ	O
mass	NN	O
index	NN	O
,	,	O
in	IN	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
:	:	O
<	$	O
22	CD	O
)	)	O
or	CC	O
recent	JJ	O
weight	JJ	O
loss	NN	O
(	(	O
>	JJ	O
7.5	CD	O
%	NN	O
over	IN	O
3	CD	O
mo	NNS	O
)	)	O
]	VBP	O
aged	VBN	O
>	$	O
65	CD	O
y	NN	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
77	CD	O
y	NN	O
;	:	O
26	CD	O
women	NNS	O
and	CC	O
23	CD	O
men	NNS	O
)	)	O
.	.	O

Hospital	JJ	O
admissions	NNS	O
and	CC	O
other	JJ	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
In	IN	O
subjects	NNS	O
receiving	VBG	O
combined	VBN	O
testosterone	NN	Pharmacological
and	CC	O
nutritional	JJ	Pharmacological
supplements	NNS	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
hospital	NN	O
admissions	NNS	O
,	,	O
whereas	IN	O
there	EX	O
were	VBD	O
9	CD	O
admissions	NNS	O
(	(	O
2	CD	O
elective	NN	O
)	)	O
in	IN	O
13	CD	O
subjects	NNS	O
in	IN	O
the	DT	O
no-treatment	JJ	O
group	NN	O
,	,	O
4	CD	O
in	IN	O
the	DT	O
testosterone-treated	JJ	Pharmacological
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
,	,	O
and	CC	O
5	CD	O
in	IN	O
the	DT	O
supplement-treated	JJ	Pharmacological
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
13	CD	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.06	CD	O
with	IN	O
no-treatment	JJ	O
compared	VBN	O
with	IN	O
combined	JJ	O
treatment	NN	O
.	.	O

When	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
no-treatment	JJ	O
group	NN	O
,	,	O
the	DT	O
combined-treatment	JJ	Pharmacological
group	NN	O
had	VBD	O
significantly	RB	O
fewer	JJR	O
subjects	NNS	O
admitted	VBN	O
to	TO	O
hospital	VB	O
(	(	O
0	CD	O
compared	VBN	O
with	IN	O
5	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
fewer	JJR	O
days	NNS	O
in	IN	O
hospital	NN	O
(	(	O
0	CD	O
compared	VBN	O
with	IN	O
74	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.041	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
longer	JJR	O
time	NN	O
to	TO	O
hospital	VB	O
admission	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.017	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
undernourished	JJ	O
older	JJR	O
people	NNS	O
,	,	O
combined	VBN	O
treatment	NN	O
with	IN	O
testosterone	NN	Pharmacological
and	CC	O
nutritional	JJ	Pharmacological
supplementation	NN	Pharmacological
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
people	NNS	O
hospitalized	VBN	O
and	CC	O
the	DT	O
duration	NN	O
of	IN	O
hospital	NN	O
admissions	NNS	O
,	,	O
which	WDT	O
are	VBP	O
important	JJ	O
endpoints	NNS	O
in	IN	O
this	DT	O
group	NN	O
.	.	O

Larger	NNP	O
,	,	O
confirmatory	NN	O
studies	NNS	O
are	VBP	O
now	RB	O
needed	VBN	O
.	.	O

This	DT	O
trial	NN	O
was	VBD	O
registered	VBN	O
before	IN	O
commencement	NN	O
at	IN	O
clinical	JJ	O
trials.gov	NN	O
as	IN	O
NCT00117000	NNP	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
radiation	NN	Surgical
therapy	NN	Surgical
compared	VBN	O
to	TO	O
split	VB	Surgical
course	NN	Surgical
radiation	NN	Surgical
therapy	NN	Surgical
combined	VBN	O
with	IN	O
mitomycin	JJ	Pharmacological
C	NNP	Pharmacological
and	CC	O
5	CD	Pharmacological
fluorouracil	NN	Pharmacological
as	IN	O
initial	JJ	O
treatment	NN	O
for	IN	O
advanced	JJ	O
laryngeal	NN	O
and	CC	O
hypopharyngeal	NN	O
squamous	JJ	O
carcinoma	NN	O
.	.	O

Two	CD	O
hundred	VBD	O
and	CC	O
twelve	JJ	O
patients	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
advanced	JJ	O
squamous	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
larynx	NN	O
or	CC	O
hypopharynx	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
initial	JJ	O
treatment	NN	O
with	IN	O
radiotherapy	NN	Surgical
,	,	O
50	CD	O
Gy	NNP	O
in	IN	O
20	CD	O
fractions	NNS	O
in	IN	O
28	CD	O
days	NNS	O
or	CC	O
split	JJ	Surgical
course	NN	Surgical
radiotherapy	NN	Surgical
and	CC	O
concurrent	NN	Pharmacological
chemotherapy	NN	Pharmacological
,	,	O
25	CD	O
Gy	NNP	O
in	IN	O
10	CD	O
fractions	NNS	O
in	IN	O
14	CD	O
days	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
4	CD	O
week	NN	O
rest	NN	O
and	CC	O
a	DT	O
further	JJ	O
25	CD	O
Gy	NNP	O
in	IN	O
10	CD	O
fractions	NNS	O
in	IN	O
14	CD	O
days	NNS	O
starting	VBG	O
on	IN	O
day	NN	O
43	CD	O
;	:	O
Mitomycin	NNP	Pharmacological
C	NNP	Pharmacological
was	VBD	O
given	VBN	O
on	IN	O
day	NN	O
1	CD	O
and	CC	O
day	NN	O
43	CD	O
and	CC	O
5FU	CD	Pharmacological
continuous	JJ	O
infusions	NNS	O
on	IN	O
days	NNS	O
1	CD	O
--	:	O
4	CD	O
and	CC	O
days	NNS	O
43	CD	O
--	:	O
46	CD	O
.	.	O

Surgery	NN	O
was	VBD	O
reserved	VBN	O
for	IN	O
persistent	NN	O
or	CC	O
recurrent	JJ	O
disease	NN	O
.	.	O

Two	CD	O
hundred	VBD	O
and	CC	O
nine	CD	O
of	IN	O
the	DT	O
212	CD	O
patients	NNS	O
randomized	VBN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analyses	NNS	O
.	.	O

Outcome	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
a	DT	O
median	JJ	O
follow-up	JJ	O
interval	NN	O
of	IN	O
4.4	CD	O
years	NNS	O
.	.	O

No	DT	O
patients	NNS	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
for	IN	O
the	DT	O
end	NN	O
points	NNS	O
of	IN	O
local	JJ	O
relapse-free	JJ	O
rate	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.91	CD	O
)	)	O
,	,	O
regional	JJ	O
relapse-free	JJ	O
rate	NN	O
(	(	O
p	JJ	O
=	NN	O
0.17	CD	O
,	,	O
adjusted	VBN	O
)	)	O
or	CC	O
overall	JJ	O
survival	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.86	CD	O
)	)	O
.	.	O

Eight-eight	JJ	O
patients	NNS	O
had	VBD	O
attempted	VBN	O
surgical	JJ	O
resection	NN	O
following	VBG	O
radiotherapy	JJ	Surgical
failure	NN	O
.	.	O

The	DT	O
contribution	NN	O
of	IN	O
salvage	NN	O
surgery	NN	O
to	TO	O
overall	JJ	O
survival	NN	O
was	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
arms	NNS	O
of	IN	O
the	DT	O
study	NN	O
as	IN	O
was	VBD	O
the	DT	O
surgical	JJ	O
complication	NN	O
rate	NN	O
.	.	O

Serious	JJ	O
late	JJ	O
radiation	NN	O
toxicity	NN	O
was	VBD	O
minimal	JJ	O
(	(	O
3	CD	O
%	NN	O
in	IN	O
the	DT	O
RT	NNP	O
group	NN	O
,	,	O
0	CD	O
%	NN	O
in	IN	O
the	DT	O
radiation	NN	O
therapy	NN	O
plus	CC	O
chemotherapy	NN	O
group	NN	O
)	)	O
.	.	O

The	DT	O
result	NN	O
of	IN	O
the	DT	O
trial	NN	O
shows	VBZ	O
no	DT	O
advantage	NN	O
in	IN	O
terms	NNS	O
of	IN	O
local	JJ	O
control	NN	O
or	CC	O
survival	NN	O
for	IN	O
the	DT	O
experimental	JJ	O
treatment	NN	O
arm	NN	O
of	IN	O
split	NN	O
course	NN	O
radiotherapy	NN	Surgical
and	CC	O
concurrent	JJ	Pharmacological
chemotherapy	NN	Pharmacological
with	IN	O
Mitomycin	NNP	Pharmacological
C	NNP	Pharmacological
and	CC	O
5	CD	Pharmacological
Fluorouracil	NNP	Pharmacological
compared	VBN	O
to	TO	O
radiotherapy	VB	O
alone	RB	O
.	.	O

Perioperative	JJ	O
fever	NN	O
and	CC	O
outcome	NN	O
in	IN	O
surgical	JJ	O
patients	NNS	O
with	IN	O
aneurysmal	JJ	O
subarachnoid	JJ	O
hemorrhage	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
examined	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
perioperative	JJ	O
fever	NN	O
and	CC	O
its	PRP$	O
relationship	NN	O
to	TO	O
outcome	VB	O
among	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Intraoperative	NNP	O
Hypothermia	NNP	O
for	IN	O
Aneurysm	NNP	O
Surgery	NNP	O
Trial	NNP	O
.	.	O

METHODS	NNP	O
One	CD	O
thousand	NN	O
patients	NNS	O
with	IN	O
initial	JJ	O
World	NNP	O
Federation	NNP	O
of	IN	O
Neurological	NNP	O
Surgeons	NNP	O
grades	NNS	O
of	IN	O
I	PRP	O
to	TO	O
III	NNP	O
undergoing	VBG	O
clipping	NN	O
of	IN	O
intracranial	JJ	O
aneurysms	NNS	O
after	IN	O
subarachnoid	JJ	O
hemorrhage	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
intraoperative	VB	Other
normothermia	NN	Other
(	(	O
36	CD	O
degrees	NNS	O
C-37	JJ	O
degrees	NNS	O
C	NNP	O
)	)	O
or	CC	O
hypothermia	NN	Other
(	(	O
32.5	CD	O
degrees	NNS	O
C-33.5	JJ	O
degrees	NNS	O
C	NNP	O
)	)	O
.	.	O

Fever	NNP	O
(	(	O
>	CD	O
or	CC	O
=38.5	VB	O
degrees	NNS	O
C	NNP	O
)	)	O
and	CC	O
other	JJ	O
complications	NNS	O
(	(	O
including	VBG	O
infections	NNS	O
)	)	O
occurring	VBG	O
between	IN	O
admission	NN	O
and	CC	O
discharge	NN	O
(	(	O
or	CC	O
death	NN	O
)	)	O
were	VBD	O
recorded	VBN	O
.	.	O

Functional	NNP	O
and	CC	O
neuropsychologic	JJ	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
3	CD	O
months	NNS	O
postoperatively	RB	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
variable	NN	O
for	IN	O
the	DT	O
trial	NN	O
was	VBD	O
dichotomized	VBN	O
Glasgow	NNP	O
Outcome	NNP	O
Scale	NNP	O
(	(	O
good	JJ	O
outcome	NN	O
versus	IN	O
all	DT	O
others	NNS	O
)	)	O
.	.	O

RESULTS	NNP	O
Fever	NNP	O
was	VBD	O
reported	VBN	O
in	IN	O
41	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

In	IN	O
97	CD	O
%	NN	O
of	IN	O
these	DT	O
,	,	O
fever	RB	O
occurred	VBD	O
in	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
from	IN	O
surgery	NN	O
to	TO	O
first	VB	O
fever	NN	O
was	VBD	O
3	CD	O
days	NNS	O
.	.	O

All	DT	O
measures	NNS	O
of	IN	O
outcome	NN	O
were	VBD	O
worse	JJR	O
in	IN	O
patients	NNS	O
who	WP	O
developed	VBD	O
fever	NN	O
,	,	O
even	RB	O
in	IN	O
those	DT	O
without	IN	O
infections	NNS	O
or	CC	O
who	WP	O
were	VBD	O
World	NNP	O
Federation	NNP	O
of	IN	O
Neurological	NNP	O
Surgeons	NNP	O
grade	VBD	O
I.	NNP	O
Logistic	NNP	O
regression	NN	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
adjust	VB	O
for	IN	O
differences	NNS	O
in	IN	O
preoperative	JJ	O
factors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
age	NN	O
,	,	O
Fisher	NNP	O
grade	NN	O
,	,	O
initial	JJ	O
neurological	JJ	O
status	NN	O
)	)	O
.	.	O

This	DT	O
demonstrated	VBD	O
that	IN	O
fever	NN	O
continued	VBD	O
to	TO	O
be	VB	O
significantly	RB	O
associated	VBN	O
with	IN	O
most	JJS	O
outcome	JJ	O
measures	NNS	O
,	,	O
even	RB	O
when	WRB	O
infection	NN	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
model	NN	O
.	.	O

An	DT	O
alternative	JJ	O
stepwise	NN	O
model	NN	O
selection	NN	O
process	NN	O
including	VBG	O
all	DT	O
fever-related	JJ	O
measures	NNS	O
from	IN	O
the	DT	O
preoperative	NN	O
and	CC	O
intraoperative	JJ	O
period	NN	O
(	(	O
e.g.	JJ	O
,	,	O
hydrocephalus	JJ	O
,	,	O
duration	NN	O
of	IN	O
surgery	NN	O
,	,	O
intraoperative	JJ	O
blood	NN	O
loss	NN	O
)	)	O
resulted	VBD	O
in	IN	O
the	DT	O
loss	NN	O
of	IN	O
significance	NN	O
for	IN	O
dichotomized	JJ	O
Glasgow	NNP	O
Outcome	NNP	O
Scale	NNP	O
,	,	O
but	CC	O
significant	JJ	O
associations	NNS	O
between	IN	O
fever	NN	O
and	CC	O
several	JJ	O
other	JJ	O
outcome	JJ	O
measures	NNS	O
remained	VBD	O
.	.	O

After	IN	O
adding	VBG	O
postoperative	JJ	O
delayed	VBN	O
ischemic	JJ	O
neurological	JJ	O
deficits	NNS	O
to	TO	O
the	DT	O
model	NN	O
,	,	O
only	RB	O
worsened	VBD	O
National	NNP	O
Institutes	NNPS	O
of	IN	O
Health	NNP	O
Stroke	NNP	O
Scale	NNP	O
score	NN	O
,	,	O
Barthel	NNP	O
Activities	NNP	O
of	IN	O
Daily	NNP	O
Living	NNP	O
index	NN	O
,	,	O
and	CC	O
discharge	NN	O
destination	NN	O
(	(	O
home	NN	O
versus	IN	O
other	JJ	O
)	)	O
remained	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
fever	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
fever	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
worsened	JJ	O
outcome	NN	O
in	IN	O
surgical	JJ	O
subarachnoid	JJ	O
hemorrhage	NN	O
patients	NNS	O
,	,	O
although	IN	O
,	,	O
because	IN	O
the	DT	O
association	NN	O
between	IN	O
fever	NN	O
and	CC	O
the	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
for	IN	O
the	DT	O
trial	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
covariates	NNS	O
used	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
(	(	O
particularly	RB	O
operative	JJ	O
events	NNS	O
and	CC	O
delayed	VBN	O
ischemic	JJ	O
neurological	JJ	O
deficits	NNS	O
)	)	O
,	,	O
we	PRP	O
can	MD	O
not	RB	O
rule	VB	O
out	IN	O
the	DT	O
possibility	NN	O
that	IN	O
fever	NN	O
is	VBZ	O
a	DT	O
marker	NN	O
for	IN	O
other	JJ	O
events	NNS	O
.	.	O

Only	RB	O
a	DT	O
formal	JJ	O
trial	NN	O
of	IN	O
fever	NN	O
treatment	NN	O
or	CC	O
prevention	NN	O
can	MD	O
address	VB	O
this	DT	O
issue	NN	O
.	.	O

1999	CD	O
WHO/ISH	NNP	O
Guidelines	NNP	O
applied	VBD	O
to	TO	O
a	DT	O
1999	CD	O
MONICA	NNP	O
sample	NN	O
from	IN	O
northern	JJ	O
Sweden	NNP	O
.	.	O

BACKGROUND	NNP	O
Treating	NNP	O
hypertension	NN	O
with	IN	O
drugs	NNS	O
is	VBZ	O
so	RB	O
far	RB	O
the	DT	O
most	RBS	O
cost-effective	JJ	O
way	NN	O
to	TO	O
reduce	VB	O
this	DT	O
important	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
,	,	O
however	RB	O
,	,	O
important	JJ	O
to	TO	O
determine	VB	O
absolute	NN	O
risk	NN	O
,	,	O
and	CC	O
thereby	RB	O
estimate	VB	O
indication	NN	O
for	IN	O
drug	NN	O
treatment	NN	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
maintain	VB	O
a	DT	O
cost-effective	JJ	O
drug	NN	O
treatment	NN	O
.	.	O

WHO/ISH	NNP	O
Hypertension	NNP	O
Guidelines	NNP	O
from	IN	O
1999	CD	O
propose	NN	O
a	DT	O
risk	NN	O
stratification	NN	O
for	IN	O
estimating	VBG	O
absolute	NN	O
risk	NN	O
for	IN	O
CVD	NNP	O
based	VBN	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
additional	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
target	NN	O
organ	JJ	O
damage	NN	O
(	(	O
TOD	NNP	O
)	)	O
and	CC	O
CVD	NNP	O
.	.	O

OBJECTIVES	NNP	O
We	PRP	O
studied	VBD	O
the	DT	O
consequences	NNS	O
of	IN	O
applying	VBG	O
the	DT	O
recent	JJ	O
WHO/ISH	NNP	Pharmacological
risk	NN	Pharmacological
stratification	NN	Pharmacological
scheme	NN	Pharmacological
to	TO	O
a	DT	O
MONICA	NNP	O
sample	NN	O
of	IN	O
6000	CD	O
subjects	NNS	O
from	IN	O
a	DT	O
geographically	RB	O
defined	VBN	O
population	NN	O
in	IN	O
northern	JJ	O
Sweden	NNP	O
,	,	O
regarding	VBG	O
indications	NNS	O
for	IN	O
treatment	NN	O
,	,	O
target	VB	O
blood	NN	O
pressure	NN	O
and	CC	O
risk	NN	O
distribution	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
have	VBP	O
risk-classified	JJ	O
each	DT	O
of	IN	O
these	DT	O
patients	NNS	O
using	VBG	O
a	DT	O
computer	NN	Other
program	NN	Other
,	,	O
according	VBG	O
to	TO	O
the	DT	O
WHO/ISH	NNP	O
scheme	NN	O
.	.	O

Data	NNP	O
on	IN	O
TOD	NNP	O
were	VBD	O
not	RB	O
available	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
all	DT	O
,	,	O
917	CD	O
(	(	O
15	CD	O
%	NN	O
)	)	O
had	VBD	O
drug-treated	JJ	O
hypertension	NN	O
.	.	O

Three-quarters	NNS	O
(	(	O
n	JJ	O
=	NNP	O
737	CD	O
)	)	O
were	VBD	O
inadequately	RB	O
treated	VBN	O
,	,	O
with	IN	O
blood	NN	O
pressure	NN	O
levels	NNS	O
at	IN	O
or	CC	O
above	VB	O
140	CD	O
or	CC	O
90	CD	O
mmHg	NN	O
.	.	O

1773	CD	O
(	(	O
30	CD	O
%	NN	O
of	IN	O
5997	CD	O
)	)	O
untreated	JJ	O
subjects	NNS	O
had	VBD	O
a	DT	O
blood	NN	O
pressure	NN	O
of	IN	O
140/90	CD	O
or	CC	O
above	RB	O
;	:	O
16	CD	O
%	NN	O
in	IN	O
the	DT	O
low-	JJ	O
,	,	O
62	CD	O
%	NN	O
in	IN	O
the	DT	O
medium-	NN	O
,	,	O
8	CD	O
%	NN	O
in	IN	O
the	DT	O
high-	NN	O
,	,	O
and	CC	O
14	CD	O
%	NN	O
in	IN	O
the	DT	O
very-high-risk	JJ	O
group	NN	O
.	.	O

The	DT	O
corresponding	JJ	O
risk-group	JJ	O
pattern	NN	O
for	IN	O
the	DT	O
inadequately	RB	O
treated	JJ	O
hypertensives	NNS	O
(	(	O
n	JJ	O
=	NNP	O
737	CD	O
)	)	O
was	VBD	O
5.5	CD	O
,	,	O
48.3	CD	O
,	,	O
11.1	CD	O
and	CC	O
35.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

If	IN	O
we	PRP	O
shifted	VBD	O
the	DT	O
target	NN	O
blood	NN	O
pressure	NN	O
from	IN	O
below	IN	O
140/90	CD	O
to	TO	O
below	VB	O
130/85	CD	O
for	IN	O
drug-treated	JJ	O
subjects	NNS	O
under	IN	O
60	CD	O
(	(	O
n	JJ	O
=	NNP	O
278	CD	O
)	)	O
the	DT	O
number	NN	O
of	IN	O
inadequately	RB	O
treated	JJ	O
subjects	NNS	O
increased	VBN	O
by	IN	O
34	CD	O
(	(	O
12.2	CD	O
%	NN	O
of	IN	O
278	CD	O
)	)	O
;	:	O
14	CD	O
in	IN	O
the	DT	O
low-risk	JJ	O
group	NN	O
,	,	O
15	CD	O
in	IN	O
the	DT	O
medium-risk	JJ	O
group	NN	O
,	,	O
and	CC	O
only	RB	O
five	CD	O
in	IN	O
the	DT	O
high-	JJ	O
or	CC	O
very-high-risk	JJ	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Only	RB	O
one-fifth	NN	O
of	IN	O
the	DT	O
drug-treated	JJ	O
hypertensives	NNS	O
were	VBD	O
well	RB	O
controlled	VBN	O
.	.	O

Moreover	RB	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
newly	RB	O
detected	VBN	O
blood	NN	O
pressure	NN	O
elevation	NN	O
was	VBD	O
high	JJ	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
younger	JJR	O
subjects	NNS	O
with	IN	O
high	JJ	O
blood	NN	O
pressure	NN	O
had	VBD	O
low	JJ	O
risk	NN	O
,	,	O
but	CC	O
in	IN	O
those	DT	O
aged	VBN	O
45-54	CD	O
this	DT	O
had	VBD	O
already	RB	O
risen	VBN	O
to	TO	O
a	DT	O
medium	NN	O
risk	NN	O
.	.	O

Changing	VBG	O
the	DT	O
target	NN	O
blood	NN	O
pressure	NN	O
to	TO	O
below	IN	O
130/85	CD	O
,	,	O
for	IN	O
subjects	NNS	O
aged	VBN	O
below	IN	O
60	CD	O
,	,	O
as	IN	O
recommended	VBN	O
by	IN	O
WHO/ISH	NNP	O
,	,	O
affects	VBZ	O
predominantly	RB	O
low-	JJ	O
and	CC	O
medium-risk	JJ	O
groups	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
hypoxemia	NN	O
on	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

A	DT	O
dose-response	JJ	O
curve	NN	O
.	.	O

To	TO	O
establish	VB	O
a	DT	O
dose-response	JJ	O
curve	NN	O
for	IN	O
the	DT	O
effects	NNS	O
of	IN	O
isocapnic	JJ	O
hypoxemia	NN	O
on	IN	O
cardiac	JJ	O
output	NN	O
(	(	O
CO	NNP	O
)	)	O
,	,	O
we	PRP	O
studied	VBD	O
20	CD	O
healthy	JJ	O
men	NNS	O
,	,	O
aged	VBD	O
20	CD	O
to	TO	O
34	CD	O
years	NNS	O
,	,	O
using	VBG	O
a	DT	O
tight-fitting	JJ	Other
face	NN	Other
mask	NN	Other
and	CC	Other
an	DT	Other
isocapnic	JJ	Other
partial	NN	Other
rebreathing	NN	Other
system	NN	Other
(	(	O
a	DT	O
modified	VBN	O
anesthesia	NN	O
machine	NN	O
)	)	O
.	.	O

We	PRP	O
blended	VBD	O
oxygen	NN	Other
and	CC	O
hypoxic	NN	Other
gas	NN	Other
to	TO	O
achieve	VB	O
arterial	JJ	O
oxygen	NN	O
saturations	NNS	O
(	(	O
SaO2	NNP	O
)	)	O
of	IN	O
80	CD	O
,	,	O
85	CD	O
,	,	O
and	CC	O
90	CD	O
percent	NN	O
;	:	O
subjects	NNS	O
also	RB	O
breathed	VBD	O
100	CD	Other
percent	NN	Other
oxygen	NN	Other
and	CC	O
room	NN	Other
air	NN	Other
(	(	O
RA	NNP	O
)	)	O
.	.	O

Target	NNP	O
SaO2	NNP	O
and	CC	O
end-tidal	JJ	O
carbon	NN	O
dioxide	NN	O
were	VBD	O
continuously	RB	O
monitored	VBN	O
using	VBG	O
an	DT	O
ear	JJ	O
oximeter	NN	O
and	CC	O
CO2	NNP	O
gas	NN	O
analyzer	NN	O
.	.	O

Subjects	NNS	O
experienced	VBD	O
the	DT	O
five	CD	O
SaO2	NNP	O
measurements	NNS	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

CO	NNP	O
was	VBD	O
measured	VBN	O
noninvasively	RB	O
at	IN	O
approximately	RB	O
two-minute	JJ	O
intervals	NNS	O
,	,	O
using	VBG	O
continuous-wave	JJ	O
Doppler	NNP	O
echocardiography	NN	O
.	.	O

Mean	NNP	O
cardiac	JJ	O
output	NN	O
increased	VBD	O
with	IN	O
increasing	VBG	O
hypoxemia	NN	O
from	IN	O
6.84	CD	O
L/min	NNP	O
at	IN	O
FIo2	NNP	O
1.0	CD	O
to	TO	O
8.44	CD	O
L/min	NNP	O
at	IN	O
SaO2	NNP	O
80	CD	O
percent	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0005	CD	O
)	)	O
;	:	O
the	DT	O
increase	NN	O
was	VBD	O
entirely	RB	O
due	JJ	O
to	TO	O
increased	JJ	O
heart	NN	O
rate	NN	O
.	.	O

We	PRP	O
concluded	VBD	O
that	IN	O
cardiac	JJ	O
output	NN	O
increases	NNS	O
significantly	RB	O
in	IN	O
a	DT	O
dose-response	JJ	O
manner	NN	O
in	IN	O
response	NN	O
to	TO	O
acute	VB	O
isocapnic	JJ	O
hypoxemia	NN	O
in	IN	O
normal	JJ	O
persons	NNS	O
.	.	O

Is	VBZ	O
chronic	JJ	Pharmacological
sildenafil	NN	Pharmacological
therapy	NN	Pharmacological
safe	JJ	O
and	CC	O
clinically	RB	O
beneficial	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
systolic	JJ	O
heart	NN	O
failure	NN	O
?	.	O
Sildenafil	NNP	Pharmacological
is	VBZ	O
a	DT	O
selective	JJ	O
phosphodiesterase-5	JJ	O
inhibitor	NN	O
and	CC	O
causes	VBZ	O
vasodilatation	NN	O
,	,	O
particularly	RB	O
in	IN	O
pulmonary	JJ	O
circulation	NN	O
.	.	O

Since	IN	O
left	JJ	O
heart	NN	O
failure	NN	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
pulmonary	JJ	O
hypertension	NN	O
out	IN	O
of	IN	O
proportion	NN	O
to	TO	O
left	VB	O
heart	NN	O
disease	NN	O
,	,	O
sildenafil	NN	Pharmacological
may	MD	O
have	VB	O
beneficial	JJ	O
effect	NN	O
in	IN	O
such	JJ	O
patients	NNS	O
.	.	O

The	DT	O
present	JJ	O
investigation	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
12-week	JJ	O
,	,	O
single-center	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
study	NN	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
sildenafil	NN	Pharmacological
on	IN	O
mean	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
primary	JJ	O
endpoint	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
systolic	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
included	VBD	O
exercise	NN	O
capacity	NN	O
assessed	VBN	O
by	IN	O
6-minute	JJ	O
walk	NN	O
test	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
106	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
1:1	CD	O
to	TO	O
sildenafil	VB	Pharmacological
(	(	O
n=53	NN	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n=53	JJ	O
)	)	O
.	.	O

Patients	NNS	O
received	VBD	O
sildenafil	JJ	Pharmacological
25	CD	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
or	CC	O
matching	VBG	O
placebo	NN	Control
for	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
and	CC	O
50	CD	O
mg	NN	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

The	DT	O
placebo-corrected	JJ	O
effect	NN	O
on	IN	O
mean	JJ	O
blood	NN	O
pressure	NN	O
was	VBD	O
1.16	CD	O
mm	NN	O
Hg	NNP	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-1.6	VBP	O
to	TO	O
5.1	CD	O
,	,	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
,	,	O
demonstrating	VBG	O
that	IN	O
sildenafil	NN	O
did	VBD	O
not	RB	O
decrease	VB	O
mean	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
sildenafil	NN	Pharmacological
increased	VBD	O
the	DT	O
6-minute	JJ	O
walk	NN	O
test	NN	O
by	IN	O
a	DT	O
nonsignificant	JJ	O
treatment	NN	O
effect	NN	O
of	IN	O
14	CD	O
m	NN	O
(	(	O
P=.67	NNP	O
)	)	O
.	.	O

Adverse	JJ	O
effects	NNS	O
occurred	VBD	O
in	IN	O
a	DT	O
comparable	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
taking	VBG	O
sildenafil	JJ	Pharmacological
and	CC	O
placebo	NN	O
,	,	O
and	CC	O
none	NN	O
of	IN	O
the	DT	O
patients	NNS	O
needed	VBN	O
to	TO	O
discontinue	VB	O
therapy	NN	O
.	.	O

Sildenafil	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
in	IN	O
left	JJ	O
heart	NN	O
failure	NN	O
patients	NNS	O
and	CC	O
does	VBZ	O
not	RB	O
decrease	VB	O
blood	NN	O
pressure	NN	O
.	.	O

It	PRP	O
can	MD	O
be	VB	O
safely	RB	O
added	VBN	O
to	TO	O
standard	VB	O
heart	NN	O
failure	NN	O
therapy	NN	O
.	.	O

Effect	NN	O
of	IN	O
ranolazine	NN	Pharmacological
on	IN	O
A1C	NNP	O
and	CC	O
glucose	JJ	O
levels	NNS	O
in	IN	O
hyperglycemic	JJ	O
patients	NNS	O
with	IN	O
non-ST	JJ	O
elevation	NN	O
acute	NN	O
coronary	JJ	O
syndrome	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
determined	VBD	O
the	DT	O
relationships	NNS	O
between	IN	O
glycemia	NN	O
at	IN	O
randomization	NN	O
,	,	O
concurrent	JJ	Pharmacological
antidiabetic	JJ	Pharmacological
therapy	NN	Pharmacological
,	,	O
and	CC	O
change	NN	O
in	IN	O
A1C	NNP	O
and	CC	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
(	(	O
FPG	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
receiving	VBG	O
standard	JJ	O
treatment	NN	O
for	IN	O
diabetes	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
ranolazine	VB	Pharmacological
or	CC	O
placebo	VB	Control
within	IN	O
the	DT	O
MERLIN-TIMI-36	NNP	O
(	(	O
MERLIN	NNP	O
)	)	O
study	NN	O
.	.	O

Ranolazine	NNP	Pharmacological
is	VBZ	O
a	DT	O
novel	JJ	O
first-in-class	JJ	O
drug	NN	O
approved	VBD	O
for	IN	O
treating	VBG	O
angina	JJ	O
pectoris	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
Randomization	NNP	O
and	CC	O
4-month	JJ	O
glycemic	NN	O
and	CC	O
antidiabetes	VBZ	Pharmacological
drug	NN	Pharmacological
usage	NN	O
data	NNS	O
from	IN	O
MERLIN	NNP	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
Spotfire	NNP	O
and	CC	O
SAS	NNP	O
version	NN	O
9.1	CD	O
software	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
and	CC	O
A1C	NNP	O
of	IN	O
>	NNP	O
or=8-10	JJ	O
%	NN	O
at	IN	O
randomization	NN	O
(	(	O
n	JJ	O
=	NNP	O
171	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
an	DT	O
absolute	JJ	O
A1C	NNP	O
reduction	NN	O
in	IN	O
the	DT	O
ranolazine	NN	Pharmacological
group	NN	O
of	IN	O
1.2	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-1.4	NNP	O
to	TO	O
-1.0	VB	O
)	)	O
,	,	O
and	CC	O
the	DT	O
placebo-adjusted	JJ	Control
(	(	O
n	JJ	O
=	NNP	O
182	CD	O
)	)	O
decrease	NN	O
in	IN	O
A1C	NNP	O
by	IN	O
ranolazine	NN	O
was	VBD	O
0.59	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-0.99	NNP	O
to	TO	O
-0.20	VB	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
FPG	NNP	O
of	IN	O
150-400	JJ	O
mg/dl	NN	O
at	IN	O
randomization	NN	O
,	,	O
ranolazine	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
131	CD	O
)	)	O
compared	VBN	O
with	IN	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
147	CD	O
)	)	O
reduced	VBN	O
FPG	NNP	O
by	IN	O
25.7	CD	O
mg/dl	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-43.3	NNP	O
to	TO	O
-8.1	VB	O
,	,	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

When	WRB	O
changes	NNS	O
in	IN	O
either	DT	O
A1C	NNP	O
or	CC	O
FPG	NNP	O
were	VBD	O
correlated	VBN	O
to	TO	O
A1C	NNP	O
or	CC	O
FPG	NNP	O
at	IN	O
randomization	NN	O
,	,	O
the	DT	O
slopes	NNS	O
were	VBD	O
significantly	RB	O
steeper	JJR	O
for	IN	O
ranolazine	NN	Pharmacological
than	IN	O
placebo	NN	Control
(	(	O
A1C	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.046	CD	O
;	:	O
FPG	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
indicating	VBG	O
that	IN	O
lowering	VBG	O
of	IN	O
A1C	NNP	O
and	CC	O
FPG	NNP	O
by	IN	O
ranolazine	NN	Pharmacological
is	VBZ	O
related	VBN	O
to	TO	O
hyperglycemia	VB	O
at	IN	O
randomization	NN	O
.	.	O

Ranolazine	NNP	O
,	,	O
compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
serious	JJ	O
hypoglycemic	JJ	O
events	NNS	O
,	,	O
associated	VBN	O
with	IN	O
significant	JJ	O
changes	NNS	O
in	IN	O
concurrent	JJ	O
antidiabetic	JJ	Pharmacological
therapy	NN	Pharmacological
,	,	O
or	CC	O
dependent	NN	O
on	IN	O
a	DT	O
history	NN	O
of	IN	O
angina	NN	O
.	.	O

CONCLUSIONS	NNP	O
Ranolazine	NNP	Pharmacological
,	,	O
when	WRB	O
added	VBN	O
to	TO	O
concurrent	VB	O
antidiabetes	NNS	O
treatment	NN	O
,	,	O
lowers	NNS	O
FPG	NNP	O
and	CC	O
A1C	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
and	CC	O
poorly	RB	O
controlled	VBN	O
diabetes	NNS	O
.	.	O

[	JJ	O
Dose-reduced	NNP	O
antihypertensive	JJ	Pharmacological
agents	NNS	Pharmacological
--	:	O
use	NN	O
in	IN	O
complex	JJ	O
nonmedicamentous	JJ	Pharmacological
therapy	NN	O
of	IN	O
hypertension	NN	O
]	NNP	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
estimate	VB	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
non-medicamentous	JJ	Pharmacological
therapy	NN	Pharmacological
(	(	Pharmacological
CNT	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
the	DT	O
consumption	NN	O
of	IN	O
medicaments	NNS	O
and	CC	O
coronary	JJ	O
risk	NN	O
in	IN	O
high	JJ	O
blood	NN	O
pressure	NN	O
73	CD	O
hypertensives	NNS	O
of	IN	O
a	DT	O
medicamentously	RB	O
stabilized	VBN	O
CNT-group	NNP	O
were	VBD	O
examined	VBN	O
in	IN	O
comparison	NN	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
the	DT	O
same	JJ	O
size	NN	O
of	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
who	WP	O
were	VBD	O
managed	VBN	O
exclusively	RB	O
medicamentously	RB	O
for	IN	O
behaviour	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
,	,	O
need	NN	O
of	IN	O
antihypertensive	JJ	Pharmacological
drugs	NNS	Pharmacological
and	CC	O
changes	NNS	O
of	IN	O
hypertension-associated	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

After	IN	O
an	DT	O
exactly	RB	O
controlled	VBN	O
6-month	JJ	O
treatment	NN	O
hypertensives	NNS	O
with	IN	O
additionally	RB	O
recommended	VBN	O
far-reaching	NN	O
CNT	NNP	O
showed	VBD	O
an	DT	O
economization	NN	O
of	IN	O
medicaments	NNS	O
by	IN	O
scarcely	RB	O
the	DT	O
half	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
reference	NN	O
group	NN	O
.	.	O

By	IN	O
means	NNS	O
of	IN	O
suitable	JJ	O
control	NN	O
methods	VBZ	O
a	DT	O
causal	JJ	O
non-medicamentously	RB	Pharmacological
conditioned	JJ	O
decrease	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
could	MD	O
be	VB	O
excluded	VBN	O
.	.	O

A	DT	O
different	JJ	O
need	NN	O
of	IN	O
antihypertensive	JJ	Pharmacological
drugs	NNS	Pharmacological
was	VBD	O
simulated	VBN	O
by	IN	O
the	DT	O
exacter	JJ	O
intake	NN	O
of	IN	O
medicaments	NNS	O
in	IN	O
the	DT	O
index-patients	NNS	O
.	.	O

Notwithstanding	VBG	O
the	DT	O
metabolic	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
additional	JJ	O
therapy	NN	O
have	VBP	O
induced	VBN	O
a	DT	O
positive	JJ	O
change	NN	O
of	IN	O
atherogenic	JJ	O
lipids	NNS	O
.	.	O

The	DT	O
examinations	NNS	O
indicate	VBP	O
in	IN	O
general	JJ	O
the	DT	O
difficulty	NN	O
of	IN	O
the	DT	O
judgement	NN	O
of	IN	O
efficacy	NN	O
of	IN	O
non-medicamentous	JJ	Pharmacological
therapeutic	JJ	Pharmacological
measures	NNS	O
in	IN	O
connection	NN	O
with	IN	O
a	DT	O
rational	JJ	O
dose-reduced	JJ	O
long-term	JJ	O
therapy	NN	O
with	IN	O
antihypertensive	JJ	O
drugs	NNS	O
.	.	O

Comparing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
peer	NN	Educational
mentoring	NN	Educational
and	CC	O
student	NN	Educational
mentoring	NN	Educational
in	IN	O
a	DT	O
35-week	JJ	O
fitness	NN	O
program	NN	O
for	IN	O
older	JJR	O
adults	NNS	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
applicability	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
a	DT	O
peer-mentored	JJ	Physical
exercise	NN	Physical
program	NN	Physical
,	,	O
this	DT	O
study	NN	O
compared	VBN	O
the	DT	O
retention	NN	O
and	CC	O
participation	NN	O
rates	NNS	O
,	,	O
and	CC	O
physical	JJ	O
improvements	NNS	O
of	IN	O
older	JJR	O
adults	NNS	O
trained	VBN	O
by	IN	O
peer	NN	Physical
mentors	NNS	Physical
(	(	Physical
PM	NNP	Physical
)	)	Physical
to	TO	O
a	DT	O
group	NN	O
trained	VBN	O
by	IN	O
young	JJ	Physical
qualified	JJ	Physical
student	NN	Physical
mentors	NNS	Physical
(	(	Physical
SM	NNP	Physical
)	)	Physical
.	.	O

A	DT	O
group	NN	O
of	IN	O
older	JJR	O
adults	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
peer	NN	O
mentors	NNS	O
through	IN	O
a	DT	O
30-week	JJ	O
preparation	NN	O
program	NN	O
.	.	O

Later	NNP	O
,	,	O
60	CD	O
older	JJR	O
adults	NNS	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
age	NN	O
:	:	O
68.7	CD	O
?	.	O
6.1	CD	O
years	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
PM	NNP	O
or	CC	O
SM	NNP	O
group	NN	O
.	.	O

Both	DT	O
groups	NNS	O
completed	VBD	O
an	DT	O
identical	JJ	O
35-week	JJ	O
fitness	NN	O
program	NN	O
.	.	O

Pre-	NNP	O
,	,	O
midterm-	JJ	O
and	CC	O
post-training	JJ	O
assessments	NNS	O
of	IN	O
fitness	NN	O
were	VBD	O
completed	VBN	O
and	CC	O
rates	NNS	O
of	IN	O
participation	NN	O
and	CC	O
retention	NN	O
were	VBD	O
documented	VBN	O
.	.	O

The	DT	O
same	JJ	O
retention	NN	O
rates	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
,	,	O
but	CC	O
SM	NNP	O
group	NN	O
had	VBD	O
higher	JJR	O
participation	NN	O
.	.	O

Both	DT	O
groups	NNS	O
improved	VBN	O
significantly	RB	O
in	IN	O
all	DT	O
measures	NNS	O
of	IN	O
fitness	NN	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
post-test	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
the	DT	O
fitness	NN	O
measures	NNS	O
.	.	O

Findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
peer	NN	O
mentor	NN	O
model	NN	O
is	VBZ	O
applicable	JJ	O
in	IN	O
an	DT	O
older	JJR	O
adult	NN	O
exercise	NN	O
program	NN	O
and	CC	O
may	MD	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
a	DT	O
program	NN	O
mentored	VBN	O
by	IN	O
young	JJ	O
professionals	NNS	O
.	.	O

Clinically	RB	O
relevant	JJ	O
improvement	NN	O
of	IN	O
recurrence-free	JJ	O
survival	NN	O
with	IN	O
5-aminolevulinic	JJ	Pharmacological
acid	NN	Pharmacological
induced	VBD	O
fluorescence	NN	O
diagnosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
.	.	O

PURPOSES	NNP	O
Fluorescence	NNP	O
diagnosis	NN	O
induced	VBN	O
by	IN	O
5-aminolevulinic	JJ	Pharmacological
acid	NN	Pharmacological
enables	VBZ	O
more	RBR	O
thorough	JJ	O
transurethral	JJ	O
resection	NN	O
of	IN	O
superficial	JJ	O
bladder	NN	O
carcinoma	NNS	O
compared	VBN	O
with	IN	O
conventional	JJ	O
white	JJ	O
light	NN	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
single	JJ	O
institution	NN	O
,	,	O
randomized	VBN	O
trial	NN	O
to	TO	O
investigate	VB	O
whether	IN	O
the	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
and	CC	O
long-term	JJ	O
tumor	NN	O
recurrence	NN	O
can	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
fluorescence	NN	O
diagnosis	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
301	CD	O
patients	NNS	O
underwent	JJ	O
transurethral	JJ	Surgical
resection	NN	Surgical
of	IN	O
bladder	NN	O
tumors	NNS	O
with	IN	O
white	JJ	O
light	NN	O
or	CC	O
fluorescence	NN	O
diagnosis	NN	O
.	.	O

Transurethral	JJ	Surgical
resection	NN	Surgical
was	VBD	O
repeated	VBN	O
5	CD	O
to	TO	O
6	CD	O
weeks	NNS	O
later	RB	O
to	TO	O
evaluate	VB	O
the	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
.	.	O

To	TO	O
determine	VB	O
recurrence-free	JJ	O
survival	JJ	O
patient	NN	O
followup	NN	O
was	VBD	O
performed	VBN	O
every	DT	O
3	CD	O
months	NNS	O
by	IN	O
white	JJ	O
light	JJ	O
cystoscopy	NN	O
and	CC	O
urine	JJ	O
cytology	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
analyzed	VBN	O
via	IN	O
Kaplan-Meier	NNP	O
methods	NNS	O
and	CC	O
multivariable	JJ	O
Cox	NNP	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
191	CD	O
patients	NNS	O
with	IN	O
superficial	JJ	O
bladder	NN	O
carcinoma	NN	O
were	VBD	O
available	JJ	O
for	IN	O
efficacy	NN	O
analysis	NN	O
.	.	O

The	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
was	VBD	O
25.2	CD	O
%	NN	O
in	IN	O
the	DT	O
white	JJ	O
light	JJ	O
arm	NN	O
versus	NN	O
4.5	CD	O
%	NN	O
in	IN	O
the	DT	O
fluorescence	NN	O
diagnosis	NN	O
arm	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Median	JJ	O
followup	NN	O
in	IN	O
the	DT	O
white	JJ	O
light	JJ	O
arm	NN	O
in	IN	O
103	CD	O
cases	NNS	O
was	VBD	O
21.2	CD	O
months	NNS	O
(	(	O
range	VB	O
4	CD	O
to	TO	O
40	CD	O
)	)	O
compared	VBN	O
with	IN	O
20.5	CD	O
(	(	O
range	NN	O
3	CD	O
to	TO	O
40	CD	O
)	)	O
in	IN	O
the	DT	O
88	CD	O
in	IN	O
the	DT	O
fluorescence	NN	O
diagnosis	NN	O
arm	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
in	IN	O
the	DT	O
fluorescence	NN	O
diagnosis	NN	O
group	NN	O
was	VBD	O
89.6	CD	O
%	NN	O
after	IN	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
compared	VBN	O
with	IN	O
73.8	CD	O
%	NN	O
and	CC	O
65.9	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
white	JJ	O
light	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

This	DT	O
superiority	NN	O
proved	VBD	O
to	TO	O
be	VB	O
independent	JJ	O
of	IN	O
risk	NN	O
group	NN	O
.	.	O

The	DT	O
adjusted	JJ	O
hazard	NN	O
ratio	NN	O
of	IN	O
fluorescence	NN	O
diagnosis	NN	O
versus	IN	O
white	JJ	O
light	JJ	O
transurethral	JJ	O
resection	NN	O
was	VBD	O
0.33	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.16	CD	O
to	TO	O
0.67	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Fluorescence	NNP	O
diagnosis	NN	O
is	VBZ	O
significantly	RB	O
superior	JJ	O
to	TO	O
conventional	JJ	O
white	JJ	O
light	JJ	O
transurethral	JJ	O
resection	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
residual	JJ	O
tumor	NN	O
rate	NN	O
and	CC	O
recurrence-free	JJ	O
survival	NN	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
recurrence-free	JJ	O
survival	NN	O
imply	NN	O
that	WDT	O
fluorescence	NN	O
diagnosis	NN	O
is	VBZ	O
a	DT	O
clinically	RB	O
relevant	JJ	O
procedure	NN	O
for	IN	O
decreasing	VBG	O
the	DT	O
number	NN	O
of	IN	O
tumor	NN	O
recurrences	NNS	O
.	.	O

B-type	JJ	Other
natriuretic	JJ	Other
peptide	NN	Other
in	IN	O
the	DT	O
evaluation	NN	O
and	CC	O
management	NN	O
of	IN	O
dyspnoea	NN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
rapid	JJ	O
and	CC	O
accurate	JJ	O
diagnosis	NN	O
of	IN	O
heart	NN	O
failure	NN	O
in	IN	O
primary	JJ	O
care	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
unmet	JJ	O
clinical	JJ	O
need	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
additional	JJ	O
use	NN	O
of	IN	O
B-type	NNP	Other
natriuretic	JJ	Other
peptide	NN	Other
(	(	Other
BNP	NNP	Other
)	)	Other
levels	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	CC	O
Twenty-nine	JJ	O
primary	JJ	O
care	NN	O
physicians	NNS	O
in	IN	O
Switzerland	NNP	O
and	CC	O
Germany	NNP	O
coordinated	VBN	O
by	IN	O
the	DT	O
University	NNP	O
Hospital	NNP	O
Basel	NNP	O
,	,	O
Switzerland	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
323	CD	O
consecutive	JJ	O
patients	NNS	O
presenting	VBG	O
with	IN	O
dyspnoea	NN	O
.	.	O

INTERVENTIONS	NNP	O
Assignment	NNP	O
in	IN	O
a	DT	O
1	CD	O
:	:	O
1	CD	O
ratio	NN	O
to	TO	O
a	DT	O
diagnostic	JJ	Other
strategy	NN	Other
including	VBG	Other
point-of-care	JJ	Other
measurement	NN	Other
of	IN	Other
BNP	NNP	Other
(	(	O
n	JJ	O
=	NNP	O
163	CD	O
)	)	O
or	CC	O
standard	JJ	Control
assessment	NN	Control
without	IN	Control
BNP	NNP	Control
(	(	O
n	JJ	O
=	NNP	O
160	CD	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
medical	JJ	O
cost	NN	O
at	IN	O
3	CD	O
months	NNS	O
was	VBD	O
the	DT	O
primary	JJ	O
end-point	NN	O
.	.	O

Secondary	JJ	O
end-points	NNS	O
were	VBD	O
diagnostic	JJ	O
certainty	NN	O
,	,	O
time	NN	O
to	TO	O
appropriate	VB	O
therapy	NN	O
,	,	O
functional	JJ	O
capacity	NN	O
,	,	O
hospitalization	NN	O
and	CC	O
mortality	NN	O
.	.	O

The	DT	O
final	JJ	O
diagnosis	NN	O
was	VBD	O
adjudicated	VBN	O
by	IN	O
a	DT	O
physician	NN	O
blinded	VBN	O
to	TO	O
the	DT	O
BNP	NNP	O
levels	NNS	O
.	.	O

RESULTS	NNP	O
Heart	NNP	O
failure	NN	O
was	VBD	O
the	DT	O
final	JJ	O
diagnosis	NN	O
in	IN	O
34	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
hospitalizations	NNS	O
,	,	O
functional	JJ	O
status	NN	O
and	CC	O
total	JJ	O
medical	JJ	O
cost	NN	O
at	IN	O
3	CD	O
months	NNS	O
[	JJ	O
median	JJ	O
$	$	O
1655	CD	O
,	,	O
interquartile	JJ	O
range	NN	O
(	(	O
IQR	NNP	O
)	)	O
,	,	O
850-3331	JJ	O
vs.	IN	O
$	$	O
1541	CD	O
,	,	O
IQR	NNP	O
859-2827	CD	O
;	:	O
P	NNP	O
=	VBD	O
0.68	CD	O
]	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

BNP	NNP	O
increased	VBD	O
diagnostic	JJ	O
certainty	NN	O
as	IN	O
defined	VBN	O
by	IN	O
the	DT	O
need	NN	O
for	IN	O
further	JJ	O
diagnostic	JJ	O
work-up	NN	O
(	(	O
33	CD	O
%	NN	O
vs.	FW	O
45	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
accelerated	VBD	O
the	DT	O
initiation	NN	O
of	IN	O
the	DT	O
appropriate	JJ	O
treatment	NN	O
(	(	O
13	CD	O
days	NNS	O
vs.	FW	O
25	CD	O
days	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
receiver-operating	JJ	O
characteristics	NNS	O
curve	NN	O
for	IN	O
BNP	NNP	O
to	TO	O
identify	VB	O
heart	NN	O
failure	NN	O
was	VBD	O
0.87	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.81-0.93	JJ	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
BNP	NNP	Other
levels	NNS	Other
in	IN	O
primary	JJ	O
care	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
total	JJ	O
medical	JJ	O
cost	NN	O
,	,	O
but	CC	O
improved	VBD	O
some	DT	O
of	IN	O
the	DT	O
secondary	JJ	O
end-points	NNS	O
including	VBG	O
diagnostic	JJ	O
certainty	NN	O
and	CC	O
time	NN	O
to	TO	O
initiation	NN	O
of	IN	O
appropriate	JJ	O
treatment	NN	O
.	.	O

Controlled	VBN	O
clinical	JJ	O
trial	NN	O
of	IN	O
IV	NNP	O
cyclophosphamide	NN	Pharmacological
versus	NN	O
IV	NNP	O
methylprednisolone	NN	Pharmacological
in	IN	O
severe	JJ	O
neurological	JJ	O
manifestations	NNS	O
in	IN	O
systemic	JJ	O
lupus	NN	O
erythematosus	NN	O
.	.	O

BACKGROUND	NNP	O
Severe	NNP	O
neurological	JJ	O
involvement	NN	O
in	IN	O
systemic	JJ	O
lupus	NN	O
erythematosus	NN	O
(	(	O
NPSLE	NNP	O
)	)	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
dreadful	JJ	O
complications	NNS	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
identify	VB	O
the	DT	O
best	JJS	O
drug	NN	O
,	,	O
dose	NN	O
,	,	O
and	CC	O
treatment	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
at	IN	O
two	CD	O
tertiary	JJ	O
care	NN	O
centres	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
SLE	NNP	O
according	VBG	O
to	TO	O
the	DT	O
ACR	NNP	O
criteria	NNS	O
,	,	O
with	IN	O
incident	NN	O
(	(	O
no	DT	O
more	JJR	O
than	IN	O
15	CD	O
days	NNS	O
)	)	O
onset	NN	O
of	IN	O
severe	JJ	O
NP	NNP	O
manifestations	NNS	O
such	JJ	O
as	IN	O
seizures	NNS	O
,	,	O
optic	JJ	O
neuritis	NN	O
,	,	O
peripheral	JJ	O
or	CC	O
cranial	JJ	O
neuropathy	NN	O
,	,	O
coma	NN	O
,	,	O
brainstem	NN	O
disease	NN	O
,	,	O
or	CC	O
transverse	JJ	O
myelitis	NN	O
.	.	O

Induction	NNP	O
treatment	NN	O
with	IN	O
3	CD	O
g	NN	O
of	IN	O
IV	NNP	O
methylprednisolone	NN	Pharmacological
(	(	O
MP	NNP	O
)	)	O
followed	VBN	O
by	IN	O
either	DT	O
IV	NNP	O
monthly	JJ	O
cyclophosphamide	NN	Pharmacological
(	(	O
Cy	NNP	O
)	)	O
versus	NN	O
IV	NNP	Pharmacological
MP	NNP	Pharmacological
bimonthly	RB	Pharmacological
every	DT	O
4	CD	O
months	NNS	O
for	IN	O
1	CD	O
year	NN	O
and	CC	O
then	RB	O
IV	NNP	O
Cy	NNP	O
or	CC	O
IV	NNP	O
MP	NNP	O
every	DT	O
3	CD	O
months	NNS	O
for	IN	O
another	DT	O
year	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
response	NN	O
to	TO	O
treatment	NN	O
:	:	O
at	IN	O
least	JJS	O
20	CD	O
%	NN	O
improvement	NN	O
from	IN	O
basal	JJ	O
conditions	NNS	O
on	IN	O
clinical	JJ	O
,	,	O
laboratory	NN	O
,	,	O
or	CC	O
specific	JJ	O
neurological	JJ	O
testing	NN	O
variables	NNS	O
.	.	O

RESULTS	NNP	O
Overall	NNP	O
,	,	O
a	DT	O
response	NN	O
rate	NN	O
of	IN	O
75	CD	O
%	NN	O
was	VBD	O
observed	VBN	O
.	.	O

Of	IN	O
the	DT	O
32	CD	O
patients	NNS	O
studied	VBN	O
,	,	O
18/19	CD	O
receiving	VBG	O
Cy	NNP	O
and	CC	O
7/13	CD	O
receiving	VBG	O
MP	NNP	O
responded	VBD	O
to	TO	O
treatment	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Cy	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
MP	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	NN	O
,	,	O
severe	JJ	O
NPSLE	NNP	O
.	.	O

Laser	NNP	Surgical
conization	NN	Surgical
versus	NN	O
cold	JJ	Surgical
knife	NN	Surgical
conization	NN	Surgical
.	.	Surgical

This	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
compares	VBZ	O
,	,	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
,	,	O
measured	VBN	O
blood	NN	O
loss	NN	O
at	IN	O
conization	NN	O
and	CC	O
within	IN	O
24	CD	O
hours	NNS	O
after	IN	O
using	VBG	O
either	CC	O
the	DT	O
cold	JJ	Surgical
knife	NN	Surgical
technique	NN	Surgical
or	CC	O
the	DT	O
carbon	NN	Surgical
dioxide	NN	Surgical
laser	NN	Surgical
scalpel	NN	Surgical
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
ten	VB	O
consecutive	JJ	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

The	DT	O
median	JJ	O
blood	NN	O
loss	NN	O
in	IN	O
the	DT	O
laser	NN	O
group	NN	O
of	IN	O
55	CD	O
patients	NNS	O
was	VBD	O
4.6	CD	O
milliliters	NNS	O
at	IN	O
,	,	O
and	CC	O
within	IN	O
,	,	O
24	CD	O
hours	NNS	O
after	IN	O
operation	NN	O
compared	VBN	O
with	IN	O
30.1	CD	O
milliliters	NNS	O
in	IN	O
the	DT	O
cold	JJ	Surgical
knife	NN	Surgical
group	NN	O
of	IN	O
55	CD	O
patients	NNS	O
.	.	O

More	RBR	O
important	JJ	O
,	,	O
however	RB	O
,	,	O
is	VBZ	O
that	IN	O
the	DT	O
corresponding	JJ	O
figures	NNS	O
for	IN	O
the	DT	O
range	NN	O
of	IN	O
bleeding	VBG	O
were	VBD	O
0.4	CD	O
to	TO	O
155.4	CD	O
milliliters	NNS	O
and	CC	O
5.6	CD	O
to	TO	O
1,570.9	CD	O
milliliters	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
incidence	NN	O
rate	NN	O
for	IN	O
bleeding	VBG	O
complications	NNS	O
requiring	VBG	O
surgical	JJ	O
intervention	NN	O
was	VBD	O
1.8	CD	O
per	IN	O
cet	NN	O
for	IN	O
the	DT	O
laser	NN	O
group	NN	O
and	CC	O
14.6	CD	O
per	IN	O
cent	NN	O
for	IN	O
the	DT	O
cold	JJ	Surgical
knife	NN	Surgical
group	NN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
,	,	O
p	RB	O
less	JJR	O
than	IN	O
0.015	CD	O
--	:	O
Fischer	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
.	.	O

Conization	NN	O
for	IN	O
treatment	NN	O
of	IN	O
premalignant	JJ	O
changes	NNS	O
of	IN	O
the	DT	O
cervix	NN	O
uteri	NN	O
will	MD	O
probably	RB	O
remain	VB	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
some	DT	O
time	NN	O
to	TO	O
come	VB	O
.	.	O

It	PRP	O
is	VBZ	O
our	PRP$	O
opinion	NN	O
that	IN	O
,	,	O
in	IN	O
the	DT	O
future	NN	O
,	,	O
laser	JJR	Surgical
conization	NN	O
will	MD	O
replace	VB	O
cold	JJ	Surgical
knife	NN	Surgical
conization	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
tailored	JJ	O
skin	NN	O
cancer	NN	O
prevention	NN	O
for	IN	O
children	NNS	O
:	:	O
the	DT	O
Project	NNP	O
SCAPE	NNP	O
family	NN	O
study	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
a	DT	O
tailored	VBN	Educational
intervention	NN	Educational
to	TO	O
promote	VB	Physical
sun	NN	Physical
protection	NN	Physical
in	IN	O
parents	NNS	O
and	CC	O
their	PRP$	O
children	NNS	O
,	,	O
hypothesizing	VBG	O
that	IN	O
the	DT	O
tailored	VBN	O
intervention	NN	O
would	MD	O
lead	VB	O
to	TO	O
improved	JJ	O
skin	NN	O
cancer	NN	O
prevention	NN	O
behaviors	NNS	O
compared	VBN	O
to	TO	O
generic	JJ	O
materials	NNS	O
.	.	O

Families	NNS	O
were	VBD	O
recruited	VBN	O
through	IN	O
schools	NNS	O
and	CC	O
community	NN	O
centers	NNS	O
and	CC	O
were	VBD	O
included	VBN	O
if	IN	O
there	EX	O
was	VBD	O
1	CD	O
child	NN	O
in	IN	O
Grades	NNP	O
1-3	JJ	O
at	IN	O
moderate	JJ	O
to	TO	O
high	JJ	O
risk	NN	O
for	IN	O
skin	JJ	O
cancer	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
intervention	NN	O
groups	NNS	O
:	:	O
a	DT	O
tailored	JJ	Educational
intervention	NN	Educational
,	,	Educational
in	IN	Educational
which	WDT	Educational
they	PRP	Educational
received	VBD	Educational
personalized	JJ	Educational
skin	NN	Educational
cancer	NN	Educational
education	NN	Educational
through	IN	Educational
the	DT	Educational
mail	NN	Educational
;	:	Educational
or	CC	Educational
a	DT	Educational
control	NN	Educational
group	NN	Educational
who	WP	Educational
received	VBD	Educational
generic	JJ	Educational
skin	NN	Educational
cancer	NN	Educational
information	NN	Educational
materials	NNS	Educational
.	.	Educational

Before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
,	,	O
parents	NNS	O
completed	VBD	O
questionnaires	NNS	O
about	IN	O
their	PRP$	O
and	CC	O
their	PRP$	O
children	NNS	O
's	POS	O
skin	NN	O
cancer	NN	O
risk	NN	O
and	CC	O
prevention	NN	O
knowledge	NN	O
and	CC	O
behaviors	NNS	O
.	.	O

Parents	NNS	O
also	RB	O
completed	VBD	O
4-day	JJ	O
sun	NN	O
exposure	NN	O
and	CC	O
protection	NN	O
diaries	NNS	O
for	IN	O
their	PRP$	O
child	NN	O
and	CC	O
themselves	PRP	O
.	.	O

Tailored	VBN	O
group	NN	O
participants	NNS	O
demonstrated	VBD	O
significantly	RB	O
greater	JJR	O
positive	JJ	O
changes	NNS	O
in	IN	O
prevention	NN	O
behavior	NN	O
after	IN	O
the	DT	O
intervention	NN	O
,	,	O
including	VBG	O
children	NNS	O
's	POS	O
use	NN	O
of	IN	O
sunscreen	NN	O
,	,	O
shirts	NNS	O
,	,	O
and	CC	O
hats	NNS	O
,	,	O
and	CC	O
parents	NNS	O
'	POS	O
use	NN	O
of	IN	O
shade	NN	O
,	,	O
and	CC	O
skin	JJ	O
examinations	NNS	O
.	.	O

Effect	JJ	O
sizes	NNS	O
were	VBD	O
small	JJ	O
and	CC	O
perceived	JJ	O
benefits	NNS	O
and	CC	O
social	JJ	O
norms	NNS	O
mediated	VBN	O
intervention	NN	O
effects	NNS	O
.	.	O

Findings	NNS	O
from	IN	O
this	DT	O
study	NN	O
support	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
focusing	VBG	O
tailored	VBN	O
communications	NNS	O
to	TO	O
families	NNS	O
in	IN	O
order	NN	O
to	TO	O
change	VB	O
skin	JJ	O
cancer	NN	O
prevention	NN	O
practices	NNS	O
in	IN	O
young	JJ	O
children	NNS	O
.	.	O

Long-term	JJ	O
evaluation	NN	O
of	IN	O
tamsulosin	NN	Pharmacological
in	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
:	:	O
placebo-controlled	JJ	Control
,	,	O
double-blind	JJ	O
extension	NN	O
of	IN	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

Tamsulosin	NNP	O
Investigator	NNP	O
Group	NNP	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
once-daily	JJ	O
tamsulosin	NN	Pharmacological
(	(	O
0.4	CD	O
and	CC	O
0.8	CD	O
mg	NN	O
)	)	O
,	,	O
a	DT	O
unique	JJ	O
selective	JJ	O
alpha1A-adrenoceptor	NN	O
antagonist	NN	O
in	IN	O
patients	NNS	O
with	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
(	(	O
BPH	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
trial	NN	O
extended	VBD	O
a	DT	O
13-week	JJ	O
,	,	O
Phase	NNP	O
III	NNP	O
multicenter	NN	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
outpatient	JJ	O
trial	NN	O
for	IN	O
an	DT	O
additional	JJ	O
40	CD	O
weeks	NNS	O
.	.	O

Of	IN	O
618	CD	O
patients	NNS	O
,	,	O
418	CD	O
(	(	O
68	CD	O
%	NN	O
)	)	O
continued	VBD	O
into	IN	O
the	DT	O
extension	NN	O
phase	NN	O
on	IN	O
the	DT	O
same	JJ	O
double-blind	JJ	O
medication	NN	O
and	CC	O
dose	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
parameters	NNS	O
were	VBD	O
total	JJ	O
American	NNP	O
Urological	NNP	O
Association	NNP	O
(	(	O
AUA	NNP	O
)	)	O
symptom	NN	O
score	NN	O
and	CC	O
maximum	JJ	O
urinary	JJ	O
flow	NN	O
(	(	O
Qmax	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
changes	NNS	O
in	IN	O
AUA	NNP	O
symptom	NN	O
score	NN	O
from	IN	O
baseline	NN	O
to	TO	O
end	VB	O
point	NN	O
were	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
all	DT	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
Qmax	NNP	O
for	IN	O
both	DT	O
tamsulosin	JJ	Pharmacological
groups	NNS	O
but	CC	O
not	RB	O
for	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
.	.	O

The	DT	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
efficacy	NN	O
parameters	NNS	O
observed	VBD	O
for	IN	O
each	DT	O
tamsulosin	NN	Pharmacological
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
13-week	JJ	O
Phase	NNP	O
III	NNP	O
trial	NN	O
were	VBD	O
maintained	VBN	O
during	IN	O
the	DT	O
long-term	JJ	O
extension	NN	O
phase	NN	O
.	.	O

Tamsulosin	NN	O
at	IN	O
both	DT	O
dosages	NNS	O
was	VBD	O
well	RB	O
tolerated	VBN	O
as	IN	O
maintenance	NN	O
therapy	NN	O
.	.	O

Clinically	NNP	O
significant	JJ	O
orthostatic	JJ	O
hypotension	NN	O
was	VBD	O
not	RB	O
observed	VBN	O
.	.	O

Vital	JJ	O
sign	NN	O
changes	NNS	O
in	IN	O
either	DT	O
hypertensive	JJ	O
or	CC	O
normotensive	JJ	O
patients	NNS	O
were	VBD	O
not	RB	O
clinically	RB	O
significantly	RB	O
different	JJ	O
across	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Tamsulosin	NNP	Pharmacological
once-daily	RB	O
at	IN	O
0.4	CD	O
or	CC	O
0.8	CD	O
mg	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
,	,	O
safe	JJ	O
,	,	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
the	DT	O
target	NN	O
BPH	NNP	O
population	NN	O
during	IN	O
long-term	JJ	O
use	NN	O
.	.	O

Short-term	JJ	O
studies	NNS	O
on	IN	O
the	DT	O
use	NN	O
of	IN	O
glycerol	NN	Pharmacological
as	IN	O
an	DT	O
osmotic	JJ	O
agent	NN	O
in	IN	O
continuous	JJ	O
ambulatory	JJ	O
peritoneal	JJ	O
dialysis	NN	O
(	(	O
CAPD	NNP	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
glycerol	NN	Pharmacological
as	IN	O
an	DT	O
osmotic	JJ	O
agent	NN	O
in	IN	O
two	CD	O
different	JJ	O
concentrations	NNS	O
(	(	O
92	CD	O
mmol/l	NN	O
and	CC	O
272	CD	O
mmol/l	NN	O
)	)	O
in	IN	O
peritoneal	JJ	O
dialysis	NN	O
fluid	NN	O
was	VBD	O
investigated	VBN	O
over	IN	O
3	CD	O
days	NNS	O
in	IN	O
six	CD	O
patients	NNS	O
on	IN	O
continuous	JJ	O
ambulatory	JJ	O
peritoneal	JJ	O
dialysis	NN	O
and	CC	O
compared	VBN	O
with	IN	O
two	CD	O
concentrations	NNS	O
of	IN	O
glucose	NN	Control
(	(	O
76	CD	O
mmol/l	NN	O
and	CC	O
215	CD	O
mmol/l	NN	O
)	)	O
in	IN	O
the	DT	O
same	JJ	O
patients	NNS	O
.	.	O

The	DT	O
calorific	JJ	O
value	NN	O
of	IN	O
the	DT	O
absorbed	JJ	O
osmotic	JJ	O
agent	NN	O
was	VBD	O
lower	JJR	O
,	,	O
by	IN	O
19	CD	O
%	NN	O
with	IN	O
isotonic	JJ	O
and	CC	O
22	CD	O
%	NN	O
with	IN	O
hypertonic	JJ	O
solutions	NNS	O
,	,	O
when	WRB	O
glycerol	NN	Pharmacological
was	VBD	O
used	VBN	O
in	IN	O
place	NN	O
of	IN	O
glucose	NN	Control
.	.	O

However	RB	O
,	,	O
glycerol	NN	O
provided	VBD	O
significantly	RB	O
lower	JJR	O
total	JJ	O
ultrafiltration	NN	O
than	IN	O
glucose	NN	O
at	IN	O
each	DT	O
concentration	NN	O
,	,	O
despite	IN	O
a	DT	O
higher	JJR	O
initial	JJ	O
osmotic	JJ	O
pressure	NN	O
of	IN	O
the	DT	O
glycerol-based	JJ	O
solutions	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
higher	JJR	O
concentration	NN	O
of	IN	O
glycerol	NN	O
required	VBN	O
to	TO	O
provide	VB	O
equal	JJ	O
ultrafiltration	NN	O
may	MD	O
offset	VB	O
any	DT	O
calorific	JJ	O
advantage	NN	O
.	.	O

Equilibration	NN	O
of	IN	O
creatinine	NN	O
and	CC	O
urea	NN	O
was	VBD	O
slower	JJR	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
lower	RBR	O
with	IN	O
glycerol	NN	Pharmacological
.	.	O

Solutions	NNS	O
containing	VBG	O
glycerol	NN	Pharmacological
were	VBD	O
initially	RB	O
less	JJR	O
acid	JJ	O
(	(	O
pH	JJ	O
6.5	CD	O
)	)	O
than	IN	O
those	DT	O
containing	VBG	O
glucose	NN	O
(	(	O
pH	JJ	O
5.1	CD	O
)	)	O
.	.	O

Blood	NNP	O
glycerol	NN	O
levels	NNS	O
,	,	O
which	WDT	O
were	VBD	O
in	IN	O
the	DT	O
physiological	JJ	O
range	NN	O
with	IN	O
glucose	NN	O
as	IN	O
the	DT	O
osmotic	JJ	O
agent	NN	O
,	,	O
reached	VBD	O
a	DT	O
peak	JJ	O
80-fold	JJ	O
greater	JJR	O
at	IN	O
4.3	CD	O
+/-	JJ	O
0.8	CD	O
mmol/l	NN	O
during	IN	O
dialysis	NN	O
with	IN	O
fluid	NN	O
containing	VBG	O
glycerol	NN	Pharmacological
at	IN	O
272	CD	O
mmol/l	NN	O
and	CC	O
eightfold	VB	O
higher	JJR	O
at	IN	O
0.42	CD	O
+/-	JJ	O
0.09	CD	O
mmol/l	NN	O
with	IN	O
glycerol	NN	Pharmacological
at	IN	O
92	CD	O
mmol/l	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
haemolysis	NN	O
or	CC	O
other	JJ	O
toxic	JJ	O
effect	NN	O
despite	IN	O
these	DT	O
levels	NNS	O
.	.	O

The	DT	O
rise	NN	O
in	IN	O
blood	NN	O
glucose	NN	O
and	CC	O
insulin	NN	O
noted	VBD	O
during	IN	O
the	DT	O
use	NN	O
of	IN	O
glucose-based	JJ	O
solutions	NNS	O
was	VBD	O
not	RB	O
found	VBN	O
with	IN	O
glycerol	NN	Pharmacological
.	.	O

Circulating	NNP	O
levels	NNS	O
of	IN	O
lactate	NN	O
,	,	O
pyruvate	NN	O
,	,	O
alanine	NN	O
,	,	O
non-esterified	JJ	O
fatty	JJ	O
acids	NNS	O
and	CC	O
the	DT	O
ketone	NN	O
bodies	NNS	O
were	VBD	O
similar	JJ	O
with	IN	O
the	DT	O
two	CD	O
agents	NNS	O
.	.	O

Although	IN	O
these	DT	O
short-term	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
no	DT	O
conclusive	JJ	O
advantage	NN	O
of	IN	O
glycerol	NN	Pharmacological
over	IN	O
glucose	JJ	Control
,	,	O
long-term	JJ	O
effects	NNS	O
of	IN	O
glycerol	NN	Pharmacological
,	,	O
particularly	RB	O
on	IN	O
circulating	VBG	O
lipid	JJ	O
levels	NNS	O
,	,	O
will	MD	O
determine	VB	O
its	PRP$	O
future	JJ	O
role	NN	O
as	IN	O
an	DT	O
osmotic	JJ	O
agent	NN	O
in	IN	O
continuous	JJ	O
ambulatory	JJ	O
peritoneal	JJ	O
dialysis	NN	O
.	.	O

Ten-year	JJ	O
incidence	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
prognosis	NN	O
after	IN	O
infarction	NN	O
.	.	O

Department	NNP	O
of	IN	O
Veterans	NNP	O
Affairs	NNP	O
Cooperative	NNP	O
Study	NNP	O
of	IN	O
Coronary	NNP	O
Artery	NNP	O
Bypass	NNP	O
Surgery	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
10-year	JJ	O
incidence	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
(	(	O
fatal	JJ	O
and	CC	O
nonfatal	JJ	O
)	)	O
and	CC	O
the	DT	O
prognosis	NN	O
after	IN	O
infarction	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
686	CD	O
patients	NNS	O
with	IN	O
stable	JJ	O
angina	NNS	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
medical	JJ	Pharmacological
or	CC	O
surgical	JJ	Surgical
treatment	NN	O
in	IN	O
the	DT	O
Veterans	NNPS	O
Administration	NNP	O
Cooperative	NNP	O
Study	NNP	O
of	IN	O
Coronary	NNP	O
Artery	NNP	O
Bypass	NNP	O
Surgery	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Myocardial	NNP	O
infarction	NN	O
was	VBD	O
defined	VBN	O
by	IN	O
either	DT	O
new	JJ	O
Q	NNP	O
wave	VBP	O
findings	NNS	O
or	CC	O
clinical	JJ	O
symptoms	NNS	O
compatible	JJ	O
with	IN	O
myocardial	JJ	O
infarction	NN	O
accompanied	VBN	O
by	IN	O
serum	NN	O
enzyme	NN	O
elevations	NNS	O
with	IN	O
or	CC	O
without	IN	O
electrocardiographic	JJ	O
findings	NNS	O
.	.	O

Treatment	JJ	O
comparisons	NNS	O
were	VBD	O
made	VBN	O
according	VBG	O
to	TO	O
original	JJ	O
treatment	NN	O
assignment	NN	O
;	:	O
35	CD	O
%	NN	O
of	IN	O
the	DT	O
medical	JJ	O
cohort	NN	O
had	VBD	O
bypass	NN	Surgical
surgery	NN	Surgical
during	IN	O
the	DT	O
10-year	JJ	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
overall	JJ	O
cumulative	JJ	O
infarction	NN	O
rate	NN	O
was	VBD	O
somewhat	RB	O
higher	JJR	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
surgery	VB	Surgical
(	(	O
36	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
medical	JJ	O
patients	NNS	O
(	(	O
31	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
0.13	CD	O
)	)	O
due	JJ	O
to	TO	O
perioperative	JJ	O
infarctions	NNS	O
(	(	O
13	CD	O
%	NN	O
)	)	O
and	CC	O
an	DT	O
accelerated	JJ	O
infarction	NN	O
rate	NN	O
after	IN	O
the	DT	O
fifth	JJ	O
year	NN	O
of	IN	O
follow-up	NN	O
(	(	O
average	JJ	O
,	,	O
2.4	CD	O
%	NN	O
/yr	NN	O
in	IN	O
the	DT	O
surgical	JJ	O
group	NN	O
versus	VBD	O
1.4	CD	O
%	NN	O
/yr	NN	O
in	IN	O
the	DT	O
medical	JJ	O
group	NN	O
)	)	O
.	.	O

The	DT	O
10-year	JJ	O
cumulative	JJ	O
incidence	NN	O
of	IN	O
death	NN	O
or	CC	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
also	RB	O
higher	JJR	O
in	IN	O
surgical	JJ	O
(	(	O
54	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
medical	JJ	O
(	(	O
49	CD	O
%	NN	O
)	)	O
patients	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.20	CD	O
)	)	O
.	.	O

According	VBG	O
to	TO	O
the	DT	O
Cox	NNP	O
model	NN	O
,	,	O
the	DT	O
estimated	VBN	O
risk	NN	O
of	IN	O
death	NN	O
after	IN	O
infarction	NN	O
was	VBD	O
59	CD	O
%	NN	O
lower	JJR	O
in	IN	O
surgical	JJ	O
than	IN	O
in	IN	O
medical	JJ	O
patients	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
reduction	NN	O
in	IN	O
postinfarction	NN	O
mortality	NN	O
with	IN	O
surgery	NN	O
was	VBD	O
most	RBS	O
striking	JJ	O
in	IN	O
the	DT	O
first	JJ	O
month	NN	O
after	IN	O
the	DT	O
event	NN	O
:	:	O
99	CD	O
%	NN	O
in	IN	O
the	DT	O
first	JJ	O
month	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
and	CC	O
49	CD	O
%	NN	O
subsequently	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
estimated	VBN	O
risk	NN	O
of	IN	O
death	NN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
infarction	NN	O
was	VBD	O
nearly	RB	O
identical	JJ	O
regardless	NN	O
of	IN	O
treatment	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.75	CD	O
)	)	O
.	.	O

Exclusion	NN	O
of	IN	O
perioperative	JJ	O
infarctions	NNS	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
findings	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
surgery	NN	O
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
overall	RB	O
,	,	O
it	PRP	O
does	VBZ	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
mortality	NN	O
after	IN	O
infarction	NN	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
first	JJ	O
30	CD	O
days	NNS	O
after	IN	O
the	DT	O
event	NN	O
(	(	O
fatal	JJ	O
infarctions	NNS	O
)	)	O
.	.	O

Pedantic	JJ	Psychological
speaking	NN	Psychological
style	NN	O
differentiates	VBZ	O
Asperger	NNP	O
syndrome	NN	O
from	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

Asperger	NNP	O
syndrome	NN	O
(	(	O
AS	IN	O
)	)	O
is	VBZ	O
a	DT	O
pervasive	JJ	O
developmental	NN	O
disorder	NN	O
recently	RB	O
introduced	VBD	O
as	IN	O
a	DT	O
new	JJ	O
diagnostic	JJ	O
category	NN	O
in	IN	O
the	DT	O
ICD-10	NNP	O
and	CC	O
the	DT	O
DSM-IV	NNP	O
.	.	O

Along	IN	O
with	IN	O
motor	NN	O
clumsiness	NN	O
,	,	O
pedantic	JJ	Psychological
speech	NN	Psychological
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
clinical	JJ	O
feature	NN	O
of	IN	O
AS	NNP	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
define	VB	O
and	CC	O
measure	VB	O
this	DT	O
symptom	NN	O
.	.	O

We	PRP	O
studied	VBD	O
17	CD	O
patients	NNS	O
with	IN	O
AS	NNP	O
(	(	O
ICD-10	NNP	O
;	:	O
14	CD	O
male	NN	O
,	,	O
3	CD	O
female	NN	O
;	:	O
mean	JJ	O
age	NN	O
16.4	CD	O
years	NNS	O
,	,	O
mean	JJ	O
full-scale	JJ	O
IQ	NNP	O
97	CD	O
)	)	O
and	CC	O
compared	VBN	O
them	PRP	O
with	IN	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
13	CD	O
patients	NNS	O
with	IN	O
normal-intelligence	JJ	O
autism	NN	O
or	CC	O
high-functioning	JJ	O
autism	NN	O
(	(	O
HFA	NNP	O
)	)	O
(	(	O
ICD-10/DSM-III-R	NNP	O
;	:	O
12	CD	O
male	NN	O
,	,	O
1	CD	O
female	NN	O
;	:	O
mean	JJ	O
age	NN	O
15.5	CD	O
years	NNS	O
,	,	O
mean	JJ	O
full-scale	JJ	O
IQ	NNP	O
81.2	CD	O
)	)	O
.	.	O

An	DT	O
operational	JJ	O
definition	NN	O
of	IN	O
pedantic	JJ	O
speech	NN	O
was	VBD	O
formulated	VBN	O
and	CC	O
a	DT	O
rating	NN	O
scale	NN	O
devised	VBD	O
.	.	O

13	CD	O
(	(	O
76	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
AS	NNP	O
patients	NNS	O
were	VBD	O
rated	VBN	O
as	IN	O
pedantic	JJ	Psychological
compared	VBN	O
to	TO	O
4	CD	O
(	(	O
31	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
HFA	NNP	O
group	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
6.3	CD	O
;	:	O
p	NN	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
pedantic	JJ	Psychological
speech	NN	Psychological
is	VBZ	O
common	JJ	O
in	IN	O
AS	NNP	O
and	CC	O
may	MD	O
help	VB	O
differentiate	VB	O
AS	IN	O
from	IN	O
high-functioning	JJ	O
autism	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
time	NN	O
required	VBN	O
to	TO	O
administer	VB	O
three	CD	O
different	JJ	O
fluke	NNS	Pharmacological
and	CC	Pharmacological
worm	VB	Pharmacological
combination	NN	Pharmacological
products	NNS	Pharmacological
to	TO	O
commercial	JJ	O
beef	NN	O
cattle	NNS	O
at	IN	O
housing	NN	O
.	.	O

Larger	NNP	O
livestock	VBD	O
units	NNS	O
,	,	O
a	DT	O
decline	NN	O
in	IN	O
the	DT	O
farm	NN	O
labor	NN	O
force	NN	O
,	,	O
animal	JJ	O
welfare	NN	O
concerns	NNS	O
,	,	O
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
more	RBR	O
selective	JJ	O
use	NN	O
of	IN	O
drugs	NNS	O
have	VBP	O
increased	VBN	O
the	DT	O
focus	NN	O
on	IN	O
animal	NN	O
handling	NN	O
,	,	O
time	NN	O
management	NN	O
,	,	O
convenience	NN	O
,	,	O
and	CC	O
compliance	NN	O
in	IN	O
administering	VBG	O
veterinary	JJ	O
therapeutics	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
quantify	VB	O
and	CC	O
compare	VB	O
the	DT	O
time	NN	O
needed	VBN	O
to	TO	O
treat	VB	O
commercial	JJ	O
beef	NN	O
cattle	NNS	O
with	IN	O
three	CD	Pharmacological
fluke	NNS	Pharmacological
and	CC	Pharmacological
worm	VB	Pharmacological
combination	NN	Pharmacological
products	NNS	Pharmacological
with	IN	O
different	JJ	O
administration	NN	O
profiles	NNS	O
.	.	O

Young	NNP	O
beef	NN	O
cattle	NNS	O
(	(	O
n	JJ	O
=	NNP	O
270	CD	O
)	)	O
weighing	VBG	O
approximately	RB	O
400	CD	O
kg	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
batches	NNS	O
of	IN	O
five	CD	O
,	,	O
which	WDT	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
ivermectin	NN	Pharmacological
+	NNP	O
clorsulon	NN	Pharmacological
injection	NN	Pharmacological
,	,	O
ivermectin	JJ	Pharmacological
+	JJ	O
closantel	NN	Pharmacological
injection	NN	Pharmacological
,	,	O
or	CC	O
levamisole	JJ	Pharmacological
+	JJ	O
triclabendazole	JJ	Pharmacological
oral	JJ	O
drench	NN	O
.	.	O

The	DT	O
mean	JJ	O
time	NN	O
needed	VBN	O
to	TO	O
administer	VB	O
ivermectin	JJ	Pharmacological
+	NN	O
clorsulon	NN	Pharmacological
(	(	O
single	JJ	O
injection	NN	O
)	)	O
to	TO	O
five	CD	O
cattle	NNS	O
was	VBD	O
31	CD	O
seconds	NNS	O
,	,	O
which	WDT	O
was	VBD	O
significantly	RB	O
less	JJR	O
than	IN	O
the	DT	O
100	CD	O
seconds	NNS	O
needed	VBN	O
for	IN	O
ivermectin	JJ	Pharmacological
+	JJ	O
closantel	NN	Pharmacological
(	(	O
two	CD	O
injections	NNS	O
)	)	O
and	CC	O
the	DT	O
126	CD	O
seconds	NNS	O
needed	VBN	O
for	IN	O
levamisole	JJ	Pharmacological
+	JJ	O
triclabendazole	NN	Pharmacological
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Such	JJ	O
quantitative	JJ	O
data	NNS	O
can	MD	O
allow	VB	O
for	IN	O
better	JJR	O
planning	NN	O
and	CC	O
selection	NN	O
of	IN	O
parasiticide	JJ	O
treatment	NN	O
approaches	NNS	O
at	IN	O
the	DT	O
farm	NN	O
level	NN	O
.	.	O

18F-FDG	JJ	O
PET/CT	NNP	O
for	IN	O
early	JJ	O
prediction	NN	O
of	IN	O
response	NN	O
to	TO	O
neoadjuvant	JJ	Pharmacological
lapatinib	NN	Pharmacological
,	,	O
trastuzumab	NN	Pharmacological
,	,	O
and	CC	O
their	PRP$	Pharmacological
combination	NN	Pharmacological
in	IN	O
HER2-positive	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
results	NNS	O
from	IN	O
Neo-ALTTO	NNP	O
.	.	O

UNLABELLED	NNP	O
Molecular	NNP	O
imaging	VBG	O
receives	NNS	O
increased	VBD	O
attention	NN	O
for	IN	O
selecting	VBG	O
patients	NNS	O
who	WP	O
will	MD	O
benefit	VB	O
from	IN	O
targeted	JJ	O
anticancer	NN	O
therapies	NNS	O
.	.	O

Neo-ALTTO	NNP	O
(	(	O
Neoadjuvant	NNP	Pharmacological
Lapatinib	NNP	Pharmacological
and/or	VBZ	O
Trastuzumab	NNP	Pharmacological
Treatment	NNP	O
Optimisation	NNP	O
)	)	O
enrolled	VBD	O
455	CD	O
women	NNS	O
with	IN	O
invasive	JJ	O
human	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
(	(	O
HER2	NNP	O
)	)	O
-positive	VBP	O
breast	NN	O
cancer	NN	O
and	CC	O
compared	VBN	O
rates	NNS	O
of	IN	O
pathologic	JJ	O
complete	JJ	O
response	NN	O
(	(	O
pCR	NN	O
)	)	O
to	TO	O
neoadjuvant	JJ	Pharmacological
lapatinib	NN	Pharmacological
,	,	O
trastuzumab	NN	Pharmacological
,	,	O
and	CC	O
their	PRP$	O
combination	NN	Pharmacological
.	.	O

Each	DT	O
anti-HER2	JJ	Pharmacological
therapy	NN	Pharmacological
was	VBD	O
given	VBN	O
alone	RB	O
for	IN	O
6	CD	O
wk	NN	O
,	,	O
followed	VBN	O
by	IN	O
12	CD	O
wk	NN	O
of	IN	O
the	DT	O
same	JJ	O
therapy	NN	O
plus	CC	O
weekly	JJ	O
paclitaxel	NN	Pharmacological
.	.	Pharmacological

The	DT	O
early	JJ	O
metabolic	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
anti-HER2	JJ	Pharmacological
therapies	NNS	Pharmacological
on	IN	O
the	DT	O
primary	JJ	O
tumors	NNS	O
and	CC	O
their	PRP$	O
predictive	JJ	O
values	NNS	O
for	IN	O
pCR	NN	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
subset	NN	O
of	IN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Eighty-six	JJ	O
patients	NNS	O
underwent	JJ	O
(	(	O
18	CD	O
)	)	O
F-FDG	CD	O
PET/CT	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
weeks	NNS	O
2	CD	O
and	CC	O
6	CD	O
of	IN	O
anti-HER2	JJ	Pharmacological
treatment	NN	Pharmacological
.	.	Pharmacological

An	DT	O
imaging	VBG	O
core	NN	O
laboratory	NN	O
provided	VBD	O
central	JJ	O
validation	NN	O
,	,	O
and	CC	O
2	CD	O
independent	JJ	O
reviewers	NNS	O
,	,	O
masked	VBD	O
to	TO	O
assigned	VB	O
treatment	NN	O
arm	NN	O
and	CC	O
clinical	JJ	O
outcomes	NNS	O
,	,	O
performed	VBN	O
consensus	NN	O
(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
readings	NNS	O
.	.	O

Maximum	NNP	O
standardized	VBD	O
uptake	JJ	O
value	NN	O
(	(	O
SUVmax	NNP	O
)	)	O
reductions	NNS	O
from	IN	O
baseline	NN	O
were	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
metabolic	JJ	O
response	NN	O
.	.	O

RESULTS	NNP	O
Seventy-seven	NNP	O
of	IN	O
the	DT	O
86	CD	O
enrolled	VBD	O
patients	NNS	O
presented	VBD	O
an	DT	O
evaluable	JJ	O
baseline	NN	O
(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
scan	JJ	O
;	:	O
of	IN	O
these	DT	O
,	,	O
68	CD	O
and	CC	O
66	CD	O
were	VBD	O
evaluable	JJ	O
at	IN	O
weeks	NNS	O
2	CD	O
and	CC	O
6	CD	O
,	,	O
respectively	RB	O
.	.	O

Metabolic	JJ	O
responses	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
tumors	NNS	O
were	VBD	O
evident	JJ	O
after	IN	O
2	CD	O
wk	NN	O
of	IN	O
targeted	JJ	O
therapy	NN	O
and	CC	O
correlated	VBN	O
highly	RB	O
with	IN	O
metabolic	JJ	O
responses	NNS	O
at	IN	O
week	NN	O
6	CD	O
(	(	O
R	NNP	O
(	(	O
2	CD	O
)	)	O
=	FW	O
0.81	CD	O
)	)	O
.	.	O

pCRs	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
SUVmax	NNP	O
reductions	NNS	O
at	IN	O
both	DT	O
time	NN	O
points	NNS	O
.	.	O

Mean	NNP	O
SUVmax	NNP	O
reductions	NNS	O
for	IN	O
pCR	NN	O
and	CC	O
non-pCR	JJ	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
54.3	CD	O
%	NN	O
versus	IN	O
32.8	CD	O
%	NN	O
at	IN	O
week	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
61.5	CD	O
%	NN	O
versus	IN	O
34.1	CD	O
%	NN	O
at	IN	O
week	NN	O
6	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
metabolic	JJ	O
response	NN	O
rates	NNS	O
at	IN	O
weeks	NNS	O
2	CD	O
and	CC	O
6	CD	O
were	VBD	O
71.6	CD	O
%	NN	O
and	CC	O
60	CD	O
%	NN	O
,	,	O
respectively	RB	O
using	VBG	O
European	JJ	O
Organization	NNP	O
for	IN	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
criteria	NNS	O
;	:	O
pCR	VBN	O
rates	NNS	O
were	VBD	O
twice	RB	O
as	RB	O
high	JJ	O
for	IN	O
(	(	O
18	CD	O
)	)	O
F-FDG	NNP	O
PET/CT	NNP	O
responders	NNS	O
than	IN	O
nonresponders	NNS	O
(	(	O
week	NN	O
2	CD	O
:	:	O
42	CD	O
%	NN	O
vs.	FW	O
21	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.12	CD	O
;	:	O
week	NN	O
6	CD	O
:	:	O
44	CD	O
%	NN	O
vs.	FW	O
19	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Early	NNP	O
metabolic	JJ	O
assessment	NN	O
using	VBG	O
(	(	O
18	CD	O
)	)	O
F-FDG	CD	O
PET/CT	NNP	O
can	MD	O
identify	VB	O
patients	NNS	O
with	IN	O
an	DT	O
increased	VBN	O
likelihood	NN	O
of	IN	O
pCR	NN	O
after	IN	O
neoadjuvant	JJ	Pharmacological
trastuzumab	NN	Pharmacological
,	,	O
lapatinib	NN	Pharmacological
,	,	O
or	CC	O
their	PRP$	O
combination	NN	Pharmacological
when	WRB	O
given	VBN	O
with	IN	O
chemotherapy	NN	Pharmacological
.	.	Pharmacological

VLDL	NNP	O
,	,	O
apolipoproteins	VBZ	O
B	NNP	O
,	,	O
CIII	NNP	O
,	,	O
and	CC	O
E	NNP	O
,	,	O
and	CC	O
risk	NN	O
of	IN	O
recurrent	JJ	O
coronary	JJ	O
events	NNS	O
in	IN	O
the	DT	O
Cholesterol	NNP	O
and	CC	O
Recurrent	NNP	O
Events	NNP	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Plasma	NNP	O
triglyceride	NN	O
concentration	NN	O
has	VBZ	O
been	VBN	O
an	DT	O
inconsistent	JJ	O
independent	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
,	,	O
perhaps	RB	O
because	IN	O
of	IN	O
the	DT	O
metabolic	JJ	O
heterogeneity	NN	O
among	IN	O
VLDL	NNP	O
particles	NNS	O
,	,	O
the	DT	O
main	JJ	O
carriers	NNS	O
of	IN	O
triglycerides	NNS	O
in	IN	O
plasma	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
nested	JJ	O
case-control	NN	O
study	NN	O
in	IN	O
the	DT	O
Cholesterol	NNP	O
and	CC	O
Recurrent	NNP	O
Events	NNP	O
(	(	O
CARE	NNP	O
)	)	O
trial	NN	O
,	,	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
pravastatin	NN	Pharmacological
in	IN	O
4159	CD	O
patients	NNS	O
with	IN	O
myocardial	JJ	O
infarction	NN	O
and	CC	O
average	JJ	O
LDL	NNP	O
concentrations	NNS	O
at	IN	O
baseline	NN	O
(	(	O
115	CD	O
to	TO	O
174	CD	O
mg/dL	NNS	O
,	,	O
mean	VBP	O
139	CD	O
mg/dL	NN	O
)	)	O
.	.	O

Baseline	NNP	O
concentrations	NNS	O
of	IN	O
VLDL-apolipoprotein	NNP	O
(	(	O
apo	NN	O
)	)	O
B	NNP	O
(	(	O
the	DT	O
VLDL	NNP	O
particle	NN	O
concentration	NN	O
)	)	O
,	,	O
VLDL	NNP	O
lipids	NNS	O
,	,	O
and	CC	O
apoCIII	NN	O
and	CC	O
apoE	NN	O
in	IN	O
VLDL+LDL	NNP	O
and	CC	O
in	IN	O
HDL	NNP	O
were	VBD	O
compared	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
either	CC	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
coronary	JJ	O
death	NN	O
(	(	O
cases	NNS	O
,	,	O
n=418	NN	O
)	)	O
with	IN	O
those	DT	O
in	IN	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
cardiovascular	JJ	O
event	NN	O
(	(	O
control	NN	O
subjects	VBZ	O
,	,	O
n=370	NN	O
)	)	O
in	IN	O
5	CD	O
years	NNS	O
of	IN	O
follow-up	JJ	O
.	.	O

VLDL-cholesterol	NN	O
,	,	O
VLDL-triglyceride	NNP	O
,	,	O
VLDL-apoB	NNP	O
,	,	O
apoCIII	NN	O
and	CC	O
apoE	NN	O
in	IN	O
VLDL+LDL	NNP	O
and	CC	O
apoE	NN	O
in	IN	O
HDL	NNP	O
were	VBD	O
all	DT	O
interrelated	VBN	O
,	,	O
and	CC	O
each	DT	O
was	VBD	O
a	DT	O
univariate	JJ	O
predictor	NN	O
of	IN	O
subsequent	JJ	O
coronary	JJ	O
events	NNS	O
.	.	O

The	DT	O
significant	JJ	O
independent	JJ	O
predictors	NNS	O
were	VBD	O
VLDL-apoB	NNP	O
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	VBZ	O
3.2	CD	O
for	IN	O
highest	JJS	O
to	TO	O
lowest	JJS	O
quintiles	NNS	O
,	,	O
P	NNP	O
:	:	O
=0.04	NN	O
)	)	O
,	,	O
apoCIII	RB	O
in	IN	O
VLDL+LDL	NNP	O
(	(	O
RR	NNP	O
2.3	CD	O
,	,	O
P	NNP	O
:	:	O
=0.04	NN	O
)	)	O
,	,	O
and	CC	O
apoE	NN	O
in	IN	O
HDL	NNP	O
(	(	O
RR	NNP	O
1.8	CD	O
,	,	O
P	NNP	O
:	:	O
=0.02	NN	O
)	)	O
.	.	O

Plasma	NNP	O
triglycerides	NNS	O
,	,	O
a	DT	O
univariate	JJ	O
predictor	NN	O
of	IN	O
coronary	JJ	O
events	NNS	O
(	(	O
RR	NNP	O
1.6	CD	O
,	,	O
P	NNP	O
:	:	O
=0.03	NN	O
)	)	O
,	,	O
was	VBD	O
not	RB	O
related	VBN	O
to	TO	O
coronary	JJ	O
events	NNS	O
(	(	O
RR	NNP	O
1.3	CD	O
,	,	O
P	NNP	O
:	:	O
=0.6	NN	O
)	)	O
when	WRB	O
apoCIII	NN	O
in	IN	O
VLDL+LDL	NNP	O
was	VBD	O
included	VBN	O
in	IN	O
the	DT	O
model	NN	O
,	,	O
whereas	JJ	O
apoCIII	NN	O
remained	VBD	O
significant	JJ	O
.	.	O

Adjustment	NN	O
for	IN	O
LDL-	NNP	O
and	CC	O
HDL-cholesterol	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
these	DT	O
results	NNS	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
VLDL	NNP	O
particles	NNS	O
and	CC	O
apoCIII	NN	O
in	IN	O
VLDL	NNP	O
and	CC	O
LDL	NNP	O
are	VBP	O
more	RBR	O
specific	JJ	O
measures	NNS	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
risk	NN	O
than	IN	O
plasma	JJ	O
triglycerides	NNS	O
perhaps	RB	O
because	IN	O
their	PRP$	O
known	VBN	O
metabolic	NN	O
properties	NNS	O
link	VBP	O
them	PRP	O
more	RBR	O
closely	RB	O
to	TO	O
atherosclerosis	NN	O
.	.	O

Psychoeducational	NNP	Educational
group	NN	Educational
intervention	NN	Educational
for	IN	O
wives	NNS	O
of	IN	O
men	NNS	O
with	IN	O
prostate	NN	O
cancer	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
6-week	JJ	O
psychoeducational	JJ	Educational
group	NN	Educational
intervention	NN	Educational
on	IN	O
the	DT	O
distress	NN	O
,	,	O
coping	NN	O
,	,	O
personal	JJ	O
growth	NN	O
,	,	O
and	CC	O
marital	JJ	O
communication	NN	O
of	IN	O
wives	NNS	O
of	IN	O
men	NNS	O
diagnosed	VBN	O
with	IN	O
prostate	JJ	O
cancer	NN	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
wives	NNS	O
completed	VBD	O
measures	NNS	O
prior	RB	O
to	TO	O
random	VB	O
assignment	NN	O
to	TO	O
either	VB	O
the	DT	O
psychoeducational	JJ	Control
group	NN	Control
intervention	NN	Control
or	CC	O
a	DT	O
no-treatment	JJ	Control
control	NN	Control
group	NN	Control
,	,	O
and	CC	O
1	CD	O
month	NN	O
after	IN	O
completion	NN	O
of	IN	O
the	DT	O
group	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
differences	NNS	O
with	IN	O
regard	NN	O
to	TO	O
wives	NNS	O
'	POS	O
general	JJ	O
distress	NN	O
or	CC	O
cancer-specific	JJ	O
distress	NN	O
were	VBD	O
noted	VBN	O
.	.	O

In	IN	O
comparison	NN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
participants	NNS	O
receiving	VBG	O
the	DT	O
intervention	NN	O
perceived	VBD	O
that	IN	O
having	VBG	O
a	DT	O
spouse	NN	O
with	IN	O
prostate	NN	O
cancer	NN	O
had	VBD	O
made	VBN	O
positive	JJ	O
contributions	NNS	O
to	TO	O
their	PRP$	O
lives	NNS	O
,	,	O
reported	VBD	O
gains	NNS	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
positive	JJ	O
reappraisal	NN	O
coping	VBG	O
and	CC	O
reductions	NNS	O
in	IN	O
denial	JJ	O
coping	NN	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
the	DT	O
psychoeducational	JJ	Educational
intervention	NN	Educational
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
changes	NNS	O
in	IN	O
psychological	JJ	O
distress	NN	O
,	,	O
improvements	NNS	O
in	IN	O
adaptive	JJ	O
coping	NN	O
and	CC	O
indicators	NNS	O
of	IN	O
psychological	JJ	O
growth	NN	O
were	VBD	O
found	VBN	O
.	.	O

The	DT	O
utility	NN	O
of	IN	O
group	NN	O
interventions	NNS	O
for	IN	O
spouses	NNS	O
of	IN	O
men	NNS	O
with	IN	O
prostate	NN	O
cancer	NN	O
is	VBZ	O
discussed	VBN	O
.	.	O

Effect	NN	O
of	IN	O
hydrochlorothiazide	NN	Pharmacological
therapy	NN	Pharmacological
on	IN	O
cardiac	JJ	O
arrhythmias	NN	O
in	IN	O
African-American	JJ	O
men	NNS	O
with	IN	O
systemic	JJ	O
hypertension	NN	O
and	CC	O
moderate	VB	O
to	TO	O
severe	VB	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hydrochlorothiazide	NN	Pharmacological
therapy	NN	Pharmacological
on	IN	O
ventricular	JJ	O
arrhythmias	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
45	CD	O
hypertensive	JJ	O
African-American	JJ	O
men	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
left	VBN	O
ventricular	JJ	O
(	(	O
LV	NNP	O
)	)	O
hypertrophy	NN	O
.	.	O

After	IN	O
medication	NN	O
washout	NN	O
,	,	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
placebo	NN	Control
followed	VBN	O
by	IN	O
hydrochlorothiazide	NN	Pharmacological
.	.	O

Clinical	NNP	O
,	,	O
biochemical	JJ	O
,	,	O
and	CC	O
48-hour	JJ	O
ambulatory	NN	O
electrocardiographic	JJ	O
data	NN	O
was	VBD	O
collected	VBN	O
after	IN	O
each	DT	O
treatment	NN	O
phase	NN	O
.	.	O

Signal-averaged	JJ	O
electrocardiograms	NNS	O
were	VBD	O
recorded	VBN	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
24	CD	O
patients	NNS	O
.	.	O

Average	JJ	O
LV	NNP	O
posterior	NN	O
wall	NN	O
thickness	NN	O
was	VBD	O
15	CD	O
+/-	JJ	O
1.1	CD	O
mm	NN	O
,	,	O
septum	VBD	O
16	CD	O
+/-	JJ	O
2	CD	O
mm	NN	O
,	,	O
LV	NNP	O
mass	VBD	O
420	CD	O
+/-	JJ	O
90	CD	O
g	NN	O
,	,	O
and	CC	O
LV	NNP	O
mass	NNP	O
index	NN	O
212	CD	O
=	NN	O
51	CD	O
g/m2	NN	O
.	.	O

Systolic	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
was	VBD	O
168	CD	O
+/-	JJ	O
18	CD	O
mm	NN	O
Hg	NNP	O
after	IN	O
the	DT	O
placebo	NN	O
phase	NN	O
and	CC	O
146	CD	O
+/-	JJ	O
15	CD	O
mm	NN	O
Hg	NNP	O
after	IN	O
hydrochlorothiazide	NN	O
;	:	O
diastolic	JJ	O
BP	NNP	O
was	VBD	O
103	CD	O
+/-	JJ	O
6	CD	O
mm	NN	O
Hg	NNP	O
and	CC	O
89	CD	O
+/-	JJ	O
9	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
respectively	RB	O
.	.	O

Serum	NNP	O
potassium	NN	O
decreased	VBD	O
significantly	RB	O
from	IN	O
4.2	CD	O
+/-	JJ	O
0.4	CD	O
mmol/L	NN	O
to	TO	O
3.7	CD	O
+/-	JJ	O
0.6	CD	O
mmol/L	NN	O
after	IN	O
hydrochlorothiazide	JJ	Pharmacological
therapy	NN	Pharmacological
.	.	Pharmacological

The	DT	O
average	JJ	O
hourly	JJ	O
incidence	NN	O
of	IN	O
ventricular	JJ	O
premature	NN	O
contractions	NNS	O
was	VBD	O
22	CD	O
with	IN	O
placebo	NN	Control
and	CC	O
25	CD	O
with	IN	O
hydrochlorothiazide	NN	Pharmacological
.	.	Pharmacological

There	EX	O
were	VBD	O
3	CD	O
and	CC	O
1	CD	O
couplets	NNS	O
and	CC	O
0.2	CD	O
and	CC	O
0.2	CD	O
runs	NNS	O
of	IN	O
ventricular	JJ	O
tachycardia	NN	O
per	IN	O
patient	NN	O
per	IN	O
hour	NN	O
,	,	O
respectively	RB	O
.	.	O

Variables	NNS	O
of	IN	O
signal-averaged	JJ	O
electrocardiography	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
2	CD	O
treatments	NNS	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
hypertensive	JJ	O
African-American	JJ	O
men	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
LV	NNP	O
hypertrophy	NN	O
,	,	O
hydrochlorothiazide	NN	Pharmacological
does	VBZ	O
not	RB	O
worsen	VB	O
ventricular	JJ	O
arrhythmias	NNS	O
or	CC	O
signal-averaged	JJ	O
electrocardiographic	JJ	O
variables	NNS	O
.	.	O

Study	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
hippotherapy	NN	Physical
simulator	NN	Physical
in	IN	O
children	NNS	O
with	IN	O
cerebral	JJ	O
palsy	NN	O
:	:	O
a	DT	O
stratified	JJ	O
single-blind	NN	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
whether	IN	O
hippotherapy	NN	Physical
(	(	Physical
when	WRB	Physical
applied	VBN	Physical
by	IN	Physical
a	DT	Physical
simulator	NN	Physical
)	)	Physical
improves	VBZ	O
postural	JJ	O
control	NN	O
and	CC	O
balance	NN	O
in	IN	O
children	NNS	O
with	IN	O
cerebral	JJ	O
palsy	NN	O
.	.	O

DESIGN	NNP	O
Stratified	VBD	O
single-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
with	IN	O
an	DT	O
independent	JJ	O
assessor	NN	O
.	.	O

Stratification	NN	O
was	VBD	O
made	VBN	O
by	IN	O
gross	JJ	O
motor	NN	O
function	NN	O
classification	NN	O
system	NN	O
levels	NNS	O
,	,	O
and	CC	O
allocation	NN	O
was	VBD	O
concealed	VBN	O
.	.	O

SUBJECTS	NNP	O
Children	NNP	O
between	IN	O
4	CD	O
and	CC	O
18	CD	O
years	NNS	O
old	JJ	O
with	IN	O
cerebral	JJ	O
palsy	NN	O
.	.	O

INTERVENTIONS	JJ	O
Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
an	DT	O
intervention	NN	Physical
(	(	Physical
simulator	NN	Physical
ON	NNP	Physical
)	)	Physical
or	CC	O
control	NN	Control
(	(	Control
simulator	VB	Control
OFF	NNP	Control
)	)	Control
group	NN	O
after	IN	O
getting	VBG	O
informed	JJ	O
consent	NN	O
.	.	O

Treatment	NNP	O
was	VBD	O
provided	VBN	O
once	RB	O
a	DT	O
week	NN	O
(	(	O
15	CD	O
minutes	NNS	O
)	)	O
for	IN	O
10	CD	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
MEASURES	NNP	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Measure	NNP	O
(	(	O
dimension	NN	O
B	NNP	O
for	IN	O
balance	NN	O
and	CC	O
the	DT	O
Total	NNP	O
Score	NNP	O
)	)	O
and	CC	O
Sitting	VBG	O
Assessment	NNP	O
Scale	NNP	O
were	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
baseline	NN	O
(	(	O
prior	JJ	O
to	TO	O
randomization	NN	O
)	)	O
,	,	O
end	NN	O
of	IN	O
intervention	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
after	IN	O
completing	VBG	O
the	DT	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Thirty-eight	JJ	O
children	NNS	O
participated	VBN	O
.	.	O

The	DT	O
groups	NNS	O
were	VBD	O
balanced	VBN	O
at	IN	O
baseline	NN	O
.	.	O

Sitting	VBG	O
balance	NN	O
(	(	O
measured	VBN	O
by	IN	O
dimension	NN	O
B	NNP	O
of	IN	O
the	DT	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Measure	NNP	O
)	)	O
improved	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
effect	NN	O
size	NN	O
=	$	O
0.36	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.71	NN	O
)	)	O
and	CC	O
the	DT	O
effect	NN	O
size	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
severely	RB	O
disabled	JJ	O
group	NN	O
(	(	O
effect	NN	O
size	NN	O
=	$	O
0.80	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
0.13-1.47	NN	O
)	)	O
.	.	O

The	DT	O
improvements	NNS	O
in	IN	O
sitting	VBG	O
balance	NN	O
were	VBD	O
not	RB	O
maintained	VBN	O
over	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
total	JJ	O
score	NN	O
of	IN	O
the	DT	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Measure	NNP	O
and	CC	O
the	DT	O
Sitting	NNP	O
Assessment	NNP	O
Scale	NNP	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

CONCLUSION	NNP	O
Hippotherapy	NNP	Physical
with	IN	O
a	DT	O
simulator	NN	O
can	MD	O
improve	VB	O
sitting	VBG	O
balance	NN	O
in	IN	O
cerebral	JJ	O
palsy	NN	O
children	NNS	O
who	WP	O
have	VBP	O
higher	JJR	O
levels	NNS	O
of	IN	O
disability	NN	O
.	.	O

However	RB	O
,	,	O
this	DT	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
overall	JJ	O
function	NN	O
of	IN	O
these	DT	O
children	NNS	O
(	(	O
Gross	NNP	O
Motor	NNP	O
Function	NNP	O
Classification	NNP	O
System	NNP	O
level	JJ	O
V	NNP	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
patient-controlled	JJ	Pharmacological
and	CC	O
nurse-administered	JJ	Pharmacological
analgesia	NN	Pharmacological
using	VBG	O
intravenous	JJ	O
fentanyl	NN	O
during	IN	O
labor	NN	O
.	.	O

Preliminary	JJ	O
observations	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
fentanyl	NN	Pharmacological
citrate	NN	Pharmacological
,	,	O
a	DT	O
potent	JJ	O
narcotic	JJ	O
,	,	O
is	VBZ	O
helpful	JJ	O
during	IN	O
labor	NN	O
without	IN	O
undue	JJ	O
side	NN	O
effects	NNS	O
.	.	O

This	DT	O
randomized	JJ	O
prospective	JJ	O
investigation	NN	O
compared	VBN	O
the	DT	O
patient-controlled	JJ	Pharmacological
administration	NN	Pharmacological
of	IN	Pharmacological
fentanyl	NN	Pharmacological
with	IN	O
that	DT	O
of	IN	O
administration	NN	Pharmacological
by	IN	Pharmacological
nurses	NNS	Pharmacological
on	IN	Pharmacological
request	NN	Pharmacological
.	.	Pharmacological

Eighty	NNP	O
healthy	JJ	O
women	NNS	O
beginning	VBG	O
active	JJ	O
labor	NN	O
(	(	O
cervical	JJ	O
dilation	NN	O
4	CD	O
cm	NN	O
)	)	O
at	IN	O
term	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
receive	VB	O
fentanyl	NN	Pharmacological
intravenously	RB	O
by	IN	O
either	CC	O
patient-controlled	JJ	Pharmacological
administration	NN	O
(	(	O
n=37	JJ	O
)	)	O
or	CC	O
nurse	JJ	Pharmacological
administration	NN	Pharmacological
on	IN	O
demand	NN	O
(	(	O
n=43	JJ	O
)	)	O
.	.	O

Pain	NNP	O
intensity	NN	O
measurements	NNS	O
during	IN	O
early	JJ	O
and	CC	O
late	JJ	O
labor	NN	O
revealed	VBD	O
the	DT	O
degree	NN	O
of	IN	O
analgesia	NN	O
to	TO	O
be	VB	O
the	DT	O
same	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
delay	NN	O
in	IN	O
setting	VBG	O
up	RP	O
the	DT	O
infusion	NN	O
system	NN	O
and	CC	O
the	DT	O
short	JJ	O
time	NN	O
between	IN	O
requesting	VBG	O
analgesia	NN	O
and	CC	O
vaginal	JJ	O
delivery	NN	O
were	VBD	O
limitations	NNS	O
with	IN	O
self-administration	NN	O
.	.	O

Maternal	JJ	O
oversedation	NN	O
and	CC	O
vomiting	VBG	O
did	VBD	O
not	RB	O
occur	VB	O
.	.	O

Neonatal	NNP	O
naloxone	NN	O
therapy	NN	O
was	VBD	O
used	VBN	O
infrequently	RB	O
,	,	O
umbilical	JJ	O
serum	NN	O
levels	NNS	O
of	IN	O
fentanyl	NN	O
were	VBD	O
the	DT	O
same	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
postnatal	JJ	O
neuroadaptive	JJ	O
testing	NN	O
revealed	VBD	O
comparable	JJ	O
results	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Despite	IN	O
the	DT	O
usefulness	NN	O
of	IN	O
fentanyl	NN	O
during	IN	O
labor	NN	O
,	,	O
administration	NN	Pharmacological
by	IN	Pharmacological
the	DT	Pharmacological
patient	NN	Pharmacological
had	VBD	O
no	DT	O
advantages	NNS	O
over	IN	O
administration	NN	Pharmacological
by	IN	Pharmacological
the	DT	Pharmacological
nurses	NNS	Pharmacological
in	IN	O
significantly	RB	O
reducing	VBG	O
drug	NN	O
use	NN	O
,	,	O
improving	VBG	O
pain	NN	O
relief	NN	O
,	,	O
or	CC	O
avoiding	VBG	O
drowsiness	NN	O
.	.	O

Failure	NN	O
of	IN	O
naltrexone	NN	Pharmacological
hydrochloride	NN	Pharmacological
to	TO	O
reduce	VB	O
self-injurious	JJ	O
and	CC	O
autistic	JJ	O
behavior	NN	O
in	IN	O
mentally	RB	O
retarded	JJ	O
adults	NNS	O
.	.	O

Double-blind	JJ	O
placebo-controlled	JJ	Control
studies	NNS	O
.	.	O

BACKGROUND	IN	O
It	PRP	O
is	VBZ	O
hypothesized	VBN	O
that	IN	O
self-injurious	JJ	O
behavior	NN	O
(	(	O
SIB	NNP	O
)	)	O
and	CC	O
symptoms	NNS	O
of	IN	O
autism	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
overactivity	NN	O
in	IN	O
some	DT	O
opioid	JJ	O
systems	NNS	O
in	IN	O
the	DT	O
brain	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
naltrexone	JJ	Pharmacological
hydrochloride	NN	Pharmacological
,	,	O
an	DT	O
opioid	JJ	O
antagonist	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
SIB	NNP	O
and	CC	O
autism	NN	O
in	IN	O
mentally	RB	O
retarded	JJ	O
adults	NNS	O
.	.	O

METHOD	NNP	O
Thirty-three	NNP	O
mentally	RB	O
retarded	VBD	O
adults	NNS	O
with	IN	O
autism	NN	O
and/or	NN	O
SIB	NNP	O
participated	VBD	O
in	IN	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
crossover	NN	O
studies	NNS	O
.	.	O

Active	JJ	O
treatment	NN	O
was	VBD	O
first	RB	O
a	DT	O
single	JJ	O
100-mg	JJ	O
dose	NN	O
of	IN	O
naltrexone	JJ	Pharmacological
hydrochloride	NN	Pharmacological
.	.	Pharmacological

Subsequently	NNP	O
,	,	O
19	CD	O
subjects	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
50	CD	O
mg/d	NNS	O
and	CC	O
14	CD	O
with	IN	O
150	CD	O
mg/d	NNS	O
of	IN	O
naltrexone	NN	Pharmacological
hydrochloride	NN	Pharmacological
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

The	DT	O
outcome	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
means	NNS	O
of	IN	O
direct	JJ	O
observations	NNS	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
and	CC	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
scores	NNS	O
on	IN	O
a	DT	O
list	NN	O
of	IN	O
target	NN	O
behaviors	NNS	O
,	,	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
,	,	O
and	CC	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impression	NNP	O
Scale	NNP	O
.	.	O

RESULTS	NNP	O
Thirty-two	JJ	O
subjects	NNS	O
(	(	O
seven	CD	O
with	IN	O
autism	NN	O
,	,	O
16	CD	O
with	IN	O
autism	NN	O
and	CC	O
SIB	NNP	O
,	,	O
and	CC	O
nine	CD	O
with	IN	O
SIB	NNP	O
)	)	O
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

Naltrexone	CD	Pharmacological
treatment	NN	O
failed	VBD	O
to	TO	O
have	VB	O
therapeutic	JJ	O
effects	NNS	O
on	IN	O
SIB	NNP	O
and	CC	O
autism	NN	O
.	.	O

On	IN	O
the	DT	O
contrary	JJ	O
,	,	O
naltrexone	RB	Pharmacological
increased	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
stereotypic	JJ	O
behavior	NN	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
,	,	O
and	CC	O
the	DT	O
care	NN	O
staff	NN	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
50-mg/d	JJ	O
treatment	NN	O
as	IN	O
being	VBG	O
significantly	RB	O
worse	JJR	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
placebo	NN	O
treatment	NN	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impression	NNP	O
Scale	NNP	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
naltrexone	NN	O
has	VBZ	O
no	DT	O
clinical	JJ	O
value	NN	O
for	IN	O
a	DT	O
broad	JJ	O
group	NN	O
of	IN	O
mentally	RB	O
retarded	JJ	O
subjects	NNS	O
with	IN	O
SIB	NNP	O
and/or	JJ	O
autism	NN	O
.	.	O

The	DT	O
relationship	NN	O
between	IN	O
repetitive	JJ	O
behaviors	NNS	O
and	CC	O
growth	NN	O
hormone	NN	O
response	NN	O
to	TO	O
sumatriptan	VB	Pharmacological
challenge	NN	O
in	IN	O
adult	NN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Autism	NNP	O
is	VBZ	O
heterogeneous	JJ	O
with	IN	O
respect	NN	O
to	TO	O
clinical	JJ	O
symptoms	NNS	O
and	CC	O
etiology	NN	O
.	.	O

To	TO	O
sort	VB	O
out	RP	O
this	DT	O
heterogeneity	NN	O
in	IN	O
autism	NN	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
specific	JJ	O
neurobiological	JJ	O
markers	NNS	O
vary	VBP	O
in	IN	O
parallel	NN	O
to	TO	O
core	VB	O
symptomatology	NN	O
.	.	O

Specifically	RB	O
,	,	O
we	PRP	O
assessed	VBD	O
growth	NN	O
hormone	NN	O
response	NN	O
to	TO	O
the	DT	O
5-HT	JJ	Pharmacological
1d	CD	Pharmacological
agonist	NN	Pharmacological
,	,	Pharmacological
sumatriptan	NN	Pharmacological
,	,	O
and	CC	O
linked	VBD	O
this	DT	O
measure	NN	O
of	IN	O
serotonergic	JJ	O
function	NN	O
to	TO	O
the	DT	O
severity	NN	O
of	IN	O
repetitive	JJ	O
behaviors	NNS	O
in	IN	O
adult	NN	O
autistic	JJ	O
patients	NNS	O
.	.	O

Eleven	NNP	O
adult	NN	O
patients	NNS	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
's	POS	O
disorder	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
single	JJ	O
dose	JJ	O
sumatriptan	NN	Pharmacological
(	(	O
6	CD	O
mg	RB	O
SQ	NNP	O
)	)	O
and	CC	O
placebo	NN	Control
challenges	NNS	O
,	,	O
separated	VBN	O
by	IN	O
a	DT	O
one-week	JJ	O
interval	NN	O
.	.	O

In	IN	O
adult	JJ	O
autistic	JJ	O
disorders	NNS	O
,	,	O
severity	NN	O
of	IN	O
repetitive	JJ	O
behaviors	NNS	O
at	IN	O
baseline	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
YBOCS-compulsion	NNP	O
score	NN	O
,	,	O
significantly	RB	O
positively	RB	O
correlated	VBN	O
with	IN	O
both	DT	O
peak	JJ	O
delta	NN	O
growth	NN	O
hormone	NN	O
response	NN	O
and	CC	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
growth	NN	O
hormone	NN	O
response	NN	O
to	TO	O
sumatriptan	VB	Pharmacological
.	.	Pharmacological

Thus	RB	O
,	,	O
the	DT	O
severity	NN	O
of	IN	O
a	DT	O
specific	JJ	O
behavioral	JJ	O
dimension	NN	O
in	IN	O
autism	NN	O
(	(	O
repetitive	JJ	O
behaviors	NNS	O
)	)	O
parallels	VBP	O
the	DT	O
sensitivity	NN	O
of	IN	O
the	DT	O
5-HT	JJ	Pharmacological
1d	CD	Pharmacological
receptor	NN	Pharmacological
,	,	O
as	IN	O
manifest	NN	O
by	IN	O
sumatriptan	NN	Pharmacological
elicited	VBN	O
GH	NNP	O
response	NN	O
.	.	O

Acute	JJ	O
effects	NNS	O
of	IN	O
decaffeinated	JJ	Pharmacological
coffee	NN	Pharmacological
and	CC	O
the	DT	O
major	JJ	O
coffee	NN	O
components	NNS	O
chlorogenic	JJ	Pharmacological
acid	NN	O
and	CC	O
trigonelline	NN	Pharmacological
on	IN	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVE	NNP	O
Coffee	NNP	Pharmacological
consumption	NN	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
lower	JJR	O
risk	NN	O
of	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
decaffeinated	JJ	Pharmacological
coffee	NN	Pharmacological
and	CC	O
the	DT	O
major	JJ	O
coffee	NN	O
components	NNS	O
chlorogenic	JJ	O
acid	NN	O
and	CC	O
trigonelline	NN	O
on	IN	O
glucose	JJ	O
tolerance	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
crossover	NN	O
trial	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
12	CD	O
g	NN	O
decaffeinated	VBD	Pharmacological
coffee	NN	Pharmacological
,	,	O
1	CD	O
g	NN	O
chlorogenic	JJ	Pharmacological
acid	NN	Pharmacological
,	,	O
500	CD	O
mg	NN	O
trigonelline	NN	Pharmacological
,	,	O
and	CC	O
placebo	NN	Control
(	(	O
1	CD	O
g	NN	O
mannitol	NN	Pharmacological
)	)	Pharmacological
on	IN	O
glucose	NN	O
and	CC	O
insulin	NN	O
concentrations	NNS	O
during	IN	O
a	DT	O
2-h	JJ	O
oral	JJ	O
glucose	NN	O
tolerance	NN	O
test	NN	O
(	(	O
OGTT	NNP	O
)	)	O
in	IN	O
15	CD	O
overweight	JJ	O
men	NNS	O
.	.	O

RESULTS	NNP	O
Chlorogenic	NNP	O
acid	NN	O
and	CC	O
trigonelline	NN	O
ingestion	NN	O
significantly	RB	O
reduced	VBN	O
glucose	NN	O
(	(	O
-0.7	JJ	O
mmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.007	CD	O
,	,	O
and	CC	O
-0.5	NNP	O
mmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.024	CD	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
insulin	NN	O
(	(	O
-73	JJ	O
pmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.038	CD	O
,	,	O
and	CC	O
-117	NNP	O
pmol/l	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.007	CD	O
)	)	O
concentrations	NNS	O
15	CD	O
min	NN	O
following	VBG	O
an	DT	O
OGTT	NNP	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
treatments	NNS	O
affected	VBD	O
insulin	NN	O
or	CC	O
glucose	JJ	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
values	NNS	O
during	IN	O
the	DT	O
OGTT	NNP	O
compared	VBN	O
with	IN	O
placebo	NN	Control
.	.	Control

CONCLUSIONS	NNP	O
Chlorogenic	NNP	O
acid	NN	O
and	CC	O
trigonelline	NN	O
reduced	VBD	O
early	JJ	O
glucose	NN	O
and	CC	O
insulin	NN	O
responses	NNS	O
during	IN	O
an	DT	O
OGTT	NNP	O
.	.	O

LNH-84	JJ	O
regimen	NNS	O
:	:	O
a	DT	O
multicenter	NN	O
study	NN	O
of	IN	O
intensive	JJ	O
chemotherapy	NN	O
in	IN	O
737	CD	O
patients	NNS	O
with	IN	O
aggressive	JJ	O
malignant	JJ	O
lymphoma	NN	O
.	.	O

From	IN	O
July	NNP	O
1984	CD	O
to	TO	O
September	NNP	O
1987	CD	O
,	,	O
737	CD	O
patients	NNS	O
with	IN	O
aggressive	JJ	O
malignant	JJ	O
lymphoma	NN	O
(	(	O
ML	NNP	O
)	)	O
were	VBD	O
treated	VBN	O
by	IN	O
an	DT	O
intensive	JJ	Pharmacological
regimen	NNS	Pharmacological
(	(	Pharmacological
LNH-84	NNP	Pharmacological
)	)	Pharmacological
comprising	VBG	O
three	CD	O
or	CC	O
four	CD	O
courses	NNS	O
of	IN	O
doxorubicin	NN	Pharmacological
,	,	O
75	CD	O
mg/m2	NN	O
;	:	O
cyclophosphamide	NN	Pharmacological
,	,	O
1,200	CD	O
mg/m2	NN	O
;	:	O
vindesine	NN	Pharmacological
,	,	O
2	CD	O
mg/m2	NN	O
x	NN	O
2	CD	O
;	:	O
bleomycin	NN	Pharmacological
,	,	O
10	CD	O
mg	NN	O
x	NN	O
2	CD	O
;	:	O
and	CC	O
prednisolone	NN	Pharmacological
,	,	O
60	CD	O
mg/m2	NN	O
x	NN	O
5	CD	O
(	(	O
ACVB	NNP	O
)	)	O
,	,	O
consolidation	NN	O
with	IN	O
high-dose	JJ	O
methotrexate	NN	Pharmacological
,	,	O
ifosfamide	NN	Pharmacological
,	,	O
etoposide	RB	Pharmacological
,	,	O
asparaginase	NN	Pharmacological
,	,	O
and	CC	O
cytarabine	NN	Pharmacological
,	,	O
and	CC	O
a	DT	O
randomized	VBN	O
late	JJ	O
intensification	NN	O
with	IN	O
two	CD	O
courses	NNS	O
of	IN	O
cytarabine	NN	Pharmacological
,	,	O
cyclophosphamide	NN	Pharmacological
,	,	O
teniposide	NN	Pharmacological
,	,	O
bleomycin	NN	Pharmacological
,	,	O
and	CC	O
prednisone	NN	Pharmacological
(	(	O
AraCVmB	NNP	O
)	)	O
.	.	O

Four	CD	O
hundred	VBD	O
forty-two	JJ	O
patients	NNS	O
had	VBD	O
intermediate-grade	JJ	O
ML	NNP	O
,	,	O
221	CD	O
highgrade	NN	O
ML	NNP	O
,	,	O
and	CC	O
74	CD	O
unclassified	JJ	O
ML	NNP	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
advanced	JJ	O
disease	NN	O
:	:	O
stage	NN	O
IIE	NNP	O
(	(	O
23	CD	O
%	NN	O
)	)	O
,	,	O
III	NNP	O
(	(	O
13	CD	O
%	NN	O
)	)	O
,	,	O
or	CC	O
IV	NNP	O
(	(	O
47	CD	O
%	NN	O
)	)	O
;	:	O
38	CD	O
%	NN	O
disseminated	JJ	O
nodes	NNS	O
;	:	O
38	CD	O
%	NN	O
two	CD	O
or	CC	O
more	JJR	O
extranodal	JJ	O
sites	NNS	O
;	:	O
and	CC	O
41	CD	O
%	NN	O
a	DT	O
tumoral	JJ	O
mass	NN	O
greater	JJR	O
than	IN	O
10	CD	O
cm	NN	O
.	.	O

Five	CD	O
hundred	VBD	O
fifty-three	JJ	O
patients	NNS	O
(	(	O
75	CD	O
%	NN	O
)	)	O
went	VBD	O
into	IN	O
complete	JJ	O
remission	NN	O
(	(	O
CR	NNP	O
)	)	O
,	,	O
63	CD	O
(	(	O
9	CD	O
%	NN	O
)	)	O
into	IN	O
partial	JJ	O
remission	NN	O
,	,	O
62	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
failed	VBD	O
to	TO	O
respond	VB	O
,	,	O
and	CC	O
59	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
died	VBD	O
during	IN	O
ACVB	NNP	O
courses	NNS	O
,	,	O
17	CD	O
of	IN	O
them	PRP	O
from	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

With	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
23	CD	O
months	NNS	O
,	,	O
the	DT	O
estimated	VBN	O
2-year	JJ	O
overall	JJ	O
survival	NN	O
time	NN	O
to	TO	O
failure	NN	O
(	(	O
TTF	NNP	O
)	)	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
relapse	VB	O
(	(	O
TTR	NNP	O
)	)	O
survival	NN	O
are	VBP	O
67	CD	O
%	NN	O
,	,	O
56	CD	O
%	NN	O
,	,	O
and	CC	O
67	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Patients	NNS	O
receiving	VBG	O
a	DT	O
late	JJ	O
intensification	NN	O
had	VBD	O
the	DT	O
same	JJ	O
relapse	NN	O
rate	NN	O
as	IN	O
the	DT	O
other	JJ	O
patients	NNS	O
.	.	O

A	DT	O
persistent	JJ	O
fibronecrotic	JJ	O
mass	NN	O
was	VBD	O
found	VBN	O
in	IN	O
150	CD	O
patients	NNS	O
(	(	O
20	CD	O
%	NN	O
)	)	O
and	CC	O
did	VBD	O
not	RB	O
influence	VB	O
the	DT	O
relapse	NN	O
rate	NN	O
.	.	O

Toxicity	NNP	O
was	VBD	O
mainly	RB	O
neutropenia	JJ	O
and	CC	O
infection	NN	O
during	IN	O
the	DT	O
ACVB	NNP	O
courses	NNS	O
,	,	O
with	IN	O
40	CD	O
patients	NNS	O
(	(	O
5	CD	O
%	NN	O
)	)	O
dying	VBG	O
from	IN	O
septic	JJ	O
complications	NNS	O
while	IN	O
responding	VBG	O
to	TO	O
treatment	NN	O
.	.	O

Fifty-three	JJ	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
neutropenia	NN	O
less	JJR	O
than	IN	O
0.500	CD	O
x	JJ	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/L	NN	O
,	,	O
58	CD	O
%	NN	O
fever	NN	O
(	(	O
6	CD	O
%	NN	O
grade	JJ	O
4	CD	O
)	)	O
,	,	O
and	CC	O
49	CD	O
%	NN	O
a	DT	O
documented	JJ	O
infection	NN	O
(	(	O
8	CD	O
%	NN	O
grade	JJ	O
4	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
obtained	VBD	O
with	IN	O
the	DT	O
LNH-84	JJ	O
regimen	NNS	O
demonstrate	VBP	O
that	IN	O
this	DT	O
therapeutic	JJ	O
scheme	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
aggressive	JJ	O
ML	NNP	O
.	.	O

Recombinant	JJ	Pharmacological
human	JJ	Pharmacological
erythropoietin	NN	Pharmacological
therapy	NN	Pharmacological
for	IN	O
anemic	JJ	O
cancer	NN	O
patients	NNS	O
on	IN	O
combination	NN	O
chemotherapy	NN	O
.	.	O

BACKGROUND	NNP	O
Patients	NNPS	O
with	IN	O
advanced	JJ	O
cancer	NN	O
frequently	RB	O
experience	VBZ	O
clinically	RB	O
significant	JJ	O
anemia	NN	O
,	,	O
which	WDT	O
is	VBZ	O
often	RB	O
exacerbated	VBN	O
by	IN	O
myelosuppressive	JJ	O
chemotherapy	NN	O
.	.	O

Consistent	JJ	O
with	IN	O
the	DT	O
anemia	NN	O
of	IN	O
chronic	JJ	O
disease	NN	O
,	,	O
studies	NNS	O
have	VBP	O
documented	VBN	O
serum	JJ	O
erythropoietin	NN	O
levels	NNS	O
that	WDT	O
are	VBP	O
inappropriately	RB	O
low	JJ	O
for	IN	O
the	DT	O
degree	NN	O
of	IN	O
anemia	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

Myelosuppressive	JJ	O
chemotherapy	NN	O
impairs	NNS	O
erythropoiesis	NN	O
,	,	O
which	WDT	O
may	MD	O
not	RB	O
fully	RB	O
recover	VB	O
between	IN	O
treatment	NN	O
cycles	NNS	O
.	.	O

Recombinant	NNP	Pharmacological
human	JJ	Pharmacological
erythropoietin	NN	Pharmacological
(	(	Pharmacological
rHuEPO	NN	Pharmacological
)	)	Pharmacological
has	VBZ	O
been	VBN	O
used	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
to	TO	O
treat	VB	O
anemia	NN	O
in	IN	O
AIDS	NNP	O
patients	NNS	O
receiving	VBG	O
zidovudine	NN	O
(	(	O
AZT	NNP	O
)	)	O
and	CC	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
clinical	JJ	O
role	NN	O
of	IN	O
rHuEPO	NN	O
in	IN	O
reducing	VBG	O
symptomatic	JJ	O
anemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
cancer	NN	O
who	WP	O
were	VBD	O
receiving	VBG	O
myelosuppressive	JJ	O
chemotherapy	NN	O
(	(	O
excluding	VBG	O
cisplatin	NN	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
studied	VBD	O
153	CD	O
anemic	JJ	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
cyclic	JJ	Pharmacological
combination	NN	Pharmacological
chemotherapy	NN	Pharmacological
in	IN	O
a	DT	O
prospective	JJ	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
rHuEPO	NN	Pharmacological
(	(	O
150	CD	O
U/kg	NNP	O
)	)	O
or	CC	O
placebo	NN	Control
subcutaneously	RB	O
three	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
or	CC	O
until	IN	O
the	DT	O
hematocrit	JJ	O
level	NN	O
increased	VBD	O
to	TO	O
38	CD	O
%	NN	O
-40	JJ	O
%	NN	O
.	.	O

If	IN	O
the	DT	O
hematocrit	NN	O
reached	VBD	O
this	DT	O
target	NN	O
level	NN	O
before	IN	O
12	CD	O
weeks	NNS	O
,	,	O
the	DT	O
rHuEPO	NN	Pharmacological
dose	NN	O
could	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
maintain	VB	O
the	DT	O
hematocrit	NN	O
at	IN	O
that	DT	O
level	NN	O
for	IN	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Response	NNP	O
to	TO	O
rHuEPO	VB	Pharmacological
therapy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
measuring	VBG	O
changes	NNS	O
in	IN	O
hematocrit	NN	O
level	NN	O
,	,	O
transfusion	NN	O
requirements	NNS	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Quality-of-life	JJ	O
assessment	NN	O
was	VBD	O
based	VBN	O
on	IN	O
patients	NNS	O
'	POS	O
responses	NNS	O
to	TO	O
questionnaires	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
courses	NNS	O
of	IN	O
therapy	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
increase	NN	O
in	IN	O
hematocrit	NN	O
in	IN	O
the	DT	O
rHuEPO-treated	JJ	Pharmacological
group	NN	O
compared	VBN	O
with	IN	O
hematocrit	NN	O
in	IN	O
the	DT	O
placebo-treated	JJ	Control
group	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
.0001	NNP	O
)	)	O
as	IN	O
measured	VBN	O
by	IN	O
percentage	NN	O
point	NN	O
of	IN	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
final	JJ	O
evaluation	NN	O
,	,	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
hematocrit	JJ	O
level	NN	O
of	IN	O
six	CD	O
percentage	NN	O
points	NNS	O
or	CC	O
more	JJR	O
unrelated	JJ	O
to	TO	O
transfusion	NN	O
,	,	O
and	CC	O
by	IN	O
a	DT	O
rise	NN	O
in	IN	O
hematocrit	NN	O
level	NN	O
to	TO	O
38	CD	O
%	NN	O
or	CC	O
more	JJR	O
unrelated	JJ	O
to	TO	O
transfusion	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
the	DT	O
reduction	NN	O
in	IN	O
mean	JJ	O
units	NNS	O
of	IN	O
blood	NN	O
transfused	VBN	O
per	IN	O
patient	NN	O
during	IN	O
months	NNS	O
2	CD	O
and	CC	O
3	CD	O
of	IN	O
therapy	NN	O
combined	VBN	O
in	IN	O
rHuEPO-treated	JJ	Pharmacological
patients	NNS	O
compared	VBN	O
with	IN	O
placebo-treated	JJ	O
patients	NNS	O
(	(	O
0.91	CD	O
U	NNP	O
versus	NN	O
1.65	CD	O
U	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.056	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
rHuEPO-treated	JJ	Pharmacological
patients	NNS	O
experienced	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
in	IN	O
energy	NN	O
level	NN	O
and	CC	O
ability	NN	O
to	TO	O
perform	VB	O
daily	JJ	O
activities	NNS	O
(	(	O
P	NNP	O
<	NNP	O
or	CC	O
=	NNP	O
.05	NNP	O
)	)	O
.	.	O

The	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
showed	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
toxic	JJ	O
effects	NNS	O
except	IN	O
for	IN	O
increased	JJ	O
incidence	NN	O
of	IN	O
diaphoresis	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
diarrhea	NN	O
(	(	O
P	NNP	O
=	NNP	O
.05	NNP	O
)	)	O
in	IN	O
the	DT	O
rHuEPO-treated	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
conclude	VBP	O
that	DT	O
rHuEPO	NN	Pharmacological
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
for	IN	O
reversing	VBG	O
anemia	RB	O
related	VBN	O
to	TO	O
advanced	JJ	O
cancer	NN	O
or	CC	O
to	TO	O
chemotherapy	VB	O
for	IN	O
cancer	NN	O
.	.	O

Low-dose	JJ	Pharmacological
aspirin	NN	Pharmacological
and	CC	O
incidence	NN	O
of	IN	O
colorectal	JJ	O
tumors	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Laboratory	NNP	O
,	,	O
clinical	JJ	O
,	,	O
and	CC	O
epidemiologic	JJ	O
studies	NNS	O
have	VBP	O
recently	RB	O
suggested	VBN	O
that	IN	O
regular	JJ	O
use	NN	O
of	IN	O
aspirin	NN	Pharmacological
can	MD	O
reduce	VB	O
colorectal	JJ	O
cancer	NN	O
incidence	NN	O
or	CC	O
mortality	NN	O
.	.	O

However	RB	O
,	,	O
observational	JJ	O
epidemiologic	NN	O
analyses	NNS	O
have	VBP	O
had	VBN	O
limited	VBN	O
opportunity	NN	O
to	TO	O
control	VB	O
for	IN	O
confounding	VBG	O
bias	NN	O
or	CC	O
to	TO	O
specify	VB	O
aspirin	JJ	Pharmacological
doses	NNS	O
used	VBN	O
.	.	O

PURPOSE	VB	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
relationship	NN	O
between	IN	O
regular	JJ	O
use	NN	O
of	IN	O
low-dose	JJ	Pharmacological
aspirin	NN	Pharmacological
and	CC	O
incidence	NN	O
of	IN	O
invasive	JJ	O
and	CC	O
noninvasive	JJ	O
colorectal	NN	O
tumors	NNS	O
by	IN	O
utilizing	VBG	O
data	NNS	O
from	IN	O
the	DT	O
Physicians	NNPS	O
'	POS	O
Health	NNP	O
Study	NNP	O
,	,	O
a	DT	O
randomized	VBN	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
aspirin	NN	Pharmacological
and	CC	O
beta	NN	Pharmacological
carotene	NN	Pharmacological
.	.	O

We	PRP	O
also	RB	O
attempted	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
invasive	JJ	O
cancers	NNS	O
among	IN	O
aspirin	JJ	Pharmacological
users	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
rectal	JJ	O
bleeding	NN	O
and	CC	O
early	JJ	O
stage	NN	O
at	IN	O
diagnosis	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
Physicians	NNPS	O
'	POS	O
Health	NNP	O
Study	NNP	O
includes	VBZ	O
22071	CD	O
U.S.	NNP	O
male	JJ	O
physicians	NNS	O
.	.	O

The	DT	O
aspirin	JJ	O
arm	NN	O
was	VBD	O
terminated	VBN	O
in	IN	O
1988	CD	O
after	IN	O
a	DT	O
mean	JJ	O
follow-up	NN	O
of	IN	O
5	CD	O
years	NNS	O
.	.	O

Stage	NN	O
at	IN	O
diagnosis	NN	O
and	CC	O
signs	NNS	O
and/or	VBP	O
symptoms	NNS	O
during	IN	O
presentation	NN	O
were	VBD	O
abstracted	VBN	O
from	IN	O
medical	JJ	O
records	NNS	O
.	.	O

Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
relative	JJ	O
risk	NN	O
(	(	O
RR	NNP	O
)	)	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
(	(	O
CIs	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
association	NN	O
between	IN	O
aspirin	NN	O
and	CC	O
bleeding	NN	O
.	.	O

Differences	NNS	O
between	IN	O
aspirin	NN	Pharmacological
and	CC	O
placebo	NN	Control
groups	NNS	O
in	IN	O
tumor	NN	O
risk	NN	O
over	IN	O
time	NN	O
were	VBD	O
visualized	VBN	O
with	IN	O
Kaplan-Meier	NNP	O
curves	NNS	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
association	NN	O
between	IN	O
aspirin	NN	O
and	CC	O
stage	NN	O
at	IN	O
diagnosis	NN	O
with	IN	O
a	DT	O
Mann-Whitney	NNP	O
rank	NN	O
sum	NN	O
statistic	NN	O
for	IN	O
non-parametric	JJ	O
comparison	NN	O
of	IN	O
two	CD	O
ordinal	JJ	O
distributions	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
RR	NNP	O
of	IN	O
developing	VBG	O
colorectal	JJ	O
cancer	NN	O
for	IN	O
aspirin	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
was	VBD	O
1.15	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.80-1.65	NN	O
)	)	O
.	.	O

For	IN	O
in	IN	O
situ	NN	O
cancers	NNS	O
and	CC	O
polyps	NNS	O
,	,	O
the	DT	O
RR	NNP	O
was	VBD	O
0.86	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.68-1.10	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
trend	NN	O
for	IN	O
decreasing	VBG	O
RR	NNP	O
by	IN	O
year	NN	O
of	IN	O
follow-up	NN	O
for	IN	O
invasive	JJ	O
cancers	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.09	NNP	O
)	)	O
or	CC	O
noninvasive	JJ	O
tumors	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.96	NNP	O
)	)	O
.	.	O

Aspirin	NNP	O
and	CC	O
placebo	NN	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
stage	NN	O
or	CC	O
prevalence	NN	O
of	IN	O
rectal	JJ	O
bleeding	NN	O
at	IN	O
diagnosis	NN	O
.	.	O

CONCLUSIONS	NNP	O
Regular	NNP	O
aspirin	NN	Pharmacological
use	NN	O
,	,	O
at	IN	O
a	DT	O
dose	JJ	O
adequate	NN	O
for	IN	O
preventing	VBG	O
myocardial	JJ	O
infarction	NN	O
,	,	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
a	DT	O
substantial	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
colorectal	JJ	O
cancer	NN	O
during	IN	O
5	CD	O
years	NNS	O
of	IN	O
randomized	JJ	O
treatment	NN	O
and	CC	O
follow-up	NN	O
.	.	O

A	DT	O
small	JJ	O
decrease	NN	O
in	IN	O
polyps	NNS	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
could	MD	O
not	RB	O
be	VB	O
reliably	RB	O
distinguished	VBN	O
from	IN	O
a	DT	O
chance	NN	O
association	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
among	IN	O
low-dose	JJ	O
aspirin	NN	Pharmacological
users	NNS	O
,	,	O
(	(	O
a	DT	O
)	)	O
colorectal	NN	O
cancer	NN	O
mortality	NN	O
is	VBZ	O
not	RB	O
likely	JJ	O
to	TO	O
be	VB	O
reduced	VBN	O
by	IN	O
earlier	JJR	O
detection	NN	O
and	CC	O
(	(	O
b	NN	O
)	)	O
incidence	NN	O
is	VBZ	O
not	RB	O
likely	JJ	O
to	TO	O
be	VB	O
increased	VBN	O
due	JJ	O
to	TO	O
aspirin-induced	JJ	O
gastrointestinal	JJ	O
bleeding	NN	O
.	.	O

IMPLICATIONS	VBZ	O
The	DT	O
potential	NN	O
for	IN	O
a	DT	O
benefit	NN	O
from	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
aspirin	NN	O
or	CC	O
longer	JJR	O
duration	NN	O
of	IN	O
use	NN	O
should	MD	O
be	VB	O
addressed	VBN	O
by	IN	O
more	JJR	O
detailed	JJ	O
observational	JJ	O
epidemiologic	NN	O
studies	NNS	O
and	CC	O
prevention	NN	O
trials	NNS	O
with	IN	O
longer	JJR	O
follow-up	NN	O
of	IN	O
randomized	JJ	O
participants	NNS	O
.	.	O

Allogeneic	NNP	Pharmacological
marrow	NN	Pharmacological
transplantation	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
in	IN	O
the	DT	O
chronic	JJ	O
phase	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
two	CD	O
irradiation	NN	O
regimens	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
compare	VB	O
two	CD	O
regimens	NNS	O
of	IN	O
total	JJ	Other
body	NN	Other
irradiation	NN	Other
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
myeloid	NN	O
leukemia	NN	O
treated	VBN	O
by	IN	O
allogeneic	JJ	Pharmacological
marrow	NN	Pharmacological
transplantation	NN	Pharmacological
while	IN	O
in	IN	O
the	DT	O
chronic	JJ	O
phase	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
cyclophosphamide	JJ	Pharmacological
120	CD	O
mg/kg	NN	O
followed	VBN	O
by	IN	O
total	JJ	Other
body	NN	Other
irradiation	NN	Other
and	CC	O
marrow	NN	Pharmacological
from	IN	Pharmacological
HLA-identical	JJ	Pharmacological
siblings	NNS	Pharmacological
.	.	O

Cyclosporine	NNP	Pharmacological
and	CC	O
methotrexate	NN	Pharmacological
were	VBD	O
used	VBN	O
for	IN	O
prophylaxis	NN	O
against	IN	O
acute	JJ	O
graft-versus-host	JJ	O
disease	NN	O
.	.	O

Fifty-seven	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
2.0	CD	O
Gy	NNP	O
fractions	NNS	O
of	IN	O
irradiation	NN	Other
daily	NN	O
for	IN	O
6	CD	O
days	NNS	O
and	CC	O
59	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
2.25	CD	O
Gy	NNP	O
fractions	NNS	O
daily	RB	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

The	DT	O
probabilities	NNS	O
of	IN	O
relapse	NN	O
at	IN	O
4	CD	O
years	NNS	O
were	VBD	O
0.25	CD	O
for	IN	O
the	DT	O
12.0	CD	O
Gy	NNP	O
group	NN	O
and	CC	O
0.00	CD	O
for	IN	O
the	DT	O
15.75	CD	O
Gy	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.008	NNP	O
)	)	O
.	.	O

The	DT	O
actuarial	JJ	O
probabilities	NNS	O
of	IN	O
survival	NN	O
and	CC	O
relapse-free	JJ	O
survival	NN	O
at	IN	O
4	CD	O
years	NNS	O
were	VBD	O
0.60	CD	O
and	CC	O
0.58	CD	O
among	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
12.0	CD	O
Gy	NNP	O
compared	VBN	O
with	IN	O
0.66	CD	O
and	CC	O
0.66	CD	O
for	IN	O
those	DT	O
who	WP	O
received	VBD	O
15.75	CD	O
Gy	NNP	O
.	.	O

The	DT	O
4-year	JJ	O
probabilities	NNS	O
of	IN	O
transplant-related	JJ	O
mortality	NN	O
were	VBD	O
0.24	CD	O
and	CC	O
0.34	CD	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
.13	NNP	O
)	)	O
while	IN	O
the	DT	O
probability	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
acute	JJ	O
graft-versus-host	JJ	O
disease	NN	O
was	VBD	O
0.33	CD	O
for	IN	O
the	DT	O
12.0	CD	O
Gy	NNP	O
group	NN	O
and	CC	O
0.44	CD	O
for	IN	O
the	DT	O
15.75	CD	O
Gy	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.15	NNP	O
)	)	O
.	.	O

The	DT	O
lower	JJR	O
relapse	NN	O
probability	NN	O
in	IN	O
the	DT	O
patients	NNS	O
receiving	VBG	O
the	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
total	JJ	Other
body	NN	Other
irradiation	NN	Other
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
improved	JJ	O
survival	NN	O
because	IN	O
mortality	NN	O
from	IN	O
causes	VBZ	O
other	JJ	O
than	IN	O
relapse	NN	O
was	VBD	O
increased	VBN	O
.	.	O

Psychosocial	JJ	Psychological
nursing	NN	Psychological
therapy	NN	Psychological
following	VBG	O
sudden	JJ	O
cardiac	JJ	O
arrest	NN	O
:	:	O
impact	NN	O
on	IN	O
two-year	JJ	O
survival	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
psychosocial	JJ	Psychological
therapy	NN	Psychological
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
mortality	NN	O
after	IN	O
myocardial	JJ	O
infarction	NN	O
,	,	O
it	PRP	O
is	VBZ	O
unknown	JJ	O
whether	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
psychosocial	JJ	Psychological
therapy	NN	Psychological
on	IN	O
mortality	NN	O
reduction	NN	O
extend	VBP	O
to	TO	O
out-of-hospital	JJ	O
sudden	JJ	O
cardiac	NN	O
arrest	NN	O
,	,	O
a	DT	O
main	JJ	O
cause	NN	O
of	IN	O
cardiovascular	JJ	O
mortality	NN	O
.	.	O

OBJECTIVE	NNP	O
Describe	NNP	O
efficacy	NN	O
of	IN	O
psychosocial	JJ	Psychological
therapy	NN	Psychological
on	IN	O
two-year	JJ	O
cardiovascular	JJ	O
mortality	NN	O
in	IN	O
sudden	JJ	O
cardiac	JJ	O
arrest	NN	O
survivors	NNS	O
.	.	O

METHOD	NNP	O
Survivors	NNPS	O
of	IN	O
out-of-hospital	JJ	O
ventricular	JJ	O
fibrillation	NN	O
or	CC	O
asystole	NN	O
(	(	O
N	NNP	O
=	NNP	O
129	CD	O
)	)	O
,	,	O
documented	VBN	O
by	IN	O
electrocardiograms	NNS	O
from	IN	O
registries	NNS	O
of	IN	O
a	DT	O
citywide	NN	O
Medic	NNP	O
One	NNP	O
unit	NN	O
and	CC	O
two	CD	O
countywide	NN	O
emergency	NN	O
units	NNS	O
,	,	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
two	CD	O
group	NN	O
,	,	O
experimental	JJ	O
,	,	O
longitudinal	JJ	O
design	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
11	CD	O
individual	JJ	O
sessions	NNS	O
,	,	O
implementing	VBG	O
three	CD	O
components	NNS	O
:	:	O
physiologic	JJ	O
relaxation	NN	O
with	IN	O
biofeedback	NN	O
training	NN	O
focused	VBD	O
on	IN	O
altering	VBG	O
autonomic	JJ	O
tone	NN	O
;	:	O
cognitive	JJ	Psychological
behavioral	JJ	Psychological
therapy	NN	Psychological
aimed	VBN	O
at	IN	O
self-management	JJ	O
and	CC	O
coping	VBG	O
strategies	NNS	O
for	IN	O
depression	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
anger	NN	O
;	:	O
and	CC	O
cardiovascular	JJ	O
health	NN	O
education	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
cardiovascular	JJ	O
mortality	NN	O
.	.	O

RESULTS	NNP	O
Risk	NNP	O
of	IN	O
cardiovascular	JJ	O
death	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
86	CD	O
%	NN	O
by	IN	O
psychosocial	JJ	O
therapy	NN	O
,	,	O
p	NN	O
=	NNP	O
.03	NNP	O
.	.	O

Six	NNP	O
of	IN	O
the	DT	O
seven	CD	O
cardiovascular	JJ	O
deaths	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
caused	VBN	O
by	IN	O
ventricular	JJ	O
arrhythmias	NN	O
.	.	O

The	DT	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
the	DT	O
therapy	NN	O
group	NN	O
was	VBD	O
due	JJ	O
to	TO	O
stroke	VB	O
.	.	O

Controlling	VBG	O
for	IN	O
depression	NN	O
,	,	O
previous	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
low	JJ	O
ejection	NN	O
fraction	NN	O
,	,	O
decreased	JJ	O
heart	NN	O
rate	NN	O
variability	NN	O
,	,	O
and	CC	O
ventricular	JJ	O
ectopic	NN	O
beats	NNS	O
had	VBD	O
little	JJ	O
impact	NN	O
on	IN	O
estimated	VBN	O
treatment	NN	O
effect	NN	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
62	CD	O
%	NN	O
in	IN	O
the	DT	O
therapy	NN	O
group	NN	O
,	,	O
p	VBP	O
=	JJ	O
.13	NNP	O
.	.	O

There	EX	O
were	VBD	O
a	DT	O
total	NN	O
of	IN	O
three	CD	O
deaths	NNS	O
in	IN	O
the	DT	O
therapy	NN	O
group	NN	O
and	CC	O
eight	CD	O
deaths	NNS	O
in	IN	O
the	DT	O
control	NN	Control
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Psychosocial	NNP	Psychological
therapy	NN	Psychological
significantly	RB	O
reduced	VBD	O
the	DT	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
death	NN	O
in	IN	O
sudden	JJ	O
cardiac	JJ	O
arrest	NN	O
survivors	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
rectal	JJ	O
midazolam	NN	Pharmacological
and	CC	O
diazepam	NN	Pharmacological
for	IN	O
premedication	NN	O
in	IN	O
pediatric	JJ	O
dental	JJ	O
patients	NNS	O
.	.	O

Rectally	RB	O
administered	VBN	O
midazolam	NN	Pharmacological
(	(	O
0.35	CD	O
mg/kg	NN	O
)	)	O
and	CC	O
diazepam	NN	Pharmacological
(	(	O
0.70	CD	O
mg/kg	NN	O
)	)	O
were	VBD	O
compared	VBN	O
with	IN	O
each	DT	O
other	JJ	O
and	CC	O
with	IN	O
placebo	NN	Control
for	IN	O
preanesthetic	JJ	O
medication	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
dental	JJ	O
extractions	NNS	O
.	.	O

All	DT	O
rectal	JJ	Pharmacological
medications	NNS	Pharmacological
were	VBD	O
very	RB	O
well	RB	O
accepted	VBN	O
,	,	O
but	CC	O
mask	JJ	O
acceptance	NN	O
,	,	O
improvement	NN	O
in	IN	O
anxiety	NN	O
,	,	O
and	CC	O
sedation	NN	O
were	VBD	O
best	RBS	O
in	IN	O
the	DT	O
midazolam	NN	Pharmacological
group	NN	O
.	.	O

Improvement	NNP	O
in	IN	O
anxiety	NN	O
and	CC	O
sedation	NN	O
were	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
two	CD	O
drug	NN	O
groups	NNS	O
than	IN	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
placebo	NN	Control
.	.	Control

Thirty	NNP	O
minutes	NNS	O
after	IN	O
rectal	JJ	O
administration	NN	O
of	IN	O
midazolam	NNS	Pharmacological
,	,	O
patients	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
.	.	O

Although	IN	O
these	DT	O
decreases	NNS	O
differed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
premedication	NN	O
values	NNS	O
,	,	O
they	PRP	O
were	VBD	O
probably	RB	O
of	IN	O
little	JJ	O
clinical	JJ	O
importance	NN	O
.	.	O

Only	RB	O
minor	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Overall	NNP	O
rectally	RB	O
administered	VBD	O
midazolam	NNS	Pharmacological
appeared	VBD	O
to	TO	O
be	VB	O
somewhat	RB	O
more	RBR	O
efficacious	JJ	O
than	IN	O
diazepam	NN	Pharmacological
.	.	Pharmacological

Effects	NNS	O
of	IN	O
weight-bearing	JJ	Physical
versus	NN	O
nonweight-bearing	JJ	Physical
exercise	NN	Physical
on	IN	O
function	NN	O
,	,	O
walking	VBG	O
speed	NN	O
,	,	O
and	CC	O
position	NN	O
sense	NN	O
in	IN	O
participants	NNS	O
with	IN	O
knee	NN	O
osteoarthritis	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
whether	IN	O
weight-bearing	NN	Physical
(	(	Physical
WB	NNP	Physical
)	)	Physical
exercise	NN	Physical
enhances	VBZ	O
functional	JJ	O
capacity	NN	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
nonweight-bearing	JJ	Physical
(	(	Physical
NWB	NNP	Physical
)	)	Physical
exercise	NN	Physical
in	IN	O
participants	NNS	O
with	IN	O
knee	NN	O
osteoarthritis	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NNP	O
Kinesiology	NNP	O
laboratory	NN	O
.	.	O

PARTICIPANTS	JJ	O
Participants	NNS	O
(	(	O
N=106	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
WB	NNP	Physical
exercise	NN	Physical
,	,	O
NWB	NNP	Physical
exercise	NN	Physical
,	,	O
or	CC	O
a	DT	O
control	NN	Control
group	NN	Control
(	(	Control
no	DT	Control
exercise	NN	Control
)	)	Control
.	.	O

INTERVENTION	NNP	O
WB	NNP	Physical
exercise	NN	Physical
and	CC	O
NWB	NNP	Physical
exercise	NN	Physical
groups	NNS	Physical
underwent	VBD	O
an	DT	O
8-week	JJ	Physical
knee	NN	Physical
extension-flexion	NN	Physical
exercise	NN	Physical
program	NN	Physical
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
function	NN	O
scale	NN	O
,	,	O
walking	VBG	O
speed	NN	O
,	,	O
muscle	NN	O
torque	NN	O
,	,	O
and	CC	O
knee	VB	O
reposition	NN	O
error	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Equally	NNP	O
significant	JJ	O
improvements	NNS	O
were	VBD	O
apparent	JJ	O
for	IN	O
all	DT	O
outcomes	NNS	O
after	IN	O
WB	NNP	O
exercise	NN	O
and	CC	O
NWB	NNP	O
exercise	NN	O
,	,	O
except	IN	O
for	IN	O
reposition	NN	O
error	NN	O
,	,	O
for	IN	O
which	WDT	O
improvement	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
WB	NNP	Physical
exercise	NN	Physical
group	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
improvements	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Simple	NNP	O
knee	NNP	O
flexion	NN	O
and	CC	O
extension	NN	O
exercises	NNS	O
(	(	Physical
WB	NNP	Physical
and	CC	O
NWB	NNP	Physical
)	)	O
performed	VBD	O
over	IN	O
8	CD	O
weeks	NNS	O
resulted	VBD	O
in	IN	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
WOMAC	NNP	O
function	NN	O
scale	NN	O
and	CC	O
knee	NN	O
strength	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

NWB	NNP	Physical
exercise	NN	Physical
alone	RB	O
may	MD	O
be	VB	O
sufficient	JJ	O
enough	RB	O
to	TO	O
improve	VB	O
function	NN	O
and	CC	O
muscle	NN	O
strength	NN	O
.	.	O

The	DT	O
additional	JJ	O
benefit	NN	O
of	IN	O
WB	NNP	Physical
exercise	NN	Physical
was	VBD	O
improved	VBN	O
position	NN	O
sense	NN	O
,	,	O
which	WDT	O
may	MD	O
enhance	VB	O
complex	JJ	O
walking	NN	O
tasks	NNS	O
(	(	O
walking	VBG	O
on	IN	O
figure	NN	O
of	IN	O
8	CD	O
route	NN	O
and	CC	O
spongy	JJ	O
surface	NN	O
)	)	O
.	.	O

Effect	NN	O
of	IN	O
acute	NN	Physical
exercise	NN	Physical
on	IN	O
executive	NN	O
function	NN	O
in	IN	O
children	NNS	O
with	IN	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
acute	NN	Physical
aerobic	JJ	Physical
exercise	NN	Physical
on	IN	O
executive	NN	O
function	NN	O
in	IN	O
children	NNS	O
with	IN	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
.	.	O

Forty	NNP	O
children	NNS	O
with	IN	O
ADHD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
exercise	NN	O
or	CC	O
control	NN	O
groups	NNS	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
performed	VBD	O
a	DT	O
moderate	JJ	Physical
intensity	NN	Physical
aerobic	JJ	Physical
exercise	NN	Physical
for	IN	Physical
30	CD	Physical
min	NN	Physical
,	,	O
whereas	IN	O
the	DT	O
control	NN	O
group	NN	O
watched	VBD	O
a	DT	O
running/exercise-related	JJ	Other
video	NN	Other
.	.	Other

Neuropsychological	JJ	O
tasks	NNS	O
,	,	O
the	DT	O
Stroop	NNP	O
Test	NNP	O
and	CC	O
the	DT	O
Wisconsin	NNP	O
Card	NNP	O
Sorting	NNP	O
Test	NNP	O
(	(	O
WCST	NNP	O
)	)	O
,	,	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
acute	JJ	O
exercise	NN	O
facilitated	VBN	O
performance	NN	O
in	IN	O
the	DT	O
Stroop	NNP	O
Test	NNP	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
Stroop	NNP	O
Color-Word	NNP	O
condition	NN	O
.	.	O

Additionally	RB	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
demonstrated	VBD	O
improvement	NN	O
in	IN	O
specific	JJ	O
WCST	NNP	O
performances	NNS	O
in	IN	O
Non-perseverative	JJ	O
Errors	NNS	O
and	CC	O
Categories	NNP	O
Completed	NNP	O
,	,	O
whereas	VBZ	O
no	DT	O
influences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
those	DT	O
performances	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Tentative	JJ	O
explanations	NNS	O
for	IN	O
the	DT	O
exercise	NN	O
effect	NN	O
postulate	NN	O
that	WDT	O
exercise	NN	O
allocates	VBZ	O
attention	NN	O
resources	NNS	O
,	,	O
influences	VBZ	O
the	DT	O
dorsolateral	JJ	O
prefrontal	NN	O
cortex	NN	O
,	,	O
and	CC	O
is	VBZ	O
implicated	VBN	O
in	IN	O
exercise-induced	JJ	O
dopamine	NN	O
release	NN	O
.	.	O

These	DT	O
findings	NNS	O
are	VBP	O
promising	VBG	O
and	CC	O
additional	JJ	O
investigations	NNS	O
to	TO	O
explore	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
exercise	NN	Physical
on	IN	O
executive	NN	O
function	NN	O
in	IN	O
children	NNS	O
with	IN	O
ADHD	NNP	O
are	VBP	O
encouraged	VBN	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
methyldopa	NN	Pharmacological
and	CC	O
labetalol	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
.	.	O

1	CD	O
Twenty	CD	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
completed	VBD	O
a	DT	O
double-blind	JJ	O
,	,	O
dose-tritrated	JJ	O
,	,	O
cross-over	JJ	O
comparison	NN	O
of	IN	O
methyldopa	NN	Pharmacological
and	CC	O
labetalol	NN	Pharmacological
.	.	O

2	CD	O
Average	JJ	O
lying	VBG	O
BPs	NNP	O
(	(	O
systolic/diastolic	JJ	O
)	)	O
were	VBD	O
reduced	VBN	O
by	IN	O
28/15	CD	O
mmHg	NNS	O
with	IN	O
methyldopa	NN	Pharmacological
and	CC	O
by	IN	O
23/15	CD	O
mmHg	NNS	O
with	IN	O
labetalol	NN	Pharmacological
.	.	Pharmacological

3	CD	O
Average	JJ	O
standing	VBG	O
BPs	NNP	O
(	(	O
systolic/diastolic	JJ	O
)	)	O
were	VBD	O
reduced	VBN	O
by	IN	O
29/14	CD	O
mmHg	NNS	O
with	IN	O
methyldopa	NN	Pharmacological
and	CC	O
by	IN	O
29/15	CD	O
mmHg	NNS	O
with	IN	O
labetalol	NN	Pharmacological
.	.	Pharmacological

4	CD	O
Both	DT	O
lying	NN	O
and	CC	O
standing	VBG	O
heart	NN	O
rates	NNS	O
were	VBD	O
reduced	VBN	O
with	IN	O
labetalol	NN	Pharmacological
.	.	Pharmacological

5	CD	O
It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
antihypertensive	JJ	O
properties	NNS	O
of	IN	O
labetalol	NN	Pharmacological
and	CC	O
methyldopa	NN	Pharmacological
are	VBP	O
similar	JJ	O
but	CC	O
that	IN	O
larger	JJR	O
patient	NN	O
populations	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
study	VB	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
subjective	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

The	DT	O
ScanBrit	NNP	O
randomised	VBD	O
,	,	O
controlled	VBD	O
,	,	O
single-blind	JJ	O
study	NN	O
of	IN	O
a	DT	O
gluten-	JJ	Other
and	CC	Other
casein-free	JJ	Other
dietary	JJ	Other
intervention	NN	Other
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

There	EX	O
is	VBZ	O
increasing	VBG	O
interest	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
gluten-	JJ	Other
and	CC	Other
casein-free	JJ	Other
diets	NNS	Other
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASDs	NNP	O
)	)	O
.	.	O

We	PRP	O
report	VBP	O
results	NNS	O
from	IN	O
a	DT	O
two-stage	NN	O
,	,	O
24-month	JJ	O
,	,	O
randomised	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
incorporating	VBG	O
an	DT	O
adaptive	JJ	O
'catch-up	NN	O
'	POS	O
design	NN	O
and	CC	O
interim	JJ	O
analysis	NN	O
.	.	O

Stage	NN	O
1	CD	O
of	IN	O
the	DT	O
trial	NN	O
saw	VBD	O
72	CD	O
Danish	JJ	O
children	NNS	O
(	(	O
aged	VBN	O
4	CD	O
years	NNS	O
to	TO	O
10	CD	O
years	NNS	O
11	CD	O
months	NNS	O
)	)	O
assigned	VBD	O
to	TO	O
diet	VB	O
(	(	O
A	DT	O
)	)	O
or	CC	O
non-diet	JJ	Control
(	(	O
B	NNP	O
)	)	O
groups	NNS	O
by	IN	O
stratified	JJ	O
randomisation	NN	O
.	.	O

Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
(	(	O
ADOS	NNP	O
)	)	O
and	CC	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
GARS	NNP	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
core	NN	O
autism	NN	O
behaviours	NNS	O
,	,	O
Vineland	NNP	O
Adaptive	NNP	O
Behaviour	NNP	O
Scales	NNP	O
(	(	O
VABS	NNP	O
)	)	O
to	TO	O
ascertain	VB	O
developmental	JJ	O
level	NN	O
,	,	O
and	CC	O
Attention-Deficit	NNP	O
Hyperactivity	NNP	O
Disorder	NNP	O
-	:	O
IV	NNP	O
scale	NN	O
(	(	O
ADHD-IV	NNP	O
)	)	O
to	TO	O
determine	VB	O
inattention	NN	O
and	CC	O
hyperactivity	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
tested	VBN	O
at	IN	O
baseline	NN	O
,	,	O
8	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
.	.	O

Based	VBN	O
on	IN	O
per	IN	O
protocol	NN	O
repeated	VBN	O
measures	NNS	O
analysis	NN	O
,	,	O
data	NNS	O
for	IN	O
26	CD	O
diet	JJ	O
children	NNS	O
and	CC	O
29	CD	O
controls	NNS	O
were	VBD	O
available	JJ	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

At	IN	O
this	DT	O
point	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
to	TO	O
mean	VB	O
diet	JJ	O
group	NN	O
scores	NNS	O
(	(	O
time*treatment	JJ	O
interaction	NN	O
)	)	O
on	IN	O
sub-domains	NNS	O
of	IN	O
ADOS	NNP	O
,	,	O
GARS	NNP	O
and	CC	O
ADHD-IV	NNP	O
measures	NNS	O
.	.	O

Surpassing	VBG	O
of	IN	O
predefined	JJ	O
statistical	JJ	O
thresholds	NNS	O
as	IN	O
evidence	NN	O
of	IN	O
improvement	NN	O
in	IN	O
group	NN	O
A	NNP	O
at	IN	O
12	CD	O
months	NNS	O
sanctioned	VBD	O
the	DT	O
re-assignment	NN	O
of	IN	O
group	NN	O
B	NNP	O
participants	NNS	O
to	TO	O
active	JJ	O
dietary	JJ	O
treatment	NN	O
.	.	O

Stage	NN	O
2	CD	O
data	NNS	O
for	IN	O
18	CD	O
group	NN	O
A	NNP	O
and	CC	O
17	CD	O
group	NN	O
B	NNP	O
participants	NNS	O
were	VBD	O
available	JJ	O
at	IN	O
24	CD	O
months	NNS	O
.	.	O

Multiple	NNP	O
scenario	NN	O
analysis	NN	O
based	VBN	O
on	IN	O
inter-	JJ	O
and	CC	O
intra-group	JJ	O
comparisons	NNS	O
showed	VBD	O
some	DT	O
evidence	NN	O
of	IN	O
sustained	JJ	O
clinical	JJ	O
group	NN	O
improvements	NNS	O
although	IN	O
possibly	RB	O
indicative	JJ	O
of	IN	O
a	DT	O
plateau	NN	O
effect	NN	O
for	IN	O
intervention	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
dietary	JJ	Other
intervention	NN	Other
may	MD	O
positively	RB	O
affect	VB	O
developmental	JJ	O
outcome	NN	O
for	IN	O
some	DT	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
ASD	NNP	O
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
placebo	NN	Control
condition	NN	O
to	TO	O
the	DT	O
current	JJ	O
investigation	NN	O
,	,	O
we	PRP	O
are	VBP	O
,	,	O
however	RB	O
,	,	O
unable	JJ	O
to	TO	O
disqualify	VB	O
potential	JJ	O
effects	NNS	O
derived	VBN	O
from	IN	O
intervention	NN	O
outside	IN	O
of	IN	O
dietary	JJ	O
changes	NNS	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
ascertain	VB	O
potential	JJ	O
best-	NN	O
and	CC	O
non-responders	NNS	O
to	TO	O
intervention	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
registered	VBN	O
with	IN	O
ClincialTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00614198	NNP	O
.	.	O

Smoking	VBG	O
cessation	NN	O
with	IN	O
smokeless	JJ	Other
tobacco	NN	Other
and	CC	O
group	NN	Educational
therapy	NN	Educational
:	:	Other
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

Smokeless	NNP	Other
tobacco	NN	Other
might	MD	O
be	VB	O
effective	JJ	O
as	IN	O
an	DT	O
adjunct	NN	O
for	IN	O
smoking	VBG	O
cessation	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
smokeless	NN	Other
tobacco	NN	Other
and	CC	O
group	NN	Educational
support	NN	Educational
for	IN	O
smoking	VBG	O
cessation	NN	O
in	IN	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
that	WDT	O
compared	VBN	O
smokeless	NN	Other
tobacco	NN	Other
plus	CC	O
group	NN	Educational
support	NN	Educational
versus	NN	O
group	NN	Other
support	NN	Other
only	RB	Educational
.	.	O

The	DT	O
study	NN	O
enrolled	VBD	O
263	CD	O
healthy	JJ	O
smokers	NNS	O
(	(	O
M	NNP	O
(	(	O
age	NN	O
)	)	O
=	VBZ	O
49	CD	O
years	NNS	O
)	)	O
who	WP	O
smoked	VBD	O
a	DT	O
mean	NN	O
of	IN	O
24	CD	O
cigarettes/day	NN	O
,	,	O
with	IN	O
a	DT	O
mean	NN	O
of	IN	O
31	CD	O
pack-years	NNS	O
.	.	O

Smokeless	NNP	Other
tobacco	NN	Other
was	VBD	O
provided	VBN	O
for	IN	O
7	CD	O
weeks	NNS	O
(	(	O
or	CC	O
up	RB	O
to	TO	O
12	CD	O
)	)	O
,	,	O
combined	VBN	O
with	IN	O
eight	CD	O
group	NN	Educational
support	NN	Educational
visits	NNS	Educational
provided	VBN	Educational
by	IN	Educational
nurses	NNS	Educational
.	.	O

The	DT	O
control	NN	Control
group	NN	Control
received	VBD	O
group	NN	Other
support	NN	Other
only	RB	Educational
.	.	O

Smoking	VBG	O
cessation	NN	O
rates	NNS	O
were	VBD	O
statistically	RB	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
smokeless	NN	O
tobacco	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
during	IN	O
the	DT	O
first	JJ	O
7	CD	O
weeks	NNS	O
.	.	O

Point-prevalence	NN	O
abstinence	NN	O
rates	NNS	O
at	IN	O
7	CD	O
weeks	NNS	O
were	VBD	O
36.4	CD	O
%	NN	O
versus	IN	O
20.8	CD	O
%	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
2.52	CD	O
,	,	O
p	NN	O
=	NNP	O
.001	NNP	O
)	)	O
,	,	O
respectively	RB	O
;	:	O
and	CC	O
continuous	JJ	O
abstinence	NN	O
rates	NNS	O
from	IN	O
weeks	NNS	O
4	CD	O
to	TO	O
7	CD	O
were	VBD	O
31.5	CD	O
%	NN	O
versus	IN	O
19.2	CD	O
%	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
1.94	CD	O
,	,	O
p	NN	O
=	NNP	O
.023	NNP	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
primary	JJ	O
outcomes	NNS	O
(	(	O
i.e.	JJ	O
,	,	O
6-month	JJ	O
point	NN	O
prevalence	NN	O
)	)	O
were	VBD	O
23.1	CD	O
%	NN	O
versus	IN	O
20.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
OR	NNP	O
=	VBZ	O
1.31	CD	O
,	,	O
ns	NN	O
)	)	O
.	.	O

Smokeless	NNP	Other
tobacco	NN	Other
was	VBD	O
relatively	RB	O
well	RB	O
tolerated	VBN	O
,	,	O
although	IN	O
15	CD	O
subjects	NNS	O
(	(	O
11.2	CD	O
%	NN	O
)	)	O
stopped	VBD	O
use	NN	O
due	JJ	O
to	TO	O
adverse	JJ	O
events	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
25	CD	O
subjects	NNS	O
(	(	O
17.5	CD	O
%	NN	O
)	)	O
were	VBD	O
still	RB	O
using	VBG	O
smokeless	JJ	O
tobacco	NN	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

This	DT	O
trial	NN	O
demonstrated	VBD	O
short-term	JJ	O
efficacy	NN	O
of	IN	O
smokeless	JJ	Other
tobacco	NN	Other
in	IN	O
combination	NN	O
with	IN	O
group	NN	O
support	NN	O
for	IN	O
smoking	VBG	O
cessation	NN	O
but	CC	O
no	DT	O
long-term	JJ	O
efficacy	NN	O
.	.	O

Cytokine	NN	O
levels	NNS	O
and	CC	O
systemic	JJ	O
toxicity	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
isolated	JJ	Pharmacological
limb	NN	Pharmacological
perfusion	NN	Pharmacological
with	IN	O
high-dose	JJ	Pharmacological
tumor	NN	Pharmacological
necrosis	NN	Pharmacological
factor	NN	Pharmacological
,	,	O
interferon	NN	Pharmacological
gamma	NN	Pharmacological
,	,	O
and	CC	O
melphalan	NN	Pharmacological
.	.	O

PURPOSE	NNP	O
Isolated	NNP	Pharmacological
limb	NN	Pharmacological
perfusion	NN	Pharmacological
(	(	Pharmacological
ILP	NNP	Pharmacological
)	)	Pharmacological
with	IN	O
tumor	NN	Pharmacological
necrosis	NN	Pharmacological
factor	NN	Pharmacological
(	(	Pharmacological
TNF	NNP	Pharmacological
)	)	Pharmacological
,	,	O
interferon	JJ	Pharmacological
gamma	NN	Pharmacological
,	,	O
and	CC	O
melphalan	NN	Pharmacological
(	(	Pharmacological
M	NNP	Pharmacological
)	)	Pharmacological
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
result	VB	O
in	IN	O
high	JJ	O
response	NN	O
rates	NNS	O
for	IN	O
extremity	NN	O
melanoma	NN	O
and	CC	O
sarcoma	NN	O
.	.	O

We	PRP	O
have	VBP	O
evaluated	VBN	O
the	DT	O
relationship	NN	O
of	IN	O
systemic	JJ	O
TNF	NNP	O
exposure	NN	O
to	TO	O
induction	NN	O
of	IN	O
several	JJ	O
secondary	JJ	O
mediators	NNS	O
and	CC	O
incidence	NN	O
of	IN	O
systemic	JJ	O
toxicity	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Nineteen	NNP	O
patients	NNS	O
with	IN	O
extremity	NN	O
melanoma	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
or	CC	O
sarcoma	NN	O
(	(	O
n	JJ	O
=	NNP	O
3	CD	O
)	)	O
,	,	O
underwent	JJ	O
90-minute	JJ	O
ILP	NNP	Pharmacological
with	IN	Pharmacological
TNF-alpha	NNP	Pharmacological
,	,	O
interferon	NN	Pharmacological
gamma	NN	Pharmacological
(	(	O
0.2	CD	O
mg	NN	O
)	)	O
,	,	O
and	CC	O
M	NNP	Pharmacological
(	(	O
10	CD	O
to	TO	O
13	CD	O
mg/L	NN	O
of	IN	O
limb	NN	O
volume	NN	O
)	)	O
(	(	Pharmacological
TNF/IFN/M	NNP	Pharmacological
)	)	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
,	,	O
or	CC	O
M	NNP	Pharmacological
alone	RB	O
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
.	.	O

Continuous	JJ	O
intraoperative	JJ	O
monitoring	NN	O
(	(	O
CIM	NNP	O
)	)	O
for	IN	O
systemic	JJ	O
leak	NN	O
from	IN	O
the	DT	O
perfusion	NN	O
circuit	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
radioactive	JJ	O
iodine-131	JJ	Pharmacological
albumin	NN	Pharmacological
.	.	Pharmacological

Cytokine	NN	O
levels	NNS	O
in	IN	O
the	DT	O
perfusate	NN	O
and	CC	O
systemic	JJ	O
circulation	NN	O
during	IN	O
and	CC	O
after	IN	O
ILP	NNP	O
were	VBD	O
measured	VBN	O
by	IN	O
enzyme-linked	JJ	Pharmacological
immunosorbent	NN	Pharmacological
assay	NN	Pharmacological
.	.	Pharmacological

RESULTS	NNP	O
Systemic	NNP	O
leaks	VBZ	O
>	CD	O
or	CC	O
=	VB	O
1	CD	O
%	NN	O
from	IN	O
the	DT	O
perfusion	NN	O
circuit	NN	O
occurred	VBD	O
in	IN	O
six	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
TNF/IFN/M	NNP	O
and	CC	O
in	IN	O
four	CD	O
who	WP	O
received	VBD	O
M	NNP	O
alone	RB	O
.	.	O

Hypotension	NNP	O
that	IN	O
required	VBD	O
vasopressor	NN	O
support	NN	O
occurred	VBD	O
in	IN	O
six	CD	O
of	IN	O
six	CD	O
patients	NNS	O
with	IN	O
evidence	NN	O
of	IN	O
a	DT	O
leak	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
1	CD	O
%	NN	O
)	)	O
and	CC	O
zero	CD	O
of	IN	O
six	CD	O
patients	NNS	O
without	IN	O
a	DT	O
leak	NN	O
(	(	O
<	JJ	O
1	CD	O
%	NN	O
)	)	O
.	.	O

These	DT	O
six	CD	O
patients	NNS	O
had	VBD	O
significantly	RB	O
higher	JJR	O
peak	JJ	O
systemic	JJ	O
TNF	NNP	O
levels	NNS	O
during	IN	O
and	CC	O
after	IN	O
perfusion	NN	O
than	IN	O
patients	NNS	O
without	IN	O
a	DT	O
leak	NN	O
(	(	O
2.8	CD	O
and	CC	O
8.2	CD	O
ng/mL	JJ	O
v	NN	O
0.7	CD	O
and	CC	O
2.0	CD	O
ng/mL	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

All	PDT	O
patients	NNS	O
who	WP	O
received	VBD	O
TNF/IFN/M	NNP	O
had	VBD	O
significantly	RB	O
greater	JJR	O
increases	NNS	O
in	IN	O
systemic	JJ	O
interleukin-6	JJ	O
(	(	O
IL-6	NNP	O
)	)	O
levels	NNS	O
than	IN	O
in	IN	O
patients	NNS	O
with	IN	O
M	NNP	O
alone	RB	O
(	(	O
12,395	CD	O
+/-	JJ	O
10,374	CD	O
pg/mL	NN	O
v	NN	O
79.4	CD	O
+/-	JJ	O
7.2	CD	O
pg/mL	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Intracellular	JJ	O
adhesion	NN	O
molecule	NN	O
(	(	O
ICAM	NNP	O
)	)	O
,	,	O
IL-8	NNP	O
,	,	O
and	CC	O
TNF-R	JJ	O
levels	NNS	O
were	VBD	O
also	RB	O
increased	VBN	O
after	IN	O
ILP	NNP	O
with	IN	O
TNF/IFN/M	NNP	O
.	.	O

CONCLUSION	NNP	O
ILP	NNP	O
with	IN	O
TNF/IFN/M	NNP	O
can	MD	O
be	VB	O
safely	RB	O
performed	VBN	O
,	,	O
as	IN	O
I131	NNP	O
albumin	VBP	O
provides	VBZ	O
a	DT	O
sensitive	JJ	O
measure	NN	O
of	IN	O
systemic	JJ	O
leakage	NN	O
from	IN	O
the	DT	O
perfusion	NN	O
circuit	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
measured	JJ	O
leak	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
1	CD	O
%	NN	O
develop	NN	O
mild	NN	O
and	CC	O
transient	JJ	O
postoperative	JJ	O
hypotension	NN	O
with	IN	O
significantly	RB	O
higher	JJR	O
systemic	JJ	O
TNF	NNP	O
levels	NNS	O
and	CC	O
lower	JJR	O
perfusate	NN	O
TNF	NNP	O
levels	NNS	O
than	IN	O
in	IN	O
patients	NNS	O
without	IN	O
leaks	NNS	O
.	.	O

Induction	NNP	Pharmacological
chemotherapy	NN	Pharmacological
in	IN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

Between	IN	O
December	NNP	O
1982	CD	O
and	CC	O
October	NNP	O
1986	CD	O
,	,	O
131	CD	O
patients	NNS	O
with	IN	O
stage	JJ	O
II-III-IV	NNP	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
of	IN	O
the	DT	O
oropharynx	NN	O
or	CC	O
oral	JJ	O
cavity	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
induction	VB	O
chemotherapy	NN	Pharmacological
,	,	O
consisting	VBG	O
of	IN	O
bleomycin	NN	Pharmacological
(	(	O
10	CD	O
mg/m2/day	NN	O
in	IN	O
continuous	JJ	O
infusion	NN	O
from	IN	O
day	NN	O
1	CD	O
to	TO	O
day	NN	O
5	CD	O
)	)	O
,	,	O
methotrexate	NN	Pharmacological
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
2	CD	O
)	)	O
followed	VBN	O
by	IN	O
folinic	JJ	Pharmacological
acid	NN	Pharmacological
,	,	O
5-fluorouracil	JJ	Pharmacological
(	(	O
5	CD	O
FU	NNP	O
)	)	O
(	(	O
600	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
2	CD	O
)	)	O
,	,	O
and	CC	O
cisplatin	NN	Pharmacological
(	(	O
120	CD	O
mg/m2	NN	O
on	IN	O
day	NN	O
4	CD	O
)	)	O
every	DT	O
4	CD	O
weeks	NNS	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
three	CD	O
cycles	NNS	O
followed	VBN	O
by	IN	O
definitive	JJ	O
locoregional	JJ	O
treatment	NN	O
versus	IN	O
locoregional	JJ	O
treatment	NN	O
alone	RB	O
.	.	O

The	DT	O
modalities	NNS	O
of	IN	O
definitive	JJ	O
treatment	NN	O
(	(	O
radiotherapy	JJ	Surgical
+/-	JJ	O
surgery	NN	Surgical
)	)	O
were	VBD	O
chosen	VBN	O
prior	RB	O
to	TO	O
randomization	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
116	CD	O
patients	NNS	O
were	VBD	O
evaluable	JJ	O
.	.	O

Of	IN	O
55	CD	O
patients	NNS	O
in	IN	O
the	DT	O
chemotherapy	NN	Pharmacological
arm	NN	O
,	,	O
four	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
complete	JJ	O
response	NN	O
(	(	O
CR	NNP	O
)	)	O
and	CC	O
23	CD	O
(	(	O
42	CD	O
%	NN	O
)	)	O
a	DT	O
partial	JJ	O
response	NN	O
(	(	O
PR	NNP	O
)	)	O
following	VBG	O
the	DT	O
induction	NN	O
regimen	NNS	O
.	.	O

At	IN	O
the	DT	O
completion	NN	O
of	IN	O
locoregional	JJ	O
treatment	NN	O
,	,	O
76	CD	O
%	NN	O
(	(	O
42	CD	O
of	IN	O
55	CD	O
)	)	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
in	IN	O
CR	NNP	O
compared	VBN	O
to	TO	O
89	CD	O
%	NN	O
(	(	O
54	CD	O
of	IN	O
61	CD	O
)	)	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	O
,	,	O
cause-specific	JJ	O
survival	NN	O
,	,	O
and	CC	O
pattern	NN	O
of	IN	O
relapse	NN	O
between	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
22	CD	O
months	NNS	O
in	IN	O
the	DT	O
chemotherapy	NN	O
group	NN	O
and	CC	O
29	CD	O
months	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Responders	NNS	O
to	TO	O
chemotherapy	VB	O
did	VBD	O
not	RB	O
fare	VB	O
better	JJR	O
than	IN	O
nonresponders	NNS	O
.	.	O

Chemotherapy-related	JJ	O
toxicities	NNS	O
were	VBD	O
few	JJ	O
and	CC	O
most	JJS	O
of	IN	O
them	PRP	O
related	VBN	O
to	TO	O
cisplatin	VB	O
which	WDT	O
was	VBD	O
reduced	VBN	O
to	TO	O
100	CD	O
mg/m2	NN	O
for	IN	O
35	CD	O
patients	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
treatment-related	JJ	O
deaths	NNS	O
and	CC	O
,	,	O
in	IN	O
the	DT	O
experimental	JJ	O
arm	NN	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
no	DT	O
increased	VBN	O
morbidity	NN	O
from	IN	O
locoregional	JJ	O
treatment	NN	O
.	.	O

This	DT	O
induction	NN	O
regimen	NN	O
does	VBZ	O
not	RB	O
offer	VB	O
any	DT	O
advantages	NNS	O
over	IN	O
standard	JJ	O
treatment	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
use	NN	O
of	IN	O
pyridostigmine	NN	Pharmacological
and	CC	O
requirement	NN	O
of	IN	O
vecuronium	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
myasthenia	JJ	O
gravis	NN	O
.	.	O

CONTEXT	NNP	O
Patients	NNPS	O
with	IN	O
myasthenia	NNP	O
gravis	FW	O
receive	JJ	O
pyridostigmine	NN	Pharmacological
,	,	O
an	DT	O
anticholinesterase	NN	Pharmacological
agent	NN	Pharmacological
,	,	O
as	IN	O
a	DT	O
part	NN	O
of	IN	O
therapy	NN	O
.	.	O

These	DT	O
patients	NNS	O
demonstrate	VBP	O
a	DT	O
heightened	JJ	O
sensitivity	NN	O
towards	IN	O
non-depolarising	JJ	O
muscle	NN	O
relaxants	NNS	O
.	.	O

Continuing	VBG	O
pyridostigmine	NN	Pharmacological
till	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
surgery	NN	O
or	CC	O
omitting	VBG	O
it	PRP	O
on	IN	O
the	DT	O
night	NN	O
before	IN	O
surgery	NN	O
could	MD	O
provide	VB	O
variable	JJ	O
results	NNS	O
with	IN	O
regards	NNS	O
to	TO	O
the	DT	O
effect	NN	O
of	IN	O
vecuronium	NN	Pharmacological
.	.	Pharmacological

AIMS	NNP	O
Myographic	NNP	O
evaluation	NN	O
of	IN	O
a	DT	O
dose	NN	O
of	IN	O
vecuronium	NN	O
in	IN	O
patients	NNS	O
with	IN	O
myasthenia	JJ	O
gravis	NN	O
on	IN	O
pyridostigmine	NN	O
therapy	NN	O
.	.	O

SETTING	NN	O
AND	CC	O
DESIGN	NNP	O
A	NNP	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
clinical	JJ	O
study	NN	O
conducted	VBN	O
in	IN	O
a	DT	O
teaching	JJ	O
hospital	NN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
Medically	NNP	O
(	(	Pharmacological
oral	JJ	Pharmacological
pyridostigmine	NN	Pharmacological
)	)	Pharmacological
well-controlled	JJ	O
adult	NN	O
patients	NNS	O
with	IN	O
myasthenia	JJ	O
gravis	NNS	O
who	WP	O
were	VBD	O
posted	VBN	O
for	IN	O
thymectomy	NN	Surgical
,	,	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
received	VBD	O
their	PRP$	O
last	JJ	O
dose	NN	O
of	IN	O
pyridostigmine	NN	Pharmacological
on	IN	O
the	DT	O
night	NN	O
before	IN	O
surgery	NN	O
while	IN	O
those	DT	O
in	IN	O
Group	NNP	O
2	CD	O
received	VBD	O
even	RB	O
the	DT	O
morning	NN	O
dose	NN	O
of	IN	O
the	DT	O
drug	NN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
.	.	O

Neostigmine	NNP	Pharmacological
(	(	O
1-2	JJ	O
mg	NN	O
)	)	O
intravenously	RB	O
was	VBD	O
used	VBN	O
as	IN	O
rescue	JJ	O
medication	NN	O
.	.	O

Vecuronium	NNP	Pharmacological
(	(	O
0.01	CD	O
mg/kg	NN	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
intubation	NN	O
and	CC	O
muscle	NN	O
relaxation	NN	O
during	IN	O
trans-sternal	JJ	Surgical
thymectomy	NN	Surgical
and	CC	O
its	PRP$	O
effect	NN	O
was	VBD	O
reversed	VBN	O
using	VBG	O
neostigmine	NN	O
and	CC	O
atropine	NN	O
.	.	O

RESULTS	NNP	O
Fourteen	JJ	O
patients	NNS	O
(	(	O
7	CD	O
in	IN	O
each	DT	O
group	NN	O
)	)	O
belonging	NN	O
to	TO	O
both	DT	O
sexes	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
intubating	VBG	O
dose	NN	O
of	IN	O
vecuronium	NN	O
showed	VBD	O
quicker	JJR	O
onset	JJ	O
time	NN	O
(	(	O
155	CD	O
sec	NN	O
or	CC	O
2.7	CD	O
min	NN	O
approx	NN	O
.	.	O

)	)	O
and	CC	O
peak	JJ	O
effect	NN	O
(	(	O
99	CD	O
%	NN	O
T1	NNP	O
suppression	NN	O
)	)	O
in	IN	O
patients	NNS	O
belonging	VBG	O
to	TO	O
Group	NNP	O
1	CD	O
,	,	O
and	CC	O
3/7	CD	O
(	(	O
43	CD	O
%	NN	O
)	)	O
complained	VBD	O
of	IN	O
respiratory	JJ	O
discomfort	NN	O
while	IN	O
waiting	VBG	O
for	IN	O
surgery	NN	O
.	.	O

By	IN	O
giving	VBG	O
the	DT	O
morning	NN	O
dose	NN	O
of	IN	O
pyridostigmine	NN	Pharmacological
(	(	O
Group	NNP	O
2	CD	O
)	)	O
,	,	O
an	DT	O
identical	JJ	O
intubating	NN	O
dose	NN	O
of	IN	O
vecuronium	NN	Pharmacological
showed	VBD	O
relative	JJ	O
resistance	NN	O
(	(	O
peak	JJ	O
effect-97	NN	O
%	NN	O
T1	NNP	O
suppression	NN	O
)	)	O
and	CC	O
delayed	VBN	O
onset	NN	O
time	NN	O
(	(	O
198	CD	O
sec	NN	O
approx.	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
reversal	NN	O
was	VBD	O
complete	JJ	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
in	IN	O
both	CC	O
the	DT	O
regimens	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Omission	NNP	O
of	IN	O
the	DT	O
pyridostigmine	NN	Pharmacological
dose	NN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
predisposed	VBN	O
patients	NNS	O
with	IN	O
myasthenia	JJ	O
gravis	NN	O
to	TO	O
the	DT	O
possibility	NN	O
of	IN	O
respiratory	JJ	O
discomfort	NN	O
and	CC	O
sensitivity	NN	O
to	TO	O
vecuronium	NN	Pharmacological
.	.	Pharmacological

Continued	VBN	O
administration	NN	O
significantly	RB	O
prolonged	VBD	O
the	DT	O
onset	JJ	O
time	NN	O
of	IN	O
vecuronium	NN	Pharmacological
and	CC	O
the	DT	O
patients	NNS	O
required	VBD	O
a	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
vecuronium	NN	Pharmacological
.	.	Pharmacological

Brief	JJ	O
report	NN	O
:	:	O
imitation	NN	Psychological
effects	NNS	O
on	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Twenty	NNP	O
children	NNS	O
with	IN	O
autism	NN	O
(	(	O
mean	JJ	O
age	NN	O
,	,	O
5	CD	O
years	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
for	IN	O
the	DT	O
study	NN	O
from	IN	O
a	DT	O
school	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
imitation	NN	Psychological
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
contingently	RB	Psychological
responsive	JJ	Psychological
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
interaction	NN	O
group	NN	O
based	VBN	O
on	IN	O
a	DT	O
stratification	NN	O
table	NN	O
for	IN	O
gender	NN	O
and	CC	O
developmental	NN	O
and	CC	O
chronological	JJ	O
age	NN	O
.	.	O

The	DT	O
sessions	NNS	O
consisted	VBD	O
of	IN	O
four	CD	O
phases	NNS	O
,	,	O
with	IN	O
each	DT	O
phase	NN	O
lasting	VBG	O
3	CD	O
minutes	NNS	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
phase	NN	O
,	,	O
the	DT	O
child	NN	O
walked	VBD	O
into	IN	O
a	DT	O
room	NN	O
that	WDT	O
was	VBD	O
furnished	VBN	O
with	IN	O
a	DT	O
sofa	NN	O
,	,	O
a	DT	O
table	NN	O
,	,	O
chairs	NNS	O
,	,	O
and	CC	O
two	CD	O
sets	NNS	O
of	IN	O
identical	JJ	O
toys	NN	O
.	.	O

An	DT	O
adult	NN	O
was	VBD	O
in	IN	O
the	DT	O
room	NN	O
sitting	VBG	O
very	RB	O
still	RB	O
like	IN	O
a	DT	O
statue	NN	O
(	(	O
first	JJ	O
still-face	JJ	O
condition	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
second	JJ	O
phase	NN	O
,	,	O
the	DT	O
adult	NN	O
either	RB	O
imitated	VBD	O
the	DT	O
child	NN	O
or	CC	O
was	VBD	O
contingently	RB	Psychological
responsive	JJ	Psychological
to	TO	O
the	DT	O
child	NN	O
.	.	O

In	IN	O
the	DT	O
third	JJ	O
phase	NN	O
,	,	O
the	DT	O
adult	NN	O
sat	VBD	O
still	RB	O
again	RB	O
(	(	O
second	JJ	O
still-face	JJ	O
condition	NN	O
)	)	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
fourth	JJ	O
phase	NN	O
,	,	O
the	DT	O
adult	NN	O
engaged	VBN	O
in	IN	O
a	DT	O
spontaneous	JJ	O
interaction	NN	O
.	.	O

During	IN	O
the	DT	O
third	JJ	O
phase	NN	O
(	(	O
the	DT	O
second	JJ	O
still-face	JJ	O
condition	NN	O
)	)	O
,	,	O
the	DT	O
children	NNS	O
in	IN	O
the	DT	O
imitation	NN	Psychological
group	NN	O
spent	VBD	O
less	JJR	O
time	NN	O
in	IN	O
gross	JJ	O
motor	NN	O
activity	NN	O
and	CC	O
more	JJR	O
time	NN	O
touching	VBG	O
the	DT	O
adult	NN	O
,	,	O
as	IN	O
if	IN	O
attempting	VBG	O
to	TO	O
initiate	VB	O
an	DT	O
interaction	NN	O
.	.	O

The	DT	O
contingency	NN	Educational
condition	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
a	DT	O
more	RBR	O
effective	JJ	O
way	NN	O
to	TO	O
facilitate	VB	O
a	DT	O
distal	JJ	O
social	JJ	O
behavior	NN	O
(	(	O
attention	NN	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
imitative	JJ	Psychological
condition	NN	O
was	VBD	O
a	DT	O
more	RBR	O
effective	JJ	O
way	NN	O
to	TO	O
facilitate	VB	O
a	DT	O
proximal	JJ	O
social	JJ	O
behavior	NN	O
(	(	O
touching	VBG	O
)	)	O
.	.	O

The	DT	O
costs	NNS	O
and	CC	O
effects	NNS	O
of	IN	O
a	DT	O
nutritional	JJ	Educational
education	NN	Educational
program	NN	Educational
following	VBG	O
work-site	JJ	O
cholesterol	NN	O
screening	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
costs	NNS	O
and	CC	O
impact	NN	O
of	IN	O
a	DT	O
nutrition	JJ	Educational
education	NN	Educational
program	NN	Educational
following	VBG	O
a	DT	O
cholesterol	NN	O
screening	NN	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
work-sites	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
educational	JJ	Educational
interventions	NNS	Educational
:	:	Educational
a	DT	O
usual	JJ	Educational
intervention	NN	Educational
of	IN	Educational
5	CD	Educational
minutes	NNS	Educational
of	IN	Educational
counseling	NN	Educational
,	,	Educational
or	CC	Educational
a	DT	Educational
special	JJ	Educational
intervention	NN	Educational
of	IN	Educational
2	CD	Educational
hours	NNS	Educational
of	IN	Educational
behaviorally	RB	Educational
based	VBN	Educational
education	NN	Educational
on	IN	Educational
dietary	JJ	Educational
changes	NNS	Educational
to	TO	Educational
lower	VB	Educational
serum	NN	Educational
cholesterol	NN	Educational
.	.	Educational

Costs	NNS	O
were	VBD	O
monitored	VBN	O
,	,	O
and	CC	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
retested	VBN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
later	RB	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
per-person	JJ	O
cost	NN	O
for	IN	O
screening	VBG	O
and	CC	O
the	DT	O
educational	JJ	O
intervention	NN	O
was	VBD	O
about	IN	O
$	$	O
50	CD	O
.	.	O

Cholesterol	NN	O
levels	NNS	O
differed	VBD	O
little	RB	O
between	IN	O
the	DT	O
two	CD	O
intervention	NN	O
groups	NNS	O
6	CD	O
months	NNS	O
after	IN	O
screening	VBG	O
,	,	O
but	CC	O
after	IN	O
12	CD	O
months	NNS	O
those	DT	O
in	IN	O
the	DT	O
special	JJ	O
intervention	NN	O
worksites	NNS	O
showed	VBD	O
a	DT	O
6.5	CD	O
%	NN	O
drop	NN	O
in	IN	O
cholesterol	NN	O
,	,	O
whereas	IN	O
those	DT	O
at	IN	O
the	DT	O
usual	JJ	O
intervention	NN	O
worksites	NNS	O
showed	VBD	O
a	DT	O
drop	NN	O
of	IN	O
only	RB	O
3.0	CD	O
%	NN	O
.	.	O

Hence	NNP	O
a	DT	O
3.5	CD	O
%	NN	O
cholesterol	NN	O
reduction	NN	O
was	VBD	O
attributable	JJ	O
to	TO	O
the	DT	O
special	JJ	O
intervention	NN	O
.	.	O

CONCLUSIONS	VB	O
A	NNP	O
behaviorally	RB	Educational
based	VBN	Educational
nutrition	JJ	Educational
education	NN	Educational
program	NN	Educational
following	VBG	O
cholesterol	NN	O
screening	VBG	O
can	MD	O
have	VB	O
a	DT	O
meaningful	JJ	O
impact	NN	O
on	IN	O
long-term	JJ	O
cholesterol	NN	O
levels	NNS	O
at	IN	O
a	DT	O
low	JJ	O
cost	NN	O
.	.	O

Nutrition	NNP	Educational
education	NN	Educational
in	IN	O
work-sites	NNS	O
may	MD	O
therefore	RB	O
be	VB	O
a	DT	O
useful	JJ	O
way	NN	O
to	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
heart	NN	O
disease	NN	O
in	IN	O
communities	NNS	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
fenretinide	NN	Pharmacological
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
using	VBG	O
DNA	NNP	O
flow	JJ	O
cytometry	NN	O
as	IN	O
an	DT	O
intermediate	JJ	O
end	NN	O
point	NN	O
.	.	O

Retinoids	NNS	O
have	VBP	O
shown	VBN	O
a	DT	O
potential	JJ	O
activity	NN	O
in	IN	O
preventing	VBG	O
tumor	NN	O
recurrence	NN	O
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
.	.	O

We	PRP	O
assessed	VBD	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
synthetic	JJ	Pharmacological
retinoid	NN	Pharmacological
fenretinide	NN	Pharmacological
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
using	VBG	O
DNA	NNP	O
flow	JJ	O
cytometry	NN	O
and	CC	O
conventional	JJ	O
cytology	NN	O
as	IN	O
surrogate	JJ	O
biomarkers	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
99	CD	O
subjects	NNS	O
with	IN	O
resected	JJ	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
(	(	O
pTa	NN	O
,	,	O
pT1	NN	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
fenretinide	NN	Pharmacological
(	(	O
200	CD	O
mg	NNS	O
day	NN	O
p.o	NN	O
.	.	O

for	IN	O
24	CD	O
months	NNS	O
)	)	O
or	CC	O
no	DT	Control
intervention	NN	Control
.	.	O

Cystoscopy	NNP	O
and	CC	O
bladder	NN	O
washing	NN	O
for	IN	O
DNA	NNP	O
flow	NN	O
cytometry	NN	O
end	NN	O
points	NNS	O
(	(	O
proportion	NN	O
of	IN	O
DNA	NNP	O
aneuploid	JJ	O
histograms	NN	O
,	,	O
hyperdiploid	JJ	O
fraction	NN	O
,	,	O
and	CC	O
percentage	NN	O
of	IN	O
apoptotic	JJ	O
cells	NNS	O
)	)	O
and	CC	O
proportion	NN	O
of	IN	O
abnormal	JJ	O
cytological	JJ	O
examinations	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
4	CD	O
months	NNS	O
for	IN	O
up	IN	O
to	TO	O
36	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
study	NN	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
DNA	NNP	O
aneuploid	JJ	O
histograms	NNS	O
after	IN	O
12	CD	O
months	NNS	O
.	.	O

This	DT	O
figure	NN	O
was	VBD	O
48.9	CD	O
%	NN	O
in	IN	O
the	DT	O
fenretinide	JJ	Pharmacological
arm	NN	O
and	CC	O
41.9	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
(	(	O
odds	NNS	O
ratio	NN	O
,	,	O
1.16	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.44-3.07	JJ	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
any	DT	O
other	JJ	O
response	NN	O
biomarker	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
up	RB	O
to	TO	O
36	CD	O
months	NNS	O
,	,	O
nor	CC	O
was	VBD	O
any	DT	O
biomarker	NN	O
able	JJ	O
to	TO	O
predict	VB	O
recurrence	NN	O
risk	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
arms	NNS	O
(	(	O
27	CD	O
events	NNS	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
versus	NN	O
21	CD	O
in	IN	O
the	DT	O
control	NN	O
arm	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.36	CD	O
)	)	O
.	.	O

Twelve	NNP	O
subjects	VBZ	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
complained	VBD	O
of	IN	O
diminished	JJ	O
dark	NN	O
adaptability	NN	O
,	,	O
and	CC	O
nine	CD	O
subjects	NNS	O
in	IN	O
the	DT	O
fenretinide	JJ	O
arm	NN	O
versus	IN	O
one	CD	O
control	NN	O
subject	NN	O
had	VBD	O
mild	JJ	O
dermatological	JJ	O
alterations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
fenretinide	NN	O
showed	VBD	O
a	DT	O
lack	NN	O
of	IN	O
effect	NN	O
on	IN	O
the	DT	O
DNA	NNP	O
content	NN	O
distribution	NN	O
and	CC	O
the	DT	O
morphology	NN	O
of	IN	O
urothelial	JJ	O
cells	NNS	O
obtained	VBN	O
in	IN	O
serial	JJ	O
bladder	NN	O
washings	NNS	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
was	VBD	O
comparable	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Because	IN	O
our	PRP$	O
data	NNS	O
are	VBP	O
hampered	VBN	O
by	IN	O
the	DT	O
lack	NN	O
of	IN	O
predictivity	NN	O
of	IN	O
the	DT	O
selected	VBN	O
biomarkers	NNS	O
,	,	O
additional	JJ	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
assess	VB	O
the	DT	O
activity	NN	O
of	IN	O
fenretinide	NN	O
in	IN	O
preventing	VBG	O
bladder	NN	O
cancer	NN	O
.	.	O

Double-blind	NNP	O
comparison	NN	O
of	IN	O
doxepin	NN	Pharmacological
versus	NN	O
bupropion	NN	Pharmacological
in	IN	O
outpatients	NNS	O
with	IN	O
a	DT	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
.	.	O

A	DT	O
double-blind	NN	O
controlled	VBN	O
study	NN	O
comparing	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
bupropion	NN	Pharmacological
to	TO	O
doxepin	VB	Pharmacological
in	IN	O
outpatients	NNS	O
with	IN	O
primary	JJ	O
depression	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
efficacy	NN	O
and	CC	O
safety	NN	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
.	.	O

Following	VBG	O
a	DT	O
7-day	JJ	O
placebo	NN	Control
washout	NN	O
period	NN	O
,	,	O
patients	NNS	O
could	MD	O
be	VB	O
treated	VBN	O
for	IN	O
up	RB	O
to	TO	O
13	CD	O
weeks	NNS	O
on	IN	O
either	DT	O
treatment	NN	O
.	.	O

Antidepressant	JJ	O
response	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
and	CC	O
Anxiety	NNP	O
Scales	NNP	O
,	,	O
Clinical	NNP	O
Global	NNP	O
Severity	NNP	O
and	CC	O
Improvement	NNP	O
Ratings	NNP	O
,	,	O
and	CC	O
the	DT	O
Zung	NNP	O
Self-Rating	NNP	O
Depression	NNP	O
Scale	NNP	O
.	.	O

Comparable	JJ	O
efficacy	NN	O
between	IN	O
the	DT	O
compounds	NNS	O
was	VBD	O
found	VBN	O
across	IN	O
the	DT	O
13-week	JJ	O
study	NN	O
.	.	O

Doxepin	NNP	Pharmacological
differed	VBD	O
from	IN	O
bupropion	NN	Pharmacological
mainly	RB	O
on	IN	O
the	DT	O
sleep	JJ	O
factor	NN	O
of	IN	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Scale	NNP	O
,	,	O
with	IN	O
doxepin	NN	Pharmacological
improving	VBG	O
sleep	NN	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
bupropion	NN	Pharmacological
.	.	Pharmacological

Doxepin	NNP	Pharmacological
produced	VBD	O
a	DT	O
greater	JJR	O
incidence	NN	O
of	IN	O
anticholinergic	JJ	O
side	NN	O
effects	NNS	O
,	,	O
including	VBG	O
dry	JJ	O
mouth	NN	O
,	,	O
constipation	NN	O
,	,	O
sleepiness	NN	O
,	,	O
and	CC	O
tiredness	NN	O
,	,	O
in	IN	O
comparison	NN	O
to	TO	O
bupropion	NN	Pharmacological
.	.	Pharmacological

Also	RB	O
,	,	O
increased	VBD	O
appetite	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
were	VBD	O
consistent	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
doxepin	NN	Pharmacological
relative	NN	O
to	TO	O
bupropion	NN	Pharmacological
.	.	Pharmacological

Online	NNP	Other
conductivity	NN	Other
monitoring	NN	Other
:	:	O
validation	NN	O
and	CC	O
usefulness	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
reduced	JJ	Other
dialysate	NN	Other
conductivity	NN	Other
.	.	O

Relatively	RB	Other
low	JJ	Other
dialysate	NN	Other
conductivity	NN	Other
(	(	Other
Cndi	NNP	Other
)	)	Other
may	MD	O
improve	VB	O
outcomes	NNS	O
by	IN	O
reducing	VBG	O
the	DT	O
overall	JJ	O
sodium	NN	O
burden	NN	O
in	IN	O
dialysis	NN	O
patients	NNS	O
.	.	O

Excess	NNP	O
sodium	NN	O
removal	NN	O
,	,	O
however	RB	O
,	,	O
could	MD	O
lead	VB	O
to	TO	O
hemodynamic	JJ	O
instability	NN	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
reduction	NN	Other
of	IN	Other
Cndi	NNP	Other
.	.	Other

For	IN	O
the	DT	O
study	NN	O
,	,	O
28	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
maintenance	NN	O
of	IN	O
Cndi	NNP	Other
at	IN	O
13.6	CD	O
mS/cm	NNS	O
(	(	O
equivalent	JJ	O
to	TO	O
135	CD	O
mmol/L	NN	O
of	IN	O
Na+	NNP	O
)	)	O
or	CC	O
serial	JJ	O
reduction	NN	O
of	IN	O
Cndi	NNP	Other
in	IN	O
steps	NNS	O
of	IN	O
0.2	CD	O
mS/cm	NNS	O
,	,	O
guided	VBN	O
by	IN	O
symptoms	NNS	O
and	CC	O
blood	NN	O
pressure	NN	O
.	.	O

Sodium	NNP	O
removal	NN	O
estimated	VBN	O
from	IN	O
pre-	NN	O
and	CC	O
postplasma	JJ	O
concentrations	NNS	O
correlated	VBN	O
well	RB	O
with	IN	O
removal	NN	O
measured	VBN	O
by	IN	O
conductivity	NN	O
monitoring	NN	O
as	IN	O
ionic	JJ	O
mass	NN	O
balance	NN	O
(	(	O
R2	NNP	O
0.66	CD	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
16	CD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
reduction	NN	Other
of	IN	Other
Cndi	NNP	Other
,	,	O
6	CD	O
achieved	VBD	O
Cndi	NNP	O
13.4	CD	O
mS/cm	NN	O
,	,	O
6	CD	O
achieved	VBD	O
13.2	CD	O
mS/cm	NN	O
,	,	O
and	CC	O
4	CD	O
achieved	VBD	O
13.0	CD	O
mS/cm	NN	O
.	.	O

No	DT	O
episodes	NNS	O
of	IN	O
disequilibrium	NN	O
occurred	VBD	O
.	.	O

Interdialytic	JJ	O
weight	NN	O
gain	NN	O
was	VBD	O
reduced	VBN	O
from	IN	O
2.34	CD	O
+/-	JJ	O
0.10	CD	O
kg	NN	O
to	TO	O
1.57	CD	O
+/-	JJ	O
0.11	CD	O
kg	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Predialysis	NNP	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
fell	VBD	O
from	IN	O
144	CD	O
+/-	JJ	O
3	CD	O
mm	NN	O
Hg	NNP	O
to	TO	O
137	CD	O
+/-	JJ	O
4	CD	O
mm	NN	O
Hg	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
reduction	NN	O
in	IN	O
convective	JJ	Physical
sodium	NN	Physical
removal	NN	Physical
was	VBD	O
balanced	VBN	O
by	IN	O
an	DT	O
increase	NN	O
in	IN	O
diffusive	JJ	O
sodium	NN	O
removal	NN	O
(	(	O
95	CD	O
+/-	JJ	O
9	CD	O
mmol	NN	O
cf	NN	O
.	.	O

175	CD	O
+/-	JJ	O
14	CD	O
mmol	NN	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

Reduction	NN	Other
in	IN	Other
Cndi	NNP	Other
monitored	VBN	O
by	IN	O
IMB	NNP	O
is	VBZ	O
safe	JJ	O
and	CC	O
practical	JJ	O
and	CC	O
leads	VBZ	O
to	TO	O
improved	VBN	O
interdialytic	JJ	O
weight	NN	O
gains	NNS	O
and	CC	O
blood	NN	O
pressure	NN	O
control	NN	O
,	,	O
while	IN	O
avoiding	VBG	O
excessive	JJ	O
sodium	NN	O
removal	NN	O
.	.	O

Reactive	JJ	O
balance	NN	O
adjustments	NNS	O
to	TO	O
unexpected	JJ	Physical
perturbations	NNS	Physical
during	IN	O
human	JJ	O
walking	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
investigation	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
unexpected	JJ	Physical
forward	NN	Physical
perturbations	NNS	Physical
(	(	Physical
FP	NNP	Physical
)	)	Physical
during	IN	O
gait	NN	O
on	IN	O
lower	JJR	O
extremity	NN	O
joint	NN	O
mechanics	NNS	O
and	CC	O
muscle	NN	O
Electromyographic	NNP	O
(	(	O
EMG	NNP	O
)	)	O
patterns	VBZ	O
in	IN	O
healthy	JJ	O
adults	NNS	O
.	.	O

The	DT	O
muscles	NNS	O
surrounding	VBG	O
the	DT	O
hip	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
most	RBS	O
important	JJ	O
in	IN	O
maintaining	VBG	O
control	NN	O
of	IN	O
the	DT	O
trunk	NN	O
and	CC	O
preventing	VBG	O
collapse	NN	O
in	IN	O
response	NN	O
to	TO	O
the	DT	O
FP	NNP	O
.	.	O

Distinct	NNP	O
lower	JJR	O
extremity	NN	O
joint	JJ	O
moment	NN	O
and	CC	O
power	NN	O
patterns	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
response	NN	O
to	TO	O
the	DT	O
FP	NNP	Physical
but	CC	O
an	DT	O
overall	JJ	O
positive	JJ	O
moment	NN	O
of	IN	O
support	NN	O
(	(	O
M	NNP	O
(	(	O
s	PRP	O
)	)	O
)	)	O
was	VBD	O
maintained	VBN	O
.	.	O

Therefore	RB	O
,	,	O
reactive	JJ	O
balance	NN	O
control	NN	O
was	VBD	O
a	DT	O
synchronized	JJ	O
effort	NN	O
of	IN	O
the	DT	O
lower	JJR	O
extremity	NN	O
joints	NNS	O
to	TO	O
prevent	VB	O
collapse	NN	O
during	IN	O
the	DT	O
FP	NNP	Physical
.	.	Physical

Pilot	NNP	O
study	NN	O
of	IN	O
Panax	NNP	Pharmacological
quinquefolius	NN	Pharmacological
(	(	Pharmacological
American	NNP	Pharmacological
ginseng	NN	Pharmacological
)	)	Pharmacological
to	TO	O
improve	VB	O
cancer-related	JJ	O
fatigue	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
dose-finding	JJ	O
evaluation	NN	O
:	:	O
NCCTG	NNP	O
trial	NN	O
N03CA	NNP	O
.	.	O

PURPOSE	NNP	O
This	DT	O
pilot	NN	O
trial	NN	O
sought	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
any	DT	O
of	IN	O
three	CD	O
doses	NNS	O
of	IN	O
American	JJ	Pharmacological
ginseng	NN	Pharmacological
(	(	Pharmacological
Panax	NNP	Pharmacological
quinquefolius	RB	Pharmacological
)	)	Pharmacological
might	MD	O
help	VB	O
cancer-related	JJ	O
fatigue	NN	O
.	.	O

A	DT	O
secondary	JJ	O
aim	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
toxicity	NN	O
.	.	O

METHODS	NNP	O
Eligible	JJ	O
adults	NNS	O
with	IN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
manner	NN	O
,	,	O
to	TO	O
receive	VB	O
American	JJ	Pharmacological
ginseng	NN	Pharmacological
in	IN	O
doses	NNS	O
of	IN	O
750	CD	O
,	,	O
1,000	CD	O
,	,	O
or	CC	O
2,000	CD	O
mg/day	NN	O
or	CC	O
placebo	VB	Control
given	VBN	O
in	IN	O
twice	JJ	O
daily	JJ	O
dosing	NN	O
over	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
Brief	NNP	O
Fatigue	NNP	O
Inventory	NNP	O
,	,	O
vitality	NN	O
subscale	NN	O
of	IN	O
the	DT	O
Medical	NNP	O
Outcome	NNP	O
Scale	NNP	O
Short	NNP	O
Form-36	NNP	O
(	(	O
SF-36	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Global	NNP	O
Impression	NNP	O
of	IN	O
Benefit	NNP	O
Scale	NNP	O
at	IN	O
4	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Two	CD	O
hundred	VBD	O
ninety	NN	O
patients	NNS	O
were	VBD	O
accrued	VBN	O
to	TO	O
this	DT	O
trial	NN	O
.	.	O

Nonsignificant	JJ	O
trends	NNS	O
for	IN	O
all	DT	O
outcomes	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
1,000-	JJ	O
and	CC	O
2,000-mg/day	JJ	O
doses	NNS	O
of	IN	O
American	JJ	Pharmacological
ginseng	NN	Pharmacological
.	.	Pharmacological

Area	NNP	O
under	IN	O
the	DT	O
curve	NN	O
analysis	NN	O
of	IN	O
activity	NN	O
interference	NN	O
from	IN	O
the	DT	O
Brief	NNP	O
Fatigue	NNP	O
Inventory	NNP	O
was	VBD	O
460-467	JJ	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
and	CC	O
750	CD	O
mg/day	NN	O
group	NN	O
versus	VBD	O
480-551	CD	O
in	IN	O
the	DT	O
1,000-	JJ	O
and	CC	O
2,000-mg/day	JJ	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
vitality	NN	O
subscale	NN	O
of	IN	O
the	DT	O
SF-36	NNP	O
was	VBD	O
7.3-7.8	JJ	O
in	IN	O
the	DT	O
placebo	NN	Control
and	CC	O
the	DT	O
750-mg/day	JJ	O
arm	NN	O
,	,	O
versus	NN	O
10.5-14.6	JJ	O
in	IN	O
the	DT	O
1,000-	JJ	O
and	CC	O
2,000-mg/day	JJ	O
arms	NNS	O
.	.	O

Over	NNP	O
twice	RB	O
as	RB	O
many	JJ	O
patients	NNS	O
on	IN	O
ginseng	NN	Pharmacological
perceived	VBD	O
a	DT	O
benefit	NN	O
and	CC	O
were	VBD	O
satisfied	VBN	O
with	IN	O
treatment	NN	O
over	IN	O
those	DT	O
on	IN	O
placebo	NN	Control
.	.	Control

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
any	DT	O
measured	JJ	O
toxicities	NNS	O
between	IN	O
any	DT	O
of	IN	O
the	DT	O
arms	NNS	O
.	.	O

CONCLUSION	NN	O
There	EX	O
appears	VBZ	O
to	TO	O
be	VB	O
some	DT	O
activity	NN	O
and	CC	O
tolerable	JJ	O
toxicity	NN	O
at	IN	O
1,000-2,000	CD	O
mg/day	JJ	O
doses	NNS	O
of	IN	O
American	JJ	Pharmacological
ginseng	NN	Pharmacological
with	IN	O
regard	NN	O
to	TO	O
cancer-related	JJ	O
fatigue	NN	O
.	.	O

Thus	NNP	O
,	,	O
further	JJ	O
study	NN	O
of	IN	O
American	NNP	Pharmacological
ginseng	NN	Pharmacological
is	VBZ	O
warranted	VBN	O
.	.	O

Immunologic	NNP	O
response	NN	O
after	IN	O
laparoscopic	NN	O
colon	NN	O
cancer	NN	O
operation	NN	O
within	IN	O
an	DT	O
enhanced	JJ	O
recovery	NN	O
program	NN	O
.	.	O

OBJECTIVE	NN	O
It	PRP	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
that	IN	O
colon	NN	O
operation	NN	O
combined	VBN	O
with	IN	O
fast-track	NN	O
(	(	O
FT	NNP	O
)	)	O
surgery	NN	O
and	CC	O
laparoscopic	NN	O
technique	NN	O
can	MD	O
shorten	VB	O
the	DT	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
,	,	O
accelerate	JJ	O
recovery	NN	O
of	IN	O
intestinal	JJ	O
function	NN	O
,	,	O
and	CC	O
reduce	VB	O
the	DT	O
occurrence	NN	O
of	IN	O
post-operative	JJ	O
complications	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
reports	NNS	O
regarding	VBG	O
the	DT	O
combined	JJ	O
effects	NNS	O
of	IN	O
FT	NNP	O
colon	NN	O
operation	NN	O
and	CC	O
laparoscopic	NN	O
technique	NN	O
on	IN	O
humoral	JJ	O
inflammatory	NN	O
cellular	JJ	O
immunity	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
controlled	VBD	O
study	NN	O
.	.	O

One	CD	O
hundred	VBD	O
sixty-three	JJ	O
colon	NN	O
cancer	NN	O
patients	NNS	O
underwent	VBD	O
the	DT	O
traditional	JJ	Surgical
protocol	NN	Surgical
and	CC	Surgical
open	JJ	Surgical
operation	NN	Surgical
(	(	O
traditional	JJ	O
open	JJ	O
group	NN	O
,	,	O
n=42	RB	O
)	)	O
,	,	O
the	DT	O
traditional	JJ	Surgical
protocol	NN	Surgical
and	CC	Surgical
laparoscopic	NN	Surgical
operation	NN	Surgical
(	(	O
traditional	JJ	O
laparoscopic	NN	O
group	NN	O
,	,	O
n=40	RB	O
)	)	O
,	,	O
the	DT	O
FT	NNP	Surgical
protocol	NN	Surgical
and	CC	Surgical
open	JJ	Surgical
operation	NN	Surgical
(	(	O
FT	NNP	O
open	JJ	O
group	NN	O
,	,	O
n=41	RB	O
)	)	O
,	,	O
or	CC	O
the	DT	O
FT	NNP	Surgical
protocol	NN	Surgical
and	CC	Surgical
laparoscopic	NN	Surgical
operation	NN	Surgical
(	(	O
FT	NNP	O
laparoscopic	NN	O
group	NN	O
,	,	O
n=40	RB	O
)	)	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
taken	VBN	O
prior	RB	O
to	TO	O
operation	NN	O
as	RB	O
well	RB	O
as	IN	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
5	CD	O
after	IN	O
operation	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
lymphocyte	JJ	O
subpopulations	NNS	O
was	VBD	O
determined	VBN	O
by	IN	O
flow	JJ	O
cytometry	NN	O
,	,	O
and	CC	O
serum	VB	O
interleukin-6	JJ	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Post-operative	JJ	O
hospital	NN	O
stay	NN	O
,	,	O
post-operative	JJ	O
morbidity	NN	O
,	,	O
readmission	NN	O
rate	NN	O
,	,	O
and	CC	O
in-hospital	JJ	O
mortality	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Compared	VBD	O
with	IN	O
open	JJ	O
operation	NN	O
,	,	O
laparoscopic	JJ	O
colon	NN	O
operation	NN	O
effectively	RB	O
inhibited	VBD	O
the	DT	O
release	NN	O
of	IN	O
post-operative	JJ	O
inflammatory	JJ	O
factors	NNS	O
and	CC	O
yielded	VBD	O
good	JJ	O
protection	NN	O
via	IN	O
post-operative	JJ	O
cell	NN	O
immunity	NN	O
.	.	O

FT	NNP	O
surgery	NN	O
had	VBD	O
a	DT	O
better	RBR	O
protective	JJ	O
role	NN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
post-operative	JJ	O
immune	NN	O
system	NN	O
compared	VBN	O
with	IN	O
traditional	JJ	O
peri-operative	JJ	O
care	NN	O
.	.	O

Inflammatory	JJ	O
reactions	NNS	O
,	,	O
based	VBN	O
on	IN	O
interleukin-6	JJ	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
levels	NNS	O
,	,	O
were	VBD	O
less	JJR	O
intense	JJ	O
following	VBG	O
FT	NNP	O
laparoscopic	NN	O
operation	NN	O
compared	VBN	O
to	TO	O
FT	NNP	O
open	JJ	O
operation	NN	O
;	:	O
however	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
specific	JJ	O
immunity	NN	O
(	(	O
CD3+	NNP	O
and	CC	O
CD4+	NNP	O
counts	NNS	O
,	,	O
and	CC	O
the	DT	O
CD4+/CD8+	NNP	O
ratio	NN	O
)	)	O
during	IN	O
these	DT	O
two	CD	O
types	NNS	O
of	IN	O
surgical	JJ	O
procedures	NNS	O
.	.	O

Post-operative	JJ	O
hospital	NN	O
stay	NN	O
in	IN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
FT	NNP	O
laparoscopic	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
three	CD	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Post-operative	JJ	O
complications	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
underwent	VBP	O
FT	NNP	O
laparoscopic	NN	O
treatment	NN	O
were	VBD	O
less	JJR	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
three	CD	O
treatment	NN	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
four	CD	O
treatment	NN	O
groups	NNS	O
regarding	VBG	O
readmission	NN	O
rate	NN	O
and	CC	O
in-hospital	JJ	O
mortality	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
laparoscopic	NN	O
technique	NN	O
and	CC	O
FT	NNP	O
surgery	NN	O
rehabilitation	NN	O
program	NN	O
effectively	RB	O
inhibited	VBD	O
release	NN	O
of	IN	O
post-operative	JJ	O
inflammatory	JJ	O
factors	NNS	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
peri-operative	JJ	O
trauma	NN	O
and	CC	O
stress	NN	O
,	,	O
which	WDT	O
together	RB	O
played	VBD	O
a	DT	O
protective	JJ	O
role	NN	O
on	IN	O
the	DT	O
post-operative	JJ	O
immune	NN	O
system	NN	O
.	.	O

Combining	VBG	O
two	CD	O
treatment	NN	O
measures	NNS	O
during	IN	O
colon	NN	O
operation	NN	O
produced	VBD	O
better	RBR	O
protective	JJ	O
effects	NNS	O
via	IN	O
the	DT	O
immune	JJ	O
system	NN	O
.	.	O

The	DT	O
beneficial	JJ	O
clinical	JJ	O
effects	NNS	O
support	NN	O
that	IN	O
the	DT	O
better-preserved	JJ	O
post-operative	JJ	O
immune	NN	O
system	NN	O
may	MD	O
also	RB	O
contribute	VB	O
to	TO	O
the	DT	O
improvement	NN	O
of	IN	O
post-operative	JJ	O
results	NNS	O
in	IN	O
FT	NNP	O
laparoscopic	NN	O
patients	NNS	O
.	.	O

Glibenclamide	NNP	Pharmacological
vs	NN	O
gliclazide	NN	Pharmacological
in	IN	O
reducing	VBG	O
oxidative	JJ	O
stress	NN	O
in	IN	O
patients	NNS	O
of	IN	O
noninsulin	JJ	O
dependent	JJ	O
diabetes	VBZ	O
mellitus	NN	O
--	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomized	VBN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Parameters	NNPS	O
of	IN	O
oxidative	JJ	O
stress	NN	O
were	VBD	O
quantitated	VBN	O
in	IN	O
50	CD	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
mellitus	VBP	O
in	IN	O
uncontrolled	JJ	O
state	NN	O
and	CC	O
after	IN	O
control	NN	O
using	VBG	O
oral	JJ	O
glibenclamide	NN	Pharmacological
or	CC	O
gliclazide	NN	Pharmacological
.	.	O

The	DT	O
estimates	NNS	O
were	VBD	O
further	RB	O
compared	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
irrespective	JJ	O
of	IN	O
drug	NN	O
used	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
difference	NN	O
,	,	O
if	IN	O
any	DT	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
uncontrolled	JJ	O
,	,	O
noncrossover	RB	O
and	CC	O
randomized	JJ	O
trial	NN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
of	IN	O
uncontrolled	JJ	O
type	NN	O
2	CD	O
diabetes	NNS	O
were	VBD	O
divided	VBN	O
in	IN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
received	VBD	O
capsule	NN	O
A	NNP	O
(	(	O
glibenclamide	NN	Pharmacological
)	)	O
while	IN	O
Group	NNP	O
II	NNP	O
(	(	O
25	CD	O
patients	NNS	O
)	)	O
received	VBD	O
capsule	NN	O
B	NNP	O
(	(	O
gliclazide	NN	Pharmacological
)	)	O
.	.	O

The	DT	O
parameters	NNS	O
studied	VBN	O
were	VBD	O
Superoxide	NNP	O
dismutase	NN	O
(	(	O
SOD	NNP	O
)	)	O
,	,	O
malonyl-dialdehyde	JJ	O
(	(	O
MDA	NNP	O
)	)	O
and	CC	O
reduced	VBN	O
glutathione	NN	O
(	(	O
GSH	NNP	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
done	VBN	O
at	IN	O
(	(	O
a	DT	O
)	)	O
uncontrolled	JJ	O
stage	NN	O
(	(	O
FBS	NNP	O
--	:	O
165	CD	O
+/-	JJ	O
16.7	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
240	CD	O
+/-	JJ	O
30.1	CD	O
mg/dl	NN	O
and	CC	O
HbA1	NNP	O
--	:	O
10.5	CD	O
+/-	JJ	O
0.9	CD	O
%	NN	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
FBS	NNP	O
--	:	O
150	CD	O
+/-	JJ	O
15.8	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
246	CD	O
+/-	JJ	O
29.1	CD	O
mg/dl	NN	O
HbA1	NNP	O
10.6	CD	O
+/-	JJ	O
0.8	CD	O
%	NN	O
in	IN	O
group	NN	O
II	NNP	O
)	)	O
and	CC	O
during	IN	O
controlled	VBN	O
stage	NN	O
at	IN	O
12	CD	O
weeks	NNS	O
(	(	O
FBS	NNP	O
--	:	O
120	CD	O
+/-	JJ	O
18.5	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
180	CD	O
+/-	JJ	O
19.1	CD	O
mg/dl	NN	O
and	CC	O
HbA1	NNP	O
--	:	O
8.4	CD	O
+/-	JJ	O
0.29	CD	O
%	NN	O
in	IN	O
group	NN	O
I	PRP	O
and	CC	O
FBS	NNP	O
--	:	O
118	CD	O
+/-	JJ	O
17.6	CD	O
mg/dl	NN	O
,	,	O
PP	NNP	O
--	:	O
176	CD	O
+/-	JJ	O
20.1	CD	O
mg/dl	NN	O
and	CC	O
HbA1	NNP	O
--	:	O
8.5	CD	O
+/-	JJ	O
0.39	CD	O
%	NN	O
in	IN	O
group	NN	O
II	NNP	O
patients	NNS	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
significantly	RB	O
raised	VBN	O
levels	NNS	O
of	IN	O
MDA	NNP	O
and	CC	O
SOD	NNP	O
,	,	O
and	CC	O
decreased	JJ	O
levels	NNS	O
of	IN	O
reduced	VBN	O
glutathione	NN	O
(	(	O
GSH	NNP	O
)	)	O
during	IN	O
uncontrolled	JJ	O
stage	NN	O
of	IN	O
diabetes	NNS	O
indicated	VBD	O
free	JJ	O
radical	JJ	O
stress	NN	O
induced	VBD	O
lipid	JJ	O
peroxidation	NN	O
.	.	O

The	DT	O
significant	JJ	O
fall	NN	O
of	IN	O
MDA	NNP	O
and	CC	O
SOD	NNP	O
and	CC	O
increased	VBD	O
levels	NNS	O
of	IN	O
GSH	NNP	O
in	IN	O
blood	NN	O
in	IN	O
both	DT	O
groups	NNS	O
after	IN	O
control	NN	O
revealed	VBD	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
glycemic	JJ	O
control	NN	O
on	IN	O
oxidative	JJ	O
stress	NN	O
.	.	O

The	DT	O
levels	NNS	O
were	VBD	O
not	RB	O
normalized	VBN	O
and	CC	O
stayed	VBD	O
higher	JJR	O
than	IN	O
those	DT	O
in	IN	O
controls	NNS	O
.	.	O

On	IN	O
intergroup	JJ	O
comparison	NN	O
;	:	O
the	DT	O
control	NN	O
of	IN	O
diabetes	NNS	O
with	IN	O
gliclazide	NN	Pharmacological
(	(	O
group	NN	O
II	NNP	O
)	)	O
showed	VBD	O
improvement	NN	O
in	IN	O
oxidative	JJ	O
stress	NN	O
(	(	O
MDA	NNP	O
,	,	O
GSH	NNP	O
)	)	O
better	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
than	IN	O
glibenclamide	NN	Pharmacological
(	(	O
group	NN	O
I	PRP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Oxidative	NNP	O
stress	NN	O
in	IN	O
uncontrolled	JJ	O
diabetes	NNS	O
is	VBZ	O
decreased	VBN	O
with	IN	O
glycemic	JJ	O
control	NN	O
.	.	O

The	DT	O
control	NN	O
of	IN	O
diabetes	NNS	O
with	IN	O
gliclazide	NN	Pharmacological
reduced	VBN	O
oxidative	JJ	O
stress	NN	O
more	JJR	O
than	IN	O
glibenclamide	NN	Pharmacological
,	,	O
indicating	VBG	O
higher	JJR	O
antioxidant	JJ	O
properties	NNS	O
of	IN	O
gliclazide	NN	O
.	.	O

Normalization	NN	O
of	IN	O
oxidative	JJ	O
stress	NN	O
was	VBD	O
not	RB	O
achieved	VBN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
required	VBN	O
to	TO	O
see	VB	O
long-term	JJ	O
effect	NN	O
of	IN	O
drug	NN	O
therapy	NN	O
in	IN	O
combating	VBG	O
oxidative	JJ	O
stress	NN	O
after	IN	O
achieving	VBG	O
acceptable	JJ	O
control	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

Phytase	NNP	Pharmacological
and	CC	O
1alpha-hydroxycholecalciferol	JJ	Pharmacological
supplementation	NN	Pharmacological
of	IN	O
broiler	NN	O
chickens	NNS	O
during	IN	O
the	DT	O
starting	NN	O
and	CC	O
growing/finishing	NN	O
phases	NNS	O
.	.	O

Supplemental	JJ	O
1alpha-hydroxycholecalciferol	JJ	O
(	(	O
1alpha-OHD3	JJ	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
qualitatively	RB	O
similar	JJ	O
and	CC	O
quantitatively	RB	O
additive	JJ	O
effects	NNS	O
to	TO	O
exogenous	JJ	O
phytase	NN	O
.	.	O

Two	CD	O
experiments	NNS	O
were	VBD	O
conducted	VBN	O
from	IN	O
0	CD	O
to	TO	O
35	CD	O
d	NN	O
in	IN	O
floor	NN	O
pens	NNS	O
to	TO	O
determine	VB	O
the	DT	O
additive	JJ	O
effect	NN	O
of	IN	O
phytase	NN	Pharmacological
and	CC	O
1alpha-OHD3	JJ	Pharmacological
when	WRB	O
supplemented	VBN	O
to	TO	O
Ca-	NNP	Pharmacological
and	CC	Pharmacological
P-deficient	NNP	Pharmacological
diets	NNS	Pharmacological
.	.	O

In	IN	O
both	DT	O
experiments	NNS	O
,	,	O
at	IN	O
least	JJS	O
4	CD	O
replicates	NNS	O
per	IN	O
treatment	NN	O
(	(	O
50	CD	O
chicks	NNS	O
per	IN	O
replicate	NN	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O

Corn-soybean-meal-and	JJ	Other
soybean-oil-based	JJ	Other
diets	NNS	Other
were	VBD	O
fed	VBN	O
and	CC	O
birds	NNS	O
were	VBD	O
raised	VBN	O
in	IN	O
a	DT	O
house	NN	O
impervious	JJ	O
to	TO	O
ultraviolet	VB	O
light	NN	O
.	.	O

During	IN	O
the	DT	O
starter	JJ	O
phase	NN	O
(	(	O
ST	NNP	O
)	)	O
,	,	O
from	IN	O
0	CD	O
to	TO	O
18	CD	O
d	NN	O
,	,	O
chicks	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
23	CD	O
%	NN	O
CP	NNP	O
diet	JJ	O
containing	VBG	O
0.60	CD	O
%	NN	O
Ca	NNP	O
and	CC	O
0.47	CD	O
%	NN	O
total	JJ	O
P	NNP	O
(	(	O
tP	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
grower/finisher	NN	O
phase	NN	O
(	(	O
GF	NNP	O
)	)	O
,	,	O
from	IN	O
19	CD	O
to	TO	O
35	CD	O
d	NN	O
,	,	O
birds	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
19	CD	O
%	NN	O
CP	NNP	O
diet	JJ	O
containing	VBG	O
0.30	CD	O
%	NN	O
Ca	NNP	O
and	CC	O
0.37	CD	O
%	NN	O
tP	NN	O
.	.	O

A	DT	O
combination	NN	O
of	IN	O
1,000	CD	O
phytase	NN	O
units/kg	NN	O
of	IN	O
Natuphos	NNP	O
phytase	NN	O
and	CC	O
5	CD	O
microg/kg	NN	O
of	IN	O
1alpha-OHD3	JJ	O
(	(	O
P+1A	NNP	O
)	)	O
was	VBD	O
supplemented	VBN	O
to	TO	O
some	DT	O
of	IN	O
the	DT	O
feed	NN	O
during	IN	O
the	DT	O
ST	NNP	O
and	CC	O
GF	NNP	O
.	.	O

Diets	NNS	O
containing	VBG	O
adequate	NN	O
Ca	NNP	O
and	CC	O
P	NNP	O
were	VBD	O
also	RB	O
fed	VBN	O
during	IN	O
the	DT	O
ST	NNP	O
(	(	O
0.90	CD	O
%	NN	O
Ca	NNP	O
,	,	O
0.68	CD	O
%	NN	O
tP	NN	O
)	)	O
and	CC	O
GF	NNP	O
(	(	O
0.80	CD	O
%	NN	O
Ca	NNP	O
,	,	O
0.67	CD	O
%	NN	O
tP	NN	O
)	)	O
.	.	O

Performance	NN	O
characteristics	NNS	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
rickets	NNS	O
and	CC	O
tibial	JJ	O
dyschondroplasia	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
18	CD	O
and	CC	O
35	CD	O
d.	NN	O
In	IN	O
experiment	JJ	O
1	CD	O
,	,	O
unsupplemented	JJ	O
chicks	NNS	O
performed	VBN	O
well	RB	O
but	CC	O
had	VBD	O
considerable	JJ	O
leg	JJ	O
problems	NNS	O
.	.	O

Chicks	NNP	O
fed	VBD	O
P+1A	NNP	O
during	IN	O
the	DT	O
ST	NNP	O
or	CC	O
GF	NNP	O
did	VBD	O
not	RB	O
perform	VB	O
as	RB	O
well	RB	O
as	IN	O
birds	NNS	O
fed	VBN	O
P+1A	NNP	O
throughout	IN	O
.	.	O

Birds	NNS	O
fed	VBD	O
P+1A	NNP	O
throughout	IN	O
performed	VBN	O
as	IN	O
well	RB	O
birds	NNS	O
fed	VBD	O
the	DT	O
adequate	JJ	O
diets	NNS	O
without	IN	O
any	DT	O
indication	NN	O
of	IN	O
leg	NN	O
problems	NNS	O
.	.	O

In	IN	O
experiment	JJ	O
2	CD	O
,	,	O
unsupplemented	JJ	O
birds	NNS	O
performed	VBD	O
similarly	RB	O
to	TO	O
unsupplemented	JJ	O
birds	NNS	O
in	IN	O
experiment	JJ	O
1	CD	O
.	.	O

However	RB	O
,	,	O
chicks	NNS	O
fed	VBP	O
the	DT	O
supplements	NNS	O
or	CC	O
the	DT	O
control	JJ	O
diets	NNS	O
did	VBD	O
not	RB	O
perform	VB	O
as	RB	O
well	RB	O
or	CC	O
accumulate	VB	O
as	IN	O
much	JJ	O
bone	NN	O
ash	NN	O
as	IN	O
birds	NNS	O
in	IN	O
experiment	JJ	O
1	CD	O
,	,	O
although	IN	O
the	DT	O
diets	NNS	O
were	VBD	O
formulated	VBN	O
identically	RB	O
in	IN	O
both	DT	O
experiments	NNS	O
.	.	O

Diets	NNS	O
with	IN	O
as	RB	O
little	JJ	O
as	IN	O
0.30	CD	O
%	NN	O
Ca	NNP	O
and	CC	O
0.37	CD	O
%	NN	O
tP	NN	O
appear	VBP	O
to	TO	O
be	VB	O
adequate	JJ	O
for	IN	O
broilers	NNS	O
older	JJR	O
than	IN	O
18	CD	O
d	NN	O
if	IN	O
supplemented	VBN	O
with	IN	O
the	DT	O
correct	JJ	O
amounts	NNS	O
of	IN	O
phytase	NN	O
and	CC	O
1alpha-OHD3	JJ	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
unknown	JJ	O
variables	NNS	O
that	WDT	O
may	MD	O
limit	VB	O
the	DT	O
potential	NN	O
of	IN	O
broilers	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
bone	NN	O
mineralization	NN	O
and	CC	O
bone	NN	O
pathology	NN	O
,	,	O
even	RB	O
when	WRB	O
adequate	JJ	O
diets	NNS	O
are	VBP	O
fed	VBN	O
.	.	O

Teacher	DT	O
and	CC	O
child	JJ	O
predictors	NNS	O
of	IN	O
achieving	VBG	O
IEP	NNP	Educational
goals	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

It	PRP	O
is	VBZ	O
encouraging	VBG	O
that	IN	O
children	NNS	O
with	IN	O
autism	NN	O
show	VBP	O
a	DT	O
strong	JJ	O
response	NN	O
to	TO	O
early	JJ	O
intervention	NN	O
,	,	O
yet	RB	O
more	JJR	O
research	NN	O
is	VBZ	O
needed	VBN	O
for	IN	O
understanding	VBG	O
the	DT	O
variability	NN	O
in	IN	O
responsiveness	NN	O
to	TO	O
specialized	JJ	O
programs	NNS	O
.	.	O

Treatment	NNP	O
predictor	NN	O
variables	NNS	O
from	IN	O
47	CD	O
teachers	NNS	O
and	CC	O
children	NNS	O
who	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
the	DT	O
COMPASS	NNP	Educational
intervention	NN	Educational
(	(	O
Ruble	JJ	O
et	NN	O
al	NN	O
.	.	O

in	IN	O
The	DT	O
collaborative	JJ	O
model	NN	O
for	IN	O
promoting	VBG	O
competence	NN	O
and	CC	O
success	NN	O
for	IN	O
students	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Springer	NNP	O
,	,	O
New	NNP	O
York	NNP	O
,	,	O
2012a	CD	O
)	)	O
were	VBD	O
analyzed	VBN	O
.	.	O

Predictors	NNS	O
evaluated	VBD	O
against	IN	O
child	NN	O
IEP	NNP	O
goal	NN	O
attainment	NN	O
included	VBD	O
child	NN	O
,	,	O
teacher	NN	O
,	,	O
intervention	NN	O
practice	NN	O
,	,	O
and	CC	O
implementation	NN	O
practice	NN	O
variables	NNS	O
based	VBN	O
on	IN	O
an	DT	O
implementation	NN	O
science	NN	O
framework	NN	O
(	(	O
Dunst	NNP	O
and	CC	O
Trivette	NNP	O
in	IN	O
J	NNP	O
Soc	NNP	O
Sci	NNP	O
8:143-148	CD	O
,	,	O
2012	CD	O
)	)	O
.	.	O

Findings	NNS	O
revealed	VBD	O
one	CD	O
child	NN	O
(	(	O
engagement	NN	O
)	)	O
,	,	O
one	CD	O
teacher	NN	O
(	(	O
exhaustion	NN	O
)	)	O
,	,	O
two	CD	O
intervention	NN	O
quality	NN	O
(	(	O
IEP	NNP	O
quality	NN	O
for	IN	O
targeted	VBN	O
and	CC	O
not	RB	O
targeted	JJ	O
elements	NNS	O
)	)	O
,	,	O
and	CC	O
no	DT	O
implementation	NN	O
quality	NN	O
variables	NNS	O
accounted	VBD	O
for	IN	O
variance	NN	O
in	IN	O
child	NN	O
outcomes	NNS	O
when	WRB	O
analyzed	VBN	O
separately	RB	O
.	.	O

When	WRB	O
the	DT	O
four	CD	O
significant	JJ	O
variables	NNS	O
were	VBD	O
compared	VBN	O
against	IN	O
each	DT	O
other	JJ	O
in	IN	O
a	DT	O
single	JJ	O
regression	NN	O
analysis	NN	O
,	,	O
IEP	NNP	Educational
quality	NN	O
accounted	VBD	O
for	IN	O
one	CD	O
quarter	NN	O
of	IN	O
the	DT	O
variance	NN	O
in	IN	O
child	NN	O
outcomes	NNS	O
.	.	O

Bitewing	NNP	O
film	NN	O
quality	NN	O
:	:	O
a	DT	O
clinical	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
loop	NN	Surgical
vs.	FW	O
holder	NN	Surgical
techniques	NNS	Surgical
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
in	IN	O
vivo	JJ	O
bitewing	NN	O
film	NN	O
quality	NN	O
using	VBG	O
the	DT	O
holder	NN	Surgical
versus	IN	Surgical
the	DT	Surgical
paper	NN	Surgical
loop	NN	Surgical
technique	NN	Surgical
.	.	O

METHOD	NNP	O
AND	CC	O
MATERIALS	NNP	O
Four	NNP	O
bitewing	VBG	O
films	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
the	DT	O
right	NN	O
and	CC	O
left	VBD	O
premolar	JJ	O
and	CC	O
molar	JJ	O
regions	NNS	O
of	IN	O
45	CD	O
dental	JJ	O
students	NNS	O
using	VBG	O
both	DT	O
the	DT	O
bitewing	NN	O
holder	NN	Surgical
and	CC	Surgical
paper	NN	Surgical
loop	NN	Surgical
techniques	NNS	Surgical
.	.	O

A	DT	O
total	NN	O
of	IN	O
360	CD	O
films	NNS	O
were	VBD	O
taken	VBN	O
and	CC	O
assessed	VBN	O
by	IN	O
an	DT	O
experienced	JJ	O
practitioner	NN	O
not	RB	O
apprised	VBN	O
of	IN	O
the	DT	O
bitewing	NN	Surgical
technique	NN	Surgical
used	VBN	O
.	.	O

Of	IN	O
interest	NN	O
were	VBD	O
:	:	O
(	(	O
1	CD	O
)	)	O
the	DT	O
number	NN	O
of	IN	O
overlaps	NNS	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
teeth	NNS	O
showing	VBG	O
the	DT	O
alveolar	JJ	O
crest	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
proper	NN	O
film	NN	O
positioning	NN	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
the	DT	O
percentage	NN	O
of	IN	O
cone	NN	O
cutting	NN	O
.	.	O

A	DT	O
Poisson	NNP	O
regression	NN	O
using	VBG	O
generalized	VBN	O
estimating	VBG	O
equations	NNS	O
(	(	O
GEEs	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
difference	NN	O
in	IN	O
overlap	NN	O
between	IN	O
the	DT	O
two	CD	O
techniques	NNS	O
.	.	O

For	IN	O
proper	JJ	O
positioning	NN	O
and	CC	O
cone	NN	O
cutting	NN	O
,	,	O
logistic	JJ	O
regressions	NNS	O
using	VBG	O
GEEs	NNP	O
were	VBD	O
used	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
average	JJ	O
number	NN	O
of	IN	O
horizontal	JJ	O
overlaps	NNS	O
for	IN	O
the	DT	O
loop	NN	Surgical
and	CC	O
holder	NN	Surgical
techniques	NNS	Surgical
at	IN	O
the	DT	O
right	JJ	O
premolar	NN	O
,	,	O
right	JJ	O
molar	NN	O
,	,	O
left	VBD	O
premolar	JJ	O
,	,	O
and	CC	O
left	VBD	O
molar	NN	O
were	VBD	O
1.64	CD	O
,	,	O
2.11	CD	O
,	,	O
2.16	CD	O
,	,	O
2.78	CD	O
,	,	O
and	CC	O
1.64	CD	O
,	,	O
2.00	CD	O
,	,	O
2.00	CD	O
,	,	O
2.18	CD	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
loop	NN	Surgical
technique	NN	Surgical
was	VBD	O
1.11	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
cause	VB	O
overlapping	VBG	O
than	IN	O
the	DT	O
holder	NN	Surgical
technique	NN	Surgical
.	.	Surgical

The	DT	O
highest	JJS	O
percentage	NN	O
of	IN	O
teeth	NNS	O
showing	VBG	O
the	DT	O
alveolar	JJ	O
crest	NN	O
by	IN	O
the	DT	O
loop	NN	Surgical
technique	NN	Surgical
was	VBD	O
97.8	CD	O
%	NN	O
in	IN	O
the	DT	O
mandibular	JJ	O
second	JJ	O
premolar	NN	O
and	CC	O
first	JJ	O
molar	NN	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
film	NN	O
positioning	NN	O
,	,	O
the	DT	O
loop	NN	Surgical
technique	NN	Surgical
was	VBD	O
1.12	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
cause	VB	O
improper	JJ	O
positioning	NN	O
than	IN	O
the	DT	O
holder	NN	Surgical
technique	NN	Surgical
.	.	Surgical

Both	DT	O
techniques	NNS	O
demonstrated	VBN	O
minimal	JJ	O
cone	NN	O
cutting	NN	O
(	(	O
1	CD	O
in	IN	O
the	DT	O
loop	NN	O
versus	NN	O
0	CD	O
in	IN	O
the	DT	O
holder	NN	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
quality	NN	O
of	IN	O
bitewing	VBG	O
films	NNS	O
taken	VBN	O
by	IN	O
the	DT	O
loop	NN	Surgical
and	CC	Surgical
holder	NN	Surgical
techniques	NNS	Surgical
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

Predictors	NNS	O
of	IN	O
postdischarge	NN	O
outcomes	NNS	O
from	IN	O
information	NN	O
acquired	VBN	O
shortly	RB	O
after	IN	O
admission	NN	O
for	IN	O
acute	JJ	O
heart	NN	O
failure	NN	O
:	:	O
a	DT	O
report	NN	O
from	IN	O
the	DT	O
Placebo-Controlled	NNP	Control
Randomized	NNP	O
Study	NNP	O
of	IN	O
the	DT	O
Selective	NNP	O
A1	NNP	O
Adenosine	NNP	O
Receptor	NNP	O
Antagonist	NNP	O
Rolofylline	NNP	Pharmacological
for	IN	O
Patients	NNP	O
Hospitalized	NNP	O
With	IN	O
Acute	NNP	O
Decompensated	NNP	O
Heart	NNP	O
Failure	NNP	O
and	CC	O
Volume	NN	O
Overload	NNP	O
to	TO	O
Assess	NNP	O
Treatment	NNP	O
Effect	NNP	O
on	IN	O
Congestion	NNP	O
and	CC	O
Renal	NNP	O
Function	NNP	O
(	(	O
PROTECT	NNP	O
)	)	O
Study	NNP	O
.	.	O

BACKGROUND	NNP	O
Acute	NNP	O
heart	NN	O
failure	NN	O
is	VBZ	O
a	DT	O
common	JJ	O
reason	NN	O
for	IN	O
admission	NN	O
,	,	O
and	CC	O
outcome	NN	O
is	VBZ	O
often	RB	O
poor	JJ	O
.	.	O

Improved	VBN	O
prognostic	JJ	O
risk	NN	O
stratification	NN	O
may	MD	O
assist	VB	O
in	IN	O
the	DT	O
design	NN	O
of	IN	O
future	JJ	O
trials	NNS	O
and	CC	O
in	IN	O
patient	JJ	O
management	NN	O
.	.	O

Using	VBG	O
data	NNS	O
from	IN	O
a	DT	O
large	JJ	O
randomized	JJ	O
trial	NN	O
,	,	O
we	PRP	O
explored	VBD	O
the	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
clinical	JJ	O
variables	NNS	O
,	,	O
measured	VBN	O
at	IN	O
hospital	JJ	O
admission	NN	O
for	IN	O
acute	JJ	O
heart	NN	O
failure	NN	O
,	,	O
to	TO	O
determine	VB	O
whether	IN	O
a	DT	O
few	JJ	O
selected	VBN	O
variables	NNS	O
were	VBD	O
inferior	JJ	O
to	TO	O
an	DT	O
extended	VBN	O
data	NN	O
set	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
The	DT	O
prognostic	JJ	O
model	NN	O
included	VBD	O
37	CD	O
clinical	JJ	O
characteristics	NNS	O
collected	VBN	O
at	IN	O
baseline	NN	O
in	IN	O
PROTECT	NNP	O
,	,	O
a	DT	O
study	NN	O
comparing	VBG	O
rolofylline	NN	Pharmacological
and	CC	O
placebo	NN	Control
in	IN	O
2033	CD	O
patients	NNS	O
admitted	VBN	O
with	IN	O
acute	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Prespecified	VBN	O
outcomes	NNS	O
at	IN	O
30	CD	O
days	NNS	O
were	VBD	O
death	NN	O
or	CC	O
rehospitalization	NN	O
for	IN	O
any	DT	O
reason	NN	O
;	:	O
death	NN	O
or	CC	O
rehospitalization	NN	O
for	IN	O
cardiovascular	NN	O
or	CC	O
renal	JJ	O
reasons	NNS	O
;	:	O
and	CC	O
,	,	O
at	IN	O
both	DT	O
30	CD	O
and	CC	O
180	CD	O
days	NNS	O
,	,	O
all-cause	JJ	O
mortality	NN	O
.	.	O

No	DT	O
variable	JJ	O
had	VBD	O
a	DT	O
c-index	NN	O
>	NN	O
0.70	CD	O
,	,	O
and	CC	O
few	JJ	O
had	VBD	O
values	NNS	O
>	$	O
0.60	CD	O
;	:	O
c-indices	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
composite	JJ	O
outcomes	NNS	O
than	IN	O
for	IN	O
mortality	NN	O
.	.	O

Blood	NNP	O
urea	NN	O
was	VBD	O
generally	RB	O
the	DT	O
strongest	JJS	O
single	JJ	O
predictor	NN	O
.	.	O

Eighteen	NNP	O
variables	NNS	O
contributed	VBD	O
independent	JJ	O
prognostic	JJ	O
information	NN	O
,	,	O
but	CC	O
a	DT	O
reduced	JJ	O
model	NN	O
using	VBG	O
only	RB	O
8	CD	O
items	NNS	O
(	(	O
age	NN	O
,	,	O
previous	JJ	O
heart	NN	O
failure	NN	O
hospitalization	NN	O
,	,	O
peripheral	JJ	O
edema	NN	O
,	,	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
serum	NN	O
sodium	NN	O
,	,	O
urea	JJ	O
,	,	O
creatinine	NN	O
,	,	O
and	CC	O
albumin	NN	O
)	)	O
performed	VBD	O
similarly	RB	O
.	.	O

For	IN	O
prediction	NN	O
of	IN	O
all-cause	JJ	O
mortality	NN	O
at	IN	O
180	CD	O
days	NNS	O
,	,	O
the	DT	O
model	NN	O
c-index	NN	O
using	VBG	O
all	DT	O
variables	NNS	O
was	VBD	O
0.72	CD	O
and	CC	O
for	IN	O
the	DT	O
simplified	JJ	O
model	NN	O
,	,	O
also	RB	O
0.72	CD	O
.	.	O

CONCLUSIONS	VB	O
A	NNP	O
few	JJ	O
simple	JJ	O
clinical	JJ	O
variables	NNS	O
measured	VBN	O
on	IN	O
admission	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
heart	NN	O
failure	NN	O
predict	VBP	O
a	DT	O
variety	NN	O
of	IN	O
adverse	JJ	O
outcomes	NNS	O
with	IN	O
accuracy	NN	O
similar	JJ	O
to	TO	O
more	RBR	O
complex	JJ	O
models	NNS	O
.	.	O

However	RB	O
,	,	O
predictive	JJ	O
models	NNS	O
were	VBD	O
of	IN	O
only	RB	O
moderate	JJ	O
accuracy	NN	O
,	,	O
especially	RB	O
for	IN	O
outcomes	NNS	O
that	WDT	O
included	VBD	O
nonfatal	JJ	O
events	NNS	O
.	.	O

Better	NNP	O
methods	NNS	O
of	IN	O
risk	NN	O
stratification	NN	O
are	VBP	O
required	VBN	O
.	.	O

CLINICAL	JJ	O
TRIAL	NNP	O
REGISTRATION	NNP	O
URL	NNP	O
:	:	O
http	NN	O
:	:	O
//www.clinicaltrials.gov	NN	O
.	.	O

Unique	JJ	O
identifiers	NNS	O
:	:	O
NCT00328692	NNP	O
and	CC	O
NCT00354458	NNP	O
.	.	O

Randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
oral	JJ	O
sirolimus	NN	O
for	IN	O
restenosis	NN	O
prevention	NN	O
in	IN	O
patients	NNS	O
with	IN	O
in-stent	JJ	O
restenosis	NN	O
:	:	O
the	DT	O
Oral	NNP	O
Sirolimus	NNP	Pharmacological
to	TO	O
Inhibit	NNP	O
Recurrent	NNP	O
In-stent	JJ	O
Stenosis	NNP	O
(	(	O
OSIRIS	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
recent	JJ	O
advances	NNS	O
in	IN	O
interventional	JJ	O
cardiology	NN	O
,	,	O
including	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
drug-eluting	JJ	O
stents	NNS	O
for	IN	O
de	FW	O
novo	FW	O
coronary	JJ	O
lesions	NNS	O
,	,	O
the	DT	O
treatment	NN	O
of	IN	O
in-stent	JJ	O
restenosis	NN	O
(	(	O
ISR	NNP	O
)	)	O
remains	VBZ	O
a	DT	O
challenging	JJ	O
clinical	JJ	O
issue	NN	O
.	.	O

Given	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
systemic	JJ	O
sirolimus	JJ	O
administration	NN	O
to	TO	O
prevent	VB	O
neointimal	JJ	O
hyperplasia	NN	O
in	IN	O
animal	JJ	O
models	NNS	O
and	CC	O
to	TO	O
halt	VB	O
and	CC	O
even	RB	O
reverse	VB	O
the	DT	O
progression	NN	O
of	IN	O
allograft	NN	O
vasculopathy	NN	O
,	,	O
the	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
10-day	JJ	O
oral	JJ	O
sirolimus	NN	O
treatment	NN	O
with	IN	O
2	CD	O
different	JJ	O
loading	VBG	O
regimens	NNS	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurrent	JJ	O
restenosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
ISR	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Three	NNP	O
hundred	VBD	O
symptomatic	JJ	O
patients	NNS	O
with	IN	O
ISR	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
treatment	NN	O
arms	NNS	O
:	:	O
placebo	NN	Control
or	CC	O
usual-dose	JJ	O
or	CC	O
high-dose	JJ	O
sirolimus	NN	Pharmacological
.	.	O

Patients	NNS	O
received	VBD	O
a	DT	O
cumulative	JJ	O
loading	NN	O
dose	NN	O
of	IN	O
0	CD	O
,	,	O
8	CD	O
,	,	O
or	CC	O
24	CD	O
mg	NN	O
of	IN	O
sirolimus	JJ	O
2	CD	O
days	NNS	O
before	IN	O
and	CC	O
the	DT	O
day	NN	O
of	IN	O
repeat	NN	O
intervention	NN	O
followed	VBN	O
by	IN	O
maintenance	NN	O
therapy	NN	O
of	IN	O
2	CD	O
mg/d	NN	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

Angiographic	JJ	O
restenosis	NN	O
at	IN	O
6-month	JJ	O
angiography	NN	O
was	VBD	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Restenosis	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
from	IN	O
42.2	CD	O
%	NN	O
to	TO	O
38.6	CD	O
%	NN	O
and	CC	O
to	TO	O
22.1	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
,	,	O
usual-dose	JJ	O
,	,	O
and	CC	O
high-dose	JJ	O
sirolimus	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.005	NNP	O
)	)	O
.	.	O

Similarly	RB	O
,	,	O
the	DT	O
need	NN	O
for	IN	O
target	NN	O
vessel	JJ	O
revascularization	NN	O
was	VBD	O
reduced	VBN	O
from	IN	O
25.5	CD	O
%	NN	O
to	TO	O
24.2	CD	O
%	NN	O
and	CC	O
to	TO	O
15.2	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	O
,	,	O
usual-dose	JJ	O
,	,	O
and	CC	O
high-dose	JJ	O
groups	NNS	O
,	,	O
respectively	RB	O
(	(	O
P=0.08	NNP	O
)	)	O
.	.	O

The	DT	O
sirolimus	JJ	O
blood	NN	O
concentration	NN	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
procedure	NN	O
correlated	VBD	O
significantly	RB	O
with	IN	O
the	DT	O
late	JJ	O
lumen	NNS	O
loss	NN	O
at	IN	O
follow-up	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
ISR	NNP	O
,	,	O
an	DT	O
oral	JJ	O
adjunctive	JJ	O
sirolimus	NN	O
treatment	NN	O
with	IN	O
an	DT	O
intensified	JJ	O
loading	NN	O
regimen	NNS	O
before	IN	O
coronary	JJ	O
intervention	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
angiographic	JJ	O
parameters	NNS	O
of	IN	O
restenosis	NN	O
.	.	O

Partial	JJ	O
depletion	NN	O
of	IN	O
tissue	NN	O
factor	NN	O
pathway	NN	O
inhibitor	NN	O
during	IN	O
subcutaneous	JJ	O
administration	NN	O
of	IN	O
unfractionated	JJ	O
heparin	NN	Pharmacological
,	,	O
but	CC	O
not	RB	O
with	IN	O
two	CD	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparins	NNS	O
.	.	O

Tissue	NNP	O
factor	NN	O
pathway	NN	O
inhibitor	NN	O
(	(	O
TFPI	NNP	O
)	)	O
is	VBZ	O
released	VBN	O
to	TO	O
circulating	VBG	O
blood	NN	O
after	IN	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
and	CC	O
subcutaneous	JJ	O
(	(	O
s.c.	NN	O
)	)	O
injections	NNS	O
of	IN	O
heparins	NNS	O
,	,	O
and	CC	O
may	MD	O
thus	RB	O
contribute	VB	O
to	TO	O
the	DT	O
antithrombotic	JJ	O
effect	NN	O
of	IN	O
heparins	NNS	O
.	.	O

We	PRP	O
have	VBP	O
recently	RB	O
shown	VBN	O
that	IN	O
total	JJ	O
TFPI	NNP	O
activity	NN	O
,	,	O
plasma	VBP	O
free	JJ	O
TFPI	NNP	O
antigen	NN	O
,	,	O
and	CC	O
heparin	NN	O
releasable	JJ	O
TFPI	NNP	O
were	VBD	O
partially	RB	O
depleted	VBN	O
during	IN	O
repeated	VBN	O
and	CC	O
continuous	JJ	O
i.v	NN	O
.	.	O

infusion	NN	O
of	IN	O
unfractionated	JJ	Pharmacological
heparin	NN	Pharmacological
(	(	O
UFH	NNP	O
)	)	O
,	,	O
but	CC	O
not	RB	O
during	IN	O
s.c.	JJ	O
treatment	NN	O
with	IN	O
a	DT	O
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
(	(	O
LMWH	NNP	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
may	MD	O
be	VB	O
attributed	VBN	O
to	TO	O
a	DT	O
different	JJ	O
mode	NN	O
of	IN	O
action	NN	O
or	CC	O
the	DT	O
different	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
randomized	VBN	O
cross-over	NN	O
study	NN	O
,	,	O
s.c.	JJ	O
administration	NN	O
of	IN	O
therapeutic	JJ	O
doses	NNS	O
of	IN	O
UFH	NNP	Pharmacological
was	VBD	O
compared	VBN	O
with	IN	O
s.c.	JJ	O
administration	NN	O
of	IN	O
two	CD	O
LMWHs	NNP	Pharmacological
.	.	O

12	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
3	CD	O
d	NN	O
with	IN	O
UFH	NNP	Pharmacological
,	,	O
250	CD	O
U/kg	NNP	O
twice	RB	O
daily	RB	O
,	,	O
dalteparin	NN	Pharmacological
,	,	O
200	CD	O
U/kg	NNP	O
once	RB	O
daily	RB	O
,	,	O
and	CC	O
enoxaparin	RB	Pharmacological
,	,	O
1.5	CD	O
mg/kg	NN	O
once	RB	O
daily	JJ	O
.	.	O

Six	CD	O
participants	NNS	O
were	VBD	O
also	RB	O
treated	VBN	O
with	IN	O
UFH	NNP	Pharmacological
,	,	O
300	CD	O
U/kg	NNP	O
once	RB	O
daily	RB	O
.	.	O

On	IN	O
day	NN	O
5	CD	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
either	DT	O
drug	NN	O
was	VBD	O
given	VBN	O
.	.	O

Peak	NNP	O
levels	NNS	O
of	IN	O
total	JJ	O
TFPI	NNP	O
activity	NN	O
and	CC	O
free	JJ	O
TFPI	NNP	O
antigen	NN	O
were	VBD	O
detected	VBN	O
1	CD	O
h	NN	O
after	IN	O
injection	NN	O
,	,	O
whereas	IN	O
maximal	JJ	O
prolongation	NN	O
of	IN	O
activated	VBN	O
partial	JJ	O
thromboplastin	NN	O
time	NN	O
(	(	O
APTT	NNP	O
)	)	O
and	CC	O
peak	JJ	O
levels	NNS	O
of	IN	O
anti-factor	JJ	O
Xa	NNP	O
activity	NN	O
and	CC	O
anti-factor	NN	O
IIa	NNP	O
activity	NN	O
were	VBD	O
detected	VBN	O
after	IN	O
4	CD	O
h.	NN	O
On	IN	O
UFH	NNP	Pharmacological
administered	VBD	O
twice	RB	O
daily	RB	O
,	,	O
free	JJ	O
TFPI	NNP	O
antigen	NN	O
decreased	VBN	O
by	IN	O
44	CD	O
%	NN	O
from	IN	O
baseline	JJ	O
level	NN	O
before	IN	O
the	DT	O
first	JJ	O
injection	NN	O
on	IN	O
day	NN	O
1	CD	O
to	TO	O
pre-injection	NN	O
level	NN	O
on	IN	O
day	NN	O
5	CD	O
.	.	O

On	IN	O
UFH	NNP	Pharmacological
administered	VBD	O
once	RB	O
daily	JJ	O
,	,	O
basal	JJ	O
free	JJ	O
TFPI	NNP	O
antigen	NN	O
decreased	VBN	O
by	IN	O
50	CD	O
%	NN	O
,	,	O
56	CD	O
%	NN	O
and	CC	O
27	CD	O
%	NN	O
on	IN	O
day	NN	O
2	CD	O
,	,	O
3	CD	O
and	CC	O
5	CD	O
respectively	RB	O
,	,	O
compared	VBN	O
with	IN	O
day	NN	O
1	CD	O
.	.	O

Minimal	JJ	O
depletion	NN	O
of	IN	O
TFPI	NNP	O
was	VBD	O
detected	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
LMWHs	NNP	O
.	.	O

The	DT	O
study	NN	O
demonstrates	VBZ	O
the	DT	O
different	JJ	O
modes	NNS	O
of	IN	O
action	NN	O
of	IN	O
LMWHs	NNP	Pharmacological
and	CC	O
UFH	NNP	Pharmacological
and	CC	O
may	MD	O
help	VB	O
to	TO	O
explain	VB	O
the	DT	O
superior	JJ	O
antithrombotic	JJ	O
efficacy	NN	O
of	IN	O
LMWHs	NNP	O
.	.	O

Extracorporeal	NNP	Physical
shock	NN	Physical
wave	NN	Physical
therapy	NN	Physical
(	(	Physical
ESWT	NNP	Physical
)	)	Physical
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
proximal	JJ	O
plantar	NN	O
fasciitis	NN	O
:	:	O
a	DT	O
2-year	JJ	O
follow-up	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
extracorporeal	NN	Physical
shock	NN	Physical
wave	VBP	Physical
therapy	NN	Physical
(	(	O
ESWT	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
chronically	RB	O
painful	JJ	O
proximal	JJ	O
plantar	NN	O
fasciitis	NN	O
with	IN	O
a	DT	O
further	JJ	O
conventional	JJ	O
conservative	JJ	O
treatment	NN	O
.	.	O

Forty-seven	JJ	O
patients	NNS	O
(	(	O
49	CD	O
feet	NNS	O
)	)	O
with	IN	O
a	DT	O
previously	RB	O
unsuccessful	JJ	O
nonsurgical	JJ	O
treatment	NN	O
of	IN	O
at	IN	O
least	JJS	O
6	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
.	.	O

Heel	NNP	Physical
cups	NNS	Physical
had	VBD	O
to	TO	O
be	VB	O
worn	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Group	NNP	O
1	CD	O
(	(	O
25	CD	O
heels	NNS	O
)	)	O
was	VBD	O
treated	VBN	O
immediately	RB	O
with	IN	O
three	CD	O
sessions	NNS	O
of	IN	O
ESWT	NNP	Physical
(	(	O
3000	CD	O
shock	NN	O
waves/session	NN	O
of	IN	O
0.2	CD	O
mJ/mm2	NN	O
)	)	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
.	.	O

The	DT	O
patients	NNS	O
of	IN	O
group	NN	O
2	CD	O
(	(	O
24	CD	O
heels	NNS	O
)	)	O
continued	VBD	O
nonsurgical	JJ	O
treatment	NN	O
(	(	O
iontophoresis	NN	Pharmacological
with	IN	Pharmacological
diclofenac	NN	Pharmacological
and	CC	O
an	DT	O
oral	JJ	O
nonsteroidal	JJ	Pharmacological
anti-inflammatory	JJ	Pharmacological
drug	NN	Pharmacological
)	)	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

After	IN	O
this	DT	O
period	NN	O
they	PRP	O
were	VBD	O
treated	VBN	O
using	VBG	O
the	DT	O
protocol	NN	O
of	IN	O
group	NN	O
1	CD	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
of	IN	O
pain	NN	O
and	CC	O
walking	NN	O
time	NN	O
after	IN	O
further	JJ	O
nonsurgical	JJ	O
treatment	NN	O
(	(	O
3	CD	O
months	NNS	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
ESWT	NNP	O
,	,	O
the	DT	O
pain	NN	O
estimation	NN	O
on	IN	O
the	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
for	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
diminished	VBN	O
significantly	RB	O
by	IN	O
62.9	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
by	IN	O
63.0	CD	O
%	NN	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

The	DT	O
comfortable	JJ	O
walking	NN	O
time	NN	O
had	VBD	O
increased	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Two	CD	O
years	NNS	O
after	IN	O
ESWT	NNP	O
,	,	O
pain	NN	O
during	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
decreased	VBN	O
by	IN	O
94	CD	O
%	NN	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
by	IN	O
90	CD	O
%	NN	O
in	IN	O
group	NN	O
2	CD	O
on	IN	O
the	DT	O
VAS	NNP	O
and	CC	O
the	DT	O
comfortable	JJ	O
walking	NN	O
time	NN	O
had	VBD	O
increased	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Chemotherapy	NN	O
of	IN	O
large	JJ	O
bowel	NN	O
carcinoma	NN	O
--	:	O
fluorouracil	NN	Pharmacological
(	(	Pharmacological
FU	NNP	Pharmacological
)	)	Pharmacological
+	VBP	O
hydroxyurea	NN	Pharmacological
(	(	Pharmacological
HU	NNP	Pharmacological
)	)	Pharmacological
vs.	FW	O
methyl-CCNU	NN	Pharmacological
,	,	O
oncovin	NN	Pharmacological
,	,	O
fluorouracil	NN	Pharmacological
,	,	O
and	CC	O
streptozotocin	NN	Pharmacological
(	(	Pharmacological
MOF-Strep	NNP	Pharmacological
)	)	Pharmacological
.	.	O

An	DT	O
Eastern	JJ	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
of	IN	O
initial	JJ	O
chemotherapy	NN	O
for	IN	O
advanced	JJ	O
measurable	JJ	O
metastatic	JJ	O
large	JJ	O
bowel	NN	O
carcinoma	NN	O
,	,	O
the	DT	O
response	NN	O
rate	NN	O
was	VBD	O
6/32	CD	O
(	(	O
19	CD	O
%	NN	O
)	)	O
for	IN	O
FU	NNP	O
+	NNP	O
HU	NNP	O
and	CC	O
5/32	CD	O
(	(	O
16	CD	O
%	NN	O
)	)	O
for	IN	O
MOF-Strep	NNP	O
;	:	O
the	DT	O
estimated	JJ	O
median	JJ	O
survival	NN	O
is	VBZ	O
43	CD	O
weeks	NNS	O
for	IN	O
both	DT	O
treatments	NNS	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
MOF-Strep	NNP	O
experienced	VBD	O
substantially	RB	O
greater	JJR	O
vomiting	VBG	O
and	CC	O
hematologic	JJ	O
toxicity	NN	O
than	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
FU	NNP	O
+	NNP	O
HU	NNP	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Hip	NNP	Physical
protectors	NNS	Physical
improve	VBP	O
falls	VBZ	O
self-efficacy	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
use	NN	O
of	IN	O
external	JJ	Physical
hip	NN	Physical
protectors	NNS	Physical
on	IN	O
subjects	NNS	O
'	POS	O
fear	NN	O
of	IN	O
falling	VBG	O
and	CC	O
falls	VBZ	O
self-efficacy	NN	O
(	(	O
belief	NN	O
in	IN	O
their	PRP$	O
own	JJ	O
ability	NN	O
to	TO	O
avoid	VB	O
falling	VBG	O
)	)	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	CC	O
Aged-care	JJ	O
health	NN	O
services	NNS	O
in	IN	O
Sydney	NNP	O
,	,	O
Australia	NNP	O
.	.	O

PARTICIPANTS	NNP	O
131	CD	O
women	NNS	O
aged	VBN	O
75	CD	O
years	NNS	O
or	CC	O
older	JJR	O
,	,	O
who	WP	O
had	VBD	O
two	CD	O
or	CC	O
more	JJR	O
falls	NNS	O
or	CC	O
one	CD	O
fall	NN	O
requiring	VBG	O
hospital	JJ	O
admission	NN	O
in	IN	O
the	DT	O
previous	JJ	O
year	NN	O
and	CC	O
who	WP	O
live	VBP	O
at	IN	O
home	NN	O
.	.	O

Sixty-one	JJ	O
subjects	NNS	O
were	VBD	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
and	CC	O
70	CD	O
in	IN	O
the	DT	O
control	NN	Control
group	NN	O
.	.	O

INTERVENTION	NNP	O
Use	NNP	O
of	IN	O
external	JJ	Physical
hip	NN	Physical
protectors	NNS	Physical
and	CC	O
encouragement	NN	Physical
to	TO	Physical
use	VB	Physical
the	DT	Physical
protectors	NNS	Physical
by	IN	Physical
an	DT	Physical
adherence	NN	Physical
nurse	NN	Physical
.	.	O

MEASUREMENTS	CC	O
At	IN	O
the	DT	O
time	NN	O
of	IN	O
enrolment	NN	O
into	IN	O
a	DT	O
wider	NN	O
study	NN	O
examining	VBG	O
the	DT	O
effect	NN	O
of	IN	O
hip	NN	Physical
protectors	NNS	Physical
on	IN	O
hip	NN	O
fractures	NNS	O
,	,	O
participants	NNS	O
recruited	VBD	O
at	IN	O
home	NN	O
completed	VBD	O
an	DT	O
assessment	NN	O
of	IN	O
fear	NN	O
of	IN	O
falling	VBG	O
and	CC	O
falls	VBZ	O
efficacy	NN	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Modified	NNP	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
.	.	O

At	IN	O
4-month	JJ	O
follow-up	NN	O
,	,	O
these	DT	O
scales	NNS	O
were	VBD	O
readministered	VBN	O
by	IN	O
an	DT	O
observer	NN	O
who	WP	O
was	VBD	O
not	RB	O
aware	JJ	O
of	IN	O
the	DT	O
allocation	NN	O
of	IN	O
the	DT	O
participant	NN	O
to	TO	O
intervention	NN	O
or	CC	O
control	NN	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Fear	NNP	O
of	IN	O
falling	VBG	O
and	CC	O
falls	VBZ	O
self-efficacy	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Falls	NNP	O
Efficacy	NNP	O
and	CC	O
Modified	NNP	O
Falls	NNP	O
Efficacy	NNP	O
Scales	NNP	O
,	,	O
were	VBD	O
similar	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Fear	NN	O
of	IN	O
falling	VBG	O
was	VBD	O
present	JJ	O
at	IN	O
follow-up	NN	O
in	IN	O
43	CD	O
%	NN	O
of	IN	O
subjects	NNS	O
using	VBG	O
hip	NN	O
protectors	NNS	O
and	CC	O
57	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
chi2	JJ	O
=	NN	O
2.58	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.11	CD	O
)	)	O
.	.	O

Hip	NNP	Physical
protector	NN	Physical
users	NNS	O
had	VBD	O
greater	JJR	O
improvement	NN	O
in	IN	O
falls	VBZ	O
self-efficacy	NN	O
at	IN	O
follow-up	JJ	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
(	(	O
t	JJ	O
=	NN	O
2.44	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.016	CD	O
)	)	O
and	CC	O
the	DT	O
Modified	NNP	O
Falls	NNP	O
Efficacy	NNP	O
Scale	NNP	O
(	(	O
t	JJ	O
=	NN	O
2.08	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Hip	NNP	Physical
protectors	NNS	Physical
improve	VBP	O
falls	VBZ	O
self-efficacy	NN	O
.	.	O

As	IN	O
users	NNS	O
of	IN	O
hip	NN	Physical
protectors	NNS	Physical
feel	VBP	O
more	RBR	O
confident	JJ	O
that	IN	O
they	PRP	O
can	MD	O
complete	VB	O
tasks	NNS	O
safely	RB	O
,	,	O
they	PRP	O
may	MD	O
become	VB	O
more	RBR	O
physically	RB	O
active	JJ	O
and	CC	O
require	VB	O
less	JJR	O
assistance	NN	O
with	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
.	.	O

B-domain	NNP	Pharmacological
deleted	VBD	Pharmacological
recombinant	JJ	Pharmacological
factor	NN	Pharmacological
VIII	NNP	Pharmacological
preparations	NNS	Pharmacological
are	VBP	O
bioequivalent	JJ	O
to	TO	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
purified	VBD	O
plasma-derived	JJ	O
factor	NN	O
VIII	NNP	O
concentrate	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
three-way	JJ	O
crossover	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Deletion	NNP	O
of	IN	O
the	DT	O
B-domain	NNP	O
of	IN	O
recombinant	JJ	O
blood	NN	O
coagulation	NN	O
factor	NN	O
VIII	NNP	O
(	(	O
BDDrFVIII	NNP	O
)	)	O
increases	VBZ	O
the	DT	O
manufacturing	VBG	O
yield	NN	O
of	IN	O
the	DT	O
product	NN	O
but	CC	O
does	VBZ	O
not	RB	O
impair	VB	O
in	IN	O
vitro	NN	O
or	CC	O
in	IN	O
vivo	JJ	O
functionality	NN	O
.	.	O

BDDrFVIII	NNP	O
(	(	O
ReFacto	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
developed	VBN	O
with	IN	O
the	DT	O
additional	JJ	O
benefit	NN	O
of	IN	O
being	VBG	O
formulated	VBN	O
without	IN	O
human	JJ	O
albumin	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
primary	JJ	O
objective	NN	O
of	IN	O
this	DT	O
three-way	JJ	O
crossover-design	NN	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
pharmacokinetic	JJ	O
(	(	O
PK	NNP	O
)	)	O
parameters	NNS	O
of	IN	O
two	CD	O
BDDrFVIII	NNP	Pharmacological
formulations	NNS	Pharmacological
(	(	O
one	CD	O
reconstituted	VBN	O
with	IN	O
5	CD	O
mL	NNS	O
of	IN	O
sterile	JJ	O
water	NN	O
,	,	O
the	DT	O
other	JJ	O
reconstituted	VBD	O
with	IN	O
4	CD	O
mL	NNS	O
sodium	JJ	O
chloride	RB	O
0.9	CD	O
%	NN	O
USP	NNP	O
)	)	O
with	IN	O
those	DT	O
of	IN	O
a	DT	O
plasma-derived	JJ	O
,	,	O
full-length	JJ	Pharmacological
FVIII	NNP	Pharmacological
preparation	NN	Pharmacological
(	(	Pharmacological
Hemofil	NNP	Pharmacological
M	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
haemophilia	PDT	O
A	DT	O
to	TO	O
determine	VB	O
bioequivalence	NN	O
.	.	O

METHODS	VB	O
A	NNP	O
series	NN	O
of	IN	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
48	CD	O
h	NN	O
after	IN	O
i.v	NN	O
.	.	O

administration	NN	O
of	IN	O
each	DT	O
of	IN	O
the	DT	O
FVIII	NNP	Pharmacological
preparations	NNS	Pharmacological
.	.	Pharmacological

Plasma	NNP	O
FVIII	NNP	O
activity	NN	O
was	VBD	O
determined	VBN	O
using	VBG	O
a	DT	O
validated	JJ	O
chromogenic	JJ	O
substrate	NN	O
assay	NN	O
.	.	O

Plasma	NNP	O
FVIII	NNP	O
activity	NN	O
vs.	FW	O
time	NN	O
curves	NNS	O
was	VBD	O
characterized	VBN	O
for	IN	O
a	DT	O
standard	JJ	O
set	NN	O
of	IN	O
PK	NNP	O
parameter	NN	O
estimates	NNS	O
.	.	O

Two	CD	O
parameter	NN	O
estimates	NNS	O
,	,	O
the	DT	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
and	CC	O
the	DT	O
area	NN	O
under	IN	O
plasma	JJ	O
concentration	NN	O
vs.	FW	O
time	NN	O
curves	NNS	O
(	(	O
AUCs	NNP	O
)	)	O
,	,	O
were	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
bioequivalence	NN	O
.	.	O

The	DT	O
two	CD	O
preparations	NNS	O
were	VBD	O
considered	VBN	O
bioequivalent	NN	O
if	IN	O
the	DT	O
90	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
for	IN	O
the	DT	O
ratio	NN	O
of	IN	O
geometric	JJ	O
means	NNS	O
for	IN	O
Cmax	NNP	O
and	CC	O
AUCs	NNP	O
fell	VBD	O
within	IN	O
the	DT	O
bioequivalence	NN	O
window	NN	O
of	IN	O
80	CD	O
%	NN	O
to	TO	O
125	CD	O
%	NN	O
.	.	O

RESULTS/CONCLUSION	NNP	O
Results	NNP	O
show	VBP	O
that	IN	O
each	DT	O
BDDrFVIII	NNP	Pharmacological
formulation	NN	Pharmacological
is	VBZ	O
bioequivalent	JJ	O
to	TO	O
Hemofil	NNP	O
M	NNP	O
and	CC	O
the	DT	O
two	CD	O
formulations	NNS	O
of	IN	O
BDDrFVIII	NNP	O
are	VBP	O
bioequivalent	JJ	O
to	TO	O
each	DT	O
other	JJ	O
.	.	O

Nutritional	JJ	O
orientation	NN	O
,	,	O
knowledge	NN	O
and	CC	O
quality	NN	O
of	IN	O
diet	NN	O
in	IN	O
heart	NN	O
failure	NN	O
:	:	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Non-pharmacological	JJ	O
measures	NNS	O
are	VBP	O
recommended	VBN	O
for	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
.	.	O

However	RB	O
,	,	O
most	JJS	O
studies	NNS	O
evaluate	VBP	O
low	JJ	O
sodium	NN	O
diet	NN	O
,	,	O
while	IN	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
effects	NNS	O
of	IN	O
interventions	NNS	O
to	TO	O
improve	VB	O
adherence	NN	O
and	CC	O
knowledge	NN	O
of	IN	O
patients	NNS	O
about	IN	O
diet	JJ	O
content	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
if	IN	O
a	DT	O
global	JJ	O
nutritional	JJ	Educational
orientation	NN	Educational
could	MD	O
affect	VB	O
nutritional	JJ	O
knowledge	NN	O
,	,	O
adherence	NN	O
to	TO	O
food	NN	O
guidelines	NNS	O
,	,	O
anthropometrics	NNS	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
six	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
intervention	VB	O
or	CC	O
control	VB	O
group	NN	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
usual	JJ	Educational
care	NN	Educational
with	IN	Educational
medical	JJ	Educational
and	CC	Educational
nursing	JJ	Educational
staff	NN	Educational
;	:	Educational
the	DT	Educational
intervention	NN	Educational
group	NN	Educational
received	VBD	Educational
additional	JJ	Educational
nutritional	JJ	Educational
guidance	NN	Educational
about	IN	Educational
diet	JJ	Educational
and	CC	Educational
its	PRP$	Educational
relationship	NN	Educational
with	IN	Educational
disease	NN	Educational
,	,	Educational
sources	NNS	Educational
of	IN	Educational
nutrients	NNS	Educational
,	,	Educational
and	CC	Educational
reduction	NN	Educational
of	IN	Educational
dietary	JJ	Educational
sodium	NN	Educational
and	CC	Educational
fats	NNS	Educational
.	.	Educational

Enforcement	NN	Physical
of	IN	Physical
the	DT	Physical
nutritional	JJ	Physical
guidance	NN	Physical
was	VBD	O
performed	VBN	O
after	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
baseline	NN	O
,	,	O
and	CC	O
after	IN	O
6	CD	O
weeks	NNS	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

Evaluations	NNS	O
included	VBD	O
anthropometric	JJ	O
parameters	NNS	O
,	,	O
sodium	NN	O
excretion	NN	O
in	IN	O
24-hour	JJ	O
urine	NN	O
,	,	O
dietary	JJ	O
recall	NN	O
,	,	O
nutrition	NN	O
knowledge	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
age	NN	O
of	IN	O
included	JJ	O
patients	NNS	O
was	VBD	O
58	CD	O
?	.	O
10	CD	O
years	NNS	O
and	CC	O
70	CD	O
%	NN	O
were	VBD	O
male	JJ	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
the	DT	O
nutritional	JJ	O
knowledge	NN	O
of	IN	O
intervention	NN	O
group	NN	O
increased	VBD	O
compared	VBN	O
to	TO	O
control	VB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Caloric	NNP	O
,	,	O
fat	NN	O
and	CC	O
sodium	NN	O
intake	NN	O
decreased	VBN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
compared	VBN	O
to	TO	O
control	VB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
or	CC	O
anthropometric	JJ	O
parameters	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Nutritional	NNP	Physical
orientation	NN	Physical
was	VBD	O
effective	JJ	O
to	TO	O
modify	VB	O
1	CD	O
)	)	O
knowledge	NN	O
about	IN	O
food	NN	O
and	CC	O
nutrition	NN	O
,	,	O
and	CC	O
2	CD	O
)	)	O
quality	NN	O
of	IN	O
diet	NN	O
in	IN	O
outpatients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
are	VBP	O
necessary	JJ	O
to	TO	O
evaluate	VB	O
the	DT	O
benefits	NNS	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
prognosis	NN	O
.	.	O

Double-blind	NNP	O
randomized	JJ	O
evaluation	NN	O
of	IN	O
intercostal	JJ	Pharmacological
nerve	NN	Pharmacological
blocks	NNS	Pharmacological
as	IN	O
an	DT	O
adjuvant	NN	O
to	TO	O
subarachnoid	VB	O
administered	JJ	O
morphine	NN	Pharmacological
for	IN	O
post-thoracotomy	JJ	O
analgesia	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVES	NNP	O
Thoracotomy	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
pain	NN	O
and	CC	O
compromised	VBD	O
pulmonary	JJ	O
function	NN	O
.	.	O

Intercostal	NNP	Pharmacological
nerve	NN	Pharmacological
blocks	NNS	Pharmacological
(	(	Pharmacological
INB	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
subarachnoid	JJ	Pharmacological
morphine	NN	Pharmacological
(	(	Pharmacological
SM	NNP	Pharmacological
)	)	Pharmacological
act	NN	O
on	IN	O
different	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
pain	NN	O
pathway	RB	O
.	.	O

Each	DT	O
is	VBZ	O
effective	JJ	O
for	IN	O
post-thoracotomy	JJ	O
pain	NN	O
relief	NN	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
these	DT	O
two	CD	O
modalities	NNS	O
in	IN	O
relieving	VBG	O
post-thoracotomy	JJ	O
pain	NN	O
and	CC	O
improving	VBG	O
postoperative	JJ	O
pulmonary	JJ	O
function	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	NN	O
study	NN	O
,	,	O
20	CD	O
patients	NNS	O
undergoing	JJ	O
lateral	JJ	O
thoracotomy	NN	Surgical
for	IN	O
lung	NN	O
resection	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
0.5	CD	O
mg	NN	O
SM	NNP	Pharmacological
preoperatively	RB	O
and	CC	O
INB	NNP	Pharmacological
with	IN	O
bupivacaine	NN	Pharmacological
(	(	Pharmacological
INB+	NNP	Pharmacological
)	)	Pharmacological
prior	RB	O
to	TO	O
wound	VB	O
closure	NN	O
or	CC	O
0.5	CD	O
mg	NNS	O
SM	NNP	Pharmacological
with	IN	O
INB	NNP	Pharmacological
using	VBG	O
saline	NN	Control
(	(	O
INB-	NNP	O
)	)	O
.	.	O

Visual	JJ	O
analog	NN	O
scale	NN	O
pain	NN	O
scores	NNS	O
at	IN	O
rest	NN	O
,	,	O
with	IN	O
cough	NN	O
,	,	O
and	CC	O
with	IN	O
movement	NN	O
of	IN	O
the	DT	O
ipsilateral	JJ	O
arm	NN	O
,	,	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
1	CD	O
second	JJ	O
(	(	O
FEV1	NNP	O
)	)	O
,	,	O
and	CC	O
forced	VBD	O
vital	JJ	O
capacity	NN	O
(	(	O
FVC	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
4	CD	O
,	,	O
24	CD	O
,	,	O
48	CD	O
,	,	O
and	CC	O
72	CD	O
hours	NNS	O
after	IN	O
the	DT	O
operation	NN	O
.	.	O

Opioid	NNP	O
use	NN	O
was	VBD	O
measured	VBN	O
during	IN	O
the	DT	O
initial	JJ	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
operation	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
4	CD	O
hours	NNS	O
,	,	O
the	DT	O
INB+	NNP	Pharmacological
group	NN	O
demonstrated	VBD	O
better	JJR	O
FEV1	NNP	O
(	(	O
56.6	CD	O
%	NN	O
vs.	FW	O
40.4	CD	O
%	NN	O
of	IN	O
baseline	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
FVC	NNP	O
values	NNS	O
(	(	O
54.6	CD	O
%	NN	O
vs.	FW	O
39.6	CD	O
%	NN	O
of	IN	O
baseline	NN	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
less	RBR	O
resting	VBG	O
and	CC	O
cough	JJ	O
pain	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
FEV1	NNP	O
continued	VBD	O
to	TO	O
decline	VB	O
in	IN	O
the	DT	O
INB+	NNP	Pharmacological
group	NN	O
at	IN	O
24	CD	O
hours	NNS	O
to	TO	O
lower	JJR	O
than	IN	O
the	DT	O
INB-	NNP	Pharmacological
group	NN	O
although	IN	O
pain	NN	O
scores	NNS	O
were	VBD	O
similar	JJ	O
beyond	IN	O
4	CD	O
hours	NNS	O
.	.	O

Opioid	JJ	O
usage	NN	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
was	VBD	O
similar	JJ	O
(	(	Pharmacological
INB-	NNP	Pharmacological
,	,	O
16.7	CD	O
mg	NN	O
vs.	FW	O
INB+	NNP	Pharmacological
,	,	O
13.2	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
.7	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
postoperative	JJ	O
INB	NNP	Pharmacological
provided	VBD	O
modest	JJ	O
improvements	NNS	O
in	IN	O
pain	NN	O
and	CC	O
pulmonary	JJ	O
function	NN	O
when	WRB	O
used	VBN	O
as	IN	O
an	DT	O
adjuvant	NN	O
to	TO	O
0.5	CD	O
mg	NNS	O
SM	NNP	Pharmacological
for	IN	O
post-thoracotomy	JJ	O
analgesia	NN	O
,	,	O
the	DT	O
benefits	NNS	O
were	VBD	O
transient	JJ	O
.	.	O

The	DT	O
authors	NNS	O
do	VBP	O
not	RB	O
recommend	VB	O
adding	VBG	O
INB	NNP	Pharmacological
for	IN	O
patients	NNS	O
undergoing	JJ	O
lateral	JJ	O
thoracotomy	NN	O
who	WP	O
receive	VBP	O
0.5	CD	O
mg	NN	O
SM	NNP	Pharmacological
.	.	Pharmacological

Social	JJ	Educational
support	NN	Educational
and	CC	O
abstinence	NN	Educational
from	IN	O
opiates	NNS	O
and	CC	O
cocaine	NN	O
during	IN	O
opioid	JJ	Pharmacological
maintenance	NN	Pharmacological
treatment	NN	Pharmacological
.	.	O

Social	NNP	Educational
support	NN	Educational
may	MD	O
play	VB	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
helping	VBG	O
drug	NN	O
users	NNS	O
achieve	VBP	O
abstinence	NN	O
;	:	O
however	RB	O
these	DT	O
benefits	NNS	O
may	MD	O
depend	VB	O
on	IN	O
the	DT	O
type	NN	O
of	IN	O
support	NN	O
experienced	VBN	O
.	.	O

In	IN	O
this	DT	O
prospective	JJ	O
observational	NN	O
study	NN	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
general	JJ	Educational
and	CC	Educational
abstinence-specific	JJ	Educational
support	NN	Educational
,	,	Educational
both	DT	Educational
structural	JJ	Educational
and	CC	Educational
functional	JJ	Educational
,	,	O
predicted	JJ	O
opiate	NN	O
and	CC	O
cocaine	NN	O
abstinence	NN	O
in	IN	O
128	CD	O
opioid	JJ	O
maintenance	NN	O
patients	NNS	O
receiving	VBG	O
either	CC	O
methadone	NN	Pharmacological
or	CC	O
LAAM	NNP	Pharmacological
.	.	O

A	DT	O
new	JJ	O
multidimensional	JJ	O
self-report	NN	O
instrument	NN	O
assessing	VBG	O
abstinence-specific	JJ	Educational
functional	JJ	O
support	NN	O
was	VBD	O
developed	VBN	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Previously	RB	O
validated	VBN	O
measures	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
remaining	VBG	O
types	NNS	O
of	IN	O
support	NN	O
.	.	O

With	IN	O
baseline	JJ	O
abstinence	NN	O
and	CC	O
other	JJ	O
statistically	RB	O
important	JJ	O
covariates	NNS	O
adjusted	VBN	O
,	,	O
hierarchical	JJ	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
demonstrated	VBD	O
that	IN	O
the	DT	O
associations	NNS	O
between	IN	O
social	JJ	O
support	NN	O
at	IN	O
study	NN	O
baseline	NN	O
and	CC	O
biochemically	RB	O
confirmed	VBN	O
abstinence	NN	O
3	CD	O
months	NNS	O
later	RB	O
varied	VBN	O
by	IN	O
type	NN	O
of	IN	O
support	NN	O
and	CC	O
by	IN	O
drug	NN	O
.	.	O

Greater	NNP	O
abstinence-specific	JJ	Educational
structural	JJ	O
support	NN	O
(	(	O
operationalized	VBN	O
as	IN	O
fewer	JJR	O
drug	NN	O
users	NNS	O
in	IN	O
the	DT	O
social	JJ	O
network	NN	O
)	)	O
and	CC	O
decreases	VBZ	O
in	IN	O
three	CD	O
types	NNS	O
of	IN	O
negative	JJ	O
abstinence-specific	JJ	Educational
functional	JJ	O
support	NN	O
(	(	O
Complaints	NNS	O
about	IN	O
Drug	NNP	O
Use	NNP	O
,	,	O
Drug	NNP	O
Exposure	NNP	O
,	,	O
and	CC	O
Demoralization	NNP	O
)	)	O
predicted	VBD	O
cocaine	NN	O
,	,	O
but	CC	O
not	RB	O
opiate	JJ	O
abstinence	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
effects	NNS	O
for	IN	O
general	JJ	O
support	NN	O
,	,	O
whether	IN	O
structural	JJ	O
or	CC	O
functional	JJ	O
,	,	O
on	IN	O
abstinence	NN	O
from	IN	O
either	DT	O
drug	NN	O
.	.	O

Interventions	NNS	O
that	WDT	O
focus	VBP	O
on	IN	O
modifying	VBG	O
patients	NNS	O
'	POS	O
abstinence-specific	JJ	Educational
support	NN	O
may	MD	O
be	VB	O
helpful	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
high	JJ	O
rates	NNS	O
of	IN	O
cocaine	NN	O
use	NN	O
disorders	NNS	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Salbutamol	NNP	Pharmacological
or	CC	O
mist	NN	Pharmacological
in	IN	O
acute	JJ	O
bronchiolitis	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
role	NN	O
of	IN	O
bronchodilators	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bronchiolitis	NN	O
remains	VBZ	O
controversial	JJ	O
.	.	O

METHODS	VB	O
A	DT	O
double-blind	NN	O
,	,	O
placebo	NN	O
controlled	VBD	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
clinical	JJ	O
response	NN	O
to	TO	O
nebulized	VBN	O
salbutamol	NN	Pharmacological
.	.	Pharmacological

One	CD	O
hundred	CD	O
and	CC	O
fifty-six	JJ	O
infants	NNS	O
aged	VBN	O
between	IN	O
7	CD	O
weeks	NNS	O
and	CC	O
24	CD	O
months	NNS	O
who	WP	O
had	VBD	O
had	VBN	O
an	DT	O
episode	NN	O
of	IN	O
wheezing	NN	O
and	CC	O
other	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
bronchiolitis	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
as	IN	O
follows	VBZ	O
:	:	O
(	(	O
i	NN	O
)	)	O
nebulized	VBD	Pharmacological
salbutamol	NN	Pharmacological
was	VBD	O
administered	VBN	O
to	TO	O
52	CD	O
patients	NNS	O
in	IN	O
group	NN	O
I	PRP	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.15	CD	O
mg/kg	NNS	O
in	IN	O
2	CD	O
mL	JJ	O
saline	NN	Control
;	:	Control
(	(	O
ii	NN	O
)	)	O
saline	NN	Control
was	VBD	O
nebulized	VBN	O
to	TO	O
52	CD	O
patients	NNS	O
in	IN	O
group	NN	O
II	NNP	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
in	IN	O
group	NN	O
III	NNP	O
52	CD	O
patients	NNS	O
received	JJ	O
mist	NN	Pharmacological
in	IN	O
a	DT	O
tent	NN	O
.	.	O

All	DT	O
three	CD	O
groups	NNS	O
were	VBD	O
administered	VBN	O
oxygen	NN	Pharmacological
during	IN	O
the	DT	O
procedures	NNS	O
.	.	O

Treatment	NNP	O
was	VBD	O
repeated	VBN	O
with	IN	O
the	DT	O
same	JJ	O
agent	NN	O
after	IN	O
30	CD	O
min	NN	O
if	IN	O
the	DT	O
respiratory	NN	O
score	NN	O
was	VBD	O
5	CD	O
or	CC	O
more	JJR	O
.	.	O

Respiratory	JJ	O
rate	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
oxygen	NN	O
saturation	NN	O
and	CC	O
presence	NN	O
of	IN	O
cyanosis	NN	O
,	,	O
wheezing	VBG	O
,	,	O
retractions	NNS	O
were	VBD	O
recorded	VBN	O
before	IN	O
and	CC	O
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
decrease	NN	O
in	IN	O
the	DT	O
respiratory	NN	O
score	NN	O
was	VBD	O
5.2	CD	O
+/-	JJ	O
1.8	CD	O
,	,	O
0.82	CD	O
+/-	JJ	O
2.4	CD	O
and	CC	O
1.7	CD	O
+/-	JJ	O
1.3	CD	O
in	IN	O
group	NN	O
I	PRP	O
,	,	O
II	NNP	O
and	CC	O
III	NNP	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
group	NN	O
I	PRP	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
in	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
.	.	O

Heart	NNP	O
rate	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

Oxygen	NNP	O
saturation	NN	O
decreased	VBD	O
in	IN	O
group	NN	O
I	PRP	O
without	IN	O
reaching	VBG	O
statistical	JJ	O
significance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Salbutamol	NNP	Pharmacological
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
and	CC	O
safe	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
bronchiolitis	NN	O
.	.	O

Enhanced	NNP	Educational
small	JJ	Educational
group	NN	Educational
instruction	NN	Educational
using	VBG	Educational
choral	JJ	Educational
responding	NN	Educational
and	CC	Educational
student	NN	Educational
interaction	NN	Educational
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
effective	JJ	Educational
instructional	JJ	Educational
strategies	NNS	Educational
in	IN	O
small	JJ	O
groups	NNS	O
was	VBD	O
investigated	VBN	O
to	TO	O
determine	VB	O
learning	JJ	O
effects	NNS	O
for	IN	O
24	CD	O
elementary	JJ	O
age	NN	O
students	NNS	O
with	IN	O
autism	NN	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
.	.	O

Effective	JJ	O
strategies	NNS	O
included	VBD	O
(	(	O
a	DT	O
)	)	O
the	DT	Educational
use	NN	Educational
of	IN	Educational
choral	JJ	Educational
responding	NN	Educational
;	:	Educational
(	(	O
b	NN	O
)	)	O
the	DT	Educational
use	NN	Educational
of	IN	Educational
student-to-student	JJ	Educational
responding	NN	Educational
;	:	Educational
(	(	O
c	NN	O
)	)	O
the	DT	Educational
rotation	NN	Educational
of	IN	Educational
materials	NNS	Educational
every	DT	Educational
5	CD	Educational
minutes	NNS	Educational
during	IN	Educational
the	DT	Educational
30-minute	JJ	Educational
group	NN	Educational
while	IN	Educational
teaching	VBG	Educational
2	CD	Educational
to	TO	Educational
3	CD	Educational
concepts	NNS	Educational
;	:	Educational
and	CC	Educational
(	(	O
d	NN	O
)	)	O
the	DT	Educational
use	NN	Educational
of	IN	Educational
random	NN	Educational
,	,	Educational
unpredictable	JJ	Educational
trials	NNS	Educational
for	IN	Educational
student	NN	Educational
responding	VBG	Educational
.	.	Educational

Thirty-minute	JJ	O
language	NN	O
groups	NNS	O
were	VBD	O
targeted	VBN	O
to	TO	O
teach	VB	O
receptive	JJ	O
and	CC	O
expressive	JJ	O
skills	NNS	O
using	VBG	O
pictures	NNS	O
and	CC	O
common	JJ	O
objects	NNS	O
across	IN	O
five	CD	O
categories	NNS	O
(	(	O
e.g.	NN	O
,	,	O
household	NN	O
items	NNS	O
,	,	O
foods	NNS	O
)	)	O
.	.	O

Results	JJ	O
showed	VBD	O
increased	JJ	O
opportunities	NNS	O
to	TO	O
respond	VB	O
,	,	O
increased	JJ	O
levels	NNS	O
of	IN	O
responding	VBG	O
and	CC	O
academic	JJ	O
engagement	NN	O
,	,	O
higher	JJR	O
gains	NNS	O
on	IN	O
weekly	JJ	O
criterion-referenced	JJ	O
pre-	NN	O
and	CC	O
posttests	NNS	O
,	,	O
and	CC	O
decreased	VBD	O
passive	JJ	O
and	CC	O
inappropriate	JJ	O
student	NN	O
behavior	NN	O
during	IN	O
interventions	NNS	O
.	.	O

Enhancing	VBG	O
the	DT	O
self-esteem	NN	O
of	IN	O
inpatient	JJ	O
alcoholics	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
pairing	VBG	O
inpatient	JJ	O
alcoholics	NNS	O
with	IN	O
nursing	NN	Other
home	NN	Other
residents	NNS	Other
(	(	Other
NHRs	NNP	Other
)	)	Other
on	IN	O
the	DT	O
alcoholics	NNS	O
'	POS	O
self-esteem	NN	O
.	.	O

In	IN	O
this	DT	O
PALS	NNP	O
program	NN	O
,	,	O
the	DT	O
alcoholic	JJ	O
inpatients	NNS	O
assumed	VBD	O
a	DT	O
helping-companion	NN	O
relationship	NN	O
with	IN	O
the	DT	O
NHRs	NNP	O
for	IN	O
2	CD	O
hr	NNS	O
per	IN	O
day	NN	O
during	IN	O
their	PRP$	O
last	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Fifty	NNP	O
alcoholic	JJ	O
inpatients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
PALS	NNP	Psychological
program	NN	Psychological
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
or	CC	O
to	TO	O
the	DT	O
library	NN	Psychological
for	IN	Psychological
free	JJ	Psychological
reading	NN	Psychological
time	NN	Psychological
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
.	.	O

The	DT	O
Tennessee	NNP	O
Self-Concept	NNP	O
Scale	NNP	O
(	(	O
TSCS	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
to	TO	O
all	DT	O
subjects	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
interventions	NNS	O
.	.	O

Of	IN	O
the	DT	O
nine	CD	O
TSCS	NNP	O
scales	NNS	O
,	,	O
the	DT	O
improvement	NN	O
on	IN	O
the	DT	O
Moral-Ethical	JJ	O
scale	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
PALS	NNP	O
group	NN	O
.	.	O

Because	IN	O
the	DT	O
alcoholic	JJ	O
inpatients	NNS	O
in	IN	O
the	DT	O
PALS	NNP	O
group	NN	O
engaged	VBD	O
in	IN	O
altruistic	JJ	O
(	(	O
moral	JJ	O
)	)	O
behavior	NN	O
,	,	O
this	DT	O
study	NN	O
provides	VBZ	O
a	DT	O
logical	JJ	O
link	NN	O
between	IN	O
the	DT	O
intervention	NN	O
and	CC	O
the	DT	O
outcome	NN	O
,	,	O
which	WDT	O
has	VBZ	O
been	VBN	O
a	DT	O
prevalent	JJ	O
weakness	NN	O
in	IN	O
previous	JJ	O
studies	NNS	O
of	IN	O
self-esteem	NN	O
in	IN	O
alcoholics	NNS	O
.	.	O

Cyclosporin	NNP	Pharmacological
versus	NN	O
cyclophosphamide	NN	Pharmacological
for	IN	O
patients	NNS	O
with	IN	O
steroid-dependent	JJ	O
and	CC	O
frequently	RB	O
relapsing	VBG	O
idiopathic	JJ	O
nephrotic	JJ	O
syndrome	NN	O
:	:	O
a	DT	O
multicentre	NN	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
(	(	O
maintenance	NN	O
of	IN	O
remission	NN	O
)	)	O
,	,	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
cyclosporin	NN	Pharmacological
(	(	Pharmacological
CsA	NNP	Pharmacological
)	)	Pharmacological
with	IN	O
those	DT	O
of	IN	O
cyclophosphamide	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
steroid-dependent	JJ	O
or	CC	O
frequently	RB	O
relapsing	VBG	O
nephrotic	JJ	O
syndrome	NN	O
(	(	O
NS	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Open	NNP	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicentre	FW	O
,	,	O
controlled	VBD	O
study	NN	O
for	IN	O
parallel	JJ	O
groups	NNS	O
,	,	O
stratified	VBN	O
for	IN	O
adults	NNS	O
and	CC	O
children	NNS	O
.	.	O

The	DT	O
setting	NN	O
was	VBD	O
in	IN	O
nephrological	JJ	O
departments	NNS	O
in	IN	O
Italy	NNP	O
.	.	O

SUBJECTS	NNP	O
AND	CC	O
INTERVENTIONS	NNP	O
Seventy-three	JJ	O
patients	NNS	O
with	IN	O
steroid-sensitive	JJ	O
idiopathic	JJ	O
NS	NNP	O
admitted	VBD	O
to	TO	O
the	DT	O
study	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
cyclophosphamide	VB	Pharmacological
(	(	O
2.5	CD	O
mg/kg/day	NN	O
)	)	O
for	IN	O
8	CD	O
weeks	NNS	O
or	CC	O
CsA	NNP	Pharmacological
(	(	O
5	CD	O
mg/kg/day	NN	O
in	IN	O
adults	NNS	O
,	,	O
6	CD	O
mg/kg/day	NN	O
in	IN	O
children	NNS	O
)	)	O
for	IN	O
9	CD	O
months	NNS	O
,	,	O
tapered	VBD	O
off	RP	O
by	IN	O
25	CD	O
%	NN	O
every	DT	O
month	NN	O
until	IN	O
complete	JJ	O
discontinuation	NN	O
at	IN	O
month	NN	O
12	CD	O
.	.	O

Seven	CD	O
patients	NNS	O
lost	VBN	O
to	TO	O
follow	VB	O
up	RP	O
were	VBD	O
not	RB	O
considered	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
.	.	O

The	DT	O
remaining	VBG	O
66	CD	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
3-24	JJ	O
months	NNS	O
after	IN	O
randomization	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Relapse-free	NNP	O
survival	NN	O
;	:	O
number	NN	O
of	IN	O
N.S	NNP	O
.	.	O

relapses/patient/year	NN	O
;	:	O
cumulative	JJ	O
dose	NN	O
of	IN	O
prednisone/patient	NN	O
;	:	O
laboratory	JJ	O
investigations	NNS	O
(	(	O
kidney	NN	O
and	CC	O
liver	NN	O
functions	NNS	O
,	,	O
haematological	JJ	O
parameters	NNS	O
)	)	O
;	:	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
month	NN	O
9	CD	O
,	,	O
26	CD	O
of	IN	O
35	CD	O
CsA-treated	JJ	O
patients	NNS	O
were	VBD	O
still	RB	O
in	IN	O
complete	JJ	O
remission	NN	O
and	CC	O
a	DT	O
further	JJ	O
five	CD	O
patients	NNS	O
were	VBD	O
in	IN	O
partial	JJ	O
remission	NN	O
;	:	O
18	CD	O
of	IN	O
28	CD	O
cyclophosphamide-treated	JJ	Pharmacological
patients	NNS	O
were	VBD	O
in	IN	O
complete	JJ	O
remission	NN	O
,	,	O
and	CC	O
one	CD	O
in	IN	O
partial	JJ	O
remission	NN	O
(	(	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
between	IN	O
adults	NNS	O
and	CC	O
children	NNS	O
was	VBD	O
seen	VBN	O
with	IN	O
either	DT	O
treatment	NN	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
relapse	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
frequent	JJ	O
relapsers	NNS	O
(	(	O
19	CD	O
of	IN	O
22	CD	O
)	)	O
and	CC	O
steroid-dependent	JJ	O
patients	NNS	O
(	(	O
8	CD	O
of	IN	O
14	CD	O
)	)	O
given	VBN	O
CsA	NNP	O
,	,	O
and	CC	O
those	DT	O
given	VBN	O
cyclophosphamide	NN	Pharmacological
(	(	O
5	CD	O
of	IN	O
15	CD	O
and	CC	O
6	CD	O
of	IN	O
15	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
relapses	NNS	O
per	IN	O
year	NN	O
and	CC	O
the	DT	O
mean	NN	O
dose	NN	O
of	IN	O
prednisone	NN	O
per	IN	O
year	NN	O
were	VBD	O
significantly	RB	O
less	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
both	DT	O
groups	NNS	O
for	IN	O
the	DT	O
experimental	JJ	O
year	NN	O
than	IN	O
for	IN	O
the	DT	O
year	NN	O
before	IN	O
randomization	NN	O
.	.	O

At	IN	O
2	CD	O
years	NNS	O
,	,	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
given	VBN	O
CsA	NNP	Pharmacological
(	(	O
50	CD	O
%	NN	O
adults	NNS	O
and	CC	O
20	CD	O
%	NN	O
children	NNS	O
)	)	O
and	CC	O
63	CD	O
%	NN	O
of	IN	O
those	DT	O
given	VBN	O
cyclophosphamide	NN	Pharmacological
(	(	O
40	CD	O
%	NN	O
adults	NNS	O
and	CC	O
68	CD	O
%	NN	O
children	NNS	O
)	)	O
had	VBD	O
not	RB	O
had	VBN	O
any	DT	O
relapse	NN	O
of	IN	O
NS	NNP	O
.	.	O

Tolerance	NN	O
to	TO	O
the	DT	O
two	CD	O
drugs	NNS	O
was	VBD	O
generally	RB	O
good	JJ	O
.	.	O

The	DT	O
CsA-related	JJ	Pharmacological
side-effects	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
disappeared	VBD	O
after	IN	O
drug	NN	O
discontinuation	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
both	DT	O
treatments	NNS	O
are	VBP	O
effective	JJ	O
and	CC	O
well	RB	O
tolerated	VBD	O
;	:	O
more	RBR	O
patients	NNS	O
given	VBN	O
cyclophosphamide	JJ	Pharmacological
had	VBD	O
stable	JJ	O
remissions	NNS	O
.	.	O

Reduced	VBN	O
platelet	NN	O
thromboxane	NN	O
formation	NN	O
after	IN	O
long-term	JJ	O
administration	NN	O
of	IN	O
a	DT	O
dihydropyridine	JJ	Pharmacological
calcium	NN	Pharmacological
channel	NN	Pharmacological
blocker	NN	Pharmacological
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
with	IN	O
nitrendipine	NN	Pharmacological
in	IN	O
borderline	JJ	O
hypertensive	JJ	O
patients	NNS	O
with	IN	O
IDDM-type	NNP	O
diabetes	NNS	O
mellitus	NN	O
.	.	O

Twenty-nine	JJ	O
IDDM	NNP	O
patients	NNS	O
with	IN	O
borderline	JJ	O
hypertension	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
placebo	VB	Control
or	CC	O
nitrendipine	VB	Pharmacological
treatment	NN	O
.	.	O

Nitrendipine	NNP	Pharmacological
was	VBD	O
given	VBN	O
orally	RB	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
20	CD	O
mg	NNS	O
once	RB	O
daily	RB	O
over	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Stimulated	VBN	O
platelet	NN	O
thromboxane	NN	O
formation	NN	O
at	IN	O
rest	NN	O
and	CC	O
after	IN	O
standardized	VBN	O
,	,	O
non	JJ	O
exhausting	VBG	O
exercise	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
standard	JJ	O
methods	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
plasma	NN	O
levels	NNS	O
of	IN	O
platelet	NN	O
factor	NN	O
4	CD	O
and	CC	O
aggregation	NN	O
responses	NNS	O
to	TO	O
collagen	VB	O
and	CC	O
ADP	NNP	O
were	VBD	O
determined	VBN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
group	NN	O
thromboxane	NN	O
formation	NN	O
after	IN	O
stimulation	NN	O
with	IN	O
collagen	NN	O
(	(	O
0.3	CD	O
and	CC	O
1.0	CD	O
micrograms/ml	NN	O
)	)	O
and	CC	O
1	CD	O
mM	NN	O
arachidonic	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
resting	NN	O
state	NN	O
.	.	O

Exercise	NN	O
induced	JJ	O
change	NN	O
of	IN	O
thromboxane	NN	O
synthesis	NN	O
in	IN	O
response	NN	O
to	TO	O
1.0	CD	O
micrograms/ml	NNS	O
collagen	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
as	IN	O
compared	VBN	O
to	TO	O
placebo	VB	Control
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
parallel	JJ	O
,	,	O
PF4	NNP	O
plasma	NN	O
levels	NNS	O
were	VBD	O
significantly	RB	O
lowered	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Whole	JJ	O
blood	NN	O
aggregation	NN	O
after	IN	O
collagen	NN	O
stimulation	NN	O
(	(	O
1.0	CD	O
micrograms/ml	NN	O
)	)	O
was	VBD	O
reduced	VBN	O
after	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
nitrendipine	JJ	Pharmacological
treatment	NN	O
,	,	O
but	CC	O
ADP	NNP	O
(	(	O
5	CD	O
microM	NN	O
)	)	O
induced	VBD	O
aggregation	NN	O
was	VBD	O
not	RB	O
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
nitrendipine	NN	Pharmacological
were	VBD	O
not	RB	O
seen	VBN	O
in	IN	O
platelet	NN	O
rich	JJ	O
plasma	NN	O
.	.	O

In	IN	O
conclusion	NN	O
long-term	JJ	O
nitrendipine	JJ	Pharmacological
treatment	NN	O
may	MD	O
inhibit	VB	O
collagen	NN	O
dependent	JJ	O
platelet	NN	O
activation	NN	O
in	IN	O
the	DT	O
blood	NN	O
of	IN	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
borderline	JJ	O
hypertension	NN	O
.	.	O

Concurrent	NNP	O
alcohol	NN	Educational
dependence	NN	Educational
among	IN	O
methadone-maintained	JJ	O
cocaine	NN	O
abusers	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
greater	JJR	O
abstinence	NN	O
.	.	O

Concurrent	NNP	Educational
alcohol	NN	Educational
dependence	NN	Educational
(	(	Educational
AD	NNP	Educational
)	)	Educational
among	IN	O
polysubstance	NN	O
abusers	NNS	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
negative	JJ	O
consequences	NNS	O
,	,	O
although	IN	O
it	PRP	O
may	MD	O
not	RB	O
necessarily	RB	O
lead	VB	O
to	TO	O
poor	JJ	O
treatment	NN	O
outcomes	NNS	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
most	RBS	O
efficacious	JJ	O
treatments	NNS	O
for	IN	O
cocaine	NN	O
abuse	NN	O
is	VBZ	O
contingency	JJ	Educational
management	NN	Educational
(	(	Educational
CM	NNP	Educational
)	)	Educational
,	,	O
but	CC	O
little	JJ	O
research	NN	O
has	VBZ	O
explored	VBN	O
the	DT	O
impact	NN	O
of	IN	O
AD	NNP	Educational
on	IN	O
abstinence	NN	O
outcomes	NNS	O
,	,	O
particularly	RB	O
among	IN	O
patients	NNS	O
in	IN	O
methadone	JJ	O
maintenance	NN	O
.	.	O

Using	VBG	O
data	NNS	O
from	IN	O
three	CD	O
trials	NNS	O
of	IN	O
CM	NNP	O
for	IN	O
cocaine	NN	O
use	NN	O
,	,	O
we	PRP	O
compared	VBN	O
baseline	JJ	O
characteristics	NNS	O
and	CC	O
posttreatment	NN	O
and	CC	O
follow-up	JJ	O
cocaine	NN	O
outcomes	NNS	O
between	IN	O
methadone-maintained	JJ	Pharmacological
,	,	O
cocaine-dependent	JJ	Pharmacological
patients	NNS	O
(	(	O
N	NNP	O
=	NNP	O
193	CD	O
)	)	O
with	IN	Educational
and	CC	Educational
without	IN	Educational
concurrent	JJ	Educational
AD	NNP	Educational
,	,	Educational
randomized	VBN	Educational
to	TO	Educational
standard	VB	Educational
care	NN	Educational
(	(	Educational
SC	NNP	Educational
)	)	Educational
with	IN	Educational
or	CC	Educational
without	IN	Educational
CM	NNP	Educational
.	.	Educational

Patients	NNS	O
with	IN	Educational
and	CC	Educational
without	IN	Educational
concurrent	JJ	Educational
AD	NNP	Educational
had	VBD	O
similar	JJ	O
baseline	NN	O
characteristics	NNS	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
that	WDT	O
AD	NNP	Educational
patients	NNS	O
reported	VBD	O
more	RBR	O
alcohol	NN	O
use	NN	O
.	.	O

AD	NN	Educational
patients	NNS	O
achieved	VBN	O
longer	JJR	O
durations	NNS	O
of	IN	O
cocaine	NN	O
abstinence	NN	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
submit	VB	O
a	DT	O
cocaine-negative	JJ	O
sample	NN	O
at	IN	O
follow-up	JJ	O
than	IN	O
non-AD	JJ	Educational
patients	NNS	O
.	.	O

Patients	NNS	O
randomized	VBD	O
to	TO	O
CM	NNP	Educational
achieved	VBD	O
better	RBR	O
outcomes	NNS	O
than	IN	O
those	DT	O
randomized	VBN	O
to	TO	O
SC	NNP	Educational
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
interaction	NN	O
between	IN	O
treatment	NN	O
condition	NN	O
and	CC	O
AD	NNP	Educational
status	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
cocaine-using	JJ	O
methadone	NN	O
patients	NNS	O
with	IN	O
AD	NNP	Educational
achieve	VBP	O
greater	JJR	O
cocaine	NN	O
abstinence	NN	O
than	IN	O
their	PRP$	O
non-AD	JJ	Educational
counterparts	NNS	O
and	CC	O
should	MD	O
not	RB	O
necessarily	RB	O
be	VB	O
viewed	VBN	O
as	IN	O
more	RBR	O
difficult	JJ	O
to	TO	O
treat	VB	O
.	.	O

Endometrial	JJ	O
cytodiagnosis	NN	O
using	VBG	O
a	DT	O
new	JJ	Other
softcyte	NN	Other
versus	NN	O
a	DT	O
conventional	JJ	Other
endocyte	NN	Other
.	.	O

A	DT	O
new	JJ	O
endometrial	JJ	O
cytologic	NN	O
sampling	VBG	O
device	NN	O
,	,	O
softcyte	NN	O
,	,	O
was	VBD	O
used	VBN	O
in	IN	O
cytological	JJ	O
screening	NN	O
for	IN	O
endometrial	JJ	O
cancer	NN	O
,	,	O
and	CC	O
was	VBD	O
compared	VBN	O
with	IN	O
the	DT	O
endocyte	NN	Other
with	IN	O
regard	NN	O
to	TO	O
manipulability	NN	O
,	,	O
adverse	JJ	O
effects	NNS	O
(	(	O
including	VBG	O
pain	NN	O
and	CC	O
hemorrhage	NN	O
)	)	O
,	,	O
and	CC	O
cellular	JJ	O
findings	NNS	O
(	(	O
including	VBG	O
the	DT	O
quantity	NN	O
of	IN	O
cells	NNS	O
collected	VBN	O
,	,	O
the	DT	O
success	NN	O
rate	NN	O
,	,	O
cell	NN	O
freshness	NN	O
,	,	O
and	CC	O
cellular	JJ	O
clumping	NN	O
)	)	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
315	CD	O
women	NNS	O
(	(	O
premenopause	IN	O
251	CD	O
,	,	O
postmenopause	RB	O
64	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
who	WP	O
underwent	VBP	O
the	DT	O
endometrial	JJ	Other
cytological	JJ	Other
screening	NN	Other
with	IN	Other
either	CC	Other
the	DT	Other
softcyte	NN	Other
or	CC	O
the	DT	O
endocyte	NN	Other
.	.	O

To	TO	O
assess	VB	O
the	DT	O
value	NN	O
of	IN	O
the	DT	O
softcyte	NN	Other
we	PRP	O
compared	VBN	O
it	PRP	O
with	IN	O
the	DT	O
endocyte	NN	Other
.	.	Other

Endometrial	NNP	O
cytology	NN	O
using	VBG	O
a	DT	O
softcyte	NN	Other
or	CC	O
an	DT	O
endocyte	NN	Other
achieved	VBN	O
high	JJ	O
correct	JJ	O
diagnosis	NN	O
rate	NN	O
for	IN	O
cancer	NN	O
,	,	O
and	CC	O
both	DT	O
instruments	NNS	O
are	VBP	O
valuable	JJ	O
as	IN	O
endometrial	JJ	O
cytologic	NN	O
sample	NN	O
devices	NNS	O
.	.	O

The	DT	O
softcyte	NN	O
causes	VBZ	O
only	RB	O
mild	JJ	O
pain	NN	O
on	IN	O
introduction	NN	O
and	CC	O
during	IN	O
collection	NN	O
,	,	O
and	CC	O
a	DT	O
large	JJ	O
quantity	NN	O
of	IN	O
cells	NNS	O
could	MD	O
be	VB	O
harvested	VBN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
softcyte	NN	O
is	VBZ	O
a	DT	O
useful	JJ	O
cytologic	NN	O
sampling	VBG	O
device	NN	O
in	IN	O
screening	VBG	O
for	IN	O
endometrial	JJ	O
cancer	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
release	NN	O
of	IN	O
digoxin	NN	Pharmacological
from	IN	O
four	CD	O
different	JJ	O
soft	JJ	O
gelatin	NN	O
capsule	NN	Pharmacological
formulations	NNS	Pharmacological
.	.	Pharmacological

A	DT	O
blinded	JJ	O
,	,	O
four-treatment	JJ	O
crossover	NN	O
study	NN	O
in	IN	O
16	CD	O
normal	JJ	O
adult	NN	O
male	NN	O
volunteers	NNS	O
compared	VBN	O
plasma	JJ	O
concentrations	NNS	O
and	CC	O
urinary	JJ	O
excretion	NN	O
of	IN	O
digoxin	NN	Pharmacological
,	,	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
,	,	O
after	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
soft	JJ	Pharmacological
gelatin	NN	Pharmacological
capsule	NN	Pharmacological
formulations	NNS	Pharmacological
of	IN	Pharmacological
digoxin	NN	Pharmacological
.	.	Pharmacological

Four	CD	O
0.4-mg	JJ	O
formulations	NNS	O
with	IN	O
different	JJ	O
in	IN	O
vitro	NN	O
burst	NN	O
times	NNS	O
and	CC	O
dissolution	NN	O
rates	NNS	O
were	VBD	O
administered	VBN	O
,	,	O
with	IN	O
2-week	JJ	O
intervals	NNS	O
between	IN	O
treatments	NNS	O
.	.	O

The	DT	O
two	CD	O
capsules	NNS	O
with	IN	O
lowest	JJS	O
in	IN	O
vitro	NN	O
burst	NN	O
times	NNS	O
(	(	O
2.9	CD	O
and	CC	O
16	CD	O
min	NN	O
)	)	O
gave	VBD	O
comparable	JJ	O
in	IN	O
vivo	JJ	O
results	NNS	O
.	.	O

The	DT	O
other	JJ	O
two	CD	O
capsules	NNS	O
,	,	O
with	IN	O
in	IN	O
vitro	NN	O
burst	NN	O
times	NNS	O
of	IN	O
62	CD	O
and	CC	O
229	CD	O
min	NN	O
,	,	O
produced	VBD	O
significant	JJ	O
delays	NNS	O
in	IN	O
digoxin	NN	O
absorption	NN	O
.	.	O

In	IN	O
vitro-in	JJ	O
vivo	NN	O
correlations	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
comparing	VBG	O
the	DT	O
logarithm	NN	O
of	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
burst	NN	O
time	NN	O
with	IN	O
time	NN	O
to	TO	O
peak	VB	O
plasma	JJ	O
level	NN	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
the	DT	O
first	JJ	O
measurable	JJ	O
plasma	NN	O
level	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
0	CD	O
.	.	O

05	CD	O
ng/ml	NN	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
mean	JJ	O
time	NN	O
to	TO	O
peak	VB	O
plasma	JJ	O
level	NN	O
correlated	VBN	O
with	IN	O
the	DT	O
logarithm	NN	O
of	IN	O
the	DT	O
time	NN	O
required	VBN	O
to	TO	O
release	VB	O
either	RB	O
50	CD	O
%	NN	O
or	CC	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
digoxin	NN	O
in	IN	O
vitro	NN	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
digoxin	NN	Pharmacological
absorbed	VBN	O
from	IN	O
each	DT	O
capsule	NN	O
as	IN	O
determined	VBN	O
by	IN	O
urinary	JJ	O
excretion	NN	O
or	CC	O
AUC0-infinity	NN	O
.	.	O

Co-administration	NN	O
of	IN	O
pethidine	NN	Pharmacological
and	CC	O
clonidine	NN	Pharmacological
:	:	O
a	DT	O
spinal	JJ	O
anaesthetic	JJ	O
technique	NN	O
for	IN	O
total	JJ	Surgical
hip	NN	Surgical
replacement	NN	Surgical
.	.	Surgical

Co-administration	NN	O
of	IN	O
pethidine	NN	Pharmacological
0.75	CD	O
mg	NN	O
kg-1	NN	O
and	CC	O
clonidine	NN	Pharmacological
75	CD	O
micrograms	NNS	O
intrathecally	RB	O
provided	VBD	O
good	JJ	O
intraoperative	JJ	O
anaesthesia	NN	O
for	IN	O
total	JJ	Surgical
hip	NN	Surgical
replacement	NN	Surgical
,	,	O
similar	JJ	O
to	TO	O
that	DT	O
obtained	VBN	O
using	VBG	O
0.5	CD	Pharmacological
%	NN	Pharmacological
isobaric	JJ	Pharmacological
bupivacaine	NN	Pharmacological
.	.	Pharmacological

Sensory	NNP	O
and	CC	O
motor	NN	O
block	NN	O
were	VBD	O
of	IN	O
shorter	JJR	O
duration	NN	O
than	IN	O
that	DT	O
after	IN	O
0.5	CD	O
%	NN	O
isobaric	JJ	Pharmacological
bupivacaine	NN	Pharmacological
and	CC	O
0.5	CD	O
%	NN	O
isobaric	JJ	Pharmacological
bupivacaine	NN	Pharmacological
with	IN	O
morphine	JJ	Pharmacological
0.5	CD	O
mg	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
sensory	JJ	O
block	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
motor	NN	O
block	NN	O
)	)	O
.	.	O

Postoperative	JJ	O
morphine	NN	Pharmacological
consumption	NN	O
,	,	O
measured	VBN	O
using	VBG	O
a	DT	O
patient-controlled	JJ	O
system	NN	O
,	,	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
in	IN	O
patients	NNS	O
in	IN	O
the	DT	O
bupivacaine	NN	Pharmacological
only	RB	O
group	NN	O
(	(	O
pethidine-clonidine	JJ	Pharmacological
:	:	O
median	JJ	O
39	CD	O
mg/24	NN	O
h	NN	O
;	:	O
bupivacaine	NN	Pharmacological
:	:	O
median	JJ	O
34	CD	O
mg/24	NN	O
h	NN	O
)	)	O
but	CC	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
bupivacaine-morphine	JJ	Pharmacological
group	NN	O
(	(	O
median	JJ	O
8	CD	O
mg/24	NN	O
h	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Visual	JJ	O
analogue	NN	O
pain	NN	O
scores	NNS	O
after	IN	O
operation	NN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
with	IN	O
bupivacaine	JJ	Pharmacological
alone	NN	Pharmacological
at	IN	O
all	DT	O
but	CC	O
one	CD	O
of	IN	O
the	DT	O
recording	NN	O
times	NNS	O
but	CC	O
were	VBD	O
greater	JJR	O
than	IN	O
those	DT	O
in	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
bupivacaine	NN	Pharmacological
and	CC	O
morphine	NN	Pharmacological
at	IN	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
10	CD	O
h	NN	O
after	IN	O
operation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.04	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
combination	NN	O
did	VBD	O
not	RB	O
offer	VB	O
any	DT	O
major	JJ	O
advantage	NN	O
over	IN	O
conventional	JJ	O
agents	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
physical	JJ	Psychological
and	CC	Psychological
emotional	JJ	Psychological
status	NN	Psychological
on	IN	O
adherence	NN	O
to	TO	O
a	DT	O
low-fat	JJ	Other
dietary	JJ	Other
pattern	NN	Other
in	IN	O
the	DT	O
Women	NNP	O
's	POS	O
Health	NNP	O
Initiative	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
whether	IN	O
the	DT	O
effects	NNS	O
of	IN	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
on	IN	O
adherance	NN	O
to	TO	O
a	DT	O
low-fat	JJ	Educational
(	(	Educational
20	CD	Educational
%	NN	Educational
energy	NN	Educational
)	)	Educational
dietary	JJ	Educational
pattern	NN	Educational
are	VBP	O
mediated	VBN	O
by	IN	O
participation	NN	O
in	IN	O
an	DT	O
intervention	NN	Educational
program	NN	Educational
(	(	Educational
attending	VBG	Educational
sessions	NNS	Educational
and	CC	Educational
self-monitoring	NN	Educational
)	)	Educational
.	.	Educational

DESIGN	VB	O
The	DT	O
Baron	NNP	O
and	CC	O
Kenny	NNP	O
mediator	NN	O
model	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
4	CD	O
regression	NN	O
analyses	NNS	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
evaluate	VB	O
whether	IN	O
:	:	O
a	DT	O
)	)	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
predicted	VBD	O
program	NN	O
participation	NN	O
,	,	O
b	NN	O
)	)	O
program	NN	O
participation	NN	O
predicted	VBD	O
dietary	JJ	O
adherence	NN	O
,	,	O
c	NN	O
)	)	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
factors	NNS	O
predicted	VBD	O
dietary	JJ	Other
adherence	NN	Other
,	,	O
and	CC	O
,	,	O
ultimately	RB	O
d	NN	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
on	IN	O
dietary	JJ	O
adherence	NN	O
were	VBD	O
mediated	VBN	O
by	IN	O
program	NN	O
participation	NN	O
.	.	O

SUBJECTS/SETTING	NNP	O
Data	NNP	O
from	IN	O
13,277	CD	O
postmenopausal	JJ	O
women	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
low-fat	JJ	Educational
intervention	NN	Educational
arm	NN	O
of	IN	O
the	DT	O
Women	NNP	O
's	POS	O
Health	NNP	O
Initiative	NNP	O
Dietary	NNP	O
Modification	NNP	O
Trial	NNP	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
nutrition	NN	O
goals	NNS	O
for	IN	O
women	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
low-fat	JJ	Educational
intervention	NN	Educational
were	VBD	O
to	TO	O
reduce	VB	Educational
total	JJ	Educational
fat	JJ	Educational
intake	NN	Educational
to	TO	Educational
20	CD	Educational
%	NN	Educational
or	CC	Educational
less	JJR	Educational
of	IN	Educational
energy	NN	Educational
from	IN	Educational
fat	JJ	Educational
and	CC	Educational
to	TO	Educational
consume	VB	Educational
5	CD	Educational
or	CC	Educational
more	JJR	Educational
fruit/vegetable	JJ	Educational
servings	NNS	Educational
daily	RB	Educational
and	CC	Educational
6	CD	Educational
or	CC	Educational
more	JJR	Educational
grain	JJ	Educational
servings	NNS	Educational
daily	RB	Educational
.	.	Educational

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Year	NNP	O
1	CD	O
program	NN	O
participation	NN	O
(	(	O
degree	NN	O
of	IN	O
attending	VBG	O
group	NN	O
sessions	NNS	O
and	CC	O
submitting	VBG	O
fat	JJ	O
scores	NNS	O
)	)	O
and	CC	O
adherence	NN	O
to	TO	O
the	DT	O
low-fat	JJ	Educational
dietary	JJ	Educational
pattern	NN	Educational
(	(	O
percent	JJ	O
energy	NN	O
from	IN	O
fat	NN	O
)	)	O
as	IN	O
predicted	VBN	O
by	IN	O
baseline	JJ	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
(	(	O
eight	CD	O
SF-36	NNP	O
Health	NNP	O
Survey	NNP	O
subscales	VBZ	O
)	)	O
.	.	O

RESULTS	NNP	O
Participating	VBG	O
in	IN	O
the	DT	O
dietary	JJ	Educational
intervention	NN	Educational
program	NN	Educational
reduced	VBN	O
(	(	O
mediated	VBN	O
)	)	O
the	DT	O
negative	JJ	O
effect	NN	O
of	IN	O
poorer	JJR	O
mental	JJ	O
health	NN	O
on	IN	O
dietary	JJ	O
adherence	NN	O
by	IN	O
15	CD	O
%	NN	O
.	.	O

Additional	JJ	O
findings	NNS	O
included	VBD	O
that	IN	O
a	DT	O
10	CD	O
%	NN	O
increase	NN	O
in	IN	O
physical	JJ	O
functioning	NN	O
increased	VBD	O
session	NN	O
attendance	NN	O
by	IN	O
0.4	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
a	DT	O
10	CD	O
%	NN	O
increase	NN	O
in	IN	O
mental	JJ	O
health	NN	O
predicted	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
percent	NN	O
energy	NN	O
from	IN	O
fat	NN	O
of	IN	O
0.3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Program	NNP	O
participation	NN	O
had	VBD	O
a	DT	O
marked	JJ	O
effect	NN	O
on	IN	O
dietary	JJ	O
adherence	NN	O
:	:	O
a	DT	O
10	CD	O
%	NN	O
increase	NN	O
in	IN	O
session	NN	O
attendance	NN	O
predicted	VBD	O
a	DT	O
1.2	CD	O
%	NN	O
decrease	NN	O
in	IN	O
percent	NN	O
energy	NN	O
from	IN	O
fat	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

APPLICATIONS/CONCLUSIONS	NNP	O
Understanding	NNP	O
and	CC	O
using	VBG	O
instruments	NNS	O
to	TO	O
assess	VB	O
the	DT	O
physical	JJ	O
and	CC	O
emotional	JJ	O
status	NN	O
of	IN	O
a	DT	O
target	NN	O
population	NN	O
will	MD	O
help	VB	O
dietetic	JJ	O
professionals	NNS	O
promote	VBP	O
healthful	JJ	O
dietary	JJ	O
change	NN	O
and	CC	O
maintenance	NN	O
.	.	O

Lactobacillus	NNP	Pharmacological
plantarum	NN	Pharmacological
CECT7315	NNP	Pharmacological
and	CC	Pharmacological
CECT7316	NNP	Pharmacological
stimulate	VBP	O
immunoglobulin	NN	O
production	NN	O
after	IN	O
influenza	JJ	Pharmacological
vaccination	NN	Pharmacological
in	IN	O
elderly	JJ	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
effectiveness	NN	O
of	IN	O
influenza	JJ	Pharmacological
vaccination	NN	Pharmacological
in	IN	O
preventing	VBG	O
illness	NN	O
is	VBZ	O
lower	RBR	O
in	IN	O
the	DT	O
elderly	JJ	O
;	:	O
this	DT	O
is	VBZ	O
why	WRB	O
the	DT	O
ability	NN	O
of	IN	O
Lactobacillus	NNP	Pharmacological
plantarum	NN	Pharmacological
CECT	NNP	Pharmacological
7315/7316	CD	Pharmacological
to	TO	O
stimulate	VB	O
the	DT	O
response	NN	O
to	TO	O
influenza	VB	Pharmacological
vaccination	NN	Pharmacological
in	IN	O
elderly	JJ	O
was	VBD	O
evaluated	VBN	O
.	.	O

RESEARCH	NNP	O
METHODS	NNP	O
AND	NNP	O
PROCEDURES	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
human	JJ	O
trial	NN	O
including	VBG	O
60	CD	O
institutionalized	JJ	O
volunteers	NNS	O
aged	VBN	O
65-85	CD	O
years	NNS	O
was	VBD	O
performed	VBN	O
.	.	O

All	PDT	O
the	DT	O
volunteers	NNS	O
were	VBD	O
vaccinated	VBN	O
with	IN	O
a	DT	O
trivalent	JJ	Pharmacological
influenza	NN	Pharmacological
vaccine	NN	Pharmacological
(	(	Pharmacological
A/Wisconsin/67/2005	NNP	Pharmacological
NYMC	NNP	Pharmacological
X-161B	NNP	Pharmacological
(	(	Pharmacological
H3N2	NNP	Pharmacological
)	)	Pharmacological
,	,	Pharmacological
A/Solomon	NNP	Pharmacological
Islands/3/2006	NNP	Pharmacological
(	(	Pharmacological
H1N1	NNP	Pharmacological
)	)	Pharmacological
and	CC	Pharmacological
B/Malaysia/2506/2004	NNP	Pharmacological
)	)	Pharmacological
for	IN	O
the	DT	O
Spanish	JJ	O
vaccine	NN	O
campaign	NN	O
2006/2007	CD	O
.	.	O

The	DT	O
consumption	NN	O
of	IN	O
the	DT	O
probiotic	JJ	O
began	VBD	O
between	IN	O
three	CD	O
and	CC	O
four	CD	O
months	NNS	O
after	IN	O
the	DT	O
vaccination	NN	O
.	.	O

Volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
following	VBG	O
groups	NNS	O
:	:	O
group	NN	O
A	NNP	O
(	(	O
receiving	VBG	O
5*10	CD	O
(	(	O
9	CD	O
)	)	O
cfu/day	NN	O
of	IN	O
L.	NNP	Pharmacological
plantarum	NN	Pharmacological
CECT	NNP	Pharmacological
7315/7316	CD	Pharmacological
in	IN	O
20	CD	O
g	NN	O
powdered	VBD	O
skim	JJ	O
milk	NN	O
)	)	O
,	,	O
group	NN	O
B	NNP	O
(	(	O
receiving	VBG	O
5*10	CD	O
(	(	O
8	CD	O
)	)	O
cfu/day	NN	O
of	IN	O
L.	NNP	Pharmacological
plantarum	NN	Pharmacological
CECT	NNP	Pharmacological
7315/7316	CD	Pharmacological
in	IN	O
20	CD	O
g	NN	O
powdered	VBD	O
skim	JJ	O
milk	NN	O
)	)	O
and	CC	O
group	NN	O
C	NNP	O
or	CC	O
placebo	NN	Control
(	(	O
20	CD	O
g	NN	O
powered	VBN	Control
skim	JJ	Control
milk	NN	Control
)	)	Control
.	.	Control

The	DT	O
participants	NNS	O
consumed	VBD	O
the	DT	O
probiotic	JJ	O
during	IN	O
3	CD	O
months	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
consumption	NN	O
of	IN	O
L.	NNP	Pharmacological
plantarum	NN	Pharmacological
CECT	NNP	Pharmacological
7315/7316	CD	Pharmacological
during	IN	O
3	CD	O
months	NNS	O
after	IN	O
influenza	JJ	Pharmacological
vaccination	NN	Pharmacological
increased	VBD	O
the	DT	O
levels	NNS	O
of	IN	O
influenza-specific	JJ	O
IgA	NNP	O
and	CC	O
IgG	NNP	O
antibodies	NNS	O
.	.	O

Moreover	RB	O
,	,	O
a	DT	O
trend	NN	O
towards	IN	O
an	DT	O
increase	NN	O
in	IN	O
influenza-specific	JJ	O
IgM	NNP	O
antibodies	NNS	O
was	VBD	O
also	RB	O
observed	VBN	O
.	.	O

CONCLUSION	NNP	O
L.	NNP	Pharmacological
plantarum	NN	Pharmacological
CECT7315/7316	NNP	Pharmacological
has	VBZ	O
an	DT	O
immunostimulating	JJ	O
effect	NN	O
and	CC	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
improve	VB	O
the	DT	O
response	NN	O
to	TO	O
influenza	VB	Pharmacological
vaccination	NN	Pharmacological
in	IN	O
elderly	JJ	O
.	.	O

Combined	VBN	Pharmacological
typhoid	JJ	Pharmacological
fever	NN	Pharmacological
and	CC	Pharmacological
hepatitis	VB	Pharmacological
A	DT	Pharmacological
vaccine	NN	Pharmacological
:	:	Pharmacological
comparison	NN	O
of	IN	O
immunogenicity	NN	O
and	CC	O
safety	NN	O
to	TO	O
concomitant	VB	O
monovalent	JJ	O
vaccine	NN	O
over	IN	O
3	CD	O
years	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
Viatim	NNP	Pharmacological
,	,	O
a	DT	O
combined	JJ	Pharmacological
hepatitis	NN	Pharmacological
A	NNP	Pharmacological
(	(	Pharmacological
HA	NNP	Pharmacological
)	)	Pharmacological
and	CC	Pharmacological
typhoid	JJ	Pharmacological
fever	NN	Pharmacological
(	(	Pharmacological
Vi	NNP	Pharmacological
)	)	Pharmacological
vaccine	NN	Pharmacological
,	,	O
were	VBD	O
compared	VBN	O
with	IN	O
the	DT	O
monovalent	JJ	Pharmacological
component	NN	Pharmacological
vaccines	VBZ	Pharmacological
up	IN	O
to	TO	O
and	CC	O
1	CD	O
month	NN	O
after	IN	O
a	DT	O
booster	NN	O
dose	NN	O
at	IN	O
3	CD	O
years	NNS	O
.	.	O

METHODS	NNP	O
Healthy	NNP	O
,	,	O
adult	NN	O
volunteers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
Viatim	NNP	Pharmacological
(	(	O
group	NN	O
A	NNP	O
,	,	O
n	JJ	O
=	NNP	O
179	CD	O
)	)	O
or	CC	O
separate	JJ	Pharmacological
HA	NNP	Pharmacological
and	CC	Pharmacological
Vi	NNP	Pharmacological
vaccines	NNS	Pharmacological
(	(	O
group	NN	O
B	NNP	O
,	,	O
n	JJ	O
=	NNP	O
181	CD	O
)	)	O
;	:	O
subgroups	NNS	O
were	VBD	O
boosted	VBN	O
after	IN	O
3	CD	O
years	NNS	O
with	IN	O
Viatim	NNP	Pharmacological
(	(	O
groups	NNS	O
C	NNP	O
and	CC	O
D	NNP	O
,	,	O
n	JJ	O
=	NN	O
56	CD	O
and	CC	O
46	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Local	JJ	O
and	CC	O
systemic	JJ	O
reactions	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
28	CD	O
days	NNS	O
postvaccination	NN	O
.	.	O

Seroconversion	NN	O
and	CC	O
seroprotection	NN	O
rates	NNS	O
and	CC	O
geometric	JJ	O
mean	NN	O
antibody	NN	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
14	CD	O
and	CC	O
28	CD	O
days	NNS	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
years	NNS	O
postvaccination	NN	O
,	,	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
the	DT	O
booster	NN	O
dose	NN	O
.	.	O

RESULTS	NNP	O
Local	NNP	O
and	CC	O
systemic	JJ	O
safety	NN	O
profiles	NNS	O
were	VBD	O
equivalent	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Immediate	NNP	O
local	JJ	O
reactions	NNS	O
were	VBD	O
infrequent	JJ	O
(	(	O
1	CD	O
in	IN	O
group	NN	O
A	NNP	O
and	CC	O
2	CD	O
in	IN	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Local	JJ	O
reactions	NNS	O
,	,	O
consisting	VBG	O
mostly	RB	O
of	IN	O
mild	NN	O
or	CC	O
moderate	JJ	O
pain	NN	O
,	,	O
were	VBD	O
least	JJS	O
frequent	JJ	O
with	IN	O
monovalent	JJ	O
HA	NNP	O
.	.	O

Antibody	NNP	O
concentrations	NNS	O
to	TO	O
both	DT	O
antigens	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
in	IN	O
which	WDT	O
HA	NNP	O
seroprotection	NN	O
rates	NNS	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
20	CD	O
mIU/mL	NN	O
)	)	O
were	VBD	O
respectively	RB	O
,	,	O
98.7	CD	O
%	NN	O
and	CC	O
100	CD	O
%	NN	O
at	IN	O
day	NN	O
28	CD	O
,	,	O
and	CC	O
99.1	CD	O
%	NN	O
and	CC	O
99.0	CD	O
%	NN	O
after	IN	O
3	CD	O
years	NNS	O
,	,	O
achieving	VBG	O
100	CD	O
%	NN	O
after	IN	O
the	DT	O
booster	NN	O
.	.	O

Vi	NNP	O
seroprotection	NN	O
rates	NNS	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
1	CD	O
microg/mL	NN	O
)	)	O
of	IN	O
85.2	CD	O
%	NN	O
and	CC	O
84.9	CD	O
%	NN	O
after	IN	O
28	CD	O
days	NNS	O
fell	VBD	O
to	TO	O
32.1	CD	O
%	NN	O
and	CC	O
35.6	CD	O
%	NN	O
after	IN	O
3	CD	O
years	NNS	O
,	,	O
increasing	VBG	O
to	TO	O
67.3	CD	O
%	NN	O
and	CC	O
69.8	CD	O
%	NN	O
after	IN	O
the	DT	O
booster	NN	O
dose	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
combined	JJ	Pharmacological
HA/Vi	NNP	Pharmacological
vaccine	NN	Pharmacological
,	,	Pharmacological
Viatim	NNP	Pharmacological
,	,	O
had	VBD	O
equivalent	JJ	O
tolerability	NN	O
and	CC	O
safety	NN	O
and	CC	O
was	VBD	O
as	IN	O
rapidly	RB	O
immunogenic	JJ	O
as	IN	O
its	PRP$	O
component	NN	O
monovalent	NN	O
vaccines	NNS	O
when	WRB	O
given	VBN	O
concurrently	RB	O
.	.	O

A	DT	O
booster	NN	O
dose	NN	O
after	IN	O
3	CD	O
years	NNS	O
significantly	RB	O
increased	VBD	O
antibody	NN	O
levels	NNS	O
with	IN	O
some	DT	O
evidence	NN	O
of	IN	O
relative	JJ	O
hyporesponsiveness	NN	O
of	IN	O
the	DT	O
typhoid	JJ	O
response	NN	O
.	.	O

How	WRB	O
does	VBZ	O
Cash	NNP	Other
and	CC	O
Counseling	NNP	Other
affect	NN	O
costs	NNS	O
?	.	O
OBJECTIVE	NNP	O
To	TO	O
test	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
consumer-directed	JJ	O
model	NN	O
(	(	O
Cash	NNP	Other
and	CC	O
Counseling	NNP	Other
)	)	O
of	IN	O
Medicaid	NNP	O
personal	JJ	O
care	NN	O
services	NNS	O
(	(	O
PCS	NNPS	O
)	)	O
or	CC	O
home-	JJ	O
and	CC	O
community-based	JJ	O
waiver	NN	O
services	NNS	O
(	(	O
HCBS	NNP	O
)	)	O
on	IN	O
the	DT	O
cost	NN	O
of	IN	O
Medicaid	NNP	O
services	NNS	O
.	.	O

DATA	NNP	O
SOURCES/STUDY	NNP	O
SETTING	NNP	O
Medicaid	NNP	O
claims	NNS	O
data	NNS	O
were	VBD	O
collected	VBN	O
for	IN	O
all	DT	O
enrollees	NNS	O
in	IN	O
the	DT	O
Cash	NNP	O
and	CC	O
Counseling	NNP	O
demonstration	NN	O
.	.	O

Demonstration	NNP	O
enrollees	NNS	O
included	VBD	O
those	DT	O
eligible	JJ	O
for	IN	O
PCS	NNP	O
(	(	O
in	IN	O
Arkansas	NNP	O
)	)	O
,	,	O
those	DT	O
assessed	VBN	O
to	TO	O
receive	VB	O
such	JJ	O
services	NNS	O
(	(	O
in	IN	O
New	NNP	O
Jersey	NNP	O
)	)	O
,	,	O
and	CC	O
recipients	NNS	O
of	IN	O
Medicaid	NNP	O
HCBS	NNP	O
(	(	O
in	IN	O
Florida	NNP	O
)	)	O
.	.	O

Enrollment	NN	O
occurred	VBD	O
from	IN	O
December	NNP	O
1998	CD	O
through	IN	O
April	NNP	O
2001	CD	O
.	.	O

The	DT	O
follow-up	JJ	O
period	NN	O
covered	VBD	O
up	RB	O
to	TO	O
24	CD	O
months	NNS	O
after	IN	O
enrollment	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Demonstration	NNP	O
volunteers	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
the	DT	O
option	NN	O
to	TO	O
participate	VB	O
in	IN	O
Cash	NNP	Other
and	CC	O
Counseling	NNP	Other
(	(	O
the	DT	O
treatment	NN	O
group	NN	O
)	)	O
,	,	O
or	CC	O
to	TO	O
receive	VB	O
Medicaid	NNP	Control
services	NNS	Control
as	RB	Control
usual	JJ	Control
from	IN	Control
an	DT	Control
agency	NN	Control
(	(	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
.	.	O

Ordinary	JJ	O
least	JJS	O
squares	NNS	O
regressions	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
estimate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
program	NN	O
on	IN	O
costs	NNS	O
for	IN	O
Medicaid	NNP	O
PCS/waiver	NNP	O
services	NNS	O
and	CC	O
other	JJ	O
Medicaid	NNP	O
services	NNS	O
,	,	O
while	IN	O
controlling	VBG	O
for	IN	O
consumers	NNS	O
'	POS	O
preenrollment	NN	O
characteristics	NNS	O
and	CC	O
preenrollment	NN	O
Medicaid	NNP	O
spending	NN	O
.	.	O

Models	NNS	O
were	VBD	O
estimated	VBN	O
separately	RB	O
for	IN	O
nonelderly	RB	O
and	CC	O
elderly	JJ	O
adults	NNS	O
in	IN	O
each	DT	O
state	NN	O
and	CC	O
for	IN	O
children	NNS	O
in	IN	O
Florida	NNP	O
.	.	O

DATA	NNP	O
EXTRACTION	NNP	O
METHODS	NNP	O
Each	DT	O
state	NN	O
supplied	VBD	O
claims	NNS	O
data	NNS	O
for	IN	O
demonstration	NN	O
enrollees	NNS	O
.	.	O

PRINCIPAL	NNP	O
FINDINGS	NNP	O
Largely	NNP	O
because	IN	O
the	DT	O
program	NN	O
increased	VBD	O
consumers	NNS	O
'	POS	O
ability	NN	O
to	TO	O
get	VB	O
the	DT	O
authorized	JJ	O
amount	NN	O
of	IN	O
paid	VBN	O
care	NN	O
,	,	O
expenditures	VBZ	O
for	IN	O
personal	JJ	O
care/waiver	NN	O
services	NNS	O
were	VBD	O
higher	JJR	O
for	IN	O
the	DT	O
treatment	NN	O
group	NN	O
than	IN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
in	IN	O
each	DT	O
state	NN	O
and	CC	O
age	NN	O
group	NN	O
,	,	O
except	IN	O
among	IN	O
the	DT	O
elderly	JJ	O
in	IN	O
Florida	NNP	O
.	.	O

Higher	JJR	O
costs	NNS	O
for	IN	O
personal	JJ	O
care/waiver	NN	O
services	NNS	O
were	VBD	O
partially	RB	O
offset	VBN	O
by	IN	O
savings	NNS	O
in	IN	O
other	JJ	O
Medicaid	NNP	O
services	NNS	O
,	,	O
particularly	RB	O
those	DT	O
related	VBN	O
to	TO	O
long-term	JJ	O
care	NN	O
.	.	O

During	IN	O
year	NN	O
1	CD	O
,	,	O
total	JJ	O
Medicaid	NNP	O
costs	NNS	O
were	VBD	O
generally	RB	O
higher	JJR	O
for	IN	O
the	DT	O
treatment	NN	O
group	NN	O
than	IN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
treatment-control	JJ	O
cost	NN	O
differences	NNS	O
ranging	VBG	O
from	IN	O
1	CD	O
percent	NN	O
(	(	O
and	CC	O
statistically	RB	O
insignificant	JJ	O
)	)	O
for	IN	O
the	DT	O
elderly	JJ	O
in	IN	O
Florida	NNP	O
to	TO	O
17	CD	O
percent	NN	O
for	IN	O
the	DT	O
elderly	JJ	O
in	IN	O
Arkansas	NNP	O
.	.	O

In	IN	O
year	NN	O
2	CD	O
,	,	O
these	DT	O
cost	NN	O
differences	NNS	O
were	VBD	O
generally	RB	O
greater	JJR	O
than	IN	O
in	IN	O
year	NN	O
1	CD	O
.	.	O

Only	RB	O
in	IN	O
Arkansas	NNP	O
did	VBD	O
the	DT	O
treatment-control	NN	O
difference	NN	O
in	IN	O
total	JJ	O
cost	NN	O
shrink	NN	O
over	IN	O
time-to	JJ	O
less	JJR	O
than	IN	O
5	CD	O
percent	NN	O
(	(	O
and	CC	O
statistically	RB	O
insignificant	JJ	O
)	)	O
in	IN	O
year	NN	O
2	CD	O
.	.	O

CONCLUSIONS	NNP	O
Medicaid	NNP	O
costs	NNS	O
were	VBD	O
generally	RB	O
higher	JJR	O
under	IN	O
Cash	NNP	Other
and	CC	O
Counseling	NNP	Other
because	IN	O
those	DT	O
in	IN	O
the	DT	O
traditional	JJ	O
system	NN	O
did	VBD	O
not	RB	O
get	VB	O
the	DT	O
services	NNS	O
they	PRP	O
were	VBD	O
entitled	VBN	O
to	TO	O
.	.	O

Compared	VBN	O
with	IN	O
the	DT	O
treatment	NN	O
group	NN	O
,	,	O
(	(	O
1	CD	O
)	)	O
control	NN	O
group	NN	O
members	NNS	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
receive	VB	O
any	DT	O
services	NNS	O
at	IN	O
all	DT	O
(	(	O
despite	IN	O
being	VBG	O
authorized	VBN	O
for	IN	O
them	PRP	O
)	)	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
service	NN	O
recipients	NNS	O
received	VBD	O
a	DT	O
lower	JJR	O
proportion	NN	O
of	IN	O
the	DT	O
amount	NN	O
of	IN	O
care	NN	O
that	WDT	O
was	VBD	O
authorized	VBN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
flaw	NN	O
in	IN	O
Florida	NNP	O
's	POS	O
reassessment	NN	O
procedures	NNS	O
led	VBD	O
to	TO	O
treatment	NN	O
group	NN	O
members	NNS	O
receiving	VBG	O
more	RBR	O
generous	JJ	O
benefit	NN	O
amounts	NNS	O
than	IN	O
control	NN	O
group	NN	O
members	NNS	O
.	.	O

To	TO	O
keep	VB	O
total	JJ	O
Medicaid	NNP	O
costs	NNS	O
per	IN	O
recipient	NN	O
at	IN	O
the	DT	O
level	NN	O
incurred	VBN	O
under	IN	O
the	DT	O
traditional	JJ	O
system	NN	O
,	,	O
consumer-directed	JJ	O
programs	NNS	O
need	VBP	O
to	TO	O
be	VB	O
carefully	RB	O
designed	VBN	O
and	CC	O
closely	RB	O
monitored	VBN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
intermittent	JJ	O
vaginal	JJ	O
administration	NN	O
of	IN	O
misoprostol	NN	Pharmacological
with	IN	O
continuous	JJ	O
dinoprostone	NN	Pharmacological
for	IN	O
cervical	JJ	O
ripening	NN	O
and	CC	O
labor	NN	O
induction	NN	O
.	.	O

OBJECTIVE	CC	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
vaginal	JJ	O
administration	NN	O
of	IN	O
misoprostol	NN	Pharmacological
(	(	Pharmacological
Cytotec	NNP	Pharmacological
)	)	Pharmacological
with	IN	O
that	DT	O
of	IN	O
dinoprostone	NN	Pharmacological
(	(	Pharmacological
Cervidil	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
cervical	JJ	O
ripening	NN	O
and	CC	O
labor	NN	O
induction	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Two	CD	O
hundred	VBD	O
patients	NNS	O
with	IN	O
indications	NNS	O
for	IN	O
induction	NN	O
of	IN	O
labor	NN	O
and	CC	O
unfavorable	JJ	O
cervical	JJ	O
examinations	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
vaginally	RB	O
administered	VBN	O
misoprostol	NN	Pharmacological
(	(	Pharmacological
prostaglandin	JJ	Pharmacological
E1	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
the	DT	O
dinoprostone	NN	Pharmacological
(	(	Pharmacological
prostaglandin	JJ	Pharmacological
E2	NNP	Pharmacological
)	)	Pharmacological
vaginal	NN	O
insert	NN	O
.	.	O

Twenty-five	JJ	O
microgram	JJ	O
tablets	NNS	O
of	IN	O
misoprostol	NN	Pharmacological
were	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
posterior	JJ	O
vaginal	JJ	O
fornix	NN	O
every	DT	O
4	CD	O
hours	NNS	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
six	CD	O
doses	NNS	O
.	.	O

Additional	NNP	O
misoprostol	NN	Pharmacological
was	VBD	O
not	RB	O
given	VBN	O
after	IN	O
either	DT	O
spontaneous	JJ	O
rupture	NN	O
of	IN	O
membranes	NNS	O
,	,	O
adequate	JJ	O
cervical	JJ	O
ripening	NN	O
(	(	O
Bishop	NNP	O
score	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
8	CD	O
or	CC	O
cervical	JJ	O
dilatation	NN	O
of	IN	O
>	NN	O
or	CC	O
=	$	O
3	CD	O
cm	NN	O
)	)	O
,	,	O
or	CC	O
beginning	NN	O
of	IN	O
active	JJ	O
labor	NN	O
.	.	O

The	DT	O
vaginal	JJ	O
insert	NN	O
,	,	O
Cervidil	NNP	Pharmacological
,	,	O
containing	VBG	O
10	CD	O
mg	NN	O
of	IN	O
dinoprostone	NN	Pharmacological
in	IN	O
a	DT	O
timed-release	JJ	O
preparation	NN	O
was	VBD	O
placed	VBN	O
in	IN	O
the	DT	O
posterior	JJ	O
vaginal	JJ	O
formix	NN	O
for	IN	O
a	DT	O
maximum	JJ	O
period	NN	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
vaginal	JJ	O
insert	NN	O
was	VBD	O
removed	VBN	O
for	IN	O
spontaneous	JJ	O
rupture	NN	O
of	IN	O
membranes	NNS	O
,	,	O
entry	NN	O
into	IN	O
active	JJ	O
labor	NN	O
,	,	O
adequate	JJ	O
cervical	JJ	O
ripening	NN	O
,	,	O
or	CC	O
abnormality	NN	O
of	IN	O
uterine	JJ	O
contractile	NN	O
pattern	NN	O
or	CC	O
fetal	JJ	O
cardiac	JJ	O
activity	NN	O
.	.	O

RESULTS	NN	O
Of	IN	O
the	DT	O
200	CD	O
patients	NNS	O
enrolled	VBD	O
,	,	O
99	CD	O
were	VBD	O
randomized	VBN	O
to	TO	O
misoprostol	VB	Pharmacological
and	CC	O
101	CD	O
to	TO	O
dinoprostone	VB	Pharmacological
.	.	Pharmacological

The	DT	O
average	JJ	O
interval	NN	O
from	IN	O
start	NN	O
of	IN	O
induction	NN	O
to	TO	O
vaginal	JJ	O
delivery	NN	O
was	VBD	O
1	CD	O
hour	NN	O
shorter	NN	O
in	IN	O
the	DT	O
misoprostol	NN	Pharmacological
group	NN	O
(	(	O
1296.7	CD	O
+/-	JJ	O
722.1	CD	O
minutes	NNS	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
dinoprostone	NN	Pharmacological
group	NN	O
(	(	O
1360.0	CD	O
+/-	JJ	O
792.0	CD	O
minutes	NNS	O
)	)	O
,	,	O
but	CC	O
this	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.97	CD	O
)	)	O
.	.	O

Oxytocin	NNP	Pharmacological
augmentation	NN	O
of	IN	O
labor	NN	O
was	VBD	O
used	VBN	O
in	IN	O
50	CD	O
(	(	O
50.5	CD	O
%	NN	O
)	)	O
misoprostol-treated	JJ	Pharmacological
patients	NNS	O
and	CC	O
43	CD	O
(	(	O
43.5	CD	O
%	NN	O
)	)	O
dinoprostone-treated	JJ	Pharmacological
patients	NNS	O
(	(	O
relative	JJ	O
risk	NN	O
1.14	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.86	CD	O
to	TO	O
1.51	CD	O
,	,	O
p	NN	O
=	NNP	O
0.35	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
routes	NNS	O
of	IN	O
delivery	NN	O
with	IN	O
misoprostol	NN	Pharmacological
or	CC	O
dinoprostone	NN	Pharmacological
.	.	Pharmacological

Overall	NNP	O
,	,	O
38	CD	O
patients	NNS	O
(	(	O
19.3	CD	O
%	NN	O
)	)	O
had	VBD	O
cesarean	JJ	O
deliveries	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
lower	JJR	O
prevalence	NN	O
of	IN	O
tachysystole	NN	O
(	(	O
six	CD	O
or	CC	O
more	JJR	O
uterine	JJ	O
contractions	NNS	O
in	IN	O
a	DT	O
10-minute	JJ	O
window	NN	O
for	IN	O
two	CD	O
consecutive	JJ	O
10-minute	JJ	O
periods	NNS	O
)	)	O
in	IN	O
the	DT	O
misoprostol	NN	Pharmacological
group	NN	O
(	(	O
7.1	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
dinoprostone	NN	Pharmacological
group	NN	O
(	(	O
18.4	CD	O
%	NN	O
)	)	O
(	(	O
relative	JJ	O
risk	NN	O
0.52	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.31	CD	O
to	TO	O
0.89	CD	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
frequency	NN	O
of	IN	O
uterine	JJ	O
hyperstimulation	NN	O
or	CC	O
hypertonus	NN	O
.	.	O

Abnormal	NNP	O
fetal	JJ	O
heart	NN	O
rate	NN	O
tracings	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
23	CD	O
(	(	O
23.2	CD	O
%	NN	O
)	)	O
of	IN	O
misoprostol-treated	JJ	Pharmacological
patients	NNS	O
and	CC	O
35	CD	O
(	(	O
35.7	CD	O
%	NN	O
)	)	O
of	IN	O
dinoprostone-treated	JJ	Pharmacological
patients	NNS	O
(	(	O
relative	JJ	O
risk	NN	O
0.73	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
0.52	CD	O
to	TO	O
1.01	CD	O
,	,	O
p	NN	O
=	NNP	O
0.0546	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
meconium	NN	O
passage	NN	O
,	,	O
1-	JJ	O
or	CC	O
5-minute	JJ	O
Apgar	NNP	O
scores	NNS	O
<	VBP	O
7	CD	O
,	,	O
neonatal	JJ	O
resuscitations	NNS	O
,	,	O
or	CC	O
admissions	NNS	O
to	TO	O
the	DT	O
neonatal	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Vaginally	NNP	O
administered	VBD	O
misoprostol	NN	Pharmacological
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
dinoprostone	NN	O
for	IN	O
cervical	JJ	O
ripening	NN	O
and	CC	O
the	DT	O
induction	NN	O
of	IN	O
labor	NN	O
.	.	O

Mean	JJ	O
time	NN	O
intervals	NNS	O
to	TO	O
delivery	NN	O
,	,	O
need	NN	O
for	IN	O
oxytocin	JJ	Pharmacological
augmentation	NN	O
,	,	O
and	CC	O
routes	NNS	O
of	IN	O
delivery	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Incidence	NN	O
of	IN	O
uterine	JJ	O
tachysystole	NN	O
with	IN	O
misoprostol	NN	Pharmacological
every	DT	O
4	CD	O
hours	NNS	O
was	VBD	O
significantly	RB	O
less	JJR	O
than	IN	O
with	IN	O
dinoprostone	NN	Pharmacological
.	.	O

White	NNP	O
coat	NN	O
effect	NN	O
detected	VBD	O
using	VBG	O
self-monitoring	NN	Physical
of	IN	Physical
blood	NN	Physical
pressure	NN	Physical
at	IN	Physical
home	NN	Physical
:	:	O
comparison	NN	O
with	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
home	NN	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	Physical
HBP	NNP	Physical
)	)	Physical
is	VBZ	O
a	DT	O
reliable	JJ	O
alternative	NN	O
to	TO	O
ambulatory	VB	Physical
blood	NN	Physical
pressure	NN	Physical
(	(	Physical
ABP	NNP	Physical
)	)	Physical
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
the	DT	O
white	JJ	O
coat	NN	O
effect	NN	O
(	(	O
WCE	NNP	O
)	)	O
.	.	O

Hypertensive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
measure	VB	O
HBP	NNP	Physical
for	IN	O
2	CD	O
weeks	NNS	O
or	CC	O
ABP	NNP	Physical
for	IN	O
24	CD	O
h.	PDT	O
The	DT	O
alternative	JJ	O
measurement	NN	O
was	VBD	O
then	RB	O
performed	VBN	O
.	.	O

Clinic	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
CBP	NNP	O
)	)	O
was	VBD	O
measured	VBN	O
in	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
a	DT	O
difference	NN	O
of	IN	O
>	NN	O
or	CC	O
=	$	O
20	CD	O
mm	NN	O
Hg	NNP	O
systolic	NN	O
or	CC	O
>	NN	O
or	CC	O
=	$	O
10	CD	O
mm	NN	O
Hg	NNP	O
diastolic	VBZ	O
BP	NNP	O
between	IN	O
CBP	NNP	O
and	CC	O
awake	VB	O
ABP	NNP	Physical
or	CC	O
CBP	NNP	O
and	CC	O
HBP	NNP	Physical
,	,	O
were	VBD	O
classified	VBN	O
as	IN	O
clinic	JJ	O
reactors	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
189	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
79	CD	O
on	IN	O
stable	JJ	O
antihypertensive	JJ	O
treatment	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
WCE	NNP	O
assessed	VBD	O
using	VBG	O
the	DT	O
ABP	NNP	Physical
or	CC	O
the	DT	O
HBP	NNP	Physical
method	NN	O
(	(	O
mean	JJ	O
discrepancy	NN	O
,	,	O
systolic	JJ	O
BP	NNP	O
:	:	O
-1.5	JJ	O
+/-	JJ	O
11.7	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
-3.2	NNP	O
,	,	O
0.2	CD	O
;	:	O
diastolic	JJ	O
BP	NNP	O
:	:	O
0.9	CD	O
+/-	JJ	O
7.0	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
-0.1	NNP	O
,	,	O
1.9	CD	O
)	)	O
.	.	O

A	NNP	O
strong	JJ	O
association	NN	O
existed	VBD	O
between	IN	O
WCE	NNP	O
calculated	VBD	O
using	VBG	O
the	DT	O
HBP	NNP	O
or	CC	O
the	DT	O
ABP	NNP	Physical
method	NN	O
(	(	O
r	VB	O
=	RB	O
0.64/0.59	CD	O
systolic/diastolic	JJ	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
classified	VBN	O
as	IN	O
clinic	JJ	O
reactors	NNS	O
was	VBD	O
identical	JJ	O
using	VBG	O
the	DT	O
HBP	NNP	Physical
or	CC	O
the	DT	O
ABP	NNP	Physical
method	NN	O
(	(	O
25.9	CD	O
%	NN	O
)	)	O
.	.	O

Agreement	NN	O
between	IN	O
methods	NNS	O
in	IN	O
the	DT	O
classification	NN	O
of	IN	O
clinic	JJ	O
reactors	NNS	O
was	VBD	O
found	VBN	O
in	IN	O
147	CD	O
patients	NNS	O
(	(	O
78	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
of	IN	O
the	DT	O
HBP	NNP	Physical
method	NN	O
to	TO	O
classify	VB	O
correctly	RB	O
clinic	JJ	O
reactors	NNS	O
(	(	O
ABP	NNP	Physical
method	RB	O
used	VBD	O
as	IN	O
the	DT	O
standard	NN	O
)	)	O
were	VBD	O
57	CD	O
%	NN	O
and	CC	O
85	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
whereas	VBD	O
its	PRP$	O
positive	JJ	O
and	CC	O
negative	JJ	O
predictive	JJ	O
value	NN	O
were	VBD	O
57	CD	O
%	NN	O
and	CC	O
85	CD	O
%	NN	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
HBP	NNP	Physical
is	VBZ	O
not	RB	O
appropriate	JJ	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
ABP	NNP	Physical
diagnostic	JJ	O
testing	NN	O
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
WCE	NNP	O
.	.	O

Nevertheless	NNP	O
,	,	O
HBP	NNP	Physical
appears	VBZ	O
useful	JJ	O
as	IN	O
a	DT	O
screening	JJ	O
test	NN	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
this	DT	O
phenomenon	NN	O
.	.	O

Transdermal	NNP	O
scopolamine	NN	Pharmacological
patch	NN	O
in	IN	O
addition	NN	O
to	TO	O
ondansetron	VB	Pharmacological
for	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	VBG	O
prophylaxis	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
ambulatory	JJ	O
cosmetic	JJ	O
surgery	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
transdermal	JJ	O
scopolamine	NN	Pharmacological
in	IN	O
addition	NN	O
to	TO	O
ondansetron	VB	Pharmacological
in	IN	O
decreasing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
.	.	O

SETTING	NN	O
Academic	NNP	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
126	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
and	CC	O
II	NNP	O
patients	NNS	O
undergoing	VBG	O
outpatient	JJ	O
plastic	NN	O
surgery	NN	O
with	IN	O
three	CD	O
or	CC	O
more	JJR	O
risk	NN	O
factors	NNS	O
for	IN	O
PONV	NNP	O
.	.	O

INTERVENTIONS	NNP	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
a	DT	O
transdermal	JJ	O
scopolamine	NN	Pharmacological
(	(	O
TDS	NNP	O
)	)	O
patch	NN	O
or	CC	O
(	(	O
Group	NNP	O
2	CD	O
)	)	O
,	,	O
a	DT	O
placebo	JJ	Control
patch	NN	O
two	CD	O
hours	NNS	O
before	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	NNP	O
Occurrence	NNP	O
of	IN	O
vomiting	VBG	O
,	,	O
severity	NN	O
of	IN	O
nausea	NN	O
using	VBG	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
,	,	O
rescue	JJ	O
medication	NN	O
,	,	O
pain	VBP	O
intensity	NN	O
and	CC	O
pain	NN	O
medications	NNS	O
,	,	O
and	CC	O
side	JJ	O
effects	NNS	O
were	VBD	O
recorded	VBN	O
every	DT	O
hour	NN	O
until	IN	O
discharge	NN	O
from	IN	O
hospital	NN	O
,	,	O
then	RB	O
every	DT	O
4	CD	O
hours	NNS	O
thereafter	RB	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
A	NNP	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
postoperative	JJ	O
nausea	NN	O
between	IN	O
8	CD	O
and	CC	O
24	CD	O
hours	NNS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
TDS	NNP	O
was	VBD	O
noted	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Transdermal	NNP	O
scopolamine	NN	Pharmacological
in	IN	O
addition	NN	O
to	TO	O
ondansetron	VB	O
benefits	NNS	O
patients	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
PONV	NNP	O
undergoing	JJ	O
outpatient	NN	O
plastic	NN	O
surgery	NN	O
for	IN	O
up	IN	O
to	TO	O
20	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Parents	NNS	O
'	POS	O
state	NN	O
and	CC	O
trait	NN	O
anxiety	NN	O
:	:	O
relationships	NNS	O
with	IN	O
anxiety	NN	O
severity	NN	O
and	CC	O
treatment	NN	O
response	NN	O
in	IN	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Comorbid	NNP	O
anxiety	NN	O
is	VBZ	O
common	JJ	O
among	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorder	NNP	O
(	(	O
ASD	NNP	O
)	)	O
,	,	O
and	CC	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
anxiety	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
parents	NNS	Psychological
'	POS	Psychological
state	NN	Psychological
and	CC	Psychological
trait	NN	Psychological
anxiety	NN	Psychological
and	CC	O
parent-reported	JJ	Educational
internalizing	NN	Educational
and	CC	Other
externalizing	VBG	Educational
symptoms	NNS	Educational
among	IN	O
adolescents	NNS	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
with	IN	O
ASD	NNP	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
relationship	NN	O
of	IN	O
parents	NNS	O
'	POS	O
anxiety	NN	O
symptoms	NNS	O
and	CC	O
adolescent	JJ	O
treatment	NN	O
response	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

Parental	JJ	O
state	NN	O
anxiety	NN	O
correlated	VBD	O
with	IN	O
severity	NN	O
of	IN	O
adolescent	JJ	O
anxiety	NN	O
,	,	O
and	CC	O
trait	NN	O
anxiety	NN	O
in	IN	O
parents	NNS	O
correlated	VBN	O
with	IN	O
parent-reported	JJ	O
adolescent	NN	O
internalizing	NN	O
and	CC	O
externalizing	NN	O
symptoms	NNS	O
.	.	O

Also	RB	O
,	,	O
parents	NNS	O
of	IN	O
adolescent	JJ	O
treatment	NN	O
responders	NNS	O
experienced	VBD	O
a	DT	O
decrease	NN	O
in	IN	O
their	PRP$	O
own	JJ	O
trait	NN	O
anxiety	NN	O
.	.	O

Findings	NNS	O
highlight	VBD	O
the	DT	O
importance	NN	O
of	IN	O
considering	VBG	O
parental	JJ	O
anxiety	NN	O
when	WRB	O
targeting	VBG	O
anxiety	NN	O
among	IN	O
youth	NN	O
with	IN	O
ASD	NNP	O
.	.	O

Warfarin	NNP	Pharmacological
for	IN	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

The	DT	O
patient	NN	O
's	POS	O
perspective	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
minimal	JJ	O
clinically	RB	O
important	JJ	O
difference	NN	O
(	(	O
MCID	NNP	O
)	)	O
of	IN	O
warfarin	NN	Pharmacological
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
nonvalvular	JJ	O
atrial	JJ	O
fibrillation	NN	O
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
patients	NNS	O
using	VBG	O
2	CD	O
different	JJ	O
elicitation	NN	O
methods	NNS	O
.	.	O

DESIGN	NNP	O
All	DT	O
patients	NNS	O
completed	VBD	O
2	CD	O
face-to-face	JJ	O
interviews	NNS	O
,	,	O
which	WDT	O
were	VBD	O
2	CD	O
weeks	NNS	O
apart	RB	O
.	.	O

For	IN	O
each	DT	O
interview	NN	O
,	,	O
they	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
1	CD	O
of	IN	O
2	CD	O
elicitation	NN	O
methods	NNS	O
:	:	O
ping-ponging	NN	O
or	CC	O
starting	VBG	O
at	IN	O
the	DT	O
known	JJ	O
efficacy	NN	O
.	.	O

SETTING	CC	O
The	DT	O
practices	NNS	O
of	IN	O
2	CD	O
university-affiliated	JJ	O
family	NN	O
medicine	NN	O
centers	NNS	O
(	(	O
8	CD	O
physicians	NNS	O
each	DT	O
)	)	O
,	,	O
14	CD	O
community-based	JJ	O
family	NN	O
physicians	NNS	O
,	,	O
and	CC	O
2	CD	O
cardiologists	NNS	O
.	.	O

PATIENTS	VB	O
Sixty-four	JJ	O
patients	NNS	O
with	IN	O
nonvalvular	JJ	O
atrial	JJ	O
fibrillation	NN	O
who	WP	O
were	VBD	O
initiated	VBN	O
with	IN	O
warfarin	JJ	O
therapy	NN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
before	IN	O
the	DT	O
study	NN	O
.	.	O

INTERVENTION	NNP	O
During	IN	O
each	DT	O
interview	NN	O
,	,	O
the	DT	O
patients	NNS	O
'	POS	O
MCIDs	NNP	O
were	VBD	O
determined	VBN	O
by	IN	O
using	VBG	O
(	(	O
1	CD	O
)	)	O
a	DT	O
pictorial	JJ	O
flip	NN	O
chart	NN	O
to	TO	O
describe	VB	O
atrial	JJ	O
fibrillation	NN	O
;	:	O
the	DT	O
consequences	NNS	O
of	IN	O
a	DT	O
minor	JJ	O
stroke	NN	O
,	,	O
a	DT	O
major	JJ	O
stroke	NN	O
,	,	O
and	CC	O
a	DT	O
major	JJ	O
bleeding	NN	O
episode	NN	O
;	:	O
the	DT	O
chance	NN	O
of	IN	O
stroke	NN	O
if	IN	O
not	RB	O
taking	VBG	O
warfarin	NN	O
;	:	O
the	DT	O
chance	NN	O
of	IN	O
a	DT	O
major	JJ	O
bleeding	NN	O
episode	NN	O
if	IN	O
taking	VBG	O
warfarin	NN	O
;	:	O
examples	NNS	O
of	IN	O
the	DT	O
inconvenience	NN	O
,	,	O
minor	JJ	O
side	NN	O
effects	NNS	O
,	,	O
and	CC	O
costs	NNS	O
of	IN	O
warfarin	JJ	O
therapy	NN	O
;	:	O
and	CC	O
then	RB	O
(	(	O
2	CD	O
)	)	O
1	CD	O
of	IN	O
the	DT	O
2	CD	O
elicitation	NN	O
methods	NNS	O
to	TO	O
determine	VB	O
their	PRP$	O
MCIDs	NNP	O
(	(	O
the	DT	O
smallest	JJS	O
reduction	NN	O
in	IN	O
stroke	NN	O
risk	NN	O
at	IN	O
which	WDT	O
the	DT	O
patients	NNS	O
were	VBD	O
willing	JJ	O
to	TO	O
take	VB	O
warfarin	NN	O
)	)	O
.	.	O

Patients	NNS	O
'	POS	O
knowledge	NN	O
of	IN	O
their	PRP$	O
stroke	NN	O
risk	NN	O
,	,	O
acceptability	NN	O
of	IN	O
the	DT	O
interview	NN	O
process	NN	O
,	,	O
and	CC	O
factors	NNS	O
determining	VBG	O
their	PRP$	O
preferences	NNS	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

MAIN	NNP	O
RESULTS	NNP	O
Given	NNP	O
a	DT	O
baseline	NN	O
risk	NN	O
of	IN	O
having	VBG	O
a	DT	O
stroke	NN	O
in	IN	O
the	DT	O
next	JJ	O
2	CD	O
years	NNS	O
,	,	O
if	IN	O
not	RB	O
taking	VBG	O
warfarin	NN	Pharmacological
,	,	O
of	IN	O
10	CD	O
of	IN	O
100	CD	O
,	,	O
the	DT	O
mean	JJ	O
MCID	NNP	O
was	VBD	O
2.01	CD	O
of	IN	O
100	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
1.60-2.42	JJ	O
)	)	O
.	.	O

Fifty-two	JJ	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
would	MD	O
take	VB	O
warfarin	NN	Pharmacological
for	IN	O
an	DT	O
absolute	JJ	O
decrease	NN	O
in	IN	O
stroke	NN	O
risk	NN	O
of	IN	O
1	CD	O
%	NN	O
over	IN	O
2	CD	O
years	NNS	O
.	.	O

Before	IN	O
eliciting	VBG	O
their	PRP$	O
MCIDs	NNP	O
,	,	O
patients	NNS	O
showed	VBD	O
poor	JJ	O
knowledge	NN	O
of	IN	O
their	PRP$	O
stroke	NN	O
risk	NN	O
,	,	O
which	WDT	O
improved	VBD	O
afterward	RB	O
.	.	O

The	DT	O
interview	NN	O
process	NN	O
was	VBD	O
well	RB	O
accepted	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
.	.	O

The	DT	O
MCID	NNP	O
using	VBG	O
the	DT	O
ping-ponging	JJ	O
elicitation	NN	O
method	NN	O
was	VBD	O
1.015	CD	O
of	IN	O
100	CD	O
smaller	JJR	O
compared	VBN	O
with	IN	O
use	NN	O
of	IN	O
the	DT	O
starting	NN	O
at	IN	O
the	DT	O
known	JJ	O
efficacy	NN	O
method	NN	O
(	(	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NN	O
We	PRP	O
were	VBD	O
able	JJ	O
to	TO	O
determine	VB	O
the	DT	O
MCID	NNP	O
of	IN	O
warfarin	NN	Pharmacological
therapy	NN	Pharmacological
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
stroke	NN	O
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
patients	NNS	O
with	IN	O
nonvalvular	JJ	O
atrial	JJ	O
fibrillation	NN	O
.	.	O

Their	PRP$	O
MCIDs	NNPS	O
were	VBD	O
much	RB	O
smaller	JJR	O
than	IN	O
those	DT	O
that	WDT	O
have	VBP	O
been	VBN	O
implied	VBN	O
by	IN	O
some	DT	O
experts	NNS	O
and	CC	O
clinicians	NNS	O
.	.	O

The	DT	O
interview	NN	O
process	NN	O
,	,	O
using	VBG	O
the	DT	O
flip	JJ	O
chart	NN	O
approach	NN	O
,	,	O
appeared	VBD	O
to	TO	O
improve	VB	O
the	DT	O
patients	NNS	O
'	POS	O
knowledge	NN	O
of	IN	O
their	PRP$	O
disease	NN	O
and	CC	O
its	PRP$	O
consequences	NNS	O
and	CC	O
treatment	NN	O
.	.	O

The	DT	O
method	NN	O
used	VBN	O
to	TO	O
elicit	VB	O
the	DT	O
patients	NNS	O
'	POS	O
MCIDs	NNP	O
can	MD	O
have	VB	O
a	DT	O
clinically	RB	O
important	JJ	O
effect	NN	O
on	IN	O
patient	NN	O
responses	NNS	O
.	.	O

The	DT	O
method	NN	O
used	VBN	O
in	IN	O
our	PRP$	O
study	NN	O
can	MD	O
be	VB	O
generalized	VBN	O
to	TO	O
other	JJ	O
conditions	NNS	O
and	CC	O
,	,	O
thus	RB	O
,	,	O
could	MD	O
be	VB	O
helpful	JJ	O
in	IN	O
3	CD	O
ways	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
from	IN	O
a	DT	O
clinical	JJ	O
decision-making	NN	O
perspective	NN	O
,	,	O
it	PRP	O
could	MD	O
facilitate	VB	O
patient-physician	JJ	O
communication	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
it	PRP	O
could	MD	O
clarify	VB	O
the	DT	O
patient	NN	O
perspective	NN	O
when	WRB	O
interpreting	VBG	O
the	DT	O
results	NNS	O
of	IN	O
previously	RB	O
completed	VBN	O
trials	NNS	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
it	PRP	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
derive	VB	O
more	RBR	O
clinically	RB	O
relevant	JJ	O
sample	NN	O
sizes	NNS	O
for	IN	O
randomized	JJ	O
treatment	NN	O
trials	NNS	O
.	.	O

Effect	NNP	O
of	IN	O
four	CD	Physical
intermediate	JJ	Physical
layer	NN	Physical
treatments	NNS	Physical
on	IN	O
microleakage	NN	O
of	IN	O
Class	NNP	O
II	NNP	O
composite	JJ	O
restorations	NNS	O
.	.	O

This	DT	O
in	IN	O
vitro	NN	O
study	NN	O
examines	VBZ	O
the	DT	O
marginal	JJ	O
sealing	NN	O
ability	NN	O
of	IN	O
four	CD	Other
different	JJ	Other
intermediate	JJ	Other
materials	NNS	Other
applied	VBN	O
before	IN	O
placement	NN	O
of	IN	O
a	DT	O
condensable	JJ	Other
composite	NN	Other
.	.	Other

Class	NNP	O
II	NNP	O
preparations	NNS	O
were	VBD	O
made	VBN	O
with	IN	O
gingival	JJ	O
margins	NNS	O
placed	VBD	O
1.0	CD	O
mm	JJ	O
apical	JJ	O
to	TO	O
the	DT	O
cementoenamel	JJ	O
junction	NN	O
of	IN	O
60	CD	O
extracted	JJ	O
teeth	NNS	O
,	,	O
randomly	RB	O
assigned	VBN	O
to	TO	O
five	CD	O
groups	NNS	O
of	IN	O
12	CD	O
.	.	O

Following	VBG	O
restoration	NN	O
,	,	O
teeth	EX	O
were	VBD	O
thermocycled	VBN	O
,	,	O
soaked	VBN	O
in	IN	O
0.5	CD	O
%	NN	O
basic	JJ	O
fuchsin	NN	O
,	,	O
and	CC	O
sectioned	VBD	O
longitudinally	RB	O
.	.	O

The	DT	O
resin-modified	JJ	Other
glass	NN	Other
ionomer	NN	Other
cement	NN	Other
demonstrated	VBD	O
significantly	RB	O
less	JJR	O
microleakage	NN	O
than	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
dentin	NN	Other
bonding	NN	Other
agent	NN	Other
alone	RB	Other
or	CC	O
in	IN	O
combination	NN	Other
with	IN	Other
flowable	JJ	Other
composite	JJ	Other
,	,	O
flowable	JJ	O
compomer	NN	O
,	,	O
or	CC	O
autoploymerizing	VBG	O
composite	JJ	O
(	(	O
p	JJ	O
<	NN	O
0.05	CD	O
,	,	O
Dunn	NNP	O
's	POS	O
test	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
supports	VBZ	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
glass	NN	Physical
ionomer	NN	Physical
open	JJ	Physical
sandwich	NN	Physical
technique	NN	Physical
in	IN	O
deep	JJ	O
Class	NNP	O
II	NNP	O
direct	JJ	O
composite	JJ	O
restorations	NNS	O
.	.	O

Behavioral	JJ	O
effects	NNS	O
of	IN	O
Org	NNP	Pharmacological
2766	CD	Pharmacological
,	,	O
a	DT	O
synthetic	JJ	O
analog	NN	O
of	IN	O
the	DT	O
adrenocorticotrophic	JJ	O
hormone	NN	O
(	(	O
4-9	JJ	O
)	)	O
,	,	O
in	IN	O
14	CD	O
outpatient	JJ	O
autistic	JJ	O
children	NNS	O
.	.	O

Fourteen	NNP	O
children	NNS	O
(	(	O
12	CD	O
infantile	NN	O
autism	NN	O
full	JJ	O
syndrome	NN	O
present	NN	O
,	,	O
2	CD	O
atypical	JJ	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
)	)	O
between	IN	O
5	CD	O
and	CC	O
13	CD	O
years	NNS	O
of	IN	O
age	NN	O
participated	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
cross-over	JJ	O
trial	NN	O
.	.	O

Each	DT	O
child	NN	O
received	VBD	O
20	CD	O
mg	NNS	O
Org	JJ	Pharmacological
2766	CD	Pharmacological
(	(	O
synthetic	JJ	O
analog	NN	O
of	IN	O
ACTH	NNP	O
4-9	JJ	O
)	)	O
/day	NN	O
during	IN	O
4	CD	O
weeks	NNS	O
,	,	O
or	CC	O
placebo	NN	O
in	IN	O
a	DT	O
randomly	NN	O
assigned	VBN	O
sequence	NN	O
.	.	O

Drug	JJ	O
effects	NNS	O
were	VBD	O
monitored	VBN	O
by	IN	O
ethological	JJ	O
playroom	NN	O
observation	NN	O
and	CC	O
by	IN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
ratings	NNS	O
by	IN	O
parents	NNS	O
and	CC	O
teachers	NNS	O
.	.	O

Data	NNP	O
of	IN	O
the	DT	O
playroom	NN	O
observation	NN	O
pointed	VBD	O
to	TO	O
an	DT	O
activating	VBG	O
influence	NN	O
of	IN	O
Org	NNP	O
2766	CD	O
,	,	O
as	IN	O
revealed	VBN	O
by	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
of	IN	O
stereotypic	NN	O
behavior	NN	O
and	CC	O
significant	JJ	O
increases	NNS	O
in	IN	O
change	NN	O
toys	NNS	O
,	,	O
locomote	NN	O
,	,	O
and	CC	O
talk	NN	O
.	.	O

Checklist	JJ	O
ratings	NNS	O
did	VBD	O
not	RB	O
show	VB	O
significant	JJ	O
changes	NNS	O
.	.	O

The	DT	O
clinical	JJ	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

Direct	JJ	Physical
trocar	NN	Physical
insertion	NN	Physical
vs.	FW	O
Verres	NNP	Physical
needle	FW	Physical
use	NN	Physical
for	IN	O
laparoscopic	JJ	O
sterilization	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
prospective	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
direct	JJ	Physical
trocar	NN	Physical
insertion	NN	Physical
with	IN	O
prior	JJ	O
peritoneal	JJ	O
insufflation	NN	O
with	IN	O
a	DT	O
Verres	NNP	Physical
needle	NN	Physical
for	IN	O
laparoscopic	NN	O
tubal	JJ	O
sterilization	NN	O
.	.	O

Direct	JJ	Physical
trocar	NN	Physical
insertion	NN	Physical
resulted	VBD	O
in	IN	O
fewer	JJR	O
instrument	NN	O
insertions	NNS	O
(	(	O
21.8	CD	O
%	NN	O
vs.	FW	O
7.8	CD	O
%	NN	O
)	)	O
and	CC	O
use	NN	O
of	IN	O
smaller	JJR	O
volumes	NNS	O
of	IN	O
CO2	NNP	O
(	(	O
2.67	CD	O
vs.	FW	O
2.32	CD	O
L	NNP	O
)	)	O
.	.	O

Direct	JJ	Physical
trocar	NN	Physical
use	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
operating	NN	O
time	NN	O
from	IN	O
9	CD	O
minutes	NNS	O
,	,	O
40	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
needle	JJ	O
group	NN	O
to	TO	O
7	CD	O
minutes	NNS	O
,	,	O
30	CD	O
seconds	NNS	O
in	IN	O
the	DT	O
trocar	NN	O
group	NN	O
.	.	O

Minor	NNP	O
omental	JJ	O
injuries	NNS	O
occurred	VBD	O
in	IN	O
a	DT	O
small	JJ	O
percentage	NN	O
of	IN	O
each	DT	O
group	NN	O
,	,	O
while	IN	O
serious	JJ	O
complications	NNS	O
occurred	VBD	O
once	RB	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Menopausal	NNP	O
quality	NN	O
of	IN	O
life	NN	O
:	:	O
RCT	NNP	O
of	IN	O
yoga	NN	Physical
,	,	O
exercise	NN	Physical
,	,	O
and	CC	O
omega-3	JJ	Pharmacological
supplements	NNS	Pharmacological
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
3	CD	O
nonhormonal	JJ	O
therapies	NNS	O
for	IN	O
the	DT	O
improvement	NN	O
of	IN	O
menopause-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
women	NNS	O
with	IN	O
vasomotor	NN	O
symptoms	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
12-week	JJ	O
3	CD	O
?	.	O
2	CD	O
randomized	VBD	O
,	,	O
controlled	VBD	O
,	,	O
factorial	JJ	O
design	NN	O
trial	NN	O
.	.	O

Peri-	NN	O
and	CC	O
postmenopausal	JJ	O
women	NNS	O
,	,	O
40-62	JJ	O
years	NNS	O
old	JJ	O
,	,	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
yoga	VB	Physical
(	(	O
n	JJ	O
=	NNP	O
107	CD	O
)	)	O
,	,	O
exercise	NN	O
(	(	O
n	JJ	O
=	NNP	O
106	CD	O
)	)	O
,	,	O
or	CC	O
usual	JJ	Control
activity	NN	Control
(	(	O
n	JJ	O
=	NNP	O
142	CD	O
)	)	O
and	CC	O
also	RB	O
assigned	VBD	O
randomly	RB	O
to	TO	O
a	DT	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
omega-3	JJ	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
177	CD	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
178	CD	O
)	)	O
capsules	NNS	O
.	.	O

We	PRP	O
performed	VBD	O
the	DT	O
following	JJ	O
interventions	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
weekly	JJ	O
90-minute	CD	O
yoga	NN	O
classes	NNS	O
with	IN	O
daily	JJ	O
at-home	JJ	O
practice	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
individualized	VBN	O
facility-based	JJ	O
aerobic	JJ	O
exercise	NN	O
training	NN	O
3	CD	O
times/week	NN	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
0.615	CD	O
g	JJ	O
omega-3	JJ	Pharmacological
supplement	NN	Pharmacological
,	,	O
3	CD	O
times/day	NN	O
.	.	O

The	DT	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
following	JJ	O
scores	NNS	O
:	:	O
Menopausal	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
Questionnaire	NNP	O
(	(	O
MENQOL	NNP	O
)	)	O
total	NN	O
and	CC	O
domain	NN	O
(	(	O
vasomotor	NN	O
symptoms	NNS	O
,	,	O
psychosocial	JJ	O
,	,	O
physical	JJ	O
and	CC	O
sexual	JJ	O
)	)	O
.	.	O

RESULTS	NNP	O
Among	IN	O
355	CD	O
randomly	NNS	O
assigned	VBN	O
women	NNS	O
who	WP	O
average	VBP	O
age	NN	O
was	VBD	O
54.7	CD	O
years	NNS	O
,	,	O
338	CD	O
women	NNS	O
(	(	O
95	CD	O
%	NN	O
)	)	O
completed	VBD	O
12-week	JJ	O
assessments	NNS	O
.	.	O

Mean	NNP	O
baseline	NN	O
vasomotor	NN	O
symptoms	JJ	O
frequency	NN	O
was	VBD	O
7.6/day	CD	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
baseline	NN	O
total	JJ	O
MENQOL	NNP	O
score	NN	O
was	VBD	O
3.8	CD	O
(	(	O
range	NN	O
,	,	O
1-8	CD	O
from	IN	O
better	JJR	O
to	TO	O
worse	VB	O
)	)	O
with	IN	O
no	DT	O
between-group	JJ	O
differences	NNS	O
.	.	O

For	IN	O
yoga	NN	O
compared	VBN	O
to	TO	O
usual	JJ	O
activity	NN	O
,	,	O
baseline	NN	O
to	TO	O
12-week	JJ	O
improvements	NNS	O
were	VBD	O
seen	VBN	O
for	IN	O
MENQOL	NNP	O
total	JJ	O
-0.3	NNP	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-0.6	VBP	O
to	TO	O
0	CD	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
,	,	O
vasomotor	NN	O
symptom	NN	O
domain	NN	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
,	,	O
and	CC	O
sexuality	NN	O
domain	NN	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
scores	VBZ	O
.	.	O

For	IN	O
women	NNS	O
who	WP	O
underwent	VBP	O
exercise	NN	Physical
and	CC	O
omega-3	JJ	Pharmacological
therapy	NN	Pharmacological
compared	VBN	O
with	IN	O
control	NN	O
subjects	NNS	O
,	,	O
improvements	NNS	O
in	IN	O
baseline	NN	O
to	TO	O
12-week	JJ	O
total	JJ	O
MENQOL	NNP	O
scores	NNS	O
were	VBD	O
not	RB	O
observed	VBN	O
.	.	O

Exercise	NN	O
showed	VBD	O
benefit	NN	O
in	IN	O
the	DT	O
MENQOL	NNP	O
physical	JJ	O
domain	NN	O
score	NN	O
at	IN	O
12	CD	O
weeks	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
All	NNP	O
women	NNS	O
become	VBP	O
menopausal	JJ	O
,	,	O
and	CC	O
many	JJ	O
of	IN	O
them	PRP	O
seek	VBP	O
medical	JJ	O
advice	NN	O
on	IN	O
ways	NNS	O
to	TO	O
improve	VB	O
quality	NN	O
of	IN	O
life	NN	O
;	:	O
little	JJ	O
evidence-based	JJ	O
information	NN	O
exists	NNS	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
,	,	O
among	IN	O
healthy	JJ	O
sedentary	JJ	O
menopausal	NN	O
women	NNS	O
,	,	O
yoga	NN	O
appears	VBZ	O
to	TO	O
improve	VB	O
menopausal	NN	O
quality	NN	O
of	IN	O
life	NN	O
;	:	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
our	PRP$	O
finding	NN	O
is	VBZ	O
uncertain	JJ	O
because	IN	O
of	IN	O
the	DT	O
modest	JJ	O
effect	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
small	JJ	Physical
needle-knife	JJ	Physical
comprehensive	JJ	Physical
therapy	NN	Physical
on	IN	O
pain	NN	O
and	CC	O
lumbar	NN	O
flexion	NN	O
range	NN	O
in	IN	O
the	DT	O
chronic	JJ	O
nonspecific	NN	O
low	JJ	O
back	RB	O
pain	NN	O
patient	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
small	JJ	Physical
needle-knife	JJ	Physical
comprehensive	JJ	Physical
therapy	NN	Physical
on	IN	O
pain	NN	O
and	CC	O
lumbar	NN	O
flexion	NN	O
range	NN	O
in	IN	O
the	DT	O
chronic	JJ	O
nonspecific	NN	O
low	JJ	O
back	RB	O
pain	NN	O
patient	NN	O
.	.	O

METHODS	NNP	O
Three	CD	O
hundred	VBD	O
and	CC	O
five	CD	O
cases	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
a	DT	O
needle-knife	JJ	Physical
group	NN	Physical
of	IN	O
153	CD	O
cases	NNS	O
and	CC	O
a	DT	O
physiotherapy	NN	Physical
group	NN	Physical
of	IN	O
152	CD	O
cases	NNS	O
.	.	O

The	DT	O
needle-knife	JJ	Physical
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
small	JJ	Physical
needle-knife	JJ	Physical
releasing	NN	Physical
therapy	NN	Physical
,	,	Physical
blocking	VBG	Physical
and	CC	Physical
functional	JJ	Physical
training	NN	Physical
.	.	Physical

The	DT	O
physiotherapy	NN	Physical
group	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
ultra-short	JJ	Physical
wave	NN	Physical
,	,	Physical
modulated	VBD	Physical
medium	NN	Physical
frequency	NN	Physical
current	JJ	Physical
,	,	Physical
massage	NN	Physical
and	CC	Physical
functional	JJ	Physical
training	NN	Physical
.	.	Physical

Pain	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
and	CC	O
the	DT	O
lumbar	NN	O
flexion	NN	O
range	NN	O
was	VBD	O
determined	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatment	NN	O
,	,	O
the	DT	O
pain	NN	O
and	CC	O
the	DT	O
lumbar	NN	O
flexion	NN	O
range	NN	O
were	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
;	:	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
the	DT	O
VAS	NNP	O
score	NN	O
and	CC	O
the	DT	O
lumbar	NN	O
flexion	NN	O
range	NN	O
were	VBD	O
(	(	O
1.60	CD	O
+/-	JJ	O
0.38	CD	O
)	)	O
points	NNS	O
and	CC	O
(	(	O
65.76	CD	O
+/-	JJ	O
15.11	CD	O
)	)	O
cm	NN	O
in	IN	O
the	DT	O
needle-knife	JJ	Physical
group	NN	O
and	CC	O
(	(	O
4.59	CD	O
+/-	JJ	O
1.09	CD	O
)	)	O
points	NNS	O
and	CC	O
(	(	O
53.74	CD	O
+/-	JJ	O
15.13	CD	O
)	)	O
cm	NN	O
in	IN	O
the	DT	O
physiotherapy	NN	O
group	NN	O
,	,	O
respectively	RB	O
,	,	O
the	DT	O
needle-knife	JJ	Physical
group	NN	O
being	VBG	O
significantly	RB	O
better	JJR	O
than	IN	O
the	DT	O
physiotherapy	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Follow-up	NNP	O
survey	NN	O
of	IN	O
6-36	JJ	O
months	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
VAS	NNP	O
score	NN	O
and	CC	O
the	DT	O
lumbar	NN	O
flexion	NN	O
range	NN	O
in	IN	O
the	DT	O
needle-knife	JJ	Physical
group	NN	O
were	VBD	O
superior	JJ	O
to	TO	O
those	DT	O
in	IN	O
the	DT	O
physiotherapy	NN	Physical
group	NN	O
.	.	O

CONCLUSION	NNP	O
Small	NNP	Physical
needle-knife	JJ	Physical
comprehensive	JJ	Physical
therapy	NN	Physical
can	MD	O
significantly	RB	O
improve	VB	O
pain	NN	O
and	CC	O
lumbar	NN	O
flexion	NN	O
range	NN	O
in	IN	O
the	DT	O
chronic	JJ	O
nonspecific	NN	O
low	JJ	O
back	RB	O
pain	NN	O
patient	NN	O
,	,	O
with	IN	O
a	DT	O
stable	JJ	O
long-term	JJ	O
therapeutic	JJ	O
effect	NN	O
.	.	O

Memantine	NNP	Pharmacological
add-on	JJ	O
to	TO	O
risperidone	VB	Pharmacological
for	IN	O
treatment	NN	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
schizophrenia	NN	O
:	:	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
memantine	JJ	Pharmacological
add-on	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
schizophrenia	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
40	CD	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
(	(	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
)	)	O
who	WP	O
were	VBD	O
stabilized	VBN	O
on	IN	O
risperidone	NN	Pharmacological
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
memantine	NN	Pharmacological
(	(	O
20	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	Control
in	IN	O
addition	NN	O
to	TO	O
risperidone	VB	Pharmacological
,	,	O
6	CD	O
mg/d	NN	O
,	,	O
for	IN	O
eight	CD	O
weeks	NNS	O
.	.	O

Assessment	NNP	O
was	VBD	O
done	VBN	O
using	VBG	O
the	DT	O
Positive	NNP	O
and	CC	O
Negative	NNP	O
Syndrome	NNP	O
Scale	NNP	O
at	IN	O
baseline	NN	O
,	,	O
week	NN	O
4	CD	O
,	,	O
and	CC	O
week	NN	O
8	CD	O
.	.	O

The	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Extrapyramidal	NNP	O
Symptom	NNP	O
Rating	NNP	O
Scale	NNP	O
at	IN	O
baseline	NN	O
and	CC	O
week	NN	O
8	CD	O
were	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
depression	NN	O
and	CC	O
extrapyramidal	NN	O
symptoms	NNS	O
,	,	O
respectively	RB	O
.	.	O

All	DT	O
40	CD	O
patients	NNS	O
had	VBD	O
at	IN	O
least	JJS	O
one	CD	O
postbaseline	NN	O
measurement	NN	O
,	,	O
and	CC	O
38	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
trial	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
memantine	NN	O
group	NN	O
showed	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
improvement	NN	O
on	IN	O
negative	JJ	O
subscale	NN	O
than	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
at	IN	O
end	NN	O
point	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
same	JJ	O
effect	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
the	DT	O
total	JJ	O
score	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
the	DT	O
general	JJ	O
psychopathology	NN	O
subscale	NN	O
score	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
reduction	NN	O
of	IN	O
positive	JJ	O
symptoms	NNS	O
score	VBP	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.757	CD	O
)	)	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
and	CC	O
the	DT	O
Extrapyramidal	NNP	O
Symptom	NNP	O
Rating	NNP	O
Scale	NNP	O
scores	NNS	O
and	CC	O
frequency	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Our	PRP$	O
study	NN	O
showed	VBD	O
that	IN	O
memantine	NN	O
is	VBZ	O
a	DT	O
tolerable	JJ	O
and	CC	O
efficacious	JJ	O
add-on	JJ	O
treatment	NN	O
for	IN	O
primary	JJ	O
negative	JJ	O
symptoms	NNS	O
of	IN	O
schizophrenia	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
transcutaneous	JJ	Physical
electrical	JJ	Physical
stimulation	NN	Physical
of	IN	Physical
auricular	JJ	Physical
Shenmen	NNP	Physical
point	NN	Physical
on	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
and	CC	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
in	IN	O
cesarean	JJ	O
section	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
transcutaneous	JJ	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Shenmen	NNP	O
point	NN	O
on	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
and	CC	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
in	IN	O
cesarean	JJ	O
section	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
IRB	NNP	O
approval	NN	O
and	CC	O
informed	JJ	O
consent	NN	O
,	,	O
one	CD	O
hundred	CD	O
and	CC	O
eighty	VB	O
singleton	NN	O
primiparas	IN	O
undergoing	VBG	O
elective	JJ	O
cesarean	JJ	O
section	NN	O
,	,	O
in	IN	O
Qingdao	NNP	O
Municipal	NNP	O
Hospital	NNP	O
,	,	O
and	CC	O
Qingdao	NNP	O
Hiser	NNP	O
Medical	NNP	O
Center	NNP	O
,	,	O
from	IN	O
November	NNP	O
2011	CD	O
to	TO	O
March	NNP	O
2012	CD	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
:	:	O
transcutaneous	JJ	Physical
electrical	JJ	Physical
stimulation	NN	Physical
of	IN	Physical
auricular	JJ	Physical
Shenmen	NNP	Physical
point	NN	Physical
group	NN	Physical
(	(	O
group	NN	O
A	NNP	O
,	,	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
,	,	O
transcutaneous	JJ	Physical
electrical	JJ	Physical
stimulation	NN	Physical
of	IN	Physical
auricular	JJ	Physical
Eye	NNP	Physical
point	NN	Physical
group	NN	Physical
(	(	O
group	NN	O
B	NNP	O
,	,	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
and	CC	O
control	NN	Control
group	NN	Control
(	(	O
group	NN	O
C	NNP	O
,	,	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
.	.	O

Women	NNP	O
of	IN	O
group	NN	O
A	NNP	O
received	VBD	O
transcutaneous	JJ	Physical
electrical	JJ	Physical
stimulation	NN	Physical
of	IN	O
auricular	JJ	O
Shenmen	NNP	O
point	NN	O
(	(	O
frequency	NN	O
1.5	CD	O
HZ	NNP	O
)	)	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
preoperation	NN	O
,	,	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
22	CD	O
hours	NNS	O
of	IN	O
postoperation	NN	O
for	IN	O
30	CD	O
minutes	NNS	O
.	.	O

The	DT	O
strength	NN	O
was	VBD	O
controlled	VBN	O
by	IN	O
themselves	PRP	O
.	.	O

Women	NNP	O
of	IN	O
group	NN	O
B	NNP	O
received	VBD	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Eye	NNP	O
point	NN	O
as	IN	O
group	NN	O
A	NNP	O
.	.	O

Women	NNP	O
of	IN	O
group	NN	O
C	NNP	O
received	VBD	O
pressurization	NN	O
and	CC	O
connected	VBN	O
line	NN	O
were	VBD	O
the	DT	O
same	JJ	O
with	IN	O
group	NN	O
A	NNP	O
,	,	O
but	CC	O
without	IN	O
electrical	JJ	Control
stimulation	NN	Control
.	.	O

The	DT	O
following	JJ	O
indexes	NNS	O
was	VBD	O
observed	VBN	O
:	:	O
the	DT	O
incidence	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
for	IN	O
48	CD	O
hours	NNS	O
;	:	O
the	DT	O
rate	NN	O
of	IN	O
metoclopramide	NN	O
;	:	O
the	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
score	NN	O
of	IN	O
rest	NN	O
pain	NN	O
,	,	O
uterine	JJ	O
contration	NN	O
pain	NN	O
and	CC	O
dynamic	JJ	O
pain	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
postoperation	NN	O
for	IN	O
6	CD	O
,	,	O
12	CD	O
,	,	O
24	CD	O
and	CC	O
48	CD	O
hours	NNS	O
(	(	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
)	)	O
;	:	O
the	DT	O
total	JJ	O
number	NN	O
and	CC	O
effective	JJ	O
compressions	NNS	O
number	NN	O
of	IN	O
patient-controlled	JJ	O
epidural	JJ	O
analgesia	NN	O
(	(	O
PCEA	NNP	O
)	)	O
;	:	O
the	DT	O
dose	NN	O
of	IN	O
analgesia	JJ	O
mixture	NN	O
;	:	O
the	DT	O
anal	JJ	O
exhaust	JJ	O
time	NN	O
;	:	O
the	DT	O
volume	NN	O
of	IN	O
postoperative	JJ	O
bleeding	NN	O
for	IN	O
6	CD	O
hours	NNS	O
of	IN	O
postoperation	NN	O
and	CC	O
the	DT	O
other	JJ	O
side	NN	O
effects	NNS	O
.	.	O

RESULTS	NNP	O
Compared	NNP	O
with	IN	O
group	NN	O
B	NNP	O
and	CC	O
group	NN	O
C	NNP	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
PONV	NNP	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
metoclopramide	NN	O
,	,	O
the	DT	O
VAS	NNP	O
score	NN	O
at	IN	O
the	DT	O
time	NN	O
T	NNP	O
(	(	O
1	CD	O
)	)	O
-T	NN	O
(	(	O
4	CD	O
)	)	O
,	,	O
the	DT	O
total	JJ	O
number	NN	O
and	CC	O
effective	JJ	O
compressions	NNS	O
number	NN	O
of	IN	O
PCEA	NNP	O
,	,	O
the	DT	O
ratio	NN	O
of	IN	O
the	DT	O
total	JJ	O
number	NN	O
with	IN	O
effective	JJ	O
compressions	NNS	O
number	NN	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
analgesia	JJ	O
mixture	NN	O
were	VBD	O
decreased	VBN	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
no	DT	O
difference	NN	O
compared	VBN	O
group	NN	O
B	NNP	O
with	IN	O
group	NN	O
C	NNP	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
anal	JJ	O
exhaust	NN	O
time	NN	O
and	CC	O
the	DT	O
volume	NN	O
of	IN	O
postoperative	JJ	O
bleeding	NN	O
for	IN	O
6	CD	O
hours	NNS	O
of	IN	O
postoperation	NN	O
were	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

No	UH	O
other	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSION	NNP	O
Transcutaneous	NNP	O
electrical	JJ	O
stimulation	NN	O
of	IN	O
auricular	JJ	O
Shenmen	NNS	O
point	NN	O
can	MD	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
PONV	NNP	O
and	CC	O
improves	VBZ	O
analgesia	JJ	O
effect	NN	O
of	IN	O
PCEA	NNP	O
in	IN	O
postoperation	NN	O
of	IN	O
cesarean	JJ	O
section	NN	O
.	.	O

Transurethral	JJ	Surgical
prostate	NN	Surgical
resection	NN	Surgical
and	CC	O
bleeding	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo	NN	Control
controlled	VBD	O
trial	NN	O
of	IN	O
role	NN	O
of	IN	O
finasteride	NN	Pharmacological
for	IN	O
decreasing	VBG	O
operative	JJ	O
blood	NN	O
loss	NN	O
.	.	O

PURPOSE	NNP	O
Bleeding	NNP	O
associated	VBN	O
with	IN	O
transurethral	JJ	O
prostate	NN	O
resection	NN	O
can	MD	O
often	RB	O
be	VB	O
significant	JJ	O
and	CC	O
lead	JJ	O
to	TO	O
increased	VBN	O
morbidity	NN	O
and	CC	O
occasionally	RB	O
mortality	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
finasteride	NN	Pharmacological
decreases	VBZ	O
bleeding	VBG	O
in	IN	O
patients	NNS	O
with	IN	O
hematuria	NNS	O
of	IN	O
prostatic	JJ	O
origin	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
bleeding	VBG	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
transurethral	JJ	O
prostate	NN	O
resection	NN	O
could	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
giving	VBG	O
finasteride	NN	Pharmacological
for	IN	O
2	CD	O
weeks	NNS	O
before	RB	O
surgery	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	JJ	O
70	CD	O
patients	NNS	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
elective	JJ	O
transurethral	JJ	O
prostate	NN	O
resection	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
5	CD	Pharmacological
mg.	NNS	Pharmacological
finasteride	JJ	Pharmacological
daily	RB	Pharmacological
or	CC	O
placebo	VB	Control
for	IN	O
2	CD	O
weeks	NNS	O
before	RB	O
surgery	NN	O
.	.	O

Serum	NNP	O
hemoglobin	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
after	IN	O
surgery	NN	O
,	,	O
and	CC	O
the	DT	O
following	JJ	O
day	NN	O
.	.	O

The	DT	O
volume	NN	O
of	IN	O
irrigation	NN	O
fluid	NN	O
used	VBN	O
and	CC	O
its	PRP$	O
hemoglobin	JJ	O
concentration	NN	O
as	RB	O
well	RB	O
as	IN	O
resected	VBN	O
prostate	NN	O
weight	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
68	CD	O
patients	NNS	O
who	WP	O
underwent	JJ	O
transurethral	JJ	O
prostate	NN	O
resection	NN	O
2	CD	O
were	VBD	O
withdrawn	VBN	O
before	RB	O
surgery	NN	O
,	,	O
and	CC	O
so	RB	O
32	CD	O
received	VBD	O
finasteride	NN	Pharmacological
and	CC	O
36	CD	O
received	VBD	O
placebo	NN	Control
.	.	O

There	EX	O
was	VBD	O
significantly	RB	O
less	JJR	O
mean	JJ	O
blood	NN	O
loss	NN	O
in	IN	O
irrigation	NN	O
fluid	NN	O
in	IN	O
the	DT	O
finasteride	NN	Pharmacological
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
43.6	CD	O
versus	NN	O
69.3	CD	O
gm	NN	O
.	.	O

hemoglobin	NN	O
,	,	O
p	NN	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
difference	NN	O
was	VBD	O
more	RBR	O
significant	JJ	O
when	WRB	O
blood	NN	O
loss	NN	O
per	IN	O
gm	NN	O
.	.	O

resected	JJ	O
prostate	NN	O
was	VBD	O
calculated	VBN	O
(	(	O
2.65	CD	O
versus	NN	O
4.65	CD	O
gm	NN	O
.	.	O

hemoglobin	NN	O
per	IN	O
gm	NN	O
.	.	O

prostate	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
shows	VBZ	O
that	IN	O
finasteride	NN	Pharmacological
given	VBN	O
for	IN	O
2	CD	O
weeks	NNS	O
preoperatively	RB	O
decreases	VBZ	O
bleeding	VBG	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
transurethral	JJ	O
prostate	NN	O
resection	NN	O
.	.	O

Further	NNP	O
study	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
timing	NN	O
and	CC	O
dose	JJ	O
duration	NN	O
to	TO	O
minimize	VB	O
blood	NN	O
loss	NN	O
and	CC	O
identify	VB	O
how	WRB	O
relevant	JJ	O
such	JJ	O
a	DT	O
decrease	NN	O
in	IN	O
bleeding	NN	O
is	VBZ	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Clonidine	NN	Pharmacological
increases	VBZ	O
the	DT	O
sweating	NN	O
threshold	NN	O
,	,	O
but	CC	O
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
gain	NN	O
of	IN	O
sweating	VBG	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
clonidine	NN	Pharmacological
produces	VBZ	O
a	DT	O
dose-dependent	JJ	O
increase	NN	O
in	IN	O
the	DT	O
sweating	NN	O
threshold	NN	O
but	CC	O
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
gain	NN	O
of	IN	O
sweating	VBG	O
.	.	O

Six	NNP	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
were	VBD	O
evaluated	VBN	O
,	,	O
each	DT	O
on	IN	O
three	CD	O
separate	JJ	O
days	NNS	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

In	IN	O
one	CD	O
,	,	O
saline	NN	Control
was	VBD	O
administered	VBN	O
;	:	O
in	IN	O
another	DT	O
,	,	O
a	DT	O
2-micrograms/kg	JJ	O
bolus	NN	O
of	IN	O
clonidine	NN	Pharmacological
was	VBD	O
followed	VBN	O
by	IN	O
an	DT	O
infusion	NN	O
at	IN	O
2	CD	O
micrograms.kg-1.h-1	NN	O
,	,	O
and	CC	O
on	IN	O
a	DT	O
third	JJ	O
day	NN	O
,	,	O
a	DT	O
4-micrograms/kg	JJ	O
bolus	NN	O
was	VBD	O
followed	VBN	O
by	IN	O
an	DT	O
infusion	NN	O
at	IN	O
4	CD	O
micrograms.kg-1.h-1	JJ	O
.	.	O

Core	NN	O
temperature	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
tympanic	JJ	O
membrane	NN	O
and	CC	O
mean	JJ	O
skin	NN	O
temperature	NN	O
was	VBD	O
determined	VBN	O
from	IN	O
four	CD	O
sites	NNS	O
.	.	O

A	DT	O
chest	JJ	O
sweating	NN	O
rate	NN	O
of	IN	O
40	CD	O
g.m-2.h-1	NN	O
was	VBD	O
considered	VBN	O
significant	JJ	O
.	.	O

The	DT	O
core	NN	O
temperature	NN	O
triggering	VBG	O
sweating	NN	O
,	,	O
adjusted	VBN	O
to	TO	O
a	DT	O
designated	VBN	O
mean	NN	O
skin	JJ	O
temperature	NN	O
of	IN	O
34	CD	O
degrees	NNS	O
C	NNP	O
,	,	O
identified	VBD	O
the	DT	O
threshold	NN	O
for	IN	O
this	DT	O
response	NN	O
.	.	O

Gain	NNP	O
was	VBD	O
defined	VBN	O
by	IN	O
the	DT	O
adjusted	VBN	O
core	NN	O
temperature	NN	O
increase	NN	O
required	VBN	O
to	TO	O
augment	VB	O
sweating	VBG	O
from	IN	O
100	CD	O
to	TO	O
300	CD	O
g.m-2.h-1	NN	O
.	.	O

degree	JJ	O
C-1	NNP	O
.	.	O

Plasma	NNP	O
clonidine	JJ	O
concentrations	NNS	O
were	VBD	O
0.8	CD	O
+/-	JJ	O
0.1	CD	O
and	CC	O
1.6	CD	O
+/-	JJ	O
0.2	CD	O
ng/mL	NN	O
on	IN	O
the	DT	O
small-	JJ	O
and	CC	O
large-dose	JJ	O
days	NNS	O
,	,	O
respectively	RB	O
.	.	O

Clonidine	NNP	O
administration	NN	O
increased	VBD	O
the	DT	O
sweating	NN	O
threshold	VBD	O
approximately	RB	O
0.4	CD	O
degree	JJ	O
C	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
the	DT	O
increase	NN	O
was	VBD	O
comparable	JJ	O
at	IN	O
each	DT	O
dose	NN	O
.	.	O

The	DT	O
gain	NN	O
of	IN	O
sweating	NN	O
was	VBD	O
approximately	RB	O
0.2	CD	O
degree	JJ	O
C	NNP	O
and	CC	O
was	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
clonidine	JJ	O
administration	NN	O
.	.	O

The	DT	O
thermoregulatory	JJ	O
effects	NNS	O
of	IN	O
clonidine	NN	O
thus	RB	O
resemble	JJ	O
those	DT	O
of	IN	O
volatile	JJ	O
anesthetics	NNS	O
,	,	O
opioids	NNS	O
,	,	O
and	CC	O
propofol	NN	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
antishivering	VBG	O
effect	NN	O
of	IN	O
clonidine	NN	O
results	NNS	O
from	IN	O
central	JJ	O
thermoregulatory	JJ	O
inhibition	NN	O
rather	RB	O
than	IN	O
a	DT	O
specific	JJ	O
peripheral	JJ	O
action	NN	O
on	IN	O
thermogenic	JJ	O
muscular	JJ	O
activity	NN	O
.	.	O

Unlike	IN	O
other	JJ	O
sedatives	NNS	O
and	CC	O
anesthetics	NNS	O
,	,	O
the	DT	O
concentration-dependence	NN	O
of	IN	O
clonidine	NN	O
demonstrates	VBZ	O
a	DT	O
ceiling	NN	O
beyond	IN	O
which	WDT	O
the	DT	O
administration	NN	O
of	IN	O
an	DT	O
additional	JJ	O
drug	NN	O
fails	NNS	O
to	TO	O
enhance	VB	O
the	DT	O
effect	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
the	DT	O
thermoregulatory	JJ	O
effect	NN	O
of	IN	O
clonidine	NN	O
may	MD	O
be	VB	O
limited	VBN	O
,	,	O
even	RB	O
at	IN	O
high	JJ	O
plasma	NN	O
concentrations	NNS	O
.	.	O

The	DT	O
gain	NN	O
of	IN	O
sweating	NN	O
was	VBD	O
well	RB	O
preserved	JJ	O
indicating	VBG	O
that	IN	O
this	DT	O
response	NN	O
remains	VBZ	O
effective	JJ	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
sedatives	NNS	O
and	CC	O
anesthetics	NNS	O
.	.	O

